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LECTURES AND SYMPOSIA

Introduction
In Italy zygote and embryo cryopreservation has been
forbidden by law 40/2004 until the decision n.
151/2009 of the Italian Constitutional Court that af-
firmed the constitutional illegitimacy of several provi-
sions of Law n. 40. Based on such conditions, in that
period gamete cryopreservation became the only op-
tion for the storage of reproductive material, so it re-
ceived a great effort to its development.
While cryopreservation of sperm and embryos has
been an integral part of infertility treatment for some
time now, on the other hand female gametes own
some particular characteristics -mostly related to their
anatomic structure- that make them more vulnerable.
Therefore, oocyte cryopreservation has not yet become
a routine procedure, and still in the 2008 the Practice
Committee of the American Society for Reproductive
Medicine affirmed that oocyte cryopreservation
should be considered an experimental technique only
to be performed under investigational protocol under
the auspices of an IRB (1).
Problems and limitations of oocytes
cryopreservation
Firstly, human oocytes are characterized by a low sur-
face-to-volume ratio and a plasma membrane perme-
ability that inhibit the passage of water and cryopro-
tectants, thus making it really difficult to protect
oocytes from intracellular ice crystals formation (2).
Secondly, mature oocytes contain the meiotic spindle,
which is known to be vulnerable to the dangerous ef-
fects of temperature variation and to oocyte dehydra-
tion/rehydration (3). Moreover, early oocyte activation
induced by cryoprotectants may impede subsequent
development (4). Finally, both freezing and thawing
expose gametes to severe stress, altering the zona pellu-
cida, therefore impairing sperm penetration or attach-
ment (5).
It must however be highlighted that the development
of oocyte cryopreservation has not been limited to the
Italian situation. Cryopreservation of oocytes has be-
come an alternative to embryo storage for several rea-
sons: first of all, oocyte storage has enormous potential
for making oocyte donation safer (by allowing a suit-
able temporal window for donor screening) and for
giving a hope for fertility preservation in women at
risk of premature loss of ovarian function (e.g. POF,
cancer patients). Nevertheless, an effective method to
preserve fertility would be appreciated by all the
women who, for several reasons, wish to delay preg-
nancy, or who prefer oocyte cryopreservation instead
of embryo freezing for ethical motivations.
In human in vitro fertilization (IVF), in which the first
reported pregnancy from cryopreserved oocytes was
described in 1986, there are two major techniques for
cryopreservation: slow freezing processes and vitrifica-
tion procedures. 
The most harmful effects are produced by ice crystals
created during the freezing procedure. Slow freezing
was the method of choice until a few years ago, but in
recent years vitrification has earned increasing consid-
eration for oocyte cryopreservation, by improving
post-storage survival rates and apparently preserving
more efficiently oocyte developmental ability (6). Vit-
rification is carried out by combining high doses of
cryoprotectants with high cooling and warming rates.
It has been proposed that vitrification process may be
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less shocking to the meiotic spindle than slow freezing
(7) and may avoid the formation of intracellular ice
crystals, using cryoprotectants in high concentrations
and ultra-rapid cooling and thawing procedures (8). It
is important to notice that, notwithstanding the possi-
ble risks for the meiotic spindle, there seem to be no
apparent increase of the incidence of chromosomal ab-
normalities in embryos derived from frozen eggs, and
the danger is far less likely when vitrification is used
(9-11). Finally, this method is cost-effective, does not
require expensive freezing equipment and just a very
small volume of vitrification medium is needed to
store the cryopreserved cells or tissues. Despite these
advantages, the main limit of vitrification is the toxic
effects linked to the use of high concentrations of cry-
oprotectants (12). This problem has however been got
over with the development of new vitrification tech-
niques using extreme cooling rates to significantly re-
duce the volume of cryoprotectants needed and so the
toxic and osmotic consequences.
In order to analyze with objectivity the reliability of
the method, it is clearly necessary to consider the dif-
ference between the procedures used, based on type of
carrier, cryoprotectant mixtures or vitrification device
and temperature. Moreover, there are other variables,
such as the age of the patient, and the consequent
oocyte quality, or the impact of other actions like ovar-
ian stimulation, culture conditions and embryo trans-
fer technique.
A glance at the current literature
Over the years, the majority of the studies in this field
showed some limitations, for example in relation to
the use of vitrified oocytes donated by young women,
which constituted a possible bias in the analysis of sub-
sequent reproductive outcomes (12-16). The origin of
the oocyte involved is, in fact, a crucial factor, with a
clear advantage of oocytes produced by young donors
compared to the ones coming from older women (17).
Likewise, until few years ago reliable randomized, con-
trolled trials comparing reproductive outcomes of cy-
cles using fresh and frozen oocytes were lacking. 
Since several accurate reviews in literature examine the
topic of the efficiency of oocyte cryopreservation in
general (18-20), we focused our attention only on the
latest researches comparing the results provided by
IVF cycles using fresh and frozen oocytes. Recently,
some studies comparing fresh and frozen oocytes re-
trieved from women of comparable average age and
other characteristics reported that pregnancy out-
comes do not seem to be greatly affected by the vitri-
fication procedure, as fertilization, embryo quality and
further development are similar to those achieved with
fresh oocytes. Especially the Cryotop system (Kitazato
Supply Co., Fujinomiya, Japan), involving a mini-
mum volume of vitrification solution, has been
showed to be very effective in oocyte cryopreservation.
On the other hand, in literature there are few data
about results obtained with closed vitrification systems
such as CryoTip (Irvine Scientific) (21). A recent
study by Paffoni et al comparing an open (Cryotop)
with a closed (Cryotip) device demonstrated lower
outcomes for the latter (22). However, to the best of
our knowledge, only one observational study was con-
ducted comparing clinical results, so that data regard-
ing gestational outcomes after closed vitrification are
missing. The prospective observational study per-
formed by Stoop et al used CBS High Security closed
straws (Cryo Bio System) and showed comparable lab-
oratory and clinical outcomes in an oocyte-donation
programme (23). As a result, further randomized con-
trolled trials should take into consideration closed vit-
rification systems as a valuable and aseptic alternative
for oocytes cryopreservation. Furthermore, studies on
animal models seem to confirm that cryo-survival of
oocytes following vitrification procedures is reliable,
but it is strongly associated with female reproductive
age: the older the woman, the worst the impact on the
oocytes (24). Vitrification may be responsible for in-
ducing slight aberrations of MII configuration in old
and in vitro aged oocytes without affecting young
oocytes (25).
Even if, recently, reduced oocyte development was re-
ported in frozen cycles in whom slow freezing was
used, compared with cycles involving sibling fresh cy-
cles (26), when vitrified oocytes are compared with
fresh counterparts in an oocyte donation program,
similar results are reported in terms of fertilization
rates, embryo development and blastocyst formation
rates (15).
Cobo et al., in 2008, published a cohort prospective
randomized study where they reported their experi-
ence with vitrification using the Cryotop method.
They compared the results of vitrified and fresh
oocytes from the same ART cycle, and they found no
significant difference in embryology data or clinical
outcomes. In that study, either vitrified or fresh
oocytes from the same cohort were inseminated with
the same semen sample, in order to compare the sole
potential of oocytes, thus eliminating any confound-
ing factors (15). To assess also the influence of the
technique on embryo development, they evaluated
embryo quality in both early and blastocyst stages, that
was similar between groups. We have to consider,
however, that all the donors were between 18 and 35
years, so that these oocytes had a better prognosis,
with respect to common infertile patients. This could
represent a possible limit for the study.
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Nagy et al. also examined the efficacy of oocyte vitrifi-
cation using the Cryotop method. The study included
153 oocytes from 10 donors assigned to 20 recipients.
When the authors compared the results of that ART
cycles with those from the donors’ previous fresh do-
nation cycles, they observed very similar outcomes.
Embryo development was similar in both groups and
a very high percentage of blastocyst development was
observed in the frozen oocytes group (27). Unfortu-
nately, also this study examined all donors under 35
years.
In addition, Rienzi et al confirmed these results in
2010 (28), when they conducted a randomized trial
comparing gestational outcomes of fresh ICSI insemi-
nation and vitrification procedure on sibling
metaphase II oocytes (MII). The vitrification and
warming procedures were performed with the Cry-
otop procedure, and, interestingly, patients were se-
lected based on the fact that they were not older than
42. The study showed that oocyte vitrification proce-
dure followed by ICSI was shown not to be inferior to
fresh insemination procedure, with regard to fertiliza-
tion and embryo developmental rates: embryo devel-
opment up to day 2 was not affected by vitrification
procedure, oocyte survival rate was higher than 95%,
and embryo quality was similar in the studied groups.
The Cryotop method was used also by Trokoudes et
al., who conducted a review of their egg-sharing pro-
gram between 2007 and 2009, where the oocytes from
one donor were shared by two groups of recipients, the
first of them receiving vitrified donor oocytes, while
the second receiving fresh donor oocytes (29). Also
this study owns the limit that the age of the donors
participating in this study varied between 22 and 35
years. Outcomes evaluated were fertilization rates,
cleavage rates, embryo quality, and clinical outcome of
both the cohort counterparts. Researchers evidenced
no statistically significant difference in fertilization
rates, and to estimate the influence of the procedure
on embryo development, they evaluated the rates of
cleavage on day 2 and good embryo development on
day 3 after insemination in both vitrified and fresh
oocytes, that were similar. Lastly, vitrified oocytes had
similar implantation potential compared to fresh
oocytes, as pregnancy rate per vitrified oocyte and im-
plantation rate were similar to that of fresh oocytes.
In 2010, Cobo et al performed a randomized, prospec-
tive, triple-blind, single-centre, parallel-group con-
trolled-clinical trial, in which they tested the concomi-
tant outcome of cryopreserved and fresh oocytes. Re-
grettably, as well as the precedent study, the donors
were all under 35 years old. The study confirmed that
there was no difference between both groups, with re-
spect to fertilization rate, embryo cleavage on Day-2
or on Day-3. Also the proportion of top-quality em-
bryos obtained was similar in both groups. There was
no significant difference also with regard to clinical
outcomes, as implantation and clinical pregnancy rates
per cycle and per embryo-transfer were similar for pa-
tients receiving vitrified or fresh oocytes (30). 
Almodin et al., in 2010, used a novel vitrification
method (Vitri-ingà), similar to Cryotop, to compare
the reproductive results obtained with oocytes vitrified
and thawed to that from fresh oocytes in a series of
IVF-ET cycles (31). The developmental potential of
embryos obtained from frozen oocytes using the Vitri-
ingà process seemed not to be greatly modified by the
vitrification procedure, as fertilization, embryo quality
and clinical results were similar to those achieved with
fresh oocytes. Only the average number of blastomeres
in the fresh-oocytes-group was significantly higher.
Conclusions
In conclusion, nowadays, we are far from the assess-
ment of a universal protocol dealing with all the knowl-
edge accumulated until now. What’s more, even though
there is a growing amount of evidences sustaining the
reliability and the general efficacy of oocyte vitrifica-
tion, large randomized, prospective and well-controlled
studies are still needed to ensure the safety of oocyte vit-
rification for its routine use in donation programs and
for future banking, and to verify beyond all doubt its
results in comparison to cycles using fresh oocytes.
Anyway, the reported studies support the hypothesis
of the potential application of oocyte vitrification in a
conventional IVF program. Besides, it might be useful
for the treatment of infertile patients with a large spec-
trum of indications. Particularly, embryo development
subsequent to the insemination of cryopreserved
oocytes seems not to be greatly impaired by the
process of cryopreservation, when it is performed with
a reliable and supported technique, as vitrification.
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Introduction
Ovarian cancer is the leading cause of death among
gynaecologic cancer and the fourth leading cause of
cancer death for women (1). Lifetime risk of ovarian
cancer is projected at 1.7% (2). Over 75% of cases are
diagnosed at an advanced stage, with a 5-year survival
rate of 30% (3). 
Several hypotheses have been proposed to explain the
association between ovarian cancer and reproductive
history. The “incessant ovulation hypothesis”, pro-
posed by Fathalla (4), supports that the repeated cycle
of damage and repair that occurs with each ovulation
may lead to genetic abnormalities and thus, could con-
tribute to the malignant transformation of the epithe-
lial cells.
The “gonadotrophin hypothesis” (5) posits that per-
sistent stimulation of the ovary by gonadotrophins can
increase the risk of malignant changes, either by a di-
rect carcinogenic effect or by inducing steroidogenesis.
Therefore, both the “incessant ovulation” and the “in-
creased gonadotrophin” hypotheses are consistent with
the known protective effect of pregnancies and oral
contraceptives (6).
Infertility: a cancer risk factor?
Several studies have investigated if infertility per se is
an independent risk factor for ovarian cancer and this
is an important issue before dealing with the potential
risks of fertility drugs.
Cohort studies
Cohort studies have compared ovarian cancer rates in
infertile patients with the general population, by using
the standardized incidence ratio (SIR). Since cohorts
of infertile women have lower parity rates than the
general population and nulliparity is a strong risk fac-
tor for ovarian cancer, an increased SIR might be sole-
ly due to the confounding effect of nulliparity. Anoth-
er potential limitation of most cohort studies is the
small number of observed ovarian cancers and there-
fore, the insufficient statistical power to draw firm
conclusions (Table 1).
Three studies have reported an increased risk of ovari-
an cancer in infertile patients (7-9). Brinton et al.
found, among infertile patients, a significantly higher
risk of ovarian cancer compared to the general popula-
tion (SIR of 1.98 95% CI 1.4-2.6) (12); in line with
these results, Rossing et al. also confirmed an increased
risk (SIR 2.5 95% CI 1.3-4.5), which was somewhat
higher for borderline ovarian tumors than for invasive
cancer (8). The other study, which is one of the largest
cohorts, describes a modestly increased ovarian cancer
risk among women reporting infertility (rate ratio of
1.36 95% CI 1.07-1.75) (9).
However, this increased risk has not been consistent-
ly reported in other cohort studies (10,11). The
study performed by Venn et al. included 10358
women referred for IVF treatment and revealed a
non significant increase of ovarian tumors (including
invasive ovarian cancer and mature cystic teratomas)
in the cohort when compared to the general popula-
tion. This cohort was years later expanded to 29700
women and still, the observed incidence of ovarian
cancer was not greater than expected (SIR 0.99, 95%
CI 0.57-1.70) (12). 
Jensen’s study was the first to determine parity-spe-
cific and parity-adjusted SIRs for ovarian cancer in a
cohort of infertile women (13). The results of this
cohort, including 54362 infertile women, revealed
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that infertile women have increased risk of ovarian
cancer, even when results were adjusted for parity
status. 
Case-control studies
Two large pooled analyses have suggested that infertile
women with long periods of infertility might be at in-
creased risk for ovarian cancer (14,15) (Table 2).
Whittemore et al. reported that a history of more than
15 years of unprotected intercourse was associated
with an increased risk of ovarian cancer, both among
gravid and nulligravid women, when compared to
those with less than 2 years of unprotected intercourse.
The other pooled analysis found that, among nul-
ligravid women, attempts for more than 5 years to be-
come pregnant compared with attempts for less than 1
year increased the risk of ovarian cancer 2.67-fold
(95% CI 1.91, 3.74) (15). 
In agreement with these results, a more recent case –
control study (16), which included 378 cases and
1637 controls, found no association of cancer risk
with a history of infertility or specific types of infer-
tility among parous women, however, this risk was
increased among nulliparous women (odds ratio =
1.6, 95% CI 1.0-2.6) 
It seems therefore, that infertility may increase the risk of
ovarian cancer in those patients who remain nulligravid
despite long periods of unprotected intercourse. 
Infertility origin
and ovarian cancer risk
The association between specific causes of infertil-
ity and ovarian cancer has also been addressed by
several studies. Ovulatory disorders, endometriosis
and unexplained infertility are the most common
diagnosis associated to ovarian cancer (17); howev-
er these associations have been inconsistently ob-
served.
Endometriosis seems to be the subtype of infertili-
ty where studies agree most. Brinton et al., in their
cohort of 12193 infertile women, observed no in-
creased ovarian cancer risk associated with ovulato-
ry, tubal or male infertility; however, an increased
risk was observed with endometriosis (RR 2.27)
(18). Melin and co-workers (19) have further in-
vestigated the possible association between en-
dometriosis and ovarian cancer after adjusting for
parity. They included 63630 women who had been
discharged from hospital with a diagnosis coded for
endometriosis with a long follow-up period. An in-
creased risk of ovarian cancer was observed (SIR
1.37, 95% CI 1.14-1.62) when compared to the
general population. Some limitations to Melin’s
study are that information regarding prior fertility
drug use is lacking and that only moderate to se-
vere endometriosis cases were included.
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TABLE 1 - COHORT STUDIES: INFERTILITY AND OVARIAN CANCER RISK.
Size Mean follow-up (yrs) Patients No. of cases Risk (95% CI)
Brinton et al. (7) 12193 18.8 Evaluated for infertility 45 SIR 1.98 (1.4-2.6)
Rossing et al. (8) 3837 6.9 Evaluated for infertility 11 SIR 2.5 (1.3-4.5)
Tworoger et al. (9) 107900 28 Infertile, not male factor 612 RR 1.36 (1.07-1.75)
Venn et al. (10) 29700 8.5 Evaluated for infertility 13 SIR 0.99 (0.57-1.70)
Modan et al. (11) 2496 21.4 Diagnosed with subfertility 12 SIR 1.6 (0.8-2.9)
Jensen et al. (13) 54362 13 Evaluated for infertility 155 SIR 1.46 (1.24-1.71)
SIR: standardized incidence ratios
CI: confidence interval
RR: relative risk
TABLE 2 - CASE-CONTROL STUDIES: INFERTILITY AND OVARIAN CANCER RISK.
No. of cases No. of controls Comparison OR (95% CI)
Whittemore et al. (14) 2197 8893 12 C-C studies
Nulligravid: 1.4 (0.86-0.23)
Gravid: 0.87 (0.67-1.1)
Ness et al. (15) 5207 7705 8 C-C studies
Nulligravid: 1.19 (0.91-1.55)
Gravid: 1.16 (1.02-1.31)
Rossing et al. (16) 378 1637 Nulliparous: 1.6 (1.0-2.6)
CI: confidence interval
OR: odds ratio
Use of fertility drugs
and ovarian cancer risk
Given the fact that fertility drugs raise temporarily
the levels of gonadal hormones and gonadotrophins
and that hormonal and reproductive factors are
known to be involved in the aetiology of ovarian can-
cer, a stimulating effect of fertility drugs in the risk of
this cancer is theoretically possible and compatible
with both the “incessant ovulation hypothesis” and
the “gonadotrophin hypothesis”. 
Cohort studies
Rossing et al. examined a cohort of 3837 infertile
women and found 11 ovarian tumors (invasive or
borderline), with a relative risk (RR) of 2.5 (95% CI
1.3-4.5). The risk was higher for borderline tumors
and was more pronounced with prolonged use of CC
(RR 11.1, 95% CI 1.5-82.3 after 12 or more cycles,
among women with and without ovulatory problems
and independent of parity status). However, these re-
sults are difficult to interpret if we take into consider-
ation the small number of cases, with almost half of
them being borderline tumors, and the limited infor-
mation on confounding factors (8) (Table 3).
Other cohort studies have not found an increased
risk of ovarian cancer among infertile patients who
used fertility drugs compared to the unexposed
group (11-20), however, only one of this studies con-
trolled for parity status.
One of the largest cohort studies evaluating the associ-
ation between fertility treatment and ovarian cancer
included 10358 infertile women referred for IVF
treatment (10). Ovarian cancer incidence was not
greater than expected in the exposed group. 
A more recent cohort study including a large cohort of
infertile women (12193 women) with a long follow-
up and information available regarding specific causes
of infertility, parity, oral contraceptive use and other
confounders, reports that women who had been ex-
posed to fertility drugs (both CC and gonadotrophins)
were not at an unusual risk of developing ovarian can-
cer compared to women who had never been exposed
to either drug; concluding that even though results
were reassuring, there is a need for continued monitor-
ing of long term effects (7). 
Another cohort study including only parous women
did not find an association between use of ovulation
inducing agents and ovarian cancer, although numbers
were small (only one exposed patient among 43 cancer
cases) and data regarding type of infertility and type,
doses and duration of treatment were absent (21).
Jensen and colleagues, in their cohort of 54362
women, found no convincing association between use
of fertility drugs (CC, hCG, gonadotropins, GnRH
analogues) and the overall risk of ovarian cancer. Risk
did not differ according to any use of fertility drug,
number of cycles, length of follow-up since first drug
use or parity. They did find an increased risk of ovari-
an cancer in infertile women, even after adjusting for
parity, suggesting therefore that other factors related to
infertility rather than the use of fertility drugs are in-
volved in this risk increase. When they analysed differ-
ences according to histological subtype, a 67% in-
creased risk for serous ovarian cancer was found after
use of CC, primarily among women followed for 15
years or more (22). 
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TABLE 3 - COHORT STUDIES: FERTILITY DRUGS AND OVARIAN CANCER RISK.
Size Mean follow-up (yrs) No. of cases Comparisons Risk (95% CI)
Treatment vs general population SIR 2.5 (1.3-4.5)
Rossing et al. (8) 3837 6.9 11 CC use vs no use RR 2.3 (0.5-11.4)
CC use vs no use RR 1.0 (0.2-4.3)
Modan et al. (11) 2496 21.4 12 Treatment vs general population SIR 1.7 (0.6-3.8)
Doyle et al. (20) 5556 8.5 6 Treated vs untreated RR 0.59 (0.12-3.00)
Venn et al. (12) 29700 7 for exposed group 13 Treated (IVF) vs general population SIR 0.88 (0.42-1.84)
Brinton et al. (7) 12193 18.8 45
CC use RR* 0.82 (0.4-1.5)
Gonadotropin use RR* 1.09 (0.4-2.8)
Calderon Margalit et al. (21) 15030 43 Ovulation inducing agents HR 0.61 (0.08-4.42)
Jensen et al. (22) 54362 16 156 Ovulation inducing agents RR* 1.03 (0.73-1.47)
Sanner et al. (23) 2768 33 17 (invasive cancers)
Gonadotropins vs no use RR 5.28 (1.70-16.47)
CC vs no use RR 1.57 (0.32-7.62)
CI: confidence interval
HR: hazard ratio
SIR: standardized incidence ratio
RR*: rate ratio
RR: relative risk
In contrast with the previous results, a recently pub-
lished cohort study with a mean length of follow-up of
33 years, found an increased risk of invasive ovarian
epithelial cancer in association with gonadotrophin
treatment in women with non-ovulatory disorders
when compared to unexposed women (RR 5.28, 95%
CI 1.70 – 16.47). However, these findings must be in-
terpreted with caution as the small number of cancer
cases makes statistical analysis imprecise with wide
confidence intervals (23).
Case-control studies
The first large case – control study reporting on a pos-
sible association between fertility drugs and ovarian
cancer was the meta-analysis performed by Whitte-
more and colleagues (14). They found a 3 fold increase
in the risk of developing an ovarian cancer with the
use of fertility drugs, when compared to women with-
out a history of infertility (OR 2.8, 95% CI 1.3-6.1)
(Table 4).
However, the article provides no information about
reasons for infertility, the type of fertility drugs used,
nor the dosage or duration of treatment. 
Some of these limitations are also met in Shushan’s
study (24), where the use of fertility drugs, particular-
ly hMG, was associated with an increased risk of ovar-
ian cancer (OR 3.95, 95% CI 1.33-12.2), being the
association stronger for borderline ovarian tumors
(OR 9.38, 95% CI 1.66-52.08). 
In contrast with these results, Moosgard et al. did not
find an increase of ovarian cancer risk among parous
and nulliparous women treated with fertility drugs
when compared to non treated (25). This study was
one of the eight case – control studies included in a
large pooled analysis (15), which concluded that there
was no association between fertility drug use and the
overall risk of ovarian cancer. 
Parazzini’s study showed reassuring evidence of the ab-
sence of a strong association between the use of fertil-
ity drugs and subsequent risk of ovarian cancer (26). 
In another case – control study, Rossing et al. did not
find an association between fertility drugs use and the
risk of ovarian cancer among either parous or nulli-
parous women (16), which is in disagreement with the
findings of a previous cohort study conducted by the
same authors (8).
A meta-analysis evaluating the risk of assisted repro-
ductive technology (ART) and ovarian cancer which
analysed separately cohort and case – control studies
(7 case – control and 3 cohort studies), found in the
cohort data that risk was not increased in treated pa-
tients, even more, they found a trend towards a de-
creased risk, which could be explained by the fact that
ART may result in pregnancy and parity is a protective
factor against ovarian cancer. Data from case – control
studies included in the meta-analysis showed no effect
of fertility treatment, but confounders were not taken
into account. A strength of this meta-analysis is that
they compared the incidence of ovarian cancer in
treated infertile vs. untreated infertile patients (27).
Conclusion
In conclusion, female infertility may be associated
with an increase in ovarian cancer risk in those pa-
tients who remain nulligravid despite long periods of
unprotected intercourse. 
Regarding the potential risk of fertility drugs, findings
seem to be reassuring, as most of the studies have
shown no overall increase in ovarian cancer risk; how-
ever, further research is warranted as some studies have
reported an increased risk of ovarian cancer with
greater exposures or extended follow-up. 
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TABLE 4 - CASE-CONTROL STUDIES: FERTILITY DRUGS AND OVARIAN CANCER RISK.
No. of cases No. of controls Comparison OR (95% CI)
OR 2.8 (1.3-6.1)
Whittemore et al. (14) 526 966 Fertility drugs vs. no infertility Nulligravid: OR 27 (2.3-315.6)
Gravid: OR 1.4 (0.5-3.6)
Shushan et al. (24) 164 408 Any drug vs. no use
OR 1.31 (0.63-2.74)
hMG vs. no use
Borderline: OR 9.38 (1.66-52.08)
Invasive: OR 3.19 (1.33-12.2)
Moosgard et al. (25) 684 1721 Fertility drugs vs. no use
Nulliparous: OR 0.83 (0.35-2.01)
Parous: OR 0.56 (0.24-1.29)
Ness et al. (15) 1060 1337 Fertility drugs vs. no use OR 0.97 (0.76-1.25)
Parazzini et al. (26) 971 2758 Fertility drugs vs. no use OR 1.1 (0.4-3.3)
Rossing et al. (16)
108 nullip. 343 nullip.
Fertility drugs vs. no use
Nulliparous: OR 1.0 (0.4-3.0)
270 parous 1291 parous Parous: OR 0.8 (0.4-1.6)
CI: confidence interval
OR: odds ratio
Specific attention should be focused on effects among
women with long-term subfertility, above all among
those who remain nulligravid.
Well-conducted studies with large sample sizes, long
follow-up periods and data on confounding factors,
the type of infertility and the type, dosages and dura-
tion of treatment, as well as on histology of tumors,
are needed (28-30).
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Introduction
In Western countries women the endometrium is fre-
quently exposed, even after menopause, to the action
of endogenous estrogens. Such a stimulation, strongly
linked to women’s metabolic pattern, increases the risk
of pathologic conditions such as endometrial hyper-
plasia and type I (endometrioid) endometrial adeno-
carcinoma. Obesity, type II diabetes and the metabol-
ic syndrome, for instance, promote the endometrial
stimulation. As a consequence, the dietary and lifestyle
changes that reduce obesity and metabolic disequilib-
rium may act as important preventive factors for the
endometrium disorders.
The postmenopausal endometrium
In asymptomatic postmenopausal women undergoing
hysterectomy for a prolapsed uterus, the endometrium
frequently shows some features of activity (1,2); even
when atrophic, 50% shows various degrees of prolifer-
ative and angiogenic activity, either diffuse or focal (2).
Similar activities has been also shown by the non-neo-
plastic atrophic endometrium adjacent to type I estro-
gen-dependent adenocarcinoma (2,3). Actually, cancer
is more frequently associated with patterns suggesting
a more definite endometrial stimulation. Compared
with women who present “disordered proliferative en-
dometrium” (considered equivocal hyperplasia), the
women with “simple hyperplasia” have a non-signifi-
cant increased risk of cancer (Relative Risk = 2.0, 95%
CI, 0.9-4.5); the women with “complex hyperplasia”
have a significant increased risk of cancer (2.8, 1.0-
7.9) and the women affected by the precancerous
“atypical hyperplasia” have a Relative Risk = 14.2 (5.3-
38.0) (4). Over 80% of cases of endometrial cancer oc-
curs after menopause; among these, 75% are the type
I tumours, while 25% are non-endometrioid estrogen-
independent cancers (3,5). Therefore, in post-
menopausal women, the majority of endometrial
pathology is a consequence of a continuous low level
estrogenic stimulation and epidemiologic data suggest
that such a stimulation is associated with metabolic
and life-style factors.
Risk factors connected with life-style
and/or metabolic alterations
The association between endometrial cancer, metabol-
ic alterations and lifestyle factors is well recognized (6).
The incidence of endometrial cancer is higher in West-
ern, industrialized countries than in rural Asia or
Africa. Observing the changes in incidence rates over
time, after industrial progress or migration from low
to high risk areas, it is clear that endometrial cancer is
strongly related to westernised diets, obesity and
sedentary lifestyles (7). 
Obesity
Postmenopausal obese women have a 3-4 fold in-
creased risk of complex hyperplasia and hyperplasia
with atypia (8-10). Regarding endometrial cancer, ev-
idence indicates that 40-50% of endometrial cancers
may be due to too much body fat, suggesting that en-
ergy balance has a critical role in the aetiology of this
disease (11,12). Different studies showed that obesity
is associated with a 2-5-fold increased risk in both pre
and post-menopausal women (5,7). 
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Diabetes
A trend to increased risk of endometrial hyperplasia
with atypia (4.0; 0.8-19.1) was observed in diabetic
women aged 52 years or more (8).
Epidemiological studies consistently showed that
women affected by noninsulin-dependent diabetes
have an increased risk of endometrial cancer both be-
fore and after menopause (5,7). This increased risk is
independent from obesity, as it persists after control-
ling for body mass index (BMI) (13). 
Sedentary behaviour
The World Cancer Research Fund and American Insti-
tute for Cancer Research (WCRF/AICR) Report, re-
viewed the totality of epidemiological evidence on
physical activity and endometrial cancer relation, con-
cluding that physical activity probably reduces en-
dometrial cancer risk (14). However, five large prospec-
tive cohort studies and a meta-analysis (15) have since
published findings on the relationship between physi-
cal activity and endometrial cancer (16-20). The total-
ity of evidence now convincingly indicates that physi-
cal activity prevents or reduces risk of endometrial
cancer (active women having an approximately 30%
lower risk than inactive women) and this effect is in-
dependent of adiposity. Consistently, sedentary behav-
iour is emerging as a risk factor in a few studies that
evaluated the risk associated with sitting for more than
5 hours/day (15-21).
Mechanisms of action
Endometrial hyperplasia (and the subsequent cancer)
arise when estrogen, unopposed by progesterone,
stimulates endometrial cell growth by binding to es-
trogen receptor and by increasing the local production
of Insulin-like Growth Factor-I (IGF-I) (7).
Progesterone contrasts the estrogen effects and
prompts the shedding of endometrial tissue by reduc-
ing the number of estrogen receptors, by increasing
the rate of conversion of estradiol (E2) to the less po-
tent estrone (E1) and by favouring the expression of
IGF Binding Protein-1 (IGFBP-1) which inhibits
IGF-I action in endometrial tissue (7).
Unopposed high estrogen levels are a risk factor for en-
dometrial hyperplasia, as shown by the results of the
randomized Post-menopausal Estrogen/ Progestin In-
terventions (PEPI) Trial, where women assigned to re-
ceive estrogen-only therapy were more likely to devel-
op simple, complex or atypical hyperplasia than
women treated with placebo (27.7% vs 0.8%, 22.7%
vs 0.8% and 11.8% vs 0%, respectively) (22).
However, endogenous estrogens in post-menopausal
women, even if at the top of the range as in obese
women, do not completely explain the association be-
tween life-style and metabolic alterations and hyper-
plastic or neoplastic endometrial pathology. Other fac-
tors in addition to estrogens, such as high serum levels
of insulin, may promote the proliferation of endome-
trial tissue. 
Endogenous estrogens and androgens
in postmenopausal women
After menopause, androstenedione and testosterone
are converted into estrone and estradiol through the
action of aromatases in the peripheral tissues, especial-
ly in the adipose tissue (5,23). After menopause, an-
drogens mainly derive from the adrenal cortex. 
In detail, the reticolar area of the adrenal cortex pro-
duces dehydroepiandrosterone (DHEA), which, espe-
cially as dehydroepiandrosterone sulphate (DHEAS),
represents the major circulating C19 steroid (24).
DHEAS and DHEA are converted in the peripheral
tissues, especially in the adipose tissue, into the delta4-
steroids androstenedione and testosterone (25-27).
Furthermore, the ovary contributes to the production
of DHEA (24) and testosterone (20-40% of the total
synthesis) (28-30).
Obesity does not influence levels of DHEA/DHEAS
but is the major determinant of levels of delta4-
steroids. Epidemiological data showed that obese
women have higher serum levels of androstenedione,
testosterone, and free testosterone (29). “In vitro” and
“in vivo” data suggest that androgens may have no ef-
fect or inhibitory effect on endometrial cell prolifera-
tion (31,32); however, through the conversion into es-
trogens androgens may represent a risk.
Elevated circulating androgens have been associated
with endometrial hyperplasia (7). Several studies
found that women with type I endometrial cancer
have higher levels of both estrogens and androgens
(33). Prospective studies showed that endometrial can-
cer risk in postmenopausal women is positively associ-
ated with levels of estrogens and androgens, and in-
versely associated with SHBG, even after adjustment
for BMI (34,35). 
Insulin
Type II diabetes (non-insulin dependent) is character-
ized by hyperinsulinemia due to insulin resistance and
is associated with an increased risk and mortality of
endometrial cancer (7,36). Epidemiological data on
postmenopausal women suggested also an increased
risk of endometrial cancer in non diabetic women
with hyperinsulinemia (7). Insulin may have impor-
tant direct effects, working as a growth factor, similar
to those of IGF-I (7,37). Elevated insulin could also
increase IGF-I activity in endometrial tissue by sup-
pressing gene expression of endometrial IGFBP-I (7)
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Moreover, insulin reduces the liver production of
SHBG (29,38) and hyperinsulinemia due to insulin
resistance is associated to high serum levels of testos-
terone in most studies (39). Insulin stimulates the
ovary and adrenal cortex production of androgens (es-
pecially androstenedione and testosterone) through
the 17α-hydroxylase and 17,20-lyase activities (40). 
Other mechanisms
It has been hypothesized that inflammatory mecha-
nisms partially mediate the relationship between obesi-
ty and endometrial cancer risk. In a large prospective
study levels C-reactive protein (CRP) were positively
associated with the risk of endometrial cancer (41). In-
terestingly in this study, the excess risk due to obesity
was reduced by 48%, 67% and 77% when either E1,
CRP or insulin, respectively, was included in the mod-
el; the risk became null in the model that simultane-
ously adjusted for all these three factors.
Epidemiologic studies suggested also that low levels of
adiponectin contribute to mediate the relationship be-
tween obesity and endometrial cancer (42,43).
Adiponectin opposes insulin resistance and inflamma-
tory factors. Normal endometrium, even if atrophic,
and endometrial cancer tissue, express adiponectin re-
ceptors (43); adiponectin may also affect cancer devel-
opment directly, at a local tissue level, through the ac-
tivation of the adenosine 5’-monophosphate-activated
protein kinase (AMPK) (43).
Prevention of endometrial pathology
A diet aimed at lowering calories and insulin levels
(low fat, refined carbohydrates and animal products,
high whole grain cereals, legumes and vegetables) and
physical activity reduce body weight and the metabol-
ic syndrome, improves insulin sensitivity, and decreas-
es the bioavailability of sex hormones and growth fac-
tors. A “lifestyle” intervention may be probably useful
for prevention of endometrial pathology.
Intentional weight loss causes an increase in SHBG
levels and a decrease in levels of insulin, CRP, andro-
gens and estrogens (12,44), with a one-third reduction
in free E2 to be expected from a 10% weight loss (12).
Observational cohort studies and randomized con-
trolled trials of both dietary interventions and bariatric
surgery indicated fairly immediate reductions in can-
cer incidence following intentional weight loss (12).
Physical activity reduces insulin level and insulin-re-
sistance independently of its influence on BMI (45).
Higher levels of sport activity are associated with low-
er levels of estrogens and androgens (46,47); however,
some data suggested a non-linear relationship between
recreational physical activity and hormone levels in
postmenopausal women (48). Anyway, findings of five
large prospective cohort studies consistently suggested
that physical activity protects against endometrial can-
cer, and this effect is independent of adiposity (15).
Based on these studies, one hour daily of moderate-in-
tensity activity (e.g. walking) significantly reduces the
risk of endometrial cancer (15,21); 74% of European
population is insufficiently active and 34% is sedentary
(21). Approximately 30000 cases of endometrial cancer
could have been prevented in 2008 in Europe (2700 in
Italy alone) if the population had maintained sufficient
levels of physical activity (21). 
In addition to life-style modifications, the antidiabetic
Metformin, a “caloric restriction mimetic” with a pos-
sible anticancer activity (49), may be proposed as pre-
ventive agent in women with metabolic syndrome,
pre-diabetes and/or obesity. Metformin inhibits liver
neoglucogenesis by activating AMPK, and reduces in-
sulin level (49). Furthermore, data from our random-
ized trial showed a 23% reduction in testosterone lev-
els in postmenopausal breast cancer patients treated
with 1500 mg/day of Metformin (50). Metformin
could also have direct anticancer effect, mainly by ac-
tivating AMPK, thus mimicking the effect of calorie-
energy restriction, which reduces all energy consuming
processes in the cells including cell proliferation (49).
Preclinical data showed that Metformin is a potent in-
hibitor of endometrial cancer cell proliferation, an ef-
fect partially mediated through AMPK activation (51). 
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Introduction
Turner’s syndrome (TS) is the most common chromo-
somal abnormality in females, and affects 1 in 2500
live female births. This condition is more common in
utero, affecting 1-2% of all conspectuses. Only 1% of
fetuses do not end up in miscarriage (1). TS is the re-
sult of the absence or the abnormality of the second
sexual chromosome, in at least one cellular line. The
chromosome might be completely lost (45X0), may
have undergone duplication of the long arm with the
loss of the short one (isochromosome Xq), may trans-
form intro a ring formation (rX), or suffer a deletion
that includes the tip of the short arm. Monosomy
45X0 is the most frequent form in peripheral blood
lymphocytes (40-60%), but other karyotypes present
mosaic patterns like 45X0/46XX, 45X/46XY or
45X/46Xq- (Table 1, Fig. 1).
TS is associated with a wide array of potential abnor-
malities, most thought to be caused by haploinsuffi-
ciency of genes that are normally expressed by both
X-chromosomes (2). The cardinal features of TS are
short stature and ovarian failure with insufficient sex
steroids. These dysfunctions cause delayed puberty
and primary amenorrhoea in most cases. Most medical
attention has therefore been focused on early diagno-
sis, looking for signs for prenatal diagnosis, or per-
forming paediatric guidelines for treatment with
growth hormone (GH) and pubertal management (3).
Nowadays, it has become evident that patients with
TS are susceptible to some disorders whose beginning
or evolution occurs in adult life, such as osteoporosis,
hypothyroidism, diabetes, dyslipemia or non congeni-
tal cardiac or nepho-urological changes. Morbidity
and mortality are increased, and life expectancy is re-
duced mainly by cardiovascular diseases (1,3-7).
Special care during adulthood is necessary, with co-or-
dination among different specialties, in order to devel-
op guidelines for the correct control of sensorineural
and endocrine disorders, to seek associated malforma-
tions, and for reproductive counselling or sexual
health. Gynaecologists should take primary responsi-
bility for the management of these patients to main-
tain and control hormone replacement, referring them
to other specialties if required. In this systematic re-
view, the complications of patients with Turner’s syn-
drome in adult life are described.
Clinical features
Short stature and gonadal dysgenesis are the main clin-
ical stigmata, accompanied or not by other dysmor-
phology secondary to lymphoedema (5,6). An associa-
tion between karyotype and phenotype exists, but it is
not predictable. For instance, external dysmorphology
and nephrologic or cardiac malformations are com-
mon in pure monosomy (1,8), while 40% of patients
© Copyright 2012, CIC Edizioni Internazionali, Roma
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TABLE 1 - KARYOTYPE DETERMINED IN BLOOD SAMPLES
OF PATIENTS IN THE GYNAECOLOGICAL ENDOCRINO-
LOGY UNIT OF HOSPITAL CLÍNIC OF BARCELONA.
Karyotype N Patients (%)
Pure monosomies 45 X0 10 (32%)
Deletions 46XdelX 2 (6%)
Translocations 46,XX t(X;7)(q26:p13) 1 (3%)
Isochromosome 46 X i(X)(q10) 2 (6%)
Mosaicisms
Pure / XX Mos 45X0/46XX 3 (10%)
Ring chromosome / XX Mos 45XrX/46XX 3 (10%)
Pure / isochromosome Mos 45X0/46XiXq 9 (29%)
Pure / XY Mos 45X0/46XY 1 (3%)
with mosaic patterns present spontaneous menarche
with fewer external features. In addition, isochromo-
some is associated with sensorineural and immunolog-
ical disorders, without congenital malformations.
Short stature is almost an invariable finding in women
with TS, with a mean final adult height between 143
and 147 cm (Fig. 2). The cause is thought to be due to
a primary bone defect, associated with a partial growth
hormone (GH) insensitivity. Therefore, patients re-
ceiving treatment during childhood with GH therapy
for a mean of 5.7 years were on average 7.2 cm taller
than the control group (9). It is recommended to begin
GH treatment 4 years before oestrogen replacement
(1), and the addition of oxandrolone associated with
GH seems to increase height gain and slow breast de-
velopment without affecting the body mass index (10).
Two genes have been identified as strong candidates
for short stature, SHOX and PHOG, both located in
the distal part of the short arm of the X- and Y-chro-
mosomes (Xp11-22, Yp11). Mutations in these genes
could also explain some skeletal abnormalities in TS,
such as Madelung deformity of the wrist, cubitus val-
gus or short fourth metacarpal. Haploinsufficiency of
SHOX expression could explain other features such as
chronic otitis media, prominent ears, and problems
learning how to suck, blow, eat or articulate (2,11).
Lymphoedema is caused by an absence or hypoplasia
of lymphatic vessels and is generally identified at birth,
improving overtime. Other external physical disorders
linked to TS are epicanthus, deformity in the pinna,
micrognathia, cleft palate, short neck, pterygium colli,
short limbs, low-set ears, cubitus valgus and genu val-
gum (4). 
Ovarian dysgenesis
Although the gonads in TS differentiate normally un-
til the third month of gestation, an accelerated degen-
eration of oocytes occurs after this period, with an in-
crease in ovarian stromal fibrosis. Consequently, ovar-
ian failure takes place within the first few months or
years of life. Despite the fact that primary amenor-
rhoea is usual in TS, the incidence of spontaneous pu-
berty is 8% in patients with the 45X0 karyotype, while
it is found to be as high as 40% in women with mo-
saicism (5). Concentrations of follicle stimulating hor-
mone (FSH) and luteinizing hormone (LH) are high
as early as 5 days of age in infants with TS; although
these levels decline afterwards, FSH and LH levels re-
main higher than in girls with a normal karyotype
(6,12). 
In up to 6% of TS patients the karyotype includes the
Y-chromosome, which may lead to the development of
35
Fig. 1 - Examples of Turner’s Syndrome
(X-chromosome abnormalities); A) mono-
somy 45X0; B) isochromosome X; C)
X-ring chromosome; D) X-delection.
Fig. 2 - Distribution of the final height according to the year of birth of Turn-
er’s syndrome patients followed in Hospital Clinic (black squares) and age-
matched controls (white circles).
gonadoblastoma, a malignant neoplasm composed of
stromal and germ cells. Hence, early prophylactic ex-
cision of the gonads is recommended in TS women,
considering that the risk increases with age (from 2%
at age 10, to 27.5% at 30 years) (5).
Hormone replacement therapy
After the induction of puberty with oestrogens, most
females with TS require long-term oestrogen replace-
ment therapy with the aim of preventing osteoporosis,
reducing risk factors for atherosclerosis and improving
aspects of cognitive function (5,13).
Replacement treatment is recommended with natural
oestrogen preparation and to be administered orally or
with transdermal patches, taking into account the pa-
tient’s preference or to avoid first-pass hepatic metab-
olism. Ethinyl-estradiol presented in contraceptive
pills has been associated with adverse effects on liver
enzymes, lipid metabolism and blood pressure, both in
women with normal and Turner karyotype. In addi-
tion, some TS females are symptomatic during the
pill-free week because of the complete lack of oestro-
gens.
Progestagen should be given for a minimum of ten
days per month in order to prevent endometrial carci-
noma, even though a continuous regimen would avoid
menstrual bleeding.
Oestrogen deficiency causes bone loss, endothelial
dysfunction, decreased insulin production, an abnor-
mal lipid pattern, increased central adiposity and early
atherosclerosis. In oestrogen deficient females with TS,
replacement therapy improves liver enzyme abnormal-
ities and some cognitive deficits (reaction time, non
verbal processing speed, short term memory) (14).
Therefore, the use of oestrogen replacement up to
physiological doses should be maintained until the ex-
pected age of menopause. Nonetheless, it is important
to emphasize that neither the risk of breast cancer nor
that of ovarian or endometrial cancer is higher in these
patients than in the general population (6).
Fertility and pregnancy
Concerning options for fertility, spontaneous preg-
nancies occur in less than 5% of TS patients, with the
risk of the development of congenital malformations
or chromosomopathies. Oocyte donation and in vitro
fertilization should be recommended because most of
women with TS are infertile. Nevertheless, the risk of
first trimestre miscarriage is higher, probably due to
uterine hypoplasia and some uterine ischaemia during
pregnancy (12,15,16). Caesarean rates are higher due
to cephalopelvic disproportion resulting from their
body habitus. 
TS is associated with many cardiovascular disorders
and as such, cardiac assessment, including echocardio-
graphy and strict blood pressure monitoring should be
recommended before the application of assisted repro-
ductive techniques.
Finally, prenatal diagnosis of TS allows the prediction
of gonadal insufficiency in women demonstrating ear-
ly evidence of ovarian function; hence, new techniques
of ovarian tissue cryopreservation with the aim of re-
plantation may be suitable for a few selected females
with TS.
Osteoporosis
Short size and osteoporosis could be due to a primary
defect in bone formation. Although this molecular
defect remains to be identified, some genes situated in
X-chromosome are associated with connective tissue
changes (17).
A reduction in peak bone mass by 25% has been de-
scribed in women with TS. Nonetheless, bone density
measurements depend on height, and short size and
GH treatments in TS may be confounding factors.
However, the incidence of fracture in girls and adult
women with TS is 3-fold higher than in normal con-
trols (18).
GH treatment for at least one year, together with oe-
strogen replacement started before 12 years of age, im-
prove bone mineral density. Indeed, girls with TS and
spontaneous menarche have been found to achieve
normal bone mass (19). 
Cardiovascular diseases
Along with all the alterations described above, cardio-
vascular complications are the main cause of increased
mortality in TS, in which life expectancy may be re-
duced by up to 13 years. Dilatation of the root of the
aorta, hypertension, and bicuspid aortic valve have
been reported as major cardiovascular complications
in TS (20). In addition, mortality due to ischaemic
heart disease is increased up to 7-fold in women with
TS, although the precise mechanisms of increased car-
diovascular risk in TS are unclear (20). 
Despite cardiovascular complications in TS being
mainly associated with hypogonadism, and a conse-
quent decrease in oestrogen production (21), differ-
ences in X-chromosome gene expression may also con-
tribute to these complications. Several genes implicat-
ed in the control of cardiovascular function have been
described in the X-chromosome, including the an-
giotensin type 2 receptor and several kinases and tran-
scription factors (22).
Bicuspid aortic valve is the most common congenital
malformation (16%) and, although it is usually an iso-
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lated abnormality, it may occur together with other
anomalies such as aortic coarctation. This combina-
tion may result in progressive valvular dysfunction due
to calcification in the aortic valve and may cause aor-
tic stenosis or regurgitation in adulthood. Coarctation
of the aorta affects 10% of women with TS causing
hypertension and seems to be more associated with se-
vere lymphoedema, perhaps due to abnormal lym-
phatic flow by compression of the ascending aorta
(2,23). 
Other abnormalities, such as partial anomalous venous
drainage and mitral valve prolapse are more common
among TS women, and left-side cardiac anomalies are
associated with endocarditis, with prophylactic antibi-
otics being essential before surgical procedures. 
However, the most serious risk for females with TS is
aortic dissection, which may occur at any age causing
even sudden death. Accordingly, echocardiography
should be included in the assessment of TS patients
and should be indicated periodically. Electrocardio-
gram should be carried out along with the imaging
studies because conduction or repolarization defects
have been reported attributed to neuroautonomic dys-
function (2).
Hypertension, a bicuspid aortic valve and dilated aortic
root (with an age-related increase of the root diameter
greater than the normal population) are risk factors for
dissection, making antihypertensive treatment in
women with two of these three disorders advisable (24).
Metabolic abnormalities
Patients with TS have a higher prevalence of other sub-
rogate cardiovascular risk factors such as dyslipidemia
and diabetes mellitus due to insulin resistance (5).
Type 2 diabetes mellitus is 2-4-fold more common in
women with TS, and an early metabolic defect in glu-
cose uptake has been described. Insulin resistance and
secondary hyperinsulinemia do not seem to be de-
pendent on the body mass index, as in the polycystic
ovarian syndrome, but obesity and an elevated waist-
to-hip ratio found in TS worsen this defect. Moreover,
hypertriglyceridemia may be a consequence of hyper-
insulinemia and obesity.
Hypercholesterolemia has been described at the ex-
pense of an increase of low density lipoproteins fol-
lowed by a decrease of high density lipoproteins. GH
therapy aggravates this disorder, but the effect is re-
versible after discontinuation of the treatment (25).
Liver enzymes are often raised in females with TS, but
this seems to be a transient and benign dysfunction
(Table 2). However, these patients have a 5-fold in-
crease in the risk of cirrhosis (1). Hence, liver function
should be checked periodically.
In conclusion, close control of blood pressure, as well
as a yearly determination of the lipid, carbohydrate
and hepatic profiles should be included in the correct
assessment of TS women in adulthood. 
Immunological disorders
Hypothyroidism affects up to 70% of TS patients, es-
pecially due to autoimmune causes, and a mild and
transient TSH elevation without thyroid autoantibod-
ies has been observed. Thyroid function should be
checked annually in order to diagnose the develop-
ment of hypothyroidism early.
Indeed, autoantibodies and consequently, autoim-
mune diseases, such as coeliac disease, inflammatory
bowel disease, vitiligo and alopecia areata, adrenal in-
sufficiency, juvenile idiopathic arthritis or type 1 dia-
betes mellitus, are increased in these patients
(26,27,28). A region in the X-chromosome where the
foxp3 gene, which defines IPEX syndrome may be
found, has been linked to these autoimmune disor-
ders. FoxP3 expression correlates with CD127low
leucocytes (leucocytes with low CD127 expression)
(29), and it has been suggested that the same alter-
ation may justify an increase in the prevalence of au-
toimmunity in TS, especially among isochromosome
karyotypes (29).
It has also been suggested that other immune disorders
may be present in TS patients; for instance a low
CD4/CD8 ratio or a low concentration of im-
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TABLE 2 - CARBOHYDRATE , LIPID AND HEPATIC PROFI-
LE PATIENTS (N=31) IN THE GYNAECOLOGICAL EN-
DOCRINOLOGY UNIT OF HOSPITAL CLINIC OF BAR-
CELONA.
Average ± SD
Number of patients
above normality limit
Carbohydrate  profile
Glucose 77,4 ± 12,3 1a
Insulin 9,0 ± 5,6 3
Lipid profile
Cholesterol 196,2 ± 36,5 2b
HDL-cholesterol 63,7 ± 14,4 0
LDL-cholesterol 116,2 ± 30,8 0
Triglycerides 77,5 ± 29,2 0
Hepatic profile
ASATc 32,8 ± 22,4 6
ALATd 39,8 ± 32,6 9
GGTe 96,9 ± 138,7 15
Alkaline phosphatase 235,6 ± 130,8 10
LDHf 423,5 ± 61,9 8
aPatient diagnosed of Diabetes Mellitus type II. Receiving treatment with metfor-
min. bOne of the cases belonged to the group of 9 patients receiving statins for pre-
vious hypercholesterolemia. The other one has never been treated for hyperchole-
sterolemia. cASAT: alanine transaminase, dALAT: aspartate transaminase, eGGT:
gamma-glutamil transferase, fLDH: lactate dehydrogenase.
munoglobulins. Despite these alterations, an increase
in infections has not been described, with the excep-
tion of otitis media (29,30).
Sensorineural disorders
Young and middle-aged women with TS have a pro-
gressive type of hearing impairment, deteriorating rap-
idly in adult age. The hearing decline seems to consist
of two patterns: a mid-frequency dip, and a high-fre-
quency loss resembling age-related hearing impair-
ment (31). The conductive hearing loss seems to be a
consequence of several episodes of otitis media during
infancy. The main cause for the infection is the defor-
mity in the pinna, more pronounced in patients with
a total delection of the short arm of the X chromo-
some, as monosomy 45X0 or isochromosome (32).
Therefore, the conductive loss may have a genetic ori-
gin. However, the pathophysiology of sensorineural le-
sions is not yet fully understood. Some studies indicate
that cochlear dysfunction is the cause of the sen-
sorineural impairment, and it is possibly influenced by
oestrogen deficiency (33,34). Therefore, regular au-
diometric checks should be performed referring pa-
tients to otorhinolaryngological departments.
As with other congenital conditions such as Kallmann
syndrome, TS has been associated in medical literature
with disordered olfactory and taste function. Unfortu-
nately, this association is based on anecdotal observa-
tions, and the mechanisms responsible for the loss of
smell are poorly understood. Considering smell and
taste dysfunctions, only two studies have been pub-
lished on TS patients. Nine TS women were found to
have elevated detection and recognition thresholds to
three odorants assessed, as well as sour and bitter thresh-
olds using a taste test (35). Valkov published similar
findings in 20 patients with TS eight years later (36).
Psychosocial development
Although there are exceptions, intelligence is within
the average range in most females with TS, with good
verbal skills. However, some have difficulties with non
verbal learning disabilities, including number work,
visuospatial and perceptual abilities and motor coordi-
nation. Moreover, parents report a reduced concentra-
tion span with less short-term memory. Again, the
severity of the cognitive impairment is linked with the
karyotype, being worse in pure monosomy than mosa-
ic patterns (24). Differences in brain structure, includ-
ing smaller parietal lobes, parietaloccipital and pre-
frontal volumes correlate with differences in brain
functions (37).
Furthermore, women with TS have some personality
traits, with greater difficulty in making friends and en-
tering into sexual relationships. Although the difficul-
ty in non verbal communication may have a role, poor
self-image as a result of short statue, dysmorphology
and delayed sexual maturation may be the main cause. 
Females with TS should have access to clinical psy-
chologists for counselling related to anxieties and for
working to improve specific areas of deficiency. Fami-
lies should have support in obtaining appropriate ther-
apy, including special accommodations at school (2).
Other disorders
Congenital renal disorders are 9-fold more common in
women with TS than in the general population (5).
These abnormalities include horseshoe kidney, duplex
systems and rotated kidneys (Fig. 3). Malformations
are more common in 45X0 monosomy females, being
related to neither hypertension nor other clinical
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Fig. 3 - Main renal malformations associated with Turner’s syndrome. (A)
Axial plane of an abdominal TC showing a right renal agenesia. (B) Abdom-
inal ultrasound showing a compensatory right renal hypertrophy in a new-
born with unilateral agenesia. (C) Coronal CT-urography reconstruction
showing a horseshoe kidney. (D) (E) Coronal CT-urography reconstruc-
tions showing a duplex system of the left kidney. (F) Axial plane of a CT
showing a horseshoe kidney. (G), (H), (I). Three different axial CT planes of
the same patient showing renal malposition, being both kidneys on the
right side.
symptoms. Nevertheless, renal ultrasound is recom-
mended at diagnosis and should be repeated at the
time of adult transfer. 
The most common ocular findings linked to TS are
strabismus, ptosis and amblyopia. All patients should
have eye assessment carried out during follow-up if re-
quired. 
Conclusions
To conclude, females with TS have a high risk of de-
veloping medical problems, from infancy to adult-
hood. After early diagnosis, they should be followed by
a multidisciplinary team of specialists to control the
comorbidities associated with this syndrome (Table 3). 
At first, specialized paediatricians should perform a
congenital malformation screening, with echocardiog-
raphy and renal ultrasound. In this period, it is recom-
mended to follow guidelines for the treatment with
growth hormone, as well as oestrogen replacement for
correct sexual development.
In adulthood, these females should be followed in spe-
cialized endocrinological-gynaecological units to diag-
nose disorders which debut in adulthood, such as
metabolic, immunological and sensorineural disor-
ders. Hormone replacement treatment should be guar-
anteed, as should reproductive and sexual advice.
Some studies from France (3), Belgium and the Unit-
ed States (38, 39) have reported that only a small mi-
nority of females (approximately 3.5%) with TS are
transferred to an adult service that provides health as-
sessment according to international guidelines. Sever-
al aspects of these recommendations are controversial:
how to optimize screening evaluations, which cardiac
malformations contraindicate assisted pregnancy, the
best options for hormone replacement therapy and
when to use them, or the evaluation of the influence
of GH. 
It should be highlighted that a small number of stud-
ies of TS patients in adult life have been published.
Furthermore, gynaecologists follow TS women in
adulthood and usually a lack of paediatric data exists,
hindering patient’s complete evaluation. Finally, pa-
tients from different ages have been managed follow-
ing different protocols, due to the improvement of the
prenatal or early diagnosis. This fact hampers the eval-
uation some studies included in the systematic review. 
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Polycystic Ovary Syndrome (PCOS) is the most com-
mon endocrinopathy in women and the most com-
mon cause of anovulatory infertility, affecting 5-10%
of the population.
Infertility is the presenting problem for about 40% of
PCOS patients. If pregnancy is achieved, other repro-
ductive problems, such as miscarriage, emerge.
Approximately 60-70% of PCOS patients are obese,
and it is well known that obesity is associated with in-
sulin resistance. However, PCOS patients have evi-
dence of insulin resistance beyond that of obese
women in the general population. Most studies have
shown that impaired insulin sensitivity is present with-
out obesity; however, any degree of obesity further im-
pairs insulin action.
Insulin resistance is defined as a pathological condi-
tion in which target cells fail to respond to ordinary
levels of circulating insulin. At the molecular level, im-
paired insulin signaling results from mutations or
posttranslational modifications of the insulin receptor
or any of its downstream effectors’ molecules. Insulin
resistance could be accounted for by a defect in insulin
binding to its receptor or to a shortage of insulin re-
ceptors; however, there is recent evidence to suggest
that insulin resistance is most often due to a postbind-
ing defect in insulin action.
Whatever the pathogenesis of insulin resistance, the
resulting hyperinsulinemia is seen as a cause of the
main features of PCOS, namely hyperandrogenism
and anovulation. It was shown that the action of in-
sulin on the ovaries is mediated by inositolglycan me-
diators and is therefore distinct from the insulin-acti-
vated tyrosine phosphate cascade that enhances glu-
cose utilization. This indicates that the pathways of in-
duction of insulin signaling are also separate in the
ovaries and that the action of insulin on steroidogene-
sis is maintained even in cases of insulin resistance.
Hyperinsulinemia may increase androgen production
in PCOS by stimulating the ovaries directly, or indi-
rectly through stimulation of LH secretion and inhibi-
tion of IGF binding protein (IGFBP) and SHBG syn-
thesis and secretion. Finally, insulin may also stimulate
adrenal androgen secretion.
On the basis of the theory that insulin resistance and
hyperinsulinemia may be a relevant contributor to the
pathophysiology of PCOS, it has been hypothesized
that insulin-lowering agents, by reducing hyperinsu-
linemia, might improve endocrine and reproductive
abnormalities with PCOS (Table 1).
There is now a large body of data documenting the clin-
ical efficacy of metformin in the treatment of PCOS-as-
sociated insulin resistance. Metformin is an “old” drug
mainly used to lower blood sugar in NIDDM. Im-
provement in insulin resistance is generally accompa-
nied by an improved metabolic profile, a significant
reduction in hyperandrogenemia, and an improve-
ment in ovarian function and menstrual cycles.
Insulin sensitizer and inositol in the treatment
of infertile PCOS patients
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TABLE 1 - INSULIN-REDUCING ORAL DRUGS.
Oral antihyperglycemic drugs
Solfonilureas Chlorpropamide
Tolbutamide
Biguanides Phenformin (withdrawn for lactic acidosis)
Metformin 500-850 mg, 1-3 times daily
Insulin resistance-reducing agents
Thiazolidinediones (TZD) Ciglitazone (no experience in PCOS) 
Pioglitazone 45 mg daily
Troglitazone 600 mg daily 
Rosiglitazone 4 mg twice daily
Ciglitazone (no experience in PCOS)
The first pharmacological approach to induction of
ovulation in women with PCOS is clomiphene citrate.
About 75% of patients ovulate in response to this
drug, and most do so at a dose of 50 or 100 mg; the
maximum dose is generally regarded as 250 mg/d. The
number of nonresponders is therefore high. These
women are defined as “clomiphene resistant” and are
generally obese and more insulin resistant than re-
sponders. Because increasing obesity is associated with
increasing hyperinsulinemia, the high degree of hyper-
insulinemia in obese women with PCOS may account
for their low responsiveness to clomiphene. 
Presuming that the pathogenetic basis of clomiphene
resistance was hyperinsulinemia, several authors inves-
tigated the effect of metformin therapy on the re-
sponse of PCOS patients to induction of ovulation
with clomiphene. Compared with placebo, metformin
therapy resulted in a more than 10-fold increase in
clomiphene-induced ovulation (90% of women ovu-
lated). 
It has been shown that the risk of ovarian hyperstimu-
lation syndrome in PCOS increases with increasing in-
sulin resistance. This again emphasizes the important
role of insulin as follicle growth factor. 
Based on this concept, a reduction in insulin resistance
by means of metformin therapy was associated with a
more “physiological” ovarian response to exogenous
gonadotropins. Indeed, combined metformin-FSH
therapy was followed by recruitment of fewer follicles
and by lower estradiol levels at the moment of hCG
administration. The percentage of cycles in which
hCG was withheld because of excessive follicular de-
velopment was therefore significantly lower in cycles
treated with metformin. 
In PCOS patients undergoing in vitro fertilization
(IVF)-embryo transfer or intracytoplasmic sperm in-
jection, combined metformin-gonadotropin treatment
has been shown to be better than gonadotropin alone
with recruitment of fewer follicles and lower plasma
concentrations of estradiol. 
Because metformin therapy improves spontaneous
and clomiphene- or gonadotropin-induced ovulation
and conception rates in women with PCOS, the safe-
ty of metformin administration during pregnancy has
to be proven. It is classified as a category B drug,
which means that in vitro studies did not demonstrate
teratogenicity. 
However, a recently published European Society of
Human Reproduction and Embryology/American So-
ciety for Reproductive Medicine (ESHRE/ASRM)
Consensus that addressed the therapeutic challenges of
women with infertility and PCOS has concluded that
metformin, the most widely studied insulin-sensitiz-
ing drug in patients with PCOS, either alone or in
combination with clomiphene citrate (CC), has no ad-
vantage in inducing ovulation in patients with PCOS,
and should be restricted only to those patients with
glucose intolerance.
In addition, a systematic review by Costello et al.
demonstrated that although the co-administration of
metformin to gonadotropin ovulation induction does
not improve ovulation, pregnancy rate (PR), or live
birth rate, it does consistently affect ovarian response
during ovulation induction, with variable effects on
the length of ovarian stimulation, total dose of FSH
used, and peak serum E2 level.
The new thiazolidinediones (rosiglitazone and piogli-
tazone) appear promising for the treatment of insulin
resistance associated with PCOS. However, data are
available only for troglitazone, a drug with high liver
toxicity that was withdrawn from commerce in 2000.
Rosiglitazone and pioglitazone are safer and have
proved effective in improving insulin sensitivity.
Rosiglitazone and pioglitazone are category C drugs
that have been demonstrated to retard fetal develop-
ment in animal studies. Because their use could restore
ovulation and fertility, their presumed embryotoxicity
would limit their use (Table 2). 
The inositol phosphoglycans (IPGs) are putative me-
diators in a nonclassic insulin signaling cascade for
glucose uptake and use. Insulin-resistant women with
PCOS display decreased insulin-stimulated release of
d-chiro-inositol (DCI)-containing IPGs (DCI-IPGs)
during an oral glucose tolerance test (OGTT), com-
pared with control women, which was related to im-
paired coupling between insulin action and the release
of the DCI-IPG.
Oral nutritional supplementation with inositol, part
of the vitamin B complex (B8) and an intracellular
second messenger, was demonstrated to enhance in-
sulin sensitivity and improve the clinical and hormon-
al characteristics of patients with PCOS. In addition,
inositol supplementation was shown to restore sponta-
neous ovulation with the consequent increase in con-
ception, either alone or when combined with go-
nadotropin.
Inositol nutritional supplementation to insulin-resist-
ant patients with PCOS, during a low-dose go-
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TABLE 2 - MECHANISM OF ACTION AND SIDE EFFECTS
OF OTHER INSULIN SENSITIZING DRUGS.
Drug Mechanism of action Side effects
Diazoxide Insulin secretion Hyperglicemia, salt
retention, hyperuricemia,
hot flushes, palpitations
Acarbose Carbohydrate digestion Abdominal discomfort
Somatostatin analogs Insulin secretion Abdominal discomfort
D-chiro-inositol Insulin post-binding signaling Not reported
nadotropin step-down ovulation induction regimen,
produces very good clinical results with a significant
reduction in cancellation rate and the consequent im-
provement in clinical PR.
These observations are in accordance with the well-es-
tablished beneficial effects of inositol on reducing in-
sulin resistance, improving ovarian function, and de-
creasing hyperandrogenism, which are comparable
with those of metformin. Therefore, not surprisingly,
by adding the inositol nutritional supplementation we
were able to achieve a more efficient and less vigorous
ovarian response to gonadotropin. This more delicate
response, as reflected by the significant decrease in the
number of growing follicles, results in the consequent
decrease in cancellation rate and improved PR.
Although the systematic review on metformin co-ad-
ministration during gonadotropin ovulation induc-
tion could not demonstrate any significant improve-
ment in ovulation or PRs, metformin intake is asso-
ciated with a significantly high incidence of gastroin-
testinal disturbance, and its safety throughout preg-
nancy is not yet established (category B drug, accord-
ing to the Food and Drug Administration). On the
other hand, inositol is a nutritional supplementation,
its intake is not associated with any significant side
effects, and its co-administration with gonadotropin
resulted in less vigorous ovarian response and the
consequent decrease in cancellation rate and im-
proved PR.
In summary, adding the inositol nutritional supple-
mentation during the low-dose gonadotropin ovula-
tion induction seems to considerably diminish the
chance of multifollicular development and its conse-
quences. An added value of this protocol is that it has
a very low cycle cancellation rate and produces very
good clinical results with an excellent safety profile.
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Background
Women with Hereditary Non-Polyposis Cancer Syn-
drome (HNPCC), also known as Lynch syndrome, are
carriers of a germline mutation in one of the mismatch
repair (MMR) genes MLH1, MSH2 and MSH6.
Their life-time risk of endometrial and colorectal car-
cinoma is 25-70% and that of ovarian carcinoma it is
approximately 10%. There is also a chance of more
than 10-25% of developing tumors of small intestine,
stomach, renal pelvis, ureter and central nervous sys-
tem (1).
Even the cancer risk of women with Lynch syndrome
is so high, on the basis of the available limited litera-
ture, there are not enough specific studies on primary
prevention and any strict advice for or against sur-
veillance for gynecologic cancers is not evidence
based (2).
Most of the studies that form the basis for the guide-
line recommendations are descriptive and/or retro-
spective in nature, many of them were based on expert
opinion (3). Being a rare disease it is unlikely that ad-
equate powered randomized controlled studies will be
available in the next future thus we tried to use the ex-
isting literature to help this patients prevent gyneco-
logic cancers and diagnose them as early as possible. A
systematic literature search using Pubmed and the
Cochrane Database of Systematic Reviews, reference
lists of retrieved articles and manual searches of rele-
vant articles was performed. We added our experience
of an ongoing specific study at our institute approved
by the Ethics Committee.
Primary prevention
of gynaecologic cancers
Endometrial and ovarian cancer in the general popula-
tion are preventable neoplasm because the majority of
risk and protective factors are modifiable: body
weight, diet, physical exercise,... Obesity increases the
risk while a diet high in fruits and vegetables may low-
er the risk. Physical activity is an understudied but
promising cancer preventive strategy (4). There is evi-
dence that the expression of Lynch syndrome is also
influenced by environmental factors. The genes
known to be involved are MSH2 and MSH6 and the
protein products of these genes help to repair mistakes
made in DNA replication. If they are mutated, the
replication mistakes are not repaired, leading to dam-
aged DNA and cancer. Dietary and lifestyle factors
could thus theoretically modify the risk, but there are
few studies on primary prevention of female cancers
specifically for the Lynch syndrome that confirm that
these high risk patients need to follow the cancer pre-
vention strategies than the general population. The
CAPP studies prove protection for colorectal cancer
only. In the CAPP2 randomised trial, carriers of Lynch
syndrome had a HR of colorectal cancer of 0·63 (95%
CI 0·35-1·13, p=0·12) with 600 mg aspirin per day for
a mean of 25 months (5).
Endometrial cancer (EC)
Women with Lynch syndrome (HNPCC) have a
high risk of developing endometrial cancer (EC):
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up to 70% lifetime risk (43-71%) with an average
+1-2% annual risk in 35-65 age group. EC risk is
about seventy times more than in the general pop-
ulation.
Early diagnosis
The peak EC incidence mean age is 49y (45-50y)
when symptom detection could be more difficult.
Starting age for surveillance of 30-35 years is therefore
advised. On the basis of literature available, no advice
can be provided regarding the age at which screening
should finish. The five-year survival after treatment of
endometrial carcinoma with Lynch syndrome is high,
as it is in sporadic cases, namely >80%.
The efficacy of surveillance by the recommended an-
nual o biannual transvaginal sonography (TVS) with
endometrial biopsy (EB) from 35y age is not estab-
lished. The efficacy of annual endometrial biopsy is
higher than exclusively transvaginal ultrasonography.
Annual surveillance with gynaecological examina-
tion, transvaginal ultrasonography and determination
of the serum tumour marker CA125 in 826 patient
years did not yield any pathological findings in a first
study (6).
An endometrial carcinoma was found in two women
of the previous study during the interval between two
surveillance visits, 6 and 24 months after the last ultra-
sound, because they had vaginal bleeding (7). In an-
other cohort study (8) three premalignant lesions of
the endometrium were detected during transvaginal
ultrasonography. The study period included a total of
197 patient years at risk. One patient developed a
symptomatic interval carcinoma of the endometrium,
stage IIA. 
Ovarian pathology was not detected in either of the
above mentionend cohort studies. In a third study
on the efficacy of gynaecological surveillance (9)
not only transvaginal ultrasonography but also en-
dometrial biopsy was performed. Out of 175 muta-
tion carriers, 759 patient years were evaluated.
Four of the 14 diagnosed endometrial carcinomas
were found by transvaginal ultrasonography. Eight
of the 14 by endometrial biopsy, which also detect-
ed a potential premalignant hyperplasia of the en-
dometrium in 14 patients. Four cases of ovarian
carcinoma occurred during this period, but none of
these were detected during surveillance. In conclu-
sion, two of the three available studies suggested
that surveillance may lead to the detection of pre-
malignant lesions, and one study suggested that it
may also lead to the detection of endometrial can-
cer at an early stage. More prospective studies are
needed to establish the most appropriate screening
protocol. 
Guidelines on endometrial surveillance
LNG IUS (Mirena®)
EC in Lynch syndrome is oestrogen-driven and
progestogens reduce endometrial hyperplasia and EC
risks. Thus when pregnancy is no more need the
intrauterine levonorgestrel system should be the first
choice for reduction of atypical endometrial
hyperplasia (AEH) and endometrial cancer in Lynch
syndrome. The high dose of levonorgestrel (20mcg per
day) locally released by Mirena® reduces endometrial
hyperplasia and it causes the development of a thin
inactive endometrium. It has also been documented to
reduce or reverse atypical hyperplasia and EC
development. This IUS is a widely-used and well-
tolerated contraceptive and it protects for four years
from endometrial hyperplasia in women using
oestrogen replacement therapy (10,11). The POET
trial (Prevention of Endometrial Tumours) is being
developed to explore the possibility of
chemoprevention using the progesterone-releasing
Mirena® intrauterine device for 4 years in reducing the
development of atypical endometrial hyperplasia and
carcinoma in women with hereditary Non-Polyposis
Colorectal Cancer (HNPCC, Lynch Syndrome) aged
35-65y. This trial was approved by or ethics
committee and it is ongoing in our institute. At the
first visit women have a full gynaecological evaluation
with transvaginal ultrasound or hysteroscopy,
endometrial biopsy, and full menstrual history. Those
with complex atypical hyperplasia or cancer will be
treated as clinically indicated. Women with normal
endometrium or simple or complex e non-atypical
Vasen Giudeline 2007, Level 3 (3)
Surveillance by gynaecological examination, transvagi-
nal ultrasound and endometrial biopsy starting from
age 30-35 years may lead to the detection of premalig-
nant lesions and early cancers.
Prophylactic hysterectomy and salpingo-oophorectomy
may be an option for women with Lynch syndrome,
since it substantially reduces site-specific cancers.
IKNL Guideline 2009, Level 3 (1)
(Annual) surveillance by transvaginal ultrasonography
may detect premalignant lesions of the endometrium.
Surveillance is more effective when endometrial biopsy
is also performed.
Despite annual surveillance by transvaginal ultrasonog-
raphy with or without endometrial biopsy, interval en-
dometrial carcinomas still occur. None of the studies,
till now, showes that surveillance improves survival.
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endometrial hyperplasia are randomised for Mirena®
insertion or only surveillance. Mirena® insertion is till
now well accepted and tolerated. Patients are followed
with annual menstrual history, transvaginal ultrasound
and endometrial biopsy. If biopsy is inadequate and/or
endometrial thickness sufficient a hysteroscopic biopsy
is performed. We are following seven patients because
this syndrome is rare and this prevents any statistically
significant conclusion about efficacy on EC by now.
We did not observe any side effect or development
endometrial hyperplasia with Mirena®.
Ovarian cancer (OC)
Lynch syndrome patients have a lifetime risk of ovari-
an cancer of 8-10% (versus a population risk of
1.45%), with younger age at diagnosis: mean 43y vs
59y. The combination of ultrasound with Ca 125 and
new markers like HE4 could improve early diagnosis of
OC and even EC which is particularly challenging in
this high risk population. Ovarian surveillance effec-
tiveness in Lynch syndrome carriers is not to be expect-
ed, at least on the basis of the most extensive literature
regarding the efficacy of this surveillance in BRCA1/2
mutation carriers. 
Prophylactic surgery
The possibility of preventative hysterectomy, includ-
ing both adnexa, should be discussed, particularly in
the case of a laparotomy in a MMR mutation carrier
after child bearing age. Prospective studies regarding
the effects of prophylactic surgery on the incidence of,
and mortality as a result of, gynaecological tumours
with Lynch syndrome and the negative effects of sur-
gical intervention are lacking. 
A retrospective study proposed preventative surgery
(hysterectomy, adnectomy) in MMR mutation carriers
to prevent endometrial and ovarian carcinoma. In a
cohort of 315 women, all mutation carriers, 61 of
whom had prophylactic surgery and were then fol-
lowed up for approximately 10 years. No endometrial
cancer or ovarian cancer developed in those women
who had prophylactic surgery, whereas 33% of women
who did not have surgery developed endometrial can-
cer and 5.5% developed ovarian cancer (12). Patients
candidates for prophylactic hystero-adnexectomy
should be informed of the limits of our current knowl-
edge on the benefit/ risk balance. 
Transvaginal ultrasound plus
Ca 125 and HE4
Transvaginal ultrasound is the most effective, econom-
ical, not invasive way to early diagnose endometrial
and ovarian cancers, but it is not accurate enough to
be sufficient ad the only screening tool for genital can-
cers in Lynch syndrome. HE4 is a new promising can-
cer marker that could be included in the gynecologic
screening because it improves ovarian cancer sensitivi-
ty, if it is combined with Ca 125, more than magnet-
ic resonance imaging (13). HE4 is more specific to dis-
criminate between endometriosis and ovarian cancer
(14). HE4 it is also more sensitive in early-stage en-
dometrial cancer compared to Ca 125 (15).
Hormonal contraceptives
Use of oral contraceptives significantly reduces the risk
of development of endometrial and ovarian carcinoma
for decades. The protective effect increases with the
length of time they are used in the general population
(16). Studies have not been specifically performed in
patients with Lynch syndrome but hormonal contra-
ceptives have many other benefits and an overall good
benefit/risk ratio.
Conclusion and proposal of a screening
protocol for gynecological cancers
Women with a genetic predisposition to Lynch syn-
drome need to be well informed about their risk of en-
dometrial and ovarian carcinoma The consultation
with the gynecologist may also contribute to reduce
endometrial and ovarian cancer by improving lifestyle
in order to act on the main modifiable risk and protec-
tive factors. The same advices could help to improve
the overall health.
Even though it is not jet demonstrated that it im-
proves survival, gynecologic periodical controls can
help Lynch syndrome patients lighten the psycho-
logical burden of the knowledge of the high risk of
gynecological malignancies. Every patient must be
specifically alerted to recognize the early symptoms
of endometrial carcinoma, considering any even
light abnormal vaginal blood loss, leading to a
greater chance that endometrial carcinoma of a low
stage is detected. 
Lynch syndrome patients must be made aware of the
real possibilities and limitations of surveillance. In or-
der to overcome the poor results of the existing screen-
ing guidelines we propose and open to discussion the
following improvements.
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A six month gynecologic control versus the standard
annual is better for this high risk cancer patients be-
cause of the following reasons:
1. the annual o or biannual screening did not demon-
strate to improve survival;
2. all the gynecologic cancers were reported in that in-
terval;
3. endometrial and ovarian cancers have a fast grow-
ing rate;
4. the gynecologic cancer risk is high enough to justi-
fy that.
An annual hysteroscopy and/or sonohysterography in
the perimenopausal period and or in selected higher risk
cases is better than a blind endometrial biopsy because:
1. random or blind endometrial biopsy is not enough
to detect focal endometrial pathology;
2. most of endometrial cancers in Lynch syndrome
patients appear at perimenopausal age (mean 49
years) where bleeding symptoms and endometrial
thickness are unreliable early detection strategies.
HE4 could be proposed as a new promising cancer
marker that could be included in the gynecologic
screening strategies in Lynch cancer patients for the
following reasons:
1. it improves ovarian cancer sensibility if it is com-
bined with Ca 125 and transvaginal ultrasound;
2. it is more specific to discriminate between en-
dometriosis and ovarian cancer;
3. it is more sensitive in early-stage endometrial can-
cer compared to Ca 125.
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Introduction
Dysmenorrhea is one of the most common complaints
in adolescence, but it is frequently underevaluated and
consequently undertreated. Despite endometriosis has
long been considered a disease of adult women, stud-
ies reveal that endometriosis rates in adolescent pa-
tients undergoing diagnostic laparoscopy for second-
ary dysmenorrhea and chronic pelvic pain evaluation,
range from 19% to 75% (1-4). Most adult patients re-
port onset of symptoms even from adolescence. Statis-
tically, the diagnosis is established after a mean of 9.28
years of the onset of symptoms (5-7). Endometriosis
has also been associated with the presence of
uterovaginal anomalies, such as complete transverse
vaginal septum, imperforate hymen and cervical agen-
esis, which in the majority of cases, are diagnosed in
adolescence (8,9).
Clinical presentation
Unlike women of reproductive age with endometrio-
sis,-in which subfertility is the main problem- in ado-
lescents the main symptom that leads them to seek
medical advice is pelvic pain. In most cases (62.6%),
pain is both cyclic and acyclic, while presenting with
acyclic or cyclic pain alone is rare. Other complaints
include: dyspareunia, gastrointestinal or urinary symp-
toms, menstrual disorders and vaginal discharge (2).
In many cases adolescents’ ability to attend and per-
form in school or to participate in social activities can
be impaired, leading to major psychological conse-
quences. Moreover, failure to control pelvic pain may
lead to negative consequences in relationships with the
young girl’s parents, in body image and in self-esteem. 
Evaluation of the patient
Initial investigation of the patient should include a
thorough medical history with specific questions
about the frequency and the duration of the pain, and
its association with bowel, bladder or sexual function.
Inquiries regarding familial history of endometriosis
should not be omitted, as studies have shown that
there might be a genetic predisposition for en-
dometriosis, but this is not a prerequisite for the devel-
opment of the disease (10).
Physical examination should begin with the inspection
of the external genitalia, and the insertion of a cotton-
tipped swab through the hymen, in the vaginal canal
in order to rule out the presence of imperforate hy-
men, low vaginal septum or any other obstructive
Müllerian duct anomaly. Clinical findings in adoles-
cents with endometriosis are different from those of
adults, representing the different stage of the disease.
In adults the uterus is fixed and retroflexed due to ad-
hesions, while in adolescents only mild tenderness
might be evoked during palpation/bimanual examina-
tion. Findings from the ovaries are also rare in this age
group, as endometriotic cysts are found more often in
adults.
Ultrasound imaging is useful in the diagnosis of en-
dometriotic cysts or in cases of deep infiltrating en-
dometriosis, which is rare in this age group. Magnetic
Resonance Imaging (MRI) can be helpful in detecting
reproductive tract anomalies. Finally, CA-125 is a very
sensitive marker of endometriosis but its low specifici-
ty makes it inappropriate as a diagnostic tool. 
The definitive diagnosis can only be set through la-
paroscopy and biopsy. Staging of the disease should be
made according to the guidelines proposed by the
American Society for Reproductive Medicine (ASRM).
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Unlike adult patients who, in most of the cases, have
the classic black/grey “powder burn” endometriotic
implants, adolescents have stage I (77-92%) or stage II
(8-22%) disease with red, white or clear lesions. Pa-
tients with endometriosis due to outflow obstruction
tend to have more extended disease, but remittance is
established as soon as the anatomic anomaly is surgi-
cally corrected (11,12).
Treatment of endometriosis 
in adolescence
Treatment of adolescents with endometriosis should
be focused to: symptom’s relief, the supression of dis-
ease progression and preservation of future fertility.
Options include:
Non-steroidal anti-inflammatory drugs (NSAIDs)
As early stage endometriotic lesions are documented to
secrete prostaglandins, NSAIDs can provide pain relief
in this age group (13,14).
Oral Contraceptive Pills (OCPs)
OCPs are the first line treatment for endometriosis in
adolescence. OCPs have a very low adverse effect pro-
file and are considered safe for long time treatments.
They inhibit endometriotic implant growth by induc-
ing a hypoestrogenic environment, and also alleviate
from luteal-phase symptoms of endometriosis by in-
hibiting ovulation. Continuous use of OCPs is sug-
gested, despite the possibility of breakthrough bleed-
ing (15-17).
GnRH agonists (GnRHa)
GnRHa cause a reversible suppression of the hypothal-
amic-pituitary-ovian axis, thus controlling growth and
bleeding of endometriotic implants. Treatment with
GnRHa has been associated with adverse effects on pa-
tients’ peak Bone Mass Density (BMD) accumulation.
It is recommended that GnRHa should not be admin-
istered in adolescents younger than 16 years old.
Moreover the U.S. Food and Drug Administration
(FDA) has not approved its use for therapy lasting
longer than six consecutive months. Add-back therapy
with norethindrone acetate or with combination of es-
trogens combined with medroxyprogsterone acetate,
can help reducing the adverse effects associated with
the administration of GnRHa and minimize bone
density loss (18-22).
Depot Medroxyprogesterone Acetate (DMPA)
Progestogen-only therapy acts by suppressing go-
nadotropins and causing decidualisation, necrosis and
absorption of functional endometrial implants. Al-
though it has been proved be effective, there are con-
cerns regarding its negative effect on bone mineraliza-
tion. It remains a relatively safe alternative therapeutic
scheme for adolescents who have contraindications or
objections against continuous use of oral contraceptive
agents (23).
Danazol
Danazol creates a hypoestrogenic environment, induc-
ing endometrial atrophy, while also raising androgen
levels and having direct androgenic action. Although it
can provide adequate relief from symptoms, its adverse
effects (weight gain, bloating, decreased breast size, ac-
ne, oily skin and hirsutism), make it an unpopular
therapeutic option for adolescents (24,25).
Surgical treatment
Surgical management has also been proved to be effec-
tive treatment for the disease associated pain in pa-
tients with endometriosis (26). Radical procedures like
oophorectomy and hysterectomy have no place in ado-
lescence, even in patients with severe endometriosis, in
order to preserve fertility. Laparoscopy is generally pre-
ferred. Special knowledge and experience are manda-
tory for the surgeon, who must be familiar with the
appearance of early stage endometriotic lesions that
are commonly found in adolescents. As with surgical
intervention only the visible endometriotic lesions of
the pelvis and the abdomen are removed, while all the
factors (hormonal, genetic and physiologic) that pre-
dispose to endometriosis remain unaltered, recurrence
of endometriosis is certain. As a result, postoperative
hormonal treatment is imperative in order to reduce
the possibility of recurrence. 
Conclusions
Endometriosis is a condition affecting both adult
women and adolescents, but there are significant dif-
ferences in the characteristics of the disease between
these groups. Adolescents usually present in a less ad-
vanced stage with early atypical lesions, while adult
women tend to have classic “powder burn” lesions and
a more advanced stage of the disease. Treatment also
differs between these two groups, as the necessity of
fertility preservation and the immaturity of the skele-
tal system, dictates the use of different therapeutic
schemes. During adolescence, endometriosis should
be diagnosed as soon as possible, so as to avoid the
physical and psychological sequalae of the disease. As
it is a chronic progressive disease, psychological sup-
port should be provided to the girl.
50
51
References
1. Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent
population: The Emory experience. J Pediatr Adolesc Gynecol
1996;9:125-128.
2. Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ.
Prevalence of endometriosis in adolescent girls with chronic
pelvic pain not responding to conventional therapy. J Pediatr
Adolesc Gynecol 1997;10:199–202.
3. Vercellini P, Fedele L, Arcaini L, Bianchi S, Rognoni MT, Can-
diani GB. Laparoscopy in the diagnosis of chronic pelvic pain
in adolescent women. J Reprod Med 1989;34: 827–830.
4. Kontoravdis A, Hassan E, Hassiakos D, Botsis D, Kontoravdis
N, Creatsas G. Laparoscopic evaluation and management of
chronic pelvic pain during adolescence. Clin Exp Obstet Gy-
necol 1999;26:76–77.
5. Houston D. Evidence for the risk of pelvic endometriosis by age,
race and socioeconomic status. Epidemiol. Rev. 1984;6:167-191.
6. Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Comil-
lie FJ. Suggestive evidence that pelvic endometriosisis a pro-
gressive disease, whereas deeply infiltrating endometriosis is as-
sociated with pelvic pain. Fertil Steril 1991;55:759–765.
7. D’Hooghe TM, Bambra CS, Raeymaekers BM, Koninckx PR.
Serial laparoscopies over 30 months show that endometriosis
in captive baboons (Papio anubis, Papio cynocephalus) is a
progressive disease. Fertil Steril 1996;65:645–9.
8. Sanfilippo JS, Wakim NG, Schikler KN, Yussman MA. En-
dometriosis in association with uterine anomaly. Am J Obstet
Gynecol 1986;154:39–43.
9. Deligeoroglou E, Tsimaris P. Menstrual disturbances in puber-
ty. Best Pract Res Clin Obstet Gynaecol. 2010;24(2):157-171.
10. Simpson JL, Elias S, Malinak LR, Buttram VC: Heritable aspects
of endometriosis. Am J Obstet Gynecol 1980;137:327-331.
11. American College of Obstetricians and Gynecologists. En-
dometriosis in adolescents: ACOG committee opinion no.
310. Obstet Gynecol 2005; 105:921–927.
12. Revised American Society for Reproductive Medicine classifi-
cation of endometriosis: 1996. Fertil Steril 1997; 67:817–821.
13. Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-
inflammatory drugs for primary dysmenorrhoea. Cochrane
Database Syst Rev 2003; 4: CD001751.
14. Ylikorkala O, Viinikka L: Prostaglandins and endometriosis.
Acta Obstet Gynecol Scand Suppl 1983;113:105. 
15. Kistner RW. The treatment of endometriosis by inducing
pseudopregnancy with ovarian hormones. Fertil Steril
1959;10:539–556.
16. Miller L, Hughes JP. Continuous combination oral contracep-
tive pills to eliminate withdrawal bleeding: a randomized trial.
Obstet Gynecol 2003;101:653–661.
17. Moore J, Kennedy S, Prentice A. Modern combined oral con-
traceptives for pain associated with endometriosis. The
Cochrane Database of Systematic Reviews 1997, Issue 4. Art.
No.: CD001019. 
18. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide ac-
etate of depot suspension) in the treatment of endometriosis:
a randomized placebo-controlled double-blind study. Fertil
Steril 1990;54:419-427.
19. Kennedy SH, Williams IA, Brodribb J. Barlow DH. Shaw RW.
A comparison of nafarelin acetate and danazol in the treatment
of endometriosis. Fertil Steril 1990; 53(6): 998- 1003.
20. Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright
JK, et al. Timing of peak bone mass in Caucasian females and
its implication for the prevention of osteoporosis: inference
from a cross-sectional model. J Clin Invest 1994;93:799–808.
21. Barbieri RL. Hormone treatment of endometriosis: the estrogen
threshold hypothesis. Am J Obstet Gynecol 1992;166:740–745.
22. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-
back therapy for symptomatic endometriosis: longterm fol-
low-up. Obstet Gynecol 2002;99:709–719.
23. Cromer BA, Bonny AE, Stager M, Lazebnik R, Rome E,
Ziegler J, Camlin-Shingler K, Secic M. Bone mineral density in
adolescent females using injectable or oral contraceptives: a 24-
month prospective study. Fertil Steril. 2008;90(6):2060-2067.
24. Barbieri RL. Evans S, Kistner RW. Danazol in the treatment of
endometriosis: analysis of 100 cases with 4-year follow up. Fer-
ti! Steril 1982; 37: 737-746.
25. Dmowski WP, Cohen MR. Antigonadotropin (danazol) in the
treatment of endometriosis: evaluation of post-treatment fer-
tility and three year follow up data. Am J Obstet Gynecol
1978;130:41.
26. Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. La-
paroscopic excision of endometriosis: a randomized, placebo-
controlled trial. Fertil Steril 2004;82:878-884.
© Copyright 2012, CIC Edizioni Internazionali, Roma
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
52
Introduction
Aging is a process that involves structural and func-
tional alterations in all organs of the human body. The
aging of gonads, to be precise, represents a particular
case, because these organs are not exactly essential for
the function of the rest of the body. 
For what concerns women, menopause is the final step
in the process defined ovarian aging, which is directly
related to the exhaustion of ovarian follicles. Testicular
endocrine function, in contrast, begins during embry-
onic stages, is interrupted between birth and puberty,
and continues from then on, along with spermatogen-
esis, with only slight decline in the old age (1). 
The current knowledge of female reproductive aging
has wide limitations: we are aware of the crucial role of
ovarian changes in this process, where the continuous
decrease in the number of follicles present in the ovar-
ian cortex and their final depletion dictate the onset of
cycle irregularity and the final cessation of menstrual
cycle. As a matter of fact, when a woman reaches
menopause, her follicular supply consists of about a
thousand or less follicles, a number that is insufficient
to sustain the cyclic hormonal variations necessary for
menstrual cycle (2). Moreover, most of the numerous
theories trying to explain aging highlight the concept
that age-related dysfunctions might, at least partially,
come from all the irreversible damages that physiolog-
ically accumulate during a cell’s lifespan, as an un-
avoidable side effect of normal metabolism (3).
Endocrine changes are triggered by the decline in the
negative ovarian feedback at the hypothalamo-pitu-
itary unit, which causes alterations in the neuroen-
docrine control of cyclic ovarian function, such as the
increase in serum FSH levels in the early follicular
phase (4-5). This event may accelerate the depletion of
the ovarian follicular reserve (6), by selecting ovarian
follicles that would otherwise be excluded, at the ex-
pense of fertility (7) However, FSH increase begins
late in the series of events that characterize aging, so it
cannot be the sole responsible of the decline of oocyte
quality associated with age. Even though the process of
loss of follicles in the ovary begins at a relatively early
stage of life, it is only when cycles lose its regularity
that women notice the signs of the ongoing reduction
of reproductive function. 
Current knowledge and 
future challenges
Several studies in literature show that the number of
follicles declines at a steady rate of 1000 follicles per
month, from the mean age of 30 years onward, with
large individual variation (8,9). Obviously, hormonal
changes are not sufficient to explain the many-sided
process of ovarian aging, especially because of their late
occurrence. Thus, these variations may relate to possi-
ble differences between genetic preprogramming of
germ cells during foetal life, damage of oocytes in the
course of a woman’s life, aberrant function of individ-
ual “meiotic clock”, or changes in the functionality of
the granulosa cells surrounding the oocyte. The role of
the somatic compartment in the process of follicular
aging has been highlighted by studies showing the
ability of aged cumulus cells to facilitate the activation
of apoptosis in the oocytes by means of specific factors
such as ceramide, a sphingolipid second messenger in-
volved in cellular senescence (10,11).
Thus, female reproductive aging is defined as a process
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that increasingly reduces monthly fecundity (the abil-
ity to have a viable embryo implanted) after the age of
30 years (8).
The parallel decline in oocyte quality, next to quanti-
ty, is expressed by the observation of an increasing risk
of aneuploidy and spontaneous miscarriages, and con-
tributes to the gradual decline in female fertility with
aging and the final occurrence of natural sterility
(8,12). Recent researches have focused on the concept
that oocytes coming from follicles selected in advanced
reproductive age own reduced chances of achieving a
level of nuclear and cytoplasmic maturation that,
along with their increased apoptotic potential, make
them less suitable for fertilization and subsequent em-
bryo development (13).
The declining cohort of antral follicles with age firstly
leads to a gradual elevation of FSH levels (14). At the
same time, the gradual decline in the number and
function of granulose cells of the antral follicle cohort
is best represented by decreasing levels of anti-Müller-
ian hormone (AMH). This endocrine factor, mostly ex-
pressed by granulosa cells of primordial growing follicle
pool, is considered a sensitive marker of ovarian reserve
and, probably, of the earlier steps of aging (15,16).
Antral follicle count (AFC), last but not least, repre-
sents the imaging corresponding of the remaining pool
of antral follicles in the ovarian cortex, and it is evalu-
ated by ultrasound, with a transvaginal probe.
AFC and AMH are considered the best markers of the
ovarian reserve, but their predictive value is limited,
and the true impact of routine ovarian reserve testing
(ORT) on the clinical management of ovarian aging
remains to be demonstrated (17).
Development of reliable tests for the identification of
women with a reduced reproductive life span is likely
to come from combining endocrine, imaging and, es-
pecially in view of the high heritability of age at
menopause, genetic informations. Recent studies have
identified several interesting loci of small genetic vari-
ation that may determine foetal follicle pool develop-
ment and subsequent decrease of this pool over time. 
Furthermore, recent observations in both animal mod-
els and humans have demonstrated that aging may im-
pede the collection of maternal RNAs required for the
normal physiology of the oocyte, and subsequently
used during early embryonic stages (18). The different
genes expressed are involved in mitochondrial func-
tion and in the assembly of an efficient antioxidant en-
zymatic defence, as well as in a variety of functional
processes, including cell cycle control, cytoskeletal
structure, metabolic pathways, transcription regula-
tion and stress responses (19). 
However, at present it is generally accepted that aging
is a result of both inborn and environmental factors
(20). In fact, many environmental and life style factors
have been suggested to affect age at natural
menopause, but only cigarette smoking has been un-
equivocally proven to be related with the age at
menopause. However, there is no single factor that
consistently explains the variation in menopausal age,
and, in short, environmental factors have been esti-
mated to play only a minimal role in the process.
At the same time, the follicular microenvironment is
considered extremely important for ovarian aging. The
availability of an adequate vascular support, represent-
ed specifically by a sufficient ingrowth of capillaries in-
to the theca, is essential for maintaining the correct
physiology of follicular growth and selection (21,22).
In this respect, it has been reported that an impaired
vascularization may have crucial effects on follicle de-
pletion, leading to reduced oxygen, hormonal and nu-
tritional supply to the leading follicle. Reduced oxygen
amount might ultimately trigger a condition of oxida-
tive stress, even if knowledge of the exact role of ROS
in ovarian aging is still conflicting (13). Despite the
fact that the reasons and the mechanisms of potential
age-related decline in ovarian follicle vascularity need
still to be clarified, the presence of elevated levels of
VEGF along with reduced blood flow in the follicular
microenvironment of aging ovaries suggests that, in
order to compensate for increasing hypoxia, granulosa
and theca cells begin to produce VEGF, which never-
theless apparently fails in its attempt (24).
Another important aspect of ovarian aging is that the
older a woman is, the higher her risk for developing
ovarian cancer (21). The majority of sporadic ovarian
cancers are diagnosed in women after menopause, al-
though women with genetic or familiar risk factors
tend to get ovarian cancer at a slightly younger age.
Only the 10-20% of ovarian cancers is diagnosed in
women under age 40: as a consequence, it seems clear-
ly ever more important to follow women in this peri-
od of life for their reproductive health (25).
Thus, improved knowledge of the ovarian aging
process may ultimately provide strategies for prediction
of menopause and manipulation of the early steps of
follicles selection for cancer prevention, contraception
purpose and fertility lifespan lengthening ambitions.
By now, we can only suppose that ovarian aging may be
the product of the prolonged exposure of follicles to
subtle oxidative damage, which irreversibly accumulate
during a woman’s reproductive life, gradually affecting
vascular supply and promoting the accumulation of
ROS in the ovarian microenvironment (19).
The real issue for ORT lies in the capacity of identify-
ing women with a shorten fertility life span at such an
early stage that adequate measures can be adopted. As
menopause and the preceding decline in fertility seem
to be related by a fixed time interval, if age at
menopause could be adequately predicted, then any
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young woman might be tested for her reproductive ex-
pectations. 
By now, we appreciate that poor response to go-
nadotropin stimulation in assisted reproductive tech-
nologies (ART) is associated with a shorten reproduc-
tive lifespan. Our present possibility consists in combin-
ing reproductive outcomes at ART and other parame-
ters with genetic tests and possible lifestyle modifica-
tions (such as weight reduction, smoking cessation) to
make an assessment of the individual reproductive aging
and reproductive expectations (26). In the future, the
study of ovarian aging should deal with a multidiscipli-
nary approach, with a strong interaction between bio-
logical and clinical research, leading to an elucidation of
the effect of aging on ovarian and follicular vasculariza-
tion and to a clear explanation of the role of oxidative
stress in the pathophysiology of the female gametes.
Conclusions
In conclusion, the need the for an efficient and safe
treatment of menopausal symptoms represents a great
challenge to the healthcare system (27). Nevertheless,
the decline in female fertility that takes place about
10-15 years earlier is less obvious and more complicat-
ed to predict, and ART cannot completely replace fe-
male reproductive function in many instances of re-
duced fertility (28). 
With the modern trend of Western countries of post-
poning pregnancies often in the late 30s, the impor-
tance of understanding the onset of ovarian senescence
and its regulation is becoming increasingly important:
notwithstanding the recent progresses of science, the
challenge is still on.
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PCOS is a common endocrinopathy that affects about
5-10% of women of reproductive age, irrespective of
the ethnic background, and typically manifests during
adolescence. It is classically characterized by features of
anovulation (amenorrhea, oligomenorrhea, menstrual
irregularity) combined with symptoms of androgen
excess (hirsutism, acne, alopecia) (1-3). 
Over the past years, research has supported the key
role of insulin resistance and associated hyperinsuline-
mia in the pathogenesis of PCOS and thus, in the de-
velopment of its associated metabolic co-morbidities,
including dyslipidemia, the metabolic syndrome, type
2 diabetes and cardiovascular disease, as well as repro-
ductive co-morbidities, such as gestational diabetes
mellitus and pre-eclampsia (4-6). Accordingly, PCOS
is nowadays viewed as a variant of the metabolic syn-
drome (7) and interventions aim at improving insulin
sensitivity, at attenuating visceral adiposity, low-grade
inflammation, dyslipidemia and dysadipocytokine-
mia, and at lowering carotid intima-media thickness
(IMT).
In non-obese adolescents with androgen excess and
without pregnancy risk, a low-dose combination of
flutamide (Flu, an androgen-receptor blocker) and
metformin (Met, an insulin-sensitizer) proved superi-
or to a drospirenone-oral contraceptive (OC) in cor-
recting the endocrine-metabolic and body-composi-
tion anomalies (8). In young PCOS women receiving
OCs, the addition of low-dose pioglitazone (Pio, 7.5
mg/d) to the FluMet combination further increased
lean body mass and circulating HMW-adiponectin,
and further reduced IMT (9). 
Recently, we compared the effects of low-dose
PioFluMet to those of an OC containing
ethinylestradiol-cyproteroneacetate. Both reduced
the androgen excess similarly, but had divergent ef-
fects on low-grade inflammation, on adipokines and
on body adiposity, all of those effects being to the ad-
vantage of PioFluMet (Fig. 1) (10). 
Genetic variants appear to influence the response to
therapy; more specifically, they may modulate the effi-
cacy of metformin. For example, genetic polymor-
phisms in the serine-threonine-kinase (STK11) that
catalyses the activation of AMPK in the liver and in the
gene encoding for the organic cation transporter 1
(OCT1), and the length of the pentanucleotide repeat
in the sex hormone-binding globulin (SHBG) gene and
of the CAG repeat in the androgen receptor gene (11).
In conclusion, a novel low-dose combination of in-
sulin sensitizers plus an anti-androgen holds potential
as a pathophysiology-based treatment of androgen ex-
cess in young girls. Such combination may avoid that
those young girls, who are not at risk of pregnancy,
are nevertheless exposed to supraphysiological doses
of estrogen. The efficacy and safety of PioFluMet re-
main to be studied over the longer term and in larger
cohorts.
References
1. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S,
Escobar-Morreale HF. A prospective study of the prevalence
of the polycystic ovary syndrome in unselected Caucasian
women from Spain. J Clin Endocrinol Metab 2000;85:
2434-2438. 
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES,
Yildiz BO. The prevalence and features of the polycystic ovary
syndrome in an unselected population. J Clin Endocrinol
Metab 2004;89:2745-2749.
3. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes
(London) 2008;32:1035-1041. 
Treatment of Polycystic Ovary Syndrome (PCOS)
in non-obese adolescents
IBÁÑEZ L.
University of Barcelona, Spain
56
4. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B,
Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N. Oxidised
low-density lipoprotein concentration - early marker of an al-
tered lipid metabolism in young women with PCOS. Eur J
Endocrinol 2006;155:131-136.
5. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glu-
cose tolerance, type 2 diabetes and metabolic syndrome in
polycystic ovary syndrome: a systematic review and meta-
analysis. Hum Reprod Update 2010;16:347-363.
6. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH,
Fauser BC, Macklon NS. A meta-analysis of pregnancy out-
comes in women with polycystic ovary syndrome. Hum Re-
prod Update 2006;12:673-683.
7. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX?
Trends Endocrinol Metab 2003;14:365-370.
8. Ibáñez L, de Zegher F. Low-dose flutamide-metformin ther-
apy for hyperinsulinemic hyperandrogenism in non-obese
adolescents and women. Hum Reprod Update 2006;12:
243-252.
9. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, del Río L,
de Zegher F. Low-dose pioglitazone and low-dose flutamide
added to metformin and oestro-progestagens for hyperinsuli-
naemic women with androgen excess: add-on benefits dis-
closed by a randomized double-placebo study over 24 months.
Clin Endocrinol (Oxf ) 2009;71:351-357.
10. Ibáñez L Diaz M, Sebastiani G, Sánchez-Infantes D, Salvador
C, Lopez-Bermejo A, de Zegher F. Treatment of androgen ex-
cess in adolescent girls: ethinylestradiol-cyproteroneacetate
versus low-dose pioglitazone-flutamide-metformin. J Clin En-
docrinol Metab 2011;96:3361-3366.
11. Díaz M, López-Bermejo A, Sánchez-Infantes D, Bassols J, de
Zegher F, Ibáñez L. Responsiveness to metformin in girls with
androgen excess: collective influence of genetic polymor-
phisms. Fertil Steril 2011;96:208-213.e2.
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The concept of adult stem cells mediating cyclic en-
dometrial regeneration is increasingly accepted. About
2% of endometrial cells display the ‚side population’-
phenotype, a surrogate stem cell marker based on the
expression of multidrug-resistance-proteins such as
MDR1 or ABCG2 (1). Additional evidence for stem
cell activity is provided by the expression of stem cell
markers in the endometrium, including the pluripo-
tency-associated transcription factors OCT-4, SOX2,
NANOG and KLF4, of mesenchymal (CD73, CD90,
CD105, CD146) and endothelial progenitor cell
markers (CD31, CD34, CD144) as well as addition-
al adult stem cell markers such as Notch-1 and Msi1
(2-5). Endometrial stem cells have been isolated and
differentiated in vitro into cell types of osteogenic, adi-
pogenic, chondrogenic, and myogenic lineages,
demonstrating high developmental plasticity resem-
bling mesenchymal-stem-cell like properties (6-9)
(Fig. 1). In Xenograft-studies, these cells were capable
of generating endometrial tissue in vivo (1,2,8). At
least a part of endometrial stem cells may originate
from the bone marrow, as demonstrated by reconstitu-
tion experiments in humans and mice (10-12). How-
ever, it is not clear if these cells are the sole source of
endometrial stem cells, as different stem cell pools ap-
pear to exist, based on differences in surface marker
expression and clonal colony formation assays (1-9).
Although the basalis may be the main location of en-
dometrial stem cells, these cells can also be obtained
from more superficial layers by low invasive tech-
niques and from menstrual blood, opening new diag-
nostic and therapeutic perspectives (2,3,9,13,14).
From an endocrinological perspective it is noteworthy
that endometrial stem cells express no or very little es-
trogen receptors. This has been demonstrated for slow
cycling murine label retaining cells (15,16), for human
endometrial side population cells (2) and for human
endometrial mesenchymal stem cells (17). Neverthe-
less, indirect estrogenic stimulation appears to occur
via estrogen-receptor positive cells in the stem cell
niche, which may secrete cytokines capable of modu-
lating stem cell behaviour in an estrogen-dependent
manner (15,16). 
Several lines of evidence suggest an involvement of
dysregulated stem cell activity in the pathogenesis of
endometriosis. Besides the presence of stem cells in
menstrual blood (13,14), which may be ectopically
distributed by retrograde menstruation, the mono-
clonal origin of some endometriotic lesions (18) and
the long-term culturing properties of cells derived
from endometriotic lesions (19) served as early indica-
tors for the potential presence of stem cells in en-
dometriosis. Noteably, increased numbers of putative
endometrial stem cells expressing the stem cell mark-
ers Msi1, Sox2, Oct4 and c-kit have been detected in
endometriotic tissue compared to healthy endometri-
um, suggesting an involvement of stem cells in the
pathogenetic process (3,5,20). At the functional level,
it could be demonstrated that ectopic endometrial
Stem cells in endometrium and in endometriosis
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mesenchymal stem cells display invasive behaviour
both in vitro and in a mouse model (21). The dysreg-
ulated stem cell activity in endometriosis suggests that
an induced differentiation of stem cells may be a
promising therapeutic approach in addition to the use
of stem cell markers for diagnostic purposes (3,22).
Moreover, therapeutic applications utilizing endome-
trial stem cells reach far beyond the field of Gynecolo-
gy and Obstetrics: The high endometrial expression
levels of pluripotency factors (5) facilitate the genera-
tion of induced pluripotent stem cells from endome-
trial tissues (23,24). Overall, research on endometrial
stem cells forms a base for the development of novel
therapeutic approaches including an in vitro differen-
tiation of endometrial stem cells into contractile car-
diomyocyte-like cells (13), dopaminergic neurons (25)
or insulin-producing cells (26,27), which have already
been successfully applied in animal models of myocar-
dial infarction, Parkinson’s disease and diabetes, re-
spectively. The encouraging data generated in these ex-
perimental disease models provide novel perspectives
for the future treatment of female patients with autol-
ogous endometrial stem cell-derived regenerative cells,
overcoming the hindrance of immune rejection associ-
ated with heterologous cellular treatment approaches. 
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Introduction
Placental tissues contain a heterogeneous population
of cells, including villous cytotrophoblasts, syncy-
tiotrophoblasts and extravillous trophoblasts (EVTs).
The human early placenta is characterized by the inva-
sion of EVTs to the decidua, leading to direct contact
between EVTs and maternal blood. EVTs are mainly
uninuclear cells comprising all the trophoblastic ele-
ments located outside the villi. EVT has two distinct
phenotypes, proliferative and invasive. The activity of
the invasive EVTs is dependent on its apoptotic capac-
ity and less on its proliferative potential. Apoptosis is
an important determinant in regulating placental
growth. Actually, apoptosis is more evident in the in-
vasive EVTs than its proliferative counterpart and the
extent of apoptosis is associated with augmented Fas
and Fas ligand expression and reduced Bcl-2 protein
expression (1). The controlled invasion of EVTs into
the decidua is an essential process for early placental
development and the maintenance of early pregnancy.
Nevertheless, the molecular mechanism involved in
EVT invasion to the decidua has been poorly under-
stood. 
In this paper, the vital roles of progesterone (P4) and
3, 5, 3’-triiodothyronine (T3) in the regulation of in-
vasive potential of EVTs in early placental development
are summarized on the basis of our recent studies.
Progesterone in the regulation 
of the invasion of EVTs
Clinically, progesterone (P4) is used in the treatment
of threatened abortion, prevention of recurrent mis-
carriage and in the luteal support in assisted reproduc-
tion program. However, little is known about the mo-
lecular mechanism of P4 in the regulation of EVTs
function. Thus, in order to evaluate the effects of P4
on apoptosis in EVTs, we first examined the presence
of progesterone receptor (PR) protein in the human
trophoblast-derived HTR-8/SV neo cells, which is a
possible model of human EVTs (2), and then deter-
mined the effects of P4 on the expressions of Fas,
Fas-L, Bcl-2, caspase-3 and cleaved poly (ADP-ri-
bose) polymerase (PARP) in those cells. 
The HTR-8/SV neo cells were cultured in RPMI
1640 medium supplemented with 10% fetal bovine
serum. When the cell population reached 50% conflu-
ence, the cells were stepped down to serum-free condi-
tions in the presence or absence of graded concentra-
tions of P4 (1, 10 and 100 ng/ml) for 48 h.
Immunocytochemistry and western blot analyses re-
vealed that PR-A and PR-B are present in HTR-8/SV
neo cell line, which is a possible model of EVTs, and
that treatment with P4 (10 ng /ml) inhibits apoptosis
in the EVT cells by down-regulating Fas, Fas-ligand,
caspase-3 and PARP expression as well as up-regulat-
ing Bcl-2 expression in those cells (2). It seems that P4
may promote the invasion of EVTs to the decidua by
inhibiting apoptosis of EVTs. This may explain the
mechanism of the usefulness of P4 in the treatment on
threatened abortion. 
Thyroid hormone in the regulation 
of the invasion of EVTs
In clinical practice, maternal thyroid hormone defi-
ciency has been implicated in early pregnancy loss, in-
The role of progesterone and thyroid hormone in trophoblast invasion
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dicating that thyroid hormone is vital for the mainte-
nance of early pregnancy. It is known that T3 plays a
crucial role in the maintenance early pregnancy
through the induction of endocrine function in villous
trophoblasts. The effects of T3 on EVTs, however, re-
main to be elucidated. 
To investigate the possible role of T3 in the regulation
of EVT invasion to the decidua, we have examined
whether T3 affects EVT invasive potential and the ex-
pression of matrix metalloproteinase-2 (MMP-2),
MMP-3, tissue inhibitor metalloproteinase-1, fetal fi-
bronectin (FN), and integrin α5β1 in cultured early
placental EVTs. Isolation and purification of tro-
phoblasts differentiating into EVTs were performed by
the enzymatic digestion of the anchoring chorionic
villi, with the use of human FN-precoated culture
dishes and FN-precoated Matrigel Transwells. The
cells attached to the dishes were subcultured in
DMEM supplemented with 10% fetal bovine serum
for 48 h and were characterized by immunocytochem-
ical analysis for specific EVT markers. Thereafter, the
cultured cells were stepped down to a 4% fetal bovine
serum condition and cultured in the presence or ab-
sence of graded concentrations of T3 (10–7 to 10–9M)
for the subsequent 72 h.
Using FN-coated dishes and FN as a molecular glue of
early placental EVTs, we successfully established a pri-
mary invasive EVT culture system. The cells attached
to the FN-coated dishes were immuno-positive for cy-
tokeratin 7, hPL and ErbB2, but immuno-negative for
ErbB2, confirming that the cells are EVTs. RT-PCR
and immunocytochemical analysis confirmed that T3
receptor mRNA (a 212-bp c-erb A‚1 transcript) and
protein are present in early placental EVTs (3). 
In cultured early placental EVTs, treatment with T3
(10-8 M) reduced the expression of Fas and Fas-ligand
as well as the cleavage of caspase-3 and PARP and sup-
pressed apoptosis in those cells (3). Furthermore, Ma-
trigel invasion assay revealed that T3 treatment re-
markably increased the number of cell projections of
EVTs over the membrane of Matrigel. Consistently,
T3 treatment increased the expression of MMP-2, -3,
fibronectin (FN) and integrin α5β1 mRNA in the cul-
tured EVTs (4). These findings suggest that T3 pro-
motes the invasion of EVTs to the decidua by sup-
pressing apoptosis and by up-regulating the expression
of MMPs and integrin in early placental EVTs. This
may explain the mechanism of thyroid hormone for
the vital role in maintaining early pregnancy (5). 
Conclusion
In conclusion, we have provided evidence that PR and
thyroid hormone receptor exist in early placental
EVTs and that both P4 and T3 promote EVT invasion
to the decidua by suppressing apoptosis of EVTs and
by.augmenting the expression of integrins and MMPs
in those cells. This may explain, at least in part, the
crucial role of an adequate supply of progesterone and
thyroid hormone in the maintenance of early pregnan-
cy and suggest the implication of maternal proges-
terone and thyroid hormone insufficiency in early
pregnancy loss. 
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Introduction
The main fear of the women treated with estrogens
remains breast cancer. For this reason main focus of
research on hormone therapy is put on this disease,
regarding clinical studies as well as experimental re-
search, which also is included in several extensive
collaboration projects between the university
women’s hospital of Tuebingen, Germany, and uni-
versity women’s hospitals of Beijing and Shanghai,
China. First results of our research on the impor-
tance of the choice of progestogens for the risk of
breast cancer using HRT we recently published else-
where (1-5). In the present review we summarize
particularly our view, including own research, on the
importance of estrogen metabolites on possible car-
cinogenesis.
The World Health Organization (WHO) has classi-
fied estrogens and estrogen/progestogen combinations
as ‘carcinogenic’ (6) although this statement has not
been accepted from societies like the International
Menopause Society and International Society of Gy-
necological Endocrinology (7,8). Regarding mecha-
nisms for a possible increase of breast cancer risk, two
main pathways are discussed: 1) increased prolifera-
tion and/or 2) development of carcinogenic estrogen
metabolites. 
Experimental research never can replace clinical stud-
ies, however, can evaluate the mechanisms of actions.
Results of clinical studies so far suggest that estrogens
indeed could be “carcinogenic”, but also “carcinopro-
tective action” should not be excluded, which is ob-
vious derived from the only placebo-controlled clini-
cal endpoint study performed on this issue.
Carcinogenesis with estrogens
in view of clinical studies
The Women’s Health Initiative (WHI) is the only
available double-blind placebo-controlled study on the
issue of breast cancer risk using HRT, and demonstrat-
ed, that this risk during combined estrogen/progestin
therapy is real if women are treated more than five
years (Hazarad Ratio, HR 1.24; 95% CI 1.01-1.54)
(9). In contrast in the estrogen-only arm of WHI no
increase but rather a reduction of breast cancer risk
was evaluated (10) In women compliant to estrogen
treatment there was even a more than 30% significant
reduction in the risk of breast cancer (HR 0.67: 95%
CI 0.47-0.97) (11). This result indicates a negative ef-
fect of progestogens concerning the breast cancer risk,
whereby this risk might be dependent on progestogen
type and dosis, which is one of the main topics of the
research on breast cancer risk and hormones (4).
But also with estrogen-only treatment an increased risk
should not be excluded. At least 20 observational stud-
ies with estrogen-only therapy or with not well-de-
fined regular progestogen addition (as often usual in
the earlier years) have demonstrated an increased risk,
as published by the Oxford Collaborative Group with-
in a large reanalyses of 51 studies (12), although the
results of these studies until today are under controver-
sial debate (13). For example the latest evaluation of
the Nurses Health Study, the most famous observa-
tional study with HRT, demonstrated no risk during
15 years of treatment but thereafter a significant in-
crease for breast cancers although the patient sample of
this subgroup with long estrogen-only treatment was
very small (14). However, derived from clinical stud-
Are estrogen metabolites carcinogenic?
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ies, it seems very clear that the main risk of breast can-
cer must be attributed to the progestogen component
of HRT. 
Carcinoprotection with estrogens –
can this be plausibel?
The primarily unexpected protection from breast can-
cer by using estrogen-only therapy recently has been
confirmed by further evaluations of the WHI data
(15). Discussing this result, the WHI investigators do
not argue for a statistical effect by chance but are dis-
cussing plausible mechanisms for this, like proaptotic
estrogen effects especially after longer withdrawal of
endogenous estrogen production (‘gap hypothesis’)
(11,15,16). Another explanation might be, that estro-
gens can be metabolized to carcinoprotective sub-
stances like 2-methoxy-estradiol, as discussed below. 
Different results in clinical studies using estrogen-on-
ly in postmenopausal women (showing increase, but
also decrease of breast cancer risk) may be explained
that the netto effect evaluated in statistical analyses is
dependent on the population tested in the study: if
more women are able to inhibit proliferation of preex-
isting cancer cells before the cancer is diagnosed clini-
cally, the statistical evaluation will calculate a decrease
of risk, if more women are not, the result will be an in-
crease. 
Carcinogenicity needs
increased proliferation
The question for a causal relationship to breast cancer
involves the production of new cancer cells followed
by increased and long proliferation up to clinical de-
tectable breast cancer. Own research suggest that the
proliferating effect of estrogens (without addition of
progestogens) is low compared to the effects of stromal
growth factors (17). With estrogens-only there is no
proof of inducing new cancer cells due to increased
proliferation followed by errors in reduplication and
mutation but this might be possible together with
apocrine effects induced by strong-proliferating stro-
mal factors like insulin growth factor, epithelial
growth factor etc (17). Although by cooperative effects
between estrogens and stromal factors the DNA repair
can be hampered due to strongly increased prolifera-
tion rate, a whole battery of mechanisms can work to
protect from reduplication errors (17,18).
Regarding carcinogenesis by stimulating already preex-
isting malignant breast cell proliferation, the additon
of progestogens is most important, because certain
progestogens can increase the cell proliferation rate
which could lead in shorter time to clinical cancer as
discussed on the basis of recent own investigations
elsewhere (4,5).
Main pathways of estradiol metabolism
The nomenclature of hydroxy-estrogen metabolites
and enzymes of of the cytochrome P450 family in-
volved in this metabolism is shown in Figure 1. The
main primary metabolites formed by A-ring metabo-
lism are 2-hydroxy-estrone and 4-hydroxy-estrone,
and by D-ring metabolism 16-alpha-hydroxy-estrone
and estriol (Fig. 2a). Most primary estrogen metabo-
lites undergo an additional degradation step by conju-
gation, either by glucuronidation, sulfation, or methy-
lation (19).
Estradiol metabolites are not, as was previously as-
sumed, inactive metabolic products destined for excre-
tion, but may have important functions to fulfil. One
such function seems to be the maintenance of home-
ostasis in the cardiovascular system, as demonstrated
in several studies and also work of our own (20). In the
context of the discussion on the “carcinogenic” prop-
erty of estrogens it is becoming more and more evi-
dent that certain estradiol metabolites produced in
secondary metabolic reactions also can influence car-
cinogenesis. 
Currently research focuses on the possible carcino-
genic estrogen metabolites which can be produced by
secondary metabolism as shown in Figure 2b, where
especially the 4-hydroxy-estrogens and 16-alpha-hy-
droxy-estrone may be precursors for toxic quinones
(21). On the other hand there is a potent anticancero-
genic estradiol metabolite, i.e. 2-methoxy-estradiol.
This metabolite may counteract possible procarcino-
genic activities of other estradiol metabolites and the
individual metabolite pattern might be decisive for
carcinogenesis. 
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Fig. 1 - Nomenclature of steroid ring, 17ß-estradiol-hydroxy-metabolites
and main metabolizing enzyme of cytochrome P450 family.
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Table 1 summarizes the most important estradiol
metabolites and their main biological activities derived
from experimental research.
Newer investigations indicate that local estradiol me-
tabolism particularly may have a high biological signif-
icance (22). Measurements in tissues, blood or urine
may reflect such local changes, and are subject to inten-
sive research which can be conducted only in a few spe-
cialised groups due to the highly sophisticated labora-
tory methods needed. The measurement of metabolites
may achieve more significance in the near future, due
to the new possibility to measure even small concentra-
tion changes in the systemic circulation. 
4-Hydroxy-estrogens
The 4-catechol-estrogens can stimulate growth of
the human breast cancer cell line MCF-7; the effect
of 4-hydroxy-estradiol is stronger than that of
4-hydroxy-estrone (23). In tumour models in ham-
sters, rats, and mice, the 4-hydroxy-estrogens have car-
cinogenic effects leading to kidney tumours in ham-
sters, and to liver tumours in rats and mice (24). They
are relatively unstable, i.e. they can be transformed in-
to highly reactive quinones (25). Adducts of DNA
with 4-hydroxy-estrogen-quinones are unstable DNA
compounds, which lead via depurination to destruc-
tion of the DNA including oxidative processes, lead-
ing to DNA strang breaks and to mutations. 
Elevated 4-hydroxylase enzyme activity has also
been found in human breast cancer specimens (26).
4-hydroxy-estradiol was found in high concentrations
in human breast cancer tissues (27,28). in addition,
concentrations of quinones were significantly higher
in the cancer tissue as compared to control tissue
(28). Animal experiments showed a mutagenic effect
of 4-hydroxy-estradiol-quinones (29,30).
Importance of “2/16 ratio of 
Hydroxy-estrogens” for carcinogenesis?
Observational trials have demonstrated that the ratio of
2- to 16-alpha-hydroxy-estrone (2-OHE1/16-OHE1)
is decreased in women with breast cancer. However,
existing studies have had different designs, have been
conducted in different populations, and some have ex-
tremely small sample sizes. Thus their results are in-
consistent, with some showing a strong inverse associ-
ation of increasing levels of the 2-OHE1/16-OHE1
ratio with breast cancer (31,32), some showing a mod-
Fig. 2a - Primary A-ring and D-ring estradiol metabolism.
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Fig. 2b - Secondary estradiol metabolism producing active toxic metabolites.
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TABLE 1 - MAIN PROPERTIES OF BIOLOGICAL ACTIVE
ESTRADIOL METABOLITES.
4-Hydroxyestrone, 4-Hydroxyestradiol
• carcinogenic in animal models
• formation of quinones with a long half-time
• proliferative in human mammary tumor cells 
• slow inactivation by methylation (COMT)
2-Hydroxyestrone, 2-Hydroxyestradiol
• not carcinogenic in animal models
• formation of quinones with a short half-time
• antiproliferative in human mammary tumor cells
• rapid inactivation by methylation (COMT)
2-Methoxyestradiol
• strong antiproliferative effect on various tumor cells
• potent inhibition of neoangiogenesis high potency to capture radicals
16alpha-Hydroxyestrone
• increase of incidence of mammary tumors in the mouse
• mutagenic effect on target cells by DNA-adducts 
• proliferative effect on tumor cells
• higher concentrations in tumor tissue of the breast
• metabolism to estriol or end product
2-Hydroxyestron : 16a-Hydroxyestron
Decrease: DMBA, pesticides, nutrition (high fat, low fibers), neoplasia
Increase: sports, nutrition (low fat, high fibers), isoflavones, 
indole-3-carbinol
est association (33-36), and still others showing no as-
sociation (37).
A study conducted in China (34) found an inverse
association of the 2/16 ratio with breast cancer using
urine samples collected before surgery but a positive
association using postsurgery samples. In an own
case/control study including 144 women with breast
cancer and 292 controls, respectively, we found low-
er excretion of 2-hydroxy-estrone and higher excre-
tion of 16-alpha-hydroxy-estrone in the cases as com-
pared to controls, but only in postmenopausal
women (38). 
Carcinoprotective 2-Methoxy-estradiol
The conversion of 2-hydroxy-estradiol by the enzyme
catechol ortho-methyltransferase (COMT) leads to
2-Methoxy-estradiol (2-ME). The growth of breast
cancer cells (and other tumour cells) has been inhibit-
ed by 2-ME (39). A finding of major significance for
tumor research was the detection of an antiangiogenic
action of 2-ME and its strong potency to capture rad-
icals like semiqinone radicals produced during second-
ary estrogen metabolism, which may be involved in
carcinogenesis of breast cancer (40,41).
We found that the combination of 2-ME with tamox-
ifen elicits additive antiproliferative actions in human
breast cancer cells (42). 2-ME was also able to increase
the effect of certain cytostatics in breast cancer cells
(43). In addition we found a similar inhibition of the
aromatase enzyme by 2-ME as compared to letrozole
(42). Thus 2-ME is a potent antiproliferative metabo-
lite decreasing proliferating activity of the mother sub-
stance estradiol.
Thus during metabolism of estradiol not only poten-
tial genotoxic, but also carcinoprotective metabolites
can be produced which may be one of the explanation
of the result of WHI during treatment with estrogens-
only (10,11,15). In general regarding regulations in
human endocrinology, there are many examples that
the organism can regulate in two contrary directions,
in this case stimulation of cell proliferation (estradiol)
as well as inhibiting negative effects (estradiol metabo-
lite 2-ME). Currently the use of 2-ME is tested in pa-
tients with refractory metastatic breast cancer.
Factors influencing estradiol metabolism
The assessment of estradiol metabolism has to consid-
er factors which can influence this metabolism. For ex-
ample endocrine diseases such as hypothyroidism or
drugs like L-thyroxine and H2-antagonists can change
estradiol metabolism (19). In addition, diet and phys-
ical activity may be of importance (44,45).
Our own interest has been focused on estradiol metab-
olism in smokers, who may produce a higher amount
of potential toxic estrogen metabolites due to in-
creased hepatic activity, as delineated elsewhere (46).
Oral estrogen therapy in postmenopausal women can
lead to an increase of 4-catechol estrogens as compared
to non-smokers which may lead to an increased breast
cancer risk (47). Using transdermal estradiol this
mechanism can be avoided, however not the mecha-
nism of proliferating preexisting cancer cells.
We also were interested if different forms of HRT re-
garding type of hormones and application form which
may influence the pattern of estrogen metabolism
(48). During treatment of postmenopausal women
with different regimens of HRT we found that the
estradiol metabolism can be influenced by administra-
tion route, and possibly also by the type of progesto-
gen addition. Transdermal application of hormones in
contrast to oral treatment may avoid the development
of high amounts of precursors which can be further
metabolized to the potential genotoxic quinones and
semiquinones, due to low dosing and avoiding of the
first hepatic passage (48,49,50) (Fig. 3) shows this dif-
ference between oral and transdermal estradiol treat-
ment.
However, there is epidemiological evidence, which
seems to support an increase of risk also with transder-
mal estrogen-only therapy: In a Finnish study an in-
creased risk also with transdermal estrogen was ob-
served although the subgroup was small (51). These
results suggest that, although the production of estra-
diol metabolites may be minimized during transder-
mal estrogen application, still enough local estrogen
concentrations may be present to promote breast car-
cinogenesis.
The toxic effects of 4-hydroxy-estrogens can probably
be prevented under normal conditions by various cel-
lular defence mechanisms. For example intracellularly
formed catechol estrogens are rapidly methylated by
by the enzyme catechol ortho-methyltransferase
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Fig. 3 - Estradiol metabolism during oral versus transdermal estradiol re-
placement in postmenopausal women (48).
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(COMT). However, patients with a COMT defect
due to genetic polymorphisms could be especially on
risk of breast cancer during HRT, and similarly other
polymorphisms of key enzymes in estrogen metabo-
lites are discussed to increase the breast cancer risk, es-
pecially if there are cumulated defects. However, the
clinical relevance still is under discussion, since those
genetic changes are very rare (52,53).
Additive oxidative cell stress necessary
for carcinogenicity
From the more detailed biochemical view the potential
genotoxic effect of estrogen metabolites are not caused
by the quinones (Fig. 2b) but by further intermediate
metabolites (25,26,54,55). The quinones can react to
“semiquinones”, which, however, needs “oxidative cell
stress” by a so called “one-electrone-oxidation” to form
an electropositive radical structure. Cells are extreme-
ly good protected against this reaction by various de-
fense mechanisms, e.g. 2-ME produced at the same
time during estradiol metabolism can “capture” this
radical substances. 
Only if all protection mechanisms fail, those very re-
active intermediate products are produced, and can in
balance with quinones form a complex molecule
(“ROS” Reactive Oxidative Substance), stable enough
for further reactions with the DNA, leading to strang
breaks which by oxidative DNA damage destroys the
DNA structure necessary for replication. Further reac-
tions like mutations finally can produce the first ma-
lignant cell which, however, needs proliferation up to
10-9 cells to be detected as clinically cancer e.g. by
mammography. 
Derived from doubling times of the most malignant
breast cancer cells during estrogen treatment this car-
cinogenesis needs at least 10-15 years, and during this
long time all the carcinoprotective mechanisms can
work (17). However, if the proliferation rate is strong-
ly increased as by addition of certain progestogens, the
protection may fail and the clinically cancer can be de-
veloped.
Conclusion
Thus, to answer the question asked for this review, es-
trogen metabolites per se are not carcinogenic, because
additional factors are needed for carcinogenesis, and
the main problem using HRT is the increase of prolif-
eration rate, e.g. by adding certain progestogens. With
estrogen-only the proliferation rate is low, and various
defense mechanism can operate in the physiological
human body. This can prevent the formation of possi-
ble genotoxic products of estradiol metabolism which
without protection would be produced during oxida-
tive stress by so called ‘one-electrone-oxidation’. Only
if protective mechanisms fail, e.g. due to genetic poly-
morphisms of key enzymes like COMT necessary for
protection, and only if the proliferation rate is strong-
ly increased, e.g. by addition of certain progestogens,
women may be at risk. Thus, only under rare special
conditions it is conceivable that the human body can-
not react sufficiently.
Besides proliferating effects or production of potential
genotoxic metabolites, estrogen also can induce car-
cinoprotection like the production of carcinoprotec-
tive metabolites and apoptotic effects, which can ex-
plain even the decrease of breast cancer risk in the
WHI study. The different statistical results in clinical
studies may depend on the different carcinoprotective
potency of women in the study. Because the excessive
risk in absolute numbers related to the whole popula-
tion is low (about 0.01%/year), only few women are
decisive for the statistical result in studies. However,
these few women may be of high risk caused by geno-
toxic estrogen metabolites. In the presence of factors,
which negatively could influence the estradiol metab-
olism such as factors like genetic polymorphisms of
protective key enzymes or excessive oxidative cell stress
like in smokers, it seems prudent to prefer transdermal
therapy to minimize the production of possible toxic
metabolites. 
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Introduction
The role of progestogen addition to estrogen therapy
in the postmenopause has come into scrutiny since the
results of the estrogen-only arm of the study Women’
Health Initiative (WHI) are published as compared to
the WHI combined arm (1,2). In contrast to the WHI
combined arm, in the estrogen-only arm no increase
but rather a reduction of breast cancer risk was evalu-
ated. This result indicates a negative effect of progesto-
gens concerning the breast cancer risk. However, the
question remains still open, in as far the combination
of estrogens with synthetic progestogens as well as
with natural progesterone may elicit the same in-
creased risk and/or if there might be important differ-
ences between the progestogens used in hormone ther-
apy and hormonal contraception. In the present paper
own experimental data focusing on the importance of
special cell components which may be crucial for dif-
ferent progestogen action are summarized. 
Rationale and limitations 
of experimental research
Despite their widespread use, in vitro models using cell
cultures have certain limitations: the choice of culture
conditions can unintentionally affect the experimental
outcome, and cultured cells are adapted to grow in vit-
ro; the changes which have allowed this ability may not
occur in vivo. Limitations of in vitro study might be the
high concentrations needed for an effective antiprolif-
erative effect. Higher concentrations may be required
in vitro in short-time tests in which the reaction thresh-
old can only be achieved with supraphysiological
dosages. However, higher concentrations may also be
reached in vivo in the vessel wall or organs compared to
the concentrations usually measured in the blood.
Thus in vitro experiments, although only conducted
for a short time and with high pharmacological con-
centrations, can simulate special in vivo conditions.
But comparisons on the effect of different substances
(like different progestogens) should always be done in
the same model, since cell culture conditions can have
a strong influence on the results.
There are numerous experimental data available on
the effect of progestogens on the proliferation of nor-
mal and cancerous breast epithelial cells (3-6). Howev-
er, only few experiments have been done with a high-
er number of progestogens in the same cell model.
Our working group of the University of Tuebingen,
Germany, recently also in close collaboration with
Chinese working groups of the University of Beijing,
China, is testing systematically all available progesto-
gens in different experimental models which have
been demonstrated to be important models regarding
the research of mechanisms of hormonal action in the
breast. Therefore we will focus here on own experi-
ments, in which we have compared all available
progestogens in the same cell model.
Overview on own experimental
research
We investigated effects on proliferation as well as on
apoptosis using different cell cultures and different
conditions. We tested the effect on malignant breast
cells, but also on benign cells, which can be important
in terms of the question, if new cancer might be devel-
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oped (for example due to very fast proliferation fol-
lowed by mistakes of DNA replication, leading to mu-
tation) or if hormones only proliferate already preex-
isting cancer cells. In addition, a possible paracrine in-
fluence of the stroma was considered by including the
most important stromal growth factors in our experi-
ments (7-13). To our knowledge this probably impor-
tant stromal influence was not incorporated in in vit-
ro experiments so far. 
In our recent experiments we also tested the impor-
tance of certain cell components which can influence
the effect of hormones in terms of proliferation mech-
anisms and can explain differences between hormones
like the impact of various progestogens added to estro-
gen-induced proliferation. In addition to variety of al-
ready published original papers on our experimental
research regarding this issue an extensive overview of
our in vitro investigations with human benign and
malignant epithelial breast cells recently has been pub-
lished (14). In the present summary we concentrate on
experiments with human cell cultures although also
animal studies can indicate differences of hormonal
action, like recently also observed in own research
(15), but to our knowledge up to date there is a lack of
head to head comparison of the available progestogens
in the same animal model. 
As a summary of our earlier experiments (7-13) we can
suggest that the differences shown in those experi-
ments can lead to the conclusion that the paracrine
impact of certain strong growth factors is important
for the influence of some, but not of all progestogens.
Even if there should be a variety of other factors re-
garding the rate of proliferation it could be concluded
already from our earlier experiments that there are dif-
ferences between the progestogens, and the choice of
progestogen may be important for the risk of breast
cancer, because we see large differences when tested
head to head in the same model.
In vitro experiments clearly cannot replace clinical
studies, but they are very useful to explore possible dif-
ferences between substances, and experimental re-
search particularly can evaluate mechanisms and
demonstrate biological plausibility (16). It has to be
noted that derived from clinical studies until today the
risk of breast cancer during hormone therapy is not
clear. For example a recent new evaluation of the “Ox-
ford Collaborative reanalysis” of 51 observational
studies (17) or even new evaluations of the data de-
rived from WHI (18,19) using systematically basic pa-
rameters of epidemiology like the “Bradford Hill crite-
ria” could not establish an increase of breast cancer us-
ing estrogen-only therapy, although a small increase of
risk adding certain progestogens to estrogen therapy
cannot be excluded. 
However, in most clinical studies only medroxyproges-
terone acetate or norethisterone have been tested. To
our knowledge the E3N-study is the only published
study in which a variety of very different synthetic
progestogens have been tested in a larger cohort for
longer duration (on avarage 7-8 years), all leading to sig-
nificantly increased risk when combined with estrogen
in contrast to progesterone and dydrogesterone (20).
However, at this time the conclusion should not be
drawn that it may be totally safe to treat patients with
more “natural” progestogens like dydrogesterone, the
retroisomer of natural progesterone. Follow up evalua-
tions of the E3N-Study suggest that longer duration of
therapy may also lead to increased risk using dydroges-
terone longer than 5 years (21). Thus to evaluate a pos-
sible risk we still need the biological plausibility, i.e. ex-
perimental research, to find the best option which may
reduce the risk of breast cancer using hormone therapy.
Importance of PGRMC1 for
different progestogen action
Recent experimental data revealed the existence of a
membrane-located progesterone receptor, called prog-
esterone receptor membrane component 1
(PGRMC1) (10). PGRMC1 has been detected in sev-
eral cancers and cancer cell lines. It is over expressed in
lung cancer and colon cancer (22). We have demon-
strated that PGRMC1 is present in human breast can-
cer tissues (23), Scientific Prize during the World
Congress of Menopause, Madrid, May 2008). Recent-
ly we published first experiments comparing MPA
with progesterone (24). The journal Menopause (Jour-
nal of the North American Menopause Society) pub-
lished a special EDITORIAL on our original paper
with a title which can express the importance of our
recent experiments, because we could demonstrate
strong proliferating of MPA in contrast to natural
progesterone which has no effect on estradiol-induced
proliferation of human breast cancer cells (25): 
“Can the increase in breast cancer observed in the estro-
gen plus progestogen arm of the Women’s Health Initiative
trial be explained by progesterone receptor membrane
component 1?” As conclusion we published that “over-
expression of PGRMC1 sensitizes the proliferative re-
sponse of human breast cancer cells to estradiol, and the
effect of progestogen on breast cancer tumorigenesis may
depend on the specific progestogen used for hormone ther-
apy and hormonal contraception”.
In further experiments we have investigated receptor
membrane-initiated actions of various other synthetic
progestogens in comparison to progesterone in human
breast cancer cells (12) (Scientific Prizes during the
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German Congress of Breast Oncology, Dresden, June
2011 and Christian Lauritzen Prize during the Ger-
man Congress of Menopause, Frankfurt, November
2011). In these experiments MCF-7 cells were stably
transfected with PGRMC1 expression plasmid (MCF-
7/PGRMC1-3HA, WT-12 cells). We tested the effect
of different estrogen concentrations which should sug-
gest, if there is a dose-related dependency of breast
cancer risk. 
Figure 1 shows our recent results demonstrating the
importance of PGRMC1 for estrogen induced prolif-
eration which is clearly dependent on the estradiol-
concentration which was much more pronounced in
WT-12 cells (26). This effect could be completely ab-
rogated by the addition of the E2-antagonist fulves-
trant.
Further we tested all availabe synthetic progestogens
in comparison with natural progesterone, i.e. head to
head comparison in the same model, which should
suggest if their might be principal differences be-
tween different progestogens used in hormone thera-
py and in hormonal contraception (27,28). For these
new experiments we tested the effects of progesterone
(P) and the synthetic progestogens chlormadinone
acetate (CMA), desogestrel (DSG), dienogest
(DNG), drospirenone (DRSP), dydrogesterone
(DYD), levonorgestrel (LNG), medroxyprogesterone
acetate (MPA), nomegestrol (NOM) and norethis-
terone (NET) on cell proliferation. MCF-7 and
MCF-7/PGRMC1-3HA (WT-12) cells were stimulat-
ed with different concentrations (10-9 M to 10-7 M).
In MCF-7 cells DNG, DSG, DYD, LNG and NET in-
creased the proliferation at 10-7 M, the effect being
highest for NET with about 20%. In WT-12 cells the
same progestogens, but additionally DRSP and MPA
showed a significant increase, which was much higher
(30-245%) than in MCF-7 cells. Here again NET
showed the highest proliferative effect. No effect was
found for CMA, NOM and P. 
Figure 2 shows the effects comparing 6 of the 10 test-
ed progestogens at the same concentration (10-7 M);
Fig. 3 shows the results for the 4 progestogens which
at this time are mostly used in hormone therapy, i.e.
MPA, NET, DRSP in comparison with natural prog-
esterone. In the experiments summarized in Fig. 4 we
tested the difference between sequential and continu-
ous combined estrogen/progestogen combinations (at
two different concentrations) which are the both most
used regimens in hormone replacement therapy.
Estradiol (10-10 or 10-12 M) was sequentially or contin-
uously combined with progesterone or with different
synthetic progestogens. Cell proliferation was investi-
gated in MCF-7 and MCF-7/PGRMC1-3HA (WT-
12) cells. In both sequential and continuous combina-
tion E2 alone elicited a significant 2-3 fold prolifera-
tive increase at 10-10 M. This increase was not signifi-
cantly influenced by the addition of the various
progestogens. However, E2 alone at the lower concen-
tration of 10-12M showed no significant effect on the
proliferation of WT-12 cells, whereby addition of
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Fig. 1 - Proliferation of breast cancer cells: dependency on estrogen
dosage and treatment duration.
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DRSP, MPA and NET triggered a significant prolifer-
ative response, the increase being higher for the con-
tinuous combination, especially combining NET with
E2. In contrast NOM and P were neutral in this ac-
tion, i.e. elicited no effect. 
Our present conclusion of all the experiments in ma-
lignant cells expressing PGRMC1 compared to other
malignant cells is, that certain synthetic progestogens
can trigger a proliferative response of PGRMC1 over-
expressed human breast cancer cells, and that the ef-
fect of progestogens on breast cancer tumorigenesis
may clearly depend on the specific pharmacology of
the various synthetic progestogens. 
In the present research we try to find a possibility for
routine screening of women overexpressing this obvi-
ously important cell component which could lead to a
decision if women can be treated or not using certain
progestogens in hormone therapy.
Importance of RANKL for
different progestogen action
Also other special cell components may be important
for increased proliferating action of certain progesto-
gens. 
In vivo administration of MPA can increase the risk
of breast cancer in mice by activating the protein
RANKL (receptor activator of NF-Kappa B ligand),
known as the key osteoclast differentiation factor) in
normal and premalignant in mammary-gland epithe-
lial cells. (29,30). Genetic inactivation of the RANKL
receptor RANK in mammary-gland epithelial cells
prevents MPA-induced epithelial proliferation, im-
pairs expansion of the CD49fhi stem-cell-enriched
population, and sensitizes these cells to DNA-damage-
induced cell death. Deletion of RANK from the mam-
mary epithelium results in a markedly decreased inci-
dence and delayed onset of MPA-driven mammary
cancer. Until now it is not known if mechanisms
working via this RANKL/RANK system would be dif-
ferent using different progestogens, and the question
remains if this by the end could lead to cancer clinical-
ly observed during treatment with hormone therapy. 
Further research should suggest if screening regarding
this cell components might be an option to assess the
women who might be of increased risk during treat-
ment with certain regimens of hormone therapy, espe-
cially with respect to the choice of the progestogen
component. 
It should be mentioned that those questions also
might be important not only for hormone therapy of
postmenopausal women but also in the field of hor-
monal contraception because the same or similar
progestogens are used. However, we already have been
able to show that the primary estrogen-induced prolif-
eration using ethinyl estradiol compared to estradiol is
much lower in rate and degree (31,32). Obviously the
breast is an important endorgan for the natural estra-
diol but not for the synthetic estrogen, i.e. ethinyl
estradiol, which main effects are in the liver. Thus the
additional proliferating effects like with growth factors
Fig. 4 - Proliferation of breast cancer cells: dependency on estrogen/progestogen regimen (used in two different concentrations).
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or by addition of the progestogen to estrogen induced
proliferation might be not such important. Presently
this question is under our research.
Conclusion
In earlier experiments we and others were able to show
that the paracrine effects of strong proliferating stro-
mal factors have to be considered which might be
modulated by certain progestogens leading to faster
breast cancer cell proliferation. In addition recent re-
search suggest that not only the classic genomic mech-
anisms are working but there is a cross-talk with cer-
tain cell components, especially located in the cell
membrane of epithelial cancer cells, which can en-
hance the proliferating effect of certain synthetic
progestogens like MPA or norethisterone, if added to
estrogen, in contrast to natural progesterone. Thus ex-
perimental data with the comparison of various
progestogens in the same models present a rather high
evidence that there may be differences between the
various synthetic progestogens regarding the breast
cancer risk during hormone therapy and that the use
of natural progesterone may be an important option to
reduce this risk.
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Introduction
The steroid hormone progesterone plays a central role
in the reproductive events associated with pregnancy
establishment and maintenance as well as delivery (1).
Physiological effects of progesterone are mediated by
the action of the hormone with specific intracellular
progesterone receptors (PRs) (2).
Progesterone action is mediated via progesterone re-
ceptors (PRs) using genomic and non-genomic path-
ways (3). This presentation is exclusively concerned
with the genomic action of progesterone in pregnancy.
There is one progesterone receptor gene present,
which leads – estrogen-dependent – to different prog-
esterone receptor isoforms called progesterone recep-
tor A (PRA) and progesterone receptor B (PRB) and
possibly other isoforms such as progesterone receptor
C (PRC). PRA is shorter by 164 amino acid at the
amino acid terminal end of the receptor. PRA appears
necessary to allow the progesterone dependent physio-
logical responses in the female reproductive tract. PRA
is required for normal ovarian and uterine function,
but is dispensable in the mammary gland. While PRB
appears to be required for maintaining quiescence of
the uterus but also appears to be required for instance
that progesterone exerts its proliferatory effects on the
breast. PRB is the principal mediator of progesterone
action (4). PRA represses the transcriptional activity of
PRB (5). The extent to which PRA represses PRB me-
diated transcriptional activity is directly related to its
abundance relative to PRB (PRA to PRB ratio) (6).
Selective ablation of PRA and PRB in mice allowed to
look for the contribution of the individual PR iso-
forms to the pleiotropic reproductive activities of
progesterone. In PRA knockout mice, in which the ex-
pression of the PRA isoform is selectively ablated re-
sults in severe abnormalities in ovarian and uterine
function. In PRB knockout mice it was shown that ab-
lation of PRB has no effect on ovarian and uterine re-
sponse to progesterone, but rather results in reduced
mammary ductal morphogenesis. Thus PRA is both
necessary and sufficient to elicit the progesterone de-
pendent reproductive responses necessary for female
fertility, while PRB is required to elicit normal prolif-
erative responses in the mammary gland to proges-
terone (2). But also other progesterone receptor iso-
forms have been reported such as PRC. PRC is de-
scribed as an amino acid terminal truncated proges-
terone receptor isoform and enhances progesterone in-
duced transcriptional activity (7). PRC has been re-
ported as a 60-kDa protein that upon hormone bind-
ing, translocates from the cytoplasma to the nucleus
and modulates the transcriptional activity of PRA and
PRB. However, the existence of the PRC has been
questioned (8). From early to late pregnancy the vari-
ous events will be scrutinized for the role of proges-
terone and progesterone receptors.
Implantation
Besides the proper conversion of the endometrium into
a secretory state on crucial aspect appears to be decidu-
alized endometrial stromal cells and extravillous tro-
phoblast invasion, which is governed by progesterone
action genomically via nuclear progesterone receptors
(n-PRs) and membrane progesterone receptors (m-PRs).
The temporal expression pattern of progesterone recep-
tors in the uterine luminal epithelium supports their re-
quirement during early events of implantation (9). 
Progesterone receptors and pregnancy
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Blood flow
Blood flow in the corpus luteum phase is related to
progesterone, which is reflected in progesterone recep-
tor activity. The relatively high resistance index during
the early follicular phase declines with progress to-
wards the luteal phase. By the mid-luteal phase the re-
sistance index is low, which corresponds with a high
blood flow to the corpus luteum. When the corpus lu-
teum regresses, reflected by a decrease of progesterone
there is an increase in the resistance index again and
therefore a reduced blood flow. When implantation
occurs placental HCG stimulates progesterone synthe-
sis and secretion by the corpus luteum and the resist-
ance index decrease and remains low throughout a
normal pregnancy. This is not the case when
preeclampsia develops. The resistance index increases
as an early warning sign for the possibility that a clin-
ical manifestation of preeclampsia may occur (11,12).
Immunology of pregnancy
The activation of the immune system is necessary for
normal pregnancy. This is possible through a number
of events:
1. Up-regulation of PRs in natural killer cells in the de-
cidua and in lymphocytes among placental cells (13).
2. Progesterone causes via progesterone receptor posi-
tive lymphocytes and decidual CD 56+cells a
34kDa immune regulatory protein known as prog-
esterone-induced blocking factor (PIBF) and ap-
pears to be the pivotal mediator in progesterone
dependent immune modulation (14).
a. PIBF enhances asymmetric antibody production
b. PIBF causes Th2-/Th1-cytokine shift
c. PIBF inhibits natural killer cell activity (15)
The profound effect of progesterone on regulation of
the immune system in pregnancy is also exemplified by
the differentiation of T-cells into T-regulatory (Treg)
cells on the one hand and progesterone suppresses the
differentiation of CD4 T-cells into inflammation-asso-
ciated Th17 cells on the other hand. So progesterone
by regulation of cell differentiation promotes immune
tolerance (16). Also other studies have indicated that
progesterone acts as a critical regulator of Treg cells in
pregnancy from CD14 + CD25+T-cells (17,18).
Progesterone-controlled T-cell
cytokines for immunological regulation
and maintenance of pregnancy
Progesterone is associated with a switch from a Th1- to
a Th2-cytokine pattern at the maternal-fetal interface.
Progesterone promotes the production of Il4 and Il5.
Leukaemia inhibitory factor (LIF) –essential for em-
bryo implantation- associated with Th2-cytokines.
This is up-regulated by Il-4 and Il-5. On the other
hand LIF is down-regulated by Th1-cell inducers (II-
2, IFN-γ und INF-α). There is a decreased production
of LIF, II-4 and II-10 by decidual T-cells in women
with unexplained recurrent miscarriage.
It can be concluded that LIF and/or Th2-cytokines
contribute to the maintenance of pregnancy (19). In-
creasing INF-γ: II-4 and TNF-α: II-4 ratios have also
been found in women with recurrent failed pregnan-
cy (20).
Actions of progesterone/progesterone
receptors throughout pregnancy 
on the uterus
Already in the 1950’s Csapo proposed the progesterone
hypothesis (21). This means pregnancy preservation by
actively blocking endometrial contractions. In many
species it was proven that progesterone is essential in
the maintenance of pregnancy and the disruption of its
production or activity initiates labor. In the 1970’s
Csapo demonstrated contractility in relation to circu-
lating progesterone. In humans removal of the corpus
luteum before the eights week of gestation started con-
tractility of the corpus uteri together with the widen-
ing of the cervical canal and shortening of the cervix in
the first trimester leading to miscarriage. This could be
avoided by progesterone treatment (22, 23). This was
followed by studying progesterone receptors. Besides
the classical progesterone action via nuclear proges-
terone receptors (nPRs A+B) there are also membrane
progesterone receptors (mPRs α+β) (3, 24).
Progesterone - progesterone receptor interaction can
affect cellular function either via the genomic pathway
(by modulating gene expression) or non-genomic
pathways such as interaction with the different mem-
brane progesterone receptors (α, β, γ) and proges-
terone membrane component-1 and -2 (PGRMC 1
and PGRMC-2) and other cell surface receptors such
as oxytocin receptor and GABA a-receptor linked with
intracellular signalling cascades and direct activation
of intracellular signal molecules (3). There are numer-
ous theories on hormonal control of labour onset.
Most consider oxitocin, prostaglandins and steroid
hormones as primary regulators of the initiation of
labour. For starting labour and parturition in humans
a functional progesterone withdrawal seems to be re-
sponsible. During normal human pregnancy proges-
terone promotes via PRB myometrial relaxation. The
functional progesterone withdrawal of parturition can
be mediated by a decrease of progesterone receptors
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rather than increased estrogen receptors (ERs) (25) or
by an increased myometrial expression of PRA, which
results in an increase in the myometrial PRA to PRB
ratio (26).
Cortisol induces PRA in human amnion fibroblast.
Induction of PRA attenuates the induction of cytoso-
lic phosholipase A2α expression by cortisol in human
amnion fibroblast leading to increased prostaglandin
synthesis (27,28). Another possibility of labour initia-
tion is up-regulation of the progesterone receptor C
isoform (29).
The result of effective treatment with a progestogen
like 17αhydroxyprogesterone caproate was thought to
be through inhibition of the endogenous progesterone
metabolism resulting in an increased concentration of
progesterone at the local receptor level (30). Histolog-
ically it was shown that PRs were significantly higher
in decidual cells from pre- versus post-labour contrac-
tion decidua basalis and parietalis sections (31).
Furthermore, progesterone receptor membrane com-
ponent 1 (PGRMC1) is lower in myometrium of
women at term either not in labour (p=0.004) or in
labour (p=0.05). Compared with tissues in women in
preterm non-labour, PGMRC1 levels are also de-
creased (p=0.02) in myometrial tissues from women
during preterm labour compared with preterm non-
labour. Progesterone rapidly inhibits contractions of
myometrial tissue compared to control (p–0.05) in
vitro. PGRMC1 mediate the non-genomic action of
progesterone and the relaxation effect on human my-
ometrium during pregnancy (32,33). However, prog-
esterone does not inhibit stretch –induced MAPK ac-
tivation or gene expression explaining most likely why
progesterone is ineffective in the prevention of
preterm labour in multiple pregnancies (34). Contrac-
tion associated proteins (CAPs) appear to be the link
between progesterone and progesterone receptor. Re-
cently a novel pathway in which progesterone repress-
es the expansion of two CAP genes: Conexin 43 C
(CNX43) and the oxytocin receptor gene was de-
scribed (OXTR) (36,37). They also found that levels
of 2miRNAs belonging to the mi-RNA-200-family
increases in the mouse and human myometrium with
advancing gestation and in parallel with CNX43 and
OXTR. The immediate miRNA-200 targets were fac-
tors that down regulate CAP levels. They identified
two repressive transcription factors ZEB1 and ZEB2.
ZEB1 and ZEB2 repress the expression of CNX43
and OXTR in mouse and human endometrial cells. In
addition it was found that ZEB1 and ZEB2 inhibited
expression of members of the miRNA-200-family sug-
gesting that these proteins and miRNAs form a mutu-
ally regressive negative feedback loop in myometrial
cells (35,36). There appears to be a significant differ-
ence between allel and haplotype frequencies in the
PR among women with preterm birth and women
with preterm birth and a family history of preterm
birth (37). The author suggests that progesterone re-
ceptor may be a candidate for association with preterm
birth or familiar preterm birth.
The role of progesterone and
progesterone receptors during
the first trimester of pregnancy
In early pregnancy many studies have indicated a
strong relationship between the levels of circulating
progesterone and the clinical outcome of pregnancy
(38). In a more recent study cytosol and nuclear PRs
were measured in the endometrium of women with ha-
bitual abortion compared with fertile women and also
the corresponding circulating plasma progesterone lev-
els (39). The data are summarized in table 1. There is a
highly significant difference of circulating plasma prog-
esterone comparing women with habitual miscarriage
and fertile women (p<0.005). This is also clearly shown
for cytosol nuclear PRs. In a recent study it was evident
that a significant low PRA expression was found in tro-
phoblast cells of miscarriages (40).
Since extravillous trophoblast invasion is related to
available progesterone, which is reflected in proges-
terone receptor levels as shown in table 1. Particular
limited trophoblast invasion is associated with sponta-
neous abortion (41). Reduced extravillous trophoblast
invasion results in nonproper spiral artery develop-
ment (42).
These limitation of invasion may be not only respon-
sible for early pregnancy loss and spontaneous and re-
current miscarriages but also for missed abortion,
preterm labour and early or late onset of preeclampsia
– a clinical spectrum of different degrees of deficient
trophoblast invasion.
Investigations were undertaken to study the genpoly-
morphism of PR in women with spontaneous recur-
rent miscarriages. In Thai women it was found that PR
polymorphism confers acceptability to idiopathic re-
current pregnancy loss (43). Furthermore, the clinical
efficacy of progesterone treatment for prevention of
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TABLE 1 - COMPARISON OF PLASMA PROGESTERONE
AND PROGESTERONE RECEPTOR  CONTENT OF THE
ENDOMETRIUM IN FERTILE WOMEN AND IN WOMEN
WITH RECURRENT MISCARRIAGE (ACCORDING TO 39).
Progesterone PR cytosol PR nuclear
ng/ml fmol mg/protein fmol mg/protein
Fertile women 8,8 ± 1,6 21 ± 6,8 30 ± 11,8
Habitual miscarriage 4,0 ± 1,5 <3 <3
Significance p<0.005
idiopathic recurrent pregnancy loss might be proges-
terone receptor gene polymorphism (44). 
However with similar studies in Brazil and India no
correlation was found in any of the investigated poly-
morphism and it was concluded that the studied gene
polymorphisms are not the major determinant of
pregnancy failure (45,46).
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During the 1990s, hormone replacement therapy
(HRT) was used to reduce heart disease risks, in addi-
tion to treating menopausal symptoms. This was based
on evidence from large observational studies that HRT
provided cardioprotection. However, it was not clear
whether HRT increased breast cancer risk. 
Cardiovascular disease (CVD) is the leading cause of
death in women and increases with aging and
menopause. Evidence suggests that endogenous estro-
gen contributes to delaying the onset of atherosclerot-
ic CVD events in women. Studies in animal models
and women provide biological plausibility for the con-
cept that estrogens can exert atheroprotective effects
via both systemic effects on circulating factors and di-
rect effects on the heart and blood vessels (1,2). These
observations allowed formulating the hypothesis that
estrogen-based HRT could reduce CVD risk in post-
menopausal women. Besides, HRT has proved to
reestablish the deteriorated lipoprotein profile fre-
quently observed in postmenopausal women. 
In 2002, the first published results of the Women´s
Health Initiative (WHI) Study provided a major
source of data for this analysis (3). The WHI study
was undertaken to determine, under the conditions of
a randomized controlled trial, whether HRT truly pro-
tected against heart disease and whether or not it in-
creased breast cancer risk. Although this study was cat-
egorized as a primary prevention trial for coronary
heart disease, the mean age at recruitment was 63
years, when menopausal symptoms have usually fin-
ished and HRT is rarely started, and only 3.5% of the
women were 50-54 years old, the age when women
usually make a decision regarding initiation of HRT.
This point was not acknowledged by the researchers
but instead, they concluded that HRT was not cardio-
protective and that its risk–benefit ratio did not favor
the use of postmenopausal hormones for prevention of
chronic diseases. As a consequence, there was an im-
portant change in prescription habits following rec-
ommendations to reserve HRT for very symptomatic
women, and to limit its use to the ‘shortest duration
needed’ and to ‘the lowest effective dosage’. After pub-
lication of the WHI findings, a number of studies have
examined the effects of HRT in 50- to 55-years-old
women more likely to consider starting HRT.
Recently, the American Endocrine Society Scientific
Statement has provided an overview about HRT use in
postmenopausal women (4). Regarding the quality of
evidence the Statement concluded that evidence from
the WHI trial is weighted less than that of a random-
ized controlled trial according to the GRADE system
criteria because of mitigating factors: large dropout rate;
lack of adequate representation of applicable group of
women (i.e. those initiating therapy at the time of
menopause); and modifying influence from prior hor-
mone use. For this reason, many of the conclusions
from the WHI are judged as level B evidence (4). 
Moreover, in relation to the analysis of the benefits and
risks of HRT in women recently menopausal (i.e. ages
50-59 or <10 years postmenopausal), different re-analy-
ses of the WHI indicated the important influences of
age and time since initiation of HRT on benefits and
risks (5,6). Because most women start HRT shortly af-
ter menopause, available data regarding these women
were specifically analyzed. Results are summarized as
the excess number of women experiencing benefit or
risk per 1000 women using HRT for 5 years of more. 
Therefore, a central issue of discussion in interpreting
the findings of the WHI study is the extent to which
the effects of HRT are influenced by the timing of its
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initiation, in terms of either the age of the recipient or
the duration of estrogen deficiency (i.e. “time since
menopause”) (7). This “timing hypothesis, that HRT
prevents CHD when administered soon after
menopause or in younger women but not if initiated
later in menopause or in older women, is supported by
animal data and by some human studies (8). Further-
more, the reduction in risk of coronary artery disease
in younger women who underwent oophorectomy
and received estrogens is also consistent with the tim-
ing hypothesis (9).
Subgroups analysis of the WHI, focused on the age is-
sues (10) and nonadhering patients (11), provide some
support for the timing hypothesis. Examining Relative
Risks (RR) first, in the conjugated equine estrogens
(CEE)-alone arm, a non-significant (p=0.12) trend to-
ward a reduction in CHD in women younger than
age 60 years was observed, this was not evident in
the women older than 60 years (i.e. RR, 0.63; CI,
0.36-1.09 for ages 50-59 year). This trend was not ap-
parent (p=0.70) in the CEE plus MPA study (i.e. RR,
1.29; CI, 0.79-2.12 for ages 50-59 year). A similar
non-significant (p=0.15) trend toward a reduction in
the RR of CHD only in the women less than 10 year
since menopause also was observed in the CEE-alone
arm. However, a significant increase in the RR of
CHD with greater time since menopause was observed
in the CEE plus MPA arm (p=0.05). A significant in-
crease in the number of CHD events per 1000 women
per 5 year with increasing age was noted in the CEE
plus MPA arm, although no such trend was observed
in the CEE-alone arm. Similarly, a significant increase
in the number of CHD events per 1000 women per 5
year was also observed with greater time since
menopause in the CEE plus MPA study, with no sig-
nificant effect in the CEE-alone arm. These subgroup
analyses support the hypothesis that timing of initia-
tion can influence the effects of HRT with either ben-
eficial or neutral effects in younger, more recently
menopausal women or harmful effects in older women
with longer duration of menopause (4).
It is clear that there is no a single randomized clinical
trial that could answer all questions about a given in-
tervention and thus many questions remained after
the completion of the WHI. As an example, it remains
unclear the cardiovascular effects of HRT adminis-
tered in lower doses, or by transdermal rather than oral
routes of delivery, (the WHI trial used only oral ad-
ministration and the same dose for all the partici-
pants). It is also unclear if formulations containing dif-
ferent estrogens and/or progestogens would be more
effective, (not only like WHI that used CEE plus
MPA) or with the progestogen given cyclically rather
than continuously. The effect of duration of therapy
also remains uncertain. 
Moreover, although oral estrogen exerts a more favor-
able influence than transdermal estrogen on tradition-
al cardiovascular risk factors such as high- and low-
density lipoprotein-cholesterol levels, recent studies
have indicated that oral estrogen adversely influences
many emerging risk factors in ways that are not seen
with transdermal estrogen. Oral estrogen significantly
increases levels of acute-phase proteins such as C-reac-
tive protein and serum amyloid A (12); procoagulant
factors such as prothrombin fragments 1+2 (13); and
several key enzymes involved in plaque disruption,
while transdermal estrogen does not have these adverse
effects (14). 
Different studies have indicated that transdermal ad-
ministration of estrogens is safer in regard to the risk
of stroke (15) and venous thromboembolism (16),
considering the first-pass effect in the liver as an im-
portant factor in the prothrombotic impact of oral es-
trogen. More recently, a case-control study compared
transdermal and oral hormone therapy and concluded
that, compared with an increased risk of stroke with
oral therapy, there was no increased risk with trander-
mal treatment at a dose of 50 ug or less (17).
Furthermore, very recently some researchers from the
WHI Study (18), reported data on post intervention
outcomes through a mean of 10.7 years of follow-up
among women with prior hysterectomy. Over the en-
tire follow-up, lower breast cancer incidence in the
CEE group persisted and was 0.27% compared with
0.35% in the placebo group (HR, 0.77; 95% CI,
0.62-0.95). Health outcomes were more favorable for
younger compared with older women for CHD
(P=.05 for interaction), total myocardial infarction
(P=.007 for interaction), colorectal cancer (P=.04 for
interaction), total mortality (P=.04 for interaction),
and global index of chronic diseases (P=.009 for inter-
action). They concluded that among postmenopausal
women with prior hysterectomy followed up for 10.7
years, CEE use for a median of 5.9 years was not asso-
ciated with an increased or decreased risk of CHD,
deep vein thrombosis, stroke, hip fracture, colorectal
cancer, or total mortality and a decreased risk of breast
cancer persisted.
The arrival of lower-dose estrogen therapies, with effi-
cacy in treating vasomotor symptoms and preventing
bone loss but with lower risk of bleeding, venous
thromboembolic phenomena and undesired effects on
vascular integrity promises good results. A significant
proportion of the older female population has hyper-
tension and this has been shown to be one of the most
important determinants of cardiovascular risk in
women. Well-planned controlled trials are needed to
examine the effects of this agent on hard cardiovascu-
lar outcomes.
In order to answer these controversies, two ongoing
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clinical trials have been developed to provide informa-
tion regarding the role of oral versus transdermal estro-
gen in younger postmenopausal women, KEEPS
(Kronos Early Estrogen Prevention Study) and ELITE
(Early versus Late Intervention Trial with Estradiol).
KEEPS Study is a currently randomized, placebo-con-
trolled, double-blinded, prospective trial of the effects
of menopausal hormone therapy on subclinical ather-
osclerosis in recently menopausal women (42-58 years
old). The KEEPS is designed to explore the hypothe-
sis that early initiation of hormone therapy, in women
who are at the inception of their menopause, will de-
crease the rate of accumulation of atherosclerotic
plaque, indicating a likely delay in the onset of clinical
cardiovascular disease. 
The ELITE Study enrolled postmenopausal women
according to their number of years since menopause,
less than 6 years or 10 years or more, to receive either
oral 17B-estradiol 1 mg daily or a placebo and vaginal
progesterone to those women with intact uterus. The
primary hypothesis to be tested is that 17β-estradiol
(estrogen) will reduce the progression of early athero-
sclerosis if initiated soon after menopause when the
vascular endothelium (lining of blood vessels) is rela-
tively healthy versus later when the endothelium has
lost its responsiveness to estrogen. 
Once these studies will be released we will know the
real effect, beneficial or not, of estrogen on post
menopausal women CVD. 
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In recent years obesity has reached dramatic dimen-
sions and the obese are more likely to develop arte-
riosclerosis, with the consequence of increased in-
stances of heart attacks and strokes. Furthermore, they
may develop type 2 diabetes and suffer from loss of
bone mass (osteoporosis), loss of joint cartilage (os-
teoarthritis, formerly called arthrosis) and loss of mus-
cle mass (sarcopenia). 
For the human, obesity is defined as a body mass in-
dex (BMI) larger than 30. The BMI, however, is no
longer used by clinical scientists because it does not ac-
count for differences in fat or muscle mass. The waist
circumference as an index of obesity is now used be-
cause it determines whether a person is in danger of
suffering from the above outlined diseases. It is gener-
ally accepted that 2 types of fat distribution exist: The
“pear type” is characterized by a fat distribution
around the gluteal and thigh area and this type bears
no health risks. People with an “apple type” of fat dis-
tribution have a high fat load in the abdomen which
endangers them to become seriously ill. The Abdomi-
nal (visceral) adipocytes secrete so called cytokines
which are also secreted during inflammatory process-
es, hence overweight person of the “apple-type” are in
a chronic inflammatory state with higher than normal
levels of circulating cytokines, primarily tumor necro-
sis factor a (TNFα), interleukin 6 (IL6), leptin,
adiponectin and others (1,2) which cause increased
levels of the marker for inflammation, i.e. C-reactive
protein (CRP). 
These cytokines have many adverse effects. They in-
crease cholesterol production, particularly the un-
healthy low density lipoproteins (LDL) and the very
unhealthy triglycerides (3). Furthermore they cause
high oxidative stress conditions (4). Altogether, this re-
sults in arteriosclerosis with the consequence of in-
creased heart attacks and strokes. Additionally, the high
amounts of circulating cytokines result in a desensitiza-
tion of insulin receptors which finally leads to type 2
diabetes and an even higher risk of arteriosclerosis (5).
Taken together, this often leads to immobility.
With increasing age, in women augmented post-
menopausally, fat tissue accumulates markedly in bone
marrow and in joint fat pads (6,7). These accumulat-
ing bone marrow and joint adipocytes have similar
properties as the visceral fat cells because they also se-
crete cytokines causing a local chronic inflammatory
state in bone and joints (8,9) and which inhibits the
activity of bone and joint cartilage forming cells and
stimulates the activity of bone and cartilage digesting
cells. This resulted in loss of bone mass (osteoporosis)
and joint cartilage tissue (osteoarthritis). In addition,
due to mechanical compression being overweight is
harmful for knee and hip joints.
The increase of obesity is primarily the result of un-
healthy nutrition, too much fat rich fast food and too
many carbohydrate rich soft drinks. Even though at-
tempts were made to improve nutritional habits of the
population, this did not change the increased inci-
dence of obesity. Therefore, affordable dietary supple-
ments of plant origin which inhibit cholesterol and
triglyceride production and fat cell formation would
be desirable and - if existent - introduced to prevent
obesity and the resulting diseases.
In Ayurveda Medicine Guduchi was shown to prevent
obesity. A search for an active compound yielded the
presence of ß-Ecdysone (Ecd) improves training in-
duced muscle performance and is therefore used by
many athletes and body builders in high quantities
without any unhealthy side effects. 
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The ovariectomized (ovx) rat is an ideal model to
study obesity, hypercholesterolemia, osteoporosis and
osteoarthritis (10-14) and in this animal model we
showed that Ecd reduced visceral fat load (Fig. 1a) and
serum leptin levels (Fig. 1b). According to the above
explained, this reduces cytokine production and the
accompanying oxidative stress. Consequently less cho-
lesterol and LDL is produced (Fig. 1c and d) and less
LDL is available for oxidation and formation of arte-
riosclerotic plaques. Hence, if such effects could be
confirmed in the human this should result in a reduc-
tion of arteriosclerosis and consequently to fewer heart
attacks and strokes. 
Earlier we showed that Ecd was able to reduce ovx in-
duced loss of bone mineral density and of joint carti-
lage tissue (14,15). The results from these animal stud-
ies encouraged us to test whether Ecd can also reduce
the fat load in the bone marrow and in joint fat pads.
Indeed, Ecd reduced bone marrow and knee joint fat
load significantly and this resulted in less loss of tra-
becular bone mineral density and of the thickness of
articular cartilage tissue.
We tested also whether Ecd has estrogenic or andro-
genic properties which could explain these favourable
results. Neither in receptor binding nor in animal
studies did we observe estrogenic or androgenic prop-
erties of this steroid (14).
To test whether these experimental data are of value to
prevent the Metabolic Syndrome in the human we per-
formed a 3 months lasting open clinical trial to study
putatively beneficial metabolic properties of Ecd. 
A widely used edible plant, namely spinach contains
Ecd. Therefore we used an Ecd enriched spinach pow-
der for our observational study in which we included
persons (n=20) with serum cholesterol levels above xx
and serum LDL values above xx and with a waist cir-
cumference between 90-100cm in women and 100-
110cm in men. They received the Ecd enriched
spinach powder in capsules which contained 75-100
mg Ecd (VerdeVital GmbH, Göttingen, Germany).
After this period serum cholesterol, particularly the
LDL was reduced by 13% and triglycerides by 42%.
Total body weight was reduced by 1.5kg, body fat
mass by 5% and most importantly the waist circum-
ference by 2.5cm. Muscle mass increased by 4%. Oth-
er parameters like liver enzymes and white and red
blood cell counts remained unchanged.
On the basis of these experimental and clinical results
we conclude that the Ecd enriched spinach extract
may well be suitable to prevent the occurrence or pro-
gression of obesity and the subsequent diseases with all
their health threatening consequences like arterioscle-
rosis, osteoporosis and osteoarthritis.
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Fig. 1 - In ovx rats abdominal fat load (a), serum leptin (b), cholesterol (c), LDL (d) are significantly reduced by Ecd.
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Introduction
Due to remarkable advances in the treatment of can-
cer, we have seen great improvements in long-term
survival rates of pediatric and reproductive-age male
patients. Unfortunately, fertility in adult life might be
severely impaired by these treatments. A number of
fertility preservation options now exists that may allow
patients to conceive once they have overcome their
disease. For females, embryo and oocyte cryopreserva-
tion are already routinely applied, but cryopreserva-
tion of ovarian tissue is the only option available for
prepubertal girls, women without partners and those
who cannot delay the start of chemotherapy. Ortho-
topic reimplantation of frozen-thawed postpubertal
ovarian tissue has proved effective (1), with the birth
of close to 20 healthy children. However, pregnancy
has not yet been achieved with transplantation of ovar-
ian tissue from prepubertal girls and the global success
rate is unclear, since the number of transplantations
performed, is unknown. Other approaches, such as
follicle isolation with subsequent in vitro maturation
(IVM), are currently under investigation.
In males, postpubertal patients (from age 12 upwards)
can benefit from sperm cryopreservation and healthy
live births have been reported with frozen-thawed
sperm stored for up to 28 years (2), but little is known
about the effects of gonadotoxic treatments on the pre-
pubertal testis. While differentiating spermatogonia are
extremely susceptible to cytotoxic agent damage, the
less active stem cell pool may also be depleted, resulting
in loss of spermatogonial stem cells (SSCs) that normal-
ly differentiate to produce sperm after puberty (3). 
For prepubertal boys, preservation of SSCs is a poten-
tial, albeit still experimental, strategy for preserving fer-
tility in the hope that future technologies will allow its
safe use (4). Although clinical experience of immature
testicular tissue (ITT) storage has already been pub-
lished (6), successful fertility restoration with frozen-
thawed ITT in humans has not yet been reported. Cry-
opreservation techniques for ITT and potential fertili-
ty restoration approaches using ITT will be reviewed.
Fertility preservation with ITT
SSCs can either be cryopreserved as a cell suspension or
in the form of tissue. However, preparation of cell sus-
pensions may compromise cell survival (6) and requires
tissue digestion, suppressing cell-to-cell interactions
necessary for cell proliferation and differentiation. Tis-
sue cryopreservation must strike a balance between op-
timal conditions for each cellular type and problems
may arise from insufficient solute penetration in high-
ly compacted tissue and formation of extracellular ice.
Three teams have reported slow-freezing protocols for
prepubertal human ITT that have yielded good struc-
tural integrity and spermatogonial recovery (7-9). Fur-
ther evaluation of the functional capacity of cryopre-
served human ITT in a xenotransplantation model
showed that spermatogonial cells were able to prolifer-
ate, although a high proportion were lost and abnor-
mal spermatogenic differentiation was observed (10).
Vitrification (V) might constitute a better approach,
preventing ice crystal formation by use of high con-
centrations of cryoprotectants and ultrafast cooling ve-
locity. Its potential was recently demonstrated in non-
human primate and human ITT, achieving good sem-
iniferous tubule (ST) integrity, survival and prolifera-
tion of spermatogonia (11,12).
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Fertility restoration after ITT
cryopreservation
In the light of results obtained from animal studies,
frozen SSCs may provide some hope of fertility
restoration in prepubertal boys. Three approaches may
be considered: transplantation of purified cell suspen-
sions back to their own testes, autografting of testicu-
lar pieces, testicular cell aggregates or whole testes, or
IVM up to a stage at which they are competent for
normal fertilization through intracytoplasmic sperm
injection (ICSI). However, none of these methods
have proved efficient or safe in humans as yet.
Spermatogenesis could be reinitiated after transplanta-
tion of isolated testicular stem cells to germ cell-de-
pleted testes (13). SSCs relocate from the lumen onto
the basement membrane of STs, self-renew and pro-
duce differentiating daughter cells. Autologous SSC
transplantation has proved successful in a number of
species, including monkeys (14), and yielded healthy
progeny (15-18). In humans, preclinical in vitro stud-
ies have demonstrated the feasibility of transplanting
germ cell suspensions into testes (19).
Testicular tissue grafting involves transplantation of
SSCs with their intact niches. Complete spermatogen-
esis following grafting has been reported in a number
of species, including non-human primates (20), and
haploid germ cells isolated from mouse testis homo-
grafts and rabbit testis xenografts have been used with
ICSI to generate offspring (21). 
Transplantation of testicular cell aggregates is challeng-
ing, since the different cell types have to form func-
tional three-dimensional cell associations after trans-
plantation in order to produce a supportive microen-
vironment for spermatogenesis. Nevertheless, com-
plete spermatogenesis has been observed (22-26) and
mouse offspring obtained (24). This technique offers
the possibility of using cell sorting methods before
grafting and could therefore be beneficial from a clin-
ical perspective when testicular tissue is potentially
contaminated with cancer cells (27).
The first convincing demonstration of human testis
transplantation was reported in 1978 (28). However,
before this strategy can be considered for fertility
preservation purposes, appropriate cryopreservation
methods should be developed for whole organs. 
IVM of SSCs, yielding in vitro-derived haploid ga-
metes available for ICSI, circumvents the risk of rein-
troducing malignant cells, making this procedure po-
tentially highly beneficial for cancer patients. Efforts
have focused on establishing optimal in vitro culture
systems to allow male germ cells to complete meiosis
and spermatid elongation in experimental conditions.
In mice, IVM recently succeeded in obtaining sperm
(29) and even offspring from fresh ITT, as well as
complete spermatogenesis in frozen ITT (30). In hu-
mans, a number of studies have investigated culture
systems suitable for in vitro spermatogenesis, but the
whole process has not yet been reproduced.
Resolving numerous technical issues should lead to
safe and efficient methodologies for fertility restora-
tion after storage of preserved gametes from today’s
prepubertal patients, which will allow them to consid-
er fertility restoration options that will emerge in the
next 20-30 years.
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Introduction
Recurrent spontaneous abortion (RSA) is defined as
the loss of three or more consecutive pregnancies in the
first trimester (1). The RSA affects 1-1.8% of women
(1,2). A wide variety of causes participate in the patho-
genesis of RSA, including uterine anomalies, cervical
incompetence, autoimmune diseases, antiphospho-
lipid antibody, chromosomal abnormalities of couples,
thrombophilic disorders, endocrinological abnormali-
ties, and microbial infections (2,3). For example,
parental chromosome abnormalities represented by
balanced type translocations are associated with ap-
proximately 4% of couples with RSA compared with
0.2% in normal population (4). However, the etiology
in approximately 50% of RSA is unknown, therefore
designated as unexplained RSA. It is postulated that
they have immunological etiologies (1). 
The precise mechanism underlying the pathology of
RSA remains poorly understood. In this context, no
standard therapeutic modality for unexplained RSA
have been established so far, despite several lines of ev-
idence indicating some therapeutic efficacy of unfrac-
tionated heparin or low molecular weight heparin with
or without low dose aspirin, paternal lymphocyte im-
munization, intravenous immunoglobulin (IVIg), pre-
donisolone, and progestin (5-7). In the recently
emerging literature, novel clinical approaches with the
use of tumor necrosis factor inhibitors (8,9) and gran-
ulocyte colony-stimulating factor (10) have been con-
ducted for the treatment of RSA. 
We for the first time developed a high dose intra-
venous immunoglobulin therapy (HIVIg) during ear-
ly gestation for severe cases with RSA of unexplained
etiology in 1993 and previously reported the efficacy
in a preliminary study (11). 
Materials and methods
Patients
This prospective study was performed as a multi-cen-
ter study in Japan, and conducted with informed con-
sent from all of the subjects. The study was approved
by the institutional ethical boards of the Kobe Univer-
sity Hospital and the Hokkaido University Hospital.
During the period between 1993 and 2010, RSA
women were admitted to the study if they met all of
the following requirements: Subjects must have (i) a
history of four or more consecutive spontaneous abor-
tions in the first trimester, (ii) unexplained etiology of
RSA, and (iii) no allergy for immunoglobulin or IgA
deficiency disease. 
All patients underwent several examinations of ul-
trasound, hysterosalpingography, endometrial biop-
sy, and conventional blood analyses for RSA screen-
ing, and were diagnosed as having RSA of unex-
plained etiology. The blood analyses included chro-
mosome karyotypes of couple; measurements of
progesterone in mid-luteal phase, prolactin, thyroid,
liver, kidney functions, hemostatic coagulation fac-
tors such as d-dimer, factor XII, protein C, protein
S; and autoimmune factors such as antinuclear anti-
body, complements, anticardiolipin, β2-glycopro-
tein I-dependent anticardiolipin antibodies, and lu-
pus anticoagulant. 
Immunoglobulin therapy
They underwent HIVIg therapy (intact type im-
munoglobulin 20 g daily in the course of 5 days; a to-
tal dosage of 100 immediately after a gestational sac
was detected in the uterus by ultrasound. Medications
of intact type immunoglobulin including Venoglobu-
lin-IH (Benesis, Osaka), Kenketsu glovenin-I (Nihon
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Parmazeutical Co., Tokyo) and Sanglopor (CSL
Behring, Tokyo) were used.
Results
We had conducted HIVIg therapy in 60 RSA women
with the ages ranging from 24 to 44 years old who had
a history of 4 to 8 spontaneous abortions, and con-
firmed pregnancy outcome (Table 1). The live birth
rate was 73.3% (44/60). Fifteen pregnancies ended in
spontaneous abortion, and one ended in intrauterine
fetal death at 31 weeks of gestation due to severe preg-
nancy induced hypertension and sudden abruptio pla-
centa. The 15 abortions consisted of 2 spontaneous
abortions of a fetus with normal chromosome kary-
otype, 11 spontaneous abortions of a fetus with abnor-
mal chromosome karyotype (SAAK), and 2 with un-
known karyotype. It was impossible to assess the effi-
cacy of HIVIg among the 11 SAAK fetuses who were
destined to die. If the 11 pregnancies resulting in
SAAK were excluded, the live birth rate was high as
89.8% (44/49).
Pregnancy complications including premature delivery
(18.2%) and intrauterine fetal growth restriction
(13.6%) were observed. Fetal anomaly of cleft lip was
seen in one case. The adverse effects of HIVIg in the
mothers including rash/fever (13.3%) and the eleva-
tion of d-dimer levels (6.7%) were found.
Discussion
It is well acknowledged that intravenous use of a high
dose of immunoglobulin (HIVIg) is practically effec-
tive, and this therapy has long been applied to a wide
variety of immune-mediated diseases such as idiopath-
ic thrombocytopenic purpura, Guillain-Barré syn-
drome, Kawasaki’s disease, and myasthenia gravis
(12,13). Several mutually non-exclusive mechanisms
of action, which include the suppression of inflamma-
tion and modification of Fc receptor, T cell, B cell or
macrophage functions, are proposed to account for the
immunoregulatory effects of the HIVIg therapy (13). 
To assess the efficacy of IVIg in women with unex-
plained RSA, randomized, double-blind, and placebo-
controlled trials with use of a medium dose of IVIg
therapy, in which 20-40 g of Ig/person is infused week-
ly or every 2-4 weeks during early and mid-gestation,
have been performed in 1990s (14-19). Conclusions
drawn from these IVIg trials are controversial. There-
after, reports of meta-analysis (20) and systematic re-
view (21) concerning efficacy of IVIg therapy suggest-
ed that a medium dose of IVIg was effective among
women with secondary RSA. On the other hand, our
group for the first time tried HIVIg therapy for severe
cases of unexplained RSA, in which 100 g of intact
type immunoglobulin was infused intravenously over
the course of 5 days at approximately 5 weeks of ges-
tation. We previously reported high live birth rates
among small-scale subjects in the preliminary HIVIg
studies (11,22). Thereafter, the study was continued
and consequently we confirmed the high birth rate
and the efficacy of HIVIg for severe cases of unex-
plained RSA in the present study. HIVIg therapy was
well tolerated in most of these subjects, and none of
them discontinued HIVIg therapy due to serious ad-
verse effects. 
Several immunological mechanisms underlying the
pathophysiology of RSA and action of IVIg have been
suggested. IVIg modulate NK cell dynamics and cy-
tokine production. The immunomodulatory effects of
IVIg on NK cells in RSA women include the reduc-
tion of peripheral NK cell number and cytotoxicity
(22-26) and the increase in expression of inhibitory re-
ceptor CD94 on NK cells (27). IVIg therapy in RSA
women was shown to drive a Th1/Th2 balance toward
Th2 shift (28,29) and to increase serum cytokine (29)
and G-CSF levels (30). 
Using a mouse model of immunological reproductive
failure, we for the first time demonstrated that a high
dose of intact type- immunoglobulin but not Fab-
immunoglobulin restored the fecundity and that
spleen cells adoptively transferred from im-
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TABLE 1 - PREGNANCY OUTCOME, COMPLICATIONS AND ADVERSE EFFECTS IN 60 WOMEN WITH SEVERE CASES
OF UNEXPLAINED RECURRENT SPONTANEOUS ABORTION (RANGE 4-8 ABORTIONS) WHO UNDERWENT A HIGH
DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY.
Pregnancy outcome Number Complications Number (%)
Live birth 44 Premature delivery 8/44 (18.2)
IUFD at 31 weeks 1 IUGR 6/44 (13.6)
Spontaneous abortion 15 Anomaly (cleft lip) 1
Normal chromosome karyotype 2 Adverse effects on mothers
Abnormal chromosome karotype 11 Rash and fever 8/60 (13.3)
Unknown karotype 2 Elevation of d-dimer 4/60 (6.7)
IUFD= intrauterine fetal death; IUGR= intrauterine growth restriction.
munoglobulin injected nonpregnant donors to preg-
nant recipient mice of reproductive failure complete-
ly restored the fecundity. The restoration of the fe-
cundity was concomitant with reduction of TNF-α
and IFN-γ expressions in the placentas. CD11b+
macrophages transferred from donor mice accumu-
lated selectively in the placentas of recipient mice,
suggesting that macrophages as mediator and/or ef-
fector cells may play a key role in mechanisms of
HIVIg efficacy (31). These observations may explain
a favorable pregnancy outcome in HIVIg treated
RSA women who have immunological abnormalities.
These data with use of HIVIg strongly support the
evidence showing the usefulness of this therapy as
immune modifier, when performed during early ges-
tation. It is likely that HIVIg correct etiological im-
munological abnormalities in RSA women. Figure 1
shows hypothetical mechanisms of immunoglobulin-
mediated prevention of spontaneous abortion. 
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Introduction 
Reproduction is a major area of research since the on-
set of biological science. However, the human female
reproduction research lags substantially behind main-
ly due to the lack of proper biological materials and
the lack of proper tools. Therefore, many ovulatory
processes that were described at the molecular levels,
mainly in rodents, were not validated in human.
Ovarian follicular development and ovulation in
mammals is a highly regulated process. This process
involves the selection of a dominant follicle, reactiva-
tion of oocyte meiosis, rupture of the follicle wall, cu-
mulus expansion and tissue remodeling to form the
corpus luteum. These processes are fundamental to
successful establishment of pregnancy, but important-
ly also impact on the developmental potential of re-
sultant embryos. Genes involved in this processes,
have been the subject of growing interest (1,2).
The LH surge, derived from the pituitary, is the single
trigger, initiating the cascade of events, leading to ovu-
lation. Elucidation of these fascinating processes and
understanding the molecular regulation of the human
ovulatory cascade is of critical importance.
The main events resulting from the LH surge are cu-
mulus expansion, oocyte maturation, follicular rup-
ture, and luteinization, all of which are essential for
proper reproduction.
In response to the LH surge, various changes in gene
expression and follicular structure occur in the theca,
granulosa, cumulus and oocyte compartments of the
ovarian follicle. Systemic and local inputs co-ordinate
with signals from the oocyte, Thus ovulation is under
complex control facilitating synchronization of
oocyte maturation with its release and permitting the
selection of oocytes with full developmental compe-
tence (3).
Traditionally, animal models have served for the study
of human biological processes (4). Animal models
have several important advantages including availabil-
ity, low variability, genetic homogenicity, use in time-
course experiments and transgenic and knock-out
models. In fact, it will be reasonable to say that re-
search on animals has taught us nearly all we know
about cell biology (4,5). 
However, animal models have also several disadvan-
tages including the variability from humans and the
ethical controversies regarding animal research and
their welfare (4,6). 
Most of the recent advances in understanding of the
molecular basis of folliculogenesis and ovulation have
come from rodent models (7). Also a considerable
contribution came from studies in domestic animal
(8) and primate species (9,10). However, which
species are most appropriate model for understanding
critical genes and processes in human ovulation is cur-
rently unclear.
In the human, like in the mouse, LH and FSH were
shown in-vitro and in clinical practice to orchestrate
the ovulatory cascade. Only few studies in human re-
vealed common mechanisms with animal studies. For
example, FSH was shown to induce LHR in mural
granulosa cells (11,12), and hCG to induce amphireg-
ulin (Areg) expression and progesterone synthesis
(12,13). However, it appears that there are differences
in a variety of molecular mechanisms between human
and animal models. For example, SULT1E1 was
found to be expressed in the rodent ovary and highly
regulated during folliculogenesis. Moreover, knock-
out mice suffered from impaired ovulation (14). How-
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ever, this gene was not found to be expressed in pri-
mate and human granulosa cells (personal communi-
cation). Another gene, sFRP4 was shown in the mouse
to be up-regulated by hCG (15-17) and presumably to
inhibit ‚-catenine, an inhibitor of the LH pathway
(16). We found that sFRP4 in human is down-regulat-
ed by hCG both in vitro and in vivo, while sFRP5 is
induced by hCG and may replace the role of sFRP4 as
LH mediated beta-catenine suppression in the human
ovary (18). 
Thus, data obtained from animal studies must be validat-
ed in human experiments. However, there are relatively
few publications on the molecular mechanism of human
ovulatory process which is probably due to ethical and
practical difficulties in obtaining relevant samples.
In-vitro maturation of human oocytes (IVM) is an
emerging technology with promising potential in spe-
cific indication. The main advantage of this technique
is the fact that it does not require gonadotropin stim-
ulation, and therefore the treatment is shorter, simpler,
less expensive, and most importantly, safer, avoiding
the risk of ovarian hyperstimulation syndrome
(OHSS). The technique was found to be particularly
suitable for women with PCOS and women who are
at high risk of OHSS (19,20). 
During IVM process, cumulus-oocyte complexes
(COCs) are obtained mostly at germinal vesicle (GV)
stage and are matured in vitro by maturation medium
into metaphase II (MII) stage (21). Human oocyte can
resume meiosis, reach metaphase II stage, and by in-
tracytoplasmic sperm injection (ICSI) can be fertilized
at high ratio (22). The application of in vitro matura-
tion (IVM) of oocytes as a technology to assist clinical
infertility treatment remains poor because of the re-
duced developmental competence of oocytes after
IVM. Pregnancy and live birth rates do not match
those reported for IVF cycles using full hormonal pro-
tocols with triggered maturation in vivo (23). Further-
more, the quality of maturation appears to be subop-
timal since embryos resulting from in vivo matured
oocytes have better developmental capacity when
compared with their in vitro matured counterparts. In-
deed, at least one major hurdle that must be overcome
before IVM becomes a mainstream procedure is the
handling of immature oocytes (24).
IVM and IVF procedures allow us to obtain biological
material from different stages of the follicular develop-
ment. This includes follicular fluid as well as granulosa
cells–mural obtained from the follicular fluid and cu-
mulus obtained during oocyte denudation. During
IVM without hCG priming, non-luteinized cells can
be obtained. Information from such research is of cru-
cial importance for improving fertility control and
treatment (25). 
Our aim is to explore the human folliculogenesis and
the preovulatory follicular events. Our model, de-
scribed in this article is based on follicular fluids and
granulosa cells obtained during ART treatments.
Gene characterization during different
stages of antral folliculogenesis
Previously we generated a murine ovulatory-selective
cDNA library (26). In order to examine the presence
of these genes and characterize their expression in fol-
licles of different size in human GCs, we used the
IVM procedure to obtain mural granulosa cells from
small (4-8 mm) and large (10-14 mm) follicles and
compare it to mural granulosa cells obtain from the
large pre-ovulatory follicles of IVF (25). We have
shown the presence of several known ovulatory genes
such as StAR, amphiregulin, epiregulin, LHR,
cyp19A1 (aromatase) and EPHX1 but also genes that
were not shown previously or were shown only recent-
ly by us in human ovary such as MAGOH, ELOVL5
(25), sFRP4 (18) and ADAMTS1 (27). 
This model system allowed the characterization of
ovulatory gene expression in-vivo during the different
stages of antral folliculogenesis. For example, we
found that the expression of sFRP4 was inversely cor-
related to follicular size: mural GCs obtained from
small luteinized IVM follicles expressed higher levels
of sFRP4 than mural GCs obtained from large
luteinized IVM follicles, and that sFRP4 expression
further decreased in mural GCs obtained from pre-
ovulatory luteinized follicles (18). 
We also have shown that LHR expression was shown to
correlate with follicle size. The small follicles had the
lowest levels of LHR expression, and these levels were
higher in medium-sized follicles, with the highest lev-
els of expression (6-fold those of the small ones) being
observed in the large preovulatory follicles (Fig. 1) (28).
IVM protocols without hCG priming allows us to ob-
tain GCs from non-luteinized follicles and compare
them to cells from luteinized follicles from IVM. This
allows us to study the effect of LH surge in-vivo on se-
lected genes. For example, we found that ADAMTS-1
levels in non-luteinized mural GCs were undetectable
compared to the high expression that were present in
luteinized mural GCs obtained from follicles of similar
size (>10 mm). These results suggest that ADAMTS-1
is an hCG regulated gene in human mural GCs (27). 
Ovulatory gene expression in luteinized
versus non-luteinized GC in cell culture
Culture of granulosa cells obtained during ART proce-
dures allows us to study ovulatory gene expression fol-
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lowing treatment with various stimulants and in-
hibitors thus enabling us to further characterize ovula-
tory pathways in humans. 
Luteinized GCs for culture are relatively easy to obtain
during IVF treatment cycles and were used by many
researchers in the past 20 years. However, there is a
concern regarding the use of luteinized GCs in cell
culture to study molecular ovulatory processes. Fol-
lowing the LH surge and luteinization there might be
major differences in the cellular mechanisms and re-
sponse to various stimuli of luteinized cells as com-
pared to non-luteinized cells.
It was previously published that granulosa cells regain
their responsiveness to gonadotropin stimulation fol-
lowing culture in hormone-free environment for 3-7
days (29) but there are only few published papers us-
ing non-luteinized GC (12) and regarding the use of
luteinized GC compared to non-luteinized GC (11).
IVM protocols without hCG priming allows us to ob-
tain GCs from non-luteinized follicles and compare
them to cells from luteinized follicle in cell culture.
Based on published data we established a culture pro-
tocol of luteinized GC for 48 hours in culture media
without gonadotropins.
We used non-luteinized mural GCs and luteinized GC
in cell culture and examined the expression of several
ovulatory genes following treatment with hCG and
FSH. We show the expression of sFRP4 in cultured
GC. We found that the expression pattern of sFRP4 in
luteinized and non-luteinized cells in response to stim-
ulus by hCG was similar, thus supporting the use of
luteinized GCs as a model system to investigate ovula-
tory processes (25). 
In order to examine LHR functionality in cumulus
cells, the expression of genes known to be up-regulat-
ed after LH surge (30) was evaluated. Cumulus GCs
were cultured and stimulated with hCG and harvest-
ed for qPCR 8 h later. The results showed that Has-
2, PTX-3, and TSG-6 were induced about 2-, 1.5-,
and 5-fold, respectively, after hCG administration
(Fig. 2) (28). 
Correlation of selected cumulus genes
to oocyte maturation, fertilization
capacity and pregnancy
Correlating gene expression in cumulus cells from in-
dividual COC to oocyte competence and fertilization
outcome can usefully serve as a high throughput and
non-invasive means for the assessment of oocyte qual-
ity, embryo competence and pregnancy outcome. This
technology using quantitative RT-PCR can help to de-
fine the potential biomarkers correlated to a compe-
tent oocyte and also improve the selection of healthy
embryos leading to pregnancy. Increasing number of
papers have shown correlation of cumulus gene ex-
pression with oocyte maturation (31,32), fertilization
rate (31) and pregnancy outcome (32-34), McKenzie
et al. have shown that the expression levels of GDF9
targets in cumulus cells of individual oocytes has a cor-
relation to embryo quality (31). Assou et al. employed
a robust multiple microarray approach to identify nov-
el cumulus genes as biomarkers for embryo and preg-
nancy outcome (33). They identified 45 genes as bio-
markers and demonstrated a good correlation between
the expression profile of these genes and pregnancy
outcome without a relationship to the morphological
grade of the embryos (33). 
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Fig. 1 - Luteinizing hormone receptor (LHR) expression pattern in mural
GCs. Total mRNA of mural GCs was purified from small follicles (<10 mm),
large follicles (10-14 mm) aspirated during human chorionic gonadotropin
(hCG)-primed in vitro maturation (IVM) procedures and preovulatory folli-
cles (>17 mm) aspirated during in vitro fertilization (IVF) procedures. The
RNAs were subjected to reverse transcription and quantitative real-time
polymerase chain reaction with LHR and â-actin (loading control) primers.
LHR expression was calculated relative to the â-actin level in the same
sample. The results are expressed as mean±SEM of three independent ex-
periments (3-5 patients in each group) Values with different superscripts
are significantly different (P<0.05). Reprinted from Maman et al. 2012 (28).
Fig. 2 - Expression of cumulus expansion genes. Cumulus cells from pre-
ovulatory follicles were cultured and supplemented with human chorion-
ic gonadotropin (hCG) 1U/ml. After 8 h total mRNA was purified and sub-
jected to reverse transcription and qRT-PCR with HAS2, PTX3, TNFAI6 and
β-actin (loading control) primers. The results are expressed as mean±SEM
of three independent experiments. Reprinted from Maman et al. 2012 (28).
We have previously shown that ADAMTS-1 and
sFRP4 can serve as a potential biomarker for oocyte
quality. We found that sFRP4 expression in cumulus
GC is inversely correlated to oocyte maturation, with
the highest expression in the cumulus of GV oocytes
compared to that of MI oocytes and the lowest expres-
sion in the cumulus of MII oocytes (18). Also we found
that ADAMTS-1 expression in cumulus GC is posi-
tively correlated to oocyte fertilization capacity (27). 
We also investigated the correlation between the levels of
LHR expression in cumulus GCs and the related oocyte
maturation stage and shown that the highest level of ex-
pression in cumulus GCs obtained from metaphase II
(MII) oocytes and lowest levels in cumulus GCs ob-
tained from immature oocytes (germinal vesicle [GV]
and metaphase I [MI]) (28). These results clearly
demonstrated that LHR expression in cumulus GCs
correlated with the oocytes’ maturational stage (Fig. 3). 
LHR expression in cumulus GCs of MII oocytes ob-
tained during IVF procedures at the time of oocyte de-
nudation was also investigated. Cumulus GCs were
then grouped based on related oocyte fertilization out-
come and subjected to RT-PCR. We found signifi-
cantly lower levels of LHR mRNA in the cumulus of
oocytes that underwent fertilization compared to
oocytes that failed to be fertilized (28), providing evi-
dence that LHR expression in human cumulus GCs
can be a marker for oocyte quality and capacity to be
fertilized. High expression of LHR correlated with
lower fertilization capacity (Fig. 4).
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Introduction
Osteoporosis is a metabolic bone disease caused by a
reduction of bone mineral density and disruption of
bone strength (1). The substance of the bone is re-
duced with ageing thus increasing the risk of fracture
(2). Hormonal dysfunction during ageing may influ-
ence the onset and manifestation of osteoporosis.
Demographic calculations in Serbia predict that the
21st century will be the century of the elderly (3). This
may be true for other countries as well, thus placing
senile osteoporosis as a major health burden. The eti-
ology of senile osteoporosis is multifactorial. Genetic
predisposition (4), low vitamin D levels, malabsorp-
tion, low estrogen and androgen levels, thyroid and
parathyroid disfunction have cumulative influence on
bone structure (5). During the ageing process biologi-
cally active parathormone (PTH) concentration in-
creases (6), inducing increased bone turnover, mainly
through osteoclast’s bone resorption. Thyroid dysfunc-
tion is not uncommon in the elderly and often goes
clinically unrecognized (7).
The aim of this study was to assess thyroid and parathy-
roid function in elderly women with osteoporosis.
Material and metods
A group 260 elderly women referred by GP for Dual
photon Absorptiometry (DEXA) to the Osteoporosis
Unit, Division of Endocrinology, Diabetes and Me-
tabolism, Department of Medicine of the “Zvezdara”
University Medical Center, were studied. All of them
have never been previously treated for osteoporosis
and have never done a DEXA examination. Bone min-
eral density of the lumbar spine and hip was assessed
by the Hologic Explorer. T score, Z score and bone
mineral density (BMD) were recorded. After obtain-
ing an informed consent, assessment of thyroid and
parathyroid function was done. It included analysis of
thyroid stimulating hormone (TSH), free thyroxine 4
(FT4), thyroglobulin antibodies (TgAb), thyroid per-
oxidase antibodies (TPOAb), parathyroid hormone
(PTH), s-calcium and s-phosphorus. 
Measuring the concentration of TSH (ultrasensitive
method), FT4, TPOAb, TgAb, PTH, were performed
using CLIA (chemiluminescent immune determina-
tion), the camera automatically determine the “Im-
mulite 1000”. TSH has been expressed in mU/L, with
reference values from 0.4 to 4.0 mU/L. Values lower
than 0.4 mU/L characteristic for hyperthyroidism,
while values greater than 4.0 mU/L are characterized
by hypothyroidism, subclinical or manifest primary
hypothyroidism. FT4 has been expressed units of
pmol/L, with reference physiologic values from 12.4
to 24.4 pmol/L. TgAb and TPOAb have been ex-
pressed in IU/mL, with reference values 0-10 IU/mL.
PTH has been expressed in pg/ml with reference val-
ues for adults 10-65 pg/ml.
All results were expressed as mean ± standard error. A
level of significance was set at p>0.05. Linear correla-
tion was used to assess the influence of hormone levels
on DEXA parameters. The study was approved by the
“Zvezdara” Ethics Committee.
Results
In the group of 260 women, 20 patients had diabetes
mellitus, 1 had pancreatitis with malnutrition, 5 had
previously received glucocorticoid therapy and 3 were
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on estrogen therapy. Osteopenia was present in 36
subjects. This left 195 women with osteoporosis that
were included in the study. The mean age of 195
women with osteoporosis was 72±0.40 years. Howev-
er, 11 women did not show up for hormonal analysis.
Hence, statistical analysis was done in the group of
184 women. 
Parathormone disorder was found in 58% of partici-
pants. Mean PTH level in this group of women was
110.97±5.15 pg/ml. Elevated PTH levels showed a
significant positive correlation with decrease of T score
levels (- 3.12 ± 0.04, r:-0.94, p<0.01), Z scores (-1.38
± 0.06, r:-0.82, p<0.01) and BMD (0.56±0.01 gr/cm2,
r=0.93, p<0.01).
Thyroid disorder was present in 31% of participants,
unaware of thyroid illness (Table 1). Decreased TSH
levels, with the mean of 0.13±0.02 mU/l, indicating
hyperthyroidism, were found in 31 women. A signifi-
cant correlation was found between decreased TSH
levels and decreased T score (-3.1 ± 0.11, r = 0.25,
p<0.01), Z score (-1.42 ± 0.15, r= 0.51; p<0.01) and
BMD (0.55 ± 0.03 gr/cm2, r = 0.92, p<0.01). Elevat-
ed TSH levels with the mean of 14.65 ± 3.2 mU/l, in-
dicating hypothyroidism, were found in 26 women. A
significant correlation was found between elevated
TSH levels and decreased T score (-3.15 ± 0.1, r =
0.69; p<0.001), Z score (-1.51 ± 0.12, r=-0.62;
p<0.01) and BMD (0.56 ± 0.02 gr/cm2, r = 0.92,
p<0.01). The analysis of TPOAb, TgAb confirmed
that 20 patients with hypothyroidism and 15 with hy-
perthyroidism had autoimmune thyroid disease.
Discussion 
Our study has shown that thyroid and parathyroid
dysfunction are not uncommon in women with senile
osteoporosis. They influence bone metabolism, con-
tributing to low bone mineral density. Their treatment
would improve therapeutic outcome of osteoporosis. 
Risk of osteoporotic fractures throughout the life peri-
od is estimated at 30-40%. It is believed that 30-50%
of women and 15-30% of men have an osteoporotic
fracture during their lifetime. The prevalence of osteo-
porotic fractures in Serbia is unknown. But it is ex-
pected to increase dramatically with the aging of the
population, according to demographic calculations in
Serbia (3). 
Osteoporosis can be primary (menopausal, senile, id-
iopathic) or secondary. Secondary osteoporosis (8) can
be precipitated by side effects of medication (anticoag-
ulants, antiepileptic drugs, antacids, corticosteroids),
metabolic disorders, a number of illnesses (chronic
pancreatitis, malnutrition syndrome, rheumatoid
arthritis, cancer) and endocrine disorders (increased or
decreased secretion of parathormone and thyroid hor-
mones, decreased secretion of estrogenic hormones,
the disorder in type 1 diabetes and 2).
The importance of senile osteoporosis as a form of pri-
mary osteoporosis is increasing. With aging, the con-
centration of biologically active parathormone (PTH,
1-84) increases. The main physiological regulatory
mechanism of synthesis and release of parathormone is
under a negative feedback of calcium ion concentra-
tion and vitamin D in plasma (9). An increase of PTH
concentration causes a rapid increase in bone re-ab-
sorption, due to the increase in number and activity of
osteoclasts. This consequently increases the mobiliza-
tion of calcium and phosphate from bone and bone
demineralization (10). The increased PTH levels in
our group of women were probably caused by vitamin
D insuficiency. However, 25(OH)D3 was not meas-
ured in this study. 
Our results are in accordance with other studies, con-
firming the negative effect of thyroid dysfunction on
bone metabolism. The function of the thyroid gland
affects bone remodeling. Our study has shown that
69% of participants had normal thyroid function, but
that 17% had hyperthyroidism and 14% hypothy-
roidism (Table 1). Thyroid hormones, in physiological
concentrations, contribute to building bones, stimu-
lating osteoblast activities. However, in patients with
hyperthyroidism, there is low osteoid bone matrix for-
mation. Hyperthyroidism in the elderly causes rapid
bone re-absorption (11). The risk of femoral neck frac-
ture increases. Osteoid matrix strength is in direct cor-
relation with TSH suppression (12). In hypothy-
roidism there is a reduced number, activity and life
span of osteoblasts, secretion of calcitonin, which in-
creases the secretion of PTH levels resulting in degra-
dation of bone, osteopenia or osteoporosis. 
Conclusion
Thyroid and parathyroid dysfunction should be diag-
nosed in women will senile osteoporosis, in order to
improve therapeutic intervention.
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TABLE 1 - BONE QUALITY IN SUBJECT WITH THYROID
DYSFUNCTION.
Parameters Hyperthyroidism Euthyroidism Hypothyroidism
TSH 0.13±0.02 1.58±0.07 14.65±3.2
FT4 24.48±2.46 16.8±0.45 12.57±0.86
T score -3.2±0.11 -3.16±0.05 -3.15±0.1
Z score -1.42±0.15 -1.41±0.06 -1.51±0.12
BMD 0.55±0.03 0.58±0.01 0.61±0.02
number 31 (17%) 127 (69%) 26 (14%)
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Background 
Current findings describe a multifactorial mechanism
of endometriosis-associated infertility, suggesting that
among others, ovarian endometriotic cysts, inflamma-
tory changes, hormonal abnormalities and hyperpro-
lactinemia might interfere with reproduction and the
amount of functional ovarian tissue.
Aim of the study
In a retrospective study, 209 women receiving repro-
ductive surgical intervention were included. These
were subdivided as follows: (i) infertile women with
moderate to severe endometriosis (rAFS III-IV), (ii)
minimal to mild endometriosis (rAFS I-II), and (iii)
without endometriosis. Serum levels ofanti-Müllerian
hormone (AMH), Sex hormone-binding globulin
(SHBG), Dehydroepiandrosterone sulfate (DHEAS),
Thyroid-stimulating hormone (TSH), prolactin and
fibrinogen were evaluated, as well as anatomical find-
ings.
Results
An association between the severity of endometriosis
and blocked Fallopian tubes was observed (p=0.016).
AMH, DHEAS and fibrinogen were significantly dif-
ferent within the mild and severe endometriosis group
(2.53±1.36 ng/ml vs. 0.68±0.44 ng/ml, p<0.001;
1.86±0.65 µg/ml vs. 1.55±0.69 µg/ml, p=0.026;
311.00±74.05 mg/dl vs. 379±326 mg/dl, p=0.025, re-
spectively). No associations between serum prolactin
levels and severity of endometriosis could be observed.
Significantly lower AMH levels could be observed in
patients with severe endometriosis compared to the
control group (2.40±1.59 ng/ml vs. 1.09±1.23 ng/ml,
p=0.001).
Conclusions
A significant decline in AMH levels can be observed in
patients with moderate to severe endometriosis. Deep
ovarian endometriosis seems to be associated with a
decrease in the follicular ovarian reserve. 
Hormonal and surgical characteristics
of infertile patients with endometriosis
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Introduction
Lymph node extension is the main prognostic factor
for overall and disease free survival in cervical cancer.
In this context, lymphangiogenesis, formation of lym-
phatic vessels, has gained a lot of interest. In our study,
we have developed a new original method based on
computerized image analysis of lymphatic vessels on
whole slide scanned tissue sections. Based on this im-
aging system, we have performed a detail characteriza-
tion of tumoral lymphatic vasculature through cancer
progression and correlated with a risk of nodal exten-
sion.
Methods
Seventy-nine cases of cervical neoplasia (12 CIN3, 10
FIGO stage 1A1 and 57 FIGO stage 1A2 to 1B1) and
10 cases of normal tissues were reacted with anti-
podoplanin antibody (D2-40), a lymphatic endothe-
lial marker. Immunostained structures were automati-
cally detected on the whole slide. Whole field of the
cervical tissue was assessed from the normal squamous
tissue to transformation zone (TZ) and normal glan-
dular tissue. An objective lymphatic vessel density
(LVD), size and spatial distributions through cancer
progression were assessed.
Results
In normal cervix tissue, prominent LVD was already
detected under the TZ. During cancer progression,
proportion of lymphatic vessels near the tumor cells
(0.5mm) was increased. In invasive lesions, LVD was
not correlated to lymph metastases but peritumoral
LVD was associated with lymphatic vascular space in-
vasion by tumor cells.
Conclusion
Whole slide analysis of LVD and vessel distributions is
a robust objective method that is not subjected to in-
terobserver variability as is the case with conventional
optical microscopy. For the first time we provide evi-
dence that TZ presents a specific lymphatic vessel dis-
tribution and density before the appearance of neo-
plastic events. Increased LVD in the closed peritu-
moral area promotes lymphatic vessel invasion by tu-
mor cells.
Whole slide characterization of lymphatic vasculature
through cervical cancer progression: assessment of parameters
with potential impact on tumoral dissemination
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Background 
Many women of reproductive age experience some
emotional, behavioral or physical symptoms in the 1-2
weeks prior to menses. Data from previous studies,
conducted in different countries, show that premen-
strual syndrome (PMS) is one of the increasingly
common health problems of female students, but for
the majority of students premenstrual symptoms are
mild (3-8).
Premenstrual dysphoric disorder (PMDD) in women
of reproductive age is frequently associated with limi-
tations on social, academic, sports and daily activities.
However, there is insufficient data on the PMDD
prevalence and clinical features in medical students. 
Objectives 
To study the prevalence and clinical features of pre-
menstrual disorders in medical students of the 1st-6th
years of education.
Material and methods 
This cross sectional study was performed in 541 female
1st-6th year medical students of ëhita State Medical
Academy by questionnaire survey. The survey included
the American College of Obstetrics and Gynecology
(ACOG) criteria to diagnose PMS (2) and PMDD cri-
teria according to the Diagnostic and Statistical Manu-
al of Mental Disorders, 4th edition (1). This study was
approved by the Ethical Committee of the ëhita State
Medical Academy (Chita, Russia). The data obtained
were analyzed by χ-square test or z-criteria. The level of
significant differences was evaluated at 5%. 
Results 
PMS was diagnosed in 21.2% of all interviewed stu-
dents (115/541) and was estimated in 53.9% of them
(62/115) as mild, in 40.9% (47/115) - as moderate
and in 5.2% (6/115) - as severe. 
PMS symptoms prevalence was significantly higher in
elder students compare to the 1st-2nd year ones: it was
diagnosed only in 4.52% of the 1-st year students; in
10.96% of the 2-nd year students (p1-2 <0,05) and in
12.43% of the 3-rd year students (p1-3 <0,01; p2-3
>0,05). Frequency of PMS in 4th-6th year students was
the following: 15.29% in the 4-th year students (p1-4
<0,01); 17.02% in the 5-th year students (p1-5 <0,01;
p2-5 <0,05) and 16.30% - in the 6-th year ones (p1-6
<0,01; p2-6 <0,05) (Fig. 1). 
The symptoms of edematous form of premenstrual
syndrome (with mastodynia, weight gain, abdominal
bloating) was significantly more frequent in medical
students of the 2nd year of education compare to oth-
ers (Fig. 2). Emotional and psychical PMS symptoms
(anxiety, stress-discomfort, nervous-anger, mild de-
pression) and cephalgia were statistically more evident
in the 4-6-year female medical students (Figs. 3-4). 
Premenstrual dysphoric disorder (PMDD) symptoms
were observed significantly rarely in the 1st-3d year stu-
dents (p1-2 <0,05) (Fig. 5). The main PMDD symp-
toms were the following: severe emotional lability
(77.8%), appetite disorders, overeating and predilec-
tion for special foods (70,3%), somnolence and fatiga-
bility (63%) and attention-deficit disorders (59.3%).
Premenstrual disorders in female medical students:
a cross sectional study
BELOKRINITSKAYA T.E.1, FROLOVA N.I.1, SUTURINA L.V.2
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Such symptoms as anxiety and tenderness, insomnia,
anger and impatience were occur more rarely (in
22.2%, 18.5% and 14.8%, accordingly). 
Conclusion 
The results of our study show the significant frequen-
cy of premenstrual syndrome and premenstrual dys-
phoric disorder in medical students. The symptoms of
edematous form of premenstrual syndrome are more
frequent in 2nd year medical students, the prevalence of
psychical and emotional PMS symptoms, cephalgia
and PMDD is significantly higher in students of the
4th-6th years of education than in the 1st-3d year med-
ical students. 
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Fig. 1 - Premenstrual syndrome prevalence in medical students of 1st-6th
years of education.
Fig. 2 - The frequency of edematous form of PMS in medical students of
1st-6th years of education.
Fig. 3 - The frequency of psychical and emotional symptoms of PMS in
medical students of 1st-6th years of education.
Fig. 4 - The frequency of cephalalgic form of PMS in medical students of
1st-6th years of education.
Fig. 5 - The frequency of PMDD in medical students of 1st-6th years of edu-
cation.
Preterm birth is an important cause of infant morbid-
ity and mortality. Infants born preterm are at high risk
of many complications: respiratory distress syndrome
(RDS), intraventricular hemorrhage (IVH), necrotiz-
ing enterocolitis (NEC), periventricular leukomalacia
(PVL), retinopathy of prematurity (ROP), patent duc-
tus arteriosus (PDA), sepsis. RDS is the principal
cause of neonatal mortality and morbidity (1). Liggins’
incidental finding of the beneficial effect of antenatal
corticosteroids (ACS) for promotion of fetal maturity
is one of the most important discoveries in obstetrics
(2,3). However, prevention of preterm birth is still in-
sufficient and preterm birth rate continues to rise par-
tially because of an increase in multiple gestations sec-
ondary to assisted reproductive technologies and an
increase in maternal age at birth (1,2). 
Two regimens of ACS are effective in the promotion of
fetal maturity. Betamathasone is administered as 2
doses of 12 mg intramuscularly, 24 hours apart. Dex-
amethasone is administered as 4 doses of 6 mg intra-
muscularly, 12 hours apart. A number of studies have
attempted to determine the superior agent and be-
tamethasone has been described by experts as the
preferable agent for treatment of women at high risk
for preterm delivery (4). In fact, it was associated with
a reduced risk for neonatal death and, in some studies,
neonates exposed to dexamethasone had a higher rate
of PVL (5-8). The result of the only randomized con-
trolled trial comparing the 2 corticosteroids was re-
cently published (9). No significant differences in rates
of RDS, PVL, NEC, sepsis, or neonatal mortality were
found. However, neonates exposed to betamethasone
had a significantly higher rate of IVH (9). At this time,
according to ACOG guidelines, both drugs are accept-
able agents for promotion of fetal maturity. 
Administration of a single course (SC) of ACS should
be mandatory in the management of preterm delivery.
In fact, it does not increase maternal morbidity and
mortality and it is associated with an overall reduction
in neonatal death, RDS, IVH, NEC, infectious mor-
bidity, need for respiratory support, duration and cost
of neonatal care (10).
However, the decrease of neonatal morbidity and mor-
tality has been established only for infants born between
24 hours and 7 days after treatment. There is much con-
troversy about how long the therapy with ACS should
continue, and whether multiple courses (MC) should
be administered if the women remain at high risk of
preterm delivery 7 days or more after initial treatment.
Despite the lack of data confirming the safety and ef-
ficacy of additional exposures, administering MC of
ACS became very common across the world in the ear-
ly 1990s and the National Institutes of Health in 2000
stated that this kind of treatment should be firmly re-
served to women participating in RCTs (11).
Recently, Crowther and Harding concluded that MC
of ACS might reduce the occurrence and severity of
neonatal lung disease and the risk of serious health
problems in the first few weeks of life. However, these
benefits were associated with a significant reduction of
weight and head circumference at birth, and there was
still insufficient evidence on the longer-term benefits
and risks to recommend this treatment (12).
Moreover, a review and meta-analysis about benefits
and risk of MC of ACS concluded that administration
of MC of ACS does not add further benefits in term
of composite neonatal morbidity, even if it is associat-
ed with some short-term benefits, as a decreased risk of
RDS, of PDA, of use of surfactant, of ventilation sup-
port, and of any maternal side effects (13).
© Copyright 2012, CIC Edizioni Internazionali, Roma
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Peltoniemi et al wrote that weekly or beweekly repeat-
ed betamethasone might raise concern about long
term consequences on neurodevelopment and metab-
olism (14). 
The latest Cochrane review about MC of ACS states
that the current available evidence shows no signifi-
cant harm in early childhood, although no benefit
(15). Further research is needed on the long-term ben-
efits and risks for the women and babies.
Long-term results after administration of MC of ACS
were recently published. For Wapner et al, at two years
of age, there was no difference in weight, head circum-
ference, or the Bayley Mental Development Index
(MDI) and the Bayley Psychomotor Development In-
dex (PDI) between infants exposed to SC versus MC
of ACS (16). Although not statistically significant, the
rate of cerebral palsy in infants exposed to MC, espe-
cially more than 4 courses, was found to be of concern
and exposure to MC of ACS should be limited (16).
Crowther et al, as well, reported a 2 years follow-up
evaluation. They concluded that administration of
MC of ACS reduced neonatal morbidity without
changing either survival free of major neurosensory
disability or body size (17). For Asztalos et al MC of
ACS, given every 14 days, did not increase or decrease
the risk of death or neurologic impairment at 18 to 24
months of age, compared with a SC of prenatal corti-
costeroid therapy (18). Continued follow-up monitor-
ing of these children is necessary.
One strategy that has come into clinical use, without
supporting data, is to administer a “rescue” steroid
course (2). 
Unfortunately, with all the benefits steroids provide to
the fetus, we should never forget their effects on the
mother. For most, there is little effect, but for a few, se-
rious consequences can arise (19).
Steroid administration has been associated to mater-
nal infection (20,21). However, risks for maternal in-
fections (either antenatal or postdelivery) are either
nonexistent, or only slightly increased (20,21). A
well-established observation associated with steroid
administration is some degree of maternal hyper-
glycemia (19). Risks for diabetic ketoacidosis after
steroid administration are well known for known di-
abetic patients, but diabetic ketoacidosis has also
been described in patients with no prior history of
glucose intolerance (22). Evaluations of serum glu-
cose and urine ketones after steroid administration
would seem prudent and to maintain tight glucose
control, an insulin drip may be necessary. Transient
hypokalemia can occur after administration of
steroids. If the steroids are given in conjunction with
a beta agonist, risks for hypokalemia may be further
increased (23). Hypokalemic paralysis has been de-
scribed for patients with certain medical conditions,
such as a variety of renal diseases, as well as hyperthy-
roidism (23,24). In conclusion when administering
steroids, insulin dosages must be adjusted for the di-
abetic mother. A complete neurological examination,
as well as routine glucose and potassium testing,
should be considered, to determine whether addi-
tional precautions or treatments may be necessary for
all patients who are prescribed steroids in pregnancy
(19). However, in a international multicentre RCT,
MC of ACS (every 14 days) were not associated with
maternal side effects (25).
Future research should address those areas in which
other studies have suggested problems, as length of
drug effect, need for and risks of retreatment, ideal
drug and dosage, maternal side effects and long-term
effects. For the moment, obstetricians should be pru-
dent in prescribing MC of ACS in women at risk of
preterm birth. 
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The Odette Cancer Centre established an inter-profes-
sional clinic to address the sexual health, reproductive
and endocrinology concerns (SHARE clinic) of
women who had been treated for cancer. Initially fo-
cusing on women with gynecologic cancers, the clinic
has expanded to offer services to women with pelvic
cancers and more recently to young women with
breast cancer. The clinic design had anticipated a high
need for sexual therapy, instead we found a very high
degree of menopausal symptoms and vaginal symp-
toms; symptoms that are very amenable to brief inter-
ventions by individuals experienced in menopause
management.
This abstract reports on experience with the first 142
patients assessed through this clinic.
Patients were referred to SHARE Clinic by their on-
cologist, with referrals coming from gynecologic on-
cology or general surgery, radiation and medical on-
cologists. The majority of patients seen were referred
with a diagnosis of gynecologic or breast malignancy:
11% ovarian, 48% cervix, 34% endometrium, 15%
breast,all others 14 (10%). The mean age was 47. The
proportion of women who had undergone pelvic irra-
diation varied by site
Across all sites of cancer, patients reported decreased
interest in close physical contact (58.3%) and low or
no desire (62.2%). 
Vaginal complaints were extremely common. 75% re-
ported vaginal dryness, 66% reported the vagina to be
“smaller”. 25% of women were not having intercourse.
An additional 34% reported that they almost never ex-
perienced vaginal lubrication, and fully 75% experi-
enced pain with intercourse.
The majority of vaginal symptoms could be easily
managed with local estrogen. In a few cases lichen scle-
rosus was detected, in one case a prolapsed fallopian
tube, and in one case a neuroma. Symptoms were
more difficult to manage in women with breast cancer
on aromatase inhibitors, in whom even local estrogen
is avoided.
Sexual health, reproductive and endocriniologic concerns in women
after cancer: early findings from a multidisciplinary clinic
BLAKE J., ADAMS L., DOYLE C., SLIWIN F., FITCH M.
Sunnybrook Health Sciences Centre, University of Toronto, Canada
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Introduction 
Hirsutism is present in 5-10% of women in reproduc-
tive age and polycystic ovary syndrome (PCOS) is the
most common cause of it. It is defined as the presence
of androgenic hair in hormonal dependent areas of the
female body. Modified Ferriman-Gallwey score
(mFG) is used to assess it and classically, hirsutism is
considered when mFG is ≥8. Although largely used,
that cut off sometimes is not adequate depending of
the population assisted. In this study we investigated
the relationship between mFG score, complaint of
hair excess, clinical and laboratorial parameters in
PCOS women.
Objectives
To assess the complaint of hair excess in PCOS women
with mFG <8 and to study the relationship between
the degree of hirsutism and clinical and laboratorial
parameters.
Methods 
A total of 299 PCOS women diagnosed with Rotter-
dam Criteria. Hirsutism was assessed through mFG
score and classified as absent (<8), mild (8-12), mod-
erate (13-18) and severe (≥19).
Clinical measurements: abdominal circumference and
body mass index. Laboratory: total and free testos-
terone, HOMA-IR index, and basal insulin.
Statistical tests used were Chi Square, ANOVA, Bon-
ferroni and Dunn’s. In 77 subjects with mFG <8 com-
plaint of hair excess was evaluated and in 245 patients,
association between hirsutism score and clinical and
laboratorial parameters were studied. Women with Di-
abetes Mellitus and impaired glucose tolerance were ex-
cluded from this analysis. 
Results 
Mean age was 25.4±5.3 (14-41 years). All PCOS
women with score 7 and 50% of those with score 6 pre-
sented complaint of hair excess (Table 1). HOMA-IR
index and basal insulin were positively associated with
higher degrees of hirsutism (p=0.007 and p=0.015, re-
spectively) (Table 2). BMI and AC presented no rela-
tionship with hirsutism degree but HOMA-IR and
basal serum insulin did (Table 3).
Assessment of hirsutism and associated factors in Brazilian women:
necessity of definition of local standards
BOUFELLI DE FREITAS G., HAYASHIDA S.A.Y., ANZAI A., CURI D., SORES J.M. JR,
MARCONDES J.A., MACIEL G.A.R., BARACAT E.C.
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TABLE 1 - RELATIONSHIP BETWEEN COMPLAIN OF HAIR EXCESS AND MODIFIED FERRIMAN-GALLWEY SCORE (MFG).
Complaint Score 0 Score 1-2 Score 3-4 Score 5 Score 6 Score 7 
(n/%) (n=11) (n=12) (n=15) (n=10) (n=12) (n=17) 
Yes 2 (18,2) 2 (16,7) 6 (40,0) 4 (40,0) 6 (50,0) 17 (100) 
No 9 (81,8) 10 (83,3) 9 (60,0) 6 (60,0) 6 (50,0) 0 (0,0) 
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Conclusion 
In the Brazilian population studied, an important
number of women with mFG <8 have complaint of
hair excess. BMI, abdominal circumference, free
testosterone and HOMA-IR were not correlated to
hirsutism. Women with score ≥13 presents greater
HOMA-IR and basal insulin, which might lead to an
increase of cardiovascular risk due. We suggest that the
hirsutism score cut off in Brazil should be ≥6. Local
standards of hirsutism score should be adopted to bet-
ter treat women with androgen excess. 
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TABLE 2 - THE RELATIONSHIP BETWEEN mFG SCORE AND FREE TESTOSTERONE (T), HOMA–IR INDEX AND
BASAL INSULIN (I0).
mFG score Absent (score <8) Mild (score 8-12) Moderate (score 13-18) Severe (score ≥19) p 
(n=59) (n=70) (n=81) (n=35)
Free T 34 (57,6) 43 (61,4) 53 (65,4) 25 (71,4) 0,557 
HOMA > 2,7 19/57 (33,3) 22/60 (36,7) 47/79 (59,5) 18/34 (52,9) 0,007
I0 > 20 8/58 (13,8) 7/60 (11,7) 24/79 (30,4) 10/34 (29,4) 0,015
↓
TABLE 3 - COMPARISON BETWEEN ABDOMINAL CIRCUMFERENCE (AC), BODY MASS INDEX (BMI), FREE TESTO-
STERONE (T), HOMA-IR ÍNDEX, BASAL INSULIN (I0) AND mFG SCORE.
Modified Absent (score <8) Mild (score 8-12) Moderate (score 13-18) Severe (score ≥19) p 
Ferriman-Gallwey score (n=59) (n=70) (n=81) (n=35) (ANOVA)
BMI (kg/m2) 27,2±6,7a 28,1±7,5 30,7±6,3a 29,8±6,5 0,015
AC (cm) 84,9±14,2b 88,0±17,5 94,1±13,4b 93,5±16,9 0,008
Free T (pmol/mL) 55,9±33,1 56,5±34,6 69,6±42,4 68,9±39,1 0,061
HOMA* 2,75±2,48c 2,57±1,88c 3,95±3,29d 4,33±3,61d 0,001
I0* (mUI/mL) 12,7±10,6d 11,8±8,3d 18,4±14,6e 20,0±16,5e <0,001
Bonferroni : a (p=0,018); b (p=0,014)
*Multiple comparisons of Dunn: all results were statistically significant except c (p=0,891), d (p=0,796) and e (p=0,959).
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Introduction
Endometrial cancer is the sixth most frequent (4.9%)
of all cancers diagnosed in the female population, the
risk of endometrial cancer being higher in patients
with high serum estrogen levels and/or low proges-
terone levels (1). Obesity increases systemic exposure
to free estrogens via the aromatization of androgens in
visceral adipose tissue, via the reduction of sex hor-
mone binding globulin production, via the reduction
of serum progesterone by anovulation, via the proin-
flammatory state (2).
Starting from the idea that in modern society the
prevalence of obesity is increasing and that adipose tis-
sue is directly correlated with a number of disorders,
today we speak of adipose tissue dysfunction as an indi-
vidual pathological condition. Adipose tissue is no
longer considered just an energy storage organ, but a
real endocrine organ whose hormones have not been
completely characterized. Adipocyte biomolecules
(leptin, adiponectin) have been identified, which are
involved in the transmission of messages from adipose
tissue to other target tissues.
Given that obesity and visceral obesity in particular is
a risk factor for endometrial cancer, and that visceral
adipose tissue secretes more than 50 inflammatory cy-
tokines, in this study we aimed to assess the correla-
tion between the plasma levels of inflammatory cy-
tokines secreted by adipose tissue (leptin and
adiponectin) and endometrial cancer.
We initiated a study that aimed to evaluate the pres-
ence of a correlation between intraabdominal adiposi-
ty assessed by ultrasounds (US) and endometrial can-
cer, as well as the presence of a correlation between in-
traperitoneal fat and cytokines (adiponectin and lep-
tin) secreted by adipocytes in patients diagnosed with
endometrial cancer.
Materials and methods
The study is a case-control analysis that includes 2
groups of patients: group I – 44 patients diagnosed
with endometrial cancer, group II – 44 patients with-
out gynecological pathology or inflammatory disor-
ders (control group).
The diagnosis of endometrial cancer was made after a
histopathological examination that analyzed the tissue
material obtained following endometrial biopsy. En-
dometrial biopsy was performed in the case of consid-
erable metrorrhagia, in the case of metrorrhagia dur-
ing climax, as well as in the case of some aspects de-
tected by US (endometrial thickness and vasculariza-
tion).
Group I
Inclusion criteria
– Diagnosis of endometrial cancer following
histopathological examination.
– Age 40-85 years.
– Willingness and ability to submit to the research
procedures.
Exclusion criteria
– Other genital diseases than endometrial cancer.
– Treatment with systemic corticosteroids.
– Metabolic or endocrine diseases.
– Chronic autoimmune diseases.
– Malignant tumors.
Visceral fat trough its products,
a risk factor for endometrial cancer
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Group II
Inclusion criteria
– Age 40-85 years.
– Willingness and ability to submit to the research
procedures.
Exclusion criteria
– Other genital diseases than endometrial cancer. 
– Treatment with systemic corticosteroids.
– Metabolic or endocrine diseases.
– Chronic autoimmune diseases.
– Malignant tumors.
After the performance of clinical examination and an-
thropometric measurements: body mass index (BMI),
abdominal circumference (AC), these patients underwent
US examination that determined intraperitoneal fat.
BMI was calculated by the formula BMI = weight
(kg)/[height (min)]2. AC (cm) was measured in ortho-
statism, at umbilical level. Ultrasonographic explo-
ration (Voluson 739) was performed in dorsal decubi-
tus at the end of a normal expiration, after a 12 hour
digestive rest, in order to evaluate visceral fat deposit.
The visceral fat area determined by ultrasound was cal-
culated using the formula 9.008+1.191×[distance be-
tween the inner side of the right abdominal muscle
and the splenic vein (mm)]+0.987×[distance between
the inner side of the right abdominal muscle and the
posterior wall of the aorta (mm)]+3.644×[fat thickness
in the posterior wall of the right kidney (mm)] (3). 
From each subject included in the study, 6 ml fasting
blood were taken by venous puncture and collected in
test tubes without anticoagulant for the measurement
of plasma leptin and adiponectin levels. The serum ob-
tained by centrifugation was divided and stored in 600
µl freezing tubes at a temperature of –30°C in order to
avoid repeated freezing-thawing cycles. The serum lep-
tin concentration was determined by the sandwich
ELISA technique using the Human Leptin Imunnoas-
say DLP00 kit, R&D Systems USA. The serum
adiponectin concentration was determined by the
sandwich ELISA technique using the Human Total
Adiponectin/Acrp30 Immunoassay DRP300 kit,
R&D Systems USA. 
All parameters were included in the study database,
and version 13 of the SPSS software and Microsoft Ex-
cel with Analysis Tool Pack were used for statistical
analysis. The Kolmogorov Smirnov test was applied
for the testing of normal distribution. The Student t
test was used for the comparison of the means and the
Mann-Whitney test for rank comparison in two inde-
pendent samples.
The informed consent of all patients was obtained.
Results 
In the control group the mean visceral fat area was
142.41±23.06 cm2 (with limits between 93.15 and
197.24), while in the group of patients with endome-
trial cancer the mean visceral fat area was
252.72±57.14 cm2 (with limits between 141.56 and
361.83 cm2). Thus, there was a statistically significant
difference in intraperitoneal fat between the two
groups (p<0.0001) (Fig. 1).
The plasma levels of the adipokines monitored in the
study – leptin and adiponectin – are shown compara-
tively between the two groups in Table 1. 
The plasma adiponectin level in the group with en-
dometrial cancer is 7374.17±4701.35 ng/ml (with
limits between 1739.95 and 20623.48 ng/ml), and in
the control group 11045.68±4920.93 ng/ml (with
limits between 2803.99 and 23494.22 ng/ml), with a
Fig. 1 - Comparison of intraperitoneal fat between the two groups.
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TABLE 1 - COMPARISON OF PLASMA ADIPOKINE LEVELS BETWEEN THE TWO GROUPS.
Arithmetic Standard Standard 95% confidence Minimum Maximum p
mean deviation error interval
Adiponectin ng/ml
Control 11045.68 4920.93 741.86 9549.58 12541.78 2803.99 23494.22 <0.00001 
Case 7374.17 4701.35 716.95 5927.30 8821.03 1739.95 20623.48
Leptin pg/ml
Control 17103.79 12002.64 1809.47 13454.65 20752.92 2271.37 50335.20 <0.00001
Case 40675.5 27912.73 4256.65 32085.23 49265.77 3151.76 122570.98
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statistically significant difference between the two
groups. The plasma leptin level in the group with en-
dometrial cancer is 40675.50±27912.73 pg/ml (with
limits between 3151.76 and 122570.98 pg/ml), being
significantly increased compared to the control group,
where a value of 17103.79±12002.64 pg/ml (with lim-
its between 2271.37 and 50335.20 pg/ml) is found.
The analysis of the relationship between intraperi-
toneal fat and plasma adipokine levels shows a positive
linear relationship between intraperitoneal fat and the
plasma leptin level (Fig. 2), while the plasma
adiponectin level is in a negative linear correlation
with intraperitoneal fat (Fig. 3). The correlation coef-
ficient between intraperitoneal fat and leptin is r=0.43,
p=0.00003 indicates a significant correlation between
intraperitoneal fat and leptin; 25% (d=r2=0.25 – dia-
gram) of the leptin value is due to intraperitoneal fat.
The correlation coefficient between intraperitoneal fat
and adiponectin is r=-0.23, p=0.03 indicates a signifi-
cant correlation between intraperitoneal fat and
adiponectin; 5% (d=r2=0.05 – diagram) of the
adiponectin value is due to intraperitoneal fat.
Discussion
The risk of cancer disease in general increases with the
increase in body weight, which is demonstrated in
both men and women. In economically developed
countries, endometrial cancer is associated with obesi-
ty in a proportion of 40% (4).
Regarding the visceral distribution of adipose tissue,
intraabdominal obesity is considered a low-grade
chronic proinflammatory state (5). In the context of
endometrial cancer, visceral obesity as a risk factor is
associated with a chronic inflammatory process, con-
firmed by the increase of inflammatory markers in the
systemic circulation of obese patients (6). This study
supports the idea that visceral adipose tissue is a risk
factor for endometrial cancer; there is a statistically sig-
nificant difference in intraperitoneal fat between the
two groups.
Visceral adipose tissue has the capacity to secrete many
substances that can be involved in the pathogenesis of
endometrial cancer. Adiponectin is an adipocytokine
exclusively secreted by adipose tissue. In women with
increased plasma adiponectin levels, the risk to devel-
op endometrial cancer is 50% lower compared to
women with low adiponectin levels. This inverse cor-
relation persists after the BMI correction, suggesting
that adiponectin is a predictor for endometrial cancer,
independently of obesity (7).
The association between low plasma adiponectin lev-
els and endometrial cancer might be explained by the
antiangiogenic properties of adiponectin. Adiponectin
inhibits angiogenesis both in vivo and in vitro.
Adiponectin inhibits tumor growth by suppressing the
development of neoformation vessels in rats. These
findings support the idea that low adiponectin levels
are associated with increased angiogenesis required for
the development of endometrial cancer (8). In this
study, plasma adiponectin levels are significantly low-
er in the group of patients with endometrial cancer
compared to the control group.
Inflammation and insulin resistance are important risk
factors for endometrial cancer. Due to the interrela-
tions between adiponectin and these risk factors, the
implication of adiponectin in the etiopathogenesis of
endometrial cancer is an increasingly supported hy-
pothesis (9).
The evidence gathered so far shows that the measure-
ment of adiponectin can be a useful screening method
for the early detection of cancer correlated with obesi-
ty. Moreover, adiponectin or its homologues may be
antioneoplastic agents and may have important thera-
peutic implications.
Fig. 3 - Correlation between adiponectin and intraperitoneal fat.
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Fig. 2 - Correlation between leptin and intraperitoneal fat.
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Regarding leptin, it was initially considered that this is
only produced by adipose tissue, but subsequent in vi-
vo and in vitro studies have identified other origins,
the stomach, liver, placental and amniotic trophoblast
cells (10,11). Regarding adipose tissue, the secretion of
leptin occurs in various areas: subcutaneous, retroperi-
toneal, omental, perilymphatic (12).
Obese persons have high serum leptin levels, but this
does not cause weight loss, suggesting that overweight
is correlated with leptin resistance.
The decrease in serum leptin levels is correlated with
the alteration of the balance between proinflammato-
ry cytokines and antiinflammatory cytokines (IL-10,
IL-1R) (13), supporting the hypothesis that leptin can
affect antiinflammatory cytokine production through
the activation of signal transducer and activator of tran-
scription 3 (STAT-3). Inflammatory cells can secrete
leptin, which in its turn can intensify the inflammato-
ry process (14). The induction of leptin by these in-
flammatory stimuli can be considered part of the sys-
temic acute phase reaction (15). Proinflammatory cy-
tokines such as TNF-α and IL-1β contribute to the
increase in serum circulating leptin levels through the
release of leptin stored in adipose tissue (16).
In contrast to increased serum leptin levels, low serum
adiponectin levels are found in obese persons, which
are inversely proportionally correlated with intraperi-
toneal fat in this study, as well as in other literature
studies (17).
Abdominal adipose tissue through the mediation of
adipocytes can change the plasma levels of adipokines
(leptin and adiponectin) and secondarily, it can favor
endometrial carcinogenesis.
Conclusions
1. Intraperitoneal fat is significantly higher in the
group of patients with endometrial cancer.
2. Endometrial cancer is associated with low plasma
adiponectin levels and high plasma leptin levels.
3. Visceral fat has a positive linear correlation with
plasma leptin levels and a negative correlation with
plasma adiponectin levels.
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Introduction
PCOS is one of the most common female endocrine
disorders. It’s a complex heterogenous disorder of un-
certain etiology, though there is evidence that it can to
a large degree be classified as a genetic disease (1,2,3).
PCOS produces symptoms in approximately 5-10%
of women in reproductive age and it is thought to be
one of the leading causes of female subfertility and the
most frequent endocrine problem in young age
(4,5,6,7).
The principal features are anovulation, resulting in ir-
regular menstruation, amenorrhea, ovulation – related
infertility and polycystic ovaries; excessive amounts or
effects of androgenic hormones resulting in acne and
hirsutism and insulin resistence, often associated with
type 2 Diabetes and high cholesterol levels.
PCOS has been strongly associated with metabolic de-
railments such as MetS and IR. (Korhonen et al.,
2001; Apridonidze et al., 2005; Dokras et al., 2005).
Both conditions imply changes in carbohydrate and
lipid metabolism and a constellation of risk factors for
development of cardiovascular disease. (Legro et al.,
1999; Talbott et al., 2000; Grundy et al., 2004; Orio
et al., 2004; Vryonidou et al., 2005; Ehrmann et al.,
2006).
Both the above mentioned conditions and progression
of undetected insulin resistence in PCOS women can
lead to type 2 Diabetes, which itself is a very impor-
tant risk factor for future cardiovascular disease in
women (Lo et al. 2008).
This illustrates perfectly the need of an early detection
of IR and subsequent application of preventive meas-
ures in PCOS in women.
The group of women diagnosed with PCOS has
broadened considerably after the application of Rot-
terdam criteria.
In 2003 a consensus workshop sponsored by
ESHRE / ASRM in Rotterdam indicates PCOS to
be present if any 2 out of 3 of the following criteria
are met; 1. oligoovulation and / or anovulation, 2.
excess of androgen activity, 3. polycystic ovaries (by
gynecologic ultrasound examination) (other entities,
are excluded (9)).
PCOS has been known in literature with different
names, such as polycystic ovaries disease, functional
ovarian hyperandrogenism, Stein – Leventhal syn-
drome, ovarian hyperthecosis, and sclerocystic ovary
syndrome.
This condition acquired its most used name due to
common signs of ultrasound examination of multiple
(poly) ovarian cysts. The “cysts” are actually immature
follicles, not cysts.
Most of the patients with PCOS have IR and / or are
obese. Their elevated insulin levels contribute to, or
cause the abnormalities seen in the hypothalamic – pi-
tuitary – ovarian axis, which will lead afterword to
PCOS. Hyperinsulinemia, increases GnRH pulse fre-
quently. LH over FSH dominance increases ovarian
androgen production (10), decreases follicular matura-
tion and decreases SHBG; all these steps contribute to
the development of PCOS. 
But IR is a common finding among patients of normal
weight, as well as overweight patients. 
Under these circumstances, we need to figure if we
should screen for the presence os MetS and IR in all
patients diagnosed with PCOS and possibly find out
what subgroups are more prone to develop these meta-
bolic complications.
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Materials and methods 
Our study was conducted between May 2008 and De-
cember 2009.
It comprised females with PCOS, who’s primer inten-
tion was to conceive. These patients were refered to
our clinic for infertility problems.
All women presenting with oligomenorrhea (mean in-
terval between bleedings >/=35 and <182 days) or
amenorrhea (mean interval between bleedings >/=182
days) were systematically evaluated in our outpatient
clinic.
Information was obtained regarding age, race, history
of cycle abnormality, medical and family history, pre-
vious, or present use of medications, presence of acne
and hirsutism, BMI, blood pressure, waist and hip cir-
cumference, fasting early morning endocrine profile,
lipid, glucose and insulin.
A systematic pelvic ultrosonography was performed al-
so in 3D images. 
The diagnosis of PCOS was based on Rotterdam cri-
teria, according to which, the diagnose of PCOS was
considered positive, if at least 2 out of the following
criteria were present: oligo / amenorrhea, clinical or
biochemical hyperandrogenism and PCO in ultra-
sound examination.
Clinical hyperandrogensim was defined as the pres-
ence of hirsutism and / or acne, while biochemical hy-
perandrogenism was present if the calculated free an-
drogen index (FAI = testosterone / sex hormone –
binding globuline x 100) was >4.5 (Vermeulen et al.
1999). 
PCO was defined as the presence of at least one
ovary >10 cm3 in volume, and / or at least one ovary
with 12 or more follicles measuring 2-9mm in diam-
eter.
Other etiology, that could mimic PCOS like, Cushing
syndrome, or androgen producing neoplasms ect, were
not subject of this study, so were left out of it.
MetS was defined according to NCEP ATP III guide-
lines. MetS was considered a positive diagnose if at
least 3 out of 5 features were present:
1. Waist circumference > 88 cm
2. Serum triglycerides >/= 1.70 mmol/l
3. HDL – cholesterol <1.30 mmol/l
4. Blood pressure >/= 130/85 mmHg
5. Fasting plasma glucose >/= 6.11mmol/l
IR was assessed using the HOMA (fasting insulin x
fasting glucose/ 22.5).
A threshold point of 3.8 was used in this study as we
have read before in Kauffman et all (2002).
A HOMA–IR value >3.8 probably reflects severe IR,
because the threshold of 3.8 was based on inslune con-
centration above the upper limit of normal after a 100
g oral glucose tolerance test as standard test.
The entire group presenting oligo or amenorrhea, un-
derwent the screening examination between May
2008 and December 2009.
The physical examination included blood pressure
measured after a 10 min. rest, with a proper inflatable
cuff size, adapted to the upper arm circumference in
order to meet individual needs of each patient.
Waist circumference, was measured in the standing
position halfway between the lower ribs and the supe-
rior anterior iliac spine of the pelvis.
The hip circumference was measured at the level of
pubic symphysis.
Hirsutism was defined after the Ferriman – Galwary
score (11).
The original score included 11 body areas to assess
hair growth, but it decreased afterword to 9 body ar-
eas in the modified method:
1. Upper lip
2. Chin
3. Chest
4. Upper back
5. Lower back
6. Upper arms
7. Forearms (deleted in the modified method)
8. Thighs
9. Legs (deleted in the modified method)
Ultrasound examination was performed with a trans-
vaginal transducer.
Results
Our study, had a modest group of women diagnosed
with PCOS, as explained above, all of which were ex-
cluded from any PCOS mimic pathologies. 
As a result of all the above mentioned examinations
performed to all the women treated in our clinic, we
found the following results, regarding the prevalence
of the two most important endocrine disorders.
The prevalence of Mets and IR were respectively
24.9% and 24.3% (p, 0.001) and the prevalence be-
tween anovulatory women with or without hyperan-
drogenism was 23.1% and 13.9% (p 0.001)
The Mets prevalence also differed among women with
or without polycystic ovary 23.1% and 63.8%.
The results, clearly show the significant difference in
the prevalence of MetS between different phenotypes
of PCOS.
What appeared to be an interesting finding was the
high prevalence of both Mets and IR in the subgroup
without any ultrasonographyc finding.
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Conclusion
In conclusion, from our study we can afferm that the
prevalence of MetS and IR varies between the pheno-
typic groups of PCOS. Specially hyperandrogenemia
PCOS phenotypes resulted in higher risk for MetS
and IR.
Though, it is still a concern, whether all women
should from a clinical point of view be part of a
screening process which has it economical cost.
As we have explained during this article, the group
chosen is small and there is lack of materials to refer to,
so further evaluation will be needed. For as much as
we can say now, it Is our modest opinion to advise
young women, in process of conception, to stick to the
screening program. This will not only help to con-
ceive, but most important it will help them stay
healthy, avoid further complications due to metabolic
imbalances. 
Discution
The current study, has it’s limitations. 
Our group is a small group, besides this is the first
time, a study of this kind was ever conducted in our
country as far as we are concearned. So there is almos
t no data, to wich we can refer, no references to help,
therefore, it will need further evaluation.
Even in this moment, we are still collecting datas of
women resulting with PCOS, hoping in a future re
proposing this article with enriched datas.
Other limitations, include the establishment of IR. It
is a very gradual phenomenon wich makes the thresh-
old values artificial. Furthermore, patients with
HOMA – IR <3.8, may still at some degree have IR. 
In this study, as in most studies like-wise, the NCEP –
ATP III was used for the assessment of Mets. Had we
instead used the IDF definition of Mets its prevalence
would have appeared to be much higher, almost double
as high as it resulted from our study, vased on NCEP
ATP II, because of stricter waist circumference criterion.
It is not yet known why women with PCOS tend to
have a more android body fat distribution, which
makes them prone to metabolic disturbances, leads to
hyperandrogenism, which precludeas a vicios cycle of
hyperandrogenism,hirsutism and metabolic abnor-
malities.
From a clinical point of view, it may be questioned
weather all women should be screned for IR and Mets.
It is our opinion, based on datas gathered in these 2
years of study, that screening for both conditions, to
help women of very young age and fertile age, get the
proper treatment in order to avoid future complica-
tion, is a wise approach. 
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Introduction
Hyperprolactinemia is a condition characterized by ex-
cessive secretion of prolactin. Pituitary tumors are its
most frequent causes, among them, the most common
is prolactinoma. Other pituitary tumors may cause an
increase in prolactin release by compressing the pitu-
itary stalk and preventing dopamine which inhibits pi-
tuitary prolactin production, from reaching the pitu-
itary. These other tumors may lead to a misdiagnosis
of the etiology and treatment of hyperprolactinemia,
due to other causes such as FSH-secreting pituitary tu-
mors.
In women, FSH-secreting pituitary tumors may be di-
agnosed at any age. In the menacme, these tumors
may cause amenorrhea and ovarian hyperstimulation
with increased ovarian volume and formation of ovar-
ian cysts. 
FSH and estradiol (E2) levels may vary in tumors se-
creting FSH and this creates difficulty in diagnosing
these tumors. Prolactin levels may also be elevated by
pituitary stalk compression, as previously mentioned.
Due to the variation in laboratory findings, immuno-
histochemistry of the tumor is important to confirm
the diagnosis.
Surgical resection of FSH-secreting tumors is current-
ly the first choice of treatment. Radiation therapy may
be another option. Only a small number of studies
have analyzed the use of GnRH antagonists in the
treatment of these patients. 
This study describes a case report of a patient with
FSH-secreting pituitary adenoma manifesting Ovari-
an Hyperstimulation Syndrome.
Objectives
To draw attention to other non-prolactinoma pitu-
itary tumors that may cause an increase in prolactin re-
lease by pituitary stalk compression and describe a case
report of a FSH-secreting pituitary tumor managed
with a new therapeutic option – Ganirelix, a GnRH
antagonist.
Methods
To report a case of a 26-year old patient who received
a diagnosis of a FSH-secreting pituitary tumor with
Ovarian Hyperstimulation Syndrome followed at the
Outpatient Facility of the Department of Obstetrics
and Gynecology in the Universidade Estadual de
Campinas School of Medicine.
The diagnosis was made by laboratory testing and im-
aging (computerized tomography-CT and magnetic
resonance imaging-MRI of the sella turcica). The pa-
tient underwent pituitary surgery and during follow-
up treatment she was given Ganirelix.
Results
The patient received follow-up care at the Outpatient
Facility of the Department of Obstetrics and Gynecol-
ogy in the Universidade Estadual de Campinas, due to
secondary amenorrhea. During the investigation, lab-
oratory tests were performed and hyperprolactinemia
was found (prolactin 269ng/mL). Following this re-
sult, CT of the sella turcica was ordered showing a pi-
tuitary tumor measuring 17×12×10mm. Ultrasonog-
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raphy (US) was also performed, revealing a increase in
ovarian volume (right:320cm3, left:513cm3). This US
finding was not initially taken into account and the
patient received a diagnosis of macroadenoma of the
pituitary. Cabergoline, a dopamine agonist, was used
for the initial treatment of the patient.
Despite a fall in prolactin levels (to 2.86ng/mL) after
treatment with Cabergoline was started, she remained
in amenorrhea and began to complain of abdominal
pain. MRI (Fig. 1) of the sella turcica was then or-
dered, showing a pituitary lesion measuring
25×15×18mm that invaded the cavernous sinus. After
the performance of MRI, new laboratory studies were
ordered, and high serum levels of E2 were detected
(3637pg/mL), with normal levels of LH and FSH.
Taken together, all these findings led us to the diag-
nostic hypothesis of an FSH-secreting tumor.
Partial resection of the tumor was performed by using
the transsphenoidal approach. Diagnostic hypothesis
was confirmed by histopathology that showed a chromo-
phobic pituitary adenoma and immunohistochemistry
that was FSH-positive in more than 50% of the adeno-
ma cells, but negative for estrogen receptors (Fig. 2). 
Following surgery, the patient experienced a period of
transient decreases in E2 levels and ovarian volume.
However, within 3 months there was an increase in
ovarian volume, with abdominal pain and a new rise
in E2 levels. Once again, MRI of sella turcica was per-
formed, disclosing the persistence of pituitary tumor.
A new therapeutic option was begun with the GnRH
antagonist, Ganirelix, in combination with Cabergo-
line. 
After 30 days of treatment, E2 levels were unde-
tectable and the patient had a new reduction in ovari-
an volume (right:22cm3, left:15cm3). Unfortunately,
Ganirelix had to be discontinued because it was no
longer available for patient supply and only Cabergo-
line was maintained. There was a recurrence of elevat-
ed E2 levels and an increase in ovarian volume
(right:89cm3, left:31cm3), with intense abdominal
pain (Table 1). The performance of bilateral oophorec-
tomy was required.
Discussion
Pituitary adenomas that secrete FSH are rare. In
women, they progress with amenorrhea with ovarian
hyperstimulation. In this case report, the diagnosis of
an FSH-secreting tumor was not made immediately
because hyperprolactinemia associated with a tumor
visualized initially by CT of sella turcica led to a mis-
diagnosis of pituitary Macroadenoma.
In FSH-secreting tumors, the serum levels of E2 vary
widely. In the majority of the cases described, they are
increased. Low E2 levels in some patients could be ex-
plained by extremely low LH levels, which is also im-
portant for the synthesis of E2. 
Since FSH levels are variable and frequently normal,
the reasons for ovarian hyperstimulation are debated.
It is questioned whether there is an increase in FSH bi-
ological activity or a failure of the methodology used
to measure this hormone. There could be a lack of de-
tection of the active FSH components or FSH isomers
produced by the tumor. The use of histopathology and
immunohistochemistry are necessary to establish the
diagnosis of FSH-secreting pituitary tumor. 
A study using a suppression test with E2 suggested
that FSH-secreting tumors do not respond to sup-
pressing levels of circulating E2 as occurs with the nor-
mal pituitary gland. Thus, in the present case report
the estrogen receptor was investigated by immunohis-
tochemistry of the tumor tissue and was negative, in-
dicating that high serum estrogen levels may not exert
suppressive activity on tumor tissue due to the lack of
receptors in these cells. 
After 4 weeks of treatment using Cabergoline and
Ganirelix, E2 levels were undetectable, ovarian volume
decreased and the patient was asymptomatic. Unfortu-
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nately, due to difficulty in drug acquisition, Ganirelix
was discontinued. It was observed that Cabergoline
alone was not capable of controlling ovarian hyper-
stimulation and there was a recurrence of clinical fea-
tures and laboratory findings. 
During medication use, a significant decrease in FSH
levels was not identified. We believe that clinical im-
provement in relation to ovarian hyperstimulation
may have occurred due to a reduction in LH levels and
to a GnRH antagonist direct effect on granulosa cells
– an inhibition on aromatase activity, in addition to its
central pituitary action. This could contribute to a sig-
nificant decrease in estrogen levels and improve the
clinical condition of the patient.
Conclusions
Ganirelix, a GnRH antagonist is a therapeutic option
that should be considered in patients with FSH-secret-
ing pituitary tumors characterized by clinical findings
of ovarian hyperstimulation. Despite the few studies
on the subject, it seems to be an effective and non-in-
vasive option, with a low morbidity, good tolerability
and comfortable dosage regimen (1 dose per day). 
Immunohistochemistry of the tumor should be per-
formed not only to measure FSH levels, but also estro-
gen receptors. Immunohistochemistry would help un-
derstand the pathophysiology of these rare tumors and
search for new therapies.
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Introduction
Endometrial carcinoma is the fourth most common
type of cancer among women in Europe. In Italy it is
the first female neoplasia, with more than 5000 newly
diagnosed cases each year. 
Targeted screening examinations for early detection,
with endovaginal sonography followed by endometri-
al biopsy, seem reasonable for high-risk women (e.g.,
women with Lynch syndrome). Yet, even for these
women up to now there is no real evidence for the
benefits of this kind of screening.
Current scientific evidence does not support the
screening of asymptomatic women. Uterine bleeding
in a postmenopausal woman is the main sign of en-
dometrial carcinoma. Pre- or perimenopausal women
with acyclical bleeding should also undergo a thor-
ough diagnostic evaluation, particularly if they present
risk factors for endometrial carcinoma.
In postmenopausal patients an endometrial thickness
of more than 5 mm is considered suspect. Hys-
teroscopy and fractionated uterine curettage are essen-
tial for a histological diagnosis.
Methods
Thanks to a financial support by the local administra-
tion of Tavagnacco, a small village near Udine, North-
East Italy, we designed a special screening program
with the aim of detecting endometrial cancer in
asymptomatic postmenopausal women.
The first phase of the programme was to send a ques-
tionnaire to all women living in Tavagnacco and older
than 48, in order to gain information about their
health condition, pre- or post-menopausal status and
reproductive history. The women also received an in-
formation leaflet with explanations about the screen-
ing program and an explicit request for participation.
This phase was handled by the local administration,
which transferred all the data to our clinic.
The second phase of the program was to invite for the
screening all the women who had accepted to partici-
pate. For this purpose we organized an ambulatory
once a week where all women underwent a thorough
gynaecological visit and an ultrasound evaluation.
Those women who showed a high endometrial thick-
ness or were suspected to have a polyp, underwent a
second level screening: a sonoisterography and an en-
dometrial cytology. 
We wish to point out that the data presented in this
study are preliminary, because they are restricted to a
part of our sample as the program is still going on;
other data will be available in the future. 
Inclusion criteria were: age, post-menopausal status,
presence of the uterus and absence of bleeding.
Statistical analysis was performed by R (2.13.1 ver-
sion) with a significativity of p<0.05. 
The distribution of data was analyzed by Kolmogorov-
Smirnoff test. Wilcoxon test, chi-square and Fisher
test were used where necessary. 
A multivariate logistic regression analysis was per-
formed and ROC curves were created, to detect cut-
off values for the description of the high-risk subgroup
of patients.
Results
We enrolled 620 patients from August 2010 to Sep-
tember 2011: 429 women underwent the screening
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program, 29 women were excluded because of a previ-
ous hysterectomy, 67 were not in a post-menopausal
status and 95 women did not accept to continue the
program.
Among 429 evaluated patients, 30 (7%) had a second
level screening because they presented a high endome-
trial thickness or a focal image which suggested the
presence of a polyp. Among these 30 patients 9
(2.1%) had an endometrial polyp, and only 1 of these
(0.2%) was an endometrial cancer (adenocarcinoma
T1aNxM0 G1).
Discussion
Endometrial cancer has an incidence of about 25 per
100.000 women. The overall 5 year survival is 80%
and stage-related. There are two types of endometri-
al cancer: estrogen-related (type 1) and non estrogen-
related (type 2). The likelihood of endometrial can-
cer can be assessed by ultrasound. Endometrial can-
cer is associated with a thickened endometrium as
measured by transvaginal ultrasound. The histologi-
cal diagnosis of endometrial cancer is usually made
through endometrial sampling. Unfortunately, un-
like type 1, an early type 2 endometrial cancer often
causes only a subtle and focal thickening of the en-
dometrium on a thin atrophic background, and it is
more likely to be missed both by ultrasound exami-
nation and sampling. Current scientific literature
therefore does not support mass screening for en-
dometrial cancer.
Normally, ultrasound is not used for endometrial can-
cer screening in asymptomatic women. Patients often
undergo a transvaginal ultrasound on the basis of indi-
cations which are unrelated to the endometrial status,
e.g. with the purpose to study a pelvic mass or to un-
derstand the nature of pelvic pain. It is therefore very
important to interpret correctly incidental ultrasound
findings, such as thickened endometrium or the pres-
ence of a polyp. For instance, one has to understand
when an endometrium in a post-menopausal woman
with a good health condition is to be considered thick-
ened. Studies conducted up to now involved women
with bleeding, which means that the population con-
sidered for transvaginal ultrasound was symptomatic.
These studies show that endometrial cancer is most
unlikely in women with a thin endometrium. The
proposed cut-off for endometrial thickness varies from
3 to 5 mm. Smith-Bindman et al. concluded that the
risk of malignancy in a post-menopausal woman is
7.3% if her endometrial thickness is more than 5 mm,
while it is 0.07% if this value is lower than the cut-off.
More recently, Timmerman et al. proposed a cut-off
value of 3 mm.
Our data confirm this finding and suggest that the
best endometrial thickness cut-off to detect a cancer is
3.3 mm. However, the novelty of our study is the
population considered, namely asymptomatic
women. We actually tried to build up a mass screen-
ing involving all the post-menopausal women of
Tavagnacco, women who did not experience an ab-
normal bleeding, in order to identify the best value
for endometrial thickness.
Among the 620 patients recruited, 429 were able to
do the screening program. In 9 women we detected a
polyp, but only one of these was diagnosed as cancer.
Polyps are often seen at ultrasound after menopause.
The reported incidence varies between 13 and 17%.
These polyps have a very low risk of malignancy:
0,1% as described in the study by Goldstein. Al-
though our sample is more restricted than Goldstein’s
and our study is still going on, the data we have col-
lected up to now seem to confirm the trend signalled
in the literature.
Ultrasound examination is easy to perform and well
tolerated, and it could therefore be an excellent screen-
ing technique for endometrial cancer in the general
population. Evidence reported in the literature as well
as the data presented by our study show an extremely
low incidence of this cancer in asymptomatic popula-
tions. Hence, ultrasound is not feasible as a large scale
screening because of its negative cost-benefit ratio. Ac-
tually, among all patients screened in our program, we
only detected one case of cancer.
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Introduction
The Heel Quantitative Ultrasound (QUS) is a useful
tool to fracture risk assessment. It uses mobile, non
X-Ray, non-expensive devices. (1) Even the diagnosis
of osteoporosis cannot be established by QUS as in
cases evaluated by DXA (Dual Energy X-Ray Absorp-
tiometry), the main concern in patients’ management
based on the fracture risk levels represent no more a
problem since there are several studies using QUS pa-
rameters in order to evaluate the fracture risk. We
used a combine parameter Stiffness Index (SI) in
units (U) (applying some known cut offs) derived
from QUS measurement to appreciated the women’s
risk of fracture. The correlation between DXA and
QUS was intensely studied also the result must be
stratified based on patient profile as age, previously
osteoporotic fracture, secondary causes of bone loss.
(2) There are several population studies related to the
DXA QUS correlations, with different results that
considerably improves if the clinical risk factors are
also used. (3)
Aim
We analyze the lumbar DXA BMD (Bone Mineral
Density) values into the high risk population accord-
ing to the heel SI QUS levels.
Patients and methods
We included 343 women in menopause. The last
menses were resumed at more than 45 years of age,
regardless surgically or spontaneously. We enrolled
the patients between January 2010 and November
2011. These were patients admitted in CI National
Institute of Endocrinology from Bucharest, Romania.
They were admitted for different diagnosis, not nec-
essary bone metabolism diseases. The inclusion crite-
ria was that the women never been previously treated
for osteoporosis with antiresorbtives or anabolic
agents. If the patients were treated with hormonal re-
placement therapy, we included them if they had at
least one year since last month of therapy. We per-
formed central DXA (lumbar spine) by a GE Lunar
device, and heel GE Lunar Achilles QUS, which is
considered the golden standard device for applying
QUS. We used the cut – off of 54U for SI which
marks the highest fracture risk group (SI ≤54U), or
group 1. The patients with high risk of suffering a fu-
ture low trauma fracture may be treated with antire-
sorbtives (as those diagnosed with osteoporosis by
DXA or evaluated with increased 10-years probabili-
ty of fracture by FRAX score) and the DXA is not
necessary. According to some studies the SI ≥ 79U
low means low fracture risk if the patient did not suf-
fer before a fragility fracture (group 3). Based on seri-
al observations, these patients do not need antiresorb-
tive therapy, only periodic follow up by QUS. (4) We
considered the “medium fracture risk” group the
women with SI between 54 and 79U (group 2). This
analyze was performed mainly related to the DXA
and QUS values, and less to the clinical risk factors
profile as the presence of corticotherapy, diabetes
mellitus or rheumatoid arthritis. The student ttest
was used for statistical analyze (statistically signifi-
cance was for P<0.005).
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Results
Out of the 343 patients, 24 had high fracture risk pro-
file (group 1), based on the SI levels. 176 patients were
included in the medium risk group and 143 in group
3. The ranges of the SI values were between 42 and
54U. The ranges of the SI in group 3 were 79-135.
The av. age was for the group 1 60.92±8.83 yrs, group
2 56.34±9.1 years, group 3 55.99±7.41 years. The
high risk patients were statistically significant older
than low risk (P<0.005). The av. BMD was 1±0.18
g/cm2 (group1), 0.98±0.16 g/cm2 (group2), 1.06±0.2
g/cm2 (group3). (Fig. 1) The student ttest between
high risk and medium risk group was p=0.65. In con-
tra to expected results, the av. BMD was higher in high
fracture risk women compare to those with medium
fracture risk but the results were not statistically signif-
icant. Generally, the patients with intermediary values
of the SI QUS (related to the SI cut-offs we mentioned
before) represent a heterogeneous category of patients
because the management of these patients is related to
the clinical risk factors profile. As expected, the values
of the BMD between high and low fracture risk
groups was statistically significant (p<0.005). 
We also evaluated for each patient the Body Mass In-
dex (BMI). The av. values of BMI for each group were:
27.62±7.93 kg/m2 (group 1), 27.86±9.1 kg/m2 (group
2), 29.93±5.46 kg/m2 (group 3). The differences be-
tween the SI groups were not statistically significant:
for high-low fracture risk groups p=0.07 (but with
some correlation, meaning that the BMI is higher as
the SI is higher), and between high-medium fracture
risk groups p=0.85. The average value of the BMI is
situated within the overweight area, while for low frac-
ture risk patients is closer to obese ranges.
Based on WHO criteria, we appreciated the osteo-
porosis/osteopenia patients into each group starting
from the BMD DXA values. (5) The repartition of the
DXA groups in the high risk group was: 29% of the
patients had osteoporosis, 54% had osteopenia and
17% had normal DXA. The low fracture risk patients
had osteoporosis 6.29% of them, osteeopenia 42.65%
of the women and normal DXA was found in 51.04%
of the patients. The medium fracture risk group in-
cluded 21.59% women with T-Score less than -2.5,
59.65% of patients with T-Score between -1 and -2.5
and 18.75% of women with normal T-Score. (Fig. 2)
The percent of the postmenopausal women diagnosed
with osteoporosis increases with SI groups (a lower SI
associates a higher chance of osteoporosis). In high
fracture risk group, more than a half of the patients
have osteopenia. But the percent of patients with os-
teopenia according to DXA is almost similarly into the
other two groups. We consider that this population is
also heterogeneous, and the decision of treatment
should be based in clinical risk factors phenotype or
FRAX analyze. 
Discussion
The QUS analyze is very useful in selected cases. The
groups revealed by SI as high and low risk for fractures
were statistically significant different based on lumbar
spine BMD DXA. The percent of women diagnosed
with osteoporosis is more than 4 times higher in pa-
tients with high risk compare to low risk but almost
50% of patients of each QUS fracture risk group have
osteopenia. This raised the issue that in fact the risk of
fracture judgment is important to be individual, in a
complex equation when other risk factors as clinical
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Fig. 1 - The average BMD (DXA) values of the three SI (QUS) based fragili-
ty fracture risk groups.
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Fig. 2 - Percent of the patients with osteoporosis/osteopenia/normal DXA
into each group of QUS fracture risk.
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parameters have a role but this was not the case of our
study. We conducted this analyze up from the idea
that the risk groups for fracture as they are revealed by
heel QUS should have some distinct features regarding
the factors that play some roles in bone health as age
or BMI (in an univariable analyze), and that the two
most used tools of the bone evaluation as DXA and
QUS may provide some interesting data.
Conclusions
The bone mass density is statistically significant lower
in patients with high risk fracture based on QUS com-
pare to low risk fracture patients. Less than a fifth of
the patients with high risk fracture have normal DXA
while most of them have osteopenia rather than osteo-
porosis. The study of the clinical risk factors is impor-
tant also for a better fracture risk evaluation.
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Introduction 
Hyperandrogenism refers to classical androgen-de-
pendent signs, such as hirsutism, acne, alopecia. The
frequent causes of hyperandrogenism are polycystic
ovary syndrome (PCOS), nonclassic congenital adre-
nal hyperplasia (NCAH) and hyperprolactinemia.
PCOS is a heterogeneous endocrine disorder that af-
fects about 6-8% women worldwide (1). PCOS fea-
tures include signs of hyperandrogenism, menstrual
irregularities and infertility. NCAH is the result of
21α-hydroxylase deficiency. The symptoms of NCAH
include menstrual dysfunction, hirsutism, acne and
infertility (4). These syndromes clinically are very close
to each other. Therefore, in a patient presenting with
phenotypic features of PCOS, it is important to con-
sider NCAH in the differential diagnosis. Hyperpro-
lactinemia associated with amenorrhea, galactorrhea,
infertility and mild hirsutism. Some clinical signs of
hyperprolactinemia are similar to that of PCOS. In
fact, the diagnosis of PCOS requires the exclusion of
hyperprolactinemia (3). The aim of the study was to
estimate correlations between abdominal obesity and
calculated androgen parameters in patients with
PCOS, NCAH and hyperprolactinemia. 
Materials and methods 
The study population consisted of 108 young women
age 13-30 referred to our clinic for hirsutism, acne
and/or irregular menstrual cycle. One of the main prin-
ciples of our sampling was to choose women who were
past at least 2 years after the menarche. They did not
take any medication, including oral contraceptives, for
at least previous 6 months. We had three groups. First
group (n=40) was presented by patients with PCOS
and fulfilled the diagnostic criteria for PCOS (Rotter-
dam 2003), group II (n=38) – by patients with NCAH
diagnosed by high level of 17α-OHP and group III
(n=30) - by patients with hyperprolactinemia. All of the
patients underwent measurement of height, weight,
waist and hip circumference, body mass index (BMI)
(weight [kg] divided by height square [m2]) and the
waist to hip ratio (WHR) as the ratio between the waist
and the hip circumferences were calculated. Hirsutism
was evaluated according to Ferriman - Gallwey scores in
9 sites of body. Total testosterone (TT), sex-hormone
binding globulin (SHBG), free testosterone (FT), 17α-
hydroxyprogesterone (17α-OHP) and prolactin (P)
were measured with Enzyme-linked immunosorbent
assay (ELISA). Calculations of free testosterone (cFT)
and bioavailable testosterone (cBio-T) were performed
using the formula available on the web site of the In-
ternational Society for the Study of an Aging Male
(ISSAM) (http://www.issam.ch/freetesto.htm). FAI was
obtained as the quotient: 100 X (TT/SHBG) (5).
Statistical analyses were performed with SPSS software
(statistical Package for the Social Sciences, version
17.0 for windows XP; SPSS, Inc, Chicago, I17). A p-
value of less than 0.05 was considered to be statistical-
ly significant. Two-group comparison of continuous
variables was performed using a two-sample t-test and
Mann-Whitney U test. More than two group means
were compared using the ANOVA with post hoc.
Results 
First group was presented by 40 (37%) patients with
PCOS, group II by 38 (35,2%) patients with NCAH
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and group III by 30 (27,8%) patients with hyperpro-
lactinemia. Hirsutism was detected in 87,5% patients
with PCOS, in 71% - with NCAH and in 70% - with
hyperprolactinemia. In patients with PCOS, NCAH
and hyperprolactinemia were not detected any signifi-
cant differences by hormonal and calculated androgen
parameters.
There were high FAI levels in all patients groups. In
PCOS women FAI mean was - 14,9; in NCAH
women - 12,4 and in women with hyperprolactinemia
– 12,9. A ratio of less than 8 of the FAI is considered
normal in women. Hirsutism score did not differ be-
tween groups (Table 1). PCOS hirsute women had sig-
nificant high level of cFT, than PCOS women without
hirsutism. Abdominal obesity more frequently was de-
tected in women with PCOS 20 (50%), than in
women with NCAH -7(18,4%) and women with hy-
perprolactinemia -10 (33,3%). Higher body mass in-
dex (BMI) also was detected frequently in women
with PCOS 17(42,5), than in women with NCAH –
7 (18,4%) and women with hyperprolactinemia -
11(36,7%).
With regard to WHR, all patients were divided into
two groups: 34,3% of women had abdominal obesity
(WHR >0,80) and 65,7% of them had peripheral obe-
sity (WHR<0,80). In patients with peripheral obesity
hirsutism was revealed in 55 (77,5%) and in patients
with abdominal obesity - in 28 (75,7%). There were
small differences by calculated androgen parameters
between groups of abdominal and peripheral obesity,
but not significant. There was detected significant low
level of SHBG in patients with abdominal obesity. 
Discussion 
In this study clinical, hormonal and calculated andro-
gen parameters differences between the different an-
drogen excess disorders were small, but FAI index was
high in all syndromes. Carmina E. et al study had the
similar evidences (2). According to this study, PCOS
patients with hirsutism had significantly high level of
cFT, than PCOS patients without hirsutism. Obesity
is common in PCOS and affects between 30-70% of
women. Our data confirmed that PCOS patients were
more obese, than patients with other syndromes. As
well as, in women with abdominal obesity SHBG con-
centrations significantly low, than in women with pe-
ripheral obesity. It is well known, that an increase of
body weight and fat tissue is associated with several ab-
normalities of sex steroid balance. Such alterations in-
volve both androgens and estrogens and their carrier
protein, SHBG. In fact women with abdominal obesi-
ty usually have lower SHBG concentrations in com-
parison with women with peripheral obesity. 
Conclusion 
This study demonstrates that abdominal obesity was a
common feature of PCOS. Hirsute women with
PCOS had significant high level of cFT, than PCOS
women without hirsutism. All women with abdominal
obesity observed higher level of FAI, than women with
peripheral obesity, but not significantly. SHBG level
was significantly low in women with abdominal obesi-
ty. There were not any differences by hormonal and
calculated androgen parameters between these syn-
dromes. 
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TABLE 1 - COMPARISON OF CLINICAL, HORMONAL
AND CALCULATED ANDROGEN PARAMETERS
BETWEEN PCOS, NCAH AND HYPERPROLACTINEMIA
PATIENTS GROUPS.
characteristics PCOS NCAH Hyperprolactinemia P-value
TT 2,4 (± 1,1) 2,4 (± 1,1) 2,2 (± 1,0) p>0,05
FT 3,4 (± 1,9) 4,2 (± 2,8 ) 3,9 (± 2,5) p>0,05
SHBG 28,3 (±21) 32,2 (± 26,4) 26,4 (± 21,8) p>0,05
FAI 14,9 (± 12,4) 12,4 (± 9,4) 12,9 (± 8,6) p>0,05
cFT 2,0 (± 0,8) 2,0 (± 0,7) 2,1 (± 0,8) p>0,05
cBio-T 39,2(± 27,4) 38,9 (± 24,2) 42 (± 27,6) p>0,05
Hirsutism score 13,8 (± 6,3) 13,5 (± 7,2) 14,5 (±8,4) p>0,05
Note: Results are expressed as the mean ± SD.
*P value consider significant when it p<0,05. NS – not significance. Total
Testosterone (TT); Free androgen index (FAI); free testosterone (FT); calculated
free testosterone (cFT); calculated bioavailable testosterone (cBio-T), sex-hormone
binding globulin (SHBG).
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Introduction
High spontaneous pregnancy rates in couples with un-
explained infertility have been demonstrated (1-3),
which leads to the question of whether expensive and
invasive fertility treatment should be the first choice
for these couples. The pregnancy rate for couples with
unexplained infertility using expectant management
methods, compared to IVF and other ART methods,
has been studied by several teams (4,5), but has not led
to a consensus on the method of choice. Some studies
indicate that the pregnancy rate using IVF is higher
than with expectant management (5), while others
show that there is no difference (6). When reviewing
the evidence, the authors of the Cochrane review indi-
cated that any effect of IVF relative to expectant man-
agement in terms of live-birth rates for couples with
unexplained infertility remains unknown (7,8). 
Current options for patients 
GP based expectant management 
Following the UK guidelines for the management of the
infertile couple, couples diagnosed with unexplained in-
fertility (1/3 of infertile couples) will be advised to
“keep trying” for a third year prior to eligibility for as-
sisted reproductive technologies. The natural pregnancy
rate is estimated by NICE at 11% over this third year. 
Specialist GP expectant management
In Ireland, a study indicated for that infertile couples
GP using the Creighton Model fertility charting and
optimally timed intercourse as well as medication when
thought necessary lead to 35.5% pregnancy after 12
months. Note that although the study included some
patients with infertility of at just one year duration, ap-
proximately one-third had previously undergone some
form of ART. The most common medications given to
patients included clomiphene citrate (75%) to stimu-
late ovulation, human chorionic gonadotropin (hCG)
(67%) or progesterone (18%) in support of luteal hor-
monal production, and a range of medications to en-
hance cervical mucus production (71%) (9).
Fertility clinic expectant management programmes
There have been no publications of specific clinic led ex-
pectant management programmes in the UK; however
in the Netherlands several studies have shown that this
can offer comparable chances of pregnancy to IVF or
IUI for couples with a good prognosis such as unex-
plained infertility. This was shown to result in a 65%
spontaneous pregnancy rate for such couples over 5 years
and the average time to pregnancy was 5.7 months (10).
Expectant management by Telemedicine 
A recent study shows that patients using a new
“telemedicine” approach to expectant management
had a significantly higher chance of conception than
using classic “expectant management” methods. The
DuoFertility programme resulted in an average clinical
pregnancy rate of 39% after 12 months of use, which
compares favourably to the in-vitro fertilisation clini-
cal pregnancy rate for couples suffering from unex-
plained infertility (31.8%) (11). Note that 3% of pa-
tients were taking clomifene citrate and none were tak-
ing other fertility medications at the time of concep-
tion, which is a significantly lower rate of drug inter-
vention that appeared necessary in the Irish study to
achieve similar outcomes. As with the pregnancy out-
comes, concurrent interventions are patient reported.
Natural pregnancy prognosis for IVF/ICSI candidates using DuoFertility
in comparison to other expectant management methods
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Materials and methods
DuoFertility programme compared to the HFEA Register
When considering the impact of expectant manage-
ment approaches on provision of assisted reproductive
services, it is important to ensure good matching of
study groups.
For detailed comparison of outcomes from expectant
management and assisted reproduction, a retrospective
cohort study of the first 500 couples on the DuoFer-
tility programme is provided. Of the 500 couples, 226
met the criteria for IVF/ICSI in the UK and provided
data sufficient for comparison to UK national statistics
on in-vitro fertilisation (IVF). The most recent pub-
licly available HFEA dataset (2008) was used for refer-
ence, excluding any use of donor embryos, eggs or
sperm (as expectant management is based on natural
conception), but including both IVF and ICSI cycles.
Of 27,360 cycles recorded in the HFEA 2008
dataset, 3,460 were excluded as containing donor
sperm, eggs or embryos. Of the remaining 23,900 cy-
cles, 7903 (33%) were for unexplained infertility,
6554 (27%) were for female-only factors, 7746
(32%) were for male-only factors, and in 1697 cases
(7%) underlying causes were identified for both part-
ners. Although the HFEA Register does not differen-
tiate mild identified causes of infertility (such as
sperm counts of 5-20M/mL or a single blocked fal-
lopian tube), anecdotal evidence suggests that more
than a quarter of identified causes are mild.
The major determinants in pregnancy rate, both for
IVF/ICSI and expectant management programs, are in
descending order female age, underlying cause of in-
fertility, and time trying to conceive. Expectant man-
agement programs are generally considered to be most
applicable to couples with unexplained infertility, so it
is this group that is used for further analysis.
The DuoFertility programme compared to IVF –
Segmented by female age 
Figure 2 presents the clinical pregnancy rate for both
IVF/ICSI patients, and that from the use of DuoFer-
tility for a 12-month period, each broken down by fe-
male age.
The DuoFertility programme compared to IVF –
Segmented by time trying to conceive 
Figure 2 presents the clinical pregnancy rate for both
IVF/ICSI patients, and that from the use of DuoFer-
tility for a 12-month period, each broken down by
time trying to conceive, or time since last pregnancy,
whichever is the shorter.
Statistical analysis
The R statistical package was used for all data analy-
sis (12).
Clinical pregnancy rates for a single cycle of IVF/ICSI
from the HFEA 2008 dataset were calculated assum-
ing that any indication of pregnancy or birth was in-
cluded, and the definition of unexplained infertility
used was lack of any indicated cause of infertility for
either partner (as opposed to patient-unexplained, i.e.
no identified female factor, as present in the raw data).
Clinical pregnancy rates for DuoFertility were calcu-
lated over a 12-month period of continuous use via
the Kaplan-Meier estimator to account for right-cen-
soring of data. Pregnancy was patient-reported, so al-
though it is probable that some under-reporting oc-
curred, it seems unlikely that a patient would falsely
report as pregnant.
Results and discussion
IVF/ICSI Clinical Pregnancy Rate –
Segmented by female age and cause of infertility 
The HFEA 2008 dataset, segmented by both age and
cause of infertility, is presented in Figure 1, which
demonstrates that IVF/ICSI clinical pregnancy rates
do not differ significantly between underlying causes
of infertility when grouped by female age, at the 95%
level. It is therefore reasonable to suppose that both
cases of unexplained infertility, mild male or female
factors, such as those included in the DuoFertility in-
clusion criteria (10), all would have substantially sim-
ilar IVF pregnancy rates.
The DuoFertility programme compared to IVF –
Segmented by female age
The clinical pregnancy rate from the HFEA 2008
dataset (all causes of infertility) are presented in Figure
2, alongside the clinical pregnancy rate from 12
months use of DuoFertility, segmented by female age.
Clearly, greater numbers of patients are needed in the
DuoFertility group to reduce the magnitude of the er-
ror bars and draw firmer conclusions; however the da-
ta suggests that DuoFertility is similarly effective as
IVF for patients suffering from unexplained infertility
or mild male- or female- factors, and who are aged less
than 45 years at the commencement of use.
The DuoFertility programme compared to IVF –
Segmented by time trying to conceive 
Figure 3 presents the HFEA 2008 dataset (all causes of
infertility) and DuoFertility dataset segmented by
time trying to conceive/time since last pregnancy
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(whichever is the shorter). This data suggests that the
DuoFertility expectant management programme has
similar effectiveness to IVF for patients who have been
trying for less than 5 years; however again the strength
of any such comparison is limited by the magnitude of
the error bars.
Conclusion
Published studies comparing expectant management
to assisted reproductive technologies are relatively few
in number, and small in scale ([10] having 437 partic-
ipants and [11] having 242 participants). However,
the data presented here argues strongly for consider-
ably more research to be undertaken in this area, giv-
en the remarkable similarity in clinical pregnancy rates
observed between costly and invasive assisted repro-
ductive technologies, and the considerably lower cost
and non-invasive use of expectant management pro-
grammes.
The data presented implies that over 50% of all IVF
non-donor cycles would meet the inclusion criteria for
DuoFertility (11), and that the prognosis for these cou-
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Fig. 1 - HFEA 2008 dataset,
segmented by both age and cause
of infertility.
Fig. 2 - IVF/ICSI clinical pregnancy
rate, segmented by female age,
alongside the clinical pregnancy
rate for DuoFertility.
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ples would be similar using DuoFertility for 12 months
compared with a cycle of IVF. This also implies that, of
the approximately 125,000 UK couples diagnosed as
infertile each year, more than 80% would be suitable
for such an expectant management approach.
It is of course vital to ensure that patients not suitable for
expectant management (i.e. sterile) are provided with as-
sisted reproduction as rapidly as possible, and it is hoped
that increased use of expectant management for infertile
couples will ensure that rapid provision of assisted repro-
ductive services to those who need it most is more
achievable within existing economic constraints.
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Introduction
A woman’s cycle is comprised of the follicular phase
(between the start of menstruation and ovulation) and
the luteal phase (between ovulation and the day pre-
ceding the start of the menstruation). The maturation
of the ovarian follicles and the release of the egg, con-
trolled by pituitary gonadotrophins govern the length
of the follicular phase. On the other hand, the corpus
luteum is dependent on the support of the pituitary
gonadotrophins during the luteal phase and the level
of these hormones determines the length of this phase
(1-3). In the event of a pregnancy the luteolysis is pre-
vented by the increased human chorionic go-
nadotropin (hCG) level produced by the placenta (4).
Several studies have looked at the general population
to assess variations in menstrual cycle length and vari-
ation in the phases of the cycle (5,6). These have
shown that cycle and phase variations have been asso-
ciated with particular conditions such as breast cancer
(7), cardiovascular diseases (8,9), and recurrent mis-
carriages (10-12). It has been established that some pa-
rameters correlate with the cycle and phase lengths
such as age (13-17), number of children (18), lifestyle
factors (19-21) and BMI (22).
It is generally agreed that the timing of ovulation is
highly variable both within and between women
(6,23). This causes follicular phase variability, which is
well accepted (24). However the luteal phase is gener-
ally thought to be relatively consistent both within and
between patients with ovulation triggering a 14-day
window of high progesterone (25). This study consid-
ers the validity of this hypothesis in a group of infer-
tile women contributing to 4799 cycles included in
this study. 
To date there have been no large-scale studies looking
at this luteal phase variability in the infertile population
(26). Using a home fertility monitor which confirms
ovulation allows the assessment of a large number of
women who can be followed up for several cycles.
Materials and methods
Information was collected from 923 infertile women
(5168 cycles) who took part in the DuoFertility pro-
gramme. All cycles for which ovulation did not occur
were then removed. This left 4854 cycles from 911
women. The average number of cycles studies studied
per women is 5.4 (with a range of 1 to 27 cycles).
The DuoFertility monitor (Cambridge Temperature
Concepts Ltd, UK) allows the user to record menstru-
ation, as well as other fertility information such as per-
ceived cervical mucus secretion, urinary LH test re-
sults and ovulation pain. Women also wear a small ax-
illary sensor that takes thousands of temperature meas-
urements every day, as well as heat flow and move-
ment. This information is used by the DuoFertility
proprietary algorithms to predict the fertile days for
couples allowing them to plan sexual intercourse dur-
ing their most fertile days. The monitor also provides
the women with a retrospective confirmation of the
ovulation date, which is of interest in the present
study. The sensitivity of the DuoFertility monitor for
determination of ovulation date compared to ultra-
sound scanning has been shown to be >80% over a 24
hour window (27). All the information from the user
is automatically transferred to the DuoFertility Fertil-
ity Centre for further analysis and advice. The couples
also provide medical information such as time spent
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trying to conceive, age, BMI and known fertility con-
ditions of both partners.
Inclusion criteria for this study were patients aged 20
to 50, with a BMI of 17 to 57, and who were diag-
nosed with infertility (trying to conceive for more than
a year with regular intercourse). All anovulatory cycles
and cycles during which a pregnancy has been estab-
lished (either by a home pregnancy test or hCG blood
test) were excluded from the analysis.
The data was analysed using the R statistical analysis
system (28). Johnson distribution (29) curves were fit-
ted to the data using the SuppDists package (30).
Comparisons of variance within and between the
groups was performed using linear mixed effects mod-
elling from the nlme package (31).
Results and discussion
The women taking part in the DuoFertility pro-
gramme have a greater variability in overall cycle
length, follicular phase and luteal phase lengths than
is generally reported in the literature. As shown in
Figure 1, the distributions of cycle length, follicular
length and luteal length are similarly spread. The cy-
cle length distribution follows a Johnson distribution
with parameters γ=-0.58, δ=1.08, ξ=26.33, λ=2.84;
the follicular phase follows a Johnson distribution
with parameters γ=-0.94, δ=1.39, ξ=11.99, λ=3.42;
and the luteal phase follows a Johnson distribution
with parameters γ=0.12, δ=2.35, ξ=13.12, λ=5.94.
This finding indicates that infertile women have more
variable cycles than the general population, and that
the variability is not restricted to just the follicular
phase. This may be due to the fact that infertility is
often linked with hormonal imbalance, which there-
fore could cause both phases of the cycle to be less
regular. A standard deviation of over 5 days was ini-
tially observed for the luteal length distribution. This
data was highly skewed by long phases – these were
attributed to cases of unreported miscarriages. Ac-
cordingly, it was decided to right-sensor the luteal da-
ta, dropping luteal lengths greater than 45 days (less
than 1% of the total number of records). This natu-
rally caused an apparent drop in luteal length vari-
ance.
Cycle variability between women is accepted, but in
the general population, the variation in cycle length
for a given woman is relatively small. In our study we
have shown that the variability of both phases is simi-
lar both between and within women in the infertile
population. In this study, the relative contribution to
variability in length of a cycle/phase was assessed
(Table 1). It was observed that both inter- and intra-
woman cycle variability needed to be considered when
analysing the data.
In this study, patients are classified into female factor in-
fertility (including dual-factor infertility) versus non-fe-
male factor (unexplained and male-only factor infertili-
ty). There is a shift towards longer cycles (and the follic-
ular phase in particular) for women in the female factor
group, and the distribution becomes more highly
skewed; this is expected as this group contains many pa-
tients with mild PCOS (polycystic ovarian syndrome),
who have irregular cycles. The added effect of splitting
the data by female factor on cycle/follicular/luteal vari-
ability was also investigated (Table 2). It was observed
that, while this had some contribution to cycle and fol-
licular variance, nearly all the contribution of luteal vari-
ance was again due to intra-woman variability.
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Fig. 1 - Overall distribution
of observed cycle, follicu-
lar/luteal lengths.
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Fig. 2 - Distributions of
cycle/follicular/luteal
lengths, female factor.
Fig. 3 - Distributions of
cycle/follicular/luteal
lengths, non female
factor.
TABLE 2 - RELATIVE CONTRIBUTION OF VARIABILITY OF A FACTOR/CYCLE/PHASE.
Mean (days) Variance (days) % variability due % variability due to % variability due to
to factor effects inter-woman effects intra-woman effects
Cycle 29.31 7.06 17 37 46
Follicular 15.33 4.47 15 37 48
Luteal 13.64 3.18 1 18 81
TABLE 1 - RELATIVE CONTRIBUTION OF VARIABILITY OF A CYCLE/PHASE.
Mean (days) Standard % variability due to % variability due to
Deviation (days) inter-woman effects intra-woman effects
Cycle 29.31 7.06 49 51
Follicular 15.33 4.47 48 52
Luteal 13.64 3.18 31 69
Particular attention should be drawn to cases of longer
luteal phase, as these may result from implantation
which doesn’t lead to a successful ongoing pregnancy.
The cycles during which a positive pregnancy test has
been recorded were excluded from the analysis; how-
ever some women who have been trying for several
years do not want to take a pregnancy test, as this in-
creases their stress level. It is therefore likely that some
of these cycles represent pregnancy followed by early
miscarriage.
As part of the infertility workup in primary care set-
tings, women frequently undergo a blood test on the
7th day after ovulation. The test typically requires a
progesterone level of at least 30 nmol/L to record con-
firm that ovulation has occurred, which is generally
the case between 3.5 and 9 days post ovulation (5,6).
This test is generally performed on day 21 of the
menstrual cycle for convenience; however our find-
ings suggest that this test will be taken at a time lead-
ing to erroneous results in 42% of cases (in 25% of
cases prior to ovulation or fewer than 3 days after ovu-
lation, and in 17% greater than 9 days after ovula-
tion).
Conclusion
This is the first large-scale monitoring study for cycles
with infertile women in the home. This has allowed us
to identify a difference in cycle length distribution and
phase length distribution in infertile women, and con-
trast this with the results of earlier studies on the gen-
eral population.
These findings highlight that the cycles of infertile
women are frequently different to those of the general
population. Given that the variation of the cycles for
women who have unexplained infertility is also greater
than that reported for the general population, this may
indicate that a significant proportion of these women
have an underlying hormonal imbalance which may
require further investigation.
These findings also highlight the potential problem
linked with using “7 days before the usual end of the
cycle” or, worse, “day 21 after the start of the cycle” as
the standard day of testing for progesterone level
rather than identifying ovulation and actually testing 7
days post-ovulation, as for many infertile women this
will lead to a potentially erroneous result (up to 42%
of the cycles in our study).
If facilities to monitor date of ovulation are not avail-
able, an alternative strategy is simply to perform the
progesterone test at some pre-determined point in the
cycle (for example, day 21), and then to discard the re-
sult if the onset of menses is not within 5 to 11 days
of the date of progesterone measurement. Our data
suggests that this will be the case in a significant pro-
portion of infertile women, and furthermore, a very
high fraction of those for whom the sampling date was
inappropriate will continue to be problematic without
implementing some form of ovulation monitoring. It
should also be noted that this strategy ignores the con-
siderable variability in luteal-phase length, which has
been shown to be almost entirely intra-woman in na-
ture.
Therefore, wherever possible, ovulation monitoring
should be utilised to confirm the date of ovulation pri-
or to progesterone measurement.
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Introduction 
The polycystic ovary syndrome (PCOS) is an impor-
tant cause of both menstrual irregularity and androgen
excess in women. It is a common endocrinopathy, oc-
curring in 5 to 7 percent of reproductive age women.
When fully expressed, the manifestations include ir-
regular menstrual cycles, hirsutism / biochemical hy-
perandrogenism (HA), and polycystic ovary morphol-
ogy (PCO). In the adult ovary, antimullerian hormone
(AMH) is produced by the granulosa cells of preantral
and small antral follicles and negatively regulates fol-
liculogenesis. AMH is overproduced in the polycystic
ovary and was recently proposed to play a role in the
ovulatory dysfunction of polycystic ovary syndrome
(an increased AMH tone within the cohort could be
involved in the follicular arrest of PCOS). 
Objective 
To explore the serum AMH level in young adult pa-
tients with polycystic ovary syndrome (PCOS), and to
evaluate its diagnostic value for PCOS. 
Patients and methods 
Serum AMH was measured in a cohort of 120 patients
with PCOS and 79 age-matched controls (80 young adult
patients with PCOS and 60 age-matched controls 18-35
yrs). Diagnosis of PCOS was established on the basis of
Rotterdam criteria after an exception of other diseases.
AMH levels were measured in the samples using immu-
noenzymatic assay. Its diagnostic potential was evaluated
by Receiver Operating Characteristic (ROC) curves.
Results 
The serum level of anti-Mullerian hormone (AMH), a
product from granulosa cells involved in follicle
growth, has been shown to correlate tightly with the
volume and small antral follicle number (FN) at ultra-
sonography (US) in controls women. Because PCOS is
associated with increase in growing FN, we investigat-
ed whether an increased AMH serum level in PCOS
patients. The serum AMH level was higher in young
adult PCOS patients than in controls (6.2±3.4 ng/mL
vs. 3.9±2.2 ng/mL, p=0.0003), and positively related
to the mean ovarian volume in PCOS patients (r = 0.3,
p<0.05). The best compromise between specificity
(76%) and sensitivity (63%) was obtained with a cut-
off value of 8 ng/mL. No difference was found between
AMH levels in the cohort 36-60 yrs in both groups.
Conclusions 
Serum AMH levels are elevated in young adult pa-
tients of PCOS. Serum AMH measurement offers a
relatively poor diagnostic potency with a sensitivity of
63% and a specificity of 76% at 8 ng/mL.
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Introduction
Obesity is an endemic disease of the 21st century, with
a continuously increasing prevalence, particularly in
young persons. In economically developed countries,
endometrial cancer is associated with obesity in a pro-
portion of 40% (1). In the context of endometrial can-
cer, visceral obesity as a risk factor is associated with a
chronic inflammatory process, confirmed by the in-
crease of inflammatory markers, CRP, IL-6, TNF-α,
in the systemic circulation of obese patients (2). This
chronic proinflammatory state is in its turn a risk fac-
tor for endometrial cancer.
Adipose tissue is no longer considered just an energy
storage organ, but a real endocrine organ. The
adipocyte is the central element that integrates multi-
ple metabolic and endocrine signals.(3) This cell rep-
resents the source for a multitude of bioactive pep-
tides, markers of the systemic inflammatory syn-
drome, IL-6, TNF-α, leptin, adiponectin (4).
Systemic IL-6 and TNF-α levels increase with age and
body mass index. The action of TNF-α is mediated by
a complex of cytokines and hormones including IL-6
and leptin (5). Obesity is associated with an increased
IL-6, leptin, as well as TNF-α expression (6).
The use of dual X-ray absorptiometry (DXA) for the
determination of body composition as a whole as well
as by regions has started to be increasingly used. The
radiation exposure resulting from the scanning of the
entire body is relatively minor (~0.3 µSv) and repre-
sents less than the unavoidable daily background radi-
ation exposure (~2.0 µSv/ 24 hours).
The study aims to evaluate the presence of a correla-
tion between abdominal adiposity assessed by DXA
and systemic inflammatory status expressed by IL-6
and TNF-α in patients diagnosed with endometrial
cancer.
Materials and methods
The study is a case-control analysis that includes 2
groups of patients: group I – 44 patients diagnosed
with endometrial cancer, group II – 44 patients with-
out gynecological pathology or inflammatory disor-
ders (control group).
The diagnosis of endometrial cancer was made after
histopathological examination that analyzed the tissue
material obtained following endometrial biopsy. En-
dometrial biopsy was performed in the case of consid-
erable metrorrhagia, in the case of metrorrhagia during
climax, as well as in the case of aspects undetected by
US (endometrial thickness and vascularization).
After the performance of clinical examination and
anthropometric measurements (BMI, abdominal
circumference - AC), the patients underwent DXA
(GE, Prodigy Lunar), which measured the amount
of abdominal adipose tissue. BMI was calculated by
the formula BMI = weight (kg)/ [height (m)]2. The
height of the subjects was accurately measured, us-
ing an anthropometer fixed to the wall (222 model;
Seca GMBH, Germany). Body mass was determined
with an accepted error of 20 g, using a calibrated
electronic scale (FW-150K model; A&D Mercury).
AC (cm) was measured in orthostatism, at umbilical
level.
Abdominal adipose tissue was obtained by total body
scans. The “abdominal region” was defined using the
software provided by the manufacturer, with the upper
limit at the junction of the lower 1/5 with the upper
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4/5 of the pelvis-to-chin distance, and the lower limit
at the upper part of the greater trochanters.
From each subject included in the study, 6 ml fasting
blood were taken by venous puncture and collected in
test tubes without anticoagulant in order to determine
plasma IL-6 and TNF-α levels. The serum obtained
by centrifugation was divided and stored in 600 µl
freezing tubes at a temperature of –300 C until tests
were performed, in order to avoid repeated freezing-
thawing cycles.
The serum IL-6 concentration was measured by the
sandwich ELISA technique using the Human IL-6
Immunoassay HS600B kit, R&D Systems USA. The
serum TNF-α level was measured by the sandwich
ELISA technique using the Human TNF-α Im-
munoassay HSTA00D kit, R&D Systems USA. 
The informed consent of all patients was obtained.
All parameters were included in the study database
and version 13 of the SPSS software and Microsoft Ex-
cel with Analysis Tool Pack were used for statistical
analysis. The Kolmogorov Smirnov test was applied
for the testing of normal distribution. The Student t
test was used for the comparison of the means and the
Mann-Whitney test for rank comparison in two inde-
pendent samples.
The study compares the two groups regarding abdom-
inal adiposity assessed by DXA and aims to evaluate
the presence of a correlation between adiposity located
at abdominal level and systemic inflammatory status
expressed by plasma IL-6 and TNF-α levels.
Results
The patients of the control group had on DXA exam-
ination a mean abdominal fat amount of
10680.27±3675.49 g (with limits between 17156.00
and 63194.00 g), while in the group of patients with
endometrial cancer, the mean abdominal fat amount
was 21616.28±4758.59 g (with limits between
1887.00 and 21110.00 g). Thus, there was a statisti-
cally significant difference in abdominal fat
(p<0.0001) between the two groups (Fig. 1).
The ROC curve for the identification of the cut-off
value for abdominal fat assessed by DXA is shown in
Fig. 2. The area under the curve was 0.97, p<0.00001.
The cut-off value identified was 16324 g. A DXA ab-
dominal fat value higher than 16324 seems to be a
cut-off value for patients with endometrial cancer
(p<0.00001).
Inflammatory status expressed by IL-6 and TNF-α
was significantly higher in the group with endometri-
al cancer compared to the control group. Thus, the
plasma IL-6 level in the group with endometrial can-
cer was 26.98±23.56 pg/ml (with limits between 5.95
and 83.48 pg/ml) compared to the control group,
11.22±6.79 pg/ml (with limits between 2.80 and
26.92 pg/ml). The plasma TNF-α level was 4.18±2.23
pg/ml (with limits between 1.83 and 10.25 pg/ml)
compared to the control group, 1.54±0.48 pg/ml
(with limits between 0.60 and 2.93 pg/ml) (Fig. 3, 4).
Abdominal fat is in a positive linear correlation with
the plasma IL-6 level (Fig. 5). The correlation coeffi-
cient between abdominal fat and IL-6 was R=0.43
p=0.0001, indicating a significant correlation. 15%
(d=r2=0.15) of the IL-6 value is due to abdominal fat.
Abdominal fat is in a positive linear correlation with
the plasma TNF-α level (Fig. 6). The correlation coef-
ficient between abdominal fat and TNF-α was
R=0.73 p=0.000001. This coefficient indicates a sig-
nificant correlation between abdominal fat and the
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Fig. 2 - ROC curve for the identification of the cut-off value for abdominal
fat.
Fig. 1 - Comparison of abdominal fat assessed by DXA between the two
groups.
plasma TNF-α level. 35% (d=r2=0.35) of the TNF-α
value is due to abdominal fat.
Following multivariate analysis, it can be stated that
abdominal fat assessed by DXA is the dominant pa-
rameter, which influences plasma IL-6 and TNF-α
levels.
Discussion
Adipose tissue, accumulating in various anatomical ar-
eas (regional adiposity) may have unique characteris-
tics related to the different expression of the enzymes
and receptors involved in triglyceride synthesis, lipoly-
sis and adipokine synthesis. Consequently, it is essen-
tial to study the relationship between regional obesity
and systemic inflammatory status and to identify the
role of systemic inflammatory status in the mediation
of the metabolic effects of regional adiposity. So far, re-
gional obesity and its correlation with systemic inflam-
matory status have not been well documented. This
study supports the idea that abdominal adipose tissue
is correlated with systemic inflammatory status ex-
pressed by IL-6 and TNF-α. 
Anthropometric indices evidenced strong correlations
with systemic inflammatory status. However, the val-
ue of these indices for the explanation of systemic in-
flammatory status was diminished after the adjust-
ment for DXA indices. Thus, although BMI and AC
can be systemic inflammation markers, DXA indices
have a better prediction in assessing systemic inflam-
matory status (7).
In this study, abdominal adiposity assessed by DXA ex-
amination is strongly correlated with inflammatory
status expressed by plasma IL-6 and TNF-α levels. The
accumulation of lipids is favored in the lower part of
the body in premenopausal women compared to men
(8). This can be due to lipoprotein lipase activity, a key
factor responsible for the release of adipocyte lipolytic
products for their storage as TG (9). On the other
hand, the adipose cells of the lower part of the body
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Fig. 3 - Comparison of IL-6 between the two groups. Fig. 4 - Comparison of TNF-α between the two groups.
Fig. 5 - Correlation between IL-6  and abdominal fat. Fig. 6 - Correlation between TNF-α and abdominal fat.
have a lower lipolytic response to catecholamines and a
higher response to insulin-mediated lipogenesis than
visceral adipocytes. Also, adipose cells in the lower
body have a lower beta 1 and beta 2 adrenoreceptor
density, as well as a higher alpha 2 adrenoreceptor
affinity (10). As a result, the adipose cells of the lower
part of the body in women are lipolysis-resistant and
predisposed to lipogenesis. This can explain the pre-
dominance of gynoid fat distribution in the female sex,
which is correlated with the reduction of coronary as
well as oncological disorders (endometrial cancer,
breast cancer, colorectal cancer). In this study, abdom-
inal fat is positively correlated with endometrial cancer.
Obesity increases systemic exposure to free estrogens
via the aromatization of androgens in visceral adipose
tissue, via the reduction of SHBG production, via the
reduction of serum progesterone by anovulation, via
the proinflammatory state (11). The relationship be-
tween endogenous steroid hormones and the risk for
endometrial cancer is described as the “unopposed estro-
gen” theory (12). According to this theory, the risk of
endometrial cancer increases in patients with high
serum estrogen and/or low progesterone levels. This
study supports the idea that in patients with endome-
trial cancer abdominal fat content is significantly high-
er compared to the control group. A DXA abdominal
fat value higher than 16324 g seems to be a cut-off val-
ue for patients with endometrial cancer.
Conclusion
Considering that abdominal fat is positively correlated
with the incidence of endometrial cancer and that it is,
at the same time, the dominant parameter, which in-
fluences plasma IL-6 and TNF-a levels, it can be inter-
preted that abdominal fat is a risk factor for endome-
trial cancer through systemic inflammatory status.
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Introduction
Polycystic Ovary Syndrome (PCOS) is a complexdis-
ease characterized by various endocrinedisorders that
can be the potential cause ofanovulation and hyperan-
drogenism condition.
This heterogenoussyndrome affects about 5-10% of
reproductive age female population, and it can be con-
sidered as the most common endocrine disorder af-
fecting women during reproductive life (1).
PCOS is a multifactorial polygenic disease: are inter-
ested genes involved in insulin-resistance, genes that
encode inflammatory factors, genes that regulate
steroidogenesis and folliculogenesis.
Chronic anovulation most often manifests as
oligomenorrhea; anovulatory cycles may lead to dys-
functional uterine bleeding and decreased fertility. Cu-
taneous manifestations of hyperandrogenemia in the
polycystic ovary syndrome include hirsutism, acne,
and male-pattern hair loss (androgenic alopecia),
whereas acanthosisnigricans is a cutaneous marker of
hyperinsulinemia.
A substantial proportion of women with the polycys-
tic ovary syndrome are overweight; many are obese,
others don’t reach high level of obesity. Although obe-
sity itself is not considered the inciting event in the de-
velopment of the syndrome, excess adiposity can exac-
erbate associated reproductive and metabolic derange-
ments (2).
D-chiro-inositol is an important second messenger in
signal transduction of insulin, intervening in the acti-
vation of serotonin receptors in the Central Nervous
System.
Dietary sources of D-chiro-inositol are rather scarce.
Deficiencies of D-chiro-inositol are related to some
metabolic and endocrinological disorders, such as in-
sulin resistance and polycystic ovary syndrome
(PCOS).
Clinical studies have shown that low levels of D-chiro-
inositol reduce insulin-sensitivity and causeHyper-
triglyceridemia.There are also several scientific evi-
dences that link D-Chiro-Inositol to PCOS.The sup-
plementation of D-chiro-inositol in women with
PCOS has led to a rebalancing of insulin levels,
triglycerides and cholesterol with a decreased testos-
terone serum levels, and reactivation of ovulation (3).
In the study conducted by Nestler were enrolled 44
women with PCOS, which were administered 1200
mg of D-Chiro-Inositol a day.
Results were: spontaneous ovulation in 86% of
women undergoing treatment with D-chiro-inosi-
tol, compared to an ovulatory rate of 26% in the
placebo group (P<0.001); significant reduction in
systolic blood pressure (P=0.05) and diastolic blood
pressure; significant reduction (P=0.002) in serum
levels of triglycerides, Total testosterone values
(P=0.003) and DHEA-S (P<0.001) in Group D-chi-
ro vs. placebo (3).
Another study havepointedoutthat in women with
PCOS, an increase of the release of DCI-IPG (D-chi-
ro-inositol containing inositol-phosphoglycan media-
tors) stimulated by glucose, is correlated significantly
with improved sensitivity to insulin effect.This signif-
icant correlation between DCI-IPG and insulin sensi-
tivity suggests the hypothesis that the DCI-IPG may
represent a novel therapeutic intervention in patients
with PCOS (4).
The aim of our study is to evaluate the clinical, en-
docrine and metabolicresponse of young women with
PCOS, treated for12 weeks with a therapeutic proto-
col D-chiro-inositol only based.
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Materials and methods
All the patients were enrolled in the Institute of Ob-
stetric and Gynecological pathology (“Santo Bambi-
no” Hospital, Catania), at the GynecologicalEn-
docrinology Clinics. 
In the 12-month enrollment phase a total of 58 wom-
enwith polycystic ovary syndrome (PCOS) were se-
lected. PCOS diagnosis was indicated by oligo-amen-
orrhea (six or fewer menstrual cycles during a
period of one year), hyperandrogenism (hirsutism, ac-
ne or alopecia) or hyperandrogenemia (elevated levels
of total or free testosterone), andtypical feature of
ovaries at ultrasound scan.
The average age was 27 years with a standard deviation
of 7 years; the mean BMI value was 28, W/H ratio was
0.87 m, and the mean blood pressure value was
130/86 mmHg. Acne was evaluated with the Cre-
moncini score and the mean value was 3.5, while the
hirsutism with the Ferriman and Gallway score with
the mean value of 15.
The study was double-blind designed and, according
to a randomization table, patients were divided into
two groups: 38 patients of Group Aintook 250 mg of
D-chiro-inositol (Chirositol™, Cyvex Nutrition)in
combination with manganese, folic acid and B12 vita-
min 2 times aday, continuously for 3 months; man-
ganese amplifies the response to D-Chiro-inositol
(synergistic action) in relation to the improvement of
the insulin-sensitivity and B12 vitamin is used as ther-
apeutic coverage in the event of combination with
metformin (which tends to induce B12 deficiency in
long-term protocols).
Instead, the 20 patients of Group Bintookan aspecific
multivitamin as placebo twice a day for 3 months. No
significant differences were found between the two
groups in mean age and body mass index (BMI).
Three months after the treatment was carried out a
clinical, endocrine and metabolic assessment of pa-
tients enrolled.
Clinical evaluation: BMI, W/H Ratio, acne score, hir-
sutism score, blood pressure value, relief of the num-
ber of spontaneous menstrual cycles and side effects.
Endocrine evaluation: Serum assay (2 samples) of LH,
FSH, E2, total and free testosterone, androstenedione,
DHEA-S, 17-OHP, SHBG, prolactin, TSH, fT3, fT4
(withdrawals made within the 8 th day of spontaneous
or progesterone-induced cycle).
Metabolic evaluation: glycemia, total and fractionated
cholesterol, serum triglycerides, BUN and Basal in-
sulin.
Results
The comparison between Group A and Group B was
performed using:
– Student t test for quantitative data normally distrib-
uted (age, BMI, W/H ratio, blood pressure, hor-
mones, cholesterol and triglycerides serum levels);
– U test for quantitative data not normally distrib-
uted (number of patients with regular menstrual,
hirsutism and acne score.
From a clinical point of view, our study has highlight-
ed a significant retrieval of menstrual-cycle regularity
(p<0.001) (Fig. 1) in a rate higher than 60% in pa-
tients treated and a significant improvement of acne
score(p<0.05) (Fig. 2) in patients of Group A in treat-
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Fig. 1 - Retrieval of menstrual-cycle regularity before and after treatment
with D-Chiro-Inositol (Group A) and placebo multivitamin (Group B).
Fig. 2 - Acne Score before and after treatment with D-Chiro-Inositol (Group
A) and placebo multivitamin (Group B).
ment with D-chiro-inositol. No significant adverse ef-
fects were reported.
With regard to endocrine evaluation, there was a sig-
nificant decrease of DHEA-S serum levels in the
Group treated with D-chiro-inositol (p<0.05). A trend
of decreasing of all other hormones tested was noticed,
but there was no significant changes.
Metabolic evaluation found a significant decrease of
triglycerides (p<0.05) and basal insulin serum levels
(p<0.05) (Fig. 3) in patients treated with D-chiro-in-
ositol.
A trend of decreasing of all metabolic parameters eval-
uated was noticed, but there was no significant
changes.
Discussion
There are several scientific evidences that show the
connection between D-chiro-inositol and PCOS.
Some actions of insulin are mediated by putative inos-
itolphosphoglycan mediators, and a deficiency in D-
chiro-inositol-containing inositolphosphoglycan
(DCI-IPG) may contribute to insulin resistance in
women with polycystic ovary syndrome (PCOS) (5). 
It was shown that PCOS patients have increased uri-
nary clearance of DCI (uClDCI), which was associat-
ed with hyperinsulinemia (6,7).
D-chiro-inositol is an important second messenger in
signal transduction of insulin, intervening in the acti-
vation of serotonin receptors in the Central Nervous
System.
Dietary sources of D-chiro-inositol are rather scarce. 
The supplementation of D-chiro-inositol in women
with PCOS has led to rebalancing of insulin levels,
triglycerides and cholesterol with a decreased testos-
terone serum levels, and reactivation of ovulation (3).
In a recent study it was explained, therefore, that the
D-chiro-inositol-to-myo-inositol ratio is regulated by
an insulin-dependent epimerase. Enzyme activity
varies among tissues, likely owing to the specific needs
of the two different molecules. An Italian group of
study hypothesizes that in the ovaries of polycystic
ovary syndrome patients, epimerase activity is en-
hanced, leading to a local myo-inositol deficiency
which in turn is responsible for the poor oocyte qual-
ity (8).
This clinical trials carried out highlights the role of D-
chiro-inositol in the ovarian function of patients with
polycystic ovary syndrome, in particular we must em-
phasize its importance in clinical restore of normal
menstrual cycle, which is often only the tip of the ice-
berg of the polycystic ovary syndrome (9), and im-
provement of acne.
From a clinical point of view, our study has highlight-
ed a significant retrieval of menstrual-cycle regularity
in a rate higher than 60% in patients treated and a sig-
nificant improvement of acne score in patients in
treatment with D-Chiro-Inositol. 
With regard to endocrine evaluation, there was a sig-
nificant decrease of DHEA-S serum levels in the
Group treated with D-Chiro-Inositol; a trend of de-
creasing of all other hormones tested was noticed, but
there was no significant changes.
Moreover, metabolic evaluation found a significant de-
crease of triglycerides and basal insulin serum levels in
patients treated with D-Chiro-Inositol. No significant
adverse effects were reported.
Our study proceeds with the recruitment of other
patients and monitoring of women previously en-
rolled also at 6 and 12 months after the beginning of
therapy.
Furthermore, preliminary data suggest an improve-
ment of the therapeutic action of D-Chiro-Inositol if
administered in higher doses: we recommend an aver-
age dose of 1000 mg daily.
For these reasons, the D-chiro-inositol could be added
to valid PCOS treatment protocols, as further ex-
plained below:
– Treatment with only D-chiro-inositol in regular
weight, with oligomenorrhea (or secondary amenor-
rhea) and low grade acne. In lean women with the
polycystic ovary syndrome, D-chiro-inositol reduces
circulating insulin, decreases serum androgens, and
ameliorates some of the metabolic abnormalities (in-
creased blood pressure and hypertriglyceridemia) of
syndrome X (10).
– Treatment with low-calories diet, D-chiro-inositol
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Fig. 3 - Basal insulin serum level before and after treatment with D-Chiro-
Inositol (Group A) and placebo multivitamin (Group B).
+ metformin in patients with insulin resistance, non-
or poorly symptomatic and oligomenorrhea or sec-
ondary amenorrhea (5).
– Treatment with low-calories diet, D-chiro-inositol
+ Metformin + Hormone Therapy and / or Anti-an-
drogens in symptomatic patients, obese or overweight,
with insulin resistance (5).
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Background
It has been twelve years since the first report suggesting
that exogenous androgens could improve ovarian re-
sponse in those women classified as having diminished
ovarian reserve (DOR) (1).Despite the argument as to
the definition of ovarian reserve (OR) (2), it is general-
ly accepted that women over the age of 40 will have de-
clining ovarian reserve and that this is the major limit-
ing factor to their success with assisted reproductive
technology. It is important to understand DOR as
women over 40 represent the most rapidly growing
group of patients seeking fertility treatment (3).
It has been suggested that ovarian reserve is not static
but rather dynamic from cycle to cycle, and that the
diagnostic indicators of OR, basal follicle stimulating
hormone (FSH), anti-Mullerian hormone (AMH) and
antral follicle count (AFC) are age-specific and change
in parallel with OR (4).FSH and AMH seem to be less
reliable prognosticators of success. In our hands AFC
and a trial of stimulation with maximum doses of go-
nadotrophins have proved to be the best markers of
ovarian response. 
Interestingly, a survey of 196 IVF units worldwide has
shown that 26% of IVF units utilize dehy-
droepiandrosterone (DHEA) for patients with DOR
(5). Since 2005 reports from Gleicher and Barad [6-8]
have shown that DHEA supplementation improves
ovarian response in terms of both quantity and quali-
ty of oocytes and embryos, leading to increased preg-
nancy rates. In addition, Gleicher and our group have
shown decreased miscarriage rates from over 50% in
women over age 40 undergoing IVF to 25% and less
with DHEA pre-treatment. [9]. There is now direct
evidence from preimplantation genetic screening that
DHEA reduces embryo aneuploidy to explain these
results (10,11).
At the 14th World Congress of Gynecological En-
docrinology in 2010 our group presented data to show
that pre-treatment of older women with DHEA fol-
lowed by controlled ovarian hyperstimulation and in-
trauterine insemination (COH-IUI) resulted in an ex-
cellent clinical pregnancy rate of 23% per cycle. The
current study was undertaken to evaluate the efficacy
of DHEA pre-treatment in the same age group of old-
er women who had failed to conceive with COH-IUI
and proceeded to in vitro fertilization (IVF). 
Patients and methods
A retrospective cohort study was conducted in a pri-
vate university affiliated fertility centre. Despite a large
intake of appropriate patients, we have been unable to
conduct prospective randomized trials (RCT) with
DHEA as women in this age range refuse to be ran-
domized. From a total of over 600 patients who began
treatment with DHEA from Feb. 2006 to Nov. 2011
we have ongoing data on over 400 patients, a signifi-
cant number having been lost to follow up.
84 IVF cycles were performed in women between ages
40 and 46 who had been pretreated with at least 3
months of oral micronized  DHEA 25 mg three times
daily. We included all patients up to age 46 for analy-
sis and then repeated the analysis after excluding pa-
tients who were age 43 and older at the time of com-
mencing the IVF cycle. This was done in order to
compare our results with those of the only RCT in the
literature that also excluded patients over age 43 (12).
Our inclusion criteria were based upon patients with
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late maternal age who demonstrated poor ovarian fol-
licular response to an oral aromatase inhibitor, or to
COH-IUI with high-dose gonadotrophins, elevated
cycle day 3 FSH levels, very low AMH levels, low
antral follicle counts, and previous failed or poor stim-
ulation for IVF at other institutions.
Informed consent for the use of DHEA was obtained
through physician discussion and patient review of all
published data on DHEA with respect to fertility
treatment.
Side effects such as acne, hirsutism, hair loss, weight gain
and sleep difficulties were rare and seldom necessitated
discontinuation of DHEA (less than 2% of patients). 
All patients had an endometrial biopsy in the mid-luteal
phase of the immediately pre-IVF menstrual cycle in or-
der to increase the implantation rate (13). Stimulation
protocols were either a microdose GnRH agonist flare
with FSH and FSH/hMG combined as described by
Schoolcraft (14), or maximal dose (450 IU) rec-FSH
and the addition of a GnRH antagonist. Intracytoplas-
mic sperm injection (ICSI) was used in all cases.
We had a significant male factor component in 33%
of cases. Embryo transfer was performed by one of two
operators at 72 hr. post-oocyte retrieval utilizing a
double-lumen, bulb-tipped catheter assisted by trans-
abdominal ultrasound guidance. 
Results
We had 16 IVF cycles cancelled due to failure to stim-
ulate with maximal doses of gonadotrophins and 52
cycles were completed to embryo transfer. Table I sum-
marizes the results of the 52 cycles with respect to
measured parameters in the Non-pregnant group and
the Pregnant group. Unfortunately AMH (data not
shown) was only obtained in 10 patients due to the re-
cent availability and high cost of the test in Canada.
Figure 1 shows the analysis of the 52 completed IVF
cycles in which there were 18 pregnancies (35%) and
34 cycles with no pregnancy (65%).
Figure 2 shows the outcome of the pregnancies. There
were 6 early pregnancy losses, including one chemical
(33%), and 12 patients delivered as of November
2011 (67%). The clinical pregnancy rate per embryo
transfer was 33% and the live birth rate per embryo
transfer was 21%. One baby was stillborn and exclud-
ed from the analysis. There were 4 multiple pregnan-
cies including one twin loss. 
Conclusion
U.S. national IVF success rates, as reported by the
CDC/SART for 2009, cite 4 to 12% live birth rates in
women over age 41. Pre-treatment with DHEA fol-
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TABLE 1
Negative (N=34) Positive (N=18)
Mean ± SD Mean ± SD p value
Age 40.8±0.7 41.0±0.8 NS
Initial D3 FSH Level 9.5±5.1 9.8±5.5 NS
BMI 23.4±3.6 22.6±3.4 NS
Months on DHEA 9.6±8.8 10.7±7.3 NS
# Cycles on COH +/- IUI + DHEA 0.8±1.3 1.3±1.1 NS
# Eggs retrieved 6.7±4.9 10.3±6.6 0.05340
# of embryos 3.8±2.8 7.4±6.5 0.03420
# D3 embryos 3.5±2.5 6.2±5.7 NS
D3 FSH 9.5±5.0 8.9±4.6 NS
D3 E2 219.1±178.3 141.3±45.3 0.02108
Antral follicle count 4.1±3.8 7.4±5.3 0.02975
E2 at HCG 5247.6±2082.9 6257.6±1631 NS
PGN at HCG 9.0±5.4 7.8±2.5 NS
Endometrial thickness at HCG 1.0±0.2 1.1±0.2 0.05794
# of follicles at HCG 4.6±2.0 7.8±3.6 0.00197
Total hMG meds 4210.8±966.3 4113.9±959 NS
*NS= Non statistical significance.
** Statistical significant adata is shown in bold.
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lowed by IVF in our study resulted in an improved live
birth rate of 21% per embryo transfer which is the ul-
timate marker of oocyte quality. Furthermore our re-
sults are in keeping with the small prospectively ran-
domized controlled trial of Shulman that reported a
23% live birth rate in the DHEA group as compared
with 4% in the control group (12).
The mechanism of action of DHEA is still unclear. As
discussed by Gleicher in his excellent review of ovari-
an aging, a direct effect of DHEA in rescuing or reju-
venating aged oocytes seems unlikely (4). New re-
search with androgen receptor knockout mice has
shown that ovarian androgens are essential to follicu-
logenesis (15), and a more plausible concept of DHEA
action may be that of follicular conditioning resulting
from an improvement in the ovarian environment
leading to improved oocyte quality. This may be in ad-
dition to the beneficial effect of DHEA on mitochon-
drial function (16). Our centre has recently added the
mitochondrial nutrient coenzyme Q10 in a dose of
600 mg per day as an additional supplement for older
women and others with DOR in response to the pos-
itive results from mouse studies reported by Bentov
and Casper (17).
In summary, androgen supplementation with DHEA
in older women represents a safe, effective, low cost
therapeutic modality to improve the ovarian environ-
ment and decrease aneuploidy that leads to excellent
clinical pregnancy and live birth rates with IVF in this
worst prognosis group of women who have failed to
conceive by other means. Although we have had ba-
bies born to DHEA-treated patients up to age 46,
both spontaneously and with COH-IUI, this study
and the Shulman RCT strongly suggest that women
age 43 and over who have failed to conceive despite
treatment with DHEA, should not be offered IVF.
They should instead be counselled with regard to the
greater success of donor oocyte programmes.
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Introduction
Since the last two decades, it has been well-known that
osteoporosis is an important public health issue. Os-
teoporosis is the most common osteometabolic disease
responsible for high medical expenses that mainly arise
from the treatment of fractures. It has been predicted
that half of north american women over the age of 50
years will have osteoporosis-related fractures during
their lifetime.
Adequate pubertal development with a resulting in-
crease in hormone production has a fundamental role
in bone development. It is considered the most impor-
tant known factor for bone development, following
the genetic factor. Thus, women with low bone min-
eral content due to hypoestrogenism in puberty are at
increased risk for osteoporosis. Therefore, women af-
fected by gonadal dysgenesis and consequently pri-
mary hypoestrogenism belong to a high-risk group for
osteoporosis.
It is known that the administration of estrogens com-
bined or not with progesterone, is capable of stimulat-
ing bone mass. Therefore, it is theoretically possible
for the exogeneous administration of sex steroids to re-
place the lack of endogeneous production. However,
the extent to which exogeneous hormones can replace
ovarian function in sustaining bone mass remains
largely unknown. 
Objectives
The aim of the article is to compare bone mineral den-
sity in women with primary amenorrhea due to Turn-
er’s syndrome 45,X0 (TS) and pure gonadal dysgene-
sis 46,XX (PGD) at the time of diagnosis and after five
years of hormone therapy (HT) use.
Methods
Twenty-nine women diagnosed with primary amenor-
rhea due to PGD (46, XX) and TS (45, X0) were eval-
uated by bone mineral density tests before HT and af-
ter five years of HT use. Women with chronic disor-
ders or those using medication that might interfere in
bone metabolism were excluded from the study. The
mean age and BMI of the patients, bone mineral den-
sity (BMD) levels before and after HT use and the cor-
relation between patient age and response to treatment
were assessed. The study was conducted in the Depart-
ment of Obstetrics and Gynecology of the Universi-
dade Estadual de Campinas, UNICAMP, Medical
School. 
Results
The mean age of the women was 23.8 years at the be-
ginning of treatment and 28.8 years (ranging from 17
to 38 years) in the study. The mean BMI was 23.3
kg/m2 (ranging from 17.03 to 35.15 Kg/m2), with lit-
tle difference between women, regardless of age. Of
the 29 women, concerning the initial evaluation of
lumbar bone mass (L2-L4), 28 had decreased bone
mineral density, 15 were osteopenic (51.7%), 13 was
osteoporotic (44.8%), and 1 (3.44%) had normal
bone mass. After 5 years of treatment, the only patient
who already had normal BMD values, gained bone
mass. Among the 15 osteopenic women, 1 (6.6%)
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worsened and became osteoporotic; 6 (40%) gained
bone mass and reached the normal range; and 8
(53.3%), despite showing improvement in bone mass,
remained osteopenic. Concerning the 13 osteoporotic
women, in 2 (15.3%) BMD was normalized, 6
(46.1%) became osteopenic, 4 (30.7%) remained os-
teoporotic, despite gaining bone mass and 1 (7.6%)
had no alteration in BMD values. Mean T- and Z-val-
ues of bone mineral density tests in these patients were
shown in Table 1 and were statistically significant. Re-
garding the initial assessment of bone mass at the
femoral neck, of the 29 studied women, 13 (44.8%)
were osteopenic, 3 (10.3%) were osteoporotic and 13
(44.8%) had normal BMD. After treatment of the os-
teopenic women, 3 (23.07%) had a normal BMD, 8
(61.5%) remained osteopenic but gained bone mass
and 2 (15.38%) had a worse bone mass but did not
become osteoporotic. Among the 3 osteoporotic
women evaluated at the beginning of treatment, 2 re-
mained osteoporotic, with 1 showing improvement in
bone mass and 1 worsening, and the third patient had
a normalized BMD. For the 13 patients with normal
BMD at the femoral neck, 4 (30.76%) became os-
teopenic, 2 (15.38%) maintained bone mass and 7
(53.8%) achieved a gain in bone mass (Table 2). Mean
T and Z values of bone mineral density tests in these
patients were shown in Table 2 and there was no sta-
tistical significance. Regarding patient age at the be-
ginning of treatment, a better therapeutic response
was noted among the younger women.
Discussion 
The proposal of this study was to take a new look at
patients with gonadal dysgenesis based on the treat-
ment of these women, treatment outcome and the re-
lationships with independent variables such as age
and BMI.
The current study retrospectively evaluated BMD in
women over a period of 5 years and showed that treat-
ment with the protocol used by the endocrine gyne-
cology outpatient clinic is beneficial for patients and
should be widely encouraged. Treatment with a regi-
men of estrogen and progestin showed a significant
difference in the lumbar spine and the majority of
women changed from an osteoporotic to normal sta-
tus. In contrast, when the femoral neck was evaluated,
no significant difference was found. Therefore, only
BMD values of the lumbar spine were used for the re-
maining statistical analysis and femoral neck BMD
values were rejected. This study corroborates the find-
ings of other studies showing that treatment with es-
trogen and progestin, alone or in combination, may
increase the BMD values found and prevent osteo-
porosis. When comparing estrogen alone or progestin
alone regarding the best dose used, it was not possible
to establish a significant difference in BMD. Women
with gonadal dysgenesis should be treated with a dose
regimen combining estrogen and progestin, initiating
treatment as soon as possible. If feasible, treatment
should be started at the time of diagnosis, since pa-
tients are diagnosed in the transition between puberty
and adulthood. We could thus reproduce the peak of
normal bone mass and decrease osteoporosis along
with its consequences.
A linear correlation between independent variables,
such as age and BMI, and BMD of the lumbar spine
had different results. While a correlation between low-
er ages in the beginning of treatment and better BMD
outcomes proved to be significant, there was no signif-
icant correlation between BMI and BMD.
BMI had no influence on lumbar spine density, al-
though this correlation has been demonstrated in oth-
er studies. The influence of BMI and body weight is
also significant for determining BMD. We believe that
the results of this study were not significant between
BMI and BMD because the mean BMI values of the
women studied were within the normal range. There-
fore, the impact of bone remodeling was limited and
did not prove to be significant in this study. However,
analysis was still able to show that the higher the BMI
was at the beginning of treatment, the greater the gain
in BMD. This confirmed the previously discussed
concepts.
Conclusions
Women with Turner’s syndrome and gonadal dysgen-
esis (46, XX karyotype) undergoing long-term hor-
mone therapy gained a significant amount of bone
mass. Treatment evoked a stronger response at the
lumbar spine than at the femoral neck. The impor-
tance of therapy and the need to stimulate patient ad-
herence to treatment were highlighted. Furthermore,
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TABLE 1 - BONE MASS DENSITY IN THE BEGINNING
AND IN THE END OF TREATMENT.
Initial Final Percentage P-value
gain
Z-score
lumbar spine -2.51 -1.54 37.28% <0.0001
T-score
lumbar spine -2.54 -1.60 33.67% <0.0001
Z-score
femoral neck -1.11 -0.88 7.88% 0.0621
T-score
femoral neck -1.20 -0.92 22.17% 0.0769
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the better therapeutic response among younger
women underlined the importance of early diagnosis
and initiation of treatment.
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Introduction 
The polycystic ovary sindrome (PCOS) strikes
around, 5-10% of the women in fertile age (37). Cur-
rently it is held a real plurimetabolic syndrome (1,2,3).
His diagnosis often is based on the criteria of PCOS
Consensus Workshop 2003, which define the presence
of PCOS: oligo- and/or anovulation, clinical signs
and/or biochemical hyperandrogenism, polycystic
ovarian ultrasonography texture, in the absence of
congenital adrenal hyperplasia, Cushing’s syndrome
and androgen-secreting ovarian or adrenal tumors
(4,21). The substratum physiopathologic, that sub-
tends the to establish him of the clinical alterations,
biochemists and echography typical of the PCOS, is
not entirely still clarified (3,38,39). However, since in-
sulin resistance (IR) has been recognized as the most
important factor in the pathogenesis of polycystic
ovary syndrome, the framework of concomitant dis-
ease or result has been greatly expanded (5). It seems
that (6,7,8), the IR and the consequent hyperinsuline-
mia, produce the excess of androgens, because of alter-
ations in the mechanisms of phosphorylation post-re-
ceptor to peripheral level. Hyperinsulinemia has been
implicated in mechanisms that increase stromal ovari-
an steroidogenesis and the activation of cytochrome P-
450 17α · c and 3-β-hydroxy-steroid dehydrogenase
in the adrenal cortex and ovary (9,40). Given the cen-
tral role played by IR (14,42), in women with polycys-
tic ovary talking about an increased risk for diseases
such as type II diabetes, dyslipidemia and cardiovascu-
lar accidents (10,11,13). Thus the way is open to the
use of insulin-sensitizing drugs (12). The first is met-
formin, which does not seem to always give satisfacto-
ry results (18,19). Instead, as part of the thiazolidine-
dione, pioglitazone has proved very effective, both in
diabetes mellitus type II, which in PCOS (15,16,17).
In the series presented here, we compare the results ob-
tained with metformin than with pioglitazone in 240
patients with PCOS. We evaluate in detail the meth-
ods of treatment, the ability to maintain the results
achieved and to prevent long-term consequences of
the syndrome, with a minimal dose of medication. 
Materials and methods 
Recruit 240 women with PCOS. 200 with symptoms
dating back to menarche (group A), and 40 from 3-4
years (group B). In group A, 160 women were not in-
terested in conceive, aged between 18 and 24 years, 40
were female sterile or infertile, aged between 22 and
34 years old and eager to children. In group B, the age
ranges were similar, and 8 were desirous of offspring.
In all patients the BMI was calculated. Among the
group A patients, 104 were overweight or obese. In
about half were no signs of hyperandrogenism. Among
the patients in group B, 16 were overweight or obese.
In one third of them were no signs of hyperandro-
genism. In all patients we measured: thyroid-stimulat-
ing hormone (TSH), thyroid peroxidase (TPO), ∆4
androstenedione (∆4), prolactin (PRL), dehy-
droepiandrosterone free (DHEA), dehydroepiandros-
terone sulfate (DHEAS), total testosterone (TT),
testosterone free (FT), luteinizing hormone (LH), fol-
licle-stimulating hormone (FSH), 17-α-hydroxy-
progesterone (17OHP). We calculated, finally, insulin
and glucose. The same tests were performed in a group
of 50 healthy subjects, taken as a control group. Prog-
esterone was measured in 80 cases, in which the men-
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strual cycles were irregular, the duration increased.
Progesterone was measured serially every 5-6 days, un-
til the onset of the next menstrual flow. DHEA,
DHEAS, PRL, TP were assayed by immuno-chemo-
luminescence (CIBA Corning ACS-180), TSH, TPO,
∆4, FTP, and insulin, with radio-immunological
methods (Diagnostic Products), glucose by the
method of glucose oxidase (Beckman Instruments).
Criteria for the assessment of insulin resistance and
hyperinsulinemia were:
1) insulin resistance, calculated by HOMA-IR adjust-
ed for BMI. According to this parameter, you can
talk about IR with BMI values greater than 2.5 to
25, above 3.2 for BMI between 25 and 35, and 3.8
for BMI greater than 35 (6,41); 
2) hyperinsulinemia, calculated with the area under
the curve insulinemic (AUC) after oral glucose
load (75 g), with sampling every 30 minutes to two
hours. As a parameter we considered the normal
maximum AUC obtained in control subjects. In-
stead, we considered indicative of hyperinsuline-
mia, the AUC in excess of at least 25% of those
considered normal.
Identified the status of IR and hyperinsulinemia, we
treated the patients as follows: 
– SCHEME 1 – Overweight or obese patients =
weight reduction program, with a 1200-1300 cal diet
and physical activity. After 4 months we have evaluat-
ed the weight loss and normalization of both the clin-
ical picture of Homo-IR. If the answer is satisfactory,
we continued with the program, otherwise we
switched to schedule 2 (which we have applied from
the beginning to the patients of normal weight).
– SCHEME 2 – Patients of normal weight patients in
the failed Scheme 1 = 24 patients treated with met-
formin, starting with 1 tablet of 500 mg daily, with in-
crements of 500 mg every 2 weeks until the dose of
2000 mg per day. 154 patients treated with pioglita-
zone, with cp 15 or 30 mg, according to HOME-IR
and AUC. Reevaluation of laboratory parameters at 6
months.
Results 
In 184 of the 200 patients in group A ’HOMA-IR
and AUC were indicative of IR and hyperinsulinemia.
Among the 40 patients in group B, the same parame-
ters were affected IN16 women, all overweight or
obese. The hormonal assays of patients with IR and
hyperinsulinemia, compared with the controls, are in
Table 1. The HOMA-IR of patients, compared with
controls, are shown in Table 2. In Table 3 shows the
AUC data. In 184 patients in group A with IR, 90
were overweight or obese and have therefore been
subjected to Schema1, along with 16 obese patients in
TABLE 1 - ANDROGEN LEVELS IN PATIENTS WITH PCOS
(200) AND CONTROLS (50).
PCOS Controls Significance
TT 0,66 +/- SD 0,15 0,57 +/- SD 0,13 NS
FT 2,12 +/- SD 0,64 1,5 +/- SD 0,48 0,05 <P <0,1
DELTA-4 2,05 +/- SD 0,53 1,74 +/- SD 0,39 0,5 <P <1
DHEA 5,1 +/- SD 1,4 4,6 +/- SD 1,25 NS
DHEA-S 303,5 +/- SD 95,7 321+/- SD 92,7 NS
17OHP 1,31 +/- SD 0,37 0,9 +/- SD 0,29 0,5 <P <1
TT = total testosterone (ng/ml) v.n. 0,06-0,86
FT = free testosterone (pg/ml) v.n. 0,2-2,5
Delta - 4 androstendione (ng/ml) v.n. 0,6-3
DHEA = Deidroepiandrosterone (in ng/ml) v.n. 1,5-8
DHEAS =Deidroepiandrosterone sulfate (in mcg/dl) v.n. 120-410
17OHP = 17 idrossi-progesterone (in ng/ml) v.n. 0,5-1,7 (follicular phase)
Tab. 3 - Values of the area under the curve insulinemic (AUC) in patients
with PCOS and controls  (0.005<p<0.01).
PCOSCONTROLS
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Tab. 2 - Mean values of HOMA-IR in patients with polycystic ovary syn-
drome (PCOS) and controls  (0.005<P<0.01).
PCOSCONTROLS
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group B. 20 patients in group A lost weight, but only
in 12 there was normalization ‘HOMA-IR and AUC,
with regularization cycles. These have continued to
Schema1. In group B lost weight, 10 of 16 patients.
Total (Group A +Group B) have lost weight, 30
(28%) patients and of these, 22 (20%) were also reg-
ulated by the metabolic and clinical point of view. It
seems that the group B patients lose weight more eas-
ily. The 84 patients in whom it failed Schema1, plus
94 normal weight, were sent to Scheme 2. 24 patients
were treated with metformin. Metformin was not al-
ways well tolerated: 6 patients had significant distur-
bances (abdominal cramps, diarrhea) with a dose of
1500 mg / die, 6 mg with that of 2000, so they had
to stop at 1000 and 1500 mg/die, respectively. Only
6 patients (all obese) regularization of 24 (25%) have
obtained the clinical and metabolic (Table 4). De-
sirous of offspring of 8, 2 gave birth to an end. From
this, it is clear that only works with metformin thera-
py in obese patients, are not effective in 51% of pa-
tients of normal weight. The remaining 154 patients
were treated with pioglitazone. 15 mg / day, in 110
patients with HOMA-IR between 2.5 and 3.5, and
30 mg / day in patients with HOMA-IR> 3.5. In 116
(75,3%) women was obtained in 3-4 months, the reg-
ularization of the menstrual cycle and the resumption
of ovulation. Of the 32 patients, desirous of offspring,
18 have given birth to an end. The hormonal results
evaluated after 6 months (except for TSH and TPO),
are in Table 5. With regard to metabolic parameters,
the comparison with baseline data, can detect a dras-
tic reduction in both AUC home-IR, with a complete
clinical and biochemical normalization in all cases
(Table 6). After 4 months, we halved the dosage,
while the results obtained. In 26 patients we contin-
ued with 7.5 mg / day, and 3 with 7.5 mg every oth-
er day. Pioglitazone was well tolerated and never
stopped.
Discussion 
We report the high incidence of IR and hyperinsuline-
mia (184 of 200) patients in group A, while patients
in group B, these metabolic abnormalities were pres-
ent only in 16 overweight or obese. One hypothesis
might be that, in this second category of patients, the
IR and hyperinsulinemia do not depend on PCOS,
but obesity (22,23). On this basis, it could explain
why these patients seem to have less difficulty in los-
ing weight. With regard to the results we can say that,
metformin was poorly tolerated and was effective in
only 25% of the patients, all of normal weight. This
date does not comfort us, whereas the majority of
women with PCOS are overweight or obese. Instead,
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Tab. 4 - Effects of metformin treatment on HOMA-IR (0.05<p<0.1) and AUC
(0.05<p<0.1) in obese patients responsive.
TABLE 5 - COMPARISON BETWEEN THE MEASURED LE-
VELS OF ANDROGENS IN PCOS PATIENTS BEFORE AND
AFTER 4 MONTHS OF TREATMENT  PIOGLITAZONE.
PCOS Pre PCOS Post Significance
TT 0,66 +/- SD 0,15 0,65 +/- SD 0,16 NS
FT 2,12 +/- SD 0,64 2,16 +/- SD 0,6 NS
DELTA 4 2,05 +/- SD 0,53 1,77 +/- SD 0,48 0,05<P<0,1
DHEA 5,1 +/- SD 1,4 5,06 +/- SD 1,35 NS
DHEAS 303,5 +/- SD 95,7 321,7 +/- SD 87,4 NS
17-OHP 1,31 +/- SD 0,37 1,21 +/- SD 0,43 0,5 <P <1
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pioglitazone, has worked in 75.3% of cases, regardless
of body weight. Moreover, it is well tolerated and does
not give side effects. In conclusion, decide to continue
treatment with Pioglitazone depends on several con-
siderations (43,44):
1. In cases of chronic anovulation, as demonstrated in
our patients, there is an increased risk of adenocar-
cinoma of the endometrium, associated with pro-
longed exposure to estrogens, unbalanced by prog-
esterone production. These patients should be
placed with more or less monthly rate of proges-
terone or a progestin (24,25). Therefore, the use of
pioglitazone, should be preferred over the use of
progesterone.
2. The risk of type II diabetes in patients with PCOS,
IR and hyperinsulinemia, is very high (46). Predic-
tive criteria have decreased glucose tolerance, or a
positive family history of type II diabetes
(14,26,29). However, given the high percentage of
IR, it seems appropriate to recommend a therapy
with pioglitazone, considered, that is well estab-
lished its protective effect on the function of pan-
creatic beta-cells (27,28). 
3. Cardiovascular risk factors in patients with PCOS
have increased: dyslipidemia, hypertension, en-
dothelial dysfunction, atherosclerosis (13,31,32).
In many studies (33,34,35) showed that pioglita-
zone decreases markers considered predictive of
cardiovascular risk.
4. Finally, our data prospect of being able to continue
treatment even at low doses of pioglitazone, while
the results over time (45). 
We believe that treatment with doses of 7.5 mg on al-
ternate days for 6 months, is far more acceptable in
economic terms, and physicians, when compared with
standard doses of 30 or 45 mg (17). This is even more
appropriate in the light of a new update of the infor-
mation security, announced June 17, 2011 by the
Food and Drug Administration of Pioglitazone on the
label, with reference to the increased risk of bladder
cancer in patients who the taking the drug for more
than one year, maximum dosage for antidiabetic ther-
apy (36).
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The new hormonal contraceptive containing nomege-
strol acetate (NOMAC) and estradiol (E2) has some
pharmacological advantages over the existing hormon-
al contraceptives. Patients will effectively be convinced
and keep using this good contraceptive only if the pre-
scriber is able to properly convince them. The main
advantages of NOMAC/ E2 will be summarized first.
Then some strategies to improve patient compliance
will be suggested in order to better traduce a very good
pharmacological profile into an effective prescription
of Zoley®.
Nomegestrol advantages vs
other progestogens
Nomegestrol acetate has many advantages, versus the
other progestogens, because of its pure progestinic
effects, longer half life and good metabolical neutral-
ity (1). 
NOMAC acetate is a potent, highly selective
progestogen: a full agonist at the progesterone recep-
tor, with no or minimal binding to other steroid re-
ceptors, including the androgen and glucocorticoid
receptors. It demonstrates moderate antiandrogenic
activity and strong antiestrogenic activity in animal
models. NOMAC is associated with effective suppres-
sion of gonadotropic activity and ovulation in pre-
menopausal women, and a neutral impact on hemo-
stasis, lipids, and carbohydrate metabolism. It has
shown favorable effects on estrogen metabolism, in
normal and cancerous human breast tissue. In human
breast cancer cell lines in vitro, it does not stimulate
cell proliferation. NOMAC in combination with E2
has a good cycle control and a favorable safety profile.
The monophasic NOMAC 2.5 mg and 17β-estradiol
(E2) 1.5mgc contraceptive administered in a 24/4-
day regimen provides a consistent and robust ovula-
tion inhibition. Zoely® provides high contraceptive
efficacy with acceptable cycle control as well as an
overall adverse event profile similar to that of
drospirenone/EE pills (2). There is a less overall im-
pact with NOMAC/E2 on hemostatic, lipid, inflam-
matory, and carbohydrate metabolism parameters
than with levonorgestrel 150 µg/EE 30 µg (3). These
clinical findings are promising even though the
Cochrane database has no jet data to demonstrate dif-
ferences between NOMAC and the existing other
progestogens used for contraception. (4) 
Estradiol advantages vs etinilestradiol
Natural estradiol (E2) has many benefits, versus
etinilestradiol (EE), for metabolism and coagulation,
but also a potential benefit for sexuality.
Lowering the estrogen dose and potency is a long term
evolution strategy that makes hormonal contraception
safer, even though it could cause more intermenstrual
bleeding (5).
NOMAC/E2 could have a more favourable venous
thromboembolism risk profile than levonorgestrel/EE,
also for the lower liver effects of E2, even though
further epidemiological data are required to confirm
this (6).
E2 seems to have a better estrogenic vaginal effect than
the 20 mcg of EE that could cause more vaginal dry-
ness. The lower effect on SHBG could make Zoely®
more neutral as to the effect on the androgenic mech-
anisms of sexual desire. 
How to improve user satisfaction and continuation
with the new hormonal contraceptive containing
nomegestrol acetate and estradiol (Zoely®)
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Natural E2 could be more acceptable versus EE, being
the physiologic estrogen.
The 24-day NOMAC/E(2) regimen is associated with
greater inhibition of follicular growth and shorter du-
ration of withdrawal bleeding than the 21-day regi-
men used by most of theexisting contraceptives. The
shorter pill-free interval results in a greater margin of
contraceptive efficacy and tolerability and fewer with-
drawal symptoms (7).
Enhancing compliance to the
NOMAC/E2 contraceptive (Zoely®)
It is not easy to explain to the patients the reasons to
preferentially prescribe this new contraceptive using
short, easy to understand and effective sentences, but
the way it is presented will strongly affect its accept-
ance and continuation. 
An improvement of the doctor patient relationship
and some communication strategies summarized here
will help the prescriber to improve Zoely® compliance.
1. Find a proper setting and enough time for the
first prescription.
The first prescription is an important moment for
its acceptance and continuation. Try to do that in
a place and in a moment when a patients can ex-
press her needs and concerns and the doctor can
address that, having at least few minutes of com-
munication without being interrupted. This is true
for every prescription but making the patient be re-
ally convinced about the choice of Zoely® needs
that.
2. Create a good doctor-patient relationship to make
the patient trust the doctor. 
The patient has to perceive that the doctor is real-
ly interested in what she expresses and wants the
best for her. The strategies to do that are difficult
to teach. Most of them are based on non verbal
communication, could be instinctive and for the
majority unconscious. Some women will experi-
ence mild initial side effects. Those who trust their
doctor will trust his/her prescription and do not
stop it.
3. Inquire which are the most important reasons to
use, and to fear, a hormonal contraceptive for that
specific women.
Find out which are the main reasons for using or stop
taking a contraceptive for each women helps to focus
the discussion on the main relevant arguments. Zo-
ley® has a lot of advantages to use to convince the pa-
tient to choose it. They are summarized above. The
benefits of NOMAC and the natural and neutral ef-
fects of E2 are the main subjects to use.
4. Try to understand if there are hidden questions
that could lie behind what the women expresses.
Many times the “real” reason why a contraceptive
is needed, or particularly feared, are not openly ex-
pressed or even conscious to the patient. If the doc-
tor feels a “resistence” beyond rational reasons this
could be a sign that there is something hidden, to
find out and discuss, that prevents the women to
use the prescription. 
5. Use the proper way to communicate according to
the patient needs.
The ideal doctor patient relation is “adult to
adult”: a peer to peer discussion of the prescription
of Zoely®. Some women prefer a “parent to chil-
dren” way of relation and let the doctor decide for
them. They like and need more reassurance than
information on the pharmacological profile of
NOMAC/E2. 
6. Discuss relevant arguments understandable for
the patient in an easy to remember way.
The discussion should be short and effective so it is
important to discuss only the relevant arguments,
restricted to only few subjects (one to three). The
reasons of the choice of a NOMAC/E2 should use
arguments relevant to the needs of that specific pa-
tient. The way to explain them has to be as simple
and easy to keep as possible.
7. Anticipate openly the possibility of adverse effects
and what to do if it happens.
Some patients will have side effects even with a
very well tolerated contraceptive like Zoely®. An
open discussion to inform about some of them,
like the occurrence abnormal bleeding, is better
than letting the women discover or experience that
later. The women that know what to do keep using
the pill end wait for the likely spontaneous disap-
pearance of the side affects after the first months of
use.
8. Reassure using consciously the non verbal com-
munication.
Even if a women is rationally convinced to use
NOMAC/E2 some unconscious fears may per-
sist. The doctor should be aware that his/her non
verbal communication can strongly strengthen
or reduce the good arguments used. If, for exam-
ple, the doctor is worried about his/her own
problems and expresses that with the mimic or
the voice, the women feels that and tends to be
more scared about using the contraceptive pre-
scribed.
9. Try to be available in case of doubts or side effects
occurrence.
If the women reads scaring information on the
package leflet or she will experince some side ef-
fects, like bleeding or amenorrhea, the possibility
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to have an easily awailable, even only telephonic,
reassurance at the time of occurrence prevents dis-
continuation of Zoely®.
10.Follow up in a short time and then periodically.
The first months of use are the most important for
the continuation. Generally side effects appear in
this period and most of them disappear sponta-
neously. An appointment within few months could
help to discuss any new event and to help the
women keep using the NOMAC/E2 contraceptive
with all its benefits versus the other contraceptives.
A further periodical check could help evaluating
any new need, symptom or sign and make this
good contraceptive use even safer. 
Conclusion
The NOMAC/E2 contraceptive has some advantages
over the existing contraceptives, but they should be
properly explained. In order to obtain the best compli-
ance the prescriber not only have to tell the women the
pharmacologic advantages of Zolely®: he/she should
better express them by using some clinical communi-
cation strategies. 
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Objective
Determining the perinatal events and the associated
material to the delivery with the help of VE.
Methodology
We prospectively studied 162 where delivery’s have
been conducted with the help of VE in the period Jan-
uary-December 2009.
Results
Of 162 cases, 33% of cases have been nulipara, and
66% multipara. VE delivery’s are carried out in 97%
of cases, while the S.C in 2% of cases.
VE is applied <10 min in 97.4% with a traksion.
Four cases or 2.5% of cases have manifested signs of
bleeding in the newborn intracranial where three cas-
es or 1.8% have no neurological deficit manifested
signs regarding clinical aspects.
Conclusion
Applying calottes the head of the newborn patients
where birth is conducted with the help of VE does not
cause a head trauma in newborns.
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Introduction
Hyperprolactinemia is characterized by persistently
high prolactin (PRL) levels in the blood, and it is the
most common endocrine disorder of pituitary hyper-
secretion on the hypothalamic-pituitary axis (1,2).
The treatment of choice for hyperprolactinemia is
dopamine agonist administration, which inhibits PRL
synthesis and release. Conversely, a dopamine antago-
nist may raise serum PRL levels, leading to hyperpro-
lactinemia. In fact, it has been shown that metoclo-
pramide is efficient in the development of a hyperpro-
lactinemia model (3,4).
Metoclopramide-induced hyperprolactinemia in fe-
male mice (5) reduces the synthesis of not only ovari-
an steroids during proestrus but also progesterone dur-
ing pregnancy. The concentration and gene expression
of PRL receptors are affected as well given their de-
pendence on the serum levels of sex hormones (6).
The role of hyperprolactinemia interaction with sex
steroids in the gene expression of PRL and its recep-
tors in the uterus is still controversial. We thus under-
took this study to evaluate the gene expression of PRL
and its receptors in the uterus after sex steroid admin-
istration using the real-time PCR technique. 
Materials and methods
This research was approved by the local institutional
committee.
Of 49 female mice (SWISS) with a normal estrous cy-
cle, previously checked by vaginal smears taken for 7
days, a random (13) total of 35 underwent bilateral
oophorectomy and were then confined to cages for 20
days. After this postoperative adjustment period, these
animals were randomly allocated (13) to 5 groups, and
the nonoophorectomized mice to 2 groups. The
groups, all of equal size (n=7), were GI (nonoophorec-
tomized control mice), GII (nonoophorectomized
mice with untreated hyperprolactinemia), GIII
(oophorectomized control mice), GIV (oophorec-
tomized mice with untreated hyperprolactinemia),
GV (oophorectomized mice with hyperprolactinemia
treated with estrogen), GVI (oophorectomized mice
with hyperprolactinemia treated with progestogen),
and GVII (oophorectomized mice with hyperpro-
lactinemia treated with estrogen and progestogen). 
The drugs, which were administered subcutaneously
for 50 consecutive days, were as follows: metoclo-
pramide (Sigma®), 200µg/day in 0.9% saline solution;
17β-estradiol (Sigma®) and micronized progesterone
(Sigma®), 1µg/day and 1mg/day, respectively, in oil-
based solution (3,4). On the last day, one hour after
drug administration, the mice were sacrificed, except
for those not in proestrus. These continued to receive
the drugs until they entered that phase (1).
Sample collection and processing
The mice were killed by decapitation and their left and
right uterine horns were removed for total RNA ex-
traction through TRIzol® (Invitrogen). The RNA thus
obtained was resuspended in sterile MilliQ water and
stored in a freezer at -80º C.
Qualitative RNA analysis, cDNA (complementary
DNA) synthesis, and quantitative real-time PCR 
(qRT-PCR)
Total RNA was treated with DNase I (Invitrogen) to
remove any genomic DNA contamination. Subse-
Effects of hyperprolactinemia on the murine uterine prolactin
gene and prolactin receptor expression
DO AMARAL V.C., CARVALHO K.C., MARCONDES R.R., MACIEL G.A.R.,
BARACAT P.M.C.1, SOARES JÚNIOR J.M.1, BARACAT E.C.1
School of Medicine - University of São Paulo, Department of Gynecology and Obstetrics,
Laboratory of Structural and Molecular Gynecology (LIM 58), São Paulo, Brazil
quent synthesis of cDNA was performed using up to
2µg of total RNA and the Hi Capacity Reverse Tran-
scription Kit (Applied Biosystems, USA) according to
the manufacturer`s instructions.
Qualitative cDNA analysis
The cDNAs were analyzed by the conventional end-
point PCR technique, using the pairs of specific acti-
vators for the β-actin gene. Following interpretation of
cDNA quality in agarose gels (Sigma®), the cDNAs
were utilized in the qRT-PCR reactions (14).
Simultaneously, standardization of reactions with the
specific initiators for the 4 prolactin receptor (PRL-R)
isoforms, L, S1, S2, and S3, was carried out. Endome-
trial prolactin expression was also assessed.
Statistical analysis
The results were subjected to the analysis of variance
(ANOVA) and, additionally when necessary, to the
Tukey-Kramer multiple comparisons test to check for
significant differences between the experimental
groups. The significance level was set at 5% (p<0.05).
Results
Gene expression analysis of endometrial prolactin
and its receptors
As shown by transcript analysis for endometrial pro-
lactin, expression of such a gene was highest in GIV
and lowest in GIII (p<0.05).
Expression of the long endometrial prolactin receptor
isoform was highest in GVI and GVII and lowest in
GI and GIII (p<0.05). Of the short prolactin receptor
isoforms, PS1, PS2, and PS3 alone were evaluated.
The highest expression of PS1 was found in GIII, and
the lowest, in GIV and GVI (p<0.05). Expression of
PS2 was highest in GII and GIII and lowest in GVI
and GVII (p<0.05). PS3 was mostly expressed in
GVII and least so in GIII (p<0.05).
Discussion and conclusion
Prolactin is known to interact with estroprogestogen
therapy (7), and such knowledge was further con-
firmed by this study. Our results highlight the influ-
ence of progesterone in increasing gene expression for
the PRL oligonucleotide while estrogen action remains
at a low point. Despite such an effect, when proges-
terone is administered along with estrogen, gene ex-
pression decreases. Thus, estrogen therapy, as well as
estroprogestogen therapy, may benefit the uterus as re-
gards prolactin expression in a hyperprolactinemic
state. 
Understanding prolactin receptor behavior is another
relevant aspect targeted in the past two decades (8).
Yet, little is known about prolactin receptor interac-
tion in animals subjected to a hyperprolactinemic
state.
Expression analysis of the receptors showed that all
isoforms (PL, PS1, PS2, and PS3) were expressed in all
of the study groups. This underscores the sensitivity of
the technique that was chosen (9). In contrast, Rossi et
al. (2009) was not able to detect transcripts for en-
dometrial prolactin receptors in any of the oophorec-
tomized animals with hyperprolactinemia. These di-
vergent results appear to stem from the choice of the
analytical techniques employed.
PRL receptors are expressed in diverse organs, such as
the uterus and the hypophysis (10). However, their
concentrations are known to be dependent on sex hor-
mone levels in the blood (4,6) as corroborated by our
results that showed that the higher the serum concen-
tration of these steroids, the higher the expression of
the long isoforms of the receptor. 
Sex steroids are fundamental in establishing the ex-
pression levels of the prolactin receptor (11,12). In the
present study, such an effect was manifested by the in-
creased expression of the long receptor isoforms, and
this took place whether the hormones were adminis-
tered separately (GV and GVI) or conjointly (GVII).
The authors report no conflict of interests. 
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Introduction
Smoking represents the most widespread substance de-
pendence in the world. The negative impact of tobac-
co smoking is complex. However, it influences biosyn-
thesis and steroids effects among others. Smoking in-
terferes with neuroactive steroid metabolism and ad-
diction arises very quickly.
Smoking in women has an anti-estrogenic effect. It
may also influence hormonal contraception effects
negatively: this may lead to higher incidence of off-cy-
cle spotting and bleeding (Rosenberg et al. Am J Ob-
stet Gynecol 1996).
However, anti-estrogenic effect has not been con-
firmed in all studies. On the contrary, the increase in
androgen production in women smokers throughout
life from puberty to menopause has been described in
studies consistently (Van Voorhis et al. Fertil Steril.
1992; Barbieri et al. Fertil Steril. 2005; Manjer et al.
Eur J Epidemiol. 2005; Cochran et al. Obstet Gy-
necol. 2008; Cupisti et al. Fertil Steril. 2010). A num-
ber of studies have focused on the impact of smoking
on female reproduction. They have reported increased
incidence of infertility in women smokers (Thomford
and Mattison, J Ark Med Soc 1986; Weigert et al. J
Assist Reprod Genet 1999).
Patients and methods 
The study involved 40 premenopausal and 60 post-
menopausal women heavy smokers who had decided
to stop smoking and sought medical help at the Cen-
tre for Tobacco Dependence. The women did not use
hormonal contraception or hormonal replacement
therapy for at least 6 months before the testing, they
did not suffer from any serious illness and did not use
any medication affecting steroidogenesis. The pre-
menopausal women had regular menstrual cycles. The
women were examined before the initiation of smok-
ing cessation, after 6, 12, 24 and 48 weeks of absti-
nence. During each examination, blood was collected
to determine steroid spectrum, LH, FSH, SHBG and
basic anthropometric data were measured. For evi-
dence of abstinence from smoking, cotinine analysis
was used. The study has been approved by the ethics
committee of the Institute of Endocrinology.
Most of the steroids and their polar conjugates were
measured using the previously described GC-MS
method (Hill et al. J Steroid Biochem Mol Biol 2010).
The 17-hydroxy-pregnenolone was measured by RIA
as described in our previous report (Hill et al. Steroids
1999) and conjugated 17-hydroxy-pregnenolone was
measured using the same method after hydrolysis as
described previously. Estradiol was measured by RIA
kit from Orion, Finland (intra-assay CV=4.4%, inter-
assay CV=4.6%) and 17-hydroxy-progesterone was as-
sayed by kit from Immunotech, France (intra-assay
CV=5.2%, inter-assay CV=6.5%). LH by IRMA kit
from Immunotech, France (intra-assay CV=3.7%, in-
ter-assay CV=4.3%), FSH by IRMA kit from Im-
munotech, France (intra-assay CV=2.6%, inter-assay
CV=4.5%) and SHBG by IRMA kit from Orion, Fin-
land (intra-assay CV=6.1%, inter-assay CV=7.9%.)
The hormonal profiles were evaluated using repeated
measures ANOVA model. The statistical software Stat-
graphics Centurion version XVI from Statpoint Inc.
(Warrenton, Virginia, USA) was used for simultane-
ous data transformations, ANOVA testing and multi-
ple comparisons.
Hyperandrogenism with women smokers and its role in the prediction
of smoking cessation treatment success
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Results
In the group of postmenopausal women, nine women
were successful in smoking cessation, 15 women failed
during the treatment, 36 women had only basal sam-
pling. Therefore the data from postmenopausal
women could be analyzed after one year abstinence. In
the group of premenopausal women, only 5 women
were successful, 12 women failed during the treatment
and 23 women had only basal sampling. Due to the
small amount of successful women, these data could
be analyzed only after the first 6 week period of cessa-
tion.
In the group of premenopausal women who discontin-
ued smoking for 6 weeks we monitored changes in
C21 steroid levels on which the smoking discontinua-
tion had no effect. We also monitored the C19 steroid
levels where we found an increase in conjugated an-
drostenediol, 5- androstene-3β, 7α, 17β-triol and de-
crease in conjugated androsterone and conjugated 5α-
androstane-3β, 17β-diol. Changes in the levels of oth-
er androgens were not significant. 
In the group of postmenopausal women, we found in-
creasing levels of androgens (testosterone, andros-
terone) during smoking cessation, increasing of
DHEA was insignificant. Conjugated to nonconjugat-
ed 20α- pregnanolon ratio was significantly decreas-
ing. Changes in the levels of other C21 steroids were
not significant. 
The higher androgen levels before the smoking cessa-
tion correlated with failure in smoking cessation in
both groups (premenopausal and postmenopausal
women).
Conclusion 
Smoking causes higher androgen levels in women. Our
results indicate that smoking discontinuation leads to
their further increase. There are several hypotheses ex-
plaining elevated levels of androgens after smoking ces-
sation. We considered the influence of nicotine in nico-
tine replacement therapy. However levels of kotinin,
which reflects nicotine income, do not correlate with
levels of androgens. Neither gaining weight nor ageing
process had influence on androgen levels. A question
remains, whether testosterone itself could play a role in
development of tobacco addiction. From the literature,
higher levels of testosterone in female smoker’s daugh-
ters are an independent risk factor for development of
nicotine dependence in future (Kandel et al. Am J Pub-
lic Health 1999). Smokers may therefore have higher
testosterone levels than non-smokers before starting
smoking. We believe that, these levels are subsequently
reduced by smoking and after cessation returned to its
original concentrations. Another explanation for high-
er levels of testosterone is irreversibly affected steroido-
genesis caused by chronic smoking.
The study has been supported by grants: NT/12340-5
of IGA MZCR and by Advanced education of own
staff in clinical and molecular endocrinology project
(CZ.2.17/1.1.00/32386).
Research on stress provocation in pregnant women has
resulted in inhomogeneous findings regarding the al-
terations of the hypothalamus-pituitary-adrenal (HPA)
axis and the autonomic nervous system (ANS) with re-
spect to the ongoing pregnancy and the type of stressor.
While some studies report sig. psychobiological re-
sponses to various stressors (1-4) others do not (5-7).
Gaining a deeper understanding of the stress response
during pregnancy is essential, as prenatal psychological
stress has been linked with a range of adverse health
consequences for the pregnant woman and her unborn
such as an increased risk of pregnancy loss, preterm de-
livery and low birth weight (8,9). In a series of studies
we examined the endocrine and autonomic responses
(a) to standardized psychosocial stress at different stages
of pregnancy and (b) to an invasive diagnostic proce-
dure (amniocentesis, AC) during the 2nd trimester.
In study 1, we exposed 30 healthy pregnant women at
the beginning of the 2nd trimester (group 1), 30
healthy pregnant women at the beginning of the 3rd
trimester (group 2) and 30 healthy non-pregnant con-
trols in the follicular phase of their menstrual cycle
(group 3) to a standardized psychosocial stress test. In
study 2, we monitored 34 healthy pregnant women
undergoing AC for karyotyping in the 2nd trimester
and re-examined them in a rest condition (RC) after
they had received the inconspicuous AC test results.
The stress responses to the psychosocial stress test and
to the psychological challenge of the AC procedure
were measured by the endocrine parameters cortisol (F)
and alpha-amylase (AA) from saliva samples as well as
by continuous monitoring of cardiac activity in order
to obtain heart rate (HR) and heart rate variability
(HRV) measures. In study 2, F and its inactive metabo-
lite, cortisone (E), as well as a ratio between the two
compounds (E/(E+F)) were additionally assessed from
amniotic fluid samples. This ratio served as a proxy for
the activity of 11β-hydroxysteroid dehydrogenase type
2 (11β-HSD2), an enzyme that is present in the pla-
centa and the fetal system and inactivates F to E. 11β-
HSD2 is, therefore, assumed to protect the foetus from
overexposure to maternal glucocorticoids (10). 
In study 1 stimulated HR and HPA responses showed
sig. increases in all three groups following stress expo-
sure. F and HR increases of both pregnant groups were
shown to be comparable with those of the controls.
AA increases of both pregnant groups were markedly
attenuated compared to non-pregnant women. Inter-
estingly, F recovery following the stress test was sig.
prolonged in 2nd trimester pregnant women (3). This
finding may be interpreted as a specific phase of stress
vulnerability during pregnancy.
In study 2 AC provoked a sig. ANS rise since AA and
HR increased sig. over time as compared to the RC.
With regard to HRV, the high frequency component,
prior to and after AC, was comparable to levels during
the RC. However during the AC condition, a sig. in-
crease over time was apparent in the period after the
AC as compared to the RC. Compared to the RC, no
sig. increase over time was revealed for the low fre-
quency component of HRV, even though these levels
were generally sig. higher during most of the amnio-
centesis condition than during the rest condition. Fi-
nally, the ratio between the low frequency and high
frequency components of HRV (LF/HF) which is pro-
posed to reflect the autonomic balance between the
sympathetic and parasympathetic activity, decreased
sig. over time during AC compared to RC. We subse-
quently examined whether the stress response of the
ANS parameters were associated with the E/(E+F) ra-
tio in the amniotic fluid. Indeed, baseline LF/HF val-
ues were negatively correlated with the E/(E+F) ratio
© Copyright 2012, CIC Edizioni Internazionali, Roma
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and positively with F in the amniotic fluid, whereas a
stronger stress response of the LF/HF ratio was posi-
tively related to the E/(E+F) ratio and negatively to F
in the amniotic fluid (11).
Our data provide evidence that healthy pregnant
women show characteristic stress responses during preg-
nancy across different stressor types. Besides the use of
standardized psychosocial stress tests, diagnostic med-
ical procedures such as an AC may also serve as a useful
method to examine the stress response under more real-
life conditions. Our data also emphasize the importance
of measuring the responses of both the HPA axis and
the ANS across different stages of pregnancy. To date
few studies have examined the response of AA and HRV
in response to acute stress during pregnancy and our re-
sults contribute to the literature in this regard.
Furthermore, our findings indicate that allostatic
processes seem to be initiated in the fetal system to
counterbalance the effects of acute stress. The activity
of 11β-HSD2 in response to acute psychological stress
has not previously been investigated in humans. The
association between a higher acute LF/HF stress re-
sponse accompanied by an increased E/(E+F) ratio but
with decreased F levels suggests that 11β-HSD2 activ-
ity was up-regulated in the fetoplacental unit. Even
though we relied on an indirect marker of the enzyme
activity and were restricted to a single measurement of
amniotic fluid levels of F, E, and the E/(E+F) ratio, the
results nevertheless indicate that the maternal and fetal
systems are linked during the experience of acute stress. 
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Introduction
Vaginal atrophy can occur in women of any age, al-
though it is more prevalentduring menopause as a
consequence of the decline in the endogenous estrogen
production that occurs during that stage of woman’s
life. An estimated 10% to 40% of postmenopausal
womenhave symptoms related to vaginal atrophy.
Most common symptoms include vaginal dryness,
vulvovaginal irritation, itching and dyspareunia, all of
them causing discomfort that, if untreated, impacts
significantly on woman’s quality of life. Vaginal mois-
turizers are used on a chronic maintenance basis to re-
place normal vaginal secretions and are useful for vagi-
nal symptomsrelief. Its regular use is recommended as
first line therapy, especially in women wishing to avoid
hormonal therapy or with a contraindication to estro-
gen use. The efficacy and acceptability of a new non-
hormonalvaginal gel was evaluated in postmenopausal
women with vaginal atrophy.
Material and methods
Fifty three postmenopausal women with symptoms of
vaginal atrophy were studied. A new non-hormonal
vaginal gel was used. The bioadhesive molecules in its
composition adhere to the vaginal wall and thus facil-
itate a prolonged moisturizing and lubricating action
of the glycerol present in the formulation. Each pa-
tient received 1g of the gel daily for 3 weeks and then
twice weekly up to 12 weeks. The presence of symp-
toms of vaginal atrophy (vulvovaginal dryness, dys-
pareunia, burning or itching) and its intensity (graded
on a scale from 0 to 3 (0=absence, 1=mild intensity,
2=moderate intensity and 3=severe intensity) was as-
sessed by patients at baseline and after 3 and 12 weeks
of treatment. Improvement of symptoms (defined as
decreasing the grade of intensity of the symptom) was
evaluated after 3 and 12 weeks administration. Addi-
tionally, at the end of the study women were asked to
rate as excellent, good, acceptable, bad or unacceptable
the acceptability of the product regarding aspects such
as easiness of administration, leakage, staining or
cleanliness.
Results
A total of 53 postmenopausal women, with a mean
age of 57.2 years old, were enrolled in the study. Pa-
tient demographics and baseline characteristics are
presented in table 1. At baseline,100% of patients pre-
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TABLE 1 - DEMOGRAPHIC AND BASELINE CHARACTERI-
STICS.
Vaginal moisturizing gel
(n=53)
Age [mean (SD)] (years) 57.2 (6.70)
Race White [n (%)] 53 (100)
Body Mass Index [mean (SD)] (Kg/m2) 26.1 (4.52)
Time since last menstrual period
[mean (SD)] (years) 10.2 (6.68)
Previous hysterectomy [n (%)] 5 (9.4)
Vaginal symptoms: [n (%)]
- Vaginal dryness 53 (100)
- Dyspareunia 48 (90)
- Itching 29 (54.7)
- Burning 18 (34)
sented vaginal dryness, 90.5% dyspareunia, 54.7%
itching and 34% burning. After 12 weeks administra-
tion an improvement of vaginal dryness, dyspareunia,
itching and burningwas observed in 66.7%, 75%,
82% and 71% of women that suffered from those
symptoms at baseline, respectively (Fig. 1). The most
bothersome symptom also improved after 12 weeks in
74.5% of women. The mean magnitude of
changeinthe intensity of the symptoms from baseline
to week 12 (Fig. 2) was 1.2 for vaginal dryness
(p<0.0001); 1.4 for dyspareunia (p<0.0001); 1.2 for
itching (p<0.0001)and 1 for burning (p=0.001). After
3 weeks daily administration an improvement of vagi-
nal dryness, dyspareunia, itching and burning was ob-
served in 70.6%, 68.9%, 64% and 66% of patients
that suffered from those symptoms at baseline, respec-
tively. The mean magnitude of change in the intensity
of the symptoms from baseline to week 3 (Fig. 2) was
1.0 for vaginal dryness (p<0.0001); 1.1 for dyspareu-
nia (p<0.0001); 0.9 for itching (p<0.001) and 0.9 for
burning (p<0.01). Regarding the product acceptabili-
ty, 84% of patients rated the product as excellent or
good in relation to ease of administration and cleaning
the product, leaving no stains or residue after applica-
tion. No patient considered the product as bad or un-
acceptable.
Conclusions
Symptoms resulting from vaginal atrophy are frequent
complaints of postmenopausal women.One of the pri-
mary goals forvaginal atrophy management is the
symptoms relief so that women’s discomfort and qual-
ity of life may be improved. Non-hormonal vaginal
moisturizers are recommended as first-line therapyfor
vaginal atrophy and they can be safely used by women
who do not want to use hormonal options.
This study has demonstrated that a new non hormon-
al vaginal gel with moisturizing and lubricant proper-
ties significantly improves symptoms of vaginal atro-
phy, such as vaginal dryness, dyspareunia, itching and
burning. Importantly, this improvement becomes evi-
dent as early as after 3 weeks of daily administration.
The acceptability of the new formulation is highly fa-
vorable, as up to 85% of women consider the treat-
ment as excellent or good.
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Fig. 1 - Improvement of vaginal symptoms after 3 and 12 weeks treatment:
percentage of improved women (%).
Fig. 2 - Improvement of vaginal symptoms after 3 and 12 weeks treatment:  
change in the intensity of the symptoms (mean±SEM).
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Introduction
Increasing emphaisis on the health of mothers, youth
and birth control as main aim of control programms
caused a range of health and medical activities to be
developed in recent years. Moreover, the term Repro-
ductive Health is used insead of birth control. The im-
portance of Reproductive Health is an individuals ap-
proval as the Reproductive Right, which is part of Hu-
man Rights 1-2 According to the International Con-
ference of Population development, Cairo 1994, the
definition of Reproductive Health is state of complete
physical, mental and social well-being not merly ab-
sence of disease or infirmity. It includes all aspects of
the Reproductive system, process and its function,
thus it means people should be able to make decision
for the time, process, and alternant of of pregnancy by
themselves, consciously and freely. However the sexu-
ality and pregnancy status of youth is one of the best
known aspects of our community, whereas the physi-
cal, mental and social health of communities is threat-
ening by unsafe abortion, AIDS and their mortality.
The most recent surveys show that 60 people are HIV-
infected all around the world and 6 people are getting
afflicted by HIV every minute. Half of the newly an-
nual HIV-infected ones and one third of the people
who take STD (Sexual Transmitted Diseas) are
younger than 25 years old (1-2-3). Although the pub-
lic access (spiecially for the youth) to the adequate in-
formation, facilities and having the consulting services
including Reproductive Health are emphasized; there
are many requirements that have not been met. As the
studies show, major obstacles contain using no contra-
ception equipment for women, inadequate consulta-
tion, lack of facilities and personnel of the Reproduc-
tive Health services (1-4-5). Since accessibility to the
high level of standards and sufficient information
about sexual issues and Reproductive Health is one of
the major parameters of the Reproductive Health
Rights, Ministray of Health and Medical sciences of
Iran insists on Reproductive Health training for all
ages (specially for youth) in order to solve the econom-
ic difficulties and to promote the birth control. Cur-
rently it is the responsibility of health officials and re-
searchers, to recognize issues and to the overall inter-
ventions for preventing the goals of this study is to
evaluate knowladge and attitudes of the female stu-
dents about the Reproductive Health in order to sug-
gest properly, considering the results of this study, to
promote Reproductive Health in these two fields.
Aims
Main goal of the project is determing the knowlege
and attitudes of female high school students about Re-
productive Health in Bandar Abass-Iran 2008. 
Sub-goals
Determing the knowlege of female high school stu-
dents about Reproductive Health in Bandar Abass-
Iran 2008. Determing the knowlege of female high
school students of Bandar Abass about Reproductive
Health depending on marital status. Determing the
knowlege of female high school students of Bandar
Abass about Reproductive Health depending on field
of education. Determing the knowlege of female high
school students about Reproductive Health Depend-
ing on type of school (public or private). Determing
the knowlege of female high school students about Re-
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productive Health depending on age. Determing the
attitudes of female high school students of Bandar
Abass about Reproductive Health. Determing atti-
tudes of female students of Bandar Abases about mar-
ital status. Determing the attitudes of female high
school students of Bandar Abass about Reproductive
Health. Determing the attitudes of female high school
students of Bandar Abass about marital status depend-
ing on field of education Determing the attitudes of
female high school students of Bandar Abass about
marrital status depending on type of school.
Materials and methods
In this analytical descriptive and cross-sectional study,
1200 female high school student of Bandar Abass-Iran,
who were selected by cluster sampling techniques, have
been studied. A well-prepared questionaire was applied
which was extracted from scientific refrences and it has
the scientific approval. The above- mentioned question-
naire contains 8 questions, open questions related to the
demographic information which include: age, course,
type of school and marital status. 8 out of 18 questions,
are about Reproductive Health and 5 view points in op-
position with that. The range of scores based on strong-
ly disagree, slightly disagree, natural, slightly agree and
strongly agree were 1 to 5. After collection the informa-
tion questionnaire, by usig a descriptive statistical test as
well as SPSS softwere version 15, the data analysed and
classified. Results: we have studied 1200 female high
school student in Bandar Abass-Iran among whom 180
(15%) students were bachelors. (50.4%) of them had ac-
quaintance with the term of Reproductive Health and
49.6% of them did not have. 40.8% believed that they
know how to prevent pregnancy at the time of emer-
gency and 42.1% believed they know when Ferrus med-
icines should be used accurately. 510 students thought
that the most common way of HIV transmission in Iran
is the shared syringes and 115 students considered blood
derivatives as most common reason. 42.1% believed that
best method of contraception is to use condom and
38.8% considered TL (tubal ligation) as best method.
81.2% (975) students notified their familiarity to gonor-
rhea, and 50 students to syphilis. 60% believed that be-
ing adhered to ethical principle is the best way to prevent
getting STD and 20.8% considered not to use contam-
inated razors or needles as best way. Only 19.2% said
they know when is the accurate time for BSE (Breast
Self-Examination) and 13.3% believed it is not required
at all. 35% strongly agreed to delayed sexual activity un-
til the time of marriage in order to prevent getting STD
or unwanted pregnancies. 42.1% storongly disagreed
that contraceptive equipment should be accessible for
the youth. 59.6% strongle agreed to get familiar, for the
youth, to contraceptive equipment before the time of
marriage. Most of students agreed to acquaint with re-
productive health and how to prevent STD or unwant-
ed pregnancy. 
Discussion
Results showed that 49.6% were not familiar to term
of Reproductive Health, while others seemed not to
realize different aspects of Reproductive health proper-
ly. This study confirms that students did not realize
the accurate time for BSE, using Ferrous medicines
during pregnancy, and lack of knowledge how to pre-
vent pregnancy at the time of emergency. 
Conclusion
These results complied with the previous studies, adher-
ing to ethical principle, delying sexual activity until mar-
riage time, keeping contraceptive and sexual equipment
out of the youth reach and cultural status of Iran, it was
expectable, as a matter of fact and it was confirmed quite
significantly in the other studies all around the country.
This study and other similar studies showed that vas ma-
jority of individuals accepted that different Reproductive
Health training should be taken necessary for the public
especially for the youth Paying attention to the training
for the various age ranges of all community individuals
seem to be intransitive and necessary, considering the
lack of awareness about the sufficient information re-
garding the term Reproductive Health or subsequent
complication of lacking awareness. Thus, community
health responsibles, as the health providers, by using
broadcasting and health announcements, play a crucial
role to promote Reproductive Health. 
References
1. Simbar M, Ramezani Tehrani F, Hashermi Z. The needs of re-
productive health of university students. The Journal of Qazvin
univ. of med. sci. No 28, autumn Supplement 2003:5-12. 
2. Mazloomi Mahmoud Abad, Saeed. Shahidi, F. Abbasi, M.
SHahrizadh, Fatima. Of knowledge, attitudes and practices re-
garding reproductive health of women in seven cities in central
Iran, 1384. Journal of Reproduction and Fertility unknown,
Winter 85. Pp. 400-391. 
3. Zanjani Habibullah, full Shadpvr, Mohammad Mirzaei. Pop-
ulation, Development and Reproductive Health. Sixth edi-
tion, published by Human (1382), pp. 117-116. 
4. Roudi-fahimi. reproductive Health in the middle East and
North Africa, Mena Policy Brief, population reference bureau.
pp. 1-8. 
5. Jaffer YA, Afifi M, Ajimi F, Alouhaishi K. Knowledge, attitudes
and practices of secondary-school pupils in Oman: Reproduc-
tive Health. East Mediter Health J 2006;12(1-2):50-60.
174
© Copyright 2012, CIC Edizioni Internazionali, Roma
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
175
Introduction
A receptive endometrium is of crucial importance for
successful embryo implantation. The human en-
dometrium, which is unique among adult tissues, un-
dergoes complex dynamic changes during each men-
strual cycle, hosts the embryo implantation process
and has been recognized as important fertility-deter-
mining factor (1). The endometrial progesterone re-
ceptor (PR) plays a crucial role in these processes and
is an important target for endogenous hormones and
drugs. PR antagonists and selective progesterone re-
ceptor modulators (SPRM) exert specific receptor-me-
diated effects on the human endometrium, and two of
them (mifepristone, RU486; ulipristal acetate) are ap-
proved for emergency contraception and abort induc-
tion (2-4). Remarkably, also environmental chemicals
(e.g. DDT, 4-nonylphenol, bisphenol A) and natural
compounds (e.g. apigenin) can interact with the PR
(5-6) as demonstrated in yeast transactivation assays.
Further, numerous traditional plant preparations have
an anti-implantation activity with unknown mode of
action (e.g. 7). Based on these findings and in view of
the rapidly growing world production of chemicals (8)
the human endometrium has to be addressed as rele-
vant target tissue for endocrine disrupting chemicals
(EDC) (9). Since embryo implantation in humans is
different to animals this chemical risk can only insuf-
ficiently be addressed by animal tests. New human in
vitro models are needed to assess endometrial effects
for chemical-safety testing and drug development. To
our knowledge, there is currently no routine in vitro
test available for endometrium-specific effects of
antigestagenic compounds in humans. We developed a
tissue-specific in vitro assay based on the human en-
dometrial epithelial Ishikawa cell line to analyze the ef-
fects of antiprogestin compounds on pre-selected gene
expression biomarkers.
Methods
Our recently developed in vitro Ishikawa model for es-
trogenic compounds (10) was modified for the detec-
tion of antiprogestin effects. Cells were grown for 3
days to subconfluency and primed with 17β-estradiol
to up-regulate the progesterone receptor. In the test
phase cells were incubated with combinations of prog-
esterone (10-7 M) and variable concentrations of test
compounds for 48 hrs. Reverse transcription quantita-
tive real-time PCR (RT-qPCR) with assays from the
Universal Probe Library (UPL, Roche) was applied to
characterize antiprogestin effects on pre-selected gene
expression biomarkers, which were identified by mi-
croarray analysis (Human Gene Arrays 1.0,
Affymetrix), by sigmoidal dose-response curves.
Western blotting was performed with a monoclonal
mouse anti-human PR antibody (M3569; Dako,
Hamburg, Germany) and with a polyclonal mouse
estrogen sulfotransferase (SULT1E1) antibody (Sig-
ma, Taufkirchen, Germany). 
Results
In experiments with mifepristone the SULT1E1 and
the PR were identified by microarray analysis as ap-
propriate gene expression biomarkers for antiprogestin
compounds. The effects on SULT1E1 mRNA were
stronger than on PR mRNA. In these experiments
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cells were treated with progesterone alone (10-8 M)
and progesterone/mifepristone (10-8 M, each). 
In our Ishikawa model for antiprogestins we observed
in the initial priming phase an up-regulation of the PR
by 17β-estradiol, but no effect on SULT1E1. After in-
cubation with progesterone alone in the subsequent
test phase we found a dose-dependent up-regulation of
SULT1E1 mRNA and a down-regulation of PR mR-
NA. In combinations of progesterone (10-7 M) and
SPRMs these progesterone effects were dose-depend-
ently antagonized by mifepristone and ZK137316
(EC50 approx. 10
-9 M, respectively). In the presence of
increasing concentrations of SPRMs SULT1E1 was
down-regulated and PR mRNA up-regulated. For the
chemicals 4-nonylphenol and bisphenol A as well as
the plant compound apigenin similar effects were ob-
served at higher EC50-values (EC50 > 10
-6 M). Methyl
acetoacetate was used as negative control and dis-
played no effects. The effects of mifepristone on PR
and SULT1E1 were confirmed on the protein level by
Western Blotting. 
Discussion
In this study we present a human endometrium-spe-
cific in vitro model for detection of anti-progestin ef-
fects. Compared to environmental estrogens, chemi-
cals acting as progesterone receptor ligands have re-
ceived little attention. The risk that environmental
chemicals act as PR antagonists and disturb embryo
implantation was hitherto not sufficiently addressed.
For our study, we selected the human endometrial
Ishikawa cell line. It is one of the best-characterized
human endometrial cell lines currently available and
expresses both functional estrogen and progesterone
receptors. These properties make Ishikawa cells an ide-
al model to study the responses of the human endome-
trial epithelium to hormones and endocrine disrupters
(11-12). In this study we demonstrated that our
Ishikawa model is appropriate to identify antiprog-
estin compounds and to characterize them by sig-
moidal dose-response curves. It can differentiate be-
tween strong and weak PR antagonistic effects and
correctly recognize negative substances. Down-regula-
tion of SULT1E1 and up-regulation of PR by PR an-
tagonists in Ishikawa cells were also described by oth-
ers (13-14). In summary, our Ishikawa in vitro model
is suitable to study quantitatively effects of SPRM-like
chemicals on endometrial target genes. It may be inte-
grated into new in vitro test batteries developed for re-
productive toxicity testing (15). Our findings demon-
strate that wide-spread environmental chemicals exert
weak PR antagonistic effects on the human en-
dometrium. There is a need to screen more chemicals
for antigestagenic effects (16), and for the respective
risk assessment the expertise of gynaecological en-
docrinologists is demanded.
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Introduction 
Androgens are the most abundant sex steroids in men
as well as in women after menopause and are also used
pharmacologically. A growing body of evidence sug-
gests that androgens affect the behavior of endothelial
cells, modulating proliferation, migration and angio-
genesis. The results of different studies remain contra-
dictory with regard to the involvement of Androgen
Receptor (AR) in Testosterone (T) mediated signaling.
In a male human umbilical cell line EA.hy926, Ling et
al (1) showed that T at concentrations from 1-100
nM, enhances apoptosis related damage under serum
deprivation for 48hrs and this was abolished by the
AR antagonist flutamide 0,1 µM. DHEA, an andro-
gen which does not bind AR, has also been shown to
inhibit proliferation (Mohan PF 1997, Zapata E
2005) by enhancing the expression of p53 and p21 in
an AR independent manner (2). Other groups have
shown that androgen stimulates proliferation of en-
dothelial cells such as primary human aortic endothe-
lial cells (3) and endothelial cells from human my-
ometrium, HMMEC (4). The mechanisms implicated
in the regulation of endothelial cell behavior are far
from being thoroughly understood. 
Hypothesis
Androgens can modulate the proliferation, migration
and angiogenesis in HUVEC by an AR mediated
mechanism. Raf-1 is an important effector of andro-
gen mediated effects on HUVEC.
Materials and methods 
The experiments were performed in primary human
umbilical vein endothelial cells (HUVEC). The prolif-
eration rate under increasing doses of testosterone (T)
from 10-12 M to 10-6M was studied by colorimetric Br-
DU ELISA. In addition we did RT-PCR, Western
Blot, Boyden Chamber migration assay, hang-drop
spheroid sprouting assay and ELISA for VEGFA and
VEGFR2. To examine whether the changes in cell be-
havior were due to apoptosis, we performed an apop-
tosis array.
Results 
Our data show that under T (10-6M) the number of
cells proliferating as assessed by BrDU ELISA as well
as the total number of cells after 24 hours treatment, is
diminished in comparison to control. Treatment with
T at lower concentrations, from 10-7M until 10-12M
did not influence the proliferation rate.
The migration rate was also lower under T treatment
in comparison to 0,1% ethanol treated cells, not only
at pharmacological but also at physiological levels. 
We made spheroid hang-drop sprouting assay to find
out whether testosterone treatment at 10-6 and 10-8M
concentrations affects sprouting as measured by total
sprout length but we could not find any difference in
comparison to control.
Treatment with AR antagonist flutamide (1µM) in
combination with T, abolished the T-induced effects
on HUVEC proliferation. T administration was asso-
ciated with an increase of AR protein expression. As
androgens are shown to induce the expression of
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VEGF in endothelial cells (3), we performed ELISA to
detect VEGFA levels. The stimulated cells do not se-
crete VEGFA and the total level of VEGFR2 does not
change when treated with testosterone. To get insight
into the mechanism by which T-treatment modifies
proliferation, we performed an apoptosis array. We ob-
served that in comparison to control, that FAS and
HSP60 expression was upregulated under treatment
with T 10-6M. Another target that was downregulated
under T 10-6M treatment as assessed by apoptosis ar-
ray, is XIAP which has a role in inhibiting apoptosis.
On the other side, the upregulation of p21, points at
cell cycle arrest.
Therefore we speculate that the upregulation of FAS
leads to an increased susceptibility to apoptosis and
the downregulation of proliferation is due to an arrest
of the cell cycle. 
In conclusion, our preliminary data confirms that the
regulation of HUVEC proliferation is AR dependent.
Furthermore we plan to elucidate the mechanism of T-
mediated modification of endothelial cell behaviour. 
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Infertility affects about 15-20% of couples world-
wide. The most common causes of infertility are:
male factor such as sperm abnormalities, female fac-
tor such as ovulation dysfunction and tubal patholo-
gy, combined male and female factors and unex-
plained infertility (1). Best possible assessment of the
ovarian reserve (OR) represents a core issue in mod-
ern infertility care in terms of prediction of ART out-
come. Determination of the OR includes traditional
markers such as age, FSH, estradiol (E2) and antral
follicles count (AFC). Recently, AMH has been pro-
posed as a new marker. AMH is a dimeric glycopro-
tein, member of the transforming growth factor-beta
superfamily. Its most clearly defined role is in male
sex differentiation. AMH is produced by fetal Sertoli
cells at the time of testicular differentiation, and in-
duces regression of the Mullerian ducts. In the ab-
sence of AMH, the Mullerian ducts develop into the
uterus, fallopian tubes and the upper part of the vagi-
na. In the ovaries of female fetuses, AMH expression
has been observed as early as 32 weeks gestation in
humans (2). 
AMH is expressed by granulosa cells of early develop-
ing follicles (primary, pre-antral and small antral folli-
cles), ending when they reach a diameter of 2-6 mm.
Small antral follicles are likely the primary source be-
cause they contain larger numbers of granulosa cells.
AMH has paracrine/autocrine action in follicle devel-
opment but it is also measurable in the serum. The
number of small antral follicles correlates with the size
of the residual follicular pool. AMH levels are almost
undetectable at birth, but levels increase, peaking dur-
ing late puberty and then show a progressive decline
throughout reproductive life, due to the depletion of
the follicular reserve. In the end AMH becomes unde-
tectable after menopause. Thus it could represent a
valid estimator of OR. Because AMH derives from
preantral and small antral follicles, levels are go-
nadotropin-independent and exhibit no variation
within and between cycles. The transition from pri-
mordial into growing follicles becomes enhanced in
the absence of AMH. Thus AMH levels reflect the
continuous FSH-independent non-cyclic growth of
small follicles in the ovary and inhibit the exhaustion
of the primordial follicle pool (2,3). 
The aim of this study was to confirm the role of AMH
as a marker for OR and as prognostic factor of ART
outcome in infertile women in terms of mature folli-
cles, retrieved oocytes, embryo number, pregnancy
rate, compared to other traditional methods. Further-
more, it was studied the correlation between AMH
and total doses of exogenous gonadotropin (EG) need-
ed to induce ovulation, and the usefulness of AMH
levels in predicting poor response to ovarian stimula-
tion.
Materials and methods
Among patients admitted to Department of ART of
Spedali Civili of Brescia (Montichiari), 46 infertile
couples underwent endocrine and echographic evalua-
tion (AFC) in early follicular phase of the cycle: FSH,
E2 (ARCHITECT Analyzer, Abbott Diagnostics Di-
vision), AMH (EIA Immunotech-Beckman Coulter
Company, Marseille). Women were classified in nor-
mal or poor responders on the base of traditional
methods: women with AFC <8 and FSH levels be-
tween 11 and 15 m UI/ml were classified as “poor re-
sponders”. “High responders” women were excluded. 
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Data were expressed as mean value and standard devi-
ation. The correlation analysis has been performed
with RHO-Spearman Test among endocrine, echo-
graphic and clinical parameters.
Results
The causes of infertility were: ovulation dysfunction
11 (24%), organic gynecologic pathologies (such as
tubal, uterine pathology, endometriosis) 9 (19%),
male factor 34 (74%), combined male and female fac-
tors 11 (24%) e idiopathic 1 (2%).
The traditional OR evaluation showed a mean FSH of
6.2±2.6 mIU/ml, E2 of 46.3±29.5 pg/ml, AFC of
5.1±3.2. Whereas AMH was 1.7±1.3 ng/ml. In partic-
ular, AMH changed between 0.4 and 3 ng/ml. 
The mean women age was 35.8±4.2 years and it was
between 32 and 38 years and the mean BMI was
22.4±4.2 kg/m2.
Fifty-nine percent of women underwent FIVET and
41% ICSI. Treatment was cancelled in 8 participants
(17%) for different causes such as hyper-response
(4%), no response (4%), drugs allergy (2%) luteal
cysts (4%). Twelve (26%) single pregnancies were ob-
tained but 2 of them (4%) miscarried. The mean
number of obtained mature follicles after ovarian stim-
ulation and the mean number of retrieved oocytes
were 3. The mean number of obtained and transferred
into the uterus embryos was 2.
Correlations between AMH and endocrine, echo-
graphic and clinical parameters were investigated. No
significant correlation was found between age and
AMH, E2, FSH, antral follicle number, mature folli-
cle number, mature oocytes number, embryo number.
This can be explained by the narrow age range. FSH
showed a negative correlation with AFC (r = –0.35,
p<0.02), thus the highest FSH level was associated
with the lowest AFC. There was no correlation among
FSH and mature follicles or retrieved oocytes. 
AMH showed a significant positive association with
AFC (r = +0.59, p<0.001), mature follicles at ultra-
sound (r = +0.44, p<0.002), retrieved mature oocytes
(r = +0.39, p<0.02) and negative with FSH (r = – 0.43,
p<0.003) and E2 (r = –0.31, p<0.05). Thus AMH is a
marker of OR and predictor of response to ovarian
stimulation. Pregnancy rate had a significant positive
association only with mature follicles after treatment
(r = +0.47, p<0.005), and so indirectly with AMH,
and with developed embryos (r = +0.36, p<0.04)
(Table 1). 
The mean age and FSH of “poor responders” were
higher than mean value of “normal responders”, on
the contrary AFC and AMH. There was a negative as-
sociation between AMH and exogenous go-
nadotropin (EG) administered to obtain ovarian
stimulation. The lowest AMH levels needed the high-
est doses of EG (r = -0.54, p< 0.001 for exogenous
FSH and r = -0.49, p < 0.01 for exogenous LH). There
was no significant correlation between EG used and
the other markers (FSH, E2 and age). This result indi-
cates that AMH may be a superior marker for predict-
ing ovarian response and total doses of EG (Fig. 1).
Discussion
In conclusion, AMH is a valid marker of OR even in
the infertile woman, and it has the same level of accu-
racy as traditional methods. The advantage of AMH is
its role as a cycle-independent test, thus it is not neces-
sary the measurement in early follicular phase. It is not
influenced by administered drugs and central anovula-
tory dysfunctions. Assessment of the OR is relevant in
ART clinic, where moreover AMH may be useful as
predictor of the extremes of ovarian response to EG. 
The predictive value of AMH for ovarian response
concerns mature follicles and retrieved oocytes. An in-
teresting field of application is the classification of
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Parameters R P
AGE – – n.s.
FSH Antral foll. num. -0.35 0.02
AMH FSH -0.43 0.003
E2 -0.31 0.05
Antral foll. num. +0.59 0.001
Mature foll. num. +0.44 0.002
Mature oocyt. num. +0.39 0.02
PREGNANCY Mature foll. num. +0.47 0.005
Embryo num. +0.36 0.04
TABLE 1.
Fig. 1
women in “poor” or “normal responders” and the in-
dividualization of treatment strategy on the basis of
AMH, in order to reduce the incidence of cycle can-
cellation and hyper-response (4).
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Introduction
Polycystic ovary syndrome (PCOS) is a common en-
docrinopathy, that affects 6-10% of women of repro-
ductive age. It is characterized by chronic oligoanovu-
lation, hyperandrogenism and polycystic ovaries.
Insulin resistance and hyperinsulinemia affect 50-70%
of PCOS and they have a key role in the pathogenesis
of the syndrome. Insulin resistance worsens clinical
features of PCOS and causes metabolic morbidities
(1). Insulin-sensitizers (ISs) represent a safe and effec-
tive long-term treatment in PCOS women, exerting
both metabolic and endocrine beneficial effects.
ISs are involved, at different levels, in insulin’s post-re-
ceptor signal transduction. Both α-lipoic acid and in-
ositol have as a final effect an improvement in the
translocation of GLUT4 on cell membrane and they
ameliorate glucose utilization. Alpha-lipoic acid is a
potent antioxidant and regulator of the intracellular
redox status. It is able to improve insulin receptor ac-
tivity and influence its pathways (1). Only one study
evaluates α-lipoic acid administration in PCOS and it
suggests that this drug is effective in ameliorating in-
sulin sensitivity and lipid pattern, but no hormonal
parameter was considered (2). Inositol is involved in
the phosphatidylinositide pathway and it seems to be
lower in women with PCOS (3). Some studies suggest
that inositol administration is effective in ameliorating
PCOS dysmetabolic features (insulin resistance, dys-
lipidemia, hypertension, weight) and endocrine pro-
file, leading to menstrual pattern regularization and
restoring fertility (3). 
The aim of this study was to assess ISs’ efficacy and
safety in PCOS treatment, and to evaluate the effect
on clinical, hormonal and metabolic parameters.
Patients and methods
Among patients admitted to the Department of Gy-
naecological Endocrinology of the University of Bres-
cia/Spedali Civili, we selected 19 overweight PCOS
(BMI 25-29 kg/m2), not previously treated with OC,
antiandrogens or metformin. Before treatment, they
underwent clinical, endocrine-metabolic and echo-
graphic evaluation. 
The patients underwent the evaluation of Body Mass
Index (BMI), menstrual pattern, Ferriman-Gallwey
and Rosenfield scores, serum LH, FSH, 17-β estradi-
ol (E), androstenedione (A), total and free testosterone
(T, fT), Sex Hormone Binding Protein (SHBG), dei-
droepiandrosterone (DHEAS), total cholesterol, HDL
cholesterol (HDLc), LDL cholesterol (LDLc), triglyc-
erides, glycemia, insulinemia, HOMA index and ovar-
ian volume. 
Patients were randomly treated for 6 months with
α-lipoic acid (9 patients with 600 mg fast-slow, twice
daily, Tiobec®, Laborest – Milano) and inositol plus
antioxidants (10 patients, with 1500 mg once daily,
Redestop®, Progine – Firenze). Clinical changes were
evaluated after 3 months of therapy and endocrine-
metabolic and echographic modifications after 6
months of therapy.
Results
After 6 months of therapy, α-lipoic acid reduced A
(-20%), fT (-45%) and increased E (+17%) and
SHBG (+30%). Furthermore, it reduced ovarian vol-
ume by 33%. Inositol determined a reduction in LH
(-35%), A (-19%), total testosterone (-25%), fT
Alternative insulin-sensitizers (Lipoic acid and Inositol)
in polycystic ovary syndrome (PCOS)
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(-56%), and increased SHBG (+15%). It also reduced
ovarian volume by 10% (Table 1).
Alpha-lipoic acid and inositol determined mild
changes in metabolic parameters, anyway it should be
noted that patients did not have altered mean insulin-
sensitivity or lipid values in basal conditions. After 6
months of therapy α-lipoic acid decreased glycaemia
(-8%) and HOMA index (-15%). Inositol reduced
glycaemia (-4%), insulinemia (-14%) and HOMA In-
dex (-19%). Only two patients (one from the α-lipoic
acid group and the other one from the inositol group)
had pathologic values of HOMA Index before treat-
ment and they both had a regularization after six
months of therapy. Furthermore, three patients were
dyslipidemic in basal conditions and two of them,
treated with inositol, ameliorated their lipid pattern
after 6 months of therapy.
Clinical results show that ISs are effective in allow
weight loss after a 3 month treatment. In particular,
67% of patients treated with α-lipoic acid and 50% of
those treated with inositol lost weight. The mean
weight loss was -3.3 kg (range from -1 to -7 kg) for the
first group and -2.0 kg (range from -1 to -4 kg) for the
second.
ISs determined regularization of menstrual pattern af-
ter 3 months of therapy: 56% of patients treated with
α-lipoic acid and 40% of those treated with inositol
showed regular ovulatory menstrual cycles. Short-term
therapy with ISs showed to be able to treat mild hyper-
androgenism clinical features such as acne.
Side effects affected one patient treated with α-lipoic
acid and one treated with inositol. In both cases, pa-
tients complained about mild nausea and diarrhea.
Discussion
In this study alternative ISs demonstrated to be effec-
tive in modifying endocrine-metabolic profile of over-
weight women affected by PCOS, determining men-
strual pattern regularization and weight loss. Further-
more, α-lipoic acid and inositol were safe and did not
show severe side effect, thus they are easily manageable
and effective therapy for PCOS.
Alternative ISs (α-lipoic acid and inositol) might be
considered as the first-choice long-term therapy for
mild to moderate PCOS. In particular, they should be
used in non-obese patients, without severe clinical
signs of hyperandrogenism or insulin-resistance and
no need of contraception. They are safe and effective
both on endocrine and metabolic alterations of
PCOS, and could prevent long-term morbidity linked
to the syndrome.
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TABLE 1 - MODIFICATION OF ENDOCRINE PROFILE AND
ECHOGRAPHY AFTER 6 MONTHS OF TREATMENT.
α-lipoic acid Inositol
LH = -19%
FSH = =
E +17% =
A -20% -19%
T = -25%
fT -45%* -56%*
SHBG +30% +15%
Ovarian volume -33%* -10%
Student t-test *P<0.05 after vs before treatment.
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Introduction
The female genital tract is particularly exposed to many
possible types of attack due to the close contact with the
external environment. In order to combat the prolifera-
tion of pathogens and micro-organisms and in general
to activate defences, there is a natural “barrier” compris-
ing the external surfaces (vaginal epithelium and mu-
cus) and the vaginal ecosystem, which maintains an acid
milieu. Changes in this system may be due to physio-
logical, behavioural or environmental causes. 
Whenever induced stresses exceed the natural defence
capabilities of the female genital tract, infections and
inflammation may develop.
Good feminine hygiene is essential to prevent irrita-
tion of the vulva and vagina.
Therefore, identifying and validating substances able
to prevent or repair damage to the vaginal epithelium
is of clinical and scientific interest.
The objective of this study is to establish an in vitro
method for efficient, straight-forward and rapid evalu-
ation of substances and systems potentially able to
protect the vaginal epithelium from damage due to ex-
ternal agents and/or to repair such damage.
In order to do this, an organotypic culture of vaginal
epithelium was used to monitor changes in some bio-
markers associated with damage caused by external
stimuli (surfactants) such as the change in cell vitality
and evaluation of the release of pro-inflammatory cy-
tokines in the culture medium (IL-1 alpha). 
Analysis of the experimental data showed that this
model is able to evaluate and differentiate substances
both in terms of their reparative potency in the case of
studies on products to be applied following damage
and the protective effect in the case of products ap-
plied preventively and, lastly, the effect of repeated ap-
plication of these products.
Materials and methods
Organotypic cultures of vaginal epithelium (Vec-100
EpiVaginalTM MatTek) were stimulated using a non-
inonic surfactant (1% Triton x100 MatTek) to simu-
late damage caused by external agents and treated (pre-
ventively, post-injury and on a repeated basis) with
two substances. The tests used are the MTT test from
Sigma-Aldrich (Gerlier & Thomasset, 1986) to moni-
tor cell viability and an ELISA test (Bender Med Sys-
tems®) to assay IL-1 alpha.
In order to evaluate the sensitivity of the method, two
natural polysaccharide substances were used which, for
simplicity’s sake, we will call substance A and sub-
stance B. 
All experiments were repeated at least 3 times, with
representative results shown. Data are expressed as
mean ± standard deviation (SD). Statistical analysis
was performed using InStat software version 3.0a
(GraphPad Software, La Jolla, CA, USA). Statistical
differences were determined using ANOVA followed
by a multiple comparison test. Effects were designated
significant if p<0.05.
Results 
Tissue compatibility (Fig. 1)
This first analysis was undertaken to verify that the
In vitro evaluation of the protective and reparative effect in relation
to damage caused by external agents on the vaginal epithelium
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two substances (A and B) have no intrinsic toxic effect
and to check whether the dose of Triton X100 (1%) is
sufficient to reveal damage. The two substances select-
ed were applied on EpiVaginal for 18 hours, and a 12-
minute insult with Triton X100 was used as a positive
control while the untreated tissue was used as a nega-
tive control. The results reveal the toxic effect of Triton
X100 and the absolute compatibility of the substances
with EpiVaginal.
Treatments: preventive (Fig. 2), reparative (Fig. 3)
and repeated (Fig. 4)
The treatments were:
– preventive treatment (Fig. 2) involving 1 hour of
pre-treatment followed by insult with Triton X100
for 12 minutes, rinsing, and 18 hours’ incubation
– reparative treatment (Fig. 3) involving a 12-minute
insult with Triton X100, rinsing, treatment with the
substances for 18 hours 
– repeated treatment (Fig. 4) involving 1 hour of pre-
treatment followed by a 12-minute insult with Tri-
ton X100, rinsing, further treatment with the sub-
stance for 18 hours. 
As can be seen in Figure 2, the two substances show
excellent protective potency, while in terms of repara-
tive properties substance A has greater potency (Fig.
3). On repeated treatment, substance A allows optimal
protection almost at untreated levels while substance B
has a slight negative effect on the viability and release
of IL-1α (Fig. 4).
Conclusions
Analysis of the experimental data showed that this
model is able to evaluate and differentiate substances
both in terms of their reparative potency in the case of
studies on products to be applied following damage
and the protective effect in the case of products ap-
plied preventively and, lastly, the effect of repeated ap-
plication of these products.
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Introduction
Human seminal plasma contains many proteins that
are important in the capacitation of the spermatozoa,
in the modulation of the immune responses in the
uterus, in the formation of the tubal sperm reservoir
and finally in both the sperm-zona pellucida interac-
tion and in the sperm and egg fusion. The complex
content of seminal plasma allows the successful fertil-
ization of the oocyte by the spermatozoa. Some of the
seminal proteins are secreted by the testis, epididymis,
and male accessory glands such as seminal vescicle,
prostatic ampulla, and bulbourethral glands. Apart
from these organ-specific proteins, human seminal
plasma is rich in other proteins, whose origin and
function are not completely clear.
The aim of the present study is to analyze human sem-
inal plasma proteome of fertile men, by LTQ-Orbitrap
mass spectrometer, in order to identify a panel of com-
mon seminal proteins in fertile men.
Materials and methods
Five fertile men, whose partners were pregnant when
the study was started, participated in this study. In all
patients, a standard semen analysis was performed ac-
cording to WHO classification.
Liquified semen samples were then centrifuged at
9,200x g for 20 minutes to obtain the seminal plas-
ma. An aliquot of each seminal sample was subjected
to in solution digestion protocol. The samples ob-
tained from the digestion procedure were resuspend-
ed in aqueous trifluoroacetic acid and analyzed with
an Ultimate 3000 Nano/Micro-HPLC apparatus
equipped with an FLM-3000-Flow manager module,
coupled with an LTQ-Orbitrap XL hybrid mass spec-
trometer.
Tandem mass spectra were analyzed by the Thermo
Proteome Discoverer 1.2 software, using SEQUEST
as a search engine against uniprot-taxonomy-
9606_human database. Protein informations were
then analyzed using the software tool for researching
annotations of proteins (STRAP), to annotate each
protein according to the gene ontology (GO) system
(1). When an individual protein was assigned to more
than one GO annotation, all of the annotations were
counted nonexclusively.
Results
All subjects had hormonal values within the normal
range. Semen parameters showed normospermic con-
dition of all subjects.
Protein identification criteria resulted in the identifi-
cation of 919 to 1,487 unique proteins per individual
subject sample and 83 proteins were present in all
samples.
The largest proportion of GO annotations for molec-
ular function were binding proteins, which occurred
in 54 proteins (58%). Twenty proteins were annotated
as involved in catalytic activity, 10 in structural mole-
cule activity, and 1 was involved in enzyme regulation.
Other activities were reported for eight proteins.
Analysis of GO cellular distribution annotations is re-
ported in Figure 1. Biological process analysis of the
proteic pattern is reported in Figure 2.
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Discussion
The importance of knowing the composition of semi-
nal plasma is essential in understanding the physiolo-
gy of reproduction. We identified 83 common pro-
teins in seminal plasma in a group of fertile subjects.
This is the first identification of the common pattern
of seminal proteins in male fertility, using high-resolu-
tion MS. We identified up to 1,487 unique proteins
per single sample, showing a greater sensitivity of the
procedure.
In our study, semenogelin (Sg) I and Sg II are ex-
pressed in all samples. This was predictable as Sg is the
main protein of human semen coagulum and plays an
important physiological role in the suppression of
sperm motility at ejaculation.
Within the group of common proteins we reported
the olfactory receptor (OR) 5R1. The G-protein-cou-
pled ORs make up a large multigene family, whose ec-
topic expression has been related to testis and germ
cells, where several dozen human and mouse ORs
were shown to be transcribed (2). The ORs appear to
be expressed in late spermatids and on the tail mid-
piece of mature spermatozoa, implying that testicular
ORs are involved in either sperm maturation, migra-
tion, or fertilization (3). These results therefore led to
the hypothesis that at least some ORs are involved in
mammalian sperm chemotaxis. Proteomic platform
may give new insight in understanding the expression
and role of ORs in germ cells and seminal plasma.
With regard to the proteins identified in all patients,
we identified some proteins involved in fertility and
reproduction such as lactoferrin, human cationic an-
timicrobial protein (hCAP18), and spindlin 1.
Lactoferrin has antibacterial, antioxidative, and an im-
mune-modulating role in seminal plasma. It is also in-
volved in maintaining normal sperm structure and
motility and modulating the composition and quality
of the semen during sperm maturation and migration
through the male genital tract (4). 
The hCAP18 has a key role in the innate immunity of
the male reproductive system. It was present in the ep-
ithelium of human epydidimis, in the seminal plasma
at high concentrations, and in association with sper-
matozoa. It is not unlikely that the spermatozoa trans-
port hCAP18 with them on their way to the ovum and
that the hCAP18 provides protection against microor-
ganisms during fertilization. 
Spindlin 1 protein is involved in spermatogenesis in
the first wave of spermatocyte meiosis. Spindlin 1 was
also localized at the tail of mouse sperm and could be
essential for normal sperm motility (5).
Considering the molecular function annotation of
the proteins, the most abundant group include pro-
teins involved in protein binding. However, it may
represent an auxiliary role to the main one of that
protein, which is closely linked to enzymatic or trans-
port activity. Catalytic activity was in fact annotated
in 22% of proteins and 1% of proteins is classified as
their regulators, implying that 23% of the seminal
fertile proteomic pattern is involved in enzymatic ac-
tivity. 
Membrane proteins are present with a frequency of 27
annotated proteins. It may depend on whether some
of these proteins are bound to the sperm surface dur-
ing ejaculation, thus forming protein-coated layers (6).
This is confirmed by the number of membrane pro-
teins that are annotated both as membrane proteins
and as extracellular or surface proteins.
The largest group of proteins is composed of 40 pro-
teins involved in cellular processes, followed by 31
proteins involved in regulation, depending by the
presence of both enzymes involved in the regulation,
processing, or degradation of seminal fluid proteins
and coagulation of semen such as in the basic cellular
processes.
Finally we offered a proteomic approach to identi-
fy a proteic panel for male fertility by using the
LTQ-Orbitrap mass analyzer.
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Fig. 2 - GO annotations for biological process.Fig. 1 - Go annotations for cellular distribution.
References
1. Bhatia VN, Perlman DH, Costello CE, McComb ME. Soft-
ware tool for researching annotations of proteins: open-source
protein annotation software with data visualization. Anal
Chem 2009;81:9819-23.
2. Parmentier M, Libert F, Schurmans S, Schiffmann S, Lefort A,
Eggerickx D, et al. Expression of members of the putative ol-
factory receptor gene family in mammalian germ cells. Nature
1992;355:453-5.
3. Walensky LD, Roskams AJ, Lefkowitz RJ, Snyder SH, Ron-
nett GV. Odorant receptors and desensitization proteins colo-
calize in mammalian sperm. Mol Med 1995;1:130-41.
4. Buckett WM, Luckas MJ, Gazvani MR, Aird IA, Lewis-Jones
DI. Seminal plasma lactoferrin concentrations in normal and
abnormal semen samples. J Androl 1997;18:302-4.
5. Zhang KM, Wang YF, Huo R, Bi Y, Lin M, Sha JH, et al.
Characterization of Spindlin1 isoform2 in mouse testis. Asian
J Androl 2008;10:741-8.
6. Varilova T, Semenkova H, Horak P, Madera M, Pacakova V,
Ticha M, et al. Affinity liquid chromatography and capillary
electrophoresis of seminal plasma proteins. J Sep Sci
2006;29:1110-5.
188
© Copyright 2012, CIC Edizioni Internazionali, Roma
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
189
Introduction
Sonography at day three of the menstrual cycle is
mandatory during infertility work-up. This ultrasound
must include the examination of the uterus and ad-
nexa in order to identify infertility factors that might
modify either the treatement or the prognosis of the
patient. It also allows planning of treatment options
through the evaluation of the ovarian reserve by
counting the total number of antral follicles (1). The
standard technique use 2D ultrasound for evaluation
of the uterus, fallopian tubes and ovaries. Although its
clinical importance is well defined, 2D has several lim-
itations, which can be surpassed by 3D ultrasound.
We want with our study to evaluate in which measure
3D ultrasound, when added to standard 2D ultra-
sound, could improve the diagnostic. 
Materials and methods
In our study we examine 44 patients with primary or
secondary infertility. This study was approved by the
local ethics committee and written informed consent
was obtained from all participants We examined this
group of patients using both 2D and 3D ultrasound in
day 2, 3 or 4 of the menstrual cycle with a Voluson E8
machine, 3 D endovaginal. We scanned the uterus and
the both adnexa and we recorded the anomalies of the
uterus for each particular case (detected by 2D or 3D
ultraosund, or both), of the ovaries or fallopian tubes.
We measured the total number of antral follicles, first
by 2D and than automated by 3D ultrasound using
sonoAVC software. For the 2D assessment of the
antral follicles we used the standard technique wich
quantifies the size of a follicle by the mean diameter
from two linear measurements of the follicle (6). In or-
der to examine the coronal plane of the uterus with
3D ultrasound we used the “Z” technique developed
by Abuhamaz (2). 
Results
We have examined 44 patients with primary infertili-
ty - 29 cases (65.9%) and secondary infertility - 15
cases (34.1%). Regarding uterine pathology, we had
four cases with uterine myoma, one case with endome-
trial polyp, 3 cases with adenomyosis and one case
with an arcuate uterus (Table 1).
All of these 9 cases, except one were diagnosed first by
2D ultrasound and the diagnosed was then confirmed
by 3D ultrasound. In a single case with a uterine mal-
formation the diagnosed was missed by 2D ultrasound
and it was established after obtaining the coronal plane
of the uterus (Table 2).
2D vs. 3D ultrasound assessment for infertility evaluation
on the 3rd day of the cycle
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TABLE 1 - UTERINE PATHOLOGY DETECTED WITH 2D
AND 3D ULTRASOUND.
Uterine pathology Nr. of cases %
No endometrial or myometrial 35 79.54
abnormalities 
Myoma 4 9,00
Endometrial polyp 1 2.20
Adenomyosis 3 6.80
Arcuate uterus 1 2.20
In all cases with myoma the diagnosis was made with
2D but adding coronal plane gave more information
regarding the exact topography of the tumor. In one
case the myoma was intracavitary and although this as-
pect was suggested by 2D, the 3D was more useful in
confirming this aspect. The exact position of a my-
oma, the impact on the ostium tubae and on the uter-
ine cavity may be difficult to assess by conventional ul-
trasound. Adenomyosis is a disease that regularly af-
fects the endometrial-myometrial junction. The diag-
nosis is possible to be found by ultrasound if striations
of the myometrium, anechoic foci in the myometrium
and asimetric uterine cavity could be visualized. In our
cases the diagnosis was evidenced with both 2D and
3D sonography.
Regarding the antral follicle count we performed a
double measurement. First we counted them on 2D
ultrasound using the standard technique. We meas-
ured each follicle with a mean size between 2 and 10
mm. Because some authors consider that is it best to
count the follicle up to 8 or 9 mm we analyzed sepa-
rately these sizes (Table 3).
We found no statistical significant difference between
the two methods (2D vs 3D) regarding the number of
follicles. We must emphasize although that the 3D
count is obvious easier than the 2D method.
Discussion
This study intended to evaluate in which extent
adding 3D ultrasound at the day 3 ultrasound of an
infertile female could bring new and valuable infor-
mation. Conventional 2D ultrasound, with a thor-
ough scan in both sagital and transverse sections, of-
fers an almost complete description of the uterus,
endometrial thickness and vascularisation pattern.
Normal uterus is easily assessed using 3D ultra-
sound, while the coronal plane gives a good image of
the endometrial cavity, the surrounding myometri-
um and of the uterine external contour, a fact of
most importance. 3D ultrasound does not substi-
tute, but completes the examination by offering a
complete image of the uterine cavity in one single
data acquisition (3). 
2D ultrasound presents the endometrial polyp as a fo-
cal, unequal thickening of the endometrium, of high-
er echogenicity than the myometrium, with an easily
detectable single feeding vessel (4). 3D sonograpahy
may facilitate diagnosis, using static acquisition, in di-
rect or inversion modes. Also, the shape, the dimen-
sions, the origin and the impact on the endometrial
cavity are clearly visualized, guiding the therapeutic
procedure. In our case the polyp was diagnosed during
2D examination and confirmed by 3D sonography
and the coronal examination also confirmed the diag-
nosis.
Uterine myomas are present on 2D ultrasound as fo-
cal enlargements of the uterus with a texture similar
to the myometrium and posterior shadowing. The ex-
act position, the impact on the ostium tubae and the
uterine cavity may be difficult to assess by conven-
tional ultrasound (5). A very easy solution in many
cases is offered by a static 3D acquisition or static
VCI-C. In our case with submucous myoma, the 3D
ultrasound showed clearly its position inside the uter-
ine cavity. 
Although the incidence of uterine anomalies is evalu-
ated in the literature as 7.7% and even higher in pop-
ulation with infertility, in our particular study we di-
agnosed only one case with arcuate uterus (7,8). It is
important to emphasize that in our case the diagnosis
was missed on 2D ultrasound and only after obtaining
the coronal plane this uterine malformation was clear-
ly seen. Uterine anomalies are undoubtedly the area
where 3D sonography has contributed the most.
While 2D transvaginal sonography is an excellent
screening examination for uterine anomalies, it is not
as effective as 3D ultrasound in distinguishing specific
malformations. 3D ultrasound does not replace 2D ul-
trasound but, rather, enhances it. 
Another important element evaluated during the day
3 ultrasound is ovarian reserve (9). It is estimated that
the number of primordial follicles in the ovary is in di-
rect correlation with the number of growing antral fol-
licles (2). Different studies using transvaginal ultra-
sound have shown decreasing numbers of antral folli-
cles as visualized by transvaginal sonography related to
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TABLE 2 - COMPARISON BETWEEN 2D AND 3 D REGAR-
DING DETECTION OF UTERINE ANOMALIES.
Uterine pathology Diagnosis Diagnosis Diagnosis
with 2D with 3D with 2D and
improved by 3D
Myoma + + +
Endometrial polyp + + +
Adenomyosis + + Not the case
Arcuate uterus - + Not the case
TABLE 3 - NUMBER OF ANTRAL FOLLICLE WITH 2D AND
3D ULTRASOUND.
Follicle size 2D mean±SD 3D mean±SD Mean difference 
2-8 mm 17.51±11.51 16.33±12.13 1.18
2-9 mm 18.24±11.51 16.67±9.68 1.57
2-10 mm 18.82±10.75 17.18±9.75 1.64
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increasing age in both women without known fertility
problems and in women with proven natural fertility
(10). The predictive value of antral follicle counts
(AFC) towards the probability of pregnancy in couples
with more or less unexplained infertility or in couples
in whom there is an indication for assisted reproduc-
tive procedures, has been the subject of many studies.
Counting the true number of follicles with 2D trans-
vaginal ultrasound could sometimes be difficult (10).
With the recent availability of three-dimensional (3D)
ultrasound equipment the assessment of the antral fol-
licle number may become more precise. Moreover,
computerized counting on the basis of digitalized
three-dimensional recordings is a new a possibility to-
day. We found no statistical difference in the number
of antral follicle by 2D or 3D ultrasound. The differ-
ence could be in the case of measuring automated the
follicle, the method beeing far more rapide than the
manually count by 2D (11).
Conclusions
Ultrasound examination of any patient performing an
infertility workup is an integral part of the standard
patient management. This is always done by 2D trans-
vaginal ultrasound. It allows proper examination of
pelvic organs: uterus, ovaries and possibly tubes. In the
last decade 3D ultrasound has been extensively devel-
oped and applied and the field of its use has broad-
ened. In day 3 ultrasound, the 3D sonographic exam-
ination is useful in uterine pathology, by obtaining the
coronal view. It could also be used in assessing the
ovarian reserve. 
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Introduction
Cervical cancer is a major health issue. Annually, an
estimated 470.000 new cases occur worldwide, of
which nearly half die. To minimize the effects of this
problem, early detection and proper treatment of cer-
vical precancerous lesions are therefore unquestionably
necessary. These two critical processes, however, are
still problematic in developing countries because of
the limitations of national screening and treatment
programs.
The “see and treat” or one-step management is an
immediate treatment of cervical precancerous le-
sions by loop electrosurgical excision procedure
(LEEP) without intervening via colposcopically-di-
rected biopsy. This strategy provides several advan-
tages including the simultaneous histological diag-
nosis and treatment of cervical precancerous lesions
resulting in reduction of either the number of pa-
tient visits or of the time intervals from diagnosis to
treatment, a more accurate histological diagnosis
due to larger specimens than those obtained by cer-
vical biopsy a decrease in cost and greater patient’s
convenience, thereby improving the compliance (1,
2, 3, 4). This study was undertaken to evaluate if
“see and treat” management in women with HSIL
Pap smear represent a good medical practice in our
medical facility.
Materials and methods
We performed an analysis of 75 cases with a cytologic
diagnosis of HSIL on the Pap smear. Exclusion criteria
were any proven genital malignancy, being a candidate
for hysterectomy for any indication, severe vaginal in-
fection, pregnancy, a delivery in the 3 previous
months, a bleeding disorder, or a recent cervical elec-
trocauterization.
All the patients had an colposcopic examination and
the severity of the lesion was graded using the ASCCP
guidelines, by which lesions with a mildly acetowhite
epithelium, no blood vessel pattern, and vague, diffuse
lesion borders that follow the normal contour of the
cervix are less severe than intensely acetowhite lesions
with punctuation or mosaic patterns, sharply demar-
cated borders, and a “humped up” contour (5).
We divided these patients in two groups and we ap-
plied two different management approaches. In the
first group (39 patients) we used the one step “see and
treat” management of the lesion and a second group
(36 patients) on which we performed biopsy followed
by LEEP or conization when necessary (depending on
the result of the biopsy). We then compared the results
of the pathology reports in order to evaluate if the “see
and treat” management is not an overtreatment in
some cases. In the second group we performed 34
LEEP based on the results obtained from the patholo-
gy department.
The patients presented for follow-up visits at the out-
patient clinic 2 weeks, 6 months, and 1 year after the
procedure to undergo Pap smear, colposcopy, and col-
poscopically-directed biopsy when the colposcopic ex-
amination was not satisfactory. The first visit allowed
an early evaluation of the procedure, the detection of
any complications and an evaluation of the patient's
satisfaction. The later visits allowed the detection of
residual or recurrent lesions.
Evaluation of “see-and-treat” approach in women with cervical
high-grade squamous intraepithelial lesions
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Results
The demographic characteristics of the patients are
presented in Table 1.
The pathological results are presented in table 2. The
hystophatological report show CIN II, III or CIS in
67 cases (89,3%). In 8 cases (10,6%) the diagnosis was
CIN I or chronic cervicitis. Among these 8 patiens, 4
belonged to group 1 and 4 to group 2, so there was no
significant difference of overtreatment between the
two groups. 
The complications which appeared during or after the
procedures are presented in table 3.
In group 2, in 34 cases the pathology report from the
colposcopic guided biopsy indicated a high-grade le-
sion and this result certified the need for further LEEP
or conization. From the 34 cases with conization in 2
cases the final diagnosis was CIN I.
The medium time length between the initial Pap
smear and LEEP was significantly longer than between
the initial Pap smear and biopsy.
The histopathologic evaluation revealed that 4 pa-
tients (10,2%) in the subgroup 1 have been overtreat-
ed, as they only had chronic cervicitis or CIN I.
The LEEP treatment was unsuccessful in 4 patients
(5,1%), 2 (2,6%) in the LEEP subgroup of group 1
and 2 (5,8%) in the LEEP subgroup of group 2. Of
those 4 patients, 2 had CIN 2 and the other 2 had
CIN3, as evidenced on colposcopy and confirmed on
histopathology.
Discussion
Tradditionally, the management algorithm of cervical
precancerous lesions has involved multiple steps in-
cluding initial colposcopy, followed by colposcopical-
ly-directed biopsy, and LEEP or conization thereafter
depending on the biopsy result. This protocol require
multiple visits and sometimes has a lower efficacy due
to poor patients' compliance. In order to improve the
patients' compliance, an alternative strategy using
LEEP for cervical conization method without prior
histogic diagnosis at the time of initial colposcopy, the
so-called “see and treat” is proposed because it could
reduce the number of visits compared with the tradi-
tional management. Due to its several advantages,
LEEP has become the preferred conization methods
among gynecological practice particularly for “see and
treat” approach (6, 7).
The problem arised by the “see and treat” approach is
the overtreatment of the cervical lesions. This
overtreatment mainly depends on the severity of the
lesions sugested by Pap smear and colposcopy. For
LSIL and ASCUS abnormalities the overtreatment is
highly probable. Our data strongly suggested that “see
and treat” policy was an inappropriate strategy for
women with low-grade cytological abnormality be-
cause of the high incidence of the overtreatment. 
In our study we evaluted this approach for patients di-
agnosed with high-grade lesions on Pap smear. In the
group where we apllied the “see and treat” approach,
we had a 10,2% overtreatment rate. However, we
found no statistical difference between this finding
and the 11.7% rate of non-high-grade results from the
LEEP specimens in group 2, after high-grade results
were obtaining from punch biopsies. Based on these
results we consider that the “see and treat” approach
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TABLE 1 - DEMOGRAPHIC PARAMETERS.
No. of cases %
Age group (years old)
≥ 20 1 1.33%
20-40 60 80.00%
41-60 13 17.33%
> 60 1 1.33%
Income status
High 23 30.66%
Medium 47 62.66%
Low 5 6.66%
Residence
Urban 70 93.33%
Rural 5 6.67%
Onset of sex
< 20 years of age 49 65.33%
≥20 years of age 26 34.66%
Parity
≥ 3 65 86.66%
> 3 10 13.33%
TABLE 2 - COMPLICATIONS DURING AND AFTER THE
PROCEDURE.
Complication Group 1 Group 2 Subgroup 2
(39 patients) (biopsy guided (LEEP after
procedure, biopsy,
36 patients) 34 patients)
Bleeding during the procedure 0 0 0
Bleeding after procedure 0 0 0
Injury to vaginal mucosa 0 0 0
TABLE 3 - PATHOLOGICAL RESULTS.
Pathology CIN III, CIS CIN II, CIN I Chronic
cervicitis
Group 1 (39 patients) 10 25 3 1
Group 2 (36 patients) 8 26 2 0
Subgroup 2*(34 patients) 9 22 3 0
*Subgroup 2- patients with LEEP after guided colposcopic biopsy
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represent a good therapeutical attitude especially when
is performed in patients who cannot afford regular
medical controls.
Our results agree with those of Numnum et al., who
reported an overtreatment rate of 16%, with overtreat-
ment defined as the excision of CIN 1 or lesser lesions
(4). On the other hand, Ferris et al. found that the his-
tologic results were normal for 36.1% of the patients
in their see-and-treat group (2). 
Sadan et al. found no differences in final histologic
findings between a 3-step protocol, in which LEEP
was performed, only in the cases when the results of
colposcopically-directed biopsies were positive for
CIN 2 and CIN 3, and a see-and-treat protocol, in
which LEEP was immediately performed if CIN 2 or
CIN 3 lesions were suspected on colposcopy (8).
Conclusions
In conclusion, the “see and treat” policy using LEEP
can be considered as appropriate management in
women with HSIL on Pap smear with an overtreat-
ment rate of 5.8%. The incidence of overtreatment
could be further reduced to 4.0% when such policy
was strictly carried out only for premenopausal pa-
tients.
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The hyperplastic processes of endometrium take the
central place among the gynaecological morbidity. En-
dometrial hyperplasia is one of the most frequent dis-
eases of the uterine mucous membrane. The prevalence
degree of this pathology among reproductive age of
women is more than 50%. It is the cause of abnormal
uterine bleeding, infertility and endometrial cancer.
Nowadays hormonal therapy is the most extended
method of treatment of endometrial hyperplasia. The
deterioration of the population’s health index significant-
ly reduces the possibility for prescription of a hormonal
treatment. It needs the search for alternative effective
treatment methods for endometrial hyperplasia of
women with contraindications to hormonal treatment.
The aim of our study was to compare the efficiency of
combined resection of endometrium and hormonal
therapy for women with nonatypic endometrial hyper-
plasia.We recruited 64 women aged 45-60 with en-
dometrial hyperplasia without atypia. 
Table 1 shows that the degree of extragenital morbidi-
ties among women with endometrial hyperplasia, i.e.
89,1 per cent that explains a great number of con-
traindications among women of this group.
The surveyed patients were divided into two groups.
The first group, which consisted of 31 women, re-
ceived the hormonal treatment during 6 months. Sim-
ple nonatypic endometrial hyperplasia was diagnosed
histologically to 11 patients (35.5%) and complex
nonatypic endometrial hyperplasia to 20 women
(64.5%) (Fig. 1). 
The effectiveness of this hormonal treatment is
67.8%. The relapse of this disease was among 4
women during the first three months (12.9%) and
among 6 women during next three months (19.3%).
Thus, the recurrence of this pathology was to 10
women and that kind of treatment wasn’t effective in
32.3% of the cases. The important thing is the high
level of negative side effects among women who took
hormonal treatment.
The combined resection endometrium was performed
to 33 patients of the second group who had con-
traindications to using hormonal treatment or refused
to take above-mentioned kind of treatment and hys-
terectomy.
The combined resection of endometrium
as hormonal alternative therapy 
GROMOVA A., AFANASYEVA O., AFANASYEV Y., GROMOVA O.
Mirgorod (Poltave), Ukraine
TABLE 1 - EXTRAGENITAL MORBIDITY OF  PATIENTS.
Extragenital Diseases n. %
Arterial hypertensia 7 10,93
Ischemic heart trouble 3 4,68
Varicose disease of leg 5 7,81
Chronic cholecystitis 7 10,93
Gastroenteric diseases 17 26,56
Chronic hepatitis 1 1,56
Thyroid gland diseases 6 9,37
Diseases of kidneys and bladder 4 6,25
Respiratory diseases 4 6,25
Adiposity (III – IV stages) 7 10,93
Diabetes 2 3,12
64,5%
35,5%
Simple nonatypic endometrial hyperplasia
Complex nonatypic endometrial hyperplasia 
Histological Structure of Endometry of I Group
Fig. 1
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Simple nonatypic endometrial hyperplasia was diag-
nosed histologically to 9 patients (27.3%) and com-
plex nonatypic endometrial hyperplasia to 24 women
(72.7%) (Fig. 2). 
The key principle of the combined resection en-
dometrium method is the usage of different types of
hysteroscopy electrodes depending on the treated part
of the mucosal membrane of uterine cavity (Figs 3-5).
The effectiveness of the combined resection en-
dometrium is 87.9%. The relapse of this disease was
among 1 women during the first three months (3.0%)
and among 3 women during next three months
(9.1%). We’d like to mark that the single side effect of
the used method was a moderate pain to 7 patients
(21.2%) during the first day after the operation which
was easily stopped by nonsteroidal anti-inflammatory
preparations. All the patients were satisfied with the
results of the used treatment. There were no vegeto-
vascular and psychoemotional disorders and flare of
somatic chronic deseases that is especially important
for this group of patients. 
As a conclusion we’d like to say that the high degree of
discomfort and side effects were determined in the
progestin-treated group and according to the results of
our research the sufficiency of hormonal therapy of
nonatypic endometrial hyperplasia is less than 70% in
comparison to 87.9% in the second group of women.
On the basis of our study we believe that hysteroscop-
ic combined endometrial resection is a safe and effec-
tive alternative to hormonal therapy for women with
nonatypic endometrial hyperplasia especially for pa-
tients with contraindications to hormonal drugs and it
gives the possibility to low the level of hysterectomy.
72,7%
27,3%
Simple nonatypic endometrial hyperplasia
Complex nonatypic endometrial hyperplasia 
Histological Structure of Endometry of II Group
Fig. 3 - Bullet-shaped electrode, the part of
internal fauces. 
Fig. 4 - Barrel-shaped electrode, coagulation of
the uterine bottom. 
Fig. 5 - Loop-shaped electrode, posterior uterine
wall.
Fig. 2
According to recent statistics, childhood cancer inci-
dence increases rapidly all over the world. In 2007  the
cases among children in Russian Federation made up-
about 11,7 o/oooo, and in 2009 about 12,9 o/oooo.
Due to new prognosis of complex treatment, mortali-
ty of cancer among children is expected to decrease.
The most common oncology diseases are hematologi-
cal tumors and those of central nervous system. These
tumors need complex treatment including surgery,
chemotherapy and irradiation. However, the men-
tioned treatment may cause late side effects, the most
common of which affect endocrine system. The rela-
tive risk of sexual dysfunction development after X-ray
treatment exceeds 86 times (Gurney JG, 2003). 
There are many factors that may affect reproductive
function of a woman during treatment of cancer. First
of all, cranial irradiation may cause complex endocrine
dysfunction due to hypopituitarism. Development of
secondary hypogonadism depends on dose and age
and occurs at radiation dose that exceeds 40Gy. 
Secondly, most chemotherapy agents are subject of
high toxicity for the ovaries. Furthermore, the use of
multi-agent protocols increases the risk of ovary func-
tion depletion. Chemotherapy-induced amenorrhea
may be transitory, and menstruation may return sever-
al months after the treatment was completed,or it may
remain permanent with total depletion of follicles.
Thirdly, ovaries are highly sensitive to irradiation. The
risk of ovarian failure is high, with the LD50 estimat-
ed to be less than 2 Gy (Wallace et al., 2003). There is
no direct irradiation of the ovaries during craniospinal
radiotherapy (Bath et al., 2001). But ovaries may be ir-
radiated during spinal X-ray treatment due to different
types of topography. In fact, girls inpost pubertal peri-
od are more sensitive to irradiation. However, it is nec-
essary to consider that volume of pelvis in younger
girls is less than in elder ones, therefore the irradiation
dose is higher.
Moreover, irradiation of the pelvis affects uterine
growth as well. This may cause problems of implanta-
tion, preterm delivery and low birth weight.
Thus, different organs can be possibly impaired dur-
ing the treatment of cancer.
Our study is aimed at determining the influence of
cranial and craniospinal irradiation on women’s repro-
ductive system by investigating menstrual and repro-
ductive anamnesis, ovarian volume and antral follicles
count along with the level of pituitary hormones in
women after treatment brain tumors and leukemia in
childhood.
Methods
Medical history, physical examination, hormonal
analyses. All participants were examined during
the early follicular phase of a menstrual cycle (i.e.
2nd-5thcycle days.) with transabdominal and transvagi-
nal ultrasound, antral follicles count and hormonal
analysis (LH, FSH, prolactin, estrogen). All examina-
tions were performed by the same investigator using
the same equipment. Hormonal data, ovarian and
uterus volume were compared using the Mann-Whit-
ney U-test.
Hormonal analysis was measured in a single assay (im-
munochemiluminiscent system, Immulite, DPC). 
The study involved 19 women.
First group included 10 women submitted to child-
hood acute lymphoblastic leukemia (ALL) treatment.
The average age of participators in this group was
© Copyright 2012, CIC Edizioni Internazionali, Roma
Effects of cranial and craniospinal irradiation on reproductive system
of women childhood cancer survivors
GUBERNATOROVA E.E.1, KAZNACHEEVA T.V.2, PAVLOVA M.G.1, MAZERKINA N.A.3,
MELNICHENKO G.A.1, TENDIEVA V.D.3
1 Department of Endocrinology, I.M. Sechenov First Moscow State Medical University;
2 Department of Reproductive Medicine and Surgery, Moscow State Medical Dental University; and
3 Institute of Neurosurgery, “N. Burdenko”, Moscow, Russian Federation
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
197
22,5(16-30), whose average age was 7,8 (2,5-13) when
the diagnosis was first stated. All these patients re-
ceived cranial irradiation 18 Gy and chemotherapy
ALL-BFM-90 (including alkylating agents: daunoru-
bicin, vincristine, L-asparaginase, prednisolone, mer-
captopurine, cytarabine, cyclophosphamide,
methotrexate, mercaptopurine).
The second group involved 9 women submitted to
treatment for brain tumors in childhood. The average
age of participators in this group was 19,7 (16-26),
their average age by the moment of stating the diagno-
sis was 13,4 (5-18). This group of the patients received
craniospinal irradiation 55Gy and chemotherapy M-
2000 (vincristine, cyclophosphamide, cisplatin, etopo-
side).
None of participators received oral contraception, 2
had primary amenorrhea, 3 had secondary amenor-
rhea, 1 received estrogen-gestogen treatment of sec-
ondary amenorrhea. None of participants obtained
gonadoprotection during treatment.
Results 
Clinical data in relation to menstrual cycle character-
istics showed that participants of the 1st group had
menarche at the age of 11,4 years old (10-14), 5
women had clinically detected pregnancies in anamne-
sis. Participants of the 2nd group had menarche at the
age of 12,6 years old (11-14), excepting 2 women with
primary amenorrhea. 
The average volume of right ovary in the 1st group
was 5,56 (0,2 to 14) ml. The average volume of left
ovary was 4,46 (0,2 to 9,2) ml. 8 of the patients had
more than 10 follicles in each ovary during ultra-
sonography of ovaries. The average volume of uterus
was 40,5 ml. The average level of FSH was 6,064 (5,2
to 12,4) mU/l, of LH was 4,3 (5,2 to 12,4) mU/l, of
estradiol was 245,8 (73,4-1322). There were 6 docu-
mented pregnancies: 4 life-births, 1 spontaneous
abortion, 1 medical abortion. All deliveries were at
gestational age 37-38 weeks, average birth weight was
3462,5 (3350-3600) kg.
The average volume of right/left ovary in the 2nd group
was 3,23 (0,22 to 8,76) / 4,58 (0,22 to 14,7) ml. 4 pa-
tients submitted to treatment of brain tumors had no
follicles, and 4 less than 6 follicles per ovary. The aver-
age volume of uterus was 10,8 ml. The average level of
FSH was 34,4 (0,19 to 105), LH was 7,1 (0,1 to 30)
mU/l, average level of estradiol was 266,6 (73,0-430).
There were no registered pregnancies in this group. 
Discussion 
This data showed that treatment of cancer in children
is associated with considerable risk of disturbances of
reproductive development. Women who underwent
craniospinal irradiation showed elevated levels of FSH
and LH. Ovarian volume was significantly smaller in
women who underwent craniospinal irradiation than
in those who under went cranial irradiation (3,23 ver-
sus 5,56 ml; p<0,05). Though the volume of ovaries
did not differ significantly in this groups, there sult of
antral follicles count was lower in the group of women
after craniospinal irradiation than after cranial irradia-
tion (2,3 versus 9,4 p<0,01). 55,5% of women after
craniospinal irradiation had amenorrhea. Moreover,
we have found that survivors who preserved menstru-
al cycles had sonographic and endocrine changes sug-
gesting impairment of ovarian reserve.
Volume of uterus was also significantly lower after
craniosponal irradiation (10,8 versus 40,5 ml, p 0,01).
This could be the consequence of either spinal irradi-
ation or amenorrhea. There were no registered preg-
nancies in the group of women who under went cran-
iospinal irradiation, but none of them had ever been
interested in becoming pregnant.
Conclusion
Therefore, craniospinal irradiation has a great impact
on reproductive and menstrual function system of
women survived cancer in childhood. Girls who un-
dergo complex treatment of brain tumors including
craniospinal irradiation are at a higher risk of amenor-
rhea than after complex treatment of acute leucosis.
This data suggests that women after craniospinal irra-
diation with spontaneous menstrual cycles have re-
duced ovarian reserve. Further researches including di-
rect markers of ovarian reserve indicators (AntiMuller-
ian hormone, Inhibin B, EFFORT-test) are employed
in order to estimate the risk of premature ovarian fail-
ure in women after cranial and craniospinal irradia-
tion.
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Endometriosis (ENDs) and adenomyosis (ADNs) are
common gynaecological disorders with variable physi-
cal symptoms and consequences. Furthermore, the bi-
ological profile of endometriosis is known as a condi-
tion which may carry a risk for malignant conversion
in some circumstances. Although ENDs and ADNs
are behaviourally different diseases, they both develop
in women during their reproductive ages and regress
after menopause, which suggests that these diseases are
estrogen-dependent disorders. The importance of aro-
matase expression as a specific marker for endometrio-
sis is still a matter of debate with equivocal conclu-
sions. Today, the diagnosis of endometriosis and/or
adenomyosis is based on physical symptoms, laparo-
scopic and histological verification. In general, these
procedures require high initial costs. We hypothesize
that the estrogen dependent fashion of the disease
could be of prognostic significance in diagnosis of
ENDs and ADNs. The aim of this study was to deter-
mine the clinical usefulness of examining endometrial
biopsy specimens for aromatase cytochrome P450
(CYP19) as a diagnostic importance for endometriosis
and adenomyosis. The tissue aromatase expression lev-
el was correlated to the type of samples and to the
stage of endometriosis. 
Caucasian women with regular menstrual period of
ages 25-55 years (mean 43.02±6.8 SD) undergoing la-
paroscopic surgery (tissue biopsy, suspicious en-
dometrioma extirpation, laparoscopically assisted vagi-
nal hysterectomy) for pelvic pain were enrolled. We di-
vided all patients with ENDs into two stage groups:
endometriosis of low stage (ENDsL; patients with
stage I+II) and advanced form of the disease (ENDsA;
patients with stage III+IV). The patients with adeno-
myosis (ADNs) were included in a separate group
(n=25). Endometrial biopsies were taken by using a
sharp curette (uterine cavity) and graspers (pelvic loca-
tion), and stored in PrepProtect (Miltenyi Biotec, Ger-
many) according to the manufacturer’s instruction. All
biopsies were obtained in the early proliferative phase
of the menstrual cycle (≤7 days).
Patients (n=55) and controls (n=46) did not differ sig-
nificantly neither in age, BMI nor in reproductive pa-
rameters (parity, onset of menarche and use of oral con-
traceptives). The increased mRNA expression of
CYP19 was detected in 10 (21.7%) cases of the healthy
controls and in 36 samples (65.5%) with ENDs and
ADNs. In general, the Reverse Transcription-PCR
analyses of 101 samples revealed increased aromatase
mRNA expression in eutopic endometrium in women
with ENDs and ADNs compared to healthy controls
(p=0.0002). We detected the highest number of posi-
tive cases (n=14, 93.3%) of aromatase expression in pa-
tients with ENDsA. The mean value of relative CYP19
mRNA level in controls was 0.68 (interval 0.02-2.63)
compared to patients with ADNs (1.21; 0.10-4.07),
ENDsL stage I-II (1.15; 0.13-3.15) and ENDsA stage
III-IV (1.65; 0.70-3.52), respectively (Figure 1). These
results point to the highest (2.45-fold) difference in
aromatase expression in patients with endometriosis
stage III-IV compared to controls (p<0.0001). 
Because it is thought that estrogen expression is affect-
ed by extragonadal aromatase activity, mainly in fatty
tissue, we further analyzed the influence of BMI on
aromatase expression in each group to achieve clearer
results. Although the data showed no impact of BMI
on the CYP19 level, specific and interesting trends
were revealed. Despite the insignificant conclusion,
the increased BMI in the controls was associated with
a slight increase of aromatase expression (r=0.282,
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p=0.06), contrary to cases where this trend was the op-
posite (r=-0.169, p=0.224).
In our study, we analyzed the mRNA expression of
CYP19 in eutopic endometrium among the healthy
women and patients with endometriosis or adeno-
myosis. A significant increased level of CYP19 mRNA in
patients was revealed and this expression was significant-
ly dependent on disease severity. These findings provide
direct evidence that screening for endometrial aromatase
in combination with clinical data could be of discrimi-
native value in the prediction of estrogen-dependent dis-
eases. Furthermore, successful treatment of unusually ag-
gressive cases of endometriosis with aromatase inhibitors
in some previous clinical trials confirmed the clinical sig-
nificance of our study, bringing results that may serve al-
so as a diagnostic marker for therapeutic intervention in
women suffering from endometriosis.
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Introduction
The Rotterdam criteria of polycystic ovary syndrome
(PCOS) include patients with different phenotypes.
Ovulatory PCOS represents the mild form of classic
PCOS (Guastella et al., 2010). According to Chang et
al., 2005, different clinical phenotypes of PCOS may
be the result of varying degree of metabolic dysfunc-
tion and greater degrees of β-cell function and circu-
lating insulin levels favored the development of hir-
sutism and frank hyperandrogenemia. The main
source of androgen in women with PCOS is the ovary
producing mainly testosterone. However 36-50% of
them have elevated adrenal androgen, dehy-
droepiandrosterone sulfate (DHEAS) (Carmina and
Lobo, 2007). DHEAS, a weak androgen, under phys-
iologic conditions may be converted to testosterone
and then to estrogen. 
Objective 
To study the clinical and laboratorial findings of
women with different etiologies of hyperandrogenism
(HA) and to correlate with the diagnosis in the Brazil-
ian population of São Paulo. 
Patients and methods 
A total of 410 patients with clinical hyperandrogenism
were evaluated in the Hyperandrogenism Unit of Hos-
pital das Clinicas of Universidade de Sao Paulo, Brazil.
All patients underwent to baseline measurements of
prolactin, TSH, free T4, FSH, LH, T, androstene-
dione, DHEAS, blood glucose and insulin and
HOMA-IR calculation, and test of synthetic ACTH.
Patients were classified into four groups: Anovulatory
PCOS, ovulatory PCOS, Late Onset Congenital
Adrenal Hyperplasia (CAH) and Idiopathic Hirsutism
(IH). Rotterdam 2003 criteria were used for diagnos-
ing PCOS; IH was diagnosed with the presence of hir-
sutism with all other clinical and laboratory parame-
ters unchanged. CAH was determined by the values
after stimulation with synthetic ACTH above 10
ng/mL and genotyping. Comparison of the laborator-
ial values among groups was performed using statisti-
cal tests ANOVA and Bonferroni. 
Results 
Seventy-nine percent (79%) were PCOS. From those,
13 (3.2%) were ovulatory PCOS. Thirty-two patients
(7.8%) had IH and 10 (2.4%), CAH. The remaining
subjects had others causes of HA (table 1). Comparing
the different groups, it was observed higher age in the IH
groups (p=0.037), higher BMI in anovulatory PCOS
(p=0.045), and significantly higher levels of DHEAS on
the ovulatory PCOS group (p<0.001). Abdominal cir-
cumference and level of LH, T, andro and HOMA-IR
were significantly lower in IH group (Table 2). 
Conclusions 
Ovulatory PCOS seems to be associated with in-
creased DHEAS, showing the influence of the adrenal
component. Lower androgenic effect may explain the
milder features of this PCOS phenotype.
Is the ovulatory phenotype of polycystic ovary syndrome
associated with adrenal hyperandrogenism?
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TABLE 1 - DIAGNOSIS IN 410 HYPERANDROGENIC WO-
MEN.
Diagnosis n %
Anovulatory PCOS 312 76,1
Ovulatory PCOS 13 3,2
Idiopathic Hirsutism 32 7,8
Hypotireoidism 16 3,9
CAH non-classic 10 2,43
Hyperprolactinemia 10 2,43
Hyperthecosis 8 1,95
Androgen Producing Tumors
Ovary 6 1,46
Adrenal 1 0,24
CAH classic 1 0,24
Cushing Syndrome 1 0,24
TABLE 2 - CLINICAL AND LABORATORIAL FEATURES BY DIFFERENT ETIOLOGIES OF HYPERDROGENISM.
Parameters PCOS Ovulatory Idiopathic CAH non-classic p
(n=312) PCOS (n=13) hirsutism (n=32) (n=10)
Age (yrs) 25,4±5,5 26,5±5,4 28,5±9,1 27,2±7,1 0,037
Menarche (yrs) 12,6±2,0 12,3±1,4 12,7±1,6 13,6±1,6 0,395
BMI (kg/m2) 29,1±7,3 26,6±4,8 25,5±6,5 28,2±6,1 0,045
AC (cm) 90,2±15,3 84,5±11,9 78,4±14,7 92,0±17,4 0,018
Hirsutism Score (mF-G) 13,2±5,9 14,8±4,5 15,3±4,5 13,9±4,3 0,191
FSH (mUI/mL) 4,98±1,68 4,53±2,00 4,44±2,90 5,86±1,41 0,407
LH (mUI/mL) 9,84±6,29 6,95±5,72 3,56±1,55 9,14±7,37 0,005
T (ng/dL) 94,1±42,3 75,5±42,1 49,4±16,9 106,6±51,2 <0,001
Free T (pmol/L) 66,9±39,8 35,2±17,5 NA NA 0,128
Andro (ng/mL) 3,38±1,54 3,58±2,11 1,61±0,55 3,45±1,44 <0,001
SDHEA (ng/mL) 2045±1279 3254±1281 1558±888 2833±1568 <0,001
17OHP (ng/mL) 1,44±0,95 1,44±1,40 1,87±1,05 6,31±6,23 <0,001
Glucose (mg/dL) 89,8±20,0 88,7±8,8 81,3±4,6 92,5±6,4 0,895
Insulin (µU/mL) 18,1±14,7 11,4±5,9 6,33±1,02 16,5±0,99 0,365
HOMA-IR 4,35±4,00 2,25±1,62 1,68±0,42 2,84±0,92 0,049
NA – Non available.
Premature ovarian failure (POF) occurs after chemo
and radiotherapy. Ovarian cortex cryopreservation fol-
lowed by autotransplantation is one of the clinical op-
tions to preserve and restore fertility. Fifteen babies
have been born worldwide following this procedure,
however this technique still need to be optimised, es-
pecially in the ischemic early stage of the graft, source
of major follicles loss. To reduce this hypoxic period,
two VEGF-A isoforms (VEGF165 and 111) were tested
on ovarian graft neovascularisation. 
Sheep cryopreserved ovarian cortex fragments were
embedded in type 1 collagen containing or not
VEGF165 or VEGF111. Those cortex fragments were
subsequently grafted in mice.
After 3 days of transplantation, functional vascular
network revealed that the percentage of perfused
transplants (33%-75%) and density of functional
blood vessels varied according to VEGF isoform and
concentration. Nevertheless,we observed that 100% of
ovarian grafts in VEGF165 50nM treated group were
perfused and associated with a moderate increase of
functional capillaries density compared to other exper-
imental groups. 
Ki-67 positive cells were localised at the ovarian graft
periphery in all groups. A higher number of proliferat-
ing cells were observed in VEGF165 group. After three
weeks of transplantation, functional blood vessels and
follicles were similar in all groups. However fibrosis
seems to be reduced in VEGF treated groups com-
pared to control group.
Our preliminary results show that VEGF165 (50 nM)
seems to improve early angiogenesis of ovarian grafts
but requirefurther investigations.
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Objective – PCOS may be associated with an in-
creased risk of endometrial hyperplasia (EH) and en-
dometrial cancer (EC), but substantial evidence re-
mains to be established. We investigated the preva-
lence of EH and EC in a well-characterized group of
women with PCOS and/or clinical/biochemical hy-
perandrogenism. 
Design – Retrospective, trans-sectional study.
Setting – Out-patient clinic at the Departments of
Endocrinology and Gynecology, Odense University
Hospital, Denmark.
Population – Nine hundred and sixty three pre-
menopausal women consecutively referred with the di-
agnoses PCOS and/or hirsutism during 1997-2008.
Methods – All women underwent a standardized
evaluation program. In 2011, The Danish Data Bank
of Pathology was used to identify patients with en-
dometrial histology diagnoses (year range of diagnosis
1982-2011). 
Main outcome measures – Histology diag-
noses, demographic variables.
Results – EH was diagnosed in 10 (1.0%) women
and EC in 1 (0.1%) woman. The median BMI in the
EH/EC group was 30.6 kg/m2 compared to 26.8
kg/m2 in the total cohort. There were no differences
between the cases and total cohort in terms of individ-
ual Rotterdam Criteria. In Denmark, 70 yearly cases
of EC are diagnosed in women 40-55 years correspon-
ding to a prevalence of 0.4 % in the corresponding
time period.
Conclusion – The results of the present study do
not suggest a higher prevalence of EC in women with
PCOS and/or clinical/biochemical hyperandrogenism
compared to the general population.
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Background and aims 
Obesity is an independent risk factor for the endome-
trial hyperplasia (EH) caused by a number of patho-
genic mechanisms (1), including insulin resistance
(IR). Hyperinsulinemia a consequence of IR is pro-
posed to increase insulin / insulin-like growth factor
(IGF) signaling in peripherial tissues, such as en-
dometrium (2). IGF system is one of the growth fac-
tor systems. It is considered as a mediator of steroid
hormone actions in the endometrium through au-
tocrine/paracrine mechanisms (3). IR may be associat-
ed with alterations in expression of IGFs and the IGF
binding proteins (IGFBPs) or may inhibit the protec-
tive effect of progestagens (3,4,5). The primary nega-
tive regulator of IGFBP-1 production is insulin (3).
Insulin and IGF-1 may directly stimulate proliferation
of the endometrium without the involvement of estro-
gen (1). The aim of this study is to compare the effec-
tiveness of two treatment therapy - gestagen and met-
formin, in patients with EH and obesity.
Study design and methods 
168 overweight and obese women (overweight –
29.8%, obesity of I degree – 33.9%, obesity of II de-
gree – 36.3%) of reproductive age (from 25 to 45
years) have been studied. Patients were divided by 2
groups according to the hyperplastic processes:
• group 1 - women with EH and/or polyposis
(n=84);
• group 2 - women with endocervical hyperplasia
and/or polyposis (n=84);
Both groups were divided by 2 subgroups:
• subgroup a - patients on gestagen therapy from
day 16 to day 25 of menstrual cycle, mean daily
dosage - 20 mg, duration - 6 months (n=42);
• subgroup b - patients on metformin therapy,
mean daily dosage 500-1500mg, duration - 6
months (n=42).
All subjects were taken a low caloric diet and per-
formed moderate physical activity.
Inclusion criteria were: fasting hyperglycemia (FH)
and/or impaired glucose tolerance (IGT); HbA1c level
varied in the range 5,5-6,4%; dyslipidemia; family histo-
ry of Diabetes Mellitus; birth weight more than 3.9 kg.
All subjects had three and more criteria and all of them
did not use other pills. 
All Patients underwent to medical exams: BMI, waist
circumference (WC); OGTT, HBA1c, serum C-pep-
tide, HOMA indices, serum IGF-1; FSH, LH, Estra-
diol, PRL, TSH; Blood coagulation test, lipidogramm;
transvaginal ultrasonography (T-US); colposcopy; Pap
smear test (PST); Hystomorfology. Investigations were
done at the initiation of the treatment and after 6
months of the treatment termination.
Indication of diagnostic scarping and hysteroscopy
was the suspicion on endometrial hyperplasia and/or
polyp observed by ultrasonography and/or colposcopy.
Hystomorfology revealed polypoid types of glandular-
cystic hyperplasia of endometrium without atypic cells
(82.7%), glandular polyp of endometrium without
atypic cells (14.9%), local glandular hyperplasia with-
out atypic cells (2.4%).
Variables were compared by the unpaired t test and
Fisher exact test. Within-group changes were assessed
by the paired t test. SPSS version 16.0 statistical soft-
ware was used for analysis. A p<0.05 was required for
statistical significance.
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Results 
After 6 month of the treatment BMI decreased non-
significantly in subgroups 1a and 2a, WC – did not
change. 
The figures of carbohydrate and lipid metabolism were
changed for the worse. At the initiation of treatment
FH were noted in 32.1% of patients; IGT - in 41.7%
of patients; both (FH and IGT) – 26.2%. After 6
months of treatment termination FH were noted in
26.2% of patients; IGT - in 35.7% of patients; both
(FH and IGT) – 38.1%.
HOMA-IR and serum level C-peptide increased sig-
nificantly (p<0.05); lipidogramm and blood coagula-
tion test were worsening. Hormonal tests revealed that
prolactin and IGF-1 were non-significantly slightly in-
creased. T-US showed the decrease of endometrium
thickness in 47.6% of patients and relapse of hyper-
plasia revealed in 52.4% of patients after 6 months of
treatment termination. The incidence of varicosity of
pelvic veins was increased significantly (p<0.05). The
colposcopy data showed hyperplastic processes oc-
curred in endocervix - micropolyposis and hyperplasia,
minor size polyps, subepithelial varicose; atrophic
changes, erosion in squamous epithelium. PST re-
vealed endocervical microglandular hyperplasia and
reserve cell hyperplasia, excess of parabasal cells, slight-
ly expressed atrophic changes, LG SIL of endocervical
glandular epithelial cells. Blasts of endometrial cells
with proliferative activity were found in endocervical
smear.
In subgroups 1b and 2b after 6 month of the treat-
ment – reduction of BMI and WC were significant
(p<0.05), FH have been remained in only 4.8% of pa-
tients, and IGT – 2.4% of patients.
HBA1c level, C-peptide and HOMA-IR indices were
decreased significantly (p<0.05). The results of coagu-
lation test and lipidogram were improved. IGF-1 de-
creased significantly (p<0.05), the values of other hor-
mones did not change significantly. T-US showed the
decrease of endometrial thickness in 78.6% of patients
and relapse of hyperplasia revealed in 21.4% of pa-
tients. Varicosity of pelvic veins had not been revealed.
Colposcopy data showed the eradication of atrophic
changes, reduction of subepithelial varicose changes,
hyperplasia in cervical channel had not been revealed
in 77.4% of patients. PST data indicated squamous
cell metaplasia and slightly expressed reserve cell hy-
perplasia in 3.6% of patients.
Conclusion
Alterations in insulin/IGF signaling systems are
starters of proliferation processes both for endometrial
and endocervical hyperplastic processes. Insulin and
IGF signaling system activation induces estrogen re-
ceptor hyperactivation. Thus, these processes are irre-
versible with decrease of IR. During the selection of
the treatment method it is necessary to take into ac-
count as well mucosal changes as the presence of con-
comitant pathologies and early detection of metabolic
disorders. Nowadays used hormones for the treatment
of hyperplastic processes contribute to the develop-
ment and worsening of the metabolic disorders and do
not influence on pathogenic chain. Besides this rou-
tinely used hormone therapy has frequently short-
term effect and its removal quickly leads to the relapse
of disease. Metformin therapy may be a choice
method for pathogenic treatment (6). It can block cell
proliferation, induce apoptosis, and regulate growth
factor signaling system (7). Insulin sensitizers decrease
not only EH but also decline risk of cardiovascular dis-
ease and diabetes mellitus.
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The significance of bacteriospermia for male subfertil-
ity has gained increasing importance in recent years.
The most discussed and tested organism concerning
male infertility is Escherichia coli, as the most impor-
tant pathogen causing prostatitis and epididymitis (1).
Several authors have postulated a negative effect of E.
coli on sperm motility. The direct inhibitory effect of
E. coli on progressive motility was found to depend
upon bacterial concentration and analysis by electron
microscopy revealed multiple adhesions of E. coli to
spermatozoa causing variable ultrastructural damage
as probable morphological correlates of immobiliza-
tion (2).
Although several studies have evaluated the ability of
bacteria to affect sperm motility by adherence, agglu-
tination and dialyzable factors, however, none have
identified receptor-ligand interaction between sperma-
tozoa and bacteria. We have shown this same interac-
tion using an E. coli strain obtained from semen of an
infertile man.
The isolates of E. coli, showing immobilization of hu-
man spermatozoa in vitro were isolated from semen of
males attending infertility clinic for semen analysis
(Department of Urology, PGIMER, Chandigarh, In-
dia). The cultures were identified using Bergey’s Man-
ual of Determinative Bacteriology (3). 
Semen samples were obtained by masturbation from
males attending infertility clinic. Only ejaculates
showing normal semen parameters according to
WHO criteria (4) were used. 
The screening of various isolates obtained from the
ejaculates of infertile males for the interaction with
human spermatozoa identified 2 isolates of E. coli
causing agglutination of human spermatozoa. The iso-
late showing maximum agglutination of human sper-
matozoa was selected for further studies. Further, iso-
lation of sperm agglutinating factor (SAF) from E. coli,
was done using the method earlier standardized in the
laboratory (5). Briefly, 48h old culture of E. coli was
given salt treatment of 3M NaCl at 37°C for 14h at
150 rpm. Supernatant so obtained, was dialyzed and
concentrated and applied to Sephadex G-200 column
and chromatographic pattern showed that SAF was
present in fractions 4-7. These fractions were pooled,
concentrated and applied to DEAE cellulose column.
The results indicated that most of the SAF could be
eluted with PBS containing 0.4M NaCl. The bioactive
fractions (31-34) when pooled, concentrated and sub-
jected to PAGE, showed one major protein band.
Minimum effective concentration (MEC) of SAF
showing complete sperm agglutination and death af-
ter 20s of incubation was determined by mixing dif-
ferent concentrations of SAF with human spermato-
zoa (40x106/ml) and results showed MEC to be 1.2
and 2.0mg/ml for agglutination and death respective-
ly. Scanning electron microscopy (SEM) was per-
formed to study any alteration in morphology of hu-
man spermatozoa on incubation with SAF on a Jeol
scanning microscope (JSM-6100, Japan) by standard
method (6). SEM studies revealed the morphological
alterations of spermatozoa such as the lesions on the
head region along with curling of tail after incubation
with SAF.
The effect of SAF on acrosome reaction (AR) was ver-
ified using Pisum sativum agglutinin- fluorescein isoth-
iocyanate (PSA-FITC) using the method of Kohn et al
(7) with slight modifications. Briefly, spermatozoa
were kept for 3h at 37°C in Ham’s F-10 HSA medi-
um containing Hepes (20mmol/l) for capacitation.
After incubation, sample was divided in three aliquots
having 1x106 motile spermatozoa in each tube. Ca-
pacitated sperm were incubated with either a) DMSO
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(spontaneous AR as negative control); b) CaI (physio-
logical AR (10µmol/l) as positive control); c) SAF
(0.5mg/ml; test). Further, acrosomal status was as-
sessed by labeling fixed sperm with PSA-FITC by
means of a fluorescence microscope (Nikon, Japan)
and at least 200 spermatozoa were differentiated
blindly according to the fluorescence pattern of their
acrosomes (bright fluorescence: acrosome intact; no
fluorescence or only fluorescence of the equatorial seg-
ment: loss of acrosomal membranes). The percentage
of AR spermatozoa obtained in negative control
(16%) after staining with PSA-FITC, were consistent-
ly lower than those incubated with SAF (88.8%) and
positive control (75%). 
Further, SAF was conjugated with FITC using FITC
Protein Labelling Kit (Banglore Genei, Pvt. Ltd, In-
dia) to check the binding of SAF to spermatozoa and
results showed florescence on spermatozoa indicating
the presence of receptor on surface of spermatozoa
for SAF. 
Using SAF as tool, receptor on spermatozoa was iso-
lated and purified. Briefly, washed spermatozoa were
treated with 1, 2, 3 and 4M NaCl for different time
intervals. The salt treated sample was then centrifuged
at 1500 rpm for 20 min. Both cell debris and super-
natant were dialyzed against PBS at 4°C overnight,
concentrated against polyethylene glycol (PEG) 6000
and checked for blocking of agglutination induced by
SAF. It was observed that the receptor of interest
could be extracted by 2M NaCl when incubated for
18h at 37°C at 150rpm. The purification of receptor
was carried out using gel filtration technique. Con-
centrated receptor was applied to Sephadex G-200
column (2 cm x 31 cm) equilibrated and eluted with
PBS. Fractions (4-5) representing receptor were
pooled, concentrated and analysed by SDS-PAGE.
Results indicated a single protein of molecular weight
~125 kDa (Fig. 1).
Blocking studies were performed to check the rever-
sion of adverse effects induced by SAF. The MEC of
receptor required to block agglutination and death of
spermatozoa induced by SAF after 20s was found to be
1.0 and 1.5 mg/ml respectively. The SEM analysis re-
vealed no morphological alterations on human sperm
when treated with ligand (1.2 mg/ml) in presence of
receptor (1 mg/ml). 
A comparison of the inducibility of acrosome reaction
in presence of SAF showed significant differences from
samples incubated with SAF and receptor. Receptor at
0.80 mg/ml could inhibit the AR induced by SAF.
These results indicate that in the presence of receptor,
SAF could not induce AR (Fig. 2). 
Further, the enthalpy of binding of ligand with the re-
ceptor was determined in PBS using a microreaction
calorimeter. Two experimental vials (reference and
test) filled with 1.5ml of receptor dissolved in buffer
were placed in each of the calorimetric blocks main-
tained at 37°C. A 250µl syringe was loaded with the
buffer in case of control experiment and with ligand
in case of test experiment. The experiment was con-
ducted using the titration mode of addition of an in-
jection of ligand solution. The binding constant, K
(765/M) and enthalpy of binding, ∆H° (-10.4
kJ/mole), were computed from the experimentally
calculated enthalpy of interaction between ligand and
receptor, using iterative non-linear least square regres-
sion method. The values of free energy and entropy
were found to be -17.11 kJ/mole and 23 J/moleK, re-
spectively (Table 1).
In conclusion, this study identifies a receptor-ligand
interaction between E. coli and spermatozoa that re-
sults in adverse effects on spermatozoa like sperm ag-
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glutination, acrosome loss and death. The sperm ag-
glutinating factor may be one of the important factors
playing role in sperm damage during infection and
isolation of corresponding receptor might act as pro-
tective measure.
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TABLE 1.
S. No. Ligand Receptor Heat released
(µmoles) (µmoles) (mJ)
1 3.53x10-4 2.4x10-3 -35.9
2 7.04x10-4 2.4x10-3 -99.3
3 10.56x10-4 2.4x10-3 -55.7
4 2.1x10-4 2.4x10-3 -56.3
5 4.2x10-4 2.4x10-3 -58.1
6 6.3x10-4 2.4x10-3 -57.8
7 8.4x10-4 2.4x10-3 -58.7
8 11.0x10-4 2.4x10-3 -58.6
9 12.6x10-4 2.4x10-3 -61.5
Introduction 
The success of pregnancy depends largely on adequate
implantation, transformation of spiral arteries as a re-
sult of trophoblast invasion and establishing adequate
blood flow in the mother-placenta-fetus. These
processes are violated because of a specified hereditary
thrombotic tendency when desynhronisation process-
es of fibrinolysis and fibrin production during implan-
tation occur. Under the conditions that formed at the
same time, the activity of proteases that are synthe-
sized by blastocyst becomes relatively insufficient to
destroy the extracellular matrix in the endometrium
and immersed in sufficient depth.
Given the peculiarities of the physiological adaptation
of coagulation in pregnancy, the absolute majority of
genetic and acquired forms of thrombophilia is clini-
cally manifested during the gestational process and, as
it turned out, not only in the form of thrombosis, but
also in the form of common obstetric complications,
and the role of different forms of thrombophilia in
their pathogenesis and structure varies.
Thus, according to data Makatsaryya A. et al. (9), FV
Leiden mutation frequently occurs in patients with
late miscarriage (15%). Prothrombin G20210A muta-
tion occurs significantly less frequently in all groups of
reproductive losses (compared with AFA, FV Leiden
and MTHFR S677T) and is 4.2 and 3% in groups of
early and late miscarriages.
Hormones feto-placental complex have different ori-
gins, being synthesized by cytotrofoblast and fetal ad-
renal glands. Changing their synthesis may indicate a
violation of the processes of formation and develop-
ment of the placenta and, therefore, serve as an early
marker of possible development of complications of
pregnancy such as IUGR, preeclampsia and premature
birth. Thus, according to modern concepts, the most
likely pathogenic mechanism of formation of these
complications are different forms of thrombophilia
and their combinations.
The significance of changes in the concentration of
various hormones feto-placental complex (estriol, pla-
cental lactogen, HCG, PAPP) are different.
Often, various complications gestational process ac-
companied by lower concentrations of PAPP-A in
maternal serum in the first trimester of pregnancy.
Very difficult to answer the question of whether the
content is lower serum PAPP-A compensatory re-
sponse or a manifestation of this breakdown of com-
pensatory mechanisms that ensure the safe outcome
of pregnancy.
Gagnon A. and colleagues (5) published a large analyt-
ical studies conducted on materials Cochrane database
and covered publications from 1966 to 2007. In the
presented output shows that the inexplicable reduc-
tion of PAPP-A (<0,4 MoM) and / or β-HCG (<0,5
MoM) in the first trimester of pregnancy is associated
with adverse obstetric outcomes outside depending on
the therapy.
The aim of the study. To analyze the concentration of
hormones feto-placental complex I and III trimesters
in patients with different types of hereditary throm-
bophilia and their combinations.
Materials and methods
78 patients who had given a birth were examined. Pa-
tients are divided into 2 groups: The first - 61 patients,
the carrier of inherited thrombophilia (factors II, V,
MTHFR) and the second, control group consisted of
© Copyright 2012, CIC Edizioni Internazionali, Roma
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17 patients who are not carriers of mutations of genes
of hemostasis.
In addition, patient of the main group were divided
into subgroups: subgroup A-18 female patients who
are carriers of multigenic thrombophilia, subgroup B -
18 patients - carriers of homozygote mutations of
MTHFR, subgroup C - 25 patients - carriers of het-
erozygote mutations of MTHFR.
The biochemical markers of chromosomal pathology
(PAPP - A, β-HCG) of the patient serum in the 11-13
weeks of pregnancy were examinated. Their values were
estimated in MoM, which were used later to calculate
the risk of chromosomal pathology by the program
“ALFA”, UK. In the third trimester (30 weeks to term)
the concentration of estriol and placental lactogen were
evaluated, a value estimated in nmol / l and mg / L, re-
spectively. Reduction concentrations of the investigat-
ed markers was ascertained with a decrease in PAPP-A
and hCG less than 0.5 IOM, estriol - by 30-50% of the
standard for gestational indices, placental lactogen –
less than average meaning for term of pregnancy.
Results
In patients I group concentrations of serum markers in
first trimester (PAPP-A, β-HCG) less than 0,5 MoM
noted in 8 and 10 cases respectively, while in the con-
trol group similar changes were reported only in 0 and
3 patients respectively.
In the third trimester estriol was more variable indica-
tor, reducing the concentration of which was recorded
in 5 patients of the main group, while in the control
group it is not significantly reduced. Concentrations
of placental lactogen was reduced only in 1 patient of
main group.
Conclusions
In pregnant women with hereditary thrombophilia in
the study of biochemical markers of the first trimester
(PAPP-A and β-HCG) significantly more often found
their decreasing below 0.5 MoM, including simulta-
neous, compared with patients without mutations in
the genes system of hemostasis. The examination has
revealed that there was a decrease of estriol level in the
third trimester among the patients in the main group
compared to the controls.
The most significant changes in feto-placental com-
plex hormones in all stages of pregnancy are found in
patients with multigenic thrombophilia. For those
pregnant women reduction, especially synchronous,
level of biochemical markers (PAPP-A, β-HCG) in the
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TABLE 1 - CONCENTRATION OF MARKER PROTEINS OF FETO-PLACENTAL COMPLEX  REDUCTION IN PATIENTS
WITH HEREDITARY THROMBOPHILIA.
Group Reduction of Reduction of Combined reduction Reduction of Reduction of
PAPP-A level, n (%) β-HCG level, n (%) of PAPP-A and β-HCG, n (%) estriol level, n (%) prolactin level n(%)
I (N61) 8(13) 10(16,3) 5(8,2) 5(8,2) 1 (1,6)
II (N17) 0 3(18) 0 0 0
TABLE 2 - CONCENTRATION OF MARKER PROTEINS OF FETO-PLACENTAL COMPLEX REDUCTION IN PATIENTS
WITH DIFFERENT GENETIC VARIANTS OF THROMBOPHILIA.
Subgroup Reduction of Reduction of Reduction of Reduction of
PAPP-A level, n (%) β-HCG level, n (%) estriol level, n (%) prolactin level n (%)
A (N18) 3(16,5) 3(16,5) 2(11) 0
B (N18) 3(16,5) 4(22) 2(11) 1(5,5)
C (N25) 2(9) 3(13,5) 1(4,5) 0
TABLE 3 - MEAN VALUES OF PROTEIN MARKERS OF FETO-PLACENTAL COMPLEX IN PREGNANT WOMEN WITH HE-
REDITARY THROMBOPHILIA.
Subgroup, Group PAPP-A level, MoM β-HCG level, MoM Estriol level, ng/l Prolactin level mg/l
A (N18) 1,03 0,84 12,6 3,5
B (N18) 1,05 1,3 23,9 4,4
C (N25) 1,59 1,54 22,7 4,3
Group II (N17) 1,6 1,62 28,8 5.32
first trimester may be predictor of later obstetric com-
plications that require additional examination, moni-
toring and, if necessary, treatment.
In patients with homozygote mutation of gene MTH-
FR, which has a higher risk of thrombophilia in the
third trimester, the most important are markers of the
first trimester, reduction level PAPP-A, β-HCG below
0.5 MoM can also serve as a basis for further monitor-
ing of coagulation as well as a feto-placental complex.
There were no significant deviations in marker FPC
compared with the control group in patients with het-
erozygote mutation of gene MTHFR, which may in-
directly indicate a lack the risk of thrombophilia and,
as a result, feto-platsentarnoy dysfunction that leads to
later obstetric complications.
More sensitive and, importantly, early markers of
hereditary thrombophilia and as a consequence, vari-
ous obstetric complications are indicators I trimester
PAPP-A and β-HCG
The data continue to accumulate and be processed be-
cause, despite numerous studies now have not had the
unequivocal scientific conclusion about the possibility
of using biochemical markers for the prediction of fe-
to-placental dysfunction. These data require clarifica-
tion and systematization for the formulation and de-
velopment of clear prognostic criteria of obstetric
complications.
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Objective
Determining the male factors in infertile marriage.
Sterilitas may be diagnosed when one woman is’nt
pregnant after one year with not protective inter-
course; 1/3 of couple arrived conception after three
months of married, and 80% arrived success in the
first year of married.
Infertility is termed primary when it occurs with-
out any prior pregnancy, and secondary when it
follows a previous conception.
Male factor is present in 30-40% of couples, when
12-15% of sterile married are steril without its
hope.
Here is present: Defect of spermatogeneses, anom-
alies of genital male tract.
Female factor is present in 40-50%. There are
many factor which is: infection of cervix uteri,
vaginitis, uterin factor, endocrinology factor.
Idiopatic factor is present in 5-10% of cases.
Aims
1. Verification of male factor in infertile couple.
2. Analysis of social factors.
Methodology
We prospectively studied history in the period January
2011-December 2011.
Results
On the 1000 cases, 463 or 46.3% were diagnosed in
the group of infertile patients. Of these,  90 (19.4%)
as a cause of male infertility (Tables 1 and 2) on this
marriages. Treatmant of sterile couple: spermiogram,
uterin–tubal factor, cervical factor, ovulation, hor-
monal status, endometrial biopsy, laparaskopy.
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Male factor 
90 cases 
19.4% 
Olygoastenospermia 
43 cases 
47.7%  
Olygospermia 
28 cases 
31.1% 
Azospermia 
19 cases 
21% 
TABLE 2
Spermiogram analysis Nr of cases %
Olygoastenospermia 43 47.7%
Olygospermia 28 31.1%
Azospermia 19 21.1%
Total 90 99.9%
TABLE 1
Conclusion
The high percentage of decreased male fertility ability
in sterile marriages indicates that in the diagnostic
procedure and treatment both partners should be sub-
ject to procedures for research, and determine which
of the partners is the cause.
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Objective and methods
To review the evidence and provide recommendations
on screening for and management of bacterial vagi-
noses (BV) in pregnancy.
Examined 286 women were divided into three re-
search groups. We have on the first group included
102 women with clinical signs of abortion in the sec-
ond group as ab habitualis 89 women, 95 women and
group checks (Table 1). This study is prospective and
was conducted in Obstetrics Gynecology Clinic in
Pristina in the period januar 2011-december 2011.
We analyze vaginal swabs of 286 pregnant women.
Obtained vaginal swabs are processed in the Microbi-
ology department of the National Institute of Public
Health Institute in Pristina. The results obtained were
subjected to statistical analysis.
Evaluation include: antibiotics treatment efficacy and
care rates, and the influence of the treatment of bacte-
rial vaginosis on the rates of the advance pregnancy
outcomes such as preterm labour and delivery and pre-
term premature rupture of membranes.
Bacterial vaginosis may be diagnosted when one
woman have more vaginal discharge.
The presence of BV heightens a nonpregnant womans
risk for pelvic inflammatory disease (PID) postopera-
tive infections and HIV transmission, and the pres-
ence of BV in pregnant woman may be caused of abort
in early pregnancy and preterm labory.
History: Pruritus burning, malodorous discharge
(worsened during menses) after intercourse.
Aims
1. Verification of the causes of abortion (Ab) with BV
in early pregnancy.
2. Role of iron in patients with BV.
3. Analysis of social factors.
4. Analysis of vaginal discharge in pregnant woman.
5. Influence of bacterial vaginosis in imminent abor-
tion.
6. Influence of bacterial vaginosis in habitual abortion.
Results
According week gestation with the highest prevalence
of bacterial vaginosis was found in week 6-9, with 24
cases or 48.0% prevalence, but was lower in recent
weeks gestacion.This changes were statistical signifi-
cant. (P <0,05) (Table 2).
Screening and management of bacterial vaginosis in pregnancy
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%
TABLE 2.
Gestation week Ab imminens Ab habitualis Normal pregnancy Total
N % N % N % N %
-5 3 2.9 0.0 0.0 3 1.0
6-9 25 24.5 17 19.1 8 8.4 50 17.5
10-15 43 42.2 51 57.3 21 22.1 115 40.2
16-21 20 19.6 17 19.1 47 49.5 84 29.4
>22 11 10.8 4 4.5 19 20.0 34 11.9
Total 102 100.0 89 100.0 95 100.0 286 100.0
TABLE 1.
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Bacterial vaginosis are associated with other micror-
ganisms: in 21.7% of cases have been with E. coli with
prevalence was 13.8%, while 8.0% Enterococcus pres-
ence (Table 3). So the presence of these bacteria may
trigger the search for bacterial vaginosis.
The use of iron has affected level of bacterial vaginosis,
which has been higher in pregnant who have used iron
39.1% compared with those who have not used
23.9%. These differences have been with statistical
values, (p <0.05) (Tables 4 and 5).
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prevalence BV
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Iron
%
Ab imminens Ab habitualis Normal pregnancy Total
N % N % N % N %
Candida species 27 26.5 16 18.0 17 17.9 60 21.0
Escheria coli 12 11.8 12 13.5 5 5.3 29 10.1
Enterococcus 3 2.9 16 18.0 6 6.3 25 8.7
Others 8 7.8 7 7.9 7 7.4 22 7.7
Total 102 100.0 89 100.0 95 100.0 286 100.0
Iron Ab imminens Ab habitualis Normal pregnancy Total
N % N % N % N %
No 53 52.0 34 38.2 30 31.6 117 40.9
Yes 49 48.0 55 61.8 65 68.4 169 59.1
Total 102 100.0 89 100.0 95 100.0 286 100.0
TABLE 3.
TABLE 4.
TABLE 5.
Background
Endometriosis affects approximately 10% of women
of reproductive age and is associated with inflamma-
tion and increased estrogen production. 
The main clinical features are chronic pelvic pain, pain
during intercourse and infertility. 
The mechanisms by which endometrial tissues attach,
proliferate, avoid immune surveillance and derive a lo-
cal vasculature at ectopic sites are not well understood
but include dysregulated estrogen and pro-inflamma-
tory cytokine production and activity. 
The medical treatment of endometriosis is limited due
to high costs, adverse side effects and chances of recur-
rence after discontinuation of therapy. 
Thus there is an unmet need for new drugs which in-
hibit the progression of endometriosis and alleviate
pain and infertility, without affecting ovulation. The
aim of this study was to evaluate the effects of the
eicosanoid Lipoxin A4 (LXA4), which exhibits both an-
ti-inflammatory and pro-resolving properties, in a
mouse model of endometriosis. 
Material and methods 
Endometriosis was surgically induced in 8-9 week old
wild type female C57/BL6 mice. 10 mice per group
received either vehicle or 5µg/kg LXA4 a day for 21
days by intraperitoneal injection.
Results 
A significant (p<0.01) reduction in lesion volume was
observed in the LXA4-treated group (1.2±0.2mm
3) vs.
vehicle-treated mice (2.6±0.36 mm3). The anti-inflam-
matory effects of LXA4 included atteutation of IL-1β
mRNA expression (100%±6.0 vs. 54±3.5). LXA4 also
attenuated the expression of HIF-1α (100±4.2 vs.
70±5.2) & its target genes COX2 (100±5.3 vs.
61.3±2.0) & VEGF at mRNA (100±2.8 vs. 62±2.2),
thus displaying anti-angiogenic effects. VEGF levels in
peritoneal lavages were reduced in LXA4-treated
(5±0.95pg) compared to vehicle-treated mice
(11±0.90pg) VEGF/50µg of total protein (p<0.0001).
LXA4 also reduced the expression of ERα (100±3.6 vs.
64±3.1), cMYC (100±3.8 vs. 62±2.2) and aromatase
(100±4.4 vs. 49±2.3) indicating that this lipid may al-
so mediate anti-estrogenic and anti-proliferative activ-
ities. These novel findings provide an insight into
mechanisms underlying the decreased lesion volume
observed upon LXA4 treatment (data shown are % ex-
pression mean ± SEM, where expression in lesions of
vehicle-treated mice is normalized to 100% expression
vs. expression in lesions of LXA4-treated mice, p val-
ue<0.0001 for all genes mentioned above). 
Conclusions
Taken together these findings indicate that LXA4 could
be a possible therapeutic for peritoneal endometriosis.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common endocrinopathies in reproductive age
women, affecting approximately 6.5-8% (1,2). PCOS
is a multifactorial disease and its exact cause remains a
mystery. 
Inflammation is thought to play a role in the patho-
genesis of PCOS (3-8). Myeloperoxidase (MPO) is a
peroxidase enzyme released by azurophilic granules of
activated neutrophils and macrophages and produces
hypochlorous acid (HOCl) and chloride anion (Cl)
(9). HOCl, which is an oxidizing species leading to
oxidative tissue damage, plays a role in the pathogene-
sis of atherosclerosis. Thereby, it has been found to be
related to cardiovascular disease (10-12).
Adenosine deaminase (ADA) is a cytosolic enzyme
found particularly in lymphoid tissue and is increased
in immune mediated diseases such as rheumatoid
arthritis, familial Mediterranean fever, and tuberculo-
sis (13-15). ADA may also be attributed to inflamma-
tion related to coronary heart disease (CHD) (16).
We have not encountered any study evaluating serum
MPO and ADA activities in women with PCOS in the
literature. In the present study, we aimed to investigate
the role of MPO and ADA activities in PCOS. We also
aimed to study whether there was a correlation between
ADA, MPO, sex hormones, and lipids in these patients.
Material and methods
Patients and setting
The study was conducted with 45 consecutive patients
with PCOS (study group) and 40 age- and body mass
index (BMI)-matched healthy women (control group)
from the outpatient clinics of the Obstetrics and Gy-
necology Department of Yuzuncu Yil University Hos-
pital, Van, Turkey. 
The diagnosis of PCOS was based on the Rotterdam
criteria (17). The subjects had not been taking any
drugs like insulin sensitizers, oral contraceptives, an-
tiandrogens, glucocorticoids, ovulation induction
agents, or other hormonal drugs for at least 6 months
before the study. All subjects were informed about the
study protocol and written consent was obtained from
each. The exclusion criteria included Cushing’s syn-
drome, androgen secreting tumor, diabetes, nonclassi-
cal congenital adrenal hyperplasia, thyroid dysfunc-
tion, estrogen intake, and hyperprolactinemia. Free
androgen index (FAI) was computed according to the
following formula (18): Total testosterone level
(nmol/l) / sex hormone-binding globulin (SHBG) lev-
el (nmol/l) x 100.
Laboratory analysis
After an overnight fast of 12 hours, 10 cc of venous
blood was taken from each woman during the early
follicular phase (between days 3 and 5) of the sponta-
neous or progestin-induced menstrual cycle between 8
AM and 10 AM. Then 2 cc was separated to assay
MPO and ADA activities. The serum samples were
obtained by centrifuging blood samples at 3000 rpm
for 15 min at 4°C and were stored at -80°C until
analysis. MPO and ADA were analyzed at the Depart-
ment of Medical Biology of Yuzuncu Yil University.
The serum concentrations of luteinizing hormone
(LH), follicle-stimulating hormone (FSH), total
testosterone, and estradiol were assessed by chemilu-
minescent immunoassay with an Immulite® 2000 an-
Serum myeloperoxidase and adenosine deaminase activities
in polycystic ovary syndrome
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alyzer (Diagnostic Products Corp., Los Angeles, CA,
USA) and SHBG was analyzed by chemiluminescence
microparticle immunoassay (Architect SHBG reagent
kit; Biokit, Barcelona, Spain for Abbott Laboratories
Diagnostic Division). 
Total cholesterol, low-density lipoprotein (LDL)
cholesterol, and triglycerides were measured by enzy-
matic colorimetric assay, using a Roche-Hitachi PP
Modular Analyzer (Roche-Hitachi, Tokyo, Japan) and
its original reagents. High-sensitive CRP (hs-CRP)
was determined using immunonephelometric meth-
ods and a BN-II analyzer (Dade Behring, Germany).
Leukocyte count was determined with an automatic
cell counter (Beckman Coulter, Coulter LH 780 Ana-
lyzer, USA).
ADA was determined by the method described by
Giusti (19) and MPO was assayed by the method de-
scribed by Bradley (20). 
Statistical analysis
Results were expressed as mean and standard deviation
(SD). Student’s t-test was performed to evaluate differ-
ences between the group means. Pearson’s correlation
coefficient was used to evaluate the relationship
among the variables, and p values <0.05 were regarded
as statistically significant. 
Results
The groups were similar with respect to mean age, BMI,
and WHR (Table 1). In the PCOS group, total testos-
terone and FAI were significantly higher in comparison
with the control group (p=0.001). Serum estradiol level
was also significantly elevated in women with PCOS
than in the controls (p<0.05). Serum FSH and LH lev-
els of PCOS patients were 4.25±1.68 and 9.24±1.86,
respectively. Although the women with PCOS had
higher hs-CRP, triglycerides, total cholesterol, and LDL
cholesterol than the healthy subjects, the difference was
not statistically significant (p>0.05) (Table 2). 
Leukocyte count was significantly higher in women
with PCOS than in the control group (p=0.001), al-
though leukocytosis was not found in either group. In
the leukocyte formula, lymphocytes, monocytes, and
neutrophils were significantly higher in the PCOS
group than in the controls (p<0.05). Although serum
MPO activity was significantly higher (p<0.05), ADA
activity was similar in women with PCOS compared
to the controls (p>0.05) (Table 3). 
There was a significant correlation between serum
ADA and hs-CRP level in the PCOS group (r=0.853
p<0.01) but we did not find any association between
serum MPO, ADA level, and serum sex hormones and
lipid profiles.
Discussion 
In our study, serum total testosterone level and FAI
were significantly higher in the PCOS group com-
pared to the controls. Cho et al. showed a higher total
testosterone level and FAI in their PCOS group and
suggested that FAI was a better marker to distinguish
hyperandrogenism in patients with PCOS (21).
Serum estradiol level was also found to be significant-
ly higher in women with PCOS than in the controls.
Amato et al. showed a low estradiol/testosterone level
in women with PCOS and associated it with chronic
oligo-anovulation and atherogenic lipid profile (22).
Chronic oligo-anovulation might cause high serum
estradiol levels in women with PCOS.
There is an interaction between the immune and re-
productive systems. In the ovary, migration of leuko-
cytes in and out of the organ is permitted by its vascu-
larization and anatomy. These leukocytes secrete nu-
merous inflammatory substances that play important
roles in the cyclic events and some ovarian disorders
like PCOS (23). In our study, we found significantly
higher leukocyte counts especially in lymphocytes,
monocytes, and neutrophils in the PCOS group com-
pared to the controls. After Orio et al. firstly demon-
strated an increased leukocyte count in PCOS (4), the
relationship between chronic low grade inflammation
and PCOS has been clarified with subsequent studies
(3,24-30). The results of most studies, including ours,
indicate an increased leukocyte count (especially the
lymphocytes, monocytes, and neutrophils), support-
ing the role of inflammation in PCOS pathogenesis.
In the present study, hs-CRP level was higher in the
PCOS group compared to the controls but the differ-
ence was not statistically significant. In some studies,
serum hs-CRP levels of women with PCOS were also
similar with the values of healthy controls (31-34). Es-
cobar-Morreale et al. reviewed the studies evaluating
the status of serum inflammatory markers in PCOS
patients. They concluded that these women had ele-
vated CRP levels in circulation independent of obesi-
ty and this result was regarded as evidence of chronic
low grade inflammation (35). The difference between
the results of the present study and their review may
be due to the relatively low number of subjects in our
groups. However, with this investigation, a significant
correlation between serum CRP and ADA levels has
been shown in normal weight women with PCOS for
the first time (p<0.01). This correlation was not de-
tected in the control group (p>0.05).
To the best of our knowledge, this is also the first study
investigating serum MPO and ADA activities in
women with PCOS. In the present study, serum MPO
level was higher in the PCOS group compared to the
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controls. Sasıkala et al. indicated that MPO was an ex-
cellent inflammatory marker and showed elevated
MPO levels in the ovarian and uterine tissues of
PCOS induced rats (36). Dursun et al. also found
higher MPO levels in gingival cervicular fluid of
women with PCOS (37). One of the mechanisms un-
derlying the pathogenesis of PCOS is chronic low
grade inflammation and MPO is an enzyme released
from activated neutrophils, and macrophages. There-
fore, the finding of increased monocyte and neu-
trophil counts observed in our study is compatible
with the elevated serum MPO activity in the women
with PCOS. Besides showing inflammation, increased
MPO level has also been associated with cardiovascu-
lar disease (10,11,16,38). 
In conclusion, PCOS pathogenesis may involve an in-
flammatory process by increasing serum MPO activi-
ty independent of sex hormones, body mass index,
and lipid profiles. Assessing the usefulness of serum
MPO activity to predict the risk of cardiovascular dis-
ease in women with PCOS may be a topic for future
studies. 
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Introduction
Sexual dysfunction and depression are common prob-
lems in patients with chronic renal failure (CRF)
(1,2). Approximately 75% of women undergoing he-
modialysis treatment have sexual problems (3).
Women with end-stage renal disease describe a de-
crease in sexual function (4). 
In these patients, psychological factors also play a role
in the mechanism of sexual dysfunction in addition to
the hormonal changes (5). The prevalence of depres-
sion in hemodialysis patients ranges from 41.7% to
58% (6,7). Sexual dysfunction as a result of biological
factors may also lead to depression. Therefore, sexual
dysfunction and depression create a vicious circle in
these patients (8). Thus, the patients with CRF should
also be managed for psychosocial well-being and sexu-
al life in addition to renal care.
We searched Pubmed in April 2011 using the key-
words “female sexual dysfunction”, “depression”, “he-
modialysis”, and “Turkey” and found only 3 studies
(8-10). However, in all of these studies, patients with
end-stage renal disease had been evaluated. We have
not seen any study evaluating both sexual dysfunction
and depression in female predialysis patients. Thus, we
aimed to investigate sexual function and psychological
status and the relation between sexual dysfunction and
depression, demographic features, and hormonal pa-
rameters in predialysis and hemodialysis patients.
Materials and methods
The study was conducted with 77 female subjects,
comprising 22 predialysis patients, 25 hemodialysis
patients, and 30 controls (Table 1). The predialysis
group consisted of randomly selected patients with
stage IV chronic kidney disease (glomerular filtra-
tion rate (GFR) = 15–29 ml/min/1.73 m2). The he-
modialysis group was composed of patients receiving
hemodialysis treatment, three times a week, 4 hours
for one dialysis procedure for at least 6 months at the
Hemodialysis Center of Yuzuncu Yil University,
School of Medicine, Van, Turkey. Healthy female
volunteers were included as controls. This study was
approved by the Ethical Committee of the universi-
ty and informed consent was obtained from all sub-
jects. The eligibility criteria included: age between
18 and 65 years, female gender, married, sexually ac-
tive, no psychiatric treatment in the previous 6
months, and the intellectual and mental capacity to
understand and answer the questionnaire. Exclusion
criteria were being younger than 18 years or older
than 65 years, being on chronic dialysis for less than
6 months (for hemodialysis patients), having a psy-
chiatric disease or infection, or having undergone
surgical menopause.
After an overnight fast of 12 h, a total of 10 cc of ve-
nous blood was taken from each woman between 8
AM and 10 AM (for hemodialysis patients, before the
dialysis). The serum concentrations of glucose, creati-
nine, phosphorous, calcium, parathyroid hormone
(PTH), follicle-stimulating hormone (FSH), luteiniz-
ing hormone (LH), prolactin, total testosterone, estra-
diol, and hemoglobin were assessed in all groups. Sex-
ual functioning was evaluated by the Arizona Sexual
Experiences Scale (ASEX). A total ASEX score ≥19,
any one item with a score ≥5, or any three items with
a score of 4 have all been found to be correlated with
sexual dysfunction (11). The reliability and validity
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study of the Turkish version of ASEX had already been
demonstrated by Soykan (12).
Depression was assessed by the Beck Depression Inven-
tory (BDI). Its 21 items were scored from 0 to 3. Each
item was rated with a four-point Likert system (13). The
BDI was adapted for Turkey by Hisli (14,15). Subjects
who had a score over 16 were classified as depressed.
Statistical analysis
The patients’ characteristics were expressed as mean ±
standard deviation (SD). When the groups were un-
equal and nonparametric, the data were analyzed using
the Kruskal-Wallis test. Comparing more than two
groups, one-way ANOVA test and then Duncan’s
method for pair-wise comparison were used for equal
and parametric groups. Pearson’s correlation analysis
was used to determine the relationships among the
variables. Odds ratios were calculated to determine the
effect of depression on sexual dysfunction. A p value
<0.05 was regarded as statistically significant. 
Results
The mean serum concentrations of PTH, FSH, and
LH were higher but estradiol and hemoglobin levels
were lower in the predialysis and hemodialysis groups
than in the controls (Table 2). 
The patients in the predialysis and hemodialysis groups
had higher mean BDI, ability to reach orgasm, and to-
tal ASEX scores than the controls (p <0.05) (Table 3).
Regarding arousal, erection/lubrication, and satisfac-
tion with orgasm, no differences were found among the
groups (p >0.05). The mean score for drive was higher
in the hemodialysis group than in the control group (p
= 0.04). The patients in the predialysis group were 6
(odds ratio: 6.00, CI: 1.68–21.48) and 3.8 times (odds
ratio: 3.8, CI: 1.09–13.18) more likely to develop de-
pressive symptoms compared to the controls and he-
modialysis patients, respectively. In the hemodialysis
group, the patients with and without depression did
not show any significant difference with respect to the
development of sexual dysfunction (p = 0.126). How-
ever, the patients with depression were 24 times more
likely to develop sexual dysfunction compared to the
patients without depression in the predialysis group
(odds ratio: 24 CI: 2.06–27.49). In the predialysis
group, age and mean serum FSH and LH levels were
positively correlated with arousal and erection/lubrica-
tion scores (p <0.05). BDI score was positively correlat-
ed with total ASEX score (r = 0.474, p <0.05) in the
predialysis group and with satisfaction with orgasm
score (r = 0.563, p <0.01) in the hemodialysis group
but we did not find any correlations between BDI score
and gonadotropins or other hormones (Table 4).
Discussion
Decreased libido and reduced ability to reach orgasm
are common problems in women on dialysis (16,17).
However, there are few studies about female sexual
dysfunction in predialysis patients. Basok et al. showed
reduced desire, arousal, orgasm, and satisfaction in
predialysis patients compared to controls (18). In our
study, total ASEX score was higher in predialysis and
hemodialysis patients compared to the controls, re-
flecting impaired sexual function (p = 0.016). We
found reduced ability to reach orgasm in both the pre-
dialysis and hemodialysis groups. We also noted that
sexual desire was significantly lower in the hemodialy-
sis group compared to the predialysis and control
groups (p = 0.04). Therefore, we may conclude that
hemodialysis treatment reduces sexual desire and leads
to sexual failure.
The occurrence of sexual dysfunction is multifactorial.
Berman et al. showed that older women and
menopausal women who did not use hormone re-
placement therapy had significantly lower physiologic
response by sexual stimulation (19). Peng et al. noted
that sexual dysfunction was common in female he-
modialysis patients and they found strong relation be-
tween sexual dysfunction and increasing age and de-
pression (20). Oksuz et al. and Cayan et al. also
showed increasing in sexual dysfunction with age
(21,22). In our study, we found a significantly positive
correlation between age and arousal, erection/lubrica-
tion, and total ASEX score in predialysis patients. In-
creasing age may be related to vascular insufficiency,
decreased estrogen concentration in circulation, de-
creased blood flow and function of urogenital organs,
and changes in body image. 
Anemia is associated with sexual dysfunction in pa-
tients with end stage renal disease (23,24). In our
study, we did not find any correlation between ASEX
scores and hemoglobin levels. This may have resulted
from the low number of patients in our study. 
Anovulatory cycles are frequent in uremic women
(25). The features of uremic hypogonadism in women
were composed of elevated gonadotropins and pro-
lactin and decreased estradiol levels (26,27). Distur-
bances in reproductive hormones may impair hypo-
thalamic-pituitary function and lead to sexual dys-
function (1,18). In the present study, we found higher
serum PTH, FSH, and LH and lower estradiol levels
in the predialysis and hemodialysis groups than in the
control group. In addition to hypothalamic-pituitary
dysfunction, vaginal dryness and atrophy due to the
reduced estrogen concentration may cause decreased
lubrication and discomfort during intercourse.
Besides hormones, psychological factors also influence
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the sexual life in women with CRF [20,28,29]. De-
pression rates ranged from 24.1% to 58% in women
with CRF (7,30). We noted depression in 54.5% and
24% of predialysis and hemodialysis women, respec-
tively. We also found that predialysis patients were 6
and 3.8 times more likely to develop depression com-
pared to the patients in the control and hemodialysis
groups, respectively. This may be associated with the
lack of behavioral compliance in predialysis patients
before dialysis treatment. These patients may be anx-
ious due to uncertainty about their health after this
and so this situation may result in stress and cause de-
pression. We also found that sexual dysfunction was
up to 24 times more common in depressive women in
the predialysis group.
In conclusion, female predialysis patients seem to be
more likely to have depression and those with depres-
sive symptoms may be at higher risk of developing sex-
ual dysfunction. In these patients, increased go-
nadotrophin levels and age may be the other contribut-
ing risk factors for developing this sexual dysfunction.
Therefore, prompt gynecologic and psychiatric evalua-
tion of female predialysis patients in terms of their psy-
chological and sexual aspects might be advisable. Fur-
ther studies with higher numbers of patients are need-
ed to obtain more information on this topic.
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TABLE 2 - COMPARISON OF BIOCHEMICAL, HORMONAL AND CLINICAL CHARACTERISTICS OF PREDIALYSIS, HE-
MODIALYSIS AND CONTROL GROUPS.
Predialysis (n=22) Hemodialysis (n=25) Control (n=30) P
Glucose (mg/dl) 95 ± 14.13 93.23 ± 11.47 91.07 ± 9.31 0.48
Creatinine (mg/dl) 3.05 ± 1.56 a 7.15 ± 2.63 b,c 0.65 ± 0.13 0.001*
Hemoglobin (g/dl) 10.57 ± 1.66 a 10.91 ± 1.90 b 13.18 ± 2.84 0.003*
Serum phosphorous (mg/dl) 4.15 ± 0.83 5.33 ± 2.25 b,c 3.43 ± 0.55 0.001*
Total serum calcium (mg/dl) 8.82 ± 0.67 a 8.57 ± 0.97 b 9.24 ± 0.50 0.004*
Intact PTH (pg/ml) 265.05 ± 253.64 a 358.33 ± 317.36 b 60 ± 26.03 0.001*
Single-pool Kt/V – 1.43 ± 0.23 –
FSH (mIU/ml) 53.68 ± 9.43 a 43.45 ± 11.04 b 15.30 ± 4.27 0.003*
LH (mIU/ml) 36.19 ± 6.64 a 39.43 ± 9.54 b 8.52 ± 1.68 0.001*
Prolactin (mIU/ml) 18.88 ± 15.76 42.69 ± 24.94 b,c 18.19 ± 14.66 0.001*
Total testosterone (ng/ml) 0.68 ± 0.25 0.65 ± 0.22 0.69 ± 0.20 0.06
Estradiol (pg/ml) 45.81 ± 13.09 a 48.38 ± 10.73 b 81.52 ± 14.30 0.03*
PTH=parathyroid hormone, FSH=follicle-stimulating hormone, LH=luteinizing hormone.
a predialysis versus control
b hemodialysis versus control
c predialysis versus hemodialysis
TABLE 1 - DEMOGRAPHIC CHARACTERISTICS OF PREDIALYSIS, HEMODIALYSIS AND CONTROL GROUPS.
Predialysis (n=22) Hemodialysis (n=25) Control (n=30) P
Age (year) 43.68 ± 7.99 45.04 ± 10.58 42.57 ± 10.84 0.56
BMI (kg/m2) 26.61 ± 5.40 24.86 ± 5.99 25.15 ± 3.90 0.54
Gravidity (number) 8.84 ± 4.34 a 7.32 ± 3.17 b 3.92 ± 3.71 0.001*
Duration of CRF (month) 46.09 ± 44.99 52.92 ± 37.36 – 0.57
Duration of dialysis (month) – 41.36 ± 35.10 –
Education (%) 0.01*
None 19 (86.4%) a 18 (72%) b 11 (36.7%) 0.005*
Primary school 3 (13.6%) a 7 (28%) 11 (36.7%) 0.04*
High school – – 4 (13.3%)
University – – 4 (13.3%)
Occupational status (%) 0.11
Unemployed 22 (100%) 24 (96%) 25 (83.3%)
Employed – 1 (4%) 5 (16.7)
Monthly income (won) 0.23
<634 $ 10 (45.5%) 12 (48%) 8 (26.7%)
>634 $ 12 (54.5%) 13(52%) 22 (73.3)
BMI=body mass index, CRF=chronic renal failure, $=United States Dollars
*p<0.05, a predialysis versus control, b hemodialysis versus control.
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Introduction
Several risk factor must be taken into consideration
approaching the prevention of osteoporosis in post-
menopausal subjects such as low body weight, mater-
nal history of fractures, falls and direction of falls, pre-
vious long period of oligo-amenorrea and some sec-
ondary causes of osteoporosis. The well known main
cause of iatrogenic osteoporosis is the glucocorticoid
therapy (1). In recent decades it has been registered a
widespread increasing use of synthetic GCs for the
treatment of autoimmune, reumathologic, pulmonary
and gastrointestinal disorders. The GC use is frequent
in aging people but is growing the use of these drugs
in several diseases in young women too often during
the transitional menopausal period. GC-induced os-
teoporosis, alike the postmenopausal osteoporosis,
mainly affects the trabecular bone determining a
BMD quick fall as a result of excessive bone resorption
(2) this leads to an increased risk of fractures which
may occur even few months after the start of the ther-
apy (3). 
In 60-year or older postmenopausal women decreased
levels of estradiol are associated with a substantial in-
crease of fractures (4) while during the early
menopause even the osteopenia might be associated to
fractures especially if combined with multiple risk fac-
tors. 
The aim of the study was to analyze the potential ef-
fects and consequences of CG treatment without any
preventing treatment in an outpatient cohort of sub-
jects who were referring to their physicians for a fol-
low-up visit in comparison with a large sample of
healthy postmenopausal women. Therefore the pur-
pose of our investigation was to highlight the impor-
tance of the G-C therapy in the female population as
a decisive risk factor for osteoporosis and fractures if
associated with early postmenopausal period. 
Materials and methods
Adult patients attending the multicenter cohort study
EGEO (GC and Osteoporosis Epidemiology) organ-
ized by Lazio GISMO group (Italian Group for Diag-
nosis of Bone Metabolism Diseases) were interviewed
and submitted to an established questionnaire. The
EGEO study was designed with the aim to study the
local epidemiology of the glucocorticoid-induced os-
teoporosis (GIO) and involved patients taking long
term GC therapy. At the same time even patients at-
tending the centre for menopause and osteoporosis of
our institution between February 2009 and November
2010 were interviewed and submitted to the same
questionnaire. Three hundred and fifty one women
were enrolled. 192 patients having had prescription of
glucocorticoids for different purpose were compared
with 139 postmenopausal patients and 20 pre-
menopausal woman. No subjects had hormonal re-
placement therapy or antiosteoporotic therapy.
Menopausal patients were women who had experi-
enced amenorrhea for over 12 months. All patients
had received a diagnosis of osteopenia or osteoporosis
in the lumbar spine (L1-L4) or femur by DXA Lunar-
DPX or Hologic according the 1994 WHO criteria.
No patients had previous GC treatments.
Data were recorded and provided information
about age, BMI, family fractures history, sponta-
neous or consequent to falls from standing position
fractures, numbers and sites of fractures, the most
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recent bone mineral density available test (prefer-
ably the Dual-Energy-X-Ray Absorptiometry (DXA).
Therefore information about glucocorticoid therapy,
type of molecule, dosage and duration of therapy as
well as type of antiresorptive drugs and/or calcium and
vitamin D supplementation and hormonal therapy
were collected. All patients were interviewed by
trained dedicated personnel. Reported fractures have
been assessed by radiological diagnosis.
Statistical analysis
Quantitative variables were tested for normal distribu-
tion and compared by means of two-tailed t-test. Dif-
ferences in groups were assessed by use of the χ2 test
and Fisher’s exact test. Data through the manuscript
are expressed as mean + SD. A P value less than 0.05
was considered statistically significant. 
Results
Three hundred and fifty one patients were included in
the study: 192 female patients who had GC treatment
for longer than 3 months without any anti-osteoporot-
ic treatment (22 patients were premenopausal and 170
postmenopausal), 139 control postmenopausal and 20
premenopausal women. No patients had hormonal
therapy or other treatment for osteoporosis.
Table 1 - Depicts the demographic and clinical fea-
tures of GC-treated patients and of healthy control pa-
tients. The two groups didn’t differ for age, BMI and
family history of falls
Table 2 - Shows clinical and densitometric data in
GC-treated patients and in pre e postmenopausal sub-
jects according to the age.
Among the GC treated subjects under 50 years the per-
centage of osteopenia /osteoporosis was significantly
higher than in the premenopausal subjects of corre-
spondent-age (P<0.001). Menopausal patients between
50 and 65 years showed a significant higer mean T
score than GC treated patients. Therefore in spite of a
similar percentage of normal T score in the two groups
and a significant higher percentage of osteopenia in
menopausal subjects (58,5% vs 32.9% p<0.01) the
percentage of ostoporosis among GC treated patients
was significantly higher (30% vs 7.3% 0.001). In the
older menopausal population (over 65 years) the preva-
lence of osteopenia was hardly higher in GC treated pa-
tients but the osteoporosis prevalence was similar.
The distribution of fractures among age-selected
groups was illustrated in the Figure 1.
Fragility fractures occurs in GC treated patientswith a
doubled or tripled frequencies in comparison with
control subjects.
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TABLE 1.
GC treated Control woman
Age 63,7±11 68,2±14
BMI 25,2±4,5 26,2±5
Family hystory of falls) 22% 20%
Duration of therapy 3-6 months 12%
6-12 month 16%
> 12 month 72%
Type of disease treated Rheumatologic 62%
Pneumatologic 22%
Dermatologic 4%
Other 12%
TABLE 2.
GC treated patients Menopausal subjects
premenopausal postmenopausal
<50 years 50-65 years >65years
<50 years 50-65 years >65years22 pts 79 pts 91 pts
20 pts 58 pts 61 pts
Age 43±2 58,7±4,2 72,5±5,3 46±3,5 56,8±4,4 69,8±3,2
BMI 22,7±3 24,2± 3,5 24,4± 3,5 25,3±4 26,8±3,9 27,2±5
T score L1-L4 (DEXA) -2,05±1,2 -2,3±1 -2,5±1 -0,63±1 -1,1±1 -1,8±0,8
Osteopenia % 37% 32,9% 47,3% 11% 58,5% 31,8%
Osteoporosis % 22,2% 30,3% 40,6% 0% 7,3% 38%
Fig. 1 - Percentage of fragility fractures.
Discussion
The use of GC in the treatment of autoimmune, pul-
monary, and gastrointestinal rheumatologic disorders
has been increasing in the last decade (2,5-8). Despite
the knowledge of the deleterious effects on skeletal bone,
till now few patients receiving GC therapy are consid-
ered at risk for bone loss. Indeed our sample of GC treat-
ed patients who haven’t had any preventing treatment
coming from the observational regional study EGEO
represent the 45% of the entire female cohort. The mod-
est attention to the GIO prevention brings about serious
consequences in the menopausal population.
Several mechanisms involved in bone loss induced by
GC therapy are well known (2): many of them cause
changes of bone metabolism similar to those induced
by estrogen loss, so that there might be likeness be-
tween two types of osteoporosis while some differences
must be significant. 
In patients GC treated the loss of bone mineral densi-
ty is biphasic; a first phase, within the first years of
treatment, determines a loss of 6-12% and a second
phase showing a reduction of approximately 3% year-
ly (1). The postmenopausal bone density reduction is
estimated to be about 0.5-3% yearly with higher bone
loss in the early period of menopause (9).
The effects of GC therapy in young population appear
to be really deleterious. Our young GC-treated popu-
lation (consisting in 22 premenopausal women and 5
early menopausal subjects) shows a worrying low
mean vertebral T-score with a significant higher per-
centage of osteoporosis in comparison with the corre-
sponding menopausal population (aged from 30 to
50, with 4 subjects with early menopause less than
40years). Particularly the incidence of fractures was
very high confirming the fact that GC treatment wors-
ens the bone strength affecting not only the bone den-
sity but even the bone quality. 
The risk of fracture was found to increase with doses
of drugs and length of therapy therefore patients who
were precociously GC treated and hadn’t prophylactic
measures at the menopausal period are at special risk
of fractures. 
Our data show that in the GC-treated menopausal pop-
ulation the prevalence of osteoporosis was significantly
higher than in control menopausal subjects. The inci-
dence of vertebral and non vertebral fractures was al-
most doubled or tripled in over 65 GC treated patients. 
Considering the istomorphometric features several
studies showed that osteoporosis GC induced is char-
acterized by fewer osteoblasts and an increased preva-
lence of osteocyte apoptosis (10). Glucocorticoids ex-
cess directly reduces osteoclast production even if the
lifespan is prolonged. Therefore, with long-term ther-
apy, the number of osteoblasts is reduced as well as the
bone formation (11) consequently the bone strength is
deeply compromized. The estrogen deficiency is asso-
ciated with an increase in lifespan of osteoclasts and
characterized by concomitant decrease in osteoblasts
action and lifespan (12). These effects are also accen-
tuated by the preresorptive action of iperPTHrp (13)
resulting in an extensive calcium mobilization.
Fractures decline after discontinuation of GC-therapy
(3) while patients becoming osteopenic or osteoporot-
ic approaching menopause, according to our data, the
fracture increases the risk of fracture.
This study highlighted the idea that in GC-treated pa-
tients (above all if they haven’t a right preventive ther-
apy) keep a damage in the skeletal structure which is
increased with an additive effect by menopause. 
The importance of this study is the precise assessment
of osteoporosis risk factors which may help to guide
any early intervention.
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Case report
A 34-year old female, with no background medical
history, presented with nocturia, polyuria, polydipsia
and abrupt cessation of menses a year post partum.
Her preceding pregnancy was uneventful, although
she delivered a pair of twins. She was a non-smoker,
non-alcoholic with a family history of diabetes (father
had type 2 diabetes on oral hypoglycemic agents).
Immediately post partum, she noted increased thirst
with a strong craving for cold drinks. She was evaluat-
ed for a suspicion of diabetes mellitus and reassured on
two occasions that random blood glucose was normal.
She had consulted a gynecologist for abnormal menses
and was started empirically on bromocriptine for a
mild hyperprolactinaemia (Prolactin = 55.7ug/L, NR
5-27.7 ug/L). 
Four months later, she presented with blurring of vi-
sion, mild headaches and progressively severe polyuria
(in excess of 7 liters a day), associated with poor ap-
petite and weight loss. She was investigated by her gy-
naecologist and a diagnosis of new-onset type 2 dia-
betes was made (random glucose 26.5 mmol/L). De-
spite optimal glycaemic control using glibenclamide
and metformin, her symptoms of polyuria and poly-
dipsia persisted.
Endocrine testing suggested diabetes insipidus (serum
osmolality of 320 mmol/kg and urine osmolality 244
mmol/kg after overnight fluid deprivation) and she
was started on nasal desmopressin with symptomatic
relief. Evaluation for the other anterior pituitary hor-
mone dysfunction revealed no abnormalities (Table 1).
Magnetic Resonance Imaging of the pituitary re-
vealed a moderate thickening of the pituitary stalk
(see Figure 1a).
The diagnosis of lymphocytic hypophysitis was con-
sidered in view of the typical presentation. Investiga-
tions done to exclude other causes of a thickened pitu-
itary stalk included a chest radiograph, scintigraphic
bone scan and lumbar puncture. These revealed no ab-
normalities. 
Two years after presentation, she developed secondary
hypogonadism which was picked up on routine bio-
chemical testing with FSH of 1.5 IU/L and an unde-
tectable level of LH. Soon after, she complained of
generalised lethargy and severe headaches. Investiga-
tions revealed hypocortisolism, with a random cortisol
of 22.9 nmol/L and 0.25mg intramuscular synacthen
stimulated cortisol of 251.2 nmol/L at 60 minutes. 
Four years after presentation, she developed secondary
hypothyroidism detected on blood tests. (FT4 7.3
pmol/L, TSH 0.982 mU/L)
Serial MRI scans (Fig. 1) showed evolution of the
The vanishing pituitary mass
LEE M., RAJASOORYA R.C.
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TABLE 1 - INITIAL EVALUATION OF ANTERIOR PITUI-
TARY FUNCTION.
Laboratory investigations Results Normal range
Follicle stimulating 4.8 IU/L Follicular 1-14
hormone (FSH) Luteal 1-12
Luteinsing hormone 3.8 IU/L Follicular 1-7.5
(LH) Luteal 2.5-24
Estradiol 179.8 pmo/L Follicular 3.7-205.5
Luteal 176.2-1284.5
FT4 16.7 pmol/L 10.3-31
Thyroid stimulating 1.3 mU/L 0.5-5
hormone (TSH)
Cortisol 373.4 nmol/L
Growth hormone (GH) 2.5 mU/L 1.0-21.0
Insulin-like growth 152.7 UG/L 114.0-492.0
factor 1 (IGF-1)
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thickened pituitary stalk to emergence of a pituitary
gland enlargement giving a mass appearance, which
progressively decreased in size with resultant disap-
pearance of the mass. She remains well 14 years after
initial presentation, on hormone replacement. 
Discussion
This patient had first presented with polyuria and
polydipsia, a year after delivery of twins. Despite con-
trol of the diagnosed diabetes mellitus her symptoms
of polydipsia and polyuria had persisted; raising the
possibility of another cause which was subsequently
demonstrated to be diabetes insipidus. It is tempting
to speculate, in retrospect, that her diabetes mellitus
was aggravated by her urge to consume soft drinks in
response to the polydipsia of diabetes inspidus occur-
ring in the background of a family history of diabetes
mellitus. Evaluation for the diabetes inspidus led to an
identification of a pituitary stalk abnormality. Further
investigations were negative for other causes of
polyuria, and biochemical testing revealed normal an-
terior pituitary function.
A thickened pituitary stalk raises the possibilility of
lymphocytic hypophysitis, as well as granulomatous or
xanthomatous inflammation. Differentials include sar-
coidosis, Wegener’s granulomatosis, tuberculosis,
Whipple’s disease, Langerhans cell histiocytosis and
neoplasms, including germ cell tumours, metastases or
pituitary tumours. 
Subsequent imaging revealed the presence of a pitu-
itary mass. Differential diagnoses include pituitary tu-
mours, other inflammatory conditions like sarcoidosis
or histiocytosis, and malignancy. This patient under-
went a bone scan and lumbar puncture, with measure-
ment of cerebrospinal fluid beta human chorionic go-
nadotrophin (B-hcg) and acid fast bacilli, all of which
were normal.
Serial MRI in this patient showed evolution of the
thickened pituitary stalk to emergence of a pituitary
gland enlargement giving a mass appearance, which
progressively decreased in size with resultant disap-
pearance of the mass.
Serial hormonal evaluation revealed progressive hor-
monal deficiencies finally resulting in panhypopitu-
itarism on hormone replacement.
Because of the temporal relationship with the delivery
and development of diabetes insipidus, as well as the
discovery of pituitary stalk enlargement on MRI scan,
the diagnosis of lymphocytic hypophysitis was con-
sidered.
The natural history of lymphocytic hypophysitis is
thought to progress from inflammation to fibrosis and
subsequent atrophy of the gland. Spontaneous resolu-
tion has also been reported, as illustrated in our pa-
tient. Inflammatory process of the hypophysis can be
misdiagnosed as their clinical and radiological features
often mimic tumours of the sellar or suprasellar re-
gion. Hyperprolactinaemia is thought to be present in
a third of patients, and can be as a result of pregnancy
or post partum, stalk compression or as a result the in-
flammatory process itself. It has been reported that
lymphocytic hypophysitis should be strongly suspect-
ed if symptoms occur during or soon after pregnancy;
if ACTH and/or TSH deficiency is present with nor-
mal gonadotrophin and GH secretion; and contrast
enhancement scans of the pituitary gland are positive
(particularly gadolinium contrast on MR scanning).
The features of hypophysitis on imaging include a ho-
mogenous enlargement of the pituitary, with a peak in
the diaphragm giving it a pear shaped appearance.
Fig. 1 - Serial MRI scans over time demonstrating a thickened pituitary stalk that evolved into a pituitary mass that progressively reduced in size leading
to final disappearance of the mass.
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Loss of the posterior pituitary bright spot and thicken-
ing of the stalk have also been reported. There are a
few characteristic features on MRI scanning that can
help to differentiate lymphocytic adenohypophysitis
from pituitary adenomas. Adenohypophysitis have rel-
atively low signal intensity on T1 weighted images
whereas pituitary adenomas are almost isointense on
both T1 and T2 weighted images. Marked contrast en-
hancement of the mass seems to be characteristic of
lymphocytic adenohypophysitis whereas solid pitu-
itary macroadenomas only show modest enhance-
ment. Thirdly, dural enhancement adjacent to the en-
larged pituitary seems to be typical in lymphocytic hy-
pophysitis which is not the case in pituitary adenomas.
Our patient’s initial MRI showed an enlarged pituitary
stalk that was enhancing brightly associated with a loss
of the posterior pituitary bright spot.
There has been some suggestion that if inflammation
of the pituitary gland is left untreated, the enlarged
gland may shrink as the glandular tissue is destroyed
by the disease process, as was the case in this patient.
In many patients with lymphocytic hypophysitis, a
misdiagnosis of pituitary adenoma has been made pre-
operatively. The distinction between a pituitary adeno-
ma and lymphocytic hypophysitis has broad and im-
portant implications in terms of treatment, follow-up,
and prognosis. 
The natural history includes a progressive develop-
ment of irreversible hypopituitarism or spontaneous
partial/total recovery. Most patients require long term
hormone replacement. Therefore, at initial presenta-
tion, the decision to sit tight and observe or to proceed
with surgery is a difficult one, especially if the patient
has evidence of a pituitary tumour on imaging. As
spontaneous remission does occur, careful follow up of
asymptomatic and subclinical patients is recommend-
ed, and to proceed with surgery if there is evidence of
severe compression. 
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Introduction 
Although the prevalence of insulin resistance (IR)
among women with polycystic ovary syndrome
(PCOS) is known to be high, the best method to use
to detect IR is still controversial. The aims of this
study were 1. to determine the prevalence of IR in a
well-characterized population of mostly normal-
weight women with PCOS, 2. to evaluate the relative
agreement of both static and dynamic methods of di-
agnosing IR, and 3. to evaluate SHBG as a simple
method for screening for IR. 
Materials and methods 
We analyzed data from 147 subjects diagnosed with
PCOS, according to the revised Rotterdam consen-
sus criteria, who presented to our university medical
center. We collected data on clinical characteristics,
fasting insulin and glucose measurements, and the
results of a 3-hour, 75 g load glucose tolerance test
with every 15 minute measurements of glucose and
insulin. IR was defined as HOMA >3.8, QUICKI
<0.33, AUC of insulin >7000 µIU*120 min/ml
(AUCI120), AUC of insulin >12000 µIU*180
min/ml (AUCI180), Matsuda-Index <4.5 (ISI
COMP) and Glucose to Insulin ratio <4.5 (G/I).
Correlation analysis was performed between static in-
sulin resistance indices (HOMA, QUICKI, G/I) and
dynamic insulin resistance indices (ISI COMP,
Stumvoll-Index (ISI STUM), area under the insulin
curve over 120 and 180 minutes). We tested the diag-
nostic potential of SHBG as a simple screening
method for those at risk of having IR. Finally, the risk
for future development of DM was assessed using the
formula ∆ I0–30 min/∆G0–30 x Matsuda-Index as
proposed by Abdul-Ghani et al. (2007). 
Results 
Using our pre-defined cut-offs for IR, we found that
the prevalence of IR was 12.2%, 34.0%, 60.5%,
43.5% and 55.1% using HOMA, QUICKI,
AUC120, AUC180 and ISI COMP respectively. The
correlation between the methods varied: HOMA and:
QUICKI (r=-1, p=0.01), G/I (r=-0.958, p=0.01),
AUCI120 (r=0.656, p=0.01), AUCI180 (r=0.659,
p=0.01), ISI COMP (r=-0.881, p=0.01), ISI STUM
(r=-0.570, p=0.01). Mean SHBG was significantly
lower in women with than those without IR, when IR
was defined using all methods except the QUICKI.
The SHBG level strongly correlated with IR using
all methods (ranging from r=-0.482, p<0.001 for
AUCI120 to r=0.543, p<0.001 for ISI COMP, respec-
tively) and was an independent predictor of the pres-
ence of IR on logistic regression. The cut-off for
SHBG of ≥26.8 nmol/L had a maximal area under the
curve with a specificity of 86.2% and sensitivity of
53.1% for excluding IR.
After applying a previously published formula to as-
sess the risk of developing DM with a cut-off of
<3.1, we found that 20.1% of our PCOS subjects
would be deemed at risk for the future development
of DM. Moreover, only the insulin resistant group
categorized by AUCI180 had a significant lower
∆I0–30 min/∆G0–30 x Matsuda index in compari-
son to the normo-insulinemic subjects (p=0.05).
What is the best method for assessing insulin resistance in PCOS
women: comparison of static and dynamic methods and SHBG
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Conclusions 
We found discrepant prevalence rates (from 12.2% to
60.5%) of insulin resistance among PCOS women de-
pending on the method and diagnostic cut-off used. A
cut off of ≥26.8 nmol/L in SHBG could be used as a
specific and simple screening method to exclude IR,
necessitating further testing in only those who test pos-
itive. There is an evident need for standardization and
agreement to use a single, most feasible method with
one single cut off for IR. Most clinically important
would be a method to determine IR that would be pre-
dictive of the future development of DM in PCOS
women. Applying a previously published index for pre-
dicting DM in an older at-risk population to our
young PCOS women, we found that over 20% would
be identified as at-risk for developing DM. Whether
this index proves to be a true prognosticator for the de-
velopment of DM in PCOS women needs to be fur-
ther evaluated in long- term longitudinal studies.
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The study aim was to show superiority of estradiol
valerate/dienogest (E2V/DNG; Qlaira®) over an
ethinylestradiol/levonorgestrel (EE/LNG; Microg-
ynon®) combined oral contraceptive (COC) in re-
ducing the severity of hormone withdrawal-associ-
ated symptoms in women aged 18-50 y using
COCs. The rationale was based on established sta-
ble E2 levels using a shorter hormone-free interval
(HFI) with E2V/DNG vs EE/LNG. This random-
ized, double-blind, Phase IIIb study assessed
headache/pelvic pain severity, recorded using a vi-
sual analog scale of 100mm during cycle days 22-
28/6 treatment cycles. Of 449 women randomized,
362 completed the study. Study drugs were well
tolerated and AEs were typical of COC use.
E2V/DNG (26/2) reduced the most severe symp-
tom (headache or pelvic pain) significantly more
(p<0.0001) than EE/LNG (longer HFI, 21/7).
Women taking E2V/DNG used considerably less
pain medication (Fig. 1).
Hormone withdrawal-associated symptoms (headache and pelvic pain)
in women taking combined oral contraceptives: comparison
of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel
MACÌAS G.1, MERKI-FELD G.S.2, PARKE S.3,
MELLINGER U.3, SERRANI M.3
1 Mexican Institute of Clinical Research, Mexico City, Mexico;
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Fig. 1 - Mean Visual Analog Scale (VAS) scores as recorded by the participants - severity of headache and severity of pelvic pain.
Introduction
Nuclear factor Kappa.B (NF-kappa B) plays an im-
portant role in the regulation of the inflammatory cas-
cade through the activation of several genes. The
translocation of this transcriptional factor from the
cytoplasm to cell nuclei involves the phosphorylation
of its inhibitor, a reaction that occurs in response to
several inflammatory mediators. In the endometrium,
progesterone exerts an inflammatory effect that is me-
diated through the inhibition of the mechanism of
NF-kappa B translocation to the nucleus. Proges-
terone withdrawal, on the other hand, leads to up-reg-
ulation of endometrial cyclooxygenase-2 (COX-2) and
subsequent increased levels of prostaglandins (PGs),
namely, PGE2 and PGF2α, which provoke the onset of
menstrual blood flow and regulate its intensity (1,2).
Nuclear factor KappaB p65 immunoreactivity was
positively associated with heavier menstrual flow in
women with adenomyosis, thus suggesting a role for
inflammation in the regulation of menstrual-related
symptoms and uterine pathology (3). Increased levels
of mRNA for Cox-2 were also observed in the en-
dometrium of patients complaining of menorrhagia
(2). These findings corroborate the hypothesis that
there is an increase in the inflammation in the en-
dometrium of patients with estrogen-dependent
pathology. The present study was designed to deter-
mine whether the presence of endometrial polyps, ade-
nomyosis, myomas and endometriosis is associated
with increased expression of nuclear factor kappa B
(NF-kappa B) in the endometrium during the differ-
ent phases of the menstrual cycle.
Patients and methods
NF-kappa B expression was investigated in the en-
dometrium of 69 patients of reproductive age with
adenomyosis (n=40), submucous myoma (n=10), en-
dometrial polyps (n=5) and endometriosis (n=14), and
compared with 36 normal, pathology-free controls.
Endometrial samples were obtained during either sur-
gical or diagnostic hysteroscopy performed in different
phases of the menstrual cycle. The presence of positive
nuclear expression was determined using immunohis-
tochemistry as previously described (4). The chi-
square test was used to compare differences in percent-
ages, with significance established at p<0.05. 
Results
In the endometrium, NF-kappa B nuclear expression
was detected mainly in the glandular epithelium and,
less frequently, in the stroma (Figure 1). In pathology-
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Fig. 1 - Positive nuclear NF-Kappa B expression in the endometrial glands
in a patient with adenomyosis.
free patients, the percentages of endometrial samples
showing positive NF-kappa B in glandular cell nuclei
were low and there were no significant changes
throughout the menstrual cycle. In uteri with pathol-
ogy, on the other hand, the percentage of endometria
with positive NF-kappa B expression was 68% in the
proliferative phase, 17% in the early luteal phase and
87% in the late luteal phase. Compared to controls,
these values were significantly higher (p<0.05) in each
phase of the cycle except for the early luteal phase
(p=0.2). These results are summarized in Table I.
Conclusion
The presence of pathology is associated with increased
NF-kappa B expression in the endometrium and this
is hormonally regulated. Progesterone decreases while
estrogen and progesterone withdrawal exert an oppo-
site effect. The increased positivity for nuclear NF-
Kappa B during the proliferative and late luteal phase
in the endometrium of uteri with pathology suggests
that both estrogenic dominance and progesterone
withdrawal increases inflammation. The reduction in
the early luteal phase is in accordance with the concept
that progesterone exerts an anti-inflammatory effect
on the endometrium through the NF-Kappa B path-
way (1,5). Estrogens potentiate TNF alpha activation
of NF-Kappa B in endometrial cells, while progestins
such as dienogest or gestodene exert a converse effect,
blocking the translocation of NF-kappa B to cell nu-
clei, which otherwise would activate the transcription
of pro-inflammatory genes (4,5). TNF is a potent in-
ducer of Cox-2 in the endometrium, acting through
NF-Kappa B. However the degree of induction was
significantly greater in the eutopic endometrial stro-
mal cells of patients with endometriosis compared to
disease-free cases (6). This would suggest a greater ac-
tivation of the NF-Kappa B pathway in the eutopic
endometrium of women with endometriosis, which is
in agreement with our findings of greater positivity for
nuclear NF-Kappa.B in the endometrial cells of uteri
with adenomyosis, myomas and endometriosis. Our
findings that the binding of NF-Kappa B to the cell
nuclei of endometrial cells is greater during the late
rather than the early luteal phase may be a conse-
quence of estrogen and progesterone withdrawal fol-
lowing the demise of the corpus luteum. This stimu-
lates COX-2 expression and PGF2 alpha production
through NF-kappa B activation, which may be re-
sponsible for the excess menstrual bleeding and pain
associated with these pathologies. The role of inflam-
matory mediators such as prostaglandins in the men-
strual process is pivotal in determining the intensity of
its related symptoms, which have an endometrial ori-
gin. Excessive endometrial inflammation may either
trigger or be a consequence of the aberrant aromatase
expression in the endometrium, thus creating a vicious
cycle of excessive local estrogen and prostaglandin pro-
duction (9). The increased nuclear binding of NF-
Kappa observed during the phases of menstrual cycle
in which there is either estrogenic dominance or prog-
esterone withdrawal may suggest that these steroid
hormones exert conflicting effects in the regulation of
endometrial inflammation.
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TABLE 1 - PERCENTAGE OF ENDOMETRIAL SAMPLES
SHOWING POSITIVE NUCLEAR NF-KAPPA B EXPRES-
SION IN THE GLANDS DURING THE MENSTRUAL CY-
CLE IN RELATION TO THE PRESENCE OR ABSENCE OF
UTERINE PATHOLOGY.
Proliferative phase Early luteal phase Late luteal phase
Normal uterus 6/21 28% 0/6 0% 1/9 11%
Pathology 19/28 67% 3/17 18% 21/24 87%
Chi square test
p<0.0001 Pathology, early luteal phase versus late luteal phase
p=0.001 Pathology, early luteal phase versus proliferative phase
p=0.09 (NS) Pathology, late luteal phase versus proliferative phase
Differences between pathology and the normal uterus were significant (p<0.05)
except for the early luteal phase.
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Introduction
Insulin resistance (IR) in obesity is related to the de-
velopment of metabolic syndrome (MS) and pituitary-
ovarian axis disorders (1). Severe obesity, after failure
of dietetic and pharmacological treatment, can under-
go bariatric surgery to prevent morbidity and mortali-
ty (2). Oxidative stress (OS) is now recognized as a
mechanism underlying the development of cardiovas-
cular complication of MS. The evidence that obesity is
related to an increase in OS has been highlighted (3-
6), but few studies have comprehensively examined
antioxidant systems in human obesity. In previous
works we demonstrated that weight loss, induced by
biliopancreatic diversion (BPD), is associated with in-
creased insulin sensitivity, but decrease of molecules,
such as Coenzyme Q10, that act as powerful antioxi-
dant system, with mechanisms (weight loss per se, lipid
malabsorption, metabolic or hormonal variations)
which are not yet clear (7). In order to delve into the
physiopathology of this condition, we have studied
three different groups of subjects, treated by different
surgical procedures - BPD, gastric bypass (GB), mini-
gastric bypass (GmB) - evaluating total antioxidants
capacity (TAC) in plasma before and at a long distance
(12-18 months) from surgery. 
Materials and methods
We studied 14 women, aged 29-48 ys, with a mean
BMI ± SD of 47.5 ± 6.8 Kg/m2; no other endocrine
disorder was present except amenorrhea or oligomen-
orrhea; after surgery they reached a mean % decrease
of BW of 40.7 ± 0.1, with no differences among the
techniques, and with normalization of menses. They
were treated with the same schedule of supplements.
We studied metabolic parameters (glycemia, insuline-
mia, total- LDL- HDL-cholesterol, triglycerides, uric
acid, albumin, transaminases), hormones (FT3, FT4,
TSH, IGF1, cortisol, ACTH) and values of copper,
zinc and Vitamin E. IR was evaluated by homesostasis
model assessment (HOMA), calculated as basal glu-
cose (mmol/l) x basal insulin (mIU/l)/22.5, where
high HOMA scores (>2.5) denote IR (8). Total antiox-
idant capacity (TAC) was assayed by a method based
on interaction between H2O2-metmyoglobin, as
source of radicals, and a chromogen (ABTS), whose
radical cation is spectroscopically revealed The latency
time (LAG, sec) in ABTS.+ appearance is proportional
to antioxidants concentration (9,10).
Mann-Whitney test was employed for statistical
evaluation.
Results
Despite in BPD different parameters were marked-
ly influenced by the procedure, in comparison to
the other techniques (Table 1), due to the prevalent
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TABLE 1 - MEAN ± SEM VALUES OF METABOLIC PARAME-
TERS AND OLIGOELEMENTS IN THE THREE GROUPS
OF BARIATRIC SURGERY TECHNIQUES.
HOMA HDL-Chol IGF-1 Zn Cu Vitamin E
mg/dl ng/ml γ/dl γ/dl mg/l
BPD 1.5 ± 0.3 38.8 ± 2.3 51.4 ± 34.3 67.7 ± 26.4 104.5 ± 6.4 8.1 ± 4.3
GB 1.4 ± 0.6 51.3 ± 6.4 170.0 ± 53.5 90.0 ± 16.2 105.8 ± 25.4 10.9 ± 2.9
GmB 0.5 ± 0.3 61.8 ± 6.7 73.0 ± 47.6 82.5 ± 24.4 92.6 ± 18.3 11.0 ± 1.3
p 0.002 < 0.001 0.001 0.321 0.519 0.249
lipid malabsorption mechanism, we found a de-
crease in TAC in all three groups (mean % decrease
of LAG values: 12.2 after BPD, 18.4 after GB,
13.0 after GmB) (Fig. 1).
Other parameters did not show significant differences
among groups (data not shown).
Discussion
BPD is a surgical procedure performed in patients
with untreatable obesity and insulin resistance and
consists in partial gastrectomy with Roux-en-Y re-
construction (2). As a consequence, nutrition does
not undergo the normal action of biliary and pancre-
atic secretions in alimentary tract; the patients devel-
op fat malabsorption and a partial starch malabsorp-
tion, while maintaining absorption of mono-disac-
charides and proteins (11). Among the consequence
of lipid malabsorption we evidenciated a marked re-
duction in Coenzyme Q10 (7). Different techniques
have been developed to reduce the impact of such
mechanism (12).
A large group of studies has been published on the role
of OS in the development of MS. In the context of a
genetic predisposition to IR, induced by excessive
caloric intake or sedentary lifestyle, it has been hy-
pothesized a diet-induced OS (13); the chronic free
fatty acids overflow can worsen insulin sensitivity (the
so colled “lipotoxicity”) inducing a reduction in in-
sulin-dependent glucose uptake (14). Insulin receptor
substrate phosphorylation is involved in OS-induced
IR (15). The evaluation of TAC fournishes an indirect
evaluation of OS, which is defined as an unbalance be-
tween the production of radicals and the defence sys-
tems. We also observed TAC values in morbid obesity
not significantly different from those in control sub-
jects (16).
Our present preliminary data show a reduction in
TAC, measured as lag phase, after all the techniques of
bariatric surgery, suggesting that body weight reduc-
tion per se, rather than the different surgical proce-
dures, can be responsible for this phenomenon.
This datum, which could indicate an initial decrease
in OS (and therefore a reduction of the compensative
antioxidant activity), could appear as a favourable in-
dex; however, at a longer distance, it could be a mech-
anism contributing to the well known phenomenon of
weight regain (17).
We suggest that antioxidants should be determined in
patients undergoing bariatric surgery, despite this is
not a routinary measure as recommended (18) and, in
case of persistent reduction, supplemented according
to a personalized approach. However, further study
can gain insight into the differential patterns of specif-
ic antioxidants, which can contribute to the antioxi-
dant power in serum.
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Fig. 1 - Mean values of TAC, expressed as lag phase, in the three groups of
bariatric surgery techniques.
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Aim
Definition of National norms of quality of life, and
manifestation of climacteric syndrome (CS) in Ar-
menian women population in age group 40-60 years.
Objectives
1. To present a comparative assessment of the
menopausal syndrome in women population of the
main cities of Armenia.
2. To assess the parameters of physical and mental
health of women of the capital and major cities of
Armenia.
Materials and methods
The study is based on data cross-sectional epidemio-
logical study (survey) of 900 women aged 40-60 years
in four major cities of Armenia:
• Yerevan, the capital of the Republic;
• Gyumri and Vanadzor, the victims of the earth-
quake in 1988;
• Stepanakert, participated in local armed conflicts.
The sampling method of partial observation was used,
which allowed to extend the results from part of the
units (we have chosen the group) to the whole popu-
lation. To ensure the representativeness of our sample
the necessary requirements were fulfilled according to
calculation of sample size and selection of observation
units in the sample.
The study of the quality of life (QOL), as well as eval-
uation of physical and mental health components were
carried out using SF-36 (1-3). SF-36 questionnaire, the
official Armenian valid version which is developed by
specialists at the American University in 2002 (G.
Yagdzhyan, D. Abrahamian, A. Vanesyan in the Center
for Plastic Surgery and Medical Science of Armenia) is
a widely used general questionnaire that measures QOL
related to health and its eight areas (subscales), i.e.
1. Physical functioning - PF (10 points)
2. Role limitations due to physical health problems –
RP (4 points)
3. Bodily pain - BP (2 points)
4. General health - GH (6 points)
5. Vitality - VT (4 points)
6. Social functioning - SF (2 points)
7. Role limitations due to problems in emotional
functioning - RE (3 points)
8. Mental Health - MH (5 points).
The most pronounced is manifestation of the CS in
Gyumri and Stepanakert, where menopausal index cor-
responds to the severe form of the CS. The population
of the age group 40-60 years in Yerevan and Gyumri are
characterized by medium degree of expression of CS.
1. Physical functioning (PF) – represents the activities
that normally performed daily. The health status limi-
tation is the lowest in women population of Yerevan
compared to other cities. The highest limitation deter-
mined in Gyumri. In half of population of Yerevan,
Vanadzor and Stepanakert the physical functioning is
above average as opposed to Gyumri, where (PF) is es-
timated as below average.
2. Role limitations due to problems in physical health
(RP) – characterized by difficulties in work or other reg-
ular daily activities due to physical condition. Problems
with work and daily activities due to physical health dis-
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orders occurred in the least degree in women popula-
tion of Yerevan and quite often in women population of
Gyumri and Vanadzor. It is interesting to mention that
50% of the population of Yerevan and 40% of the pop-
ulation of Stepanakert noted that there are no problems
connected to work and other daily activities due to
physical health, while one of three women in Gyumri
and Vanadzor, revealed significant difficulties.
3. Bodily pain (BP) – the severity of physical pain ex-
perienced in the last 4 weeks, as well as its influence on
the performance of daily work (outside and house-
work). The lowest average score in a comparative aspect
on the bodily pain scale scored women population of
Gyumri, moreover, for the past 4 weeks pain signifi-
cantly interfered in normal daily life of women popu-
lation of this city, as the points scored by half of women
(50th percentile = 46) was below average (51.3).
4. General health (GH) – the overall self-appraisal of
health and its dynamics for the last year, where the
women describe their health as a whole, comparing
their health at the time of the survey, to the fact that
was one year ago. Calculations have shown that the
highest self-appraisal of health is in women population
who live in the capital. Below all rated their health
women of Stepanakert, although more than in half of
the studied women (75%) the indicator of general
health is twice the average.
5. Vitality (VT) – representation about the safety of vi-
tal forces concerning to how respondents felt during
the last four weeks. Relatively more state exhaustion
and fatigue accompanied by women living in Gyumri.
Average values on a scale of VT in three other cities ap-
proximately the mid-level, which indicates that
women of these research groups basically gave an-
swers about a feeling of cheerfulness, fullness of energy.
6. Social functioning (SF) includes the question
of how physical or emotional condition within the
previous month disturbed to spend time with family,
friends, neighbors, or in a team. On a scale SF women
of the capital gained (68.8), the half the population
(median) exceeds the level of social activity (75). In the
cities Vanadzor and Stepanakert the average values are
almost close to the capital (67.1 and 66.6, respective-
ly), but the level of social activity of every second
woman of mentioned cities remains below average
(62.5 and 62.4, respectively). Comparative evaluation
showed that for the last 4 weeks women living in
Gyumri compared to women living in the rest of men-
tioned cities, had more problems with physical health
and emotional disorders interfering with various ha-
bitual communication and social life (meetings and
visits to friends, relatives and etc.).
7. Role limitations due to problems in the sphere of
emotional health (RE) – if there were emotional diffi-
culties at work and routine activity during the last 4
weeks. Comparative analysis of the calculations
showed that most difficulties because of emotional in-
stability, experienced women of Gyumri. The level
of the average value on the scale RE in Gyumri is al-
most 2 times lower than in Yerevan and Stepanakert.
The status of “floor” and “ceiling” are clearly displayed
on the scale: 47% of women of the capital and 42% of
women of Stepanakert scored the highest possible score,
indicating that there are no issues with work and daily
activities caused by emotional state. Totally different is
the situation in 2 other cities: 44% of women of Gyum-
ri and 46% of women of Vanadzor were forced to re-
duce to minimum the amount of working time and
volume of work due to serious emotional disorders.
8. Mental health (MH) – the mood of respondent
during the last 4 weeks. The highest average scores for
all parameters obtained by women in the capital -
(54.2). Feeling of nervousness, depression, grief and
discouragement are relatively often accompanied by
women of Gyumri (46.5), thus, the emotional state
with a tendency to depression made the women of this
city psychologically vulnerable.
Conclusion
For the first time were obtained the national norms of
quality of life necessary to carry out scientific research-
es in the given age group of women. The quantitative
indicators of received norms in comparison to similar
data of developed countries reveal a number of anom-
alies, the explanation of which requires further investi-
gation. The lowest normative indicators for all eight
parameters of the questionnaire SF 36, obtained in
Gyumri, located at approximately the same level as the
norms from the United States. What could this mean?
High self-appraisal? Underestimated requirements of
quality of life? Or higher mental and physical stamina?
The answers to these questions require further research.
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Introduction
Endometriosis is a common disease defined as the
growth of endometrial tissue outside the uterine cavi-
ty and results in a vast array of gynecological problems
including dyspareunia, dysmenorrhea, pelvic pain and
infertility.Progesterone is a potent antagonist of estro-
gen?induced proliferation in the endometrium and
may play a pivotal role in the pathogenesis of en-
dometriosis. There is some evidence to justify using
hormonal drug treatments following surgery to sup-
press the growth and development of any remaining or
new endometrial implants.The progestins are effective
treatments for the symptoms of endometriosis. How-
ever, like all the hormonal drugs used for endometrio-
sis, they have side effects, which some women find in-
tolerable. They are safer and cheaper than the GnRH-
agonists and danazol, which some gynaecologists be-
lieve makes them appropriate for women who need
prolonged or repeated treatments. It is not known pre-
cisely how progestins relieve the symptoms of en-
dometriosis, but they probably work by suppressing
the growth of endometrial implants in some way, caus-
ing them to gradually waste away. They may also re-
duce endometriosis-induced inflammation in the
pelvic cavity. Unfortunately, there is no consensus in
the literature on the optimal dose and treatment time
for lessions’regression. Furthermore, there are very few
data on the type of progestin that is most effective, and
the regimens advocated are essentially arbitrary. Our
primary goal was to assess the differences between the
results of various progestins regarding amelioration of
clinical symptoms, ultrasonographic findings and in-
traoperative bleeding, adhesions and ease of cyst dis-
section.
Patients and methods
We performed a retrospective single-center study in-
cluding one hundred fifty patients diagnosed with en-
dometriosic ovarian cysts operated in the University
Women’s Hospital Cuza Voda Iasi, Romania, in the
period 1.06.2005- 01.06.2010 which followed at least
6 months of preoperative treatment with various prog-
estins. The diagnostic circumstances were pelvic exam-
ination or vaginal ultrasound performed to evaluate
pelvic pain (n = 68), ovarian stimulation (n = 14), ini-
tial infertility workup (n = 39), or routine gynaecolog-
ical examination (n = 29). All cysts were > 20 mm in
diameter, and none had thick septa, papillations, or as-
sociated ascites. All patients were examined by vaginal
ultrasound with associated Doppler at the moment of
diagnosis and every three months after and met the
classical ultrasonographic criteria for endometriosic
cysts. We assessed the cysts dimensions, appearance,
shape, vascularisation, situation related to the uterus
and the controlateral ovary, uni- or bilaterality of the
cysts, the vascularisation, sludging and presence of
horizontal levels. The diagnosis was confirmed in all
cases postoperatively by histological examination,
which demonstrated the presence of histopathologic
features similar to endometrium, namely endometrial
stroma, endometrial epithelium, glands that respond
to hormonal stimuli and haemosiderin deposits. 33
(27%) patients followed treatment with lynestrenol
(Exluton), 23 (23%) were prescribed injectable
medroxyprogesterone acetate (DepoProvera), and 76
(50%) were treated with desogestrel (Cerazette). Age
of the patients varied between 20-49 years (with an av-
erage of 32), all of them being still menstruating. 53
patients were referred for associated infertility. Dura-
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tion of treatment was 6-12 months before laparoscopy
and 3 other months after surgery. The parameters fol-
lowed intraoperatively were the ease of dissection, the
amount of bleeding, the possibility of conservative
treatment, the extension of adhesions, the staging of
disease. The bleeding was subjectively assessed as mild,
moderate and severe. Postoperatively the patients were
reevaluated every three months by clinical examina-
tion and vaginal ultrasound.
Results
The characteristics of the three groups were compared
using Student’s t- and χ2-tests. A significant decrease
of cysts diameter and vascularisation was found in
most cases, usually associated with sludging and de-
creased hyperechogenicity, as shown in Table 1. The
most evident improvement of the ultrasonographic
appearance regarding size decrease and sludge forma-
tion belonged to patients treated with desorgestrel.
Vascularisation decrease and horizontal levels appear-
ance were similar for all progestins.
Intraoperatively we noticed less bleeding during cyst dis-
section and a better cleavage plan between the cyst cap-
sula and the normal ovarian tissue (Table 2). These ef-
fects were most visible in the desorgestrel group. 55% of
the patients obtained a pregnancy in the first year after
laparoscopy and another 12% during the second year.
The overall recurrence rate of endometriosic cysts after
stopping the progestative treatment was 6% (Table 3).
Discussion
This study showed that treatment with progestative
improves operative conditions mainly by decreasing
the bleeding and increasing the laxity of the connective
tissue between the cyst capsula and the normal ovarian
tissue. Since the main effect of progesterone on en-
dometrium is decidualisation of stromal cells, these
changes could be due to a local decrease of angiogene-
sis and increase of glycan cell content. There has been
some controversy regarding the distribution of proges-
terone receptors A and B in endometriosis, which have
been reported to be both low and unusually high in en-
dometriotic tissue. The slightly different effects no-
ticed in various progestatives could be owed to some
differences in their affinities for the two types of recep-
tors. There was no case of complete resistance to the
treatment in any group. We are not aware of another
study comparing the effects of different progestins in
endometriosis, but there is a recent study which does
not find a significant difference between the effects of
various progestins in endometrial hyperplasia. 
Conclusions
Desorgestrel, lynestrenol and medroxyprogesterone ad-
ministered for at least 6 months preoperatively have a
shrinking effect on endometriosic cyst, decrease the in-
traoperative bleeding and improve the dissection con-
ditions, with desorgestrel having the most significant
effects. Further studies at molecular level and more ex-
tended clinical trials are necessary to standardise the
progestative preoperatory treatment in endometriosis.
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TABLE 1 - ULTRASONOGRAPHIC PREOPERATIVE CHAN-
GES.
Lynestrenol Medroxyprogesterone Desorgestrel
Size decrease (mm) 29 31 38
Vascularisation 
decrease (%) 79 82 85
Sludge appearance
(%) 27 25 37
Horizontal levels 
appearance (%) 31 28 32
TABLE 2 - SURGICAL PARAMETER MODIFICATIONS
FOR DIFFERENT PROGESTINS.
Lynestrenol Medroxyprogesterone Desorgestrel
Easy dissection and 
capsula cleavage (%) 80 85 89
Heavy bleeding  (%) 12 10 5
Thick adhesions (%) 34 25 21
Conservative 
treatment (%) 98 95 100
Operative time (min) 85 90 79
TABLE 3 - POSTOPERATIVE FOLLOW-UP.
Lynestrenol Medroxyprogesterone Desorgestrel
Recurrence (%) 6 7 5
Pregnancy in the first  
6 months after 
progestin 
interruption (%) 79 82 85
Symptom-free (%) 87 89 92
Introduction
Endometriosis is a relatively frequent chronic gyneco-
logic disease usually presenting with infertility or
chronic pelvic pain. The confirmation of the disease
can only be made with surgical intervention, usually
laparoscopy. Endometriomas are particularly difficult
to excise because surgical intervention may reduce
ovarian reserve, the capsula is very adherent and well
vascularised. The surgical treatment of endometriosis
is effective in the short-term, but if the patient does
not get pregnant very soon after the operation, the re-
currence is common. Recurrence rates after surgical
intervention can be decreased with the use of menstru-
ation suppressive medical therapy such as hormonal
contraceptives. 
Desogestrel is a progestogenic 19-nortestoterone de-
rivative, which is widely used for oral contraception
both combined with ethinyl estradiol and alone in
progestin-only pills. The parent drug does not possess
progestogenic activity and bioactivation to 3-ketodes-
ogestrel is needed for the contraceptive activity. In one
parralel study we demonstrated it has properties supe-
rior to other progestins in the preoperative treatment
of endometriotic lesions, therefore we studied its ef-
fects when the treatment was continuated postopera-
tively in patients operated for endometriosic cysts.
Aim of the study
To evaluate the effects of a continuous desorgestrel
treatment in the prevention of ovarian endometriosic
cysts postoperative recurrence.
Materials and methods
Our study design was retrospective, including 120 pa-
tients with endometriosic cysts operated in the Uni-
versity Women’s Hospital Cuza Voda Iasi, Romania
during the period 1.06.2005-1.06.2010. The cysts
were diagnosed during pelvic examination or vaginal
ultrasound done for infertility, chronic pelvic pain, ab-
normal vaginal bleeding or routinely. The minimum
cyst diameter was 20 mm and patients which had cyst
septa, papillae or peritoneal fluid were excluded from
the study. The patients followed at least 6 months of
preoperative treatment with various progestins. 105
patients were operated laparoscopically and 15 had a
laparotomy, from which 11 were converted laparo-
scopies and 4 first intention laparotomies due to the
big size of the cysts and/or previous extended abdom-
inal surgery.
We evaluated the cysts size, homogenicity, shape, vas-
cularisation, position related to the uterus and the
controlateral ovary, presence of sludging and horizon-
tal levels. All cases were confirmed by pathology exam-
ination showing the histological aspects characteristic
to endometriosis: endometrial stroma, endometrial
epithelium, glands that respond to hormonal stimuli
and haemosiderin deposits. 80 patients received for at
least 6 months 75 micrograms of desorgestrel daily
and 40 patients did not receive any treatment. Vaginal
ultrasound with Doppler examination and CA 125
were done for follow-up at every 3 months. The char-
acteristics of the two groups were compared using Stu-
dent’s t- and χ2-tests.
Age of the patients varied between 18-47 years (with
an average of 34), all of them being still menstruat-
ing. 53 patients were referred for associated infertili-
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ty. 37 out of the 40 patients who did not receive any
postoperative treatment were infertile and willing to
be able to conceive as soon as possible after the oper-
ation.
Results
Desorgestrel was well tolerated and no patient had to
withdraw because of side effects. 48 women became
amenorrhoeic, 23 had irregular vaginal bleeding and 9
women had regular periods. The bleeding amount was
described as much lower than a normal period. 12 pa-
tients complained of weight gain, the maximum being
5 kg. 5 patients complained of vaginal dryness and
sexual discomfort. 4 patients treated with desorgestrel
had another laparoscopy after 6 months to check tubal
patency and in none of them recurrent lesions were
seen.
The cyst recurrence rate was significantly lower (5%)
in the desorgestrel group than in the control group
(37,5%), as well as the pelvic pain, dyspareunia and
dysmennorrhea. The main side effects during des-
orgestrel treatment were amenorrhea, irregular bleed-
ing, weight gain and decreased libido. 
Conclusions
According to the Practice Committee of the American
Society for Reproductive Medicine (2008), ‘en-
dometriosis should be viewed as a chronic disease that
requires a life-long management plan with the goal of
maximizing the use of medical treatment and avoiding
repeated surgical procedures’. Medical treatment
should reach two main goals: relief of pain for pro-
longed periods and prevention of disease progression
during the interval between conservative surgery and
conception seeking.
Continuous desorgestrel treatment significantly pre-
vents recurrence of endometriosic cysts and clinical
symptoms related to endometriosis. Desorgestrel of-
fers the associated benefits of a well-tolerated contra-
ceptive and allows a safe delay for child planning with-
out risking a recidive of the disease. This therapy is
low-cost, efficient and brings a considerable improve-
ment of patients’ quality of life.
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TABLE I - RECURRENCE RATE OF CYSTS AND SYMP-
TOMS IN THE STUDY GROUPS.
Desorgestrel group No treatment
(n=80) group (n=40)
Cyst recurrence rate at 6 months, % 5 37,5
Pelvic pain 6 15
Introduction
Endometriosis is a chronic condition characterized by
the presence of endometrial tissue outside the uterine
cavity. It affects between 2 and 7% of young women
of mainly of reproductive age (1-3). The first and best
treatment option is surgery, even so, recurrence rates
are high at 47% (4-6). Recent treatment studies have
aimed to reduce the number of invasive procedures,
improve prognostic evolution, and reduce recurrence
indices. 
However, testing treatments with new medications re-
quires experimental models prior to clinical tests with
humans. We decided to use acetylsalicylic acid (as-
pirin) in this study because of its widespread use and
previous experimental data that we have gathered on
the subject (9-14). 
Materials and methods
Animal housing and endometriosis induction
Forty female adult virgin rabbits were used, weighing
approximately 1500g; All animals were submitted to
implant of endometrium according to technique de-
scribed by Silva et al. (2004) (17). 
Second surgical procedure and groups
Thirty days after endometrial tissue implants, all ani-
mals were randomly allocated into four groups (10
rabbits per group): Group 1 (control): treated with
physiological solution; Group 2 (acetylsalicylic acid):
treated with acetylsalicylic acid; Group 3 (Control):
treated with physiological solution; and Group 4
(acetylsalicylic acid): treated with acetylsalicylic acid. 
Solution test
A 5% solution was obtained by diluting 2500mg of
acetylsalicylic acid in 50ml 10% sodium bicarbonate
and applied by insulin syringe and needle directly in-
to the endometriosis foci. 
Protocols 1 and 2
The early effects were evaluated by sacrificing rabbits
(Groups 1 and 2) 24h after (Protocol 1), and the late
effects by sacrificing rabbits (Groups 3 and 4) 10 days
after the end of treatment (Protocol 2). 
Third surgical procedure 
After sacrifice, all rabbits were submitted to a third la-
parotomy to collect and perform gross analysis on
specimens. All gross characteristics and sizes (width
and length) of all endometriotic implants were evalu-
ated using a pachymeter. 
Effects of treatment evaluation
Fragments were prepared for mounting on histologi-
cal slides. After histological evaluation, the whole re-
maining area of endometrial tissue was analysed using
OPTIMAS® 6.1 System imaging software. 
Statistical analysis
To analyze the results Kolmogorov-Smirnov, ANOVA
and Tukey test was used. 
Results
Protocol 1
Group 1–Control
Histopathological analyses of these 9 lesions were con-
sistent with endometriosis (Fig. 1). 
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Group 2–Acetylsalicylic acid 
Microscopically, all collagen capsule neoformed cyst
slides were covered by a fusiform columnar epitheli-
um, associated with neutrophil exudation differing
from the endometriosis cysts on the Control group
slides (Fig. 2).
Control Group versus Acetylsalicylic acid Group
A significant difference was found between the two
groups. The affected area in acetylsalicylic acid- treat-
ed animal implants was smaller than in the control
group one day after treatment; this was also observed
in analysis of the remaining endometrial tissue. 
Protocol 2 
Group 3–Control 
Microscopic analyses were consistent with endometri-
al tissue cyst (Fig. 3). The endometrium was in the
proliferative phase, demonstrating that the endometri-
al tissue was in free growth during this period.
Group 4–Acetylsalicylic acid 
Histopathological evaluation of these lesions revealed
endometrial tissue with rare stroma in 7 implants, on-
ly one of these with a bleeding focus. On 6 slides, en-
dometriotic foci with their respective stroma were sur-
rounded by weak conjunctive tissue delimiting en-
dometrial islands. Inflammatory cells could be seen in
the formed lumen, thus maintaining columnar epithe-
lial integrity (Fig. 4). 
Control Group versus Acetylsalicylic acid Group
A significant difference was found between the two
groups. The affected area in acetylsalicylic acid- treat-
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Fig. 1 - Group 1 (Control) after 24 Hour – Well developed cystic formation
with bleeding foci, visualized in stromal vessels. (10x – HE staining).
Fig. 2 - Group 2 (Acetylsalicylic acid) after 24 Hour – Granulomatous reac-
tion around the suture thread formed by newly formed conjunctive tissue
and covered by tall columnar epithelium of fusiform cells. Differently to no
treated tissue (PBS) sinuous endometrial glands and hemo-neutrophilic
exudate (arrows) can be seen. (10x magnification – HE staining).
Fig. 3 - Group 1 (Control) after 10 days - Endometrial implant and cystic
configuration, covered by epithelium in proliferation. (10x magnification –
HE staining).
Fig. 4 - Group 2 (Acetylsalicylic acid) after 10 days - Clusters of endometri-
al tissue isolated by conjunctive tissue, circular formations of endometri-
um, showing inflammatory exudate from stroma composed of neutrophils,
macrophages with intracellular lipid content, and cell debris (arrows) (10x
magnification – HE staining).
ed animal implants was smaller than in the control
group 10 days after treatment; this was also observed
in analysis of the remaining endometrial tissue. 
Gross (area) and histological (percentage remaining)
measurements
Tables 1 and 2 show that the percentage of remaining
viable endometrial tissue was much lower in acetylsal-
icylic acid-treated groups 2 and 4 than that in saline
solution groups 1 and 3 (p<0.0001); this was also true
for total lesion area (gross evaluation).
Protocol 1 versus Protocol 2
Statistical analysis comparing protocol 1 to 2 showed
no differences between the controls groups, or the
acetylsalicylic acid groups (p=0.2905), and no differ-
ences between times (p=0.7475).
Discussion
Acetylsalicylic acid is a well-known inhibitor of cy-
clooxygenase activity, even 100 years after its discovery
new possibilities are still being explored. 
Based on previous reports (10,11), we decided to eval-
uate the effects of acetylsalicylic acid at two different
moments (24 hours and 10 days after intra-lesion ap-
plication); acetylsalicylic acid concentration (5%) and
quantity injected in each animal in this study were al-
so based on these studied (10-12).
The study solution effectively induced a neutrophilic
inflammatory response in the first 24 hours after ap-
plication. In the long term (2-10 day protocol), there
was less tissue growth, which was held inside weak new
conjunctive tissue. The inflammatory reaction also
lasted over 10 days, but without direct destruction of
epithelial tissue from the endometrium, in contrast to
reports from in vitro studies (9,12).
The effect of acetylsalicylic acid in promoting en-
dometrial tissue destruction was clearly observed both
macroscopically by the evidence of smaller lesions and
by the important decrease in viable endometrium in
these lesions. 
When the effect of time was analysed, no difference
was seen between 24 hours and 10 days, which means
that acetylsalicylic acid can destroy endometrial tissue
24 hours after injection, and that the effect continues
to prevent endometrial growth over time (10 days).
We observed that physiological solution allows frag-
ment evolution and free development of implanted
tissue over time without causing any inflammatory
changes.
As pointed out in the Introduction, data is scarce in
literature on the use of topical and local medicines in
endometriosis treatment, which makes comparing our
results with other studies difficult. However, the good
results found in our previous investigations (9-13) us-
ing acetylsalicylic acid and its derivatives reinforce the
results shown in this study.
In this experimental study, acetylsalicylic acid directly
injected into endometriosis foci was very effective in
their destruction; this presents new perspectives for
endometriosis treatment and its clinical application
based on further clinical studies.
Financial Support: FAPESP - BRAZIL
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TABLE 1 - MEAN AND STANDARD DEVIATION VALUES FOR ENDOMETRIAL TISSUE AREA FOR EACH TIME AND
GROUP.
Time Group No. of observations Mean Standard deviation P-value
24h
Control 10 7124.40 (A) 665.21
<0.0001Aspirin 10 4293.20 (B) 784.42
10d
Control 10 7015.70 (A) 1316.18
<0.0001Aspirin 10 4010.40 (B) 1037.85
Means followed by same letter do not differ significantly at 5% of probability by Tukey test.
TABLE 2 - MEAN AND STANDARD DEVIATION VALUES FOR ENDOMETRIAL TISSUE PERCENTAGE FOR EACH TIME
AND GROUP.
Time Group No. of observations Mean Standard deviation P-value
24h
Control 10 80.20 (A) 6.41
<0.0001Aspirin 10 10.20 (B) 4.13
10d
Control 10 81.70 (A) 9.71
<0.0001Aspirin 10 7.40 (B) 2.88
Means followed by same letter do not differ significantly at 5% of probability by Tukey test.
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Introduction
Endometriosis is a gynaecological condition character-
ized by ectopic endometrial tissues located outside of the
uterus, most commonly found on the pelvic peritoneum
or ovary. Endometriosis, occurs in about 7-10% of
women in the general population and 71-87% of
women with chronic pelvic pain (Ozawa et al. 2008).
The pathogenesis of this gynaecological condition re-
mains enigmatic and its long-term management may
be inadequate in a substantial number of patients
(Szamatowicz 2008). Endometriosis may be totally
asymptomatic or reveal itself by severe intractable dys-
menorrhoea, menorrhagia, and dysparuenia. Distress-
ing complications related to endometriosis also include
infertility and gynaecological surgical interventions for
endometriomas and adhesion formation. In some cas-
es the only definitive treatment is a total abdominal
hysterectomy and bilateral salpingo-ophorectomy. 
The anatomical proximity of the female reproductive
organs and the gastrointestinal tract may infer at the
possibility of a relationship between both systems. En-
dometriosis has been shown to be a significant cause of
gastroenterologic distress in young women. Clinical
manifestations vary considerably depending upon the
anatomic extent of disease, abdominal complaints and
physical findings frequently resulting in misdiagnosis
and delayed recognition of gastrointestinal involve-
ment (Zwas et al. 2008). Moreover endometriosis may
coexist with or be misdiagnosed as inflammatory bow-
el disease (Seaman et al. 2008). 
Gastrointestinal symptoms may suggest bowel pathol-
ogy or possible dietary intolerance. The latter possibil-
ity is related to immunological surveillance which may
be altered even in the peritoneal milieu. Deficient
peritoneal surveillance has been shown to correlate
with the existence of peritoneal endometriosis (Ulukus
et al. 2008). Indirectly dietary intolerance may there-
fore encourage the endometriotic peritoneal coloniza-
tion by retrograde menstrual flow. 
This study looked at the 54 women, divided in two
groups differentiated by the diagnosis of laparoscopi-
cally confirmed endometriosis. A questionnaire was
devised to detect the occurrence of gastrointestinal/gy-
naecological/general symptoms and dietary intoler-
ance in these two groups of women.
Materials and methods
Fifty-four women who complained of gynaecological
symptoms and/ or complained of infertility under-
went laparoscopy in effort to reach a diagnosis. These
women were recruited sequentially into the study so as
to avoid bias (age range 20-55 years). The study was
conducted at Department of Obstetrics and Gynaecol-
ogy, St Luke’s Hospital and Mater Dei Hospital from
1st January 2005 to 31st December, 2007. 
Following the laparoscopy a questionnaire was set up
so as to enquire on occurrence of dietary intolerance
and gastrointestinal and gynaecological symptoms in
these women.
Results (Tables 1-9)
Out of a total of 54 women, twenty-two women were
diagnosed to have pelvis endometriosis. The group of
women in the endometriosis group were significantly
younger than the other group The gynaecological and
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past obstetric history did not reveal any significant dif-
ferences between both groups. Due to the small num-
ber of events occurring within each variable, the
groups were compared by category of events i.e. gas-
trointestinal symptoms, dietary intolerance, general
and gynaecological symptoms. 
When all the gastro-intestinal symptoms were collated
together, these symptoms were more commonly found
in the endometriosis group (53%) as compared to the
other group of women (31%). Similarly more women
with endometriosis complained of intolerance to one
or more dietary components (26% versus 14%). These
differences did not reach statistical significance possi-
bly because the study was not adequately powered to
show this. No significant differences were noted for
the other parameters such as infertility, gravidity/pari-
ty, gynaecological and general symptoms.
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TABLE 3 - GYNAECOLOGICAL HISTORY OF WOMEN RECRUITED IN STUDY.
Number of Patients Menarche Regular cycles Irregular Cycles Duration Menstrual Cycle 
No Endometriosis 34 12.2 27 5 5.8 30.4
Endometriosis 23 12.4 20 2 4.7 26.2
TABLE 4 - GASTROINTESTINAL SYMPTOMS IN BOTH GROUPS OF WOMEN.
Number of Patients Abdominal Pain Constipation Diarrhoea Bloating Flatulence 
No Endometriosis 34 23 14 5 13 14
Endometriosis 23 22 18 9 9 9
Number of Patients Flatulence Heartburn Indigestion Belching Mucus in stools 
No Endometriosis 34 14 9 5 6 0
Endometriosis 23 9 19 14 4 2
TABLE 5 - DIETARY INTOLERANCE TO VARIOUS TYPES OF FOOD.
Number of Patients Bread Pizza Pasta Red Meat White Meat 
No Endometriosis 34 9 9 5 0 2
Endometriosis 23 10 10 5 3 0
Chicken Fish Dairy Products Milk Yoghurt Vegetables 
No Endometriosis N=34 1 1 5 4 1 8
Endometriosis N= 23 0 0 8 7 3 11
TABLE 6 - PAST OBSTETRIC HISTORY.
Number of Patients Gravidity/woman Parity/woman Miscarriages /woman
No Endometriosis 34 2.2 1.9 18
Endometriosis 23 2.1 1.9 9
Number of Patients Infertility Duration of Infertility (years) Primary Infertility Secondary Infertility 
No Endometriosis 34 13 3.6 3 10
Endometriosis 23 8 4 6 2
TABLE 1 - CHARACTERISTICS OF PATIENTS RECRUITED
FOR THIS STUDY.
Number Age Laparoscopy Laparotomy
of Patients
No Endometriosis 34 44.6±9.2 32 2
Endometriosis 23 39±10.2 21 2
TABLE 2 - REASONS FOR LAPAROSCOPY.
No Endometriosis Endometriosis Group
Dysmenorrhoea/Dysparuenia 12 10
Ovarian Cyst 4 1
Infertility 10 8
Pain 8 4
Total 34 23
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Discussion
This study reviewed a large number of variables be-
tween two groups of women who required laparoscopy
so as to establish a diagnosis for a variety of gynaeco-
logical complaints. The two groups were differentiated
by the presence of pelvic endometriosis which was
found in twenty-three of the fifty-four women recruit-
ed. Following the laparoscopy a large number of symp-
toms were broadly categorized into gastrointestinal
symptoms, gynaecological complaints, general symp-
toms and enquiry on dietary intolerance to a variety of
foods was asked in a comprehensive questionnaire.
The results were assessed on individual symptoms and
according to symptom category. In view of the large
number of individual complaints the parameters were
statistically examined according to category. The two
categories covering gastrointestinal symptoms and di-
etary intolerance showed nonstatistically different re-
sults when comparing both groups of women. When
comparing gynaecological complaints and general
symptoms no statistical difference was borne out.
Gastrointestinal symptoms and dietary intolerance (in
the main gluten and lactose based) are obviously linked
and this finding may explain the above findings. It is
interesting to note that both variables showed the same
trend in the group of women with endometriosis. This
suggests a connection possibly due to an underlying
immunological cause that may be relevant to the
pathogenesis and may possibly shed light on a more ef-
fective management of endometriosis. 
Current thinking supports the initiating mechanism
to peritoneal endometriotic colonization to be due to
retrograde menstrual flow as expounded by Sampson.
However, since retrograde menstruation occurs in
most women of the reproductive age, it is clear that
TABLE 8 - GENERAL SYMPTOMS.
Number of Patients Wheezing Hypothyroid Depression Numbness
No Endometriosis N = 34 9 4 7 14
Endometriosis  N = 23 9 2 13 8
Number of Patients Painful joints PID Drowsiness Irritability Poor Coordination 
No Endometriosis N = 34 14 6 13 17 7
Endometriosis N = 23 12 3 9 14 6
Number of Patients Mood Swings Headaches Muscle ache Muscle weakness
No Endometriosis N = 34 14 25 15 4
Endometriosis N = 23 15 14 14 7
Number of Patients Dizziness Swollen fingers Itching Rashes
No Endometriosis N = 34 14 10 11 0
Endometriosis N = 23 9 7 4 2
TABLE 9 - COMPARISON OF OCCURRENCE OF EVENTS BY CATEGORY IN BOTH GROUPS OF WOMEN.
N Gastrointestinal Symptoms Dietary Intolerance Gynaecological Symptoms General Symptoms
No Endometriosis 34 89 45 82 190
Endometriosis 23 105** 57* 69 149
p= NS P=NS p=NS p=NS
TABLE 7 - GYNAECOLOGICAL HISTORY.
Mild Dysmenorrhoea Moderate Dysmenorrhoea Severe Dysmenorrhoea
No Endometriosis N=34 12 6 5
Endometriosis N=23 11 6 6
Mild PMS Moderate PMS Severe PMS Superficial Dysparuenia Deep Dyspareunia 
No Endometriosis N=34 10 7 4 4 4
Endometriosis  N=23 14 3 4 7 9
there must be other factors which may contribute to
the implantation of endometrial cells and their subse-
quent development into endometriotic disease. Fol-
lowing the retrograde menstrual flow a number of im-
munological mechanisms have been implicated. There
is a substantial body of evidence to support that the al-
terations in both cell-mediated and humoral immuni-
ty contribute to the pathogenesis of endometriosis
(Ulukus et al. 2005). 
Alterations in cellular immunity may result in inade-
quate removal of ectopic endometrial cells from the
peritoneal cavity. This may be deduced by the increased
number and activation of peritoneal macrophages and
the paradoxically decreased T cell and natural killer cell
cytotoxicities in the presence of endometriosis natural
killer activity and the cytotoxicity against autologous
endometrial cells have been shown to decrease in
women with endometriosis and correlate with the
severity of the disease. Decreased cytotoxicity to en-
dometrial cells in women with endometriosis is there-
fore thought to be due to a defect in natural killer ac-
tivity but is also partially because of a resistance of the
endometrium to natural killer cytotoxicity (Oostelynck
et al. 1991). Polymorphisms in killer cell immunoglob-
ulin-like receptors may be responsible, in part, for ge-
netic susceptibility to endometriosis. The frequency of
killer cell immunoglobulin-like receptors (KIR3DS1)
has been shown to be s significantly decreased in pa-
tients with endometriosis compared with controls
(32% versus 44%, P=0.028). These results suggest that
polymorphism in killer cell immunoglobulin-like re-
ceptors may be associated with susceptibility for en-
dometriosis (Kiwatawa et al. 2007).
Increased levels of several cytokines and growth fac-
tors which are secreted by either immune and en-
dometrial cells seem to promote implantation and
growth of ectopic endometrium by inducing prolifer-
ation and angiogenesis. Immunoreactivities of both
chemokines interleukin-8 (IL-8) and monocyte
chemotactic protein-1 (MCP-1) have been shown to
be significantly increased in the epithelial cells of ec-
topic endometrial tissues compared with those of nor-
mal endometrium. These findings suggest that IL-8
and MCP-1 may be involved in the pathogenesis of
endometriosis (Ulukus et al. 2008). Serum levels of
MCP-1 were found to be significantly higher in pa-
tients with endometriosis. These results imply the po-
tential of MCP-1 measurements for the diagnosis of
endometriosis (Agic et al. 2008).
Tumour necrosis factor alpha of peritoneal fluid is be-
lieved to have important pro-inflammatory and angio-
genic activities in the complex mechanisms of devel-
opment of peritoneal endometriotic lesions. Impair-
ment of macrophage function supports the theory that
an inappropriate immunological reaction of the peri-
toneal milieu to retrograde ejected endometrium may
play a part in the initial phases of endometriotic im-
plants (Calhaz-Jorge et al. 2000).
In addition to the impaired capacity of the immune
cells to mediate endometrial cell removal, inherent re-
sistance of the ectopic endometrial cells against im-
mune cells is another interesting concept in the patho-
genesis of endometriosis. In the initial stages of en-
dometriosis the activated peritoneal fluid natural killer
cells can be intensively eliminated, thus providing con-
ditions for the survival of ectopic endometrial cells and
the development of the disease (Eidukaite et al. 2006).
Sera from patients with endometriosis suppressed nat-
ural killer cell zeta expression, which resulted in sup-
pression of these cell interferon gamma induction
(Bohler et al. 2007). Increased expression of
CD94/NKG2A in peritoneal natural killer cells may
mediate the resistance of endometriotic tissue to natu-
ral killer cell-mediated lysis, thus contributing to the
progression of endometriosis (Galandrini et al. 2008).
Endometriosis has also been considered to be an au-
toimmune disease, since it is often associated with the
presence of autoantibodies, other autoimmune dis-
eases, and possibly with recurrent immune-mediated
miscarriage. Patients with endometriosis also exhibit
autoantibodies reactive with cellular proteins; en-
dometrial membrane proteins exhibited the greatest
reactivity, followed by nuclear antigens. A spectrum of
auto-immunity has been noted when in subcellular
fractions, patients with stage III endometriosis exhib-
ited significantly more immunoreactivity than did
stage II patients, which was greater than that observed
in stage I patients (Bohler et al. 2007). 
Immune reactions similar to those found in en-
dometriosis have been shown with dietary proteins
such as gluten and casein may result in alteration in
both humoral and cell mediated immunity. In partic-
ular, similar cytokines and T cell reactivity have been
noted in endometriosis and oral dietary gluten and
lactose intolerance. Abnormal immunity to foods, due
to inappropriately high titers of antibodies or qualita-
tively altered cell mediated responses such as natural
killer cells, produce disease. This may be epidemiolog-
ically significant its prevalence in some populations,
for example of lactase deficiency, with dose-related
lactose and milk-intolerance, occurring in as much as
50-90% of most populations. (Ferguson 1995).
Immunoregulatory invariant natural killer cells rap-
idly produce interleukin (IL)-4 and other cytokines
that suppress a Th1 response and are deficient in
some autoimmune diseases and this deficiency is
thought to also influence the immunoregulatory nat-
ural killer T-cells in gluten enteropathy. Natural killer
T-cells in coeliac subjects were shown to be reduced to
30% of those in normal subjects. These findings sug-
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gest that immunoregulatory natural killer T-cells are
deficient in celiac disease (Grose et al. 2007, Grose et
al. 2008).
Ingested gliadin, the triggering agent of the disease on
crossing the epithelial barrier may elicit a harmful T
cell-mediated immune response. This seems to be me-
diated through an increased secretion of chemokines
and cytokines mainly of IL-6, IL-8, IL-10, TNF-al-
pha, growth-related oncogene, MCP-1 and
macrophage-derived chemokine. Maturation was ac-
companied by a greater capacity to stimulate prolifer-
ation of allogeneic T cells and significantly reduced
endocytic activity (Palova-Jeninkova et al. 2005).
As regards milk intolerance, lactose has been shown to
block galectin-3 is a beta-galactoside-binding protein
implicated in diverse biological processes. Galectin-3
induces a human monocyte migration in vitro in a
dose-dependent manner, and it was chemotactic at
high concentrations but chemokinetic at low concen-
trations (Sano et al. 2000).
A lactose-binding protein, MCF-pl5-L exhibited an
evident dose-dependent monocyte chemotactic activi-
ty for monocytes and macrophages. The biological
functions of MCF-pl5-L include prolonging the life
span of macrophages, probably by inhibiting apoptosis
of macrophages, and stimulate the production of
TNF-alpha from macrophages (Yamanaka et al. 2000). 
The immunological pathways of both endometriosis
and food intolerance are undoubtedly protean as evi-
denced by the abundant and complex literature cur-
rently available. It is not unreasonable that however
complex these immunological pathways are they may
each other’s path including in the initiation of disease.
The findings in this study may lend support to this hy-
pothesis with the significant preponderance of gas-
trointestinal symptoms and frequency of dietary intol-
erance noted in the women diagnosed with en-
dometriosis.
Undoubtedly further research in this direction is re-
quired. However if a connection between endometrio-
sis and dietary intolerance is indeed proven this may
have a favourable impact on the deduction of the
pathogenesis of endometriosis and possibly a useful
adjunct in the treatment of this enigmatic disease. 
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Introduction
At present most investigators consider hormonal re-
placement therapy (HRT) in peri- and postmenopause
pathogenetically proved as it provides adaptation of
women’s organism to a new metabolic balance as a re-
sult of ovarian failure (1). But various types of HRT,
different in the way of drug effect, especially progestin
effect, HRT regimens, dose schedule may have differ-
ent effects on cardiovascular system. Most progestins
found in HRT combinations are third generation
agents. In the present study was used HRT, containing
drospirenone, a spironolactone analogue, which has a
unique pharmacologic profile that is similar to that of
natural progesterone (2). It combines progestogenic,
antimineralocorticoid properties and has virtually no
androgenic activity. As a component of HRT regimen
its antimineralocorticoid effects may prevent weight
gain secondary to water retention and the decrease of
blood pressure (3). The prospective, controlled cohort
study EURAS-HRT (European Active Surveillance
Study of Women taking HRT) showed the decrease in
systolic blood pressure and stable body weight in the
E2/DRSP group and these effects were consistent with
drospirenone anti-aldosterone properties (4). Thus,
the objectives of our study were to estimate-
menopause-related symptoms and consider the influ-
ence of HRT on blood pressure (BP), waist circumfer-
ence, body mass in postmenopausal women. 
Materials and methods
This prospective study included examination of 170
postmenopausal women, average age was 51.0±5.0
years. All women underwent clinical, laboratory, ultra-
sound, X-ray and cytological examination. It is known
that after menopause women have a tendency to de-
velop different components of metabolic syndrome
which to a certain extent explains the cardiovascular
risk increase. That is why we estimated anthropomet-
rical parameters, including weight, body mass index
(BMI) and waist circumference (WC). While ques-
tioning patients we used Kupperman menopausal in-
dex, Spielberger test assessing personality and reactive
anxiety, Beck scale assessing the presence and expres-
siveness of depression and eating behavior tests (emo-
tional, external, restrictive). The 24-hour ambulatory-
blood pressure monitoring data and officeblood pres-
sure measurement were also determined. The study
lasted 12 months. According to the results of anthro-
pometrical measurement the average waist circumfer-
ence was 84.5+13. 4sm, average BMI was 27.3+1.4
kg/m2 and average weight was 73.5+14.1 kg. Average
systolic blood pressure (BP) before the therapy was
140.8+5.0 mmHg and diastolic BP was 77.9+5.0
mmHg. Different menopausal symptoms included:
hot flushes-72.3%, joint and muscular discomfort -
69.5%, sexual problems-70.1%, dryness of vagina-
68.9%, physical and mental exhaustion-50.7%, irri-
tability-70.1%, insomnia-43.6%, depression- 30.4%,
heart discomfort-35.1%. According to the results of
the examination women who had indications and
without contraindications, willing to get HRT, were pre-
scribed 1mg 17-beta-estradiol and 2mg drospirenone.
Exclusion criteria were: arterial hypertension stages 2
and 3, secondary (symptomatic) hypertension, coro-
nary heart disease, territorial stroke or transient is-
chemic attack in anamnesis; diabetes mellitus 1 and 2
types; comorbidities demanding additive therapy and
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making difficult the evaluation of drug effectiveness
and tolerance, severe hepatic disorders, verified or sup-
posed diagnosis of breast cancer, verified or supposed
diagnosis of premalignant estrogen-depended disease
or estrogen-depended cancer; history of venous and
arterial thrombosis and thrombembolia; unknown
bleeding from genital tracts; hypertriglyceridemia (>6
mmol/L). 
Results
We noted a general decrease of the manifestation de-
gree of complaints in women, who were prescribed
HRT (p<0.05), after 12 months. HRT resulted in
40% decrease of the sympathetic nervous system
tonus, associated with the decrease of systolic blood
pressure (SBP) and diastolic blood pressure (DBP) by
8.7 mm.Hg and 5.3 mm.Hg respectively (p<0.001).
The HRT, containing 1mg 17-beta-estradiol and 2 mg
drospirenone was efficacious in the treatment of
menopausal disorders (p<0.005). After 12 months-
there was observed the decrease of psycho-emotional,
vegetative-vascular, metabolic-endocrine disorders.
The average grade of vegetative-vasculardisorders was
3.3+0.5, psycho-emotional disorders was 1.6+0.3,
metabolic-endocrine disorders was 1.1+0.2(p<0.05).
Mild degree of vegetative-vascular disorders was pres-
ent in 3% women, and 97% had less than 10 grades,
i.e. vegetative-vascular disorders were practically ab-
sent. 50% women had milddegree of psycho-emotion-
al disorders, 3.1% had meandegree, a severe degree of
symptoms was absent. Metabolic-endocrine disorders
were of mild degree and were present in 90% of
women. The average gradewas 1.1+0.2. Our study
demonstrated positive interactions between HRT pre-
scription and significant decrease of SBP and DBP.
The HRT has a favorable influence on the body mass
and waist circumference. Waist circumference de-
creased by 1.7 sm (12% of initial value), weight de-
creased by 3.3 kg. BMI decreased from 27.3+1.4
kg/m2 to 25.6+1.2 kg/m2. The side effects were mini-
mal, of temporary character and did not influence
therapy compliance. 
Discussion
Climacteric is one of the major risk factors developing
CVDs in middle-aged women (5,6,7). And though
menopause is not a disease, it leads to the impaired en-
docrine balance in the organism contributing to CVD
developing. The main way to correct the climacteric
disorders is HRT prescription. The effectiveness of
HRT according to data of different studies ranges
from 70 to 90%. Many authors recognize that the ef-
fect from HRT varies concerning different symptoms
of climacteric syndrome, and is dependent on the
characteristic of present complaints and components
of the drug. After the menopause begins, women have
a tendency to develop different components of the
metabolic syndrome which to a certain extent explains
the cardiovascular risk increase. Weight gain is fre-
quent in postmenopausal women. Particularly, the
menopause is associated not with the increase of sub-
cutaneous fat, but with the developing visceral obesity
(intra-abdominal visceral fat, epicardial adipose mass,
liver fat). It is now well- established that abdominalcir-
cumference, which is used as a surrogate marker of vis-
ceral fat, is an easily available clinical measurement of
both cardiovascular risk and type 2 diabetes risk in
obesity. An expanded visceral fat mass, when measured
as waist circumference, is a better predictor of insulin
resistance, dyslipidemia, low-grade inflammation, and
other risk factors for both type 2 diabetes and cardio-
vascular disease than obesity measured with body mass
index. Besides, obesity is associated with the BP in-
crease, especially SBP that is associated with a higher
cardiovascular risk than DBP in women with arterial
hypertension (8). Studying the impact of HRT on car-
diovascular system and metabolic parameters will en-
able to use it wider and more rationally in complex
therapy of climacteric syndrome in postmenopausal
women. The differentiated approach of hormonal
therapy with the integrated evaluation of the quality of
life, emotional background, expressiveness of climac-
teric syndrome, status of cardiovascular system is very
important and timely. 
Conclusion
In conclusion, the HRT prescription, containing 1mg
17-beta-estradiol and 2mg drospirenone, showed a
significant decline of menopause disorders and a sig-
nificant decrease of SBP and DBP. Positive changes
with the HRT prescription are more expressed in
women with initial metabolic disturbances. 
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Introduction
Among traditional risk factors, associated with increased
arterial stiffness, the age-related estrogendeficiency is par-
ticularly important. Cardioprotective effect of female hor-
mones is determined by their beneficial impact on lipid
profile changes (1), improvement of the endothelium
functional condition, suppression of vascular smooth
muscle cell’s proliferation, the decrease of collagen produc-
tion in vascular wall in a response to injury, blocking slow
calcium canals and antimineralcorticoid activity, the de-
crease of inflammatory processes associated with atheroge-
nesis, the suppression of procoagulation activity (2,3).
With hormonal changes, occurring in menopause, special
clinical features, characteristic of early climacteric period,
begin to appear: psycho-emotional, vegetative-vascular,
metabolic-endocrine disorders (4,7). Because of estrogen
deficiency the balance of vasoactive mediators is impaired
with the predominance of vasoconstriction production
and vasodilatation secretion decline, reported increased
collagen production in vascular wall that initiates process-
es of vascular remodeling and results in the arterial stiffness
increase. Presumably, early prescription of combination
hormonal therapy, containing estradiol and drospirenone
in premenopausal women could have a beneficial impact
on arterial stiffness. The aim of this work was to study the
dynamics of indicators, characterizing circadian arterial
stiffness, in perimenopausal women and its variation dur-
ing combined oral contraception containing drospirenone
3 mg and etinilestradiol 20 mcg in take.
Methods
The study included 65 women: group 1 consisted of 37
women in premenopause with climacteric symptoms who
were prescribed combined oral contraceptive containing
drospirenone 30mg and ethinylestradiol 20 mcg, average
age was 49.2±2.6years, and control group 2-28 women in
perimenopause, average age was 53.3±5.1 years
(p<0.001), who didn’t take oral contraceptives. In group
1-6 women (16.2%) had obesity stage 1 and 3 women
(8.1%) with stage 2. In control group 2: 6 women
(21.4%), 4 women (14.3%) and 2 women (7.1%) had
obesity stage 1, 2 and 3 respectively. Duration of hyper-
tension stage 1 was on average 1.2+1.1 years in group 1
and 1.3+1.1 in group 2. Body mass index (BMI) was
27.3+5.2 kg/m2, waist circumference (WC) was
85.5+12.9sm in comparison with group 2: BMI was
30.5+5.7kg/m2, WC was 95.4+14.8sm (p<0.01) respec-
tively. The study lasted 12 months. All patients underwent
clinical examination, including the anthropometrical
measurement, 24-hour ambulatory blood pressure moni-
toring (ABPM) with determining pulse blood pressure
(PBP), arterial oscillometry for vascular stiffness evalua-
tion. During arterial stiffness examination there were esti-
mated pulse transit time (PTT2), augmentation index
(AIx,%), arterial stiffness index (ASI) and ambulatory ar-
terial stiffness index (AASI), modified indices PTT100-
60, ASI100-60 AIx-75. All women underwent ECHO-
KG with determining aortic pulse wave velocity (PWV).
Unlike aortic pulse wave velocity, as a more direct indica-
tor, characterizing the arterial stiffness, such values as aug-
mentation index, arterial stiffness index of the brachial ar-
tery and ambulatory arterial stiffness index are indirect in-
dicators of arterial stiffness (6). 
Results
In the study we found that BP dynamics with the begin-
ning of the menopause has its particular characteristics
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–predominant systolic blood pressure (SBP) increase,
higher PBP level, insufficient SBP and diastolic blood
pressure (DBP) nocturnal decrease, higher BP variability.
According to the results it was established that arterial stiff-
ness is a dynamic characteristics and the dynamics of indi-
cators shows the decrease of arterial elastic properties in
women during menopause. Vascular elastic properties dif-
fer along the arterial tree – proximal arteries are more elas-
tic than the distal ones and, consequently, PWV differs a
lot in various regions of the arterial bed. It was shown that
normal PWV rate varies from 4 to 6 m/s and in arteries of
muscular type it increases to 8-12 m/s (6). 
After 12 months PWV mediana was significantly higher
in group 2: 7.2 (5.9;8.3) m/s in group 1 and 6.4
(5.7;7.3)m/s in group 2 respectively (p<0.05). Significant
increase of PBP was marked in group 2: 49.5(42.0;56.0)
mm.Hg versus group 1: 43.5(39.0;45.0) mm.Hg
(p<0.05). PBP is determined as an interaction between
left ventricular contractile function and expansibility of
magistral arteries (direct component) and the value of the
reflected wave (indirect component). The PBP and SBP
increase is associated with the elevation of arterial stiffness
and accompanied by the increase of wave reflection ampli-
tude. PBP is an independent factor of cardiovascular
events and demonstrates the real arterial age (5,6). The in-
crease of AIx-75 was observed in 39.2% women in group
2 and in 10% in group 1 (p<0.05) respectively. AIx-75 is
a modified index, characterizing the expressiveness of the
reflected wave and its contribution to the PBP increase.
Main factors, determining this parameter, areaortic rigidi-
ty and peripheral resistance. 
The value of AIx can potentially be considered as a crite-
rion of cardiovascular risk. In perimenopausal women
higher ASI100-60 – 125.0(110.0;160.0) c.u. was ob-
served compared with group 1 - 114.0 (104.0;124.0) c.u.
(p<0.05). ASI is a dynamic parameter, reflecting arterial
stiffness and depends on structural changes in arteries, BP
level and vascular tone. At present the significance of this
parameter continues to be specified, but recent data points
to its possible prognostic role in cardiovascular risk evalu-
ation. At the moment of the research termination there
was marked the decrease of pulse blood pressure (PBP) to
1.2 mm.Hg, modified index AIx-75 to 1.2%, ASI on 10.2
c.u. (p=0.06), AASI on 0.04 and the increase of modified
index PTT2100-60 on 3.8 ms. Women in control group
2 had the opposite changes: PBP increase by 2 mm.Hg,
AIx-75 by 7.4% (p=0.06), ASI by 9.7 c.u., AASI by 0.02
c.u. and significant decrease of daily average modified
PTT2100-60 by 10.5 ms (p<0.01). PWV significantly
decreased by 0.2m/s in group 1 and increased by 0.2m/s
in group 2 (p>0.05). In comparison with daytime it was
mentioned that in nocturnal hours there were determined
significantly higher values of Aix, a distinct tendency to
the ASI, modified AIx-75 and ASI100-60 increase, signif-
icantly less values of PTT2100-60. According to the re-
sults of the study there were detected interactions between
PWV and main studying parameters. There were deter-
mined moderate correlations between PWV and PBP
(R=0.43,p<0.001), PWV and AIx-75(R=0.35,p<0.01),
PWV and PTT2100-60 (R=-0.5,p<0.0001), average dai-
ly SBP variability (R=0.57, p<0.00001) and DBP (R=
0.60, p<0.0001). However such parameters as ASI and
AASI had weak correlation with PWV and, increasingly,
had interactions with average daily BP parameters. There
were detected moderate correlations between SBP and
ASI100-60 (R=0.53, p<0.0001), PBP and AASI (R=0.64,
p<0.0001), DBP and AASI (R=0.32, p<0.05). During the
analysis of relative correlations between AIx, ASI and
AASI, they were revealed only between AIx-75 and AASI
(R=0.45, p<0.0001).
Conclusion
Perimenopausal women in comparison with pre-
menopausal women have significantly increased indica-
tors, characterizing circadian arterial stiffness, and ear-
ly prescription of combined oral contraceptive, con-
taining drospirenone 30 mg and ethinylestradiol 20
mcg in premenopausal women can supposedly prevent
its increase. Most informative indicators in evaluation
according to the results of our study were PWV, PBP,
and modified indices PTT100-60, ASI100-60 AIx-75.
It is reasonable to analyze all these indicators in combi-
nation as they reflect various aspects of arterial stiffness.
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Introduction 
Thyroid hormones (THs) play critical roles in differ-
entiation, growth and metabolism. THs are needed in
an adequate concentration to support CL formation
and pregnancy. 
We have found that experimental hypothyroidism in
pregnant rats produces a delay in luteolysis and partu-
rition. 
Conversely, hyperthyroidism (hyperT) advances the
decrease in circulating progesterone and parturition by
approximately 12 hours. 
The classic genomic action of THs are mediated by
nuclear receptors (TR) acting as hormone inducible
transcription factors. 
The TRα1, TRα2 and TRβ1 isoforms are widely ex-
pressed whereas TRβ2 is mostly restricted to the hypo-
thalamus-pituitary axis. TRα1, α2 and β1 mRNA and
protein are present in ovarian surface epithelial cells in
human, while human oocyte, granulose and cumulus
cells also express TRβ2 in addition to the other iso-
forms. 
Although at present the presence of TRs in corpus lu-
teum has not been confirmed, we have found that ex-
perimental hypothyroidism/hyperT delay or advance
luteolysis and parturition in rats. Thus, thyroid hor-
mones affect luteal function. 
In order to establish the existence of luteal TRs, we de-
termined which isoforms of thyroid receptor are ex-
pressed in rat corpus luteum by real time PCR and
Western-Blot and if these proteins are regulated by ex-
perimental hyperthyroidism.
Materials and methods 
For this purpose, groups of Co (control) and hyperT
(induced by daily injection of 0.25 mg/kg of T4) Wistar
rats (n= 6-8) were sacrificed at day 19 (G19), 20 (G20)
and 21 (G21) of gestation. Total CL RNA and proteins
were prepared using TRIzol. Luteal TR mRNA was
measured by real time RT-PCR and expressed relative to
the expression of the housekeeping gene rat ribosomal
protein S16 cDNA. Proteins, isolated from the phenol-
ethanol supernatant obtained from RNA isolation, were
analyzed for TRα1 and TRβ1 abundance by Western
blot and expressed as the ratio of signal intensity for the
protein relative to that of b-tubulin.
Results and conclusions 
Corpus luteum of pregnancy expresses TRα1, TRα2
and TRβ1 mRNA. There were no changes in TRα1
and TRα2 expression between days and groups stud-
ied. TRβ1 expression was similar in the three days in
controls and was increased in hyperT rats on G19 and
G21. TRα1 and TRβ1 protein decreased significantly
in hyperT rats on G20. This decline in TRα1 and
TRβ1 protein can be due to degradation at the time of
functional luteolysis that occurs in this day in hyperT
rats. These results show that both isoforms of TRs are
present at luteal level, that they are sensitive to regula-
tion by thyroid hormones and that there may be a dis-
sociation between TH regulation in the expression at
mRNA and protein levels.
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Introduction 
There is a physiological interaction, functional and
protective action between neurotransmitters and hor-
mones that have not yet been fully codified. The dy-
namics of these metabolic substances is dependent on
changing endogenous and exogenous factors. The
same potential and variability of expression (demand-
response) produce different systemic inductions we
call para-pathological situation determining a reduced
quality of life of every woman in menopause. These
events are coded and predictable only if you have a
comprehensive understanding of the female body. It
would thus produce a coherent response to these func-
tional and therapeutic events of brainstorming that
have resulted not only as a cognitive function and sys-
temic body decrease but also in terms of drugs and
specialistics consulting, giving an inevitable loss of
quality of life.
Aim of the study
From the time that the ovarian reserve ceases upon ces-
sation of the menstrual cycle in an irreversible situa-
tion, you have two bio-neuro-hormonal definitions:
peripheral climateric and central climateric. They are
followed by three different conditions of the same sit-
uation as defined: limbic menopause, hypothalamus
menoapuse and central menopause syndrome.
Observations and deduction
Those frameworks, different from both clinical and
symptomatic point of wiev are independents units
from hormonal impregnation and need custom thera-
py to stabilize symptoms properly. 
Female neuro-endocrine axis need a stimulating and
protecting action from the estrogen on the direct pitu-
itary and hypothalamic gland.
Each step and especially the bio-processing of signals
from chemical (neuro-hormone cytokines) to electrical
(neuro plasticity and dielectric phasic potential) and the
resulting effector response depends on hormone con-
ditions that predisposes to the possible neuro-biologi-
cal response due to the estrogen presence.
In turn, the sex hormone acts at the level of neuronal
cells in different ways by interacting with modulatory
responses in microglia and neuronal astroglia in differ-
ent ways depending on the pro-inflammatory state.
The concept of general knowledge is essential as the
metabolic state of the body exerts a central question in
this report answer: from inflammation of excretory or-
gans, connective, enteric (dysbiosis or candidiasis) re-
cruited through direct paths of the lymphatic spread of
blood cytokines and chemokines dissemination, myco-
toxins or fractions that are viral tropism are highest in
the cerebral cortex (the brain is the only organ that has
no potential to accumulate glycogen but extremely lim-
ited in time and needs a steady flow through the metab-
olism of cholesterol, triglycerides above). 
So this inflammatory event has its maximum expres-
sion at both central and peripheral neurons. Predis-
posed to neuro-biological response due to the presence
of estrogen (Table 1).
The climacterics and menopauses: 
paraphysiological bio-neuro-endocrine evolution
NERVI S.A.
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TABLE 1.
Defect production Metabolic defect Defect-induced Receptor defect
Ineffective response Variable response Answer blocked Desensitization
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The endocrine system is not able to be modulated in-
dependently, only through a pure chemical interfer-
ence factor (hormone-receptor-effector-hormone) but
through a great transformation of electrical messages
that are translated from the hypothalamus (electro-
neurochimica) in chemical substances (neurotropic)
which in turn are transformed through a process of
translation of-chemical hormones by the anterior pitu-
itary lobe and from there superspecifica induce pro-
duction of factors Realising hormons (ACTH, TRH,
etc.). This will produce target organs for a chain reac-
tion back to the periphery to the CNS which will reg-
ulate productivity itself.
This process explains the process of circuit corticalized
information devices and their endocrine control. To all
this we add that any alteration in this process can cause
physiological stress response. Endocrinological studies
show that a stress condition can interfere directly on
neuro-endocrine female body as the main name plate
but not the reproductive organs through the adrenal
glands that produce cortisol ACTH reactive interfer-
ence. Cortisol, in turn, causes a direct negative feed-
back towards the hypothalamus and anterior pituitary
lobe that consequently the produce the same modula-
tion of estrogen.
The same stimulus depending on the stress-neuronal
cells (microglia, neurons, astrocytes) with which it in-
teracts has a release of substances in response to
chemokines and cytokines stimulating a systemic in-
flammatory process. Consequently, depending on the
cell phone off again possible, neuro-plasticity, physio-
logical and metabolic capacity of connective tissue
apoptosis is a “restitutio ad integrum” of the system
but at the time of menopause in the hormonal storm
in the first period of post-menopausal such an event
may be exacerbated, unstable and reversible if recog-
nized!
This is why women already in menopause and post-
menopausal women may develop other symptoms at-
tributable to peripheral or central involution of the
central nervous system and metabolism. In Tables 2
and 3 characteristic symptoms of the various types of
events have been coded.
TABLE 2.
Climateric Periferic Synd. => CPS Climateric Central Synd. => CCS
Hormone deficiency / reproductive Increased aggression/Hyperexcitability
Anxiety / Insomnia Small panic attacks 
Headache / Migraine Lite Hot flashes / sweats
Reduced Libido Hinstability Hypertension
Mood Swings Increased vascular tone
Depressive State Weight gain weight
Loss of Concentration / Memory Digestive disorder
TABLE 3.
Menopause Limbic Menopause Hypothalamus Menopause Central
Synd.=>MLS Synd. => MHS Syndrome => MCS
Anxiety / Insomnia Increased aggression Ipoergia 
Mood Swings Hyperexcitability Altered sleep-wake rhythm
Headache / Migraine Hot flashes / sweats Progressive cachexia
Depressive State Hypertension Progressive loss of mental agility
Reduced Libido Increased vascular tone Cardio-pulmonary disease
Loss of Concentration / Memory Weight gain weight Multiple dysmetabolism
Alzheimer Type Dementia Digestive disorders Intestinal malabsorption / 
intolerance multiple / allergies
Introduction
From the last research on the alfa and beta estrogen
breast receptors specificity, have been see a possible in-
teraction using soy isoflavons derivates. Conversely the
isoflavons derivates of trifolio pratensis have a small re-
action only to the beta helpless receptors for the breast.
All this new information limits the possibility of phy-
toderivates prescription and create the need to use oth-
er pharmaceutical products, specially made for the
menopausal symptoms, respecting the woman body
physiology.
So, for the control of the menopausal syndrome, to
propose and to use other standard therapeutical
choice, controllable, reproducible and therapeutical
functionally, as well stable in the future, result “mod-
ern”.
Background
Considering that is not longer allowed to talk “gener-
ally” about menopause, the symptoms, sometime
highly disabling for women, can be grouped in two
separate types: Menopause Limbic Syndrome and
Menopause Hypothalamus Syndrome (will see the dif-
ferences); those assume specific connotations and need
therapeutical customizations to stabilize the cohort of
symptoms.
Considering this, we can understand the failure of
some unique replacement therapeutical proposals
for both Syndromes. This is the starting point of
our innovative research and therapeutical applica-
tion.
Materials and methods
SAT-Therapy® is know for a long time ago, even in
science, as support as neo-adjuvant, adjuvant and
coadjuvant in various fields such as immunology, en-
docrinology and oncology, in situation as side effects
from radio and/or chemotherapy  it has any replace-
ment function, neither active ingredients that can
destabilize tissue and organ function physiological bal-
ance!
Certified free of side effects. Hormone-free. Deriva-
tive-free tissue.
It is based on “fine” selection of antibody fractions
(FAB) affinity for specific tissue (confirmed by im-
munofluorescence studies by the end of last century)
who do not have any direct interference in the internal
system function, but rather aimed at mobile business
rules induced by “activity” of selective protein specific
cell membrane (g protein). This level of  molecular en-
gineering was produced based on scientific studies re-
peatable and stable over time. The certification of the
quality of the active ingredients produced is is granted
by the Pasteur Institute of Paris with anti-viral and an-
ti-prion controls.
150 women aged from 48 to 60 years have been re-
cruited.
Recruitment examinations were evaluated the general
clinical parameters with routine sero-sanguineous
check.
The subjective symptoms reported at recruitment were
selected with yes or no questionnaires: 
– 43 pt (28.67%) had already made TOS for 5 years,
then stopped it. Without any other opportunity
they come back to the starting symptoms;
– 70 pt (46.67%) had already tried a number of
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herbal or homeopathic variety but with small or no
stable results;
– 37 pt (24.67%) were approaching menopausal syn-
drome for the first time and did not want to take
HRT.
Were assessed for symptoms and menopausal clinic
and recruited in two separate protocols.
Have been settled the following protocols: 
MLS=> Monday EMONC-TR® / Tuesday DIEN-
PH® alternating with SYM-TO® / Wednesday
COR-TX® / Thursday NEU-VAS® 
mode: 3 following weeks, followed by 1 week off,
for 6 cycles corresponding at 6 months
MHS => Monday EMONC-TR® / Tuesday
NEUGLAN-F® / Wednesday FO-E® alternating
with DV-PF® / Thursday NEU-VAS® 
mode: 3 following weeks, followed by 1 week off,
for 6 cycles corresponding at 6 months.
The active ingredients used correspond to the fol-
lowing functional characteristics of relevance: 
EMONC-TR® => functional stimulation of multi
excretory organs for a body global drain
works on: intestine, liver, kidney, pancreas, reticu-
lo-endothelial system, gall bladder, lungs, skin,
lymph nodes.
Directions: during metabolic diseases / with com-
plex therapies/ that weighed down with side effects
/ restoration of organic response / to module or re-
store the functionality and metabolism of the above
mentioned parts
DIEN-PH® => functional regulation of psycho-
neuro-endocrine TOP neurovegetative system,
“key point” of the cascade, contains diencephalon 
SYM-TO® => addressed with remodeling TOP psy-
cho-neuro ... .... from the “key point” of the cascade ...
NEUGLAN-F®  => functional adjusting of the
women and men psycho neuro-endocrine axis, in-
cludes: ovarian-pituitary-diencephalon-front; thy-
roid and surrenal ghlands
COR-TX® => regulation of cortical brain trophic,
metabolism and nerve conductance in support of
glia neurogenic
NEU-VAS® => regulation of neuro-vascular
trophic. Protein fractions derived from nerve-ves-
sel-skin-tess.connectives
FO-E® => to support the liver work, in detoxifica-
tion and overall support the organ provides
DV-PF® => regulation of the hepato-biliary and
digestive functional integrate axis, supporting duo-
denum - gall bladder - pancreas – liver.
Results (Tabs 1 and 2)
After 6 months of treatment, patients were asked to re-
view clinical routine examinations and to report about
symptoms  at recruitment with yes or no answers.
The clinical data reported do not indicate any change
on health status or hormonal after treatment.
The gynecological clinical status was stable with any
effects (inflammation of haemorrhoids, fissures, or
urogenital dystrophy).
both groups, after a 12 months check, confirm the
therapeutic benefits of treatment, but all patients asks
medical treatment under medical control to not lose to
the overall benefit obtained, even if stable in time!
This is a subjective parameter that was not initially
suspected, but is reported by all patients at each con-
trol as “fundamental change during treatment”.
This is a “general resentment energy”, a background
TABLE 1.
Menopause Limbic Syndrome before - SAT After 12 month SAT 23.21%
= > MLS 56 pt 37,33% of symptoms related to limb function treatment resistant symptoms
Anxiety / Insomnia 56 pt - 100% 1 pt - 1,79%
D / therapies recent = past -> weaning
Mood Swings 50 pt - 89,29% 0 pt - 0%
Headache / Migraine 6 pt - 10,70% 0 pt - 0%
D / being treated for headaches => weaning
Depressive State 39 pt - 69,64% 1 pt - 1,79%
D / psychological therapy also => weaning
Reduced Libido 56 pt - 100% 11 pt - 19,64%
Loss of Concentration / Memory 39 pt - 69,64% 0 pt - 0%
Alzheimer Type Dementia 6 pt - 10,71% 0 pt - 0%
D / psychological
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tone of psycho-physical well-being which has nothing
to do with the psychological side, but rather with a
kind of improvement of psycho-physical and metabol-
ic endurance that causes the therapeutic proposal con-
tinue with only 2 cycles of 3 months between October
and December and between April and June. data are
being developed for long-term period.
Conclusions
The SAT-Therapy®, considering our clinical and
psychophysical data, is therefore placed as a valid
proposal and choice in the general treatment of
menopausal syndrome under the compliance of pa-
tients.
TABLE 2.
Menopause Hypothalamus Syndrome before - SAT after 12 month SAT 16,16%
= > MHS 99 pt 66% symptoms related to hypothalamic function of treatment resistant symptoms
Increades aggression 30 pt - 30,3% 0 pt - 0%
Hyperexcitability 80 pt - 80,81% 0 pt - 0%
Hot flashes /sweats 99 pt - 100% 7 pt - 7,07%
Hypertension 70 pt - 70,71% 9 pt - 9,09%
D / systemic hypertension evaluated by a great reward in classical
Doppler of 24 hours pharmacological stability
Increased vascular tone 40 pt - 40,4% 0 pt - 0%
D / doppler carotid-AAll
Weight gain weight 99 pt - 100% 0 pt - 0%
stability or decrease in body weight
Digestive disordes 45 pt - 45,45% 0 pt - 0%
D / EGD = reflux esophagitis / gastritis Ab anti HP + 12 months after endoscopy negative
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Introduction
One of the goals of Assisted Reproduction Techniques
(ART) is the recruitment of multiple follicles and the
recovery of good quality oocytes. 
Ovarian response (OR) can be defined as the reaction
of the ovaries to an exogenous stimulation: it varies
substantially among women and in the same woman
between various cycles (1). Hence, poor ovarian re-
sponse indicates a reduced follicular response resulting
in a low number of retrieved oocytes, despite the high
dose of gonadotropins administered.
In recent years there is an increasing number of in vit-
ro-fertilization (IVF) patients in whom few oocytes are
obtained in response to controlled ovarian hyperstim-
ulation (COH), mainly due to the postponement of
childbearing and the decrease of ovarian reserve. As a
consequence, it is important to choose the most ap-
propriate technique of fertilization to maximize the
chances of pregnancy in this group of patients, that is
really challenging for IVF specialists.
Conventional IVF and intracytoplasmic sperm injec-
tion (ICSI) are the two principal techniques used to
obtain fertilization.
While conventional IVF implies insemination of
oocytes with a determined quantity of spermatozoa,
on the other hand ICSI involves injection of a single
spermatozoon into a mature oocyte (Table 1). 
ICSI is usually indicated when a male factor for infer-
tility exists, but sometimes this technique is preferred
also if an age-related infertility is present or if few
oocytes are retrieved at pick up. 
In Italy, assisted reproduction technology treatments
have been regulated since 2004 by Law n. 40/2004,
until the decision n. 151/2009 of the Italian Constitu-
tional Court, that addressed the constitutional legiti-
macy of several provisions of Law n. 40. One of the
crucial points of the law 40 was that no more than
three oocytes could be inseminated, in order to pre-
vent the formation of unused embryos. All the devel-
oped embryos must be transferred into the uterus, and
embryo cryopreservation was not allowed. As a conse-
quence, many Italian clinics began to perform ICSI
even when sperm quality was suitable for convention-
al IVF (2).
In comparison with conventional IVF, certain disad-
vantages exist when oocytes are subjected to ICSI. Be-
yond the mechanical damage that may be caused to
the oocyte during injection, gametes carrying chromo-
somic alterations -that otherwise would be eliminated
by natural selection- might be fertilized (3).
The aim of our study was to compare reproductive out-
comes in patients undergoing conventional IVF-ET
(Group A) or ICSI (Group B), in whom only 1 or 2
oocytes were retrieved at ovarian pick up.
Material and methods
Study design (Fig. 1)
We retrospectively analysed a total of 75 patients (83
cycles) attending assisted reproductive technologies at
the Centre of Reproductive Pathophysiology of the
Department of Reproductive Medicine and Child De-
velopment of University of Pisa in the period between
January 2010 and November 2011. Patients were all
poor responders and were included in this study when
only one or two oocytes were retrieved during oocytes
pickup.
Comparison of reproductive outcomes using IVF-ET and ICSI
in ART cycles in which only one or two oocytes are retrieved
OBINO M.E., CARLETTI E., PINELLI S., PAPINI F., CASAROSA E.,
CELA V., GENAZZANI A.R., ARTINI P.G.
Department of Reproductive Medicine and Child Development,
Division of Obstetrics and Gynecology,
University of Pisa, Italy
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Publication Type of study  Characteristics of 
patients  
No. of cases and 
controls  
Outcomes reported  
Ludwig et 
al. 4(1997)  
Retrospective 
study  
12, 18, and 20 cases 
treated with 1, 2, and 3 
oocytes  
50 cycles with <4 
oocytes retrieved  
Rate of metaphase II oocytes injected and fertilized, and intact 
oocytes similar in the three groups. Transfer rate  not significantly 
different from those  cases with >3 oocytes  
Moreno et 
al.5(1998) 
Prospective 
study  
6 or fewer retrieved 
oocytes  
96 non-male 
infertile coup les 
(104 cycles),  
randomly divided 
into 2  groups, 
one by IVF and 
the other by ICSI. 
Similar fertilization rates (FR) per inseminated oocyte and per 
obtained oocyte. Equal number and quality of embryos obtained 
and comparable pregnancy (PR) and implantation rates (IR). 
Neither the number of retrieved oocytes, nor patient age was 
relevant for the fertilization rates obtained with both techniques. 
Number of complete fertilization failure similar in both 
procedures.  
Staessen 
et al .6 
(1999) 
Auto-
controlled 
study  
Tubal infertility  and 
normozoospermic semen  
56 couples  
randomly divided  
into 2  groups 
inseminated either 
by  IVF or by ICSI.  
 Total cleavage rates were quite similar, no difference in embryo 
quality. At 42 h post -insemination more embryos were at the 
four-cell stage after ICSI than after IVF.   There appeared to be no 
difference in implantation potency of the embryos obtained with 
either technique after the non-randomized transfers.  
Fishel et 
al.7 (2000) 
Prospective 
randomized 
study  
5  groups of 
patients,inseminated 
with husband's 
sperm atozoa or with 
donor’s  
221 patients  ICSI with husband's spermatozoa had a higher FR as compared 
with IVF or IVF with HIC with donor spermatozoa (if previous 
failure of fertilization had occurred) for unexplained infertility.ICSI 
with husband's spermatozoa had similar FR to IVF with donor 
spermatozoa for patients with male factor. A significant 
proportion of the oocytes that failed to fertilize with conventional 
IVF eventually fertilized after ICSI. 
Khamsi  et 
al.8 (2001) 
Prospective 
controlled 
study  
Non-male factor 
infertility.  
35 patients  Per retrieved oocyte, ICSI resulted in better FR compared  with 
conventional IVF. Per retrieved oocyte, ICSI also resulted in better 
formation of good-quality embryos at 48 hours after retrieval 
compared with conventional IVF.  
Elizur et al. 9
(2004)  
Retrospective 
study  
Couples with mild 
oligoteratoasthenozoosp
ermia  and in couples 
with normal sperm and 
previous low  
fertilization rates (<30%) 
in conventional IVF. 
69 couples  FR after IVF were significantly lower compared with those after 
ICSI, when male factor was present, but in the other group FR 
were not significantly different. The numbers of rapid-cleaving 
embryos at 2 days after fertilization were similar in both groups.  
Three days after fertilization, however, there were significantly  
fewer rapid-cleaving embryos after ICSI in the mild OTA group 
compared with aft er conventional IVF.There were no couples with 
complete fertilization failure in the normal sperm group, either 
after conventional IVF or after ICSI. In the mild OTA group, 
however, three couples had complete fertilization failure after 
conventional IVF, vs. none after ICSI. 
Kim et al.10 
(2007) 
Retrospective 
study  
The study compared 
patient’s characteristics, 
cycle, and outcomes.  
696 consecutive  
assisted 
reproductive 
technology cycles  
Patient characteristics were similar between the two groups. 
More oocytes were fertilized per cycle for the IVF group. 
Fertilization failure, PR, and live birth rates did not differ between 
IVF and ICSI. Using logistic regressions, having had previous ART 
was found to be positively associated with ICSI. Treatment choice 
of ICSI was not associated with better fertilization, pregnancy, or 
live birth rates.  
Gozlan et 
al.11 (2007)  
Retrospective 
study  
Stimulated or 
spontaneous IVF cycles 
resulted in single oocyte 
retrieval.  
311 patients (425 
cycles)  
In patients <39 years old with favorable semen quality, ICSI and 
standard insemination produced similar FR and PRs. Conversely, 
in cases with apparent lower semen quality, ICSI gave a 
significantly higher fertilization rate (85.4% vs. 44.2%) but no 
significant difference in PRs. In patients >39 years old and with 
favorable semen quality, ICSI and standard insemination 
produced similar FR and PRs. The ICSI for lower 
semen quality produced both higher FRs and PRs.  
Borini et 
al.12 (2009) 
Retrospective 
study  
Each recipient received 
three to five eggs  
601 women (  671 
cycles) donated 
their excess oocytes 
to 694 patients 
(1606 cycles). 
The results showed that, when comparing donor versus recipients 
and among these, IVF vs. ICSI, no significant differences were 
found in terms of PR,IR and miscarriage rates.  
Ou et al. 13  
(2010) 
Case-control 
study.  
Couples had 1, 2 or 3 
oocytes retrieved at PU  
211 couples (243 
cycles)  
The FR was significantly higher after ICSI than after standard IVF. 
The cycle cancellation and complete  fertilization  failure rates 
were comparable between the 2 groups. The clinical PR per 
transfer, IR, and live birth rate per transfer had a favorable trend 
in the ICSI group, but no statistically significant differences.  
TABLE 1 - PRESENT LITERATURE.
Patients were excluded from the study if severe male
factor was present.
The male partner submitted a semen sample for sperm
analysis. Both male and female partners signed an in-
formed consent form.
Ovarian stimulation was performed by a regimen in-
cluding GnRH antagonists combined with rFSH
treatment. The age of patients included in the study
ranged from 27 and 47 years (mean age 38,4 yrs).
Cycles were divided into two groups based on the
technique used: Group A was constituted by 45
FIVET cycles (43 patients, mean age 39,3 yrs), while
Group B contained 38 ICSI cycles (35 patients, mean
age 37,3 yrs), and results of the two group were com-
pared. Some patients underwent both procedures, in
different cycles. Group A and Group B were further-
more divided in 3 subgroups based on the age of pa-
tients (<35 yrs, 35-38 yrs, >38 yrs), whose results were
also compared.
Finally, we analyzed and compared results of the group
of patients in whom 1 oocyte was retrieved at pick up.
Laboratory procedure
Treatment protocol
Controlled ovarian stimulation was carried out with
150 to 450 UI/day, according to basal FSH levels and
age, of recombinant FSH (Gonal F®, Serono, Italy).
All patients were administered cetrorelix (Cetrotide®,
Serono, Italy), a GnRH antagonist, according to a per-
sonalized regimen, i.e. when the lead follicle reached
14 mm in diameter, to prevent premature ovulation.
Recombinant hCG (Ovitrelle®, Serono, Italy) was ad-
ministered when at least 1-2 follicles reached a mean
diameter of 18 mm. After approximately 36 hours,
transvaginal follicular aspiration was performed for
oocyte retrieval.
Progesterone supplementation was administered with
90 mg (Crinone; Merck Serono, Italy) via the vaginal
route every day, plus 341 mg i.m. each 3 days (Lento-
gest; IBSA Farmaceutici Italia S.r.l.), starting on the
day of embryo transfer.
Semen preparation
At the time of fertilization, sperm concentration and
percent motility were used to assess fertilization poten-
tial of a given semen sample. Volume, sperm count,
forward motility and morphology were considered ac-
cording to the World Health Organization (WHO)
criteria.
All semen samples were collected following masturba-
tion after 3-4 days of abstinence and were allowed to
liquefy for at least 20 min at 37°C before processing.
Sperm not meeting the defined threshold was classi-
fied as subfertile sperm, possessing questionable fertil-
ization potential and patients were consequently ex-
cluded from the study.
Oocyte preparation
Oocytes were retrieved by vaginal ultrasound probe
and incubated in oocyte culture medium (Sydney IVF
Oocyte Wash Buffer; Cook Ireland Ltd, Limerick, Ire-
land).
Fertilization technique was chosen based on the clini-
cal history of patients and reproductive outcomes in
previous ART cycles. In cases where we choose to per-
form ICSI, we hypothesized that the impairment in
fertilization was the cause of the past failures in previ-
ous ART cycles.
4-5 h after oocyte retrieval, in cases where IVF was
performed, each oocyte was inseminated with
200,000-300,000 motile washed spermatozoa, and be-
fore proceeding to ICSI, the cumulus cells were re-
moved from the oocytes after 3-4 h of incubation in
hyaluronidase (type VIII; Sigma, USA) at a concentra-
tion of 80 IU/ml for approximately 15-20 s. 
Thus, oocytes were transferred to fresh medium and
the corona cells were removed by softly pipetting in
and out. The oocytes were subsequently controlled un-
der an inverted microscope at x100 to check the mat-
uration stage, based on the presence of the first polar
body. 
ICSI was accomplished as previously described by Ar-
tini et al., 1998 (14).
Fertilization was confirmed by the observation of two
270
Fig. 1 - Design of the study.
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pronuclei about 14-18 h after fertilization technique.
All the fertilized oocytes were transferred into a fresh
cleavage medium and cultured until transfer. On day
2, at 46-48 h post-insemination, the embryos were
evaluated for cell number and rate of fragmentation
and consequently graded as I-IV (best–worst) (15).
Results
IVF-ET vs ICSI (A vs B n=83)
In regard to fertilization rate, there were no differences
between the Group A (79%) and Group B (68%). On
the other hand, taking into consideration good quality
embryo rate, Group A obtained 65%, versus 72% of
Group B. For what concerns pregnancy rate, IVF-ET
was found to be more advantageous (biochemical PR
13 vs 11%; clinical PR 11% vs 5%). (Table 2) 
Age <35 years (A1 vs B1, n=18)
When fertilization rates using fertile sperm were com-
pared between ICSI and conventional IVF in this sub-
group of patients, results were similar in both groups
(87% vs 73%). (Table III)
For what concerns good quality embryo rate, ICSI
group <35 yrs (B1) obtained a better result (A1 57%
vs B1 69%). Furthermore, biochemical and clinical
PRs using fertile sperm were superior after IVF-ET
compared to ICSI (40% vs 8% and 40% vs 8%, re-
spectively). 
Age 35-38 (A2 vs B2, n=22)
In this subgroup of patients, we found that ICSI did
not significantly improve the parameters evaluated
(Table 3).
Age >38 (A3 vs B3, n=43)
In this subgroup of patients, we found that IVF-ET
improved fertilization rates. In fact, Group A3 ob-
tained a better result (82% vs 60%). For what con-
cerns good quality embryo rate, ICSI group >38 yrs
(B3) was shown to be more effective (A3 63% vs B3
75%). When biochemical PRs were compared be-
tween ICSI and conventional IVF, there were no dif-
ferences between the two groups, on the contrary clin-
ical pregnancy rate was better in IVF-ET group (7% vs
0%). (Table 3) 
Comparison of IVF-ET and ICSI 
in patients with single oocyte retrieval
From the analysis of this subgroup of patients, we
highlighted no significant differences for all the pa-
rameters tested. (Table 4)
TABLE 2 - OUTCOMES OF IVF-ET AND ICSI.
Group A Group B
IVF-ET n=45 ICSI n=38
(54%) (46%)
Biochemical pregnancy rate 6 (13%) 4 (11%)
Clinical pregnancy rate 5 (11%) 2 (5%)
Miscarriage rate 2 (40%) 1 (50%)
Number of oocytes retrive 74 60
Fertilization rate 59 (79%) 41 (68%)
Embrio cleavage rate 57 (96%) 39 (95%)
Good-quality embrio rate 37 (65%) 28 (72%)
TABLE 4 - COMPARISON OF IVF-ET AND ICSI IN PA-
TIENTS WITH SINGLE OOCYTE RETRIEVAL.
IVF-ET n=16 ICSI n=16
Biochemical pregnancy rate 1 (6%) 2 (13%)
Clinical pregnancy rate 1 (6%) 1 (5%)
Miscarriage rate 0 (0%) 1 (100%)
Number of oocytes retrieved 16 16
Fertilization rate 13 (81%) 13 (81%)
Embrio cleavage rate 13 (100%) 13 (100%)
Good-quality embrio rate 7 (53%) 9 (69%)
TABLE 3 - OUTCOMES OF IVF-ET AND ICSI ORGANIZED ON THE BASIS OF  AGE.
Age <35 Age 35-38 Age <38
Group A1 Group B1 Group A2 Group B2 Group A3 Group B3
IVF-EN ICSI IVF-EN ICSI IVF-EN ICSI
n=5 n=13 n=11 n=11 n=29 n=14
(6%) (16%) (13%) (13%) (35%) (17%)
Biochemical pregnancy rate 2 (40%) 1 (8%) 2 (18%) 2 (18%) 2 (7%) 1 (7%)
Clinical pregnancy rate 2 (40%) 1 (8%) 1 (9%) 1 (9%) 2 (7%) 0 (0%)
Miscarriage rate 1 (50%) 1 (100%) 0 (0%) 0 (0%) 1 (50%) 0 (0%)
Number of oocytes retrive 8 22 20 18 46 20
Fertilization rate 7 (87%) 16 (73%) 14 (70%) 13 (72%) 38 (82%) 12 (60%)
Embrio cleavage rate 6 (86%) 15 (94%) 13 (92%) 12 (92%) 38 (100%) 12 (100%)
Good-quality embrio rate 4 (57%) 11 (69%) 9 (64%) 8 (62%) 24 (63%) 9 (75%)
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Discussion
When dealing with male factor infertility, it is well
known that use of ICSI is recommended. However,
when seminal parameters are normal, is still a debated
dilemma if the ICSI technique brings any special ben-
efit with respect to IVF. Although some studies in lit-
erature show that ICSI is advantageous for poor re-
sponder patients, others failed to demonstrate any su-
periority of ICSI on conventional IVF.
Moreover, our results confirmed the studies that ques-
tioned the advantages of ICSI over conventional IVF
in patients with non–male factor infertility as well as
patients with poor ovarian response.
Conclusions
Our results allow us to affirm that ICSI is not always
the gold standard in the management of poor respon-
der patients, especially those in whom only one or two
oocytes are retrieved at oocytes pick up. As a conse-
quence, probably performing ICSI in all these patients
is not useful, and surely it is more expensive and time
consuming. 
In conclusion, when choosing the ART technique it is
better to consider the single patient and all her clinical
characteristics, such as age, and her response to ovari-
an hyperstimulation in the previous cycles. 
ICSI is recommended as the technique of choice on-
ly in case of male factor infertility, while in other cas-
es is still object of controversy if it is better to perform
ICSI or IVF-ET.
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Acromegaly is rare severe neuroendocrine disorder due
to chronic excess of growth hormone (GH) and in-
sulin-like growth factor type 1 (IGF-1). The principal
cause of the increased GH release is usually a benign
pituitary tumor – somatotropinoma, in 75% of cases
pituitary tumors are more than 10 mm in size and
with extrasellar extension (macroadenoma). 
Acromegaly commonly occurs in middle-aged men
and women, male to female ratio is 1:2. The preva-
lence of the disease is about 6 of every 100,000 adults,
and the incidence is 3-5 new cases per million per
year. The clinical features associated with acromegaly
include the effects of GH over-production and – in in-
stance of macroadenoma – effects of tumor compress-
ing and injuring the normal pituitary gland, optic
nerves and optic chiasm. 
Active acromegaly results in marked bony and soft tis-
sue changes including an altered facial appearance
(frontal bossing, prognathism), enlargement of the
hands and feet, sleep apnea, and carpal tunnel syn-
drome, arthritis, excessive sweating, besides tiredness,
fatigue, depression, hypertension, impotence, loss of
libido, interrupted menstrual cycle and some other
clinical symptoms.
In the Moscow Region 140 patients with acromegaly
are included in special Acromegalic Registry. Accord-
ing to this Acro-Registry, among acromegalic patients
there are 111 (79%) women, including 60 (43%)
women in a postmenopause. Thus, up to 43% of pa-
tients with acromegaly are postmenopausal women.
However, it is not enough data on this topic.
We examined 27 postmenopausal women 50-73 years
old (median 57) with acromegaly. Median duration of
acromegaly 13.3 years; active acromegaly in 19 (70.3%)
patients, remission in 8 (29.7%) cases. Macroadenomas
had 74% of patients, microadenomas – 26%. At pa-
tients with active acromegaly (n=19) median of basal
GH was 8.6 [4.3; 19.9] mMe/l, median of IGF-1 was
404 [317; 819] ng/ml (reference range 94-269). 
Sixteen women had natural menopause, median
menopause age 50 [47; 51]. Uterine myomas were ob-
served in 10 (37%) patients, including 4 (14.8%)
women with de novo myomas. In most cases myomas
were asymptomatic, of small size, with low blood flow
in the uterine vessels and the vessels feeding the my-
oma node; in 1 case it was submucosal myoma that re-
quired surgery treatment. Myomas were associated
with other pathological conditions: adenomyosis
(n=3), endometrial polyps (n=3) and ovarian ter-
atomas (n=3). Ovarian cystomas were found in 3 oth-
er patients. 
Eleven women (40.7%) had been operated concerning
a progressing uterine myoma before the study, median
surgical menopause age 47 [43; 50] years old, there
was no significant difference compared to median age
of natural menopause (p=0.05). In 6 (22.2%) cases
myomectomy was performed before the appearance of
other typical symptoms of acromegaly. Age of surgical
menopause at these women varied from 38 to 48 y.
Fast growth of myoma that require surgical treatment
could be considered as one of the first symptoms of
acromegaly, and determination of GH & IGF-1 levels
can be recommended in these cases. 
Interestingly, 4 (14.8%) patients (2 with natural and 2
with surgical menopause) had hypogonadotropic hy-
pogonadism: LH ranged from 1.1 to 5.1 U/l, FSH –
from 4.1 to 15.5 U/l, PRL 43-170 mMe/l. All patients
had macroadenoma and were operated on pituitary (in
1 case in combination with radiotherapy). Age of
menopause was 38, 45, 46 and 51 years.
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In other patients (n=21), an adequate increase of go-
nadotropin levels were observed: median of FSH was
47.2 [37; 66.3] mIU/ml, median of LH was 15.8
[11.5; 22.3] mIU/ml. 
Only 1 woman from our cohort with de novo
acromegaly had hyperprolactinemia 1115 mMe/l. She
has natural menopause at 48 y.o. and her go-
nadotropin levels were not suppressed: LH 11.5 U/l,
FSH 39.4 U/l. We considered that probably hyperpro-
lactinemia was a consequence to mass effect of
macroadenoma.
Median score according to Greene Climacteric Scale
was 23. Only few patients had moderate or severe
symptoms like panic attacks (Q5, 33.3% of patients),
difficulty in concentrating (Q6, 14.8%), loss of inter-
est in most things (Q8, 29.6%), feeling unhappy or
depressed (Q9, 3.7%), crying spell (Q10, 14.8%), ir-
ritability (Q11, 18.5%), feeling dizzy or fain (Q12,
18.5%), parts of body feel numb or tingling (Q14,
7.4%) hot flashes (Q19, 14.8%). Approximately half
of the patients complained on heart beating quickly or
strongly (Q1, 44.4%), feeling tense or nervous (Q2,
51.8%), difficulty in sleeping (Q3, 51.8%), pressure
or tightness in head or body (Q13, 48.1%), loss of
feeling in hands or feet (Q17, 40.7%), breathing diffi-
culties (Q18, 40.7%), sweating at night (Q20,
40.7%), loss of interest in sex (Q21, 51.8% of pa-
tients). The majority of patients suffered from moder-
ate or severe headache (Q15, 70.3%), feeling tired or
lacking in energy (Q7, 70.3%), muscle and joint pain
(Q16, 70.6%). Nevertheless, symptoms of active
acromegaly are similar to some postmenopausal symp-
toms and may contribute to the high Greene score.
Urogenital disorders (stress incontinence) that re-
quired further treatment were detected in 14 (51.8%)
patients. The frequency of urogenital disorders was
higher among patients with surgical menopause com-
pared to women with natural menopause (9 from 11
vs 5 from 16 patients respectively, p=0.02)
In conclusion, various gynecological disorders were
detected in all postmenopausal women with
acromegaly. Median age of menopause did not differ
from general population, however, prevalence of uter-
ine myomas (77.8%) was much higher in the acrome-
galic women than in the population (up to 40% in
Russian population). Fast growth of myoma that re-
quire surgical treatment could be considered as one of
the first symptoms of acromegaly, and determination
of GH & IGF-1 levels can be recommended in these
cases. 
According to our study, some climacteric symptoms
and clinical signs of acromegaly might be similar (for
example, headache, feeling tired or lacking in energy
muscle and joint pain, heart beating quickly or strong-
ly, sweating at night, breathing difficulties) so it is dif-
ficult to differentiate them. Probably, due to this rea-
son Greene Climacteric Scale is not appropriate for
acromegalic postmenopausal women. Among climac-
teric symptoms urogenital disorders were very com-
mon (51.8%) especially at women with surgical
menopause. 
The frequency of hypogonadotropic hypogonadism
was 14.8% at our cohort, and the main cause was op-
eration on the pituitary macroadenoma. Hyperpro-
lactinemia is not common among postmenopausal pa-
tients with acromegaly.
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Objective 
We have previously demonstrated that with an acute
L-Arginine (L-Arg) infusion we were able to reveal a
Nitric-Oxide Syntase (NOS) impairment in pre-
eclamptic (PE) women, as demonstrated by signifi-
cantly lower L-Citrulline conversion than in Controls
(1). Moreover, an acute L-Arg infusion induced a va-
sodilation in placenta-related foetal growth restriction
(2). On the other hand, L-Arg/NO pathway is also
involved in glucose metabolism. In particular, In-
sulin exert an important biological effect on adipose
tissue, skeletal tissue and vascular tissue, through dif-
ferent intracellular kinase signaling including PI3-ki-
nase activation, glucose transport, by Glut 4 and
Glut 1 activation, and NO production by Akt activa-
tion (3,4). Near this physiological metabolic path-
way, in several situation like during Insulin-Resis-
tance (IR), Insulin induce extracellular signal-regu-
lated kinase (ERk1/ERk2) and, as a consequence,
MAPk (Mitogen-activated protein kinase) that lead to
Endothelin-1 production and atherosclerosis onset,
while, on the other hand, there is a deficiency of intra-
cellular signaling transmission.
Insulin resistance and resultant hyperinsulinemia are
physiological characteristics of pregnancy, expecially in
third trimester. In obese women this situation is exas-
perated and may be associated with the endothelial
dysfunction. Both glucose metabolism and vascular
activity are modulated by L-Arg/NO pathway: en-
dothelial NO production and Insulin sensitivity are
positively related in healthy people (5). Unfortunately,
in obese people, such system seems blunted. Consider-
ing that the prevalence of obesity is increasing in the
general population and top BMI (Body Mass Index)
categories in pregnant women are also increasing, we
aim at evaluating L-Arg-NO regulatory system in dif-
ferent BMI categories during pregnancy.
Methods 
Eight normal weight (BMI 18.3-24.9 Kg/m2) and 14
overweight/obese women (BMI 26.3-45.2 Kg/m2)
underwent twice during pregnancy (at 9-12th and at
24-27th weeks) to L-Arginine infusion (20g in 500 ml
physiological solution, in 3 hours). Serum assay for
glucose, insulin and nitrite/nitrate (NOx) levels were
fasting and hourly performed. Serum NOx concentra-
tion was obtained by reduction of nitrate to nitrite
with cadmium. The essay was performed with colori-
metric method based on Griess reaction. The results
are expressed in µM/L. The quantitative determina-
tion of plasma insulin was obtained by ELISA
method. Concentrations are expressed in µIU/ml. 
The ultrasound assessment of endothelial-dependent
flow mediated vasodilation (FMD) of the brachial ar-
tery was also performed, measured as the percent
change of brachial artery diameter in response to in-
creased blood flow shere stress (6). 
Data obtained were recorded on a database and ana-
lyzed through SPSS® Statistics version 19. Compar-
isons between groups were performed using Student’s
t test for independent samples. For the analysis be-
tween the same group we used Wilcoxon’s test for non-
parametric models. For comparisons, NOx produc-
tion was evaluated as Area Under the Curve. All values
are expressed as mean ± standard deviation. We con-
sider p value less than 0.05 as threshold for statistical
significance.
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Results 
At 1st trimester L-Arg infusion induce a glucose de-
cline in both groups. In overweight/obese women such
reduction is more evident (p=0.04). At 2nd trimester
the reduction is present only in obese/overweight
women (p=0.03). Fasting insulin levels were signifi-
cantly higher in overweight/obese than lean group:
19.1±18.1 vs 7.9±5.1 µUI/ml at 1st trimester (p=0.05)
and 21.3±8.0 vs 12.1±5.1 µUI/ml in 2nd trimester
(p=0.03). At 1st trimester, L-Arginine significantly re-
duced insulin levels in both groups. NOx levels were
similar in both groups at 1st trimester, but the differ-
ence between groups became significant at 2nd
trimester with NOx values significantly higher in nor-
mal weight women than in overweight/obese women
after 120 (p=0.03) and 180 minutes (p=0.05). FMD
of brachial artery at 2nd trimester was significantly re-
duced in overweight/obese (16±13%) vs lean (32±6%,
p=0.03) women.
Conclusions 
Our study showed that overweight and obesity actual-
ly cause metabolic alteration from the earliest stages of
pregnancy, as demonstrated by higher glucose and in-
sulin levels at 1st trimester in women with BMI >25
kg/m2. This agrees with several studies that correlate
obesity ad insulin resistance. NO production in re-
sponse to L-Arg administration is overall similar be-
tween groups at 1st trimester. This agrees with the re-
sponse in terms of endothelium-dependent vasodila-
tion assessed by FMD, which is preserved in both
groups (Table 1). 
At 2nd trimester in normal-weight patients we observe
the physiological increase in insulin levels, but over-
weight/obese women maintain higher glucose and in-
sulin levels. It is evident the poor response of over-
weight/obese women in terms of NO production,
which is, instead, increased in normal-weight women.
This impacts on vascular function: at FMD endothe-
lium-dependent vasodilation is significantly reduced
in overweight/obese patients (Table 2). 
Our data suggest an alteration of L-arg-NO system at
2nd trimester, shown as a reduced NO production as-
sociated with a decrease in endothelium-dependent
vasodilation in overweight/obese women. 
In conclusion, L-Arginine-NO pathway seems im-
paired in overweight/obese women at 2nd trimester and
it is associated with a reduction in FMD. These find-
ings may explain vascular and metabolic dysfunction
in women with BMI >25 Kg/m2. If chronic L-Arg
supplementation could be helpful to obese women for
glucose utilization remain to be discovered.
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TABLE 2 - 2ST TRIMESTER NOx LEVELS AND ENDOTHE-
LIAL-DEPENDENT VASODILATION.
Normal-weight Overweight/obese p value
NOx (AUC) 8194.0 ± 2906.8 5576.7 ± 3794.2 0.045
FMD (%) 32.2 ± 6.7 16.8 ± 13.3 0.033
TABLE 1 - 1ST TRIMESTER NOx LEVELS AND ENDOTHE-
LIAL-DEPENDENT VASODILATION.
Normal-weight Overweight/obese p value
NOx (AUC) 7953.0 ± 6711.2 7779.9 ± 5608.3 0.953
FMD (%) 67.4 ± 32.9 24.7 ± 16.9 0.078
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Introduction
Except for the golden standard DXA (Dual energy X-
Ray Absorptiometry), the quantitative ultrasound
(QUS) is a practical device to evaluate the fracture
risk in women after menopause. The best site is the
heel and the most accepted results are based on GE
Lunar Achilles studies. (1) The Stiffness Index (SI) in-
dicates the risk fracture and it represents the combi-
nation of BUA (Broadband Ultrasound Attenuation)
and SOS (Speed of Sound) parameters. (2) As sug-
gested previously in literature, the similar parameters
as Z or T-Score do not apply in QUS, as in DXA. (3)
In patients with no fragility fractures and high SI (over
80 Units) DXA is not necessary, neither therapy for
osteoporosis as they are considered as having the low-
est risk for osteoporotic fractures. Generally, the data
from literature suggests that the combined results of
DXA and QUS identify best at risk patients but there
are some specific segments of the population to whom
DXA (as the most expansive of the two devices and
more difficult to perform) is not necessary. (4)
Aim
We compare the DXA and other parameters of the low
fracture risk group (baseed on QUS results) to non-
low risk patients.
Subjects and methods
All the patients were women in least 6-12 months of
secondary amenorrhea (postmenopausal) who were
antiresorbtives-free. They were all evaluated by lumbar
and hip GE Lunar DXA and Heel GE Achilles Quan-
titative Ultrasound. The study was conducted for 2
years (2010-2011) in CI Parhon National Institute of
Endocrinology from Bucharest, Romania. The Body
Mass Index (BMI) was also registered. We analyzed
the bone turn over markers like formation markers
(serum osteocalcin) and resorption markers (serum al-
kaline phosphatase and CrossLaps). Moreover, the
bone status hormones were performed serum
parathormon (iPTH) and serum 25 OH-vitamin D.
We considered as low risk for fracture 143 patients to
whom the SI was ≥80 U. The control group included
200 women with the same inclusion and exclusion cri-
teria but with heel SI <80U. The statistical analyze in-
cluded student ttest, statistically significant being
p<0.05.
Results 
The studied group included the women SI between 80
and 143U. The av. age for the low risk group was
55.99±7.41 year, as for non-low risk group was
57.23±9.28 years. As expected, the low risk patients
are younger but not with a strong significance
(p=0.06). The av. BMI for the low/ non-low fracture
risk groups was: 29.93±5.46, respective 27.92±5.94
g/cm2. The BMI increases as the fracture risk decreas-
es, with statistical significance (p=0). The av. fat mass
percent as revealed by Body Mass Analyzer was
37.64±18.55% versus 39.2±10.88% in control
groups. This was not statistically significant (p=0.4).
Also, it is important to mention the fact that the fat
mass influences the QUS measurements as it interfere
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with the wave. (5) The av. serum Alkaline Phosphatase
was within the normal range (60-210U/l) and did not
differ from the groups: 77.89±27.49U/l versus
77.63±27.72U/l in low risk groups (p=0.91). The
serum CrossLaps were lower in low risk women
0.43±0.25ng/ml versus 0.52±0.3ng/ml (p=0.01), with
normal values between 0.2 and 0.704 ng/ml. The av.
osteocalcin was lower in low risk patients: 21.51±0.25
ng/ml versus 24.46±12.97 ng/ml, also with av. values
within the normal range of 14 up to 46 ng/ml
(p=0.04). These last two parameters were statistically
significant. The iPTH is not statistically significant be-
tween the groups (46.75±24.01 pg/ml in low risk pa-
tients, and 50.34±36.67pg/ml in control group, with
normal ranges of 15 to 65 pg/ml, and p=0.32). Simi-
lar results were found in average levels of 25 OH-vita-
min D: 13.66±7.14ng/ml versus 13.29±7.05ng/ml in
non-low risk groups, with deficiency of vitamin D
based on average values.
The lumbar BMD was statistically significant higher
in low risk fracture group, as 1.1±0.19 g/cm2 versus
0.98±0.17 g/cm2 (p=0), as well as femoral neck BMD
0.94±0.15 g/cm2 versus 0.84±0.11 g/cm2 (p=0), and
hip BMD 1.05±0.15 versus 0.92±0.11 g/cm2 (p=0).
Discussions
The changes in bone turn over markers, as well as the
fat tissue clues are important in evaluation of the
bone health. We realized an uni-variable analyze be-
tween the groups of patients who were at low risk of
fragility fractures and a control group, meaning
women with high and intermediate risk for fracture.
The low risk group is important to be identified es-
pecially for economical reasons because no DXA is
necessary for them, only follow up by heel QUS. The
studied group differs statistically significant by BMI,
but not by fat mass percent. They tend to be younger.
The serum osteocalcin and CrossLaps are higher,
while the iPTH and 25 OH-vitamin D are not dif-
ferent between the groups. Good results were found
in BMD-DXA analyze, meaning that the BMD is
lower in patients with increased risk for fracture
based on SI QUS.
Conclusions
We consider that based on these results in low risk for
fragility fractures women, the bone markers and body
mass index indicate a difference to the higher risk pop-
ulation, while the two sites central DXA results con-
firm the differences between the two groups.
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Fig. 1 - The BMD values (g/cm2) for lumbar spine, femoral neck and hip in
low risk for fracture, respective control groups.
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Introduction
Infertility affects 13% to 15% of the couples world-
wide (1). A male factor is solely responsible in about
20% of infertile couples and contributory in another
30-40% (2). If a male infertility factor is present, it is
almost always defined by an abnormal semen analysis.
However, since WHO references were adopted, it has
become evident that a basic semen analysis is insuffi-
cient to determine the fertility status of the male (3). 
Subclinical hypothyroidism is more frequent in
women with ovulatory disorders than in women with
other causes of infertility (4) and can be considered as
an infertility factor by itself (5). Levothyroxine (LT4)
therapy can reverse thyroid disfunction and may im-
prove fertility.
Therefore, tubal factor infertility accounts for approx-
imately 25-35% of cases of female infertility. Identifi-
able causes of tubal infertility are postinfectious tubal
damage, post-surgical adhesion formation, and en-
dometriosis-related adhesions (7).
We report a large retrospective study in a population
of infertile couples who conceived after ethiological
therapies and provide informations regarding the rela-
tionship between semen parameters and spontaneous
conception, the association between ovarian disfunc-
tion and thyroid function and the role of a minimally
invasive approach in the diagnosis and treatment of
tubo-peritoneal infertility. 
Materials and methods
3807 infertile couples were evaluated at our infertility
clinic between January 2004 and December 2010.
Each couple underwent evaluation by gynaecologists,
andrologists and endocrinologists. Physical examina-
tion, hormonal assessment of ovulatory function,
screening for cervical and vaginal infections, transvagi-
nal sonogram, evaluation of tubal patency and genetic
assessment (if indicated) were carried out in the female
patients.
The male patients underwent physical examination,
genetic assessment and evaluation for endocrine fac-
tors, non-endocrine testicular dysfunctions and acces-
sory gland infections. Standard semen analysis was
performed periodically, according to WHO guide-
lines (8). 
Etiological treatments were performed in presence of
identified causes of infertility. ARTs were not per-
formed, according to our ethical guidelines. All cou-
ples expressed informed consent to this protocol.
592 couples obtained a spontaneous pregnancy. Clin-
ical and laboratory data, including standard semen
analysis and female thyroid function, were retrospec-
tively evaluated. Pregnancy rate was calculated for 152
patients who underwent, for tuboperitoneal infertility,
diagnostic or operative laparoscopy and hysteroscopy. 
Results
Normal semen analysis was present only in 35% of pa-
tients; 65% subfertile patients showed alterations in at
least one seminal parameter. A sperm count lower than
WHO reference values, isolated or associated with
motility or morphology alterations, was present in
26% of the total pregnancies. Isolated asthenospermia
was the most frequent semen abnormality and was
present in 27% of the total pregnancies. 9% of the to-
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tal pregnancies were obtained by men with oligoast-
enoteratospermia. 
65 women, without other infertility causes than thy-
roid disfunction, began LT4 therapy no more than 6
months before the conception. When stratified ac-
cording to TSH values, 32 patients had a TSH lower
then 2.8 mcUI/ml while in 33 was described a sublin-
ical hypothyroidsm. In the group of patients with
TSH<2.8 mcUI/ml, 15 had an autoimmune thyroidi-
tis, 6 had a positive TRH test and in the remaining
110 was reported an ultrasound pattern of thyroid
nodes. 
Of the 152 patients who underwent diagnostic or op-
erative laparoscopy and hysteroscopy for tuboperi-
toneal infertility, 61 obtained a pregnancy (40%).
Twenty-three pregnancies resulted in miscarriage, 2 in
tubal pregnancy and one patient aborted after a diag-
nosis of Down syndrome. 32% of the patients
achieved a term pregnancy.
Discussion
We report 592 pregnancies occurred between 2004
and 2010 among 3807 infertile couples evaluated at
our institute. In the infertile couples, we applied stan-
dard protocol in terms of investigation and therapeu-
tical management of infertile couples, performed in
both partners in a sequential and parallel way. This
was achieved by a unified clinical management of the
couple, which include gynecologists, endocrinologists
and andrologists, with specific interest in the field of
human reproduction. 
Our data support the possibility of spontaneous con-
ception with semen parameters below the WHO ref-
erences, as documented by the 65% of pregnancies
that occurred in our center, and call into question the
predictive value of WHO reference values, which are
not always predictive of fertility. In order to improve
the clinical value of seminal parameters, WHO revised
its laboratory manual for the examination and process-
ing of human semen (9), giving the lower reference
limit for seminal parameters at the 5th percentile in a
population of men of proven fertility, in agreement
with our evidence of spontaneous conception by men
with reduced seminal parameters. 
Our data evidence therefore that subclinical hypothy-
roidism is a cause itself of female infertility. In the cou-
ples with TSH values higher than 2.8 µUI/ml, the LT4
treatment achieved pregnancy. In women with idio-
pathic infertility the presence of TSH value in the up-
per limit of the normal laboratory references, with as-
sociated thyroid alterations at laboratory or ultrasound
evaluation, could represent also an indication for treat-
ment with levothyroxine in hypofertility. 
The diagnostic/therapeutic mini-invasive approach for
tuboperitoneal infertility allowed to obtain pregnancy
naturally with a pregnancy rate of 40% and 32% for
term pregnancy. When efficacious, this approach al-
lows additional spontaneous conceptions without re-
newed therapy.
Finally, our experience confirm the importance of eti-
ological therapies for infertility. As a consequence
ART techniques should be considered only after a suf-
ficient time of etiological therapies, also according to
ethical criteria of distributive justice, fairness and pri-
oritization (9). 
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Introduction
Osteoporosis is the result of the bone remodeling im-
balance, which depends on the action of Rank-RankL
system, OPG, M-CSF, cytokines and hormones. Hy-
poestrogenism acts on bone loss, increasing cytokines
levels, osteoclasts differentiation and activation, beyond
promoting osteoblasts and osteocytes apoptosis (1).
Temporomandibular disorder (TMD) is more preva-
lent in women and it is believed that sex hormones are
part of its etiology, because it begins at puberty, with
peaks during the reproductive period and decreasing
after menopause, also cause different responses on tem-
poromandibular joint (TMJ) among the genera (2,3).
Hypoestrogenism leads to cartilage thickening, condyle
flattening and increase of eroded surfaces (4), other-
wise, high levels of estrogen causes the opposite (5). 
Essential remodeling elements (OPG and RankL) are
present in the TMJ and the greatest OPG expression
occurs in the presence of estrogen in less committed
joints (6,7). The level of RankL decreases with estro-
gen, not related to the TMJ degeneration (8). 
The jaw restraint (immobilization) results in TMJ os-
teoporotic characteristics (9).
Given the sexual hormones involvement during the
osteoporosis and doubts about their influence over the
TMD, we analyzed whether these two diseases pre-
dominantly female were related, whereas bone loss
might be a possible risk factor for articular TMD.
Methodology
From 2008 to 2011, 1291 women were evaluated by a
single examiner.
Inclusion criteria: age between 48 and 70 years old,
without hormone replacement therapy for at least 1
year or any medication that could interfere with bone
metabolism and current routine tests (hemogram and
bone densitometry).
Exclusion criteria: diabetes, fibromyalgia, thyroid disor-
ders, rheumatoid arthritis, osteoarthrosis, autoimmune
diseases, Lyme disease, dyslipidaemia, disorders of calci-
um metabolism and parathyroid hormone levels.
Densitometry exams were done on a QDR-4500A
densitometer for analysis of the lumbar vertebrae and
femoral neck. The values of T score grouped the pa-
tients, based on established criteria in 1994 by the
WHO. Articular TMD diagnoses were obtained with
the RDC/TMD, classifying patients with up to 5 di-
agnoses within 3 groups: muscle disordersI) and
Group III (arthralgia, osteoarthritis or osteoarthrosis).
In this work, only articular diagnoses were considered,
namely those from Groups II and III.
Catmaker System (2004) calculated bone mass risk of-
fered to the articular TMD, structuring the “PICO”:
Patient (women between 48 and 70 years), Interven-
tion (osteopenia/osteoporosis), Comparison (normal
bone) and Outcome (articular TMD). It was assumed
significance level of 0.05. The sample size calculation
was based on increased relative risk, and for a 80%
power, only 40 osteopenic and 30 osteoporotic
women could’ve been considered.
Results and discussion
Osteoporotic women (n=34) had higher mean age
(59.1±5.7), while osteopenic (n=46) had an average of
57.5 (±4.4) years old. The normal bone mass group
Mineral bone mass as a risk factor for temporomandibular disorders
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(n=20) had an average age of 56.3 (±5.1). From all ob-
tained diagnoses, 18% corresponded to Group I, not
considered for analysis. Were identified 68% articular
diagnostic as a likely consequence of systemic bone
loss, since most of them were present in osteoporotic
women (25%). These were compared to the absence of
diagnoses (14%) present in most women with normal
bone mass (Table 1). The lack of estrogen increases the
TMJ cartilage thickness, flattening the articular sur-
faces (degenerative diseases characteristic) and reduce
bone volume and osteoid (4). Estrogen excess reduces
chondroblasts number and maturation, thinning the
cartilage and decreasing proteoglycan content, making
TMJ less resistant to disorders (5). As the condyle mi-
totic compartment is at a subarticular layer, hypoestro-
genism activate remodeling units located there, estim-
ulating resorption. Thus, estrogen at physiological lev-
els is critical to TMJ health. As evaluated women were
over a declining estrogen period, hypoestrogenism
bone effects reflected on their joints, given that, from
the total joint diagnoses, 25% were osteoporosis and
33% osteopenia. Of these, 16% were in severe os-
teopenia, ie, closer to osteoporosis than normal bone.
All these aspects confirm the existence of estrogen re-
ceptors at TMJ (4,5). Hypoestrogenism promotes the
expression of cytokines and osteoclast precursors, en-
hancing bone resorption (1). These elements are also
found in inflamed TMJ, where cells differentiation in-
to osteoclasts stimulates bone degeneration (8).  
The risk posed by osteoporosis to articular TMD was
higher than osteopenia, respectively 1.39 (CI95% 1.23
to 1.55) and 1.33 (CI95% 1.20 to 1.46), increased by
33% to osteopenia and 39% to osteoporosis (ARR of
0.33 and 0.39). The mandibular function protected
TMJ from bone loss in animals (9), but did not spare
bone loss risk at women assessed here, since all were
doing this function properly. It is known that the re-
sistive movement produces bone, different from the
usual in terms of impact, but in the case of masticato-
ry system, it would be a parafunction.  
In equilibrium, OPG and RankL-Rank system ensure
TMJ bone metabolism. However, there is less OPG in
joints with degenerative diseases, ie, the cartilage degra-
dation is greater due to the lower OPG concentration
(6,7), showing the possibility of therapeutic benefits of
its use at TMD by bone destruction. Despite the sub-
tle expression of RankL in dysfunctional joints (8), its
presence confirms the existence of a cellular source for
osteoclastogenesis, that would be more related to carti-
lage degradation than bone destruction itself. 
We conclude that the TMJ component also suffers hy-
poestrogenism negative consequences, especially in os-
teoporotic women.
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TABLE 1 - TOTAL DIAGNOSTICS (TMD) X BONE.
Bone mass TMD No TMD
Normal 16 (9%) 9 (5%)
Slight 23 (12%)
Osteopenia Moderate 10 (5%) 6 (3%)
Severe 31 (16%) 5 (3%)
Osteoporosis 48 (25%) 6 (3%)
Total* 128 (68%) 26 (14%)
* maximum 4 articular diagnoses: 2 for each TMJ.
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Introduction 
Human endometrium is a hormone dependent tissue
in which cells undergo a variety of adaptive reactions
in response to the hormonal changes that occur during
the menstrual cycle. These changes involve various sig-
naling pathways, which regulate the behavior of en-
dometrial cells such as proliferation, migration and
apoptosis. The actions of 17-ß-estradiol can be medi-
ated through the two classical estrogen receptors estro-
gen receptor α (ERα) and estrogen receptor ß (ERβ).
They are ligand-activated nuclear transcription factors
and mainly responsible for the genomic estrogen sig-
naling (effects on gene expression). A third receptor
emerged in the last decade to also mediate estrogen-in-
duced effects, namely a seven transmembrane G-pro-
tein coupled receptor GPR30 (=GPER1, G-protein
coupled estrogen receptor 1). This receptor is thought
to mediate non-genomic estrogen effects in many tis-
sues of the body by rapid modulation of cell signaling
pathways eg. myometrium, brain, vasculature. It is al-
so able to indirectly exert transcriptional activity (1).
The role of GPR30 in terms of contributing to car-
cinogenesis in the breast or endometrium is now un-
der intensive investigation (2). Therefore to explore
the physiological role of this receptor in the reproduc-
tive system is very important to understand its ways of
participating in hormonal signal transduction (3).
Aim 
In this study, we examine the role of the estrogen re-
ceptors ERα, ERβ and G-protein coupled estrogen re-
ceptor (GPR30) in the regulation of the 17β estradiol
(E2)-induced non-genomic MAPK/ERK activation in
normal primary human endometrial stromal cells
(hESC).
Materials and methods 
hESC obtained from eutopic endometrium of women
(n=10) undergoing laparoscopy and curretage during
the proliferative phase of the menstrual cycle were
used. The absence of endometrial disease was con-
firmed by additional histological examination. Before
stimulation, the cells were cultured in serum free
DMEM-F12 medium for 24 hrs and, when indicated,
12 hrs before stimulation they were pre-treated with
either vehicle or specific inhibitory compounds. In the
present study the following inhibitory compounds
were used: 1 µM ER inhibitor ICI 182,780, 100
ng/ml specific G-protein inhibitor pertussis toxin
(PT), 1 µM EGFR inhibitor AG1478, 150 nM Src ty-
rosine kinase inhibitor (Src-I), 5 µM specific Src fam-
ily of tryrosine kinases inhibitor PP2 and 1 µM specif-
ic GPR30 inhibitor G15. The cells were stimulated
with: either E2 (1 nM or 1 µM), or PPT, or 10 nM
specific ER-β agonist DPN or with 1 µM or 1 nM
GPR30 specific agonist G1 in the presence or absence
of inhibitors for short periods of time (from 2 to 60 min)
at 37°C. PCR and Western blot analyses for ER-α ERβ,
GPR30 and Western blots for pERK, total ERK and
α-tubulin were performed in control and treated
hESC as well as after specific GPR30 and ERα-siRNA
knockdown. Real time (Q)-PCR was performed 48
hours after the initial GPR30-knockdown in hESC
without hormonal stimulation and mRNA-levels of
GPR30, ERα and ERβ were determined. 
Estrogen receptor α and β cooperate with GPR30 in the regulation
of estrogen-induced ERK activation in primary human endometrial
stromal cells
QUAN P., PATEISKY P., GABA A., SZABO L., LEDITZNIG N.,
KURZ C., TSCHUGGUEL W.,YOTOVA I.
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Results and discussion 
Maximal ERK activation was observed within ten min
following either E2 or G1 (GPR30 non-steroidal ago-
nist) administration, which was abolished by the spe-
cific inhibitors ICI 182,780 or G15, respectively. The
inhibition of ERs with ICI 182,780 abolished
GPR30-mediated ERK activation and the inhibition
of GPR30 with G15 abolished the stimulatory effects
of E2, respectively. We further show that G-proteins
and Src kinase family members are required for effi-
cient ERK activation in hESC. The specific EGFR
phosphorylation inhibitor AG1478 blocked the E2-
and G1-induced ERK activation in hESC. 
Knockdown of either ERα or GPR30 confirmed the
data obtained from antagonist treatments and showed
that both receptors are involved in the regulation of
MAPK/ERK signaling pathway activity after hormon-
al stimulation. In addition to the changes in ERK ac-
tivation, GPR30 knockdown in hESC coursed signif-
icant reduction of c-jun expression levels as well as in
the levels of pAkt seen after G1 stimulation. Long-
term treatment of hESC with either E2 or G1 alone or
in combination with a MAPK inhibitor (PD) showed
E2-induced ERK activation might be important for
the regulation of hESC proliferation and migration. In
contrast to E2, G1-induced ERK activation was suffi-
cient for the regulation of hESC migration. The real
time Q-PCR (preliminary data) in GPR30-knock-
down hESC showed that we could reduce the mRNA-
level of GPR30 effectively in comparison to the con-
trols. Surprisingly, GPR30-knockdown reduced the
mRNA-levels of ERα and ERβ simultaneously in the
absence of hormonal stimulation. 
Conclusion 
In conclusion, we provide evidence for a complex reg-
ulation of the non-genomic activation of ERK in nor-
mal hESCs. Furthermore we propose a working mod-
el, explaining how this is achieved in our in vitro cell
system. E2 binds to ERα/ERß and/or GPR30 and
these receptors then form an “activation unit” with c-
Src family kinases and G-proteins. This results either
directly or via transactivation of EGFR in the upregu-
lation of the levels of pERK. It then goes into the nu-
cleus and acts on its downstream target c-jun (Fig. 1).
The future perspective is to evaluate the proposed
working model in human endometrial stromal cells
(hESC) after the GPR30-knockdown. 
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Background 
Endometrial hormone regulation is an attempt for
non-surgical, conservatory management of dysfunc-
tional uterine bleeding (DUB).
Objectives 
Endometrial regulation after two years of hormone
treatment (HT) different by administration route in
perimenopausal dysfunctional uterine bleeding (DUB).
Study design 
Pathological endometrial prospective assessment dur-
ing January 2008-December 2010, in two in-patient
gynecology departments of 35 perimenopausal
DUB, hormonally treated if accomplished inclu-
sion/exclusion criteria (Table 1), compared to 15 un-
treated. 
Endometrial samples [collected at enrollment, after
one, and two years of HTin the 9-11th days of proges-
terone or in the 22-25th days of HT] are stained with
commune histological techniques (hematoxyline- eo-
sine, van Gieson). Endometrial assessment is done by
a single, independent pathologist, using the WHO
classification (1994) and the criteria of Endometrial
Collaborative Group (2000) for endometrial hyperpla-
sia (EH) and endometrial intraepithelial neoplasia
(EIN) or endometroid neoplasia (European Study,
2001).
Endometrial changes are appreciated in the terms of
hyperplasia prevention, on epithelium, glands, stroma,
vessels.
Two years monitoring of hormone endometrial regulation
in perimenopausal dysfunctional uterine bleeding
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TABLE 1 - INCLUSION/EXCLUSION CRITERIA.
Inclusion Exclusion
•  40-50 years
•  minimum 3 months with DUB
•  no previous HT for at least 3 months 
•  submucous leiomyomas
•  endometrial hyperplasia with atypia
•  history of endometrial, breast cancer or other hormone dependent tumor
•  ovarian cysts 
•  suspect mammographic changes one previous year
•  actual pelvic inflammatory disease 
•  actual/history of thromboembolism
•  severe liver disease, jaundice or generalized pruritus during pregnancy 
•  Dubin Johnson/Rotor Syndrome
•  Von Willebrandt disease
•  congenital disturbances of lipids metabolism
•  history of gestational herpes
•  pregnancy aggravated othosclerosis 
•  intolerance to ethynil-estradiol/estradiol, progestogens/progesterone 
Pathologic analysis of endometrial
structures
• Architecture and cytological analysis of glandular ep-
ithelium is done looking for atrophic, weak prolif-
erative, secretory endometrium, hyperplasia: mito-
sis for proliferative effect, subnuclear glycogen ac-
cumulation and intraluminal secretions for secreto-
ry changes. Mitosis per se are not quantified, the
categories 2-3 (WHO, 1997) do not have mitosis
by definition. The regulation effect of progesterone
is analyzed for the degree of proliferation suppres-
sion- mild, moderate, strong, when is not possible
an accurate assessment of secretory transformation
treatment induced.
• Stromal analysis: characteristic aspects for peri-
menopause and menopause/postmenopause: the fi-
broblast-fibrocytic proliferation-marked (MP) and
moderate (mP), the fibrosis, and the presence of in-
flammatory elements (I). In oder to differentiate
and discriminate between EH and EIN- a prema-
lignant lesion, it is specially assessed the stromal
volume. EIN diagnosis is based on the presence of
cytological demarcation, crowded gland architec-
ture, minimum size of 1mm, careful exclusion of
mimics, and diminution of stromal volume to less
than approximately half of the total sample volume
(a new architectural criterion for EIN) (Mutter
GL, 2000, 2002; Dietel M, 2001). Most EIN le-
sions have been diagnosed as atypical endometrial
hyperplasias in the WHO system. 
• Vasculature analysis: vessels’ number on examined
fields: high (HV) and low number (LV), and sub-
epithelial hemorrhages (H).
• EIN diagnosis is based on presence of cytological
demarcation, crowded gland architecture, mini-
mum size of 1mm, mimics exclusion, diminution
of stromal volume to less than approximately half
of the total sample volume (Mutter GL, 2000,
2002; Dietel M, 2001).
Statistic analysis
Paired-sample t test. 
Results
The patients are registered in Table 3, with the demo-
graphic characteristics in Table 4.
The demographic characteristics are similar, with the
exception of parity (more multiparous treated) and
smoking (more controls).
At enrollment microscopy registered similar endome-
trial aspects: hyperplasia (complex hyperplasia without
atypia: 1 case in group 1 and controls; simple hyper-
plasia without atypia: 16-45.7% treated, and 5-33.3%
controls), weak proliferative (16-45.7% treated, and
8-53.3% controls), secretory (1 in group 1, and con-
trols), 1 case with endometrial polyps in the second
group.
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TABLE 2 - CLASSIFICATION OF BIOPSIES (WHO, 1997
AND ENDOMETRIAL COLLABORATIVE GROUP, 2000).
0= no tissue
1= insufficient tissue for diagnosis
2= atrophic/inactive endometrium
3= secretory endometrium
4= normal proliferative endometrium
5= endometrial hyperplasia (EH): simple, complex without and with atypia
6= endometrial intraepithelial neoplasia (EIN)
7= carcinoma (endometrioid, non- endometrioid type) 
TABLE 3 - PATIENTS AND TREATMENTS.
Group 1: 15 cases transdermal (trd) 17-β-E2 gel (Oestrogel®) 1g/day,
delivering 1mg E2, 28 days and vaginal micronised
progesterone (VMP-Utrogestan®) 200mg/day for 12
days, from the 14th day of 17-β-E2
Group 2: 10 cases 200 mg/day  VMP  for 12 days from the 14th day of
menstrual cycle
Group 3: 10 cases Ethynil-estradiol (0.030mg) + Dienogest (2 mg) for 21
days (Jeanine®)
Controls: 15 cases Untreated perimenopausal patients, who refused
treatment 
TABLE 4 - PATIENTS CHARACTERISTICS.
Treated Controls
Number 35 15
Age (yrs)
Average 47.3 48
Variation 45-52 46-55
Weight (kg)
Average 59.6 59.7
Variation 44-91 50-79
Height (cm)
Average 160.8 160.6
Variation 135-168 154-164
Parity:
Nuliparous 1 5
Multiparous 34 10
Smokers 2 5
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After 12 months HT: 4-40% inactive/atrophic en-
dometrium in O vs 3-12% in NO groups - p<0.01;
secretory changes in NO groups (21-80.6%) vs O
(5-64%) -p <0.01, with accentuation after 2 years (at-
rophy: O 9-47.3% vs NO 6-26% -p<0.01; secretory:
NO 16-66.6% vs O 1-10.0%- p<0.01 ); special men-
tion when VMP (8- 80%); 1 case with simple hyper-
plasia without atypia after 24 months on transdermal
estrogen (proliferative endometrium at prestudy) vs
7-46.6% controls (among which 2 are complex hyper-
plasias without atypia, at prestudy being simple hyper-
plasias without atypia). In controls: from 8 prolifera-
tive endometrium at prestudy, 5 are registered after 2
years. No carcinoma registration.
The analysis of the three hormone regimens from the
baseline is focusing on secretory and atrophic changes,
appreciated as safe for endometrium health. After 12
and 24 months treatment there are recorded: 
• low grade secretory changes, characterized by cyto-
plasmic vacuolization: 74.3%, respective 48.7%;
• atrophy/inactive endometrium: 20.0%, respective
40.0%;
• inadequate progestogenic response: 6 cases;
• proliferative endometrium: 3 cases at 12, 1 case at
24 months;
• simple hyperplasia without atypia:1 case at 24
months;
• increase of blood vessels number, and sub-epithe-
lial hemorrhages (more frequent at 24 months).
The NO groups have at 12, and 24 months marked fi-
broblastic-fibrocytic proliferations, fibrosis reduction,
and increase of granulocytes inflammatory cells - spe-
cially in the first year; the group on COC has marked
stromal edema after the first year (Table 6).
Proliferative endometrium is more frequent after NO
vs O: 8.0% vs 9% at 12 months (4.0% vs 0 at 24
TABLE 5 - ENDOMETRIAL BIOPSIES.
Group 1 E2 trd + VMP Group 2 VMP Group 3 E2 + Dienogest
months months months
0 12 24 0 12 24 0 12 24
Insufficient tissue 0 0 0 0 0 0 0 0 0
Atrophy/inactive 0 2 3 0 1 2 0 4 9
Proliferative 8 1 1 6 1 0 2 1 0
Secretory 1 13 8 0 8 8 0 5 1
Hyperplasia 6 0 1 4 0 0 7 2 0
Others 0 0 0 0 0 0 1 0 0
Carcinoma 0 0 0 0 0 0 0 0 0
Total 15 15 15 10 10 10 10 10 10
Control Total 
months months
0 12 24 0 12 24
Insufficient tissue 0 – 0 0 0 0
Atrophy/inactive 0 – 2 0 7 15
Proliferative 8 – 5 24 3 3
Secretory 1 – 1 2 26 25
Hyperplasia 6 – 7 23 0 8
Others 0 – 0 1 2 0
Carcinoma 0 – 0 0 0 0
Total 15 – 15 50 35 50
TABLE 6 - STROMAL AND VASCULATURE  CHANGES.
Stroma Vasculature
Number of Cases/Percentage MP mP F I HV LV H
Enrolment = 35 19/52.3 21/40.8 4/7.6 33/60 23/47.6 19/52.3 7/13.8
12 months = 35 31/88 3/12 1/2 21/70 24/82 7/18 8/24
24 months = 35 30/87 3/12.5 0 21/70 30/82.5 6/17 9/25
Legend: MP=marked, mP=moderate fibroblast-fibrocytic proliferation; F=fibrosis; I=inflammatory elements; HV=high; LV=low number of vessels; H=sub-epithelial
hemorrhages.
months); proliferative aspects are more frequent at 12
than at 24 months. 
Secretory changes are more frequent after NO:
(80.6%) vs O (64.0.%) at 12 months, and 66.6% vs
10.0% at 24 months, p<0.01.
Atrophy is predominant after oral HT vs NO: p<0.01
(40.0% vs 12.0% at 12 months, 90.0% vs 20.0% at
24 months). 
Discussion 
Dysfunctional uterine bleeding is defined as abnormal
uterine bleeding caused by a hormonal mechanism.
Any alteration of the normal menstrual cycle mecha-
nisms can lead to steady-state estrogen production and
DUB. 
Perimenopause is the period of 2-8 years preceding
menopause and one year after the final menses
(WHO), and a better practical definition is the phase
preceding the onset of menopause, generally occurring
around 40-50 years of age (beginning at age 47.5, last-
ing for 4 years) during which the regular cycle of a
woman transitions to a pattern of irregular cycles, be-
cause of luteal phase insufficiency, or anovulation. 
The ages of patients enrolled in this study were in
years of menopausal transitions, the histopathologi-
cal reports of endometrial pattern were in the limits
of abnormal dysfunctional bleeding: weak prolifera-
tive (16- 45.7% in treated, and 8- 53.3% in con-
trols), hyperplasia without atypia (simple: 16- 45.7%
in treated, and 5- 33.3% in controls; complex: one
case in treated and one case in controls), and. sereto-
ry endometrium (one case of in group 1 and in con-
trol), one case with endometrial polyps in the second
group.
Our analysis regarding endometrial stroma has re-
vealed two important aspects to be discussed: 1) the
increase of the fibroblast-fibrocytic proliferation in the
stroma and the reduction of fibrosis in all treated cas-
es, indirectly the maintain of the stromal volume (an
important criteria when discussing about endometrial
intraepithelial neoplasia).
2) the increase of the granulocyte inflammatory reac-
tion is like a pseudodecidualisation and not a sign for
endometritis, which need to discover the presence of
periglandular plasma cells and leukocytes. In the nat-
ural menstrual cycle the presence in the stroma of
these leukocytes infiltration is normally in the pre-
menstrual phase, when starts the estrogen and proges-
terone decline.
In UK a recent endometrial analysis for peri-
menopausal dysfunctional bleeding (84 cases)
(Michail G, Karahaliou A, Skiadopoulos S, et al.,
2007), besides proliferative endometrium (9.79%),
simple hyperplasia (8.53%), there were found en-
dometrial inflammation (20.7%), endometrial atro-
phy (21.9%).
The risks revealed by HERS, WHI for oral HT im-
posed the analysis of endometrial effects of other regi-
mens with: only low dose estrogens, low dose synthet-
ic estrogens as in combined oral contraceptives, new
types of progestogens (gonan, norpregnan, spironolac-
tone derivates- in reduced doses parallel with reduced
doses of estrogen) as alternatives to medroxyproges-
terone acetate, norethisterone or non- oral route of ad-
ministration [transdermal estrogens, (total) transder-
mal estrogens and progestogens, or vaginal micronized
progesterone] for prevention of endometrial hyperpla-
sia, and carcinoma.
Oral contraceptives exert a predominant progestation-
al effect on the endometrium, inducing an arrest of
glandular proliferation, pseudosecretion, and stromal
edema and granulocytes, progressive endometrial atro-
phy after prolonged use, and indirect reduction of en-
dometrial hyperplasia/carcinoma.
We consider that oral combined contraceptive meth-
ods, progesterone/other HT, recommended during
menopausal transition, to regulate the menstrual cycle,
and to protect from excessive endometrial prolifera-
tion/ hyperplasia/ cancer can be continued in
menopause, in order to use the “window of opportu-
nity”, to control climacteric complains. These are the
reasons for this study of vaginal micronized proges-
terone, or transdermal estrogen plus vaginal mi-
cronized progesterone, versus the oral combined con-
traceptive regimen with ethynil estradiol plus
dienogest for DUB in perimenopause.
The endometrial protection from proliferation, hyper-
plasia, or carcinoma was ensured by continuous ad-
ministration of ethinyl estradiol and dienogest, and by
the 12 days of 200 mg micronized progesterone vagi-
nally administrated alone, or sequential to transder-
mal estradiol; in all the cases, and specially in those
with hyperplasias without atypia at enrolment, we
used the WHO’s classification (1994) and the The
Endometrial Collaborative Group (Mutter GL,
2000), regarding EIN.
The case with simple hyperplasia without atypia after
transdermal estrogen and sequential vaginal mi-
cronized progesterone for 12 days (incidence 1/35 cas-
es) is inside the oncological safety (2 cases/100 women
year), if we appreciate the considerations of de Lig-
nieres B (1999) regarding the risks with micronized
progesterone, or the latest review regarding endometri-
al hyperplasia (Palmer EJ, Perunovic B, Tidy AJ,
2011). EIN lesions originate focally and expand in size
over time, in keeping with a proliferative monoclonal
origin. EIN arises through complex interactions in-
volving the sequential accumulation of genetic damage
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in endometrial glands and the positive selective pres-
sure of unopposed estrogen.
EIN is characterized by closely packed glands (volume
percentage stroma <55%) with cytology that is clearly
demarcated from that of the adjacent field. A mini-
mum homogeneous field of cytologically demarcated
glands is required to accurately assess the architecture
diagnostic of EIN, and morphometry-diagnosed le-
sions with a largest diameter of at least 1 to 2 mm have
previously been shown to predict the relevant clinical
outcome of concurrent or future endometrial adeno-
carcinoma.
Regarding the pathological characteristics of EIN, the
case with hyperplasia is conserving the stromal volume
due to marked broblastic- fibrocytic proliferation.
At authors knowledge it is no study assessing endome-
trial safety on the association of transdermal estrogen
and vaginal micronized progesterone in peri-
menopausal women. There were assessements of en-
dometrial safety in postmenopause of the transdermal
associations, such as: 
1. Estradiol 50 µg with norethindrone acetate 140,
250, or 400 µg /day (CombiPattch Study Group,
Archer DF, Furst K, et al, 1999);
2. Estradiol 0.045 mg/day with levonorgestrel 0.015,
0.030, and 0.040 mg/day (Shulman LP, Yankov V,
Uhl K, 2002); 
3. 17β estradiol: 4.4/2.74 and levonorgestrel:
4.5/3.75mg (Dando TM, Perry CM, 2004); 
4. Estradiol 50 µg/day and NETA, 170 µg/day or 350
µg/day, either continuously or sequentially (Yliko-
rkala O, Rozenberg S, 2000); 
5. Estradiol 25 µg/day and NETA 125 µg/day (Estal-
is 25/125 Study Group: Samsioe G, Dvorak V,
Genazzani AR, et al, 2007).
All these researches concluded the endometrial safety:
no hyperplasia.
Conclusions
• NO and oral HT induce similar endometrial as-
pects, but not identic to those of the reproductive
age. 
• Non-oral hormone therapy is endometrial safe for
2 years. 
• Proliferative endometrium is more frequent after
NO vs O: P<0.01; secretory changes are more fre-
quent after NO: P<0.01, and atrophy is predomi-
nant after oral HT vs NO: P<0.01. 
• The highest percentages of secretory changes are af-
ter VMP.
• The case with simple hyperplasia without atypia af-
ter transdermal estrogen plus sequential vaginal mi-
cronized progesterone (incidence 1/35 cases) is in-
side the oncological safety (2 cases/100 women year). 
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Polycystic ovary syndrome (PCOS) is one of the
most common endocrine-metabolic diseases, affect-
ing 6-10% of women in fertile age (1). Increasing ev-
idence supports the central role of insulin resistance
(IR) and compensatory hyperinsulinemia in the
pathogenesis of PCOS and in the increased cardiovas-
cular risk (2). Previous studies have found a deficien-
cy and/or altered metabolism of D-chyro insoitol
(DCI), a specific putative insulin mediator, and have
shown that oral administration of DCI to PCOS
women improves IR, ovulatory function and hyper-
androgenism (3-6).
PCOS is associated with a proinflammatory state and
an elevated production of reactive oxygen species
(ROS) is involved in the pathogenesis and in the fu-
ture complications of the syndrome (7). We recently
demonstrated that patients affected by favism or en-
dometriosis show high oxidative stress in the erythro-
cyte membrane, characterized by increased tyrosine
phosphorylation (Tyr-P) level of membrane band 3,
which represents a useful parameter in the evaluation
of oxidation-related cell damage (8,9).
The aim of this study was to investigate oxidative-re-
lated alterations in erythrocyte membrane status and
in vitro and in vivo anti-inflammatory effects of inos-
itol in PCOS women. 
For in vivo study, we enrolled 26 PCOS patients, 22
to 30 years of age, who were randomized to receive
MYO dietary supplement powder 1200 mg/day (Re-
destop, Progine, Firenze) (n=18) or matched placebo
powder (n=8) for 12 weeks. 
All patients met the inclusion/exclusion criterion of the
ESHRE/ASRM consensus for diagnosis of PCOS (11).
Before (T0) and after (T1) MYO treatment, blood
samples were collected in fasting conditions to measure
serum testosterone, androstenedione, and glucose and
insulin during oral glucose tolerance test (OGTT). Val-
ues are expressed as the area under the curve (AUC) of
glucose and insulin, respectively. A peak of serum in-
sulin value during OGTT > 70 mU/L was considered
an IR index. Homeostasis Model of Assessment - In-
sulin Resistance (HOMA-IR) was also used.
For the evaluation of the oxidative-related alterations
we analysed Tyr-P levels induced by 1.5 mM diamide
incubation for 30 min in purified human erythrocytes
from PCOS patients (in vivo study), or from both pa-
tients (n=6) and healthy volunteers matched for age
and BMI (n=6) after a pre-treatment in the absence or
presence of 2 mM inositol (in vitro study).
Membranes were recovered, analyzed by Western blot-
ting and immunorevealed with anti P-Tyr antibodies. 
The Tyr-P value of diamide-treated erythrocytes be-
fore (T0) and after (T1) in vitro or in vivo treatment
was calculated as the ratio to the Tyr-P level of di-
amide-treated erythrocytes obtained in healthy con-
trols (chosen as arbitrary comparison unit). To express
a standardized measure of Tyr-P variation after in vit-
ro or in vivo treatment [Tyr-P variation index, Vi(Tyr-
P)] with respect to baseline value, the following for-
mula was used:
Vi(Tyr-P) = 1 - (Tyr-PT1/Tyr-PT0)
Comparisons were obtained with Student’s t-test for
paired or unpaired data, as appropriate. Data are ex-
pressed as mean±SD. p<0.05 (two-tailed) was consid-
ered significant.
Baseline clinical characteristics and haematochemi-
cal parameters determined in the two groups of
PCOS showed no significant differences. Following
the 12-week treatment, comparing the two groups, in
the MYO group we observed a significant reduction of
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BMI (p<0,02), serum values of testosterone
(p<0,0001) and androstenedione (p<0,003), fasting
insulin (p<0,003), AUC insulin after OGTT
(p<0,006) and HOMA-IR (p<0,001). No significant
changes were observed in the placebo group.
Increased systemic oxidative stress was studied on ery-
throcytes membrane status by Tyr-P levels of band 3.
In baseline conditions, in absence of diamide stimula-
tion Tyr-P could not be detected in erythrocytes from
either patients or controls, but when PCOS RBC were
incubated with diamide, membranes showed a signifi-
cantly higher Tyr-P levels (185±20% compared to
healthy controls, considered as 100%).
Both in vitro (p<0,02) and in vivo (p<0,05) MYO
treatment significantly reduced Tyr-P levels of band 3
(17±2% and 35±7% respectively). No variations were
found in the placebo group.
To assess interrelationships between RBC parameters
and hormonal/metabolic data at T0 and T1, a linear
regression was performed and the strength of correla-
tion was assessed by Pearson’s correlation coefficient r
(by ANOVA). In the MYO-group we obtained a sig-
nificant correlation between serum testosterone and
Tyr-P levels (p<0.05). Comparison of the two regres-
sion lines, at T0 and T1 respectively, revealed a signif-
icant difference between the intercepts in MYO-treat-
ed patients (p<0.0001); the slope remained the same,
indicating that, although phosphorylation kinetic
mechanisms were unaffected by MYO administration,
they were quantitatively reduced. The same analysis,
applied to the placebo group, confirmed the signifi-
cant correlation between Tyr-P and serum testosterone
levels only at T0 (p=0.0032). A significant correlation
was detected also between insulin AUC and Tyr-P, but
only at baseline (p<0,05). After MYO treatment, the
concomitant reduction found for Tyr-P and insulin
AUC values produced a clustering of data that abol-
ished the regression of the two variables.
Our study underlines that PCOS patients suffer from
systemic redox impairment, as indicated by oxidative-
related alterations in erythrocytes band 3 Tyr-P of all
patients in basal conditions. Interestingly, inositol
treatment both in vitro and in vivo positively affected
the oxidative status of RBC, as shown by the signifi-
cant reduction in band 3 Tyr-P levels. The present
study also confirms the beneficial effects of MYO
treatment on ameliorating hyperandrogenism and IR.
In particular, the significant reduction of Tyr-P levels
in RBC and insulin AUC found at T1, confirms the
strength relationship between IR and oxidative stress
in the pathogenesis of PCOS and that MYO uptake
can modulate insulin intracellular pathways and ox-
idative stress induced by the inappropriate hyperinsu-
linemic response linked to IR.
Another novel data is the significant correlation be-
tween Tyr-P and testosterone levels at T0 and, more
interestingly, at T1, suggesting that alteration of the
phosphorylation process of erythrocyte band 3 is me-
diated by higher testosterone levels in serum. We hy-
pothesize that administration of MYO improves band
3 Tyr-P through a decrease of testosterone level (11).
In conclusion, Tyr-P process could be very useful in
monitoring patients’ conditions and in choosing the
adequate therapy. MYO can be considered an alterna-
tive to metformin for PCOS.
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Introduction 
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine and metabolic disorders that affect
5-10% of women during reproductive age. Being the
most frequent cause of anovulatory infertility and hy-
perandrogenism. In addition 40 to 50% of these pa-
tients exibit hyperinsulinemia and insulin resistance.
Adipocytes and muscle cells of PCOS women have a
reduced uptake of glucose and expression of gluco-
transporters, without changes in receptor number or
affinity for insulin. It is thought that insulin resistance
of these tissues is associated with impaired post-recep-
tor signaling. PPAR γ are key transcription factors that
regulate metabolism of glucose and Insulin. Rosiglita-
zone belongs to the family of thiazolidinediones, it is a
potent selective agonist of PPAR γ receptors, regulating
the expression of genes involved in lipid and glucose
metabolism. Glitazones increase the incorporation of
glucose-insulin-dependent in cultured myocytes and
adipocytes modulating the expression of GLUTs. 
Conversely, the glucose metabolism and the insulin
signaling pathway in granulosa cells (GCs) of PCOS
patients are virtually unknown. The aim of this study
was to determine the role of PPAR γ and its agonist
Rosiglitazone in the metabolic pathway of Insulin in
granulosa cells of PCOS patients. 
Methodology 
Follicular fluid (FF) from the first aspirated follicle
and granulosa cells (GCs) from the whole follicle aspi-
rated were collected from PCOS (n= 15) patient par-
ticipating in the IVF program of our institute (Insti-
tute of Maternal and Child Research IDIMI, Faculty
of Medicine University of Chile. Campus Centro).
Similar samples were collected from normal women
involved in our IVF program due to male factor infer-
tility and were used as control group (n=18).
GLUTs and PPAR γ genes expression were evaluated
by qRT-PCR, the proteins were localize by immuno-
cistochemistry, (ICQ) inmunofluorescence and pro-
tein levels were determined by Western blot. Glucose
was measure in follicular fluid by glucose oxidase tech-
nique and its uptake was assessed by incorporation of
2-desoxy-[3H]-glucose (2-DG) in both basal and stim-
ulated condition (Insulin 100 ng/ml), as well as in pre
incubated cells with Rosiglitazone (0,01-1 µM). 2-DG
can be uptake by the cell but can’t be metabolized or
degraded so we can measure the exact amount of glu-
cose that the cell incorporates.
Data are presented as mean ± SEM. Comparison be-
tween groups was performed using analysis of variance
(ANOVA) in conjunction with Turkey test or Stu-
dent’s t-test. The result was considered statistically sig-
nificant when  p values ≤0.05.
Results 
Both groups were similar in age and BMI. PCOS
group were hyperandrogenic and had insulin resist-
ance with compensatory hyperinsulinemia.
Glucose levels in follicular fluid of PCOS follicles were
significant higher compared to the control group
(41,14±5,1 v/s 18,33±2,8 mg/dl p<0,05). PCOS GCs
show a marked decrease in the expression of mRNA of
GLUT1 and GLUT4 compared to the control group
(p<0,01). The same decrease was observed at the pro-
© Copyright 2012, CIC Edizioni Internazionali, Roma
Functional role of peroxisome proliferator-activated receptors gamma
in glucidic metabolism of granulosa cells from normal
and polycystic ovary syndrome women
SALINAS QUERO S.A., PUSTOVRH M.C., GODOY A., ARGÜELLO B.,
MUÑOZ A., KOHEN P., DEVOTO L.
Institute of Maternal and Child Research (IDIMI), Department of Obstetrics and Gynecology, Hospital “San Borja Arriarán”,
Faculty of Medicine, University of Chile - Campus Centro, Santiago, Chile
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
292
tein expression level in the PCOS CGs determined by
ICQ using Expression Level Score (ELS).
Basal glucose uptake diminished signifincantly in the
PCOS GCs compare with control GCs (0,66±0,1 v/s
1,016±0,017 pmol/105 cel/min p <0.05). The addi-
tion of insulin (100 ng / ml) to the culture medium for
1 hour enhanced the glucose uptake in the control
group without modification in the sugar uptake of
PCOS GCs.
PCOS GCs expressed significant lower abundance of
PPAR γ mRNA (p <0,05) and the PPAR γ protein is
mainly localized at the nuclear level (p <0.001) com-
pare with control. The incubation with Rosiglitazone
0.1 µM for 12 hours significantly improved the incor-
poration of 2-desoxy-[3H]-glucose (p <0,05) in PCOS
GCs and increased the levels of GLUT4 mRNA and
its protein.
The results of this study show that PCOS GCs have dif-
ferent metabolic and molecular profile than CGs of nor-
mal women. Glucotransporters are decreased in PCOS
GCs and revealed resistance to insulin modulation. 
In turn, the followig in vitro data indicate that the ac-
tivation of PPAR γ by the pharmacological agonist
Rosiglitazone improves glucose uptake in the granu-
losa cells of PCOS women. This effect is probably
driven by the increase of GLUT4. 
Supported by Conycyt. Chilean Research Council. FONDAP
Proyect 15010010
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Introduction
Human Prolactin (PRL) is a proteic hormone pro-
duced by the anterior pituitary gland. The secretion is
regulated by different endogenous factors: dopamine is
the predominant prolactin-inhibiting neurotransmit-
ter, serotonin and TRH stimulate secretion of PRL (1).
PRL circulates in three different isoforms: monomeric
(mPRL) with a molecular weight of 23kDa, that has
the highest receptor affinity and biological activity;
Big-PRL, which has a molecular mass of 50kDa and is
a dimer of PRL; macroprolactin (MPRL) with a mo-
lecular weight greater than 150kDa and an abstent
bioactivity. MPRL is a complex of mPRL and antibod-
ies (IgG, IgA, IgE) and different glicosilation (2).
Moreover, post-transcriptional modification of pitu-
itary PRL generates a variety of additional species, in-
cluding glycosylated and phosphorilated variants, to-
gether with 16kDa proteolysed form (3).
PRL promotes breast development and stimulates milk
production, but PRL hypersecretion interferes with
pulsatile gonadotropin releasing hormone secretion,
resulting in mestrual irregularities and gonadal dys-
function. Macroprolactinaemia is found in 9.6-29% of
patient with hyperprolactinaemia (4).
The aim of this study in to evaluate the secretion of
the different isoforms of PRL and their clinical impact
on gynaecological pathologies. In particular, mPRL
and MPRL’s behavior were studied in order to make a
differential diagnosis based on clinical signs and values
of different isoforms.
Materials and methods
Eighty-two patients with hyperprolactinaemia and ir-
regular menses were admitted to the Department of
Endocrinology of University of Brescia/Spedali Civili
between 2008 and 2010. All patients underwent to
endocrine evaluation: hormone evaluation, MPRL as-
say (precipitation with Poliethylen Glycole) and Mag-
netic Resonance Imaging of the turcic sella. 
Results
Diagnosis of prolactin secreting adenomas was con-
firmed in 49% of patients, whereas in 51% there was
a dysfunctional hyperprolactinaemia. In this second
group the diagnosis was Polycystic Ovary Syndrome
(PCOS) in 48% of patients, iatrogenic anovulation in
36%, obesity/metabolic syndrome in 11% and en-
dometriosis in 5%. 
Secondary amenorrhea was present in 97.5% of pa-
tient with adenomas, whereas in 38.1% of dysfunc-
tional patients. Oligoamenorrhea was present in
47.6% of dysfunctional forms.
Galactorrhea was found in 87.5% of women with pro-
lactinomas and in 9.5% of dysfunctional patients
(Tab. 1).
The highest level of total PRL were found in patients
with adenomas, showing increased prevalence of
mPRL than MPRL. In dysfunctional pathologies
MPRL was the prevalent isoform (Tab. 2).
Conclusions
Different isoforms of PRL are associated to different
gynaecological pathologies. Prolactinomas are associat-
ed with a MPRL/PRLm ratio <1, galactorrhea and
amenorrhea, whereas dysfunctional pathologies are as-
sociated to an elevation of MPRL and MPRL/PRLm
ratio >1. These forms of hypermacropralctinaemias do
Different prolactin isoforms in gynaecological pathologies
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not have clinical consequence on the ovary. In these
patients the menstrual irregularities were caused by
other endocrinological pathologies.
In conclusion, differential diagnosis of hyperprolacti-
naemia could be made with clinical signs and values of
different isoforms of PRL.
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TABLE 1.
Group 1 Group 2
(Disf. HyperRPL) (Adenomas)
Number 42 40
Age (years) 28.9±11.4 30.0±10.2
BMI (kg/m2) 25,6±6,1 24,5±3,1
Regular menses 2 (4,7%) 0
Irregular menses 40 (95,3%) 40 (100%)
Oligoamenorrhea 20 (47,6%) 1 (2,5%)
Amenorrhea 16 (38,1%) 39 (97,5%)
Hyperpolymenorrhea 4 (9,5%) 0
Galactorrhea 4 (9,5%) 35 (87,5%)
TABLE 2.
Group 1 Group 2
(Disf. HyperRPL) (Adenomas)
Total PRL (ng/ml) 68.2±10.5* 80.1±20.5
MPRL(ng/ml) 45.9±15.8* 20.2±8.8
mPRL(ng/ml) 22.4±11.2* 65.3±30.2
Student t test P<0.05 group 1 vs group 2.
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Introduction
Polycystic ovary syndrome (PCOS) is the most com-
mon endocrine disorder among reproductive-age
women, affecting 5 to 10% of them. Although clinical
features of the syndrome are heterogeneous and ex-
tremely different between individuals, Rotterdam
Consensus in 2003 established that diagnosis should
be based in presence of at least two of the three major
criteria, including: chronic oligo-anovulation, clinical
or biochemical signs of hyperandrogenism, and poly-
cystic ovarian morphology based on ultrasound scan,
excluding other androgen excess causes. 
Aetiology of the syndrome is still controversial, but
insulin-resistance and hyperandrogenism play a cen-
tral role in the development of the syndrome, deter-
mining clinical signs, infertility, obesity, hypergly-
caemia and dyslipidaemia, which are potential risk
factors for these patients, and are involved in long
term consequences, such as cardiovascular events and
cancer. 
Hyperandrogenism is the key feature of PCOS, and it
is primarily due to an excessive androgen production
in ovaries, mainly caused by an increased LH stimu-
lation (abnormal LH pulse secretion) and by hyperin-
sulinemia. Insulin resistance improves the action of
LH and increases with the obesity. So, insulin and LH
in synergy contribute to stimulate androgens produc-
tion.
The aim of this study is to evaluate long term mor-
bidities of PCOS. In particular, the relationship be-
tween the syndrome and the development of cardio-
vascular, metabolic, neoplastic and pregnancy events
was studied.
Materials and methods
Among patients admitted from 80’ to the Department
of Gynaecological Endocrinology of University of
Brescia/Spedali Civili, 515 PCOS underwent long
term follow-up of 25.3±4.8 years (17-37 years).
Long term morbidities of polycystic ovary syndrome (PCOS)
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TABLE 1 - METABOLIC AND CLINICAL FEATURES OF
PCOS AT ADMISSION.
PCOS (n = 515) %
Mean age (yr) 22.3±4.8 (13-36)
Mean BMI (kg/m2) 23.12±4.6
Underweight 47 9.1
Normal weight 330 64.1
Overweight 89 17.3
Obese 49 9.5
Menarche (yr) 12.8 ±2.7 (9-17)
Cycles
Oligomenorrhea 306 59.6
Amenorrhea 139 26.9
Regular 45 8.7
Polimenorrhea/Menometrorrhagia 25 4.8
Hypercholesterolemia 76 14.7
Hypertrigliceridemia 29 5.6
Glucidic intollerance 9 1,7
Blood pressure (mmHg)
Systolic blood pressure 118.5±12.9
Diastolic blood pressure 72.9±9.95
Patients with acne 186 36.1
Patients with hirsutism 262 50.9
Parity (women with children) 18 3.4
Miscarriage 21 4.1
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Results
PCOS women show a progressive weight gain, with a
greater incidence of obesity from 26.8% to 41.5%
during life, due to abnormalities in insulin action and
secretion. In fact insulin resistance is associated with
the development of abdominal obesity. 
Oligomenorrhea is the most common feature in pa-
tients with PCOS, but during years spontaneous reg-
ularization of menstrual cycles was obtained in 64.4%,
especially after pregnancy.
This is probably due to adrenopause process (a gradual
reduction in adrenals androgens production, which
began by the third decade of life) and to pregnancy,
which represents an essential moment in the restoring
of hormonal balance, due to the estrogenic milieau
that contrasts androgenic effects.
Chronic anovulation is one of the most important cause
of infertility. In fact, it was present in 40.7% of patients,
and 65% of these required ovulation induction (using
clomiphene citrate). 21.4% of PCOS was clomiphene
resistant and were not able to get pregnancy. 
PCOS has an increased risk of pregnancy adverse
events (higher rate of miscarriage, gestational hyper-
tension, preeclampsia and premature delivery (1)).
This may be due to hyperinsulinaemia and hyperan-
drogenemia that can adversely affect endometrial and
ovarian function. In addition, endothelin-1 and PAI-1
(plasminogen activator inhibitor-1) which are present
in high levels in PCOS, are associated with placental
thrombosis and fetal loss (2).
Insulin-resistance and hyperandrogenism modulate
plasmatic levels of some haemostatic factors and they
improve lypolisis, increasing the release of free fatty
acids, secretion of VLDL and triglycerides (3). For
these reasons, cardiovascular risk factors are increased
in PCOS versus general population (4,5). In particular,
diabetes was present in 5.9% of patients, hypertension
in 20.4%, hypercholesterolemia in 27.3% and hyper-
trigliceridaemia in 4.2%. Despite that, no differences
in major cardiovascular events (stroke, thrombosis,
myocardial infarction) were found in treated PCOS
when comparing with the general population, but the
incidence of phlebitis was two times greater (6.9%),
perhaps because of a long estroprogestinic use (6).
We did not found any dissimilarity in thyroid func-
tion between PCOS and general population (7).
No significant differences in benign gynaecologic
pathology (uterin polyps, leiomyoms, ovarian cysts
and breast fibroadenomas) seek out in PCOS. A con-
dition of relative hyperestrogenism may increased
these disorders, but estroprogestin therapies seems to
have a protective effect.
Incidence of neoplastic pathologies (endometrial,
breast, ovarian and colon cancer) was not different
from local general population (6). This can be partial-
ly explaned by a prolonged estroprogestin treatment,
which explicate a protective effect in some of those
diseases. In fact, in patients who didn’t submitted es-
troprogestin treatment the incidence was higher.
Conclusions
In conclusion, patients with PCOS showed infertility,
menstrual irregularity, a greater rate of adverse preg-
nancy outcomes, predisposition to obesity and higher
cardiovascular risk factors than general population, but
cardiovascular events are not increased in treated pa-
tients. Furthermore cancer incidence is not significant-
ly increased in treated PCOS than general population.
Treatment of PCOS is also able to change or minimize
the development of long term sequelae. Therapies pre-
maturely introduced restored a proper hormonal bal-
ance before vascular and metabolic consequences oc-
curred. Treating “the whole state” rather than “the dis-
ease” should be the principal on dealing with PCOS.
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Introduction
Premature ovarian failure (POF) affects 1% of women
and is defined as the occurrence of amenorrhoea last-
ing more than 6 months along with high levels of go-
nadotropins (follicle-stimulating hormone, FSH >40
mU/ml, in at least two occasions) which is observed
before the age of 40 (1). The aethiology of POF is un-
clear in the majority of cases; nevertheless either ge-
netic or acquired pathogenetic mechanisms should be
theoretically implicated: genetic mechanism include
mutations in genes coding proteins that are essential
for ovarian development, whereas acquired mecha-
nisms include the effect of various environmental fac-
tors that can cause POF through autoimmune (2-4)
or viral (5-7) oophoritis, the effect of environmental
toxins and iatrogenic factors (surgery, radiotherapy
and chemotherapy). 42.9% of POF cases are charac-
terized as idiopathic/sporadic, 7.8% of cases are
caused by autoimmune multiple endocrinopathy,
whereas 4% of the cases are iathrogenic. As expected,
cases with extremely early POF experience the conse-
quences of oestrogen deprivation with more detri-
mental impact. 
POF is associated with higher risk of osteoporosis,
changes in lipid metabolism, cardiovascular system
diseases. Infertility is a severe problem, especially, if
woman is younger than 30 years. There are different
treatment possibilities; most often used is HRT to-
gether with glucocorticosteroids.
To solve infertility, donor egg is used together with
man’s semen. Usually POF is in 1-5% women aged
20-35, when the donor’s egg psychologically is diffi-
cult to accept.
Methods
We report two clinical cases (patient A and B).
Both patients were younger than 37, with proven
POF – 6-8 months amenorrhoea, FSH>70 U/L,
estradiol _˜ 30 pg/ml, ovarian US (some little folli-
cles 2-4 mm in diameter), infertility. Both patients
agree that their data will be used on this publica-
tion. 
Results
Pacient A
Anamnesis
Pacient A, age 28, born as third sister in family. Both
sisters have irregular menstrual cycle, often only with
oval contraceptives (OC), have no children, are mar-
ried. One sister is proved to have POF.
Menarche since age 16, periodical irregular menstrua-
tions, amenorrhoea since the age of 26.
Infertility five years. For cycle regulation used OC or
Duphaston. No hormonal investigations were done at
that time.
Complaints (on admission in 2008)
Pacient had anenorrhoea for 2 years, hot flushes,
sweating, palpitations, vaginal dryness and infertility
for five years. 
Investigations: Per vaginam: atrophic colpitis, small
uterus. US – linear endometrium, some pointlike fol-
licules in ovaries.
Hormonal analyses:
FSH – 55,9 U/L, LH – 1,3 U/L, E2 < 20 pg/ml, TSH
– 0,838 mU/ml, thyroid antibodies – norm, PRL –
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310 mU/l, ovarian antibodies - negative, AMH <0,16
ng/ml.
Husband spermogramme – normal
Treatement
Oral contraception with regular FSH controle. When
FSH reached ~ 20 U/L on cycle days 3-5, then estro-
gen (4 mg Estradiol and Duphaston 10 mg) cyclic
therapy was started.
Follicule formation was observed with US, as well as
FSH and E2 levels detected. When the dominant fol-
licule was forming in the middle of the cycle, reaching
18-20 mm, endometrium 8-10 mm, FSH – 20 U/L,
the pacient received intramuscular Pregnyl 10000
units, continuing estrogen and progesterone therapy.
Pregnancy occured only during the 4th cycle. During
every cycle ovulation possibility was documented by
hormonal analyses. 
Treatement during pregnancy
After menstruation delay we checked HCG, estradion
and progesterone.
Substitutional treatement during pregnancy was start-
ed at HCG 40-60 mU/ml. Pacient received Estrofem
2-4 mg and Utrogestan 400-600 mg/d. Hormonal lev-
el was checked regulary, fetal US was performed.
Reaching pregnancy 10-12 weeks hormonal substitu-
tion was slowly decreased and after 16th week
stopped. Genetical screening tests were normal.
12.07.2010 after 39 weeks of pregnancy a girl was
born- weight- 3510g, Apgar scale 8/9 points. Probably
pacient A had a geneticaly determined POF.
Pacient B
Anamnesis
In March 2010 pacient B, age 36 came in with com-
plaints about having no menstruations for one year
and infertility for three years. 
Menarche since age 13, regular, 4/28 days.
In 2005 normal delivery, in 2006 missed abortion 7/8,
followed by one year of infertility, after that unsuccess-
ful IVF, then irregular cycle, followed by amenorrhoea.
As a treatement she has been given cyclic HRT with-
out effect and the infertility was continuing.
Investigations
FSH – 62,4 U/L, LH – 38,4 U/L, E2 <20 pg/ml, TSH
– 1,5 mU/L, homocystein – 8,59 mmol/l, ATPO – 47
U/mL, ovarian antibodies- positive. USG – small
uterus, some small foloculies in both ovaries. 
Husband spermogramm – normal
Treatment
Oral contraception and dexmetasone 0.5 mg every day
(to block ovarian antibodies), then with Estradiol
growing endometrium till 10 mm and folicules till 20
mm, Pregnyl i/m 10000 units. Pregnancy occured
during second cycle.
Treatment during pregnancy
Estradiol and Progesterone, at the begining small dose
Dexametasone (0.25 mg per day till 8 gestation week
to block ovarial antibodies), from week 14 no addi-
cional therapy, because analyses and fetal growth was
normal. Genetic tests normal, pacient refused amnio-
centesis.
Pregnancy result
14.08.2011, at 39th gestation week with spontaneus
delivery boy 3500g, Apgare scale 9/10 was born. Now
breastfeeding, child development normal.
For pacient B POF appeared as autoimune reaction to
missed abortion after IVF.
Conclusion
It is desirable to try to obtain POF patients own ovu-
lation with medication (HRT+glucoccorticosteroids),
and only after failure send to IVF with donor eggs. 
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Introduction
Uterine leiomyomas are the most common gynecolog-
ical pelvic tumor, diagnosed in more than 25% of
woman during their reproductive years and identified
in about 80% of all histerectomy specimens (1).
Retroperitoneal myoma are a rarer entity that consti-
tute a diagnostic challenge for any clinician.
Although this entity was first described by Kelly and
Cullen in the beginning of the twentieth century, few
cases have since been reported, usually referring to in-
dividual case reports. Soliman et al. recently reviewed
published literature and in December 2011 there were
51 cases reported, including their case report (2).
Case report
We report the case of a 54-year-old, multiparous, Cau-
casian female, who was referred to our out-patient
clinic due to an adnexal mass with no pertinent clini-
cal complaints. Her past medical history was relevant
only for a vaginal hysterectomy due to fibroids, which
she had undergone nine years previously.
On routine vaginal ultrasound a heterogeneous oval
mass, with 52x39mm, was identified at the left ovary.
Laboratory values were normal, including a CA 125
level of 7,5 U/ml.
An exploratory laparoscopy was performed and intra-
operatively the ovaries where found to be of normal
size without any macroscopic alterations. On further
inspection of the pelvic cavity a well circumcised
retroperitoneal mass was identified in the left pelvic
side wall, behind the left ovary. Bilateral oophorecto-
my was then performed and the pelvic side wall tumor
was totally excised with blunt dissection. The speci-
men was then removed through the umbilical incision
in a LapSac® (Fig. 1).
The postoperative period was uneventful and patient
was discharged on the first postoperative day.
The histopathological examination of the surgical
specimen was consistent with a parasitic fibroleiomy-
oma, weighing 32g.
Discussion
Uterine myoma are a relatively common finding, but
some rare extra-uterine growth presentations have
been described in the literature, such as benign metas-
tasizing leiomyoma, disseminated peritoneal leiomy-
omatosis, intravenous leiomyomatosis, parasitic
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Fig. 1 - Retroperitoneal myoma after surgical resection.
leiomyoma and retroperitoneal leiomyoma (3).
Retroperitoneal myoma are thus a rare finding and the
great majority, like the case of our patient, are identi-
fied in the pelvic cavity. 
The pathologic basis for parasitic myoma is still un-
clear and two main theories have been hypothesized.
The older theory suggests that parasitic myoma arise
from pedunculated subserosal myoma that have sep-
arated from the uterus and have managed to implant
and receive blood supply from another source. A
more recent theory suggest that these parasitic my-
oma are “iatrogenic” in nature and result from the
seeding of portions of fibroids left in the abdominal
cavity during morcellation at the time of myomecto-
my or hysterectomy. Poliquin et al. reported that
over 40% of patients with retroperitoneal leiomy-
omas have concurrent uterine leiomyoma or a past
medical history of hysterectomy due to uterine
leiomyoma (4). In the case of our patient she had
been previously hysterectomized due to fibroids,
thus constituting in our view a possible risk factor
for the development of the retroperitoneal parasitic
myoma.
Although ultrasound is an excellent screening tool in
these cases, magnetic resonance imaging is the most
reliable imaging technique for the evaluation of
retroperitoneal masses.
Conclusion
Parasitic myoma are a rare finding in clinical practice
and thus constitute a diagnostic and therapeutic chal-
lenge. These benign tumors sometimes mimic adnexal
masses and clinicians should be familiar with extra-
uterine presentations of leiomyoma. This entity
should thus be included in the differential diagnosis of
pelvic masses, especially in patients with concomitant
uterine myoma or a previous history of myomectomy
or hysterectomy due to fibroids. 
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Background
Cervical cancer is one of the most common neoplasic
deseases affecting women with a combined worldwide
incidence exceeded only breast and colonrectal cancer.
The etiologic relationship of HPV infections to cervi-
cal cancer as well as to cancers at several other sites, is
firmly established. Low grade lesions of the cervix re-
flect the pathologic effects of infection with HPV. Al-
though about 100 HPV viral types have been identi-
fied, only 30 are known to infect anogenital tract.
HPV have been divided into low risk and high risk
types, based on their association with high grade squa-
mous intraepithelial lesions and invasive cervical can-
cer. Although several of the low risk HPV types (most
commonly types 6 and 11) are frequently found in
LSIL. It is important to note that high risk HPV types,
including types 16, 18, 31, 33, 35, 45, 56 are also
found in ASCUS–Pap smears.
Objective
To evaluate the age as a risk factor in patients with AS-
CUS-Pap smears and how does it influence in the pro-
gression to precancerous lesions. The estimation is
done by correlating the ASCUS citologic diagnosis
with histologic biopsy.
Methods
This is a cross sectional study of patients refered to col-
poscopy in Regional Hospital of Durres, Albania, dur-
ing the period 2009-2011. We selected the patients
with the diagnose of ASCUS-Pap smears and we ap-
plied Hybrid Capture 2 (Quiagen) technique, for eval-
uation of High Risk HPV DNA (type 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68).
A 12 months interval was specified in order to obtain
the most valid correlation between the citologic and
histologic diagnosis.
We analised patients in two groups: 30 years old and
younger and older than 30 years old.
Result 
We applied Pap test in 241 patient. A total of 43
(17.8%) patients were diagnosed with ASCUS accord-
ing to the criteria of the Bethesta system.
From those; 26 (60.4%) patients were 30 years old
and younger and 17 (39.5%) patients were older than
30 years old.
The patient’s age ranged from 17-30 year old with a
mean age of 23 year for the first group and 31-55 year
old with a mean age of 43 year for the second group.
The occurence of High Risk HPV DNA infections in
patients with ASCUS was 34.6% (9 cases) in patients
30 years old and younger and 23.5% (4 cases) in pa-
tients older than 30.
There is a significant difference in occurence on iden-
tifying the high risk HPV DNA among the women 30
years old and younger than women older than 30,
with ASCUS diagnose; d=0.11, CI95% ]0.2-0.2[,
p<0.01.
The high risk HPV DNA is significantly found more
often among female 30 years old and younger rather
than female older than 30 years old.
We performed biopsy 12 months later, according to
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the fact that histologic diagnosis is considered to be
the gold standart.
In patients older than 30 years old, 75% of cases (3 pa-
tients) with positive High Risk HPV DNA test, pro-
gressed to precancerous lesions: 1 patient (25%) in
CIN1 and 2 patients (50%) in CIN2.
In patients 30 years old and younger, 33.3% of cases
(3 patients) progressed in precancerous lesiones: 2 pa-
tients (22.2%) in CIN1 and 1 patient (11.1%) in
CIN2 (Table 1).
Meanwhile, difference in propotion on progression to
the precancerous lesions between patients of age older
than 30 and patients 30 years old and younger, is
d=0.42 with CI 95% ]0.14-0.8[, p<0.05.
There is a significant difference between the patients
older than 30 years and 30 years old and younger, di-
agnosed with ASCUS and high risk HPV DNA, re-
garding the progression to precancerous lesions.
Conclusion 
From our study we concluded that the prevalence of
High Risk DNA HPV (in cases with ASCUS Pap
smears) is higher in patients 30 years old and younger
than in patients older than 30 years old. But the pro-
gression to precancerous lesions is higher in patients
older than 30 years old.
Discussion 
ASCUS is not a precancerous change. It is a category
that indicates some cellular irritation and one that
bears repeating to see if there is any change toward dis-
plasia in a later time. For some women an ASCUS re-
sults is due to changes in the cervical cells caused by
HPV infection. The category of ASCUS is reserved for
lesions in which a clear distinction between reactive
and neoplastic cells can not be made. ASCUS diag-
nose is very common in young women whereas inva-
sive squamose cell carcinoma is very rare. The risk of
high grade lesions in women with ASCUS is an age re-
lated phenomen.
On the other side a risk factor identified in most stud-
ies of HPV infections is age. The maximum prevalence
occured between 20 and 24 years old, followed by a
decrease under age 35 years. The prevalence remained
stable through age 50 years and than gradually de-
clined again.
This study shows that the the prevalence of High risk
HPV DNA in patients with ASCUS is higher in cases
younger (34.5%) in comparison with cases older
(23.5%). 
The trends of decreasing prevalence of HPV infection
with age, could be explained as a cohort effect, owing
to a higher risk of HPV infection among young
women today than in the past perhaps as a result of
changes of sexual behavior. The prevalence rises as
newly sexually active young women are exposed for
the first time and than declines among older women
because of decresed exposures (or acquisition of pro-
tective immunity).
According to the data of colposcopy and punch biop-
sy applied 12 months later, we concluded that the pro-
gression to precancerous lesions is higher in patient
older than 30. 
As best as can determined, the natural history of cer-
vical carcinogenesis spams at least 1 if not 2 decades.
Because of this, the likelyhood that women with an
ASCUS diagnosis have HSIL on biopsy is very low if
they are younger than 30 year. Because of its lower
prevalence, a similar abnormality in a women older
tha 30-40 years have a higher positive predictive value
of finding HSIL on biopsi, especially if it is associated
with HPV positive for high-rish HPV types. It is pos-
sible that lesions grows faster in this age group or that
low grade lesions may not have been properly dealt
with, when the patients were younger and thus pro-
gressed to higher grades.
The result of this study congruent with those of previ-
ous studies.
Investigations found high risk HPV types in as many
as 86.1% of women with ASCUS.
The percentage of SIL in ASCUS smears observed
from the persent and previous studies indicates that a
significant porportion of ASCUS smears rapresent
preneoplasic lesions. In fact in a 1998 Kaiser review,
52.6% of high grade lesion were proceed by a smear of
ASCUS.
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Age, yrs ASCUS case High risk HPV case Biopsy case
nr % nr % CIN1 CIN2 Totali
<30 26 60.5% 9 34.5% 2 22.2% 1 11.1% 3 33.3%
>30 17 39.5% 4 23.5% 1 25% 2 50% 3 75%
Totali 43 100% 13 58% nr % nr % nr %
TABLE 1.
A long term follow up study by Nasell et al. showed
that fewer HSIL progressed to cancer in patients
<25 years old than in patients >50 years old. Fur-
thermore the progression time was significally
longer for the age group <25 than for the age group
25-50 year old.
As women grow older incidence of HPV infection be-
comes less, but the ocurrence of cervical cancer in-
creases. 
The age, less than 30 years old seems to be a predictor
factor on presence of high risk HPV ADN in patient
with ASCUS, but the older age is a predictor on the
progression towards the precancerous lesions. There-
fore continued Pap smear screening in older woman
with adjuvant high risk HPV testing can identify those
woman who need further intervention for cervical
cancer prevention. 
All patient will high risk HPV type, including 16, 18,
31, 32, etc. should be refered for colposcopy-directed
biopsy.
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Introduction
Successful outcome of pregnancy depends on adequate
implantation, transformation of spiral artery as a result
of trophoblast invasion and placentation with acquisi-
tion of adequate blood flow in the system mother-fe-
tus-mother. Disorder of these processes is associated
with genetically determined thrombi tendency when
resynchronization of the processes of fibrinolysis and
fibrinogenemia at implantation takes place. Under
such conditions activity of protease produced by blas-
tocyst becomes comparatively insufficient to interrupt
extracellular matrix of endometrium and to invade to
necessary depth. If additionally there is circulation of
antiphospholipid antibodies, it makes things worse. 
Taking into consideration peculiarities of physiologi-
cal adaptation of hemostasis system to the pregnancy,
absolute number of genetic and acquired forms of
thrombophilia declares itself clinically specifically dur-
ing gestational process and as it appears not only in the
form of thrombosis but as well in the forms of typical
obstetric complications, at that the role of various
forms of thrombophilia in their pathogenesis and
structure is different. 
It is well known that biochemical markers of chromo-
somal abnormality of the I trimester (PAPP, HCG)
could be the predictors of various obstetric complica-
tions (Gagnon A, Wilson RD, Audibert F et al Obstet-
rical complications associated with abnormal maternal
serum markers analytes. J Obstet Gynaecol Can. 2008
Oct;30(10):918-49). 
Lower concentrations of PAPP, HCG in the I
trimester may correlate with such unfavorable lapses
for pregnancy outcome as gestational toxicosis, syn-
drome of fetal growth retardation, premature delivery,
abruption of normally situated placenta. It is worth
mentioning that the latest studies show that often in-
herited and acquired thrombophilia is a pathogenic
mechanism.
That is why we could assume that the patients with
tendency for thrombophilic states at late terms of
pregnancy could have accurate lower concentrations of
PAPP, HCG of the I trimester. 
Objective
To determine interaction between simultaneous drop-
ping level of PAPP, HCG of the I trimester and state
of hypercoagulation at late term of pregnancy.
Materials and methods
Seventy-five patients with pregnancies terminated
with delivery were examined. The patients were divid-
ed into two groups. Index group was formed by 40
patients that had simultaneous inclination of PAPP,
HCG lower than 0.5 MoM at gestational age of 11-
13 weeks (mean value is 0.385 MoM and 0.424 Mom
respectively). Control group included 35 patients
with normal basal level of PAPP, HCG at the same
gestational age (mean value is 1.19 MoM and 1.1
MoM respectively). The concentration of biochemi-
cal markers was determined by way of immunofluo-
rescent method using reagent “Delphia” and analyser
“Victor” (Finland). Determination of multiple of me-
dian and further assessment of risk of chromosomal
abnormality was carried out with the help of pro-
gramme “ALFA”, UK.
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The state of hemostasis was analyzed on the basis of the
following markers of clotting test: prothrombin time,
prothrombin ratio, INR, thrombotest, fibrinogen,
APTT. The assessment of the markers mentioned above
was done in 2 steps: simultaneously with of the level of
PAPP, HCG and before the delivery. Thrombophilic
tendency was identified on the basis of declination of
some markers (rise of PTI, thrombotest, significant rise
of fibrinogen (more than 6 g/l), drop of INR, shorten-
ing of PT; marker of APTT was interpreted in two ways:
inclination characterized hypercoagulation, Anti-Phos-
pholipids Syndrome was suspected at significant rise. 
Results
Thrombophilic state of the I trimester in index group
was found out in 4 cases (10%) vs 5 (14.29%) in con-
trol group. 
Before the delivery significant hypercoagulation
(which did not correspond to gestation age) was found
out in index group in 10 (25%) vs control group 3
(8.57%), consequently (p<0,1).
Additional tests showed inherited thrombophilia in
index group in 6 cases (15%) vs 1 (2.86%) in control
group (mutation of prothrombin G20210A, FV Lei-
den G1691A and MTHFR C677T – isolated muta-
tions as well as their combinations were taken into
consideration); Anti-Phospholipids Syndrome in 3
(7.5%) vs 1 (2.86%) (Tab. 1).
Conclusions
Apparently simultaneous inclination of PAPP, HCH
in the I trimester may predict thrombophilic states
that lead to adverse obstetric outcomes. This is con-
firmed by more frequent states of hypercoagulation of
the patients of index group before the delivery and
more frequent detection of inherited thrombophilia in
the group of such patients. 
As well it is quite difficult to give answer to the ques-
tion if inclination of serum content of PAPP, HCG is
a compensatory reaction or if it is an evidence of
breakage of compensatory mechanisms that assure fa-
vorable pregnancy outcome.  However confirmation
of such correlation needs further investigations of big-
ger amount of statistically-valid samplings.
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Group Thrombophilic Thrombophilic Inherited Anti-
state of state thrombophilia Phospholipids
11-13 weeks before the Syndrome
of gestation delivery
Index 4 (10%) 10 (25%) 6 (15%) 3 (7,5%)
Control 5 (14.29%) 3 (8,57%) 1 (2,86%) 1 (2,86%)
TABLE 1.
Introduction
Neurons in discrete hypothalamic nuclei i.e., the me-
dial preoptic and ventromedial, are known to respond
to vagino-cervical stimulation (vcs) resulting from
manual probing or copulation (1,2). Mechanical vcs
or mating stimulates similar hypothalamic neurons
that regulate pulsatile secretion of gonadotropin-re-
leasing hormone and the gonadotropins which affect
deciduoma formation of decidualization, an essential
for successful mammalian pregnancy, via induced
ovarian steroidogenesis (3,4). These precisely applied
dual reproductive signals of normal/natural copulation
plus blastocyst implantation of pregnancy or artificial
vcs followed by deciduogenic induction during
pseudopregnancy (PPG) both elicit mechanosensory
input to the brain. The two neurogenically-induced
events promote synchronous endometrial prolifera-
tion/differentiation transformational responses that re-
spectively produce a feto-maternal placenta of preg-
nancy, or a maternal placenta or deciduum of PPG.
Additionally, any success in pregnancy is also depend-
ent on concerted implantation, decidual and placental
interactions. In fact, in our rodent model, decidual de-
velopment which attains maximal growth between
PPG days 9-11 in rats and mice (5), embodies either a
maternal placenta under artificially-induced PPG, or a
feto-maternal placenta under normal pregnancy. This
progesterone-regulated decidual proliferation (6,7)
and subsequent endometrial stromal cell transforma-
tion that involve regression/apoptosis (8,9), are
processes that are promoted by numerous paracrine
factors. Included among these factors are uterine stores
of pituitary adenylate cyclase-activating polypeptide
(PACAP) which promotes angiogenesis and endome-
trial vascularity (10) and subsequent availability of de-
cidual metabolic substrates; decidual prolactin-related
protein (dPRP) which affects decidualization by stim-
ulating cyclic AMP (11,12); and the matrix metallo-
proteinases (MMPs), particularly MMP-2 and –9, en-
zymes that contribute to decidual invasive transforma-
tion by degrading the extracellular matrix and remod-
eling the decidual tissue (13,14,15).
Objective
The aim of the study was to time-relatedly assess the
effects of neurogenic stimulation on: 1. decidual/pla-
cental proliferative responses triggered by copulation
and blastocyst implantation during normal pregnancy
and 2. on similar responses initiated by neurogenic
copulomimetic vcs followed by deciduogenic stimula-
tion under artificially-induced PPG.
Materials and methods
Female Sprague-Dawley rats (210-240g, n=5/point,
under a 12L:12D photoperiod), whose estrous cycles
were monitored daily by vaginal lavages and micro-
scopic smear examination for 2-3 consecutive cycles,
were randomly selected and subjected to mechanical
vcs (proestrus and estrus). This was followed by surgi-
cal, laparotomized-mediated bilateral uterine trauma
(PPG day 4) for PPG/decidualization induction. Oth-
er animals in groups of 2 to 3, cohabitated with a fer-
tile male to induce pregnancy. The RT-PCR deter-
mined mRNAs of the progesterone receptor (PR),
PACAP and dPRP were derived on days 3, 6, 9, 12
© Copyright 2012, CIC Edizioni Internazionali, Roma
Variability in endometrial proliferative responses
to neurogenically-induced reproductive signals
SPENCER F.1, THOMPSON M.L.1, QI L.2
1 Southern University, Biological Sciences & Health Research Center, Baton Rouge, Louisiana, USA
2 University of Illinois, Biomedical and Therapeutic Sciences, Peoria, Illinois, USA
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
307
and 15 (1000-1100 hr) during PPG (from the decid-
ual endometrium), or during gestation (from the
gravid uterus or placenta). Deciduoma-endometrial
MMP activity was detected by substrate zymography
and semi-quantitated by scanning densitometric
analysis during PPG.
Results
The summarized results are:
• During PPG, the levels of the PR, PACAP and
dPRP transcripts increased from days 3 to 9
(p<0.05) and then declined.
• The anti-progesterone agent (RU-486) inhibited
all mRNA expressions (dPRP, PACAP and the PR)
on PPG or gestation day 9.
• There were modest elevations in MMP-2 and –9
(92 and 72 kDa) activities during deciduoma de-
velopment on PPG days 3-9. Additional increases
occurred during decidual regression on PPG day
15 (p<0.05).
• During gestation, all gravid endometrial mRNA
expressions rose from days 3 to 9 (p<0.05) and re-
mained elevated. Placental mRNA was consistent-
ly high from gestation days 9 to 15.
Conclusions
1. By way of the hypothalamic-hypophyseal-ovarian
neuroendocrine axis, decidual/placental prolifera-
tive (endocrine and molecular) and remodeling
mechanisms responded in correlated and compara-
ble time-related profiles to artificial and normal
neurogenic signals, i.e., a. copulomimetic vagino-
cervical stimulation plus deciduogenic induction,
or b. copulation plus blastocyst implantation.
These signals induce pseudopregnancy or pregnan-
cy in rats and mice.
2. Thus, the results indicate a potential for the artifi-
cially-induced decidual/placental rodent model to
assist in the in vivo analysis of chronobiologically-
related neuroendocrine communicative mecha-
nisms between the maternal decidua and fetal cells
during pregnancy.
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Background 
The menorrhagia is an excessive uterine bleeding at
regular intervals of time or the uterine bleeding that
lasts more than 7 days and involves a blood loss
greater than 80 mL (1). This symptomatology is pres-
ent at 9-14% of healthy women. 
Objective 
The primary objective of this study is to investigate
the effectiveness of progestogen therapy in achieving a
reduction in menstrual blood loss in women of repro-
ductive years with heavy menstrual bleeding.
Materials and methods 
Our study includes 30 cases of menometrorrhagia at
women aged between 38 and 42 years (the AUB-O
group, corresponding to FIGO-PALM-COEIN classi-
fication of the abnormal uterine bleeding – polyp; ade-
nomyosis; leiomyoma; malignancy and hyperplasia;
coagulopathy; ovulatory dysfunction; endometrial; ia-
trogenic; and not yet classified) (2). Because the quan-
tity of blood lost at the menstruation it’s hard to esti-
mate, we used for its evaluation some individual study
sheets, based on the observational criteria; the analysis
relies on the obtained scores. The menorrhagia is de-
fined through a score PBAC over 100. The patients
were investigated as follows: clinical exam, cytologic
exam Babes-Papanicolau, transvaginal ultrasound and
biopsy fractional curettage. Using these investigations,
we excluded the cervical pathology, the bleeding
caused by uterine pathology - endometrial polyps or
uterine fibroma. We performed hormonal analysis in
days 3, 14 and 21 of a menstrual cycle, to evaluate the
ovarian function.
The inclusion criteria in the study were: exclusion of
the endometrial polyps and submucosal fibroids; his-
terometry under 10 cm; anovulatory cycles; en-
dometrium with simple or complex hyperplasia with-
out atypical after the endometrial sampling; en-
dometrium measured by transvaginal ultrasound pre-
menstrual, having a medium thickness of 1.3 cm; ex-
clusion of haematological diseases.
The initial group was divided in 3 subgroups:
- A - 10 patients benefited of intrauterine disposi-
tive with levonorgestrel (Mirena);
- B - 10 patients were treated with 200 mg natural
progesterone intravaginal (200 mg progesterone
intravaginal, between days 14 and 25 of the men-
strual cycle);
- C - 10 patients received synthetic progesterone
orally (lynestrenol, oral, 5 mg/day, between days 14
and 25 of the menstrual cycle).
At 6 months and 1 year a transvaginal ultrasound was
effectuated to appreciate the endometrial thickness in
the premenstrual stage. Analyzing individual case files
using the criteria of observational study made our in-
terpretation.
Results 
After the intrauterine dispositive with Levonorgestrel
(IUD-LNG) (Group A) was set, it was noted the dis-
appearance of the menorrhagia, on an average of 5
months after they started the therapy, at 70% of pa-
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tients. The main adverse effects were: breast tenderness
and intermenstrual spotting in the first 3 months of
treatment. The ultrasound evaluation at 6 months af-
ter the insertion of IUD-LNG shows an endometrium
with a medium thickness of 6.54 mm ±1,03mm, the
medium score PBAC of 63,2. At one year after start-
ing the treatment, the PBAC score was on average 32
and the medium thickness of the endometrium was
5,84±0,52 mm. 
At group B the improvement of the quality of life
was present in 40% of cases. The answer to the ther-
apy appeared on average at 4 months after starting
the treatment (appreciated with PBAC score). The
ultrasound evaluation at 6 months after starting the
therapy with micronized progesterone showed a pre-
menstrual endometrium of 7.55±1,2 mm and the
medium PBAC score was 78. At one year after start-
ing the therapy, the PBAC score was on average of
65,2 and the medium thickness of endometrium of
6.65±0.83 mm
At patients who received lynestrenol (group C), orally,
the answer was obvious from the first month of thera-
py, but in this group it was registered the lowest com-
pliance because of the adverse effects, mainly (gas-
trointestinal disorders, gaining weight). 40% (4 pa-
tients) of women in Group C dropped the oral hor-
mone therapy after 3 months due to side effects and
due to insignificant reduction of bleeding. The ul-
trasound evaluation at 6 months after starting the
treatment with lynestrenol points out an endometri-
um of 6.9±1.34 mm and an average PBAC score of 55.
At one year after beginning therapy, the PBAC score
was 45,7 and the medium thickness of the endometri-
um 6.3±0.58 mm.
The most persistent effect regarding the decreasing of
the menstrual flow was noted in the group with
IUD-LNG and the fastest answer at group C of pa-
tients treated with lynestrenol oral.
The cases with AUB-O associated with simple or
complex endometrial hyperplasia were evaluated to
estimate the answer to the therapy with IUD-LNG
vs. progesteron oral, by estimating echographically
the endometrium thickness and the blood lost at
menstruation at 6 months and one year after treat-
ment. The data does not reveal any statistical rele-
vance between the two groups neither after 6 months
(6,54±0,32 versus 6,96±0,54, n=10, p >0.05), nor af-
ter one year of treatment (5,84±1,8 versus 6,3±2,5
mm, n=10, p>0.05). Instead of this, the decreasing of
endometrial thickness comparing with endometrial
thikness at the begining of treatment, was pointed out
at 6 months after the insertion of IUD-LNG – the
endometrium thickness being on average 6.54 mm
±1,03mm and after one year significantly decreased to
5.84±0,52 mm.
Discussions 
The oral therapy with progesterone has the important
disadvantage of a low compliancy to the treatment.
The studies reveal that the therapy with IUD-LNG
decreases the menstrual bleeding with 75-90%, this
treatment being better than a cyclic administration of
progesterone (3). The results of IUD-LNG in the
treatment of AUB-O are similar to the ones obtained
after the endometrium ablation with hysteroscopic
guidance (4). 
The abnormal uterine bleeding AUB-O is better
treated with IUD-LNG, comparative with the oral
therapy with progesterone, when we take into ac-
count the number of bleeding days. The thickness of
the endometrium, estimated by transgavinal ultra-
sound, premenstrual, decreases significantly at one
year after the insertion of IUD- LNG. As far as cases
with anovulation associated with a simple or complex
endometrium hyperplasia concern uterine mucosa
thickness is not statistical relevant when compare
IUD-LNG therapy with the orally administered
progesterone.
Conclusions 
The inside uterin or intravaginal hormonal treatment
are an optimal alternative therapy of bleeding caused
by anovulation cycles at women with persistent bleed-
ing in perimenopause. The oral regimen of progesto-
gen therapy has a positive role for obtaining in the
short-term the correction of menorrhagia but in many
cases it is abandoned due to significant side effects. For
long-term treatment, the best choice is IUD-LNG be-
cause of its high compliance among patients and the
most significant reduction of bleeding, even at slow
rate. 
References
1. Fraser IS, Critchley HO, Munro MG. Abnormal uterine
bleeding: getting our terminology straight. Curr Opin Obstet
Gynecol 2007;19(6):591-5. 
2. Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO
Working Group on Menstrual Disorders FIGO classification
system (PALM-COEIN) for causes of abnormal uterine bleed-
ing in nongravid women of reproductive age. IntJ Gynaecol
Obstet. 2011 Apr;113(1):3-13. Epub 2011 Feb 22.
3. Lethaby A.E., Cooke I., Rees M.: Progesterone or progesto-
gen-releasing intrauterine systems for heavy menstrual bleed-
ing. Cochrane Database Syst Rev 2.2000;CD002126.
4. Istre O, Trolle B: Treatment of menorrhagia with the lev-
onorgestrel intrauterine system versus endometrial resection.
Fertil Steril 2001;76:304.
310
Introduction 
The ovarian neoplasm mortality is still elevated, what
endorses the approach of this subject and especially
the focus to precocity of a presurgical detection, with
a high probability of the ovarian tumor’s histopatho-
logical type. In America, the ovarian tumor represents
the third cause of mortality, after the breast and gas-
trointestinal cancer. In Romania, the ovarian neo-
plasm incidence varies between 3,5 and 5,8/100
000/year. 
Objective 
The objective of our study is to evaluate the efficiency
of standard investigation parameters used in clinical
practice to differentiate, before the surgical interven-
tion, the benign, borderline and malignant ovarian tu-
mors relying on echographic features and seric value of
CA125. 
Materials and methods
This retrospective study includes 40 cases, which were
operated in the Gynecology Department of “St. Pan-
telimon” Clinical Hospital, Bucharest, between 2009
and 2011, based on the presurgical diagnosis of adnex-
al tumor. The addition criteria are: pacient age, echo-
graphic features of the ovarian mass, seric value of
CA125. The abdominal/transvaginal ultrasound was
performed using an echograph Voluson, 2D. All the
cases were examined with a transvaginal transducer,
with a frequency of 4-8 MHz. If the transvaginal ultra-
sound didn’t detect the tumor totally, an abdominal
ultrasound was performed. We analyzed the next echo-
graphic features of the ovarian tumor: dimensions (<6
cm, 6 cm, 9 cm, >10 cm), echogenity (anechogenic,
hyperechogenic), unilocular/multilocular ovaries,
presence of the septa, uniform/mixed echogenity, pres-
ence of papillary protuberances (solid protuberances
from the cyst wall towards it’s cavity measuring at least
3 mm), ± ascites. The information obtained allowed us
to work with 5 study classes according to the
histopathological evaluation: benign tumors, border-
line tumors, malignant epithelial tumors, malignant
non-epithelial tumors and rare cases of malignancy
and cases with metastates (Table 1). The seric evalua-
tion of CA125 was performed regarding all the cases
of adnexal tumor. We analyzed the statistical mean of
each parameter in comparison with the postoperative
histopathological diagnosis of the ovarian tumor: be-
nign, borderline and malignant, which was elaborated
by the Morphopathology Department of our hospital.
Results 
The operated ovarian tumors were benign in 77.5% of
all cases, borderline in 5% and malignant in 17.5%.
The mean value of the presurgical investigated param-
eters (age-years, CA125-U/mL, diameter of the tu-
mor-cm, ±septa, vegetations), for the benign tumors
are 46.58, 34.51 and 7.41. The analysed mean for bor-
derline tumors corresponds to a value of 35, 79.58 and
7.5. As concerning the malignant tumors, the mean
pertains to a value of 46, 370.83 and 12.57. The post-
operative histopathological diagnose was: benign tu-
mor for 31 cases (serous ovarian cysts, mucinous cysts,
© Copyright 2012, CIC Edizioni Internazionali, Roma
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endometriotic cysts, cystadenofibroma, granulose tu-
mor), borderline tumors for 2 cases (1 case-serous bor-
derline tumor; mucinous borderline tumor), invasive
primary epithelial ovarian cancer for 7 cases: en-
dometriotic adenocarcinoma, carcinoma with clear
cells, serous papillary adenocarcinoma, well differenti-
ated adenocarcinoma, another nonepithelial cases:
ovarian fibrosarcoma.
The echographic features described in documents
point out data that differentiates a malignant tumor
from a benign one (Table 2). The analysis of these as-
pects shows that the malignant tumors are defined by
the presence of a solid echodense tissue inside the tu-
mor (71.42%), intense vascularization and the pres-
ence of the ascites. The ovarian tumors that were
proved to be borderline and the well-differentiated
malignant epithelial ovarian tumors have intracystic
papillary protuberances.
Discussions 
The results of multicenter studies conducted within
International Ovarian Tumor Analysis study (IOTA)
and published in Ultrasound Obstet Gynecol
2000;16:500-5 and J Clin Oncol 2005; 23:8794-801
prove that the distinction between benign and malig-
nant adnexal tumors is possible preoperatively even
under the subjective interpretation of ultrasound im-
ages. The mentioned works estimate that the sensitiv-
ity and specificity in relation to the diagnosis of ovari-
an tumor malignancy is 88% and 96%. This is due to
the differences between malignant and benign ultra-
sound images. Ultrasound characteristics contained in
the documents reveal aspects that differentiate benign
from malignant tumors. 
The studies emphasize the significance of ovarian
cancer screening based on determining the value of
CA125 and transvaginal ultrasound. Thus, the study
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TABLE 1 - THE HISTOPATHOLOGICAL CLASSIFICATION OF THE OVARIAN TUMORS.
Benign
tumor
Histo-
pathological
subtypes
Borderline
tumor
Histo-
pathological
subtypes
Invasive
primary
epithelial
tumors
Histo-
pathological
subtypes
Invasive
primary
non-epithelial
tumors
Histo-
pathological
subtypes
Ovarian
tumors with
metastates
Histo-
pathological
subtypes
16 Serous 1 Endometriotic
adeno-
carcinoma
1 Ovarian
fibro-sarcoma
1 Endometrial
adeno-
carcinoma
with clear
cells, with
ovarian
bilateral
metastates
1Serous
9 Mucinous 1 Carcinoma
with clear
cells
1Mucinous
2 Serous
papillary
adeno-
carcinoma
1Endometriotic
3 Well
differentiated
adeno-
carcinoma
2Adenofibroma
1Granulosa
tumor
31 Total
Borderline
tumor
2 Total
Invasive
primary
epithelial
tumors
5 Total
Invasive
primary
non-epithelial
tumors
1 Total
Ovarian
tumors with
metastates
1Total benign
tumor
Prostate, Lung, Colorectal and Ovarian (PLCO) Tri-
al conducted on a total of 39115 patients revealed
that transvaginal ultrasound has been shown to be
abnormal in 1338 (4.7%) of cases and abnormal
CA-125 have been identified in 402 (1.4%) of cases.
PLCO trial results show that the positive predictive
value for invasive cancer is 3.7% for CA-125, 1% for
transvaginal ultrasound and 23.5% for both tests
(1). UK Collaborative Trial of Ovarian Cancer
Screening, that enrolled between the years 2001-
2005 a total of 50640 patients using a screening al-
gorithm based on transvaginal ultrasound and
CA125 determination, shows that the sensitivity of
both screening methods is similar in primary ovarian
and fallopian cancer, specificity being greater for
multimodal screening (specificity 99.8% and 98.2%
respectively, p <0.0001) (2). 
The Risk of Malignancy Index - RMI estimates the
risk for ovarian cancer at patients presenting adnexal
tumor using CA-125 value, menopausal status and ul-
trasound characteristics of tumor formation (multiloc-
ular cyst, solid mass, ascites, bilateral lesions, metas-
tases). Resulting values assign the patient to a low,
moderate or high-risk group for ovarian cancer. The
Risk of Ovarian Malignancy Algorithm (ROMA
score) uses HE4 marker (Human epididymis protein
4) and CA-125 to classify in low or high-risk groups
both pre-menopausal and post-menopause women. In
different studies this score showed a specificity and
sensitivity larger than RMI. 
The preoperative CA-125 level is a good indicator for
optimal cytoreductive surgery; the threshold is
500U/mL, these patients also being candidates for ad-
juvant chemotherapy (3). 
Conclusions 
The highest risk of malignancy is present at perimenopausal
women for whom the highest average values both for the
serum CA125 (370.83 U/ml) and for the size of adnexal tu-
mor mass (12.57 cm respectively) were found. Serum
CA125 is not suggestive for the diagnosis of borderline tu-
mors in contrast with ultrasound changes observed in these
cases. The parameters used in our clinic as preoperative in-
vestigation permit a relatively accurate estimate of the
histopathological nature of ovarian tumors without any ad-
ditional expensive investigations (CT, MRI).
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TABLE 2 - ULTRASOUND FEATURES OF THE OVARIAN TUMORS.
Benign Borderline Malign
Ultrasound characteristics
Number % Number % Number %
Dimensions
<= 6 cm 0 0 1 50 0 0
6-9 cm 28 90.3 0 0 1 14.28
>10 cm 3 9.67 1 50 6 85.71
Chysts
Unilocular 26 83.87 1 50 1 14.28
Multilocular 5 16.12 1 50 6 85.71
Irregular contour of the tumor walls 0 0 1 50 6 85.71
Intratumoral septa 11 35.48 2 100 6 85.71
Echogenicity
Anechogen 26 83.87 0 0 0 0
Hyperechogen 4 12.9 0 0 5 71.42
Mixt 1 3.22 2 100 2 28.57
Papilliform images
Missing 31 100 0 0 0 0
<3 mm 0 0 0 0 1 14.28
>3 mm 0 0 2 100 6 85.71
Vascularisation Low Medium High
Ascites 0 0 0 0 5 71.42
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Introduction
Beside oral contraceptives, IUDs are one of the most
common methods of contraception in industrialized
world. In addition to copper releasing intrauterine de-
vices, Mirena®, a levonorgestrel releasing intrauterine sys-
tem has been available in Central Europe since 1997 (1).
According to international studies, most users of the
LNG-IUD are thoroughly satisfied with it, which of-
ten depends on several factors (1,2). 
Since there already exist data from international or ur-
ban areas, it seemed interesting to evaluate the situa-
tion in an Austrian region. The main effort of the
study was to point out the degree of user satisfaction
in women using the LNG-IUD, and to find influenc-
ing factors with special consideration of bleeding pat-
terns and body mass index. Due to that fact, that
amenorrhea is - according to other studies - not always
considered to be favored in women (3,4) we checked
the degree of satisfaction only concerning bleeding
patterns, as well the general user satisfaction in de-
pendence of bleeding behaviour. Furthermore factors,
influencing bleeding patterns were investigated.
Materials and methods
Sample size
In this cross sectional study, data from 1825 women
from 18-60 years, who visited the gynecological offices
in the Austrian industrialized region during 6 months
in the year 2007, was collected. All participating
women received a questionnaire, concerning 26 ques-
tions, of which one question was used to allocate every
women into one of three subcategories, i.e. current -,
former -, or not user of Mirena. This was necessary to
determine women, who had been users of Mirena but
had removed it before the time of questioning, so that
we were able to avoid a selectional bias. Question-
naires were filled out voluntarily and the participants
gave informed consent. The local office of the research
ethics comitee decided that a vote was not necessary.
Questionnaire
To evaluate the quality of the questionnaire used, a pre
– test was started a few weeks ago, to have the chance
to upgrade questions, which were possibly ambiguos
for the patients asked. The common part of the ques-
tionnaire covered demographic topics such as age, ed-
ucation, number of children, body weight and height.
The special part, which was only filled out from Mire-
na users, covered topics like changing of bleeding pat-
terns, general user satisfaction, satisfaction concerning
bledding patterns, menstrual pain, breast tenderness
and skin imperfections. The purpose for using Mirena
(medical reason, only for contraception, contraception
and medical reason) was evaluated, too, as well as the
person recommending Mirena (doctor, family mem-
ber or own information).
Statistical analyses
For statistical analysis, descriptive methods and statis-
tical tests were used. To determine differences in satis-
faction dependending bleeding patterns, χ2 tests for
nominal variables and cross tabulations were done. If
test criteria for the χ2 test could not be reached, exact
tests like Monte Carlo or Fisher’s exact test were used.
To check median values of metric variables such as
body – mass – index or duration of use in context to
satisfaction groups, t – test and ANOVA (analysis of
variance) were conducted. 
Amenorrhea and BMI as independent determinants
of patient satisfaction in LNG-IUD users: cross sectional study
in a Central European district
STOEGERER–HECHER E., KIRCHENGAST S., HUBER J.C., HARTMANN B.
Hospital of Neunkirchen, Neunkirchen, Austria
Results
Total overview and demographic characteristics
From a total number of 2000 questionnaries, 1929
were returned and 1825 could be used for computer
based analysis. From all 1825 questionnaires, 415 were
filled out from women who had experiences with
Mirena. Table 1 gives an overview about the allocation
into the categories of use. 
The median age of women, who actually carried or
had used a Mirena coil, was 39,2±7,1 years and was
significantly higher than in women who had no expe-
riences with a LNG-IUD (35,4±10,9 years). 319
(77,1%) of all women, who had experiences with
Mirena were married, whereas women without experi-
ences were married in 702 (49,9%) of the cases (signif-
icant with p=0,000). In 184 (45,7%) of the cases
Mirena was only used for contraception and 146
(36,2%) of all carried the LNG-IUD for contracep-
tion as well as for medical reasons (e.g. heavy bleed-
ing). 73 (18,1%) of the women tested were not satis-
fied with the previous method of contraception.
Satisfaction rates and bleeding patterns
In general, 266 (65,7%) of all women asked were
“very satisfied” with the LNG-IUD, 83 (20,5%) were
“quite satisfied”, 18 (4,4%) were “moderate satisfied”
and 19 (4,7%) in each case were “less satisfied” or “re-
ally not satisfied”. Concerning bleeding patterns, 295
(74,1%) were “very satisfied”, with only 23 (5,8%)
stating “really not satisfied”. The percentage of “very
satisfied” women concerning bledding patterns varied
from 203 (91,0%) in women with amenorrhea to 2
(9,5%) in women with hypermenorrhea. 80 (60,2%)
women of all cases with hypomenorrhea were “very
satisfied” with their bleeding patterns. Amenorrhea
occured in 231 women (56,9%) and was the most
favoured bleeding pattern of all. In contrast to this, 13
(61,9%) of all women with hypermenorrhea were “re-
ally not satisfied” with their bleeding quality.
Table 2 gives a total overview of bleeding patterns af-
ter Mirena insertion, whereas Figure 1 shows the asso-
ciated satisfaction rates: 
178 (78,4%) of all amenorrhoeic women were also
“very satisfied” with Mirena in general. 73 (54,1%)
women of all, who had a lighter period after Mirena
insertion, were “very satisfied”, and in 42 cases
(31,1%) “quite satisfied”. While 178 (67,9%) of the
“very satisfied” women for general satisfaction were
amenorrhoeic, the main part with of all “really not sat-
isfied” women were women with hypermenorrhea
(38,9% =7). The latter were only represented for 1,1%
(=3) in the group of “very satisfied” women. All these
differences were significant (α=0,05, p<0,001).
Bleeding patterns and duration of LNG-IUD use
In our analysis, there was a negative correlation between
duration of use and bleeding patterns (r=-0,271). As
shown in Figure 2, the longer the usage of Mirena, the
lighter was the menstrual blood loss. While the medi-
an use of Mirena in amenorrhoeic women was 5,1±2,4
TABLE 2 - BLEEDING PATTERNS AFTER MIRENA INSER-
TION – TOTAL OVERVIEW.
Bleeding patterns after n % total valid %
LNG-IUD insertion
Decreased blood loss 137 33,0 33,7
Increased blood loss 21 5,1 5,2
Amenorrhea 231 55,7 56,9
No changes 17 4,1 4,2
Valid total 406 97,8 100,0
Missing values 9 2,2
Total, n 415 100,0
TABLE 1 - TOTAL OVERVIEW ABOUT THE ALLOCATION
INTO THE CATEGORIES OF USE.
Women using LNG-IUD: Overview
n %
Current user 313 17,2
Former user 102 5,6
Never using LNG-IUD 1250 68,5
Missing values 160 8,8
TOTAL 1825 100
315
Fig. 1 - Satisfaction rates in dependance of bleeding patterns.
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years, the median use in women with hypermenorrhea
was 2,1±2,1 years. These differences were significant
with p<0,001. A more detailled analysis showed, that
hypermenorrhea mostly occured after 6-12 months
duration of use, but not after 36 months.
There was a significant correlation between dura-
tion of use and general satisfaction rates: the longer
the usage of Mirena, the higher the satisfaction rates
(r=-0,330). “Very satisfied” women used Mirena about
5,1±2,7 years, while “moderate satisfied” women had
used Mirena for about 2,4±1,7 years. “Really not sat-
isfied” user carried Mirena about 1,8±1,7 years. These
differences also were significant. 
BMI and satisfaction
Amenorrhea especially occurred in women with lower
BMI. While the menstrual blood loss in women with
a mean BMI of 27,6±6,5 kg/m2 was subjectively de-
scribed as increasing, women with a mean BMI of
24,4±4,4 kg/m2 described amenorrhea. These differ-
ences were significant (α = 0,05 and p=0,018) Figure
3 shows the BMI differences between women with hy-
permenorrhea and amenorrhea.
Women who described their bleeding patterns as un-
changed since using the LNG-IUD had a mean BMI
of 25,9±3,5 kg/m2. As amenorrhea was mostly consid-
ered to be a positive change and frequently found in
women with a lower BMI, we also tested if there was
an association between satisfaction rate and BMI. Be-
tween general satisfaction rates and BMI there proved
to be no association, but between satisfaction rates
concerning bleeding patterns and BMI an association
was found: While “very satisfied” women had a mean
BMI of 24,3±4,4 kg/m2, “less satisfied” women had a
BMI of 25,1±5,1 kg/m2, and “really not satisfied”
women of 26,2±5,4 kg/m2 (not signficant with p =
0,268-0,976 in the particular group comparisons).
Bleeding patterns in dependance to different body –
mass – index and duration of use
As described at 3.3 and 3.4, amenorrhea occured both,
in women with lower BMI and in women with long
duration of use. Therefore evaluating bleeding pat-
terns by considering the categories of BMI and cate-
gories of lenght of use simultaneously made sense: For
this purpose we took the widely used BMI – categories
“underweight” for BMI <18,5 kg/m2, “normal weight”
for BMI 18,5-24,9 kg/m2, “overweight” for 25,0-29,9
kg/m2, obese class I for BMI 30,0-39,9 kg/m2 and II
for BMI >40,0kg/m2 (5).
While 2 (50%) of the normally weighted women got
amenorrhoeic in the first three months of use, 0% of
overweighted and obese women did (not significant).
After 6 months-1,0 year of use, 9 (50%) of all nor-
mally weighted women described amenorrhea, where-
as only 1 (11,1%) woman with overweight and 1
(25,0%) with obesity class I did. After 1,1-2,0 years of
use, 8 (42,1%) of all normally weighted women de-
scribed amenorrhea, but 9 (60,0%) of overweighted
women and 2 (100%) of obese women class I did. 18
(28,6%) of all oveweighted women and 5 (23,8%) of
all obese class I women had amenorrhea after 4,1-5
years of use. So in general, women with higher BMI
also got amenorrhoeic when using the LNG-IUD,
but showed a longer time of LNG-IUD use than nor-
mally weighted women. Figure 4 gives a total
overview of all amenorrhoeic women after LNG-IUD
insertion considering the body mass index and lenght
of IUD use.
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Fig. 2 - Time of usage and changes in bleeding patterns.
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Menstrual pain and satisfaction
Menstrual like pain disappeared in 138 (37,3%) cases
after Mirena insertion, and was lightened in 71
(19,2%) women. 33 (8.9%) women had no changes in
menstrual pain and 9 (2,4%) suffered from increased
menstrual like pain 2,4% (=9).
There was a significant correlation (r=0,605) between
bleeding patterns and menstrual pain. In amenorrhoe-
ic women menstrual like pain disappeared in 106
(54,5%) of the studied cases, and 29 (21,6%) of
women with lighter period also reported less menstru-
al pain. 4 (20,0%) of women with heavier menstrual
bleeding after LNG-IUD insertion also reported in-
creased menstrual like pain. All differences were signif-
cant with p<0,001. 132 (95,7%) of the participantes,
who had no pain at all, were “very satisfied” with their
situation. 43 (61,4%) of all women with lighter men-
strual pain were “very satisfied”, whereas 7 (63,6%)
with no changes of menstrual pain were “really not sat-
isfied”. The results concerning general satisfaction
were similar: While 108 (79,4%) of all women with
reduced pain were “very satisfied”, most of the not sat-
isfied women had no changes in menstrual pain. All
these differences were significant with p<0,001.
Intention for using the LNG-IUD and satisfaction
From a total number of 406 women (9 missing), 184
(45,3%) used the LNG-IUD only for contraception.
146 (36,0%) used it for contraception and had at least
one medical reason (e.g. lighter bleeding). 73 (18,0%)
used the coil for contraception and were unsatisfied
with the previous method of contraception. 3 (0,7%)
women declared other reasons for using the IUD.
110 (62,1%) of all women who used the LNG-IUD
only for contraception were very satisfied in general;
(13 missing values from total excluded). 103 (71,0%)
of women who used the LNG-IUD for contraception
and a medical reason were very satisfied. (1 missing).
49 (68,1%) women who used the coil for contracep-
tion and were unsatisfied with the previous contracep-
tive method, were very satisfied it. (1 missing from to-
tal). Comparing all groups, most “really not satisfied”
women with n=10 (58,8%) were found in the group
of women, who used the coil only for contraception.
Table 3 gives an overview.
Continuation rates:
58 (56,9%) of a total of 102 former Mirena users re-
moved the IUD within 4,5 years and 41 (40,2%) after
Fig. 4 - Overview of all amenor-
rhoeic women after LNG-IUD in-
sertion, considering BMI and du-
ration of use simultaneously.
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TABLE 3 - INTENTION FOR USING LNG-IUD AND SATISFACTION RATES, OVERVIEW. MISSING VALUES EXCLUDED.
Grade of SatisfactionIntention for using LNG-IUD 
very quite moderate not really not Total
Only for contraception 110 34 10 13 10 177
For contraception and medical reason 103 31 3 5 3 145
Contraception + unsatisfied with previous method 49 17 3 1 2 72
Other 1 0 0 0 2 3
TOTAL 263 82 16 19 17 397*
* missing values caused by cross tab-analysis, excluded. 
5 years of use, 3 (2,9%) values missing. So we had a
discontinuation rate of 14,0% for our total number of
415 women.
The most frequently declared reasons for discontinua-
tion in multiple answer system were “unsatisfied with
bleeding” and “wish for children” with 14 (15,2%)
women in each case. 11 (12,0%) participants reported
pain, followed by weight increase from 8 (8,7%)
women, expulsion and skin imperfections in 7 (7,6%)
cases respectively. The wish for children excluded, the
most important reason for discontinuation was “unsat-
isfied with bleeding” with 12,1% (=7). 11 (55,0%) of
the women with increased menstrual blood loss re-
moved the LNG-IUD prematurely, whereas only 24
(10,5%) with amenorrhea and 16 (11,7%) with hy-
pomenorrhea did.
3 (33,3%) of all women with increased menstrual pain
stopped using the IUD. With a percentage of 37,5%
(=12) the discontinuation rate was a little bit higher in
women with no changes in menstrual pain. Similar to
the results concerning bleeding patterns, also the dis-
continuation rate concerning menstrual pain were
lowest in women without any pain (6,6% = 9) or
rather decreased menstrual pain (14,1% = 10). Ac-
cording to Fisher’s exact test, all these differences were
significant with p<0,001.
Discussion
International comparisons
According to international data, most Mirena users are
really satisfied with the LNG-IUD (6). Backman et al
showed, that 74% of Mirena users were “very” or
“quite” satisfied (2), which is comparable with our re-
sults of 65,7% “very” – and 20,5% “quite” satisfied
women. Of the 313 current users in our study, 95,1%
were “very” or “quite” satisfied with Mirena, which is
nearly as high as the percentage of satisfied women de-
scribed by Backman et al 2002 with 91% (2). Changes
in bleeding patterns seem to be an important influenc-
ing factor on satisfaction: Women with amenorrhea
were more often “very satisfied” as well for general sat-
isfaction as for satisfaction rates only considering men-
strual changes, than women with increased blood loss.
The fact, that 78,4% of all amenorrhoeic women, but
only 15,8% of women with hypermenorrhea were
“very satisfied” leads to the aspect, that nowadays ab-
sence of menorrhea is favoured. However, conflictive
opinions were found (3). According to Glasier et al.
2003, amenorrhea was not accepted in 1970/80, while
in 2000/01 women of well developed countries prefer
amenorrhea or reduced menstrual blood loss (4). Bal-
daszti et al. described in 2003, that amenorrhea was
seen as a positive change in 81% of Mirena users (1),
which is similar to the results of a study from 2006,
where decreased blood loss was also favoured by
women (7). In our study, which was conducted in
2007, women with amenorrhea or decreased blood
loss were more often “very satisfied” than women with
other bleeding patterns, which leads to the conclusion,
that the “modern woman” seems to prefer lighter peri-
ods or absence of menorrhea. In contrast to this,
amenorrhea was described as a negative change in a
study from 2007, when 40% of all LNG-IUD users
declared amenorrhea as an unwanted effect (8). How-
ever, this result has to be seen very critically, because
amenorrhea was automatically countered as a negative
change, independent of the women’s real attitude to-
wards it. In our analyses, amenorrhea occurred in
56,9% of Mirena users, and lighter periods in 33,7%,
which is well comparable with other studies, where
amenorrhea and hypomenorrhea were described in
56-88% (1,6,9).
According to international data, a decreased men-
strual blood loss could be reached in women with hy-
permenorrhea in 79-97%, when treated with the
LNG-IUD (3).
In our results, the usage of Mirena was longer in
women with amenorrhea or hypomenorrhea, than in
women with hypermenorrhea, which was statistical-
ly measured with a correlation of r=-0,271 and
p<0,0001. That showed, that longer usage lead to a
lighter menstrual blood loss. The median value of
use was 5,1 years in women with amenorrhea, and
2,1 years in women with hypermenorrhea. The latter
was more often described after 6-12 months of use,
but not after 36 months. Kriplani et al. also de-
scribed a decreased menstrual blood loss more often
in women with long-time use of the LNG-IUD,
than in women with shorter time of use (10). Simi-
lar to that were the results of Backman, who showed
in 2004, that the menstrual blood loss decreased
continuosly with the lenght of using LNG-IUD (6).
Although the LNG-IUD is admitted for 5 years of
use, our analyses also show women with lenght of use
more than 5 years: Reasons for that are, that women
have a second coil, that they forgot to remove or that
the IUD was used for off label use (e.q. prae-
menopausal menstrual disorders). Absence of menor-
rhea is well described as a result of the local endome-
trial receptor interaction with the LNG, but is not
mainly caused by hormonal plasma levels (6). Further-
more, the individual bleeding behaviour was described
as independent from the ovarial function (11). In our
study we found an association between length of use
and amenorrhea, which can be of course explained
with the local endometrial interaction, but we also
found an association between individual BMI and
bleeding patterns. However, our results showed, that
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women with hypermenorrhea had a significantly high-
er BMI than women with no bleeding changes (~27,6
kg/m2 vs ~ 25,9, kg/m2). Women with amenorrhea
had a BMI of ~ 24,4 kg/m2, which was the lowest val-
ue of all group – comparisons. Therefore we conclude,
that in our study women with a higher BMI were
more likely to have heavier periods than women with
a lower one. The BMI difference of 3,2 kg/m2 between
women with hypermenorrhea and women with amen-
orrhea doesn’t seem to be excessively high, but means,
that a difference of 10kg weight in 170cm high per-
sons is enough, to influence the bleeding pattern. As
lenght of use and BMI seem to be necessery influenc-
ing factors for bleeding patterns in each case, and in-
teraction between them is not clear, bleeding patterns
afte all normally weighted women had amenorrhea in
the first three months of use, 0% of overweighted and
obese class I women had. In contrast to this, 18
(28,6%) of all oveweighted women and 5 (23,8%) of
all obese class I women had amenorrhea after 4,1-5
years of use. So it seems, that women with higher BMI
get later amenorrhoeic than normally weighted
women.
However, according to earlier studies, LNG-IUD users
with a high BMI are not likely to suffer more often
from unwanted pregnancies than other women (6). In
contrast to this, the rate of contraceptive failures can
be higher in women with a high BMI when using the
hormonal patch (12).
In our study we found no association between general
satisfaction rate and BMI, but between satisfaction
rate concerning bleeding patterns and BMI (not sig-
nificant): Concerning bleeding patterns, “very satis-
fied” women had a median BMI of ~24,3 kg/m2, while
“really not satisfied” women had a median value of ~
26,2 kg/m2, which would be a difference in weight of
6 kg for 170cm high persons. The percentage of “very
satisfied” women concerning bleeding patterns varied
from 91,0% for women with amenorrhea to 9,5% for
women with hypermenorrhea. For general satisfaction
rate, women with amenorrhea also were more satisfied
than women with hypermenorrhea. Previous studies
showed that menstrual pain as well as bleeding disor-
ders are common reasons for discontinuation (6), and
that user satisfaction increased with decrease of men-
strual pain (1). In our study women with increased
menstrual blood loss removed the IUD for a higher
percentage prematurely than women with lighter or no
periods (55,0% vs 11,7% 10,5%). Backman et al.
showed in 2002 similarly, that women with hypo- or
amenorrhea, had a lower discontinuation risk than
women with heavy menstrual bleeding (13). Concern-
ing dysmenorrhea, 33,3% of women with increased
menstrual pain discontinued LNG-IUD use, while
6,6% of women without any pain did. The highest dis-
continuation rate with 37,5% was observed in women
with no changes in menstrual pain since using Mirena.
We conclude that menstrual bleeding patterns and
pain are important factors that don’t only influence
patient satisfaction, but also decisions for or against
discontinuation. 
According to Backman et al. (2002), advanced infor-
mation, especially concerning bleeding patterns, can
improve user satisfaction (2). If we take Backman’s
finding into account and note that women with a
higher BMI are more likely to suffer from heavier
menstrual bleeding, women should given individual
information about Mirena and it’s causing bleeding
changes, depending on BMI and body composition.
Limitation(s) of the study
Because of the retrospective study design, we can of
course not avoid recall bias or prove the correctness of
women’s answers. But satisfaction is anyway a very
subjective sensation. As our sample size of 415 women
was divided into small sub categories for analysing, the
statistical power of our results is of course limited. We
mostly used normally scaled – or ordinally scaled val-
ues, therefore some statistical tests were not feasible,
and often statistical tests of lower level had to be done.
Therefore often descriptive statistic was used. Howev-
er, infomative value is still high, because there don’t ex-
ist any studies, which deal in detail with the same top-
ic. We are not aware of any papers, that remind the
body mass index when evaluating patient’s satisfaction
or bleeding patterns in women with the LNG-IUD.
But this aspect is of course relevant for everyday’s
working life, because women with higher BMI could
given another information about bleeding changes by
the use of IUD than women with lower BMI.
Even though our sample size was of only 415 women,
the dimensions of our BMI groups were similar to that
of the Central European average: According to the
Austrian average 64,0% of the 30-44 years old Austri-
an women were in the BMI group of 18,5-24,9 kg/m2,
whereas in our study 63,6% of women at the same age
were. To obesity class I, the public Austrian statistic
counters 5,8% of all 20-29 years old women, and
9,4% of all 30-44 years old women. Similarly to that,
6,5% of all women 20-29 years old in our study were
in obesity group I, and 10,2% of all women aged be-
tween 30-44 years. Despite of our small sample size,
the study seems to reflect well the average Austrian
women.
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Introduction 
Endometriosis is one of the most common gynecolog-
ical conditions. The prevalence of endometriosis is re-
ally unknown. The disease is found in about 0,5-5%
women of reproductive age, mostly in those (25-40%)
with fertility problems. Some authors reported a more
frequent occurrence of the disease. The most common
symptom for women who have endometriosis is cyclic
pelvic pain, which may also be chronic in nature and
that may fluctuate with age. Angiogenesis and inflam-
matory response play a pivotal role in the pathogene-
sis of endometriosis and implantation of endometrial
tissue outside the uterus. Angiogenesis is a process par-
tially regulated by vascular endothelial growth factor
(VEGF) – a signalling protein family which takes part
in creating new blood vessels. The severity of en-
dometriosis symptoms is a common cause of work ab-
sence. This fact and the necessity of invasive proce-
dures: laparoscopy or open surgery conducted to es-
tablish the diagnosis, affect social costs associated with
endometriosis. 
There is no treatment option that could be efficient
enough in all types of endometriosis. Danazol –
known from early 80-ties of the XX century is a ther-
apeutic option that is cheap, easy available and accept-
able by patients. The in vivo influence of danazol on
angiogenesis and inflammatory response is not well
documented. Nowadays the main goal is to find a
marker or a group of biomarkers for endometriosis
which could also be helpful in monitoring the treat-
ment. Having such a marker would avoid second-look
laparoscopies for endometriosis and lower the costs as-
sociated with the disease. Our research on peritoneal
fluid concentration of some markers typical for angio-
genesis and inflammatory response is a part of a major
experiment which goal is to find a non-invasive proce-
dure to diagnose endometriosis. Besides we evaluate
VEGF (vascular endothelial growth factor), Ca-125,
IL-1β and CRP concentration in plasma of patients
with endometriosis and after treatment this disease
with danazol. 
Aim 
The main goal of this study was to evaluate Ca-125,
VEGF, IL-1β and CRP concentrations in peritoneal
fluid (PF) in patients with endometriosis 
Materials and methods
This case-control study included 103 Caucasian
women in reproductive age admitted to the First De-
partment of Gynaecology and Obstetrics Medical
University of /Lódz´ (Poland) for diagnostic or thera-
peutic laparoscopy. The patients underwent laparo-
scopic surgery for infertility, pelvic pain or en-
dometriosis suspicion between February and Novem-
ber 2010. Those with laparoscopically confirmed en-
dometriosis who fulfilled inclusion criteria were quali-
fied to the study group, patients without this condi-
tion served as a comparative group for the statistical
analysis. Women with any conditions known as influ-
encing Ca-125, VEGF or CRP concentration and
with ovarian malignancy established by intraoperative
histopathologic examination as well as women in the
luteal phase of the cycle were excluded from the study.
The study protocol was approved by the Ethics Com-
mittee of the Medical University of /Lódz´ . All subjects
included in the study signed informed consent. Dur-
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ing the laparoscopy a peritoneal fluid specimen and an
endometrium biopsy was taken. The biopsy of the en-
dometrium was histopathologicaly examined to estab-
lish a phase of the menstrual cycle. The analysis of
concentrations of Ca-125 and CRP was conducted by
radioimmunoenzymatic methods. VEGF and IL-1β
levels were established by ELISA strictly according to
the manufacturer’s instructions. The presence and ex-
tent of endometriosis were carefully assessed, in accor-
dance with the rASRM 1996 (The Revised American
Society for Reproductive Medicine) classification of
endometriosis. rASRM classification was adopted for
statistical purposes: mild endometriosis = EEC of I
and II stage, severe endometriosis = EEC of III and IV
stage. Statistical comparisons were performed using
Statistica 7.0 (Stat Soft Polska). Regardless of the sta-
tistical test, only P-value ≤ 0.05 was considered signif-
icant.
Results
Endometriosis was confirmed laparoscopically in
68,9% of the women (n=71). The differences in age,
menarche, menstruation length and duration of infer-
tility were not statistically significant between the
study and comparative group. There were statistically
significant differences in the BMI and pain associated
with the menstrual bleeding between groups (78,9%
women with this symptom in the study group vs
43,8% in the comparative group; p<0,001).
The group with endometriosis presented significantly
higher plasma concentration of Ca-125 and signifi-
cantly lower levels of VEGF. IL-1β and CRP plasma
concentrations were comparable between groups.
There were also no differences in concentration of
these two markers between subgroups with the mini-
mal-mild and severe endometriosis. 
Analysis of PF concentration of the studied markers
showed, that groups varied significantly only in Ca-
125 levels (controls: mean value: 1054,85; SD
1135,61, n=32 vs. mean value: 2128,04; SD 2058,95,
n = 70 in study group; p=0,006) and VEGF concen-
trations levels (controls: mean value: 175,76, SD
116,13, n=19 vs. mean value: 354,65 SD 609,12
n=48; p=0,055). VEGF was also significantly higher
in the subgroup with severe endometriosis in compar-
ison to the group with mild endometriosis (controls:
median: 235,95 Q25: 212,20 Q75: 352,50 vs median:
190,70 Q25: 129,79 Q75: 231,70 p=0,012). Its con-
centration in peritoneal fluid correlated well with the
stage of the disease (Spearman’s rank correlation coef-
ficient R=0,35; p=0,016). The concentration of CRP
(mg/l) and IL-1β (pg/ml) between the groups was not
statistically significantly different.
Discussion 
The role of determining Ca-125 concentration in
plasma is well known in the diagnosis of endometrio-
sis. Studies on its role in peritoneal fluid present dis-
crepancies. The levels of Ca-125 in PF in our study
are higher than those determined by other re-
searchers. This fact is probably influenced by the use
of one of the newest tests for detecting antigen OC
125 (VIDAS II). One of the most important angio-
genic factors, i.e. VEGF, was selected to evaluate an-
giogenesis in endometriosis. The influence of VEGF
on IL-1β plays a role in angiogenesis and inflamma-
tion response. It was therefore concluded that the
analysis of the concentration of these markers will best
characterize the mentioned processes in the women
with endometriosis. Some studies confirmed the high-
er concentration of VEGF and Il-1β but others found
no correlation between endometriosis and the concen-
tration of mentioned biomarkers in PF. In our study
the concentration of VEGF was significantly higher in
women with the disease in comparison to the control
group but we did not find any relation between Il-1β
level in PF and the disease. Moreover, a strict adher-
ence to the criteria for the qualification procedure (e.g.
excluding the women in whom a cycle phase was not
histopathologically confirmed) seems to have an influ-
ence on the correlation between the VEGF concentra-
tion and the severity of the disease. 
Conclusions
Despite high prevalence of endometriosis in the stud-
ied population, the group with endometriosis was well
characterized by parameters known as typical for the
disease: painful menses, increased Ca-125 concentra-
tion in plasma and in peritoneal fluid, increased
VEGF concentration in peritoneal fluid.
Higher VEGF values in PF confirm the role of angio-
genesis in the development of endometriotic foci out-
side the uterus in the first cycle phase of women with
endometriosis. 
There is a clear correlation between the severity of the
disease and VEGF concentration in PF (p=0.012). 
Il-1β and CRP are not enough sensitive to distinguish
between women with and without endometriosis.
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Introduction
Microalbuminuria (urinary albumin excretion in the
range of 30-300 mg/24 h) is an early manifestation of
diabetic kidney disease. It is associated with slightly el-
evated blood pressure (BP) within normal range and
subclinical edema due to universal vascular leakage of
albumin, and it predicts overt diabetic nephropathy
with persistent proteinuria and hypertension (1,2,3).
The most important problem in the pregnancy com-
plicated by type 1 diabetes is increased perinatal mor-
bidity associated with preterm delivery. Up to one-
third of infants of mothers with type 1 diabetes are de-
livered preterm (4,5,6), while the prevalence of
preeclampsia characterized by hypertension, protein-
uria, and edema is 10-20%. Diabetic nephropathy
(urinary albumin excretion >300 mg/24 h) presents at
conception is a major contributor to increased perina-
tal morbidity and mortality (7,8). Diabetic women
with high early pregnancy proteinuria of 190-499
mg/day have been reported to have an increased risk of
developing preeclampsia, similar to that in women
with diabetic nephropathy (9,10,11). The aim of this
study was to determine the influence of microalbu-
minuria on fetal outcome and maternal complications
in pregnant women with type 1 diabetes. 
Patients and methods
In our study were enrolled 80 women with type 1
diabetes before gestation who were admitted to the
Department of Obstetrical Gynecology at Ameri-
can Hospital, “Hygeia” Hospital, Diagnostic Cen-
ter “Ikeda-Euromedica”and Diagnostic Center
“Med.al” before 17 weeks of gestation with a living
fetus. Women who had miscarriages (≤ 22 weeks of
gestation) were excluded.
The cases were analized for urinary albumin excre-
tion, BP, HbA1c, that were measured by various
methods in the respective centers. The women were
categorized according to their level of urinary albu-
min excretion, calculated as geometric mean of two
to three measurements. Normal urinary albumin
excretion was defined as <30 mg/24 h, microalbu-
minuria was defined as urinary albumin excretion
of 30-300 mg/24 h, and diabetic nephropathy was
defined as urinary albumin excretion >300 mg/24h
(12,13). Data regarding kidney function and BP
status at baseline are summarized in the following
sections.
Normal urinary albumin excretion
In 54 women without kidney involvement, geometric
mean urinary albumin excretion was 7 mg/24 h (range
1-27). Two of them (2,5%) were treated with
antihypertensive drugs before pregnancy (ACE
inhibitors, beta blockers, and/or diuretics). 
Microalbuminuria
In 18 women with microalbuminuria, geometric
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mean urinary albumin excretion was 65 mg/24 h
(range 14-270). Five of them were normotensive, be-
cause they were diagnosed with hypertension and
treated with ACE inhibitors before pregnancy. 
Diabetic nephropathy
In 8 women with diabetic nephropathy, geometric
mean urinary albumin excretion was 1,115 mg/24 h
(range 458-5,480). Two women had nephrotic pro-
teinuria >3 g/24 h; the mean serum creatinine was 87
µmol/l (range 58-165), and in the first trimester, three
women had a creatinine clearance <1.13 ml/s. Five
women were treated with antihypertensive drugs
(three with ACE inhibitors and three with beta block-
ers, possibly in combination with diuretics), because
they were diagnosed with hypertension before preg-
nancy.
The women were classified according to the White
classification, which is traditionally used in obstet-
rics to grade the severity and duration of diabetes.
White class B was defined as onset of type 1 diabetes
after 19 years of age and duration of diabetes <10
years. White class C was defined as onset of type 1
diabetes between 10 and 19 years of age or duration
of diabetes 10-19 years. White class D was defined
as onset of type 1 diabetes before 10 years of age or
duration of diabetes ≥20 years or presence of
retinopathy. White class R was defined as presence
of proliferative retinopathy, and White class F was
defined as presence of diabetic nephropathy (15). A
woman was categorized as a smoker if she smoked
≥1 cigarette per day.
The women were asked to perform home blood glu-
cose measurements at least four times daily during
their pregnancy and to adjust insulin doses according-
ly in order to maintain preprandial blood glucose lev-
els between 3 and 6 mmol/l. They visited the obstetric
clinics every 1 or 2 weeks during pregnancy. Labor was
routinely induced at 37-40 weeks of gestation based
on individual evaluation.
Single measurements of 24-h urinary albumin excre-
tion, HbA1c, and office BP were performed at least five
times throughout the pregnancy (weeks 10, 14, 20,
28, and 34). Urine samples were analyzed for albumin
by enzyme-linked immunosorbent assay (14) or by a
turbidimetric method using the same antibodies and
buffers. HbA1c was analyzed by high-performance liq-
uid chromatography (17) or by antibody immunoas-
say (normal range 4.1-6.4%). Office BP was meas-
ured in a sitting position with the arm at heart level
after 5-10 min rest.
The diagnosis of preeclampsia in women with normal
urinary albumin excretion or microalbuminuria was
based on the presence of office BP >140/90 mmHg
(three measurements) accompanied by proteinuria
>0.3 g/24 h (two urine samples) later than 20 weeks of
gestation (proteinuria of 0.3 g/24 h is equivalent to a
urinary albumin excretion of 190 mg/24 h). The diag-
nosis of preeclampsia in women with diabetic
nephropathy was based on the same findings as well as
a sudden increase of ≥15% in systolic or diastolic BP
(11). Pregnancy-induced hypertension without pro-
teinuria was defined as the development of BP
>140/90 mmHg (three measurements) later than 20
weeks of gestation in women who were previously nor-
motensive and proteinuria <0.3 g/24 h. Antihyperten-
sive treatment with methyldopa was initiated due to
preeclampsia (n = 13) or if diastolic BP was higher
than 95 mmHg without proteinuria (n = 11) or if pro-
teinuria exceeded 3 g/24 h (n = 2) in the absence of
hypertension. None of the women with normal uri-
nary albumin excretion or microalbuminuria required
antihypertensive treatment early in pregnancy (<20
weeks of gestation). In addition to insulin and hyper-
tensive drugs, four women were taking levothyroxine
for Hashimoto Thyroiditis, five were taking antide-
pressive drugs and one was taking an antiepileptic
drug during the pregnancy.
Preterm delivery (<37 weeks of gestation completed)
included spontaneous delivery and delivery based on
obstetric indications such as uncontrolled hyperten-
sion, severe symptoms of preeclampsia, or macroso-
mia. Small for gestational age was defined as <10th
centile for gestational age. Perinatal mortality was de-
fined as fetal death later than 22 weeks of gestation or
within 1 week after delivery. Major congenital malfor-
mations were considered those responsible for death,
those causing a significant future disability, or those re-
quiring major surgery for correction (16). During the
study period, no fetuses with congenital malforma-
tions were aborted as late abortions. 
Statistical analysis
Normally distributed continuous variables are given as
means ± SD, and urinary albumin excretion is given as
geometric mean and range. χ2 trend test for categori-
cal data and one-way analysis of variance linear trend
test (regression) for continuous variables were applied
to compare groups. Multivariate logistic regression
analysis was applied to identify variables independent-
ly associated with development of preterm delivery
and preeclampsia. Category of urinary albumin excre-
tion and tertiles for HbA1c (≤ 7, 7.1, 7.9, and ≥8%)
were applied as independent variables in the logistic
regression analysis. Probability value <0.05 (two-
tailed) was considered significant. 
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Results
A total of 54 women (67.5%) had normal urinary al-
bumin excretion, 18 (22.5%) had microalbuminuria,
and 8 (10%) had diabetic nephropathy at baseline
(Table 1). There was a trend toward longer duration of
diabetes and higher BMI, HbA1c, and BP with increas-
ing category of urinary albumin excretion.
Antihypertensive therapy was given in 9 of 54 women
with normoalbuminuria, 8 of 18 women with mi-
croalbuminuria, and all 8 women with diabetic
nephropathy. Mean systolic blood pressure during
pregnancy was 124 mmHg (range 105-151), 125
mmHg (119-138), and 138 mmHg (113-147) in
women with normoalbuminuria, microalbuminuria,
and diabetic nephropathy, respectively (P=0.0095).
No differences in mean diastolic blood pressure or
HbA1C were detected between the groups. No women
with microalbuminuria developed preeclampsia. The
frequency of preterm delivery was 22% in women
with normoalbuminuria and microalbuminuria, in
contrast to 75% in women with diabetic nephropathy
(P<0.01) where the median gestational age was 254
days. When excluding the group with diabetic
nephropathy from analysis, women with microalbu-
minuria still had a higher prevalence of preterm deliv-
ery compared with women with normal urinary albu-
min excretion (P<0.05). The increased prevalence of
preterm delivery was mainly due to the higher preva-
lence of preeclampsia in women with microalbumin-
uria or diabetic nephropathy. A total of 24% of the
women with microalbuminuria and 60% of the
women with diabetic nephropathy delivered preterm
due to preeclampsia. Preterm delivery due to other
causes (spontaneous or for obstetrical reasons) was
comparable in the three groups. 
Increased prevalence of intrauterine growth retarda-
tion was seen in women with diabetic nephropathy
but not in women with microalbuminuria (Table 2).
Diabetic nephropathy was also associated with in-
creased prevalence of jaundice requiring treatment,
and there was a tendency toward a higher proportion
of development of tachypnea requiring assisted venti-
lation. Perinatal mortality and major congenital mal-
formations were comparable in the three groups.Using
multivariate logistic regression analysis, the baseline
variables of urinary albumin excretion, systolic BP,
HbA1c, White classification, age, BMI, parity, and
smoking were tested as predictors of preterm delivery.
Increased category of urinary albumin excretion
(P<0.01) and high HbA1c at 2-6 weeks of gestation
(P<0.05) were independently associated with preterm
delivery.
Discussion
In our study, the presence of microalbuminuria during
the pregnancy and higher HbA1c at 2-6 weeks of ges-
tation has been associated with increased risk of
preterm delivery in women with type 1 diabetes mel-
litus. The substantially increased prevalence of preterm
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TABLE 1 - BASELINE DATA ON 80 PREGNANT WOMAN WITH TYPE 1 DIABETES AND NORMAL URINARY ALBUMIN
EXCRETION, MICROALBUMINURIA AND NEPHROPATHY.
Normal urinary
Microalbuminuria Nephropathy P valuealbumin excretion
Patients, n 54 18 8 –
Age (years) 28±5 30±3 30±4 NS
Duration of diabetes (years) 10±6 17±4 18±5 <0.01
BMI (kg/m2) 23±4 25±6 26±4 <0.05
Urinary albumin excretion (mg/24 h) 7 (1–26) 72 (18–280) 1,118 (470–5,540) ND
HbA1c at 2–6 weeks (%) 7.2±1.4 8.0±1.1 9.0±1.4 <0.001
Early systolic BP (mmHg) 124±13 125±12 138±11 <0.001
Early diastolic BP (mmHg) 67±9 70±7 79±7 <0.001
White classification
B + C 30 (55.5) 7 (39.9) 0 ND
D + R 24 (45.5) 11 (61.1) 0 ND
F 0 0 8 (100) ND
Nullipara 29 (55.5%) 9 (50%) 4 (50%) NS
Smokers 14 (25.9%) 4 (33.3%) 4 (50%) NS
Data are means ± SD, mean (range), or n (%).
The statistics applied are χ2 trend test when comparing categorical data and linear trend test (regression) for one-way analysis of variance when comparing continuous data.
ND: not done.
NS: not significant. 
delivery with the increasing degree of albuminuria was
caused by higher prevalence of preeclampsia.
Our findings are in accordance with Combs et al. (11),
who reported an increased prevalence of preeclampsia
and preterm delivery in women with early pregnancy
proteinuria of 190-499 mg/24 h.
A substantial number of the women with microalbu-
minuria increased their protein excretion to the
nephrotic range during pregnancy. This is in accor-
dance with Biesenbach et al. (19), who found that
nephrotic proteinuria developed in 4 of 12 women
with microalbuminuria during pregnancy. One might
speculate whether antihypertensive treatment during
pregnancy should be indicated with increasing albu-
min excretion. We chose to initiate antihypertensive
treatment in normotensive women with proteinuria
exceeding 3 g/24 h during pregnancy. After delivery,
the albumin excretion has been shown to return to
prepregnancy levels (12,17).
The prevalence of preterm delivery in our study was
comparable to the literature (6), although some au-
thors have reported a higher prevalence of women de-
livering at term (5,6,).
The association between high levels of HbA1c and de-
velopment of preeclampsia has been described earlier
in type 1 diabetes (9,18). In our study we have noticed
a correlation between elevated HbA1c at 2-6 weeks of
gestation and increased prevalence of preterm delivery.
The presence of hypertension is of importance for the
prediction of preeclampsia (19,20).
In women with microalbuminuria or diabetic
nephropathy, development of preeclampsia was the
most important single cause of preterm delivery. In
women with normal urinary albumin excretion, we al-
so found a surprisingly high prevalence of preterm de-
livery associated with poor metabolic control.
Treatment with ACE inhibitors before pregnancy
along with tight metabolic control in women with di-
abetic nephropathy, resulting in urinary albumin ex-
cretion <500 mg/24 h, has been reported to have a
prolonged protective effect on maternal renal function
and results in a favorable maternal-fetal outcome with-
out development of preeclampsia (20). Unfortunately,
we are unable to support this report, because in our
study all women with microalbuminuria or diabetic
nephropathy treated with ACE inhibitors before preg-
nancy demonstrated progression of proteinuria during
pregnancy. 
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Introduction
The incidence of thyroid cancer in women in Ecuador
is 20 for 100.000 inhabitants. This incident increases
at the ages of 35 and is the third most common disease
(1) after breast and cervix cancer. The global incidence
goes from 5 in South America to the 8.5 in Western
Europe and 24.4 in Polynesia (2).
Throughout women’s lifetime many events are fol-
lowed by hormone level variations since puberty until
menopause, during the last, thyroid dysfunction
comes along with changes in concentration of estrogen
levels (3,4). Clinical signs are weakness, lethargy,
amenorrhea and depression (7) which may be con-
fused with hypothyroidism, rendering difficult to per-
form a differential diagnosis.
The purpose of this study is to justify among
menopausal women, an algorithm that can be easily
performed in order to achieve an early diagnosis of be-
nign or malignant thyroid pathology.
Therefore, this study proposes after detecting high lev-
els of TSH, to perform a thyroid ultrasound and pro-
vided that nodules are found, a fine needle aspiration
(FNA) as an initial procedure conductive to accurate
clinical and histological diagnosis.
Objective
To improve the diagnosis of thyroid neoplasms using
TSH routine test in the evaluation of menopausal
women.
Patients and methods 
Descriptive epidemiological study for groups per-
formed at Instituto de Ginecología y Mastología
(GINECOMAST) Quito – Ecuador, in which
menopausal women according to amenorrhea and
FSH levels ≥30 mUI/ml and no clinical signs of thy-
roid pathology were studied. TSH was measured by
RIA (radioimmunoassay), and patients who had a re-
sult 4 mUI/ml, were selected for a thyroid ultrasound.
Given the presence of thyroid nodules, a FNA was
performed and the positive results for malignancy
were confirmed by the histopathology after radical
thyroidectomy. 
Results
Among 543 menopausal patients (amenorrhea) that
went through FSH and TSH tests; 373 (68.7%), be-
tween 39 and 85 years old (x = 52 years old), were
menopausal with elevated FSH, and 115 (30.83%) of
them had elevated TSH levels (x=5.64, r=4 -36). The
ultrasound found thyroid nodules in 24 (20.86%) pa-
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TABLE 1.
tients, who had TSH levels much higher than women
without nodules (Tab. 1).
The FNA of the nodule was suspicious or conclusive
of malignancy in 8 patients (33%), goiter in 14
(58.33%) and follicular adenoma in 2 (8.33%). Five
were confirmed as papillary carcinoma (20.83%). Two
of them were Hashimoto’s thyroiditis (8.33%) and
one a benign nodular hyperplasia (4.16%) (Figs 1-6).
The average of TSH among patients who were diag-
nosed with cancer was 7.62 (r=6.2-10) significantly
higher than patients without thyroid nodules (7.62 vs
5.64; p=0.0034), but similar to the serum TSH values
of patients with benign nodules (7.62 vs 8.89;
p=0.07).
Discussion
The aging phenomenon is associated with plenty of
metabolism disturbances. The hypothalamic and pitu-
itary system cannot avoid these changes and modifica-
tions are not exclusive to the reproductive system. Sev-
eral reports have demonstrated very important
changes in the secretion of thyroid stimulating hor-
mone (TSH) throughout our lives (8,9).
The prevalence of hypothyroidism increases as pa-
tients grow older and it reaches 10% in older women.
The influence of age on the response of the thyroid
gland to TSH is not clear. Most elderly people main-
tain normal T4 plasma levels without a significant
change due to age. In this study, we observed an in-
creasing trend in the prevalence of subclinical hy-
pothyroidism in older women, surpassing 40% in
women over 55 years. This may be a reflection of the
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Fig. 2 - Hipoechogenic nodule with very important vascularization on the
right thyroid lobe.
Fig. 1 - Right thyroid lobe of heterogeneous echogenicity, and undefined
medial borders, it does not have cleavage plains with the right tracheal
wall. Histopathology: Papillary carcinoma.
Fig. 3 - Left thyroid lobe with multiple hypoechogenic nodules. HP: nodu-
lar goiter.
Fig. 4 - Nodular Goiter.- Proliferation of follicles with abundant amount of
colloid without cellular atypia.
progressive decrease in the secretion of T4 in relation
to age (10).
The prevalence of thyroid nodules in the general pop-
ulation depends on the diagnostic method used. Nod-
ules on physical examination are found in 4 to 7% of
the population with predominance in females (11),
counting on thyroid imaging the prevalence reaches
19 to 67% (12).
It is estimated that 5% of thyroid nodules are malig-
nant (11) and autopsy studies in patients with no his-
tory of thyroid disease prevalence is around 49% (13).
The vast majority of thyroid nodules are asympto-
matic. It is estimated that only 1% of them causes hy-
perthyroidism (14).
The incidence of thyroid disease in our country jus-
tifies the implementation of routine screening for
thyroid tumors in menopausal women. Our data
suggest that TSH alone should be enough screening
provided that the reference values are reliable.
World’s medical literature considers that 10% of the
population might have a thyroid nodule (15), and
even if the general population undergoes a thyroid
ultrasound, a nodule will be found in about 20 to
45% of women (16) and through autopsy in up to
50% of all cases (16).
The Swedish Sorderstrom, Lowhagen and colleagues
in 1952 at th Karolinska Hospital in Stockholm, used
the FNA technique for thyroid nodule which was lat-
er accepted worldwide (17).
Conclusion
TSH in the routine evaluation of menopausal patients
(Tab. 2) allows to select benign or malignant tumor
pathology, even if there is no clinical criteria.
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Tg: Thyroglobulin 
TPO: Thyroid peroxidase (19)
* The dosage of antithyroid antibodies is still under investigation in our Institute for publication.
TABLE 2 – TSH AND FSH ALGORITHM IN MENOPAUSE
*
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Fig. 5 - Hashimoto’s thyroiditis.- Follicles with oncocytic and inflammatory
changes of follicular pattern lymphocytic infiltrates.
Fig. 6 - Papillary carcinoma.- Papillary pattern proliferation of anaplastic
thyroid cells with pseudo-inclusions and “coffee beans like cleft” sur-
rounded by lymphoid follicles
Introduction
The Polycystic Ovary Syndrome (PCOS) is a common
endocrine disorder of women in the reproductive age,
with a mean incidence of 5-10% (1). The criteria for
polycystic ovaries (PCO) as defined by the 2003 Rot-
terdam consensus are based on the follicle number and
ovarian volume, which decrease with age. (2) The syn-
drome is diagnosed when two of the following three
criteria are present (1): Anovulation or oligoovulation
(2), biochemical hyperandrogenemia or hyperandro-
genism (3), polycystic ovaries observed ultrasonograph-
ically (2) PCOS is also accompanied by a number of
metabolic disorders, such as insulin resistance and hy-
perinsulinemia, dyslipidemia and obesity. However, the
metabolic manifestations of the syndrome are not in-
cluded in its criteria.The frequency of the metabolic
syndrome in PCOS patients reaches 25% (4). Blood
hormone measuements and ultrasound examination of
the ovaries are useful in confirming clinical suspicion of
the disease. Hyperandrogenism, a high human luteiniz-
ing hormone (LH) concentration level compared with
human follicle stimulating hormone (FSH), hirsutism
are frequent reasons for consultation of teenagers in
adolescence and paediatric centers The aim of this
study was to elucidate the frequency of the PCO syn-
drome especially in teenagers without health-problems. 
Patients and methods
The study -teenagers were selected from the total pop-
ulation of 140 teenagers, who had completed a men-
strual history questionnaire and received no oral con-
traceptives at the time of the study.
The study-teenagers suffered from abdominal pain de-
pending on various reasons . A group consisting of 56
participants was selecteced from the original group of
140 according to the following criteria oligomenor-
rhoea, anovulatory cycle using a basal body tempera-
ture chart, hirsutism using the clinical Ferriman and
Gallway score, increased LH and LH/ FSH ratio >2.5.
The sample comprises of 40 healthy teenagers, aged
16-18 years, during a spontaneous menstrual cycle in
the department of Adolescence Medicine in Democri-
tus University of Thrace and in others 16 adolescents,
aged 15-18 from the Department of Obstetrics and
Gynecology in Clinicum Aschaffenburg, Germany
during the time from September 2007 until December
2010. The study respondents given were agree to par-
ticipate in the follow up study for the next five months
after the first doctor visiting. The menstrual cycle pat-
terns were defined as follows: regular menstrual cycles:
an average cycle length between 22 and 41 days; no
more than a single cycle with a length of less than 22
or greater than 41 days during the past year; irregular
menstrual cycles: an average cycle length between 22
and 41 days; two or more cycles with a length of, 22
or .41 days during the past year; oligomenorrhea: an av-
erage cycle length between 42 and 180 days;Transvagi-
nal sonography was performed between cycle day 7
and 10 to determine the follicle number and revealed
more than 10 follicles of 2-8 mm in diameter, typical-
ly distributed peripherally and central stroma was in-
creased (3,4). Hormone levels (FSH, LH, DHEAS)
were measured on day 6 or 7 after menses.
Results
The teenager-participants were monitored for about 5
months. The clinical characteristics of the teenagers
© Copyright 2012, CIC Edizioni Internazionali, Roma
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are shown in table 1. Most PCO subjects had anovu-
latory cycles, hirsutism and oligomenorrhea. 
LH and androgen concentrations were significantly
higher in teenagers with PCO. Oligomenorrheic par-
ticipants with PCO had the highest LH levels. 
Elevated LH levels were found to represent the most
common endocrine abnormality in oligomenorrheic
adolescents with an incidence 42%. In our study high
LH levels were associated with high androgen levels and
the prevalence of PCO in our population was 42%. 
Discussion
The present study demonstrates the prevalence of
PCO in a general population of adolescence. PCO was
found to be very common in young women. The
pathogenesis of PCOS is possibly based on interac-
tions between genetic and certain environmental fac-
tors. Although our sample of adolescents is small, our
findings suggest clearly relationship between PCO
syndrome and menstrual cycle pattern as well as ele-
vated LH concentration. In our collective we found
high androgen levels but the role of hirsutism and ac-
ne is unclear. Consonant to our findings was the PCO
prevalence found in other studies in teenagers and
adults with oligomenorrhea. (45%) (6). The PCO
prevalence in adults with oligomenorrheic populations
is higher referred according to same authors, although
are used the same PCO definitionscriteria (7-9) PCO
is associated with irregular menstrual cycles,
oligomenorrhea, high LH and androgen levels but
their relationship in adolescents has been not satisfac-
tory documented (10). The recognition of the early
signs of PCOS during or even before adolescence is of
great importance. In young women with hyperandro-
genism it is important to establish the correct diagno-
sis for PCOS and rule out other causes of androgen ex-
cess. Early treatment is crucial to prevent the long
term complications of the syndrome, especially infer-
tility and cardiovascular disease. Treatment of PCOS
in adolescent girls should aim in achieving ovulation,
normalizing the menstrual cycle, reducing and if pos-
sible eliminating hirsutism and acne, losing weight
and treating hyperlipidemia and hyperglycemia in or-
der to reduce the risk of cardiovascular disease. Further
research is necessary to elucidate how PCOS behaves
and disturbs the endocrine harmony of the young fe-
male body in that transitional place of a woman’s life.
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TABLE 1 - CLINICAL LEADING SYMPTOMS OF PCOS.
Anovulation 66.6%
Hirsutism 30.5%
Acne 29.4%
Obesity 20.6%
Irregular cycles 82.5%
Oligomenorrhea 90.5%
TABLE 2 - LABORATORY FINDINGS  OF PCOS.
Hormones
LH > 12 IU/I in (40/56) cases 71.4%
> 16 IU/I in (16/56) cases 28.6%
LH/FSH ratio > 2.5 in (50 /56) cases 89.2%
DHEAS > 8.9 µmol/ l in (50/56) cases 89.2%
Introduction
Combined therapy (surgery with consequent glandu-
lar therapy) is, in the opinion of majority of re-
searchers, most effective in treating endometriosis
(Krasopolskiy et al., 2000, Adamyan L.V., 2005).
However, many doctors and patients in Kazakhstan
and Middle Asia prefer only surgery with laparoscopic
access. In this connection, substantiation of combined
therapy is very important as mandatory for treating
symptoms of endometriosis. 
Aim
Definition of efficiency of combined therapy for re-
ducing symptoms of endometriosis.
Patients and methods
For the period from March 2008 until March 2011
120 women with histologically confirmed external
genital endometriosis with 1,2,3 stages of diffusion in
accordance with classification R-AFS (Revised Classi-
fication of American Fertility Society, 1985) were clin-
ically examined and treated. 60 patients had only en-
dosurgery treatment (I group). 60 patients received
glandular therapy by dufaston - 10 mg 3 times per day
from 5 to 25 day of the cycle for 6 month after endo-
surgery (II group). Surgery was made on the 6-8 days
of menstrual cycle with the use of operational block of
«Storz» firm (Germany), mono-polar coagulator.
Average age of patients in research group sequaledto
(34,6±1,1) years and (31,6±1,4) years accordingly.
Examined and treated patients had the following
forms of endometriosis: ovary endometriosis 43.3%
(52); peritoneal form of endometriosis 45.0% (54);
combined from (ovary endometriosis and peritoneal
form) 11.6% (14).
In the 1st group, 1 stage of endometriosis diffusion was
observed at 35.0% (21), 2 stage at 35.0% (21) and 3
stage at 30.0% (18) of the patients. In the 2nd group,
1 stage of endometriosis diffusion was diagnosed at
40.0% (24), 2 stage at 30.0% (18) and 3 stage at
30.0% (18) of the patients.
For estimating efficiency of therapy, were estimated
the basic clinical symptoms: pain syndrome, and men-
orrhagia. Expression of pain syndrome was estimated
on visual-analogues scale (0 mm – absence of pains,
100mm – acute pain) at the beginning and end of re-
search. The results of research were statistically
processed.
Results
Pain syndrome was observed at 90.4% (108) of pa-
tients, involved in the research, with this we had high
rate of dysmenorrhea (51.9%), as well as continuative
pelvis pains (47.5%), dyspareunia was observed at
32.8% of patients. Average intensity of pain syndrome
before beginning of treatment equaled to 70mm on vi-
sual analogue scale in both of group.
Before treatment in the 1st group patients the pain syn-
drome was observed at 91.7% (55), here with at
90.5% (19) with 1 stage, at 90.5% (19) with 2 stage
and at 94.4% (17) patients with 3 stage of the disease.
Intensity of pain syndrome on visual analogue scale
equaled to 55mm, 70mm and 80mm accordingly on
© Copyright 2012, CIC Edizioni Internazionali, Roma
Efficiency of combined therapy for treating
symptoms of endometriosis
TULETOVAA.S.
University of Astana, Kazakhstan 
Giorn. It. Ost. Gin. - Vol. XXXIV - n. 1
Gennaio-Febbraio 2012
334
stages of endometriosis diffusion. Pains were preserved
at only 61.9% (13) patients with 1 stage, at 81.5%
(17) patients with 2 stage and all of the patients with
3 stage of disease - 94.4% (17). With 1 stage of en-
dometriosis diffusion intensity of pain syndrome was
reduced to 25mm, at the 2 stage of endometriosis dif-
fusion to 35mm, at the 3 stage it was reduced to
47mm. The average intensity of pain was 35 mm after
treatment instead of 70 mm before the treatment.
Thus, the effect of treatment were at 28.6% (6) of pa-
tients with 1 stage, at 9.5% (2) patients with 2 stage.
Among the patients with 3 stage of endometriosis did-
n’t have the effect of treatment. Therefore, in the 1st
group only 14.5% (8 out of 55) of patients had effect
(absence of pain) of surgery therapy. Despite the small
percentage of effectiveness, pain intensity decreased an
average of 2 times.
In the 2nd group patients the pain syndrome before
treatment was observed at 88.3% (53), herewith at
83.3% (20) with 1 stage, at 88.9% (16) with 2 stage
and at 94.4% (17) patients with 3 stage of the disease.
Intensity of pain syndrome on visual analogue scale
equaled to 55mm, 75mm and 80mm accordingly on
stages of endometriosis diffusion.6 months after treat-
ment, this syndrome was observed at 33.9% (18 out of
53) of patients. During the treatment, ranging from 1
month, pain disappeared in most patients with stage 1
and the end of treatment was observed in 12.5% (3 pa-
tients). In patients with second and third stages of en-
dometriosis pain syndrome was observed in 33.3% (6)
and 52.9% (9), respectively. Pain intensity decreased to
10 mm - 1 Stage, 15mm - 2 stage, 25mm - 3 stage of
endometriosis diffusion. The average intensity of pain
was 17mm after treatment, instead of 70 mm before
treatment. Thus, the effect of treatment for1 stage was
obtained in 70.8% (17), at 2stage in 55.6% (10), at 3
stage in 44.4% (8). So at 66.0% (35 out of 53) of pa-
tients 2st groups the effect of the therapy was observed
and pain intensity decreased by 4 times.
Menorrhagia were observed at 34.2% (41) of studied
patients. In the 1st group before treatment menorra-
giawere at 35.0% (21) patients: at 1 stage – 23.8% (5);
at 2 stage – 33.3% (7), at 3 stage– 50.0% (9). After
treatment in that group menorrhagia were preserved at
21.7% (13) of patients: at 1 stage – 9.5% (2); at 2
stage – 14.3% (3), at 3 stage – 44.4% (8). In the 2nd
group before treatment this symptom were at 33.3%
(20) patients and 15.0% (9) patients after therapy. At
1 stage menorrhagia were at 16.7% (4) instead of
4.8% (1) patients after therapy. At 2 and 3 stage were
33.3% (6) and 55.6% (10) of patients who had these
symptoms before treatment. After 6 months it was at
16.7% (3) and 27.8% (5) of patients with 2 and 3
stage, respectively.
Analysing the data, we can say that the significant de-
crease of the main symptoms of the disease (p<0,01)
was noted in all types of therapy. However, the com-
bined method of therapy turned out to be most effec-
tive in reducing symptoms of disease. In it, clinical
symptoms after treatment were less frequent, than the
ones after surgery (p=0,01). Clinical efficiency of com-
bined treatment was for the most part related with re-
duction of pain syndrome. Was noted direct correla-
tion dependence between endometriosis stage and re-
sults of therapy. The heavier pathologic process is, the
less therapy is efficient (r=0,98).
Conclusions
Comparative estimation of efficiency of methods of
endometriosis treatment allowed to state, that com-
bined therapy turned out to be more efficient, than
endosurgery at all stages of pathologic process. Results
of treatment of genital endometriosis are directly pro-
portional to its stage: the more diffusive endometriosis
is, the less therapy is efficient. Using dufaston after
surgery reduces frequency of endometriosis symptoms
and improves life quality of women.
References
1. Aliev MA, Seysembekov MA et al. Laparoscopy in the diag-
noses and treatment of endometriosis. Actual problems of re-
production. Almaty 1999;101.
2. Kira EF, Yermolinskiy II, Melnichenko AI. Endometrioid dis-
ease, modern principles of therapy. Gynecology, 2004;6(5):
19-24.
3. Overton CE, Lindsay PC, Johal B. A randomized, double-
blind, placebo controlled study of luteal phase dydrogesterone
(Duphaston) in women with minimal to mild endometriosis.
Fertil Steril 1994;62:701-7.
4. Olive DL. Medical therapy of endometriosis. SeminReprod
Med 2003;21:209-22.
5. Trivedi P, Selvarai K, et al. Effective post-laparoscopic treat-
ment with dydrogeterone. Gyn. Endocrin 2007 oct; 23Suppl
1:73-6.
335
Introduction
Endometrioma (ovary endometriosis) is the most fre-
quent form of endometriosis at women in reproduc-
tive age. Treatment of endometriosis cysts is in remov-
ing them by surgery with laparoscopic access. Howev-
er, relapses of disease are observed after surgery (1,2).
Different methods of removing cysts are used during
surgery. Accessible literature lacks information about
efficiency of different methods of removing en-
dometriosis cysts. For preventing relapse, glandular
therapy is offered (3,4). But many doctors and pa-
tients prefer only surgery method of treating en-
dometriosis.
Purpose of research
Providing basis for efficiency of after-operational glan-
dular therapy for reducing pain syndrome and relapse
of endometrioms (ovary endometriosis).
Subject and methods of research
Since November 2005 until May 2009 we had laparo-
scopic removal of symptomatic endometriomas at 95
patients 24-35 years old. Diagnosis is histologically
verified. During surgery were held ovary resection 40,
cyst enucleation 20, adnexectomy 17, endocoagula-
tion for 18 patients. Accordingly, in 33 cases was made
adhesiolysis. Surgery was made with use of coagulator
of mono-polar type of high-frequency endosurgery on
operational laparoscopic block of «Storz» firm (Ger-
many). After surgery 33 patients received low-dose
combined oral contraceptive (COC), containing deso-
gestrel, in contraceptive mode, for 6 months. 30 pa-
tients received didrogesteron (dufaston) in dose 10 mg
3 times per day from 5th to 25th day of the cycle for 6
months. The rest 32 patients refused glandular thera-
py. Thus, all patients, depending on method of thera-
py, were divided in 3 groups: 1st group - 32 patients,
not receiving anti-relapse glandular therapy, 2nd group-
33 patients, who received COC after endosurgery, 3rd
group - 30 patients, who received didrogesteron. Effi-
ciency of therapy was estimated on reduction of fre-
quency of main syndromes of disease (pains and dis-
menorrhea), on stage of reduction of pain according to
Visual Analog Scale and relapse frequency in 12
months after therapy. Intensity of pain syndrome was
estimated on VAS (0mm – absence of pain, 100mm –
acute pains) at the beginning and end of therapy. Re-
sults of research were undergoing statistic processing.
Results of research 
Age of patients, involved in research, varied from 19 to
35 years. Pain syndrome was observed at all the pa-
tients before surgery. Intensity of the pain syndrome
was estimated at 88.6 mm average. Irregularity of
menstrual cycle was observed at 45 patients, equaling
to 47.4%.
In the 1st group of women, preservation of pain syn-
drome after endosurgery was observed at 34.4% (11)
of patients, in 12.5% (before surgery observed at 11
out of 32) –irregularity of menstrual function. Pain in-
tensity was estimated at 46 mm average instead of 91
mm before therapy. 
Depending on volume of surgery, patients of the 1st
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group showed the following results. Pain syndrome
was preserved at 50% (7 out of 14) patients after ovary
resection, at 28.6% (2 out of 7) after adne sectomy, at
12.5% (1 out of 8) after cyst enucleation and at 25.0%
(1 out of 4) of patients after endocoagulation. Relapse
of endometrioma after 12 months was observed at
18.2% (6). Relapse of disease was observed at 21.4%
(3 out of 14) of patients after ovary resection, at
14.3% (1 out of 7) of patients after adnexectomy, at
12.5% (1 out of 8) after cyst enucleation, at 25.0% (1
out of 4) after coagulation of endometrioid hetero-
topia.
In the 2nd group of women preservation of pain syn-
drome was observed at 18.8% (6), menstrual irregular-
ity at 9.3% (before surgery observed at 17out of 32).
Intensity of pains was estimated average at 32 mm (be-
fore surgery it was equal to 88 mm). Relapse of disease
was observed at 12.5% (4) cases. Relapse of disease
was observed at 2 out of 11 (18.1%) patients, who had
ovary resection, at 1 out of 5 after adnexectomy, at 1
out of 9 after coagulation of endometroid heterotopias
and in no case out of 5 after cyst enucleation.
In the 3rd group of women after 12 months of treat-
ment, pain syndrome was preserved at 16.7% (5)pa-
tients, at 10% (before surgery was observed at 17 out
of 30) – irregularity of menstrual cycle. Intensity of
pain syndrome was estimated at 39 mm (before sur-
gery it was estimated at 87 mm). Relapse of disease
was observed at 13.3% (4) cases. Relapse of disease
was observed at patients, who had ovary resection 2
out of 15 (13.3%), after adnexectomy at 1 out of 5, af-
tercoagulation at 1 out of 5, at none of 5 after cyst
enucleation.
Results received state, that after endosurgery (first
group) pain syndrome was preserved at every third pa-
tient (34.4%) and was observed 15.6% more frequent,
than at patients, who received COC after operation
and 17.7% more frequent, that at patients, who re-
ceived gestagenafter operation. Regarding intensity of
the pain syndrome, it was reduced by the end of 12
month in all groups. However, at the patients with en-
dosurgery it was reduced at 1,3 time, at combined
therapy with COC by 2,6 times, at combined therapy
with gestagen by 2,2 times. 
Relapses of disease were more frequently observed at
patients after surgery – at 18.2% of patients versus
12.5% at usage of COC after surgeryand 13.3% at us-
age ofgestagen after surgery. For the most part, relaps-
es are observed at patients, who had ovary resection (at
10 out of 40 patients, who had resection, i.e. 25%),
with that, without usage of anti-relapse glandular ther-
apy (21.4% versus 18.2% and 13.3% in 2nd and 3rd
groups). As we can see from this data, frequency of re-
lapse of ovary endometriosis, was lesser after ovary re-
section at patients, who received gestagen.
Conclusion 
Pain syndrome after one year was more frequently pre-
served at patients with endometriosis, who had only
surgical removal of ovary endometriosis (p=0,01). Effi-
ciency of surgery with consequent receipt of hormones
turned out to be better, independent of type of glandu-
lar therapy in the sphere of reducing frequency of pain
syndrome. Intensity of pain syndrome was reduced at
all types of therapy. However, after endosurgery receiv-
ing COC and gestogen allowed reduce frequency of
pain syndrome more, than at using only surgery. 
Thus, using glandular therapy after surgical removal of
ovary endometriosis allows reduce frequency, intensity-
of pain syndrome and frequency of relapse of disease.
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Introduction
Cardiovascular disease (CVD) claims more female
lives than cancer and accidents combined in Latvia. In
2006 CVD caused death for 73% of Latvian women
(58% men). CVD related death-rate is higher and the
average life expectancy of patients is lower than in
most of the European countries (1).
With increase of diabetes, obesity and metabolic syn-
drome CVD will continue to rise. The share of obese
persons in the age group of 25-44 year-olds is 9.6%,
and in the age group of 45-64 year-olds - 31% (2). For
women there is a clear pattern: share of obese persons
increases with age. The levonorgestrel-releasing in-
trauterine system (LNG IUS) has been approved for
contraception and heavy menstrual bleeding therapy
in Latvia since 1998. The LNG IUS use is increasing,
particularly in the treatment of endometriosis, en-
dometrial hyperplasia and even endometrial cancer (3). 
Since 2006 LNG IUS has been included in the list of
reimbursable drugs in Latvia with the indication N92
- excessive, frequent and irregular menstruation
(ICD-10). Each year about 1500 LNG IUS are ad-
ministered to patients having this diagnosis. Contrary
to other progestogen-only contraceptives the activity
of LNG IUS is based on a local effect on the en-
dometrium and non-essential systemic effects. The ef-
fects on various metabolic indicators have been stud-
ied for young women using LNG IUS for contracep-
tion (4) and for women suffering from heavy menstru-
al bleeding (5). Poor patient compliance to this treat-
ment is common as patients are afraid of systemic ef-
fects caused by hormonal preparations, mainly the
weight gain.
The purpose of the study was to clarify the metabolic
characteristics of long-term LNG IUS users and the
possible LNG IUS impact on these parameters. 
Materials and methods
102 women, who had LNG IUS inserted at I.Vasa-
raudze’s Private Clinic Ltd during 01.01.1998 -
31.01.2011 were invited to participate in a retrospec-
tive descriptive study. The examination plan included:
determining the BMI, the measurement of arterial
blood pressure and abdominal circumference, as well
as the collecting of blood count, where the fasting glu-
cose level, C peptide level, total cholesterol (TC), high
density cholesterol (HDC), low density cholesterol
(LDC), triglyceride levels, thyreotropin level, follicle
stimulating and luteinizing hormone level were deter-
mined. The HOMA Calculator© The University of
Oxford 2004 was used in order to determine the beta
cell function and insulin sensitivity. The exclusion cri-
teria were as follows: LNG IUS was not used any more
or it was not possible to carry out the planned exami-
nations for some reason. The patients were dividend in
groups depending on their BMI. Women received
electronic invitation letter and no payments or gifts
were offered for participation. The patients paid for all
the examinations. Prior to the study an informed pa-
tient consent was obtained to use the clinical informa-
tion gathered for statistical analysis and publication.
This study was approved by the Ethics Committee of
Riga Stradins University.
Data analysis
Microsoft Excel was used in creating the database and
producing graphs while the data were analyzed using
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Statistical Package for The Social Sciences (SPSS) ver-
sion 17 for Windows. The commonly used p<0.05
rule was applied to detect significant differences. 
Results
102 invitations were sent; 54 women (52,9%) agreed
to participate in the study; 15 were excluded from the
study since they did not want or could not do the
blood tests. 39 women (31%) underwent all the exam-
inations, and the analyses were based on this sample.
The patients were randomized into three groups:
Group 1 (BMI 18,5-24.90) - 18 women (49%);
Group 2 (BMI 25-29,9) - 19 women (49%); Group 3
(BMI over 30)- 2 women (5%). 
22 women (56%) were using LNG IUS for contra-
ception, 17 women (46%) – for heavy menstrual
bleeding therapy. The average age of the women was
42,7 (SD =7,31 years), without statistically significant
difference between the groups (p=0.141), the oldest
users were in the BMI Group 3. The total indicators
referring to demographic characteristics and biochem-
ical analyses are given in tables 1 and 2.
Table 1 data does not show any statistically significant
differences between the groups based on the indicators
of age (p=0.1941), LNG IUS use duration
(p=0.8710), systolic blood pressure (p=0.0607) and
diastolic blood pressure (p=0.0215). The highest indi-
cators were found in BMI Group 3. 
As Table 2 shows, BMI Group 1 had a statistically sig-
nificant lower level of LDL (p=0.0007); cholesterol
(p=0.0040), triglycerides (0.0425), HDL (p=0.5937),
glucose (p=0.9659), C peptide (p=0.8273), HOMA-
IR (p=0.9594), TSH (p=0.6237), FSH (p=0.3751)
and LH level (p=0.3206) did not have a statistically
significant difference between the groups, while the
highest indicators were in BMI group 3.
By means of the method of linear regression it was
identified that the increase in BMI leads to a statisti-
cally significant increase in glucose level (p>0.003) and
insulin resistance indicators (>0.001); the increase in
glucose level results in the increase of insulin resistance
(p>0.001).
Discussion
According to the results of the present study, LNG
IUS does not have a systemic impact on metabolic pa-
TABLE 2 - THE METABOLIC INDICATORS OF THE STUDY GROUP.
Variables
Mean±Standard deviation (SD)
Total group Group1 Group2 Group3
Cholesterol (mmol/L) 5.2±0.96 4.74±0.91 5.69±0.80 5.48±1.1
Triglycerides (mmol/L) 1.02±0.58 0.78±0.37 1.2±0.67 1.35±0.81
HDL (mmol/L) 1.65±0.36 1.70±0.38 1.62±0.37 1.46±0.16
LDL (mmol/L)* 3.05±0.90 2.53±0.78 3.54±0.71 3.31±0.10
Glucose (mmol/L) 5.15±0.67 5.06±0.45 5.05±0.69 6.62±0.10
C peptid (ng/mL) 1.66±0.67 1.54±0.50 1.59±0.66 3.01±0.57
HOMA-IR 1.26±0.48 1.169±0.29 1.176±0.45 2.4±0.69 
TSH (mU/L) 1.54±1.17 1.68±1.26 1.47±1.17 1.11±0.26
FSH (U/L) 15.28±20.59 11.06±15.58 17.25±22.98 32.25±37.40
LH (U/L) 8.20±8.41 6±5.68 8.81±9.27 19.9±13.01
* Significantly different at the 5% level of significance.
TABLE 1 - BASELINE CHARACTERISTICS OF THE STUDY GROUP.
Total group Group1 Group2 Group3
Age (years) 42.7±7.31 41±1.54 44.15±1.80 45.5±7.32
Height (cm) 171(164-183) 172(164-182) 169(164-184) 169(164-174)
Weight (kg) 73.03((53.6-93.4) 67.1(53.6-76.6) 76.8(66-92.8) 93.03(92.7-93.4)
LNG IUS use duration (months) 53.02(6-150) 50.61(6-150) 48.36(6-144) 84(54-114)
Systolic BP (mmHg) 119.46(100-180) 114.27(100-130) 122.21(100-150) 140(100-180)
Diastolic BP (mmHg) 77.53(58-110) 72.11(58-80) 81.36(60-110) 90(70-110)
Abdominal circumference (cm) 86.47(76-95) 83.88(76-94) 88.31(79-95) 93(92-94)
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rameters. Changes in the metabolic parameters do not
depend on the duration of LNG IUS use.
54% of the women in the sample had an increased
BMI reflecting the statistical situation in the country.
There is a direct correlation between an increase in the
glucose level and insulin resistance, along with the
changes in BMI. 
An increased BMI was observed among older patients,
also observing an elevated level of gonadotropin. The
LNG IUS are administered primarily to women over
40, the same age group where the most significant
changes in metabolic characteristics have also been in-
dentified. The design of the present study did not al-
low us to evaluate whether changes in the go-
nadotropin level are connected with the use of LNG
IUS. Since the number of LNG IUS users undergoing
heavy menstrual bleeding therapy is increasing every
year, additional evaluation of this correlation is neces-
sary. 
This study shows significant relationships between
BMI, glucose level and insulin resistance. The meas-
urements of the BMI and abdominal circumference
could be included in the annual examination plan of
LNG IUS users in order to select a group of patients
for further, more extensive examination in a timely
manner. 
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Background
Preterm birth 22+0 – 36+6 gestational weeks occurs in
5% in developed countries and up to 25% in develop-
ing areas and is the cause of 70% of all perinatal mor-
tality and morbidity. Risk factors for spontaneous
preterm birth include poor nutrition, low socioeco-
nomic status, smoking, prior preterm birth, subpla-
centar bleeding, systemic or urogenital tract infection
or inflammation, cervical or uterine anomalies and
psychophysical maternal stress.
Synthetic progestins and natural progesterone have
been widely used as luteal phase support in patients
with recurrent miscarriages and in assisted reproduc-
tion since the 1950s, and for preventing premature
birth since the 1960s. Prophylactic weekly intramus-
cular injections of 17α-P significantly prevented the
incidence of premature birth and to improve early
neonatal outcome in comparison to placebo in pa-
tients with a medical history of a previous premature
birth, and in asymptomatic patients with a sonograph-
ically short cervix. Prophylactic daily doses of a vaginal
gel or tablet containing natural progesterone signifi-
cantly reduced the incidence of premature birth and
improved early neonatal outcome as compared to
placebo in patients with a previous preterm birth, pro-
phylactic cervical cerclage or uterine malformation
and in asymptomatic women with a sonographically
short cervix, but was not proven to be efficient in the
largest randomized controlled trial.
Only a few studies have investigated the effect of prog-
esterone treatment in women who remained undeliv-
ered after successful parenteral tocolysis because of
preterm labor. In one study 60 women with preterm
labour (24-34 gestational weeks) were randomized to
receive either an intramuscular injection of 341 mg of
17α-P twice a week or observation alone after atosiban
infusion. In another study 70 women with preterm la-
bor (24-34 gestational weeks) were randomized to ei-
ther receive a progesterone suppository 400 mg daily
or to observation after magnesium sulphate infusion.
Human studies have focused on early neonatal out-
come, i.e. mortality, morbidity and neonatal intensive
care unit (NICU) admittance within the first week of
life. Further studies are required concerning natural
progesterone, and to establish the optimal dose and
type of agent as well as long term effects on the new-
born. In our study, daily progesterone vaginal gel 90
mg after successful parenteral tocolysis in 60 women
with a singleton pregnancy, premature uterine con-
tractions between 24 and 34 gestational weeks and a
cervical length <25 mm will be presented. Clinical ma-
ternal and neonatal outcome, infant well-being at 6
and 12 months of age, plasma levels of steroid hor-
mones, pro-inflammatory and anti-inflammatory cy-
tokines are monitored.
Comment 
Data from animal studies suggest, that natural proges-
terone is more efficient than 17α-P in preventing pre-
mature ripening of the cervix uteri. Progesterone, like
androgens and corticosteroids, exert anti-inflammato-
ry effects and is a strong immunosuppressor. Prelimi-
nary data suggests that progesterone, which in contrast
to 17α-P has no androgenic effects, also has fewer side
effects than 17α-P. The genomic and non-genomic ef-
fects of progesterone and possible adverse effects of to-
colysis and progesterone treatment will be discussed.
Natural progesterone treatment in preterm labor
VLADIC STJERNHOLM Y., MARCHINI G.
Karolinska Institute and University Hospital, Women’s and Children’s Health, Stockholm, Sweden
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Introduction
In the last decades we can see a rapid increase of vari-
ous thyroid disease rates in Ukraine. Infertility rates
are stabile high. This leads to the increase of quantity
of women with thyroid diseases who want to become
pregnant. Sometimes the only way to achieve pregnan-
cy is ART treatment.
There are various definitions for ART. According to the
definition used by CDC, ART includes all fertility
treatments in which both eggs and sperm are handled;
ART procedures involve surgically removing eggs from
a woman’s ovaries, combining them with sperm in the
laboratory, and returning them to the woman’s body or
donating them to another woman; they do not include
treatments in which only sperm are handled (i.e., in-
trauterine–or artificial–insemination) or procedures in
which a woman takes medicine only to stimulate egg
production without the intention of having eggs re-
trieved. In Ukraine, nevertheless, all the above men-
tioned methods of treatment are meant as ART. In this
study we use “ART” only for the IVF treatment.
It is also discussed what method is the best for calcu-
lating fertility success rates. In our study we use the
pregnancy rate per one stimulation cycle as the criteri-
on for fertility success rates. 
The aim of our study was to examine the influence of
the thyroid function on the effectiveness of infertility
treatment with ART, that is IVF. 
Materials and methods
A retrospective analysis of 130 cases of infertility treat-
ment with ART in the department of diagnosis and
treatment of infertility (Donetsk regional center of
motherhood and childhood protection, Donetsk,
Ukraine) during 5 years (2006-2009). The patients
were divided into 2 groups: 
1) 65 women - with thyroid pathology; 
2) 65 women - with normal function of the thyroid
gland.
In both groups we analyzed the pregnancy rates fol-
lowing ART and also the frequency of different dis-
eases of the thyroid gland in the first group.
Results 
We found that the thyroid pathology had influenced
the effectiveness of infertility treatment with ART. The
pregnancy rates were almost 20% lower in the group
of infertile women with thyroid pathology compared
with the group of infertile women with normal thy-
roid function, p≥0,05.
When women with thyroid dysfunction started their
infertility treatment, they had different thyroid diseases
in different combinations (goiter, chronic thyroiditis
etc), but their thyroid function was as follows: euthy-
roid – almost 75%, subclinical hypothyroidism – al-
most 15%, hypothyroidism – almost 10% of women.
ART treatment could only be started when hypothy-
roidism wascompensated. So we can see that even eu-
thyroid status influenced the effectiveness of the ART
treatment in the group of women with thyroid diseases. 
Conclusions
The thyroid function influences greatly the effective-
ness of infertility treatment with ART. We suggest an
obligatory screening (TSH and aTPO) of thyroid
function among infertile women in order to find and
treat the thyroid pathology before the treatment with
ART. It is also necessary to find new methods for in-
creasing the ART success rates in women with thyroid
dysfunction, because even euthyroid status by chronic
thyroiditisdecreases pregnancy rates significantly. 
How does the thyroid function influence the effectiveness
of infertility treatment with ART?
VUSTENKO V., CHAYKA V., KVASHENKO V., AKIMOVA I.
DonNMU, Department of Obstetrics, Gynecology and Perinatology, Donetsk, Ukraine
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